<SEC-DOCUMENT>0000875045-19-000029.txt : 20190724
<SEC-HEADER>0000875045-19-000029.hdr.sgml : 20190724
<ACCEPTANCE-DATETIME>20190723174707
ACCESSION NUMBER:		0000875045-19-000029
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190724
DATE AS OF CHANGE:		20190723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		19968619

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2019630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:CC950A33AE9D55288267217596E579F1,x:74854fa6a558475f96fdd28a6825f5cb-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:biib="http://www.biogenidec.com/20190630" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-DC2363294D15B74C4955F6259D8198BD-wk-Fact-DC2363294D15B74C4955F6259D8198BD">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-74703AAE2BD12C30A5DBF6259D81DCFA-wk-Fact-74703AAE2BD12C30A5DBF6259D81DCFA">Indefinite</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:AmendmentFlag" id="Fact-F3D469DC9E7E1FA74315F6259D716052-wk-Fact-F3D469DC9E7E1FA74315F6259D716052" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-5A126993C837E662020DF6259D43FB99-wk-Fact-5A126993C837E662020DF6259D43FB99">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-35557C07B8F2FD40B118F6259D047756-wk-Fact-35557C07B8F2FD40B118F6259D047756">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-43B941E4D3B98E65C63EF6259D04D992-wk-Fact-43B941E4D3B98E65C63EF6259D04D992">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-F7ACC83A6C7F62AC81A9F6259CF51FF0-wk-Fact-F7ACC83A6C7F62AC81A9F6259CF51FF0">0000875045</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-5039E0EFDC14A7AF8494F6259D717262-wk-Fact-5039E0EFDC14A7AF8494F6259D717262">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-6E121E9445E85B479E08F6259D3361F6-wk-Fact-6E121E9445E85B479E08F6259D3361F6">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-7A997D0B576EE901A6D2F6259D81748E-wk-Fact-7A997D0B576EE901A6D2F6259D81748E">0.052</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-E92F0E3BF7CF663F4737F6259D813239-wk-Fact-E92F0E3BF7CF663F4737F6259D813239">0.0405</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-21E0AFF426C06BBE8D94F6259D813EDB-wk-Fact-21E0AFF426C06BBE8D94F6259D813EDB">0.03625</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-73EA653E34D9526F99ECF6259D819D7D-wk-Fact-73EA653E34D9526F99ECF6259D819D7D">P18Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-7DB894B851F66023C865F6259D812FA3-wk-Fact-7DB894B851F66023C865F6259D812FA3">P23Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-C99BABFFE2F044AB9E5BF6259D8166FB-wk-Fact-C99BABFFE2F044AB9E5BF6259D8166FB">P23Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-331384F6B048A2116782F6259D8150B7-wk-Fact-331384F6B048A2116782F6259D8150B7">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-FC082F7B9A11EF18F799F6259D81E61A-wk-Fact-FC082F7B9A11EF18F799F6259D81E61A">P13Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-44726AD7F55D00805CAEF6259D816745-wk-Fact-44726AD7F55D00805CAEF6259D816745">P15Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-03F5B983F5B60C947337F6259D337BC1-wk-Fact-03F5B983F5B60C947337F6259D337BC1">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q2" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-93EB9787A98FC27070F6F6259D3306DD-wk-Fact-93EB9787A98FC27070F6F6259D3306DD">0.001</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="biib-20190630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s16E3D4F226CA5BD9AFFE72AD1226C4CA"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;</span><span><ix:nonNumeric id="d30702571e795-wk-Fact-ECF48E61C3CED7A5F589F6259DA27745" name="dei:DocumentType" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d30702571e813-wk-Fact-15C9BCDD4254055AB4D9F63C9F2517D9" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d30702571e823-wk-Fact-7DB925690F09665D39D1F6259D8113C6" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q2YTD" format="ixt:datemonthdayyearen">June 30, 2019</ix:nonNumeric></span></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d30702571e843-wk-Fact-9DB8690C64FDC5C7870AF63D3CE292E7" name="dei:DocumentTransitionReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number </span><span><ix:nonNumeric id="d30702571e853-wk-Fact-BD7D5E32C535B3A4D7BBF63D98B91AE4" name="dei:EntityFileNumber" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">0-19311</span></ix:nonNumeric></span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><img src="biogenlogostandardrgbr.jpg" alt="biogenlogostandardrgbr.jpg" style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;height:30px;width:92px;"></img></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d30702571e862-wk-Fact-141FF02D24228C55769BF6259DA41D9B" name="dei:EntityRegistrantName" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d30702571e884-wk-Fact-3278885681EB66F214B3F64090F9DA23" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d30702571e894-wk-Fact-67B3B629C144166A671AF640ADAA4BF7" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q2YTD">33-0112644</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d30702571e919-wk-Fact-4EE423FA3CAF99DBE4F6F640DAF42912" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">225 Binney Street</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d30702571e924-wk-Fact-EE3A1931AE93AF14DDD6F641123A425A" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">Cambridge</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d30702571e929-wk-Fact-543D93899F4066EB758AF64150FEEE5D" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">MA</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d30702571e934-wk-Fact-093DA0C7F16CB324B730F6417025690B" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q2YTD">02142</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d30702571e941-wk-Fact-2E13BDCE7461D9F742A4F641944DEDE6" name="dei:CityAreaCode" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)&#160;</span><span><ix:nonNumeric id="d30702571e946-wk-Fact-148BCC8FE9E5CA133214F641B5884501" name="dei:LocalPhoneNumber" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">679-2000</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30702571e1007-wk-Fact-748E8D4D42F46174182EF642017334A1" name="dei:Security12bTitle" contextRef="FD2019Q2YTD">Common Stock, $0.0005 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30702571e1017-wk-Fact-878F4139F49AFCBBDEDDF642152B71A0" name="dei:TradingSymbol" contextRef="FD2019Q2YTD">BIIB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30702571e1032-wk-Fact-2A4DA4607DF9C518772CF64244763590" name="dei:SecurityExchangeName" contextRef="FD2019Q2YTD" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d30702571e1037-wk-Fact-2476BC79D90B352124CAF64286CC1989" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d30702571e1055-wk-Fact-70574750234C3B3FF305F642AFD14985" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:3%;"></td><td style="width:43%;"></td><td style="width:28%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30702571e1090-wk-Fact-86728A13832940E24676F6452D9D9F33" name="dei:EntityFilerCategory" contextRef="FD2019Q2YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d30702571e1136-wk-Fact-91325945C06D36444343071C3C3327E6" name="dei:EntitySmallBusiness" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d30702571e1162-wk-Fact-632665AEA1F68DFE7AEA071C5EDBA3BA" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d30702571e1172-wk-Fact-C5B7E204B0FE656A3100F646A6301759" name="dei:EntityShellCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox"><span style="font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July&#160;19, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702571e1190-wk-Fact-FD165FADE2295E59F991F6259DA20922" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q2SharesOutstanding" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">184,447,218</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s4EFD59117A4E5773AB2E94F1F94FE283"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#sC3C15C79AF1A5DF080D1BEE17C2E7B3A"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4F8A29ADE6955869990C923E41932375"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s4F8A29ADE6955869990C923E41932375">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC92569EF1C455E83BBD1BA2EAF901F0D"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sC92569EF1C455E83BBD1BA2EAF901F0D">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFF6D9AE2D1545E0FABC1ACDB52244274"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of June 30, 2019 and December&#160;31, 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sFF6D9AE2D1545E0FABC1ACDB52244274">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s39665F6B88EC5736A645B3FACA079CF4"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s39665F6B88EC5736A645B3FACA079CF4">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6FCE2BB0567D5735A8772CC606906626"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Equity &#8212; For the Three and Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6FCE2BB0567D5735A8772CC606906626">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s004DACDB857F5FD18D6DEDB4B841E237"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s004DACDB857F5FD18D6DEDB4B841E237">13</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8A5B83111CBC5D448F1E323F88567F3D"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8A5B83111CBC5D448F1E323F88567F3D">48</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sA9D938BBC4F85A6497B0638E2E1D02EA"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sA9D938BBC4F85A6497B0638E2E1D02EA">74</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB63B8B10076F5943ACAB8B5A267EE1DD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB63B8B10076F5943ACAB8B5A267EE1DD">76</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#sADFDF881245F540E91E2A9CCDE9F4188"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sF1A1B5903B425193955D10B7CD35853E"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sF1A1B5903B425193955D10B7CD35853E">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE3216EF0B9ED55D59E0F3C1191AAA0C9"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE3216EF0B9ED55D59E0F3C1191AAA0C9">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s162E89A1CF495921871071633C2717AD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s162E89A1CF495921871071633C2717AD">92</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7586889C4F855BC8BA9BBA38CBBE5AF7"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7586889C4F855BC8BA9BBA38CBBE5AF7">92</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sF5DEF489EED05DA18092129BE52C8FC9"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sF5DEF489EED05DA18092129BE52C8FC9">94</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8871E8867EF55B6CB5258D35D1792E74"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; "would" and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans and investments in our core and emerging growth areas, as well as implementation of our corporate strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intention to commit resources relating to research and development programs and business development opportunities, as well as the potential benefits and results of, and the anticipated timing to complete, certain business development transactions, including divestitures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products or generic or biosimilar versions of our marketed products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, including anticipated investments and divestitures, and activities in new or existing manufacturing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) intent to voluntarily depart from the European Union (E.U.);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, including the Swiss Federal Act on Tax Reform and AHV Financing, regulatory requirements, judicial decisions and accounting standards.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are registered trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ENBREL&#174;, FAMPYRA</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174;, SkySTAR</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and other trademarks referenced in this report are the property of their respective owners. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC3C15C79AF1A5DF080D1BEE17C2E7B3A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</span></div><div><a id="sDB979FD4324B569D841BB52DBBF26743"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s4F8A29ADE6955869990C923E41932375"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1063-wk-Fact-C3F1908781ECB2F108F9F6259D62D489" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,880.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1082-wk-Fact-2B45585D36E41B2DB864F6259D23ADFD" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,757.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1101-wk-Fact-AF0A6B5FA115FD6CFF39F6259D1417AF" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,560.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1121-wk-Fact-C04EBFA41990DA29BFA8F6259D52D55F" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,281.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1136-wk-Fact-5B9EC13DF76E0C64D4C9F6259D71CF78" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1155-wk-Fact-09FB62AF2F4874DE36DDF6259D330ABD" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">490.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1174-wk-Fact-2EBAB557DC84FE08A211F6259D622116" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,093.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1194-wk-Fact-2091EADF344F99481D24F6259D621286" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">933.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1214-wk-Fact-CC0CC7DC660BF5C38699F6259D334216" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1233-wk-Fact-7F5F6340692D7DDE0318F6259D814253" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1252-wk-Fact-67EF5E7D2920FD15A8F6F6259D6276B9" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">452.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1272-wk-Fact-18A0A15D9AE9D88D7F55F6259D235B1F" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">273.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1292-wk-Fact-C7FDF5E25322082D0991F6259D049965" name="us-gaap:Revenues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,616.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1311-wk-Fact-1C5290B3B3CB7DD0C9D7F6259D335955" name="us-gaap:Revenues" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,356.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1330-wk-Fact-0F0DB851024A5AA84F7FF6259D71A480" name="us-gaap:Revenues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,106.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1350-wk-Fact-A77911B12733251103BFF6259DA238F3" name="us-gaap:Revenues" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,487.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1452-wk-Fact-BCE188F5B8289B326622F6259D231634" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1471-wk-Fact-AEE38EC55DD969338755F6259D71A115" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1490-wk-Fact-DD4CF4890052B549F881F6259D81FC12" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,078.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1510-wk-Fact-D02171DA0CC2696B405EF6259D23F0FE" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">867.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1530-wk-Fact-78B14F963FA10EB8E8A5F6259D04E349" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">484.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1549-wk-Fact-9769E0D3B78857CD81B0F6259D5254B1" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">981.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1568-wk-Fact-07EF1F112AE2E5AF6159F6259DB265DA" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,048.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1588-wk-Fact-655DB4C361C2687DEA2BF6259D714A3B" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,477.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1608-wk-Fact-3A65D7580D1256F88110F6259D71652E" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">587.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1627-wk-Fact-BA669425A7864CA9D22BF6259D7146B5" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">516.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1646-wk-Fact-81F603803BA6BB05FD07F6259D3330DE" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,155.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1666-wk-Fact-AC7C9BCF6E9A8D9E0660F6259D044118" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,017.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1687-wk-Fact-B3BD168EB3801729A63FF6259D621F86" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1706-wk-Fact-7779EF5CE57D18E76221F6259D624E02" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1725-wk-Fact-B5DFD812D22F420158BDF6259D237ACF" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">138.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1745-wk-Fact-3A52F769615790191266F6259D23382B" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">211.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1765-wk-Fact-9B6251B03F97D7A33E2AF6259D14531F" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1784-wk-Fact-DD8C1B21C56443052CC8F6259D04427F" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1803-wk-Fact-5E4C5FBDC495F8A1A707F6259D14AFA2" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1823-wk-Fact-8F6BCE61193B007C0584F6259D43E3CE" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on assets and liabilities held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30709305e1843-wk-Fact-1CB61165D41CFE0E7A0EF6259D046651" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1863-wk-Fact-A4CB49C6CAA6798C106AF6259D331021" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e1882-wk-Fact-62F4DD8F603903FB7B89F6259D715EC0" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">113.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1902-wk-Fact-83CCF52D84FD932D2D8BF6259D43A2B6" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30709305e1922-wk-Fact-6ACFF58C36896C0429A5F6259D7118EC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e1942-wk-Fact-5D3F92B3D26D4145CC8DF6259D71B2D9" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30709305e1961-wk-Fact-33C2C3244E3CB3B9F4C0F6259D6216FA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30709305e1982-wk-Fact-7BA913E8E376F5770455F6259D81E7AA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2003-wk-Fact-A4C4510A0A15FFDAB0EDF6259D71E10D" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2022-wk-Fact-2C06C29C747E562ADC51F6259D230196" name="us-gaap:RestructuringCharges" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2041-wk-Fact-F705CBBE3FBA002A8C29F6259D1437CC" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2061-wk-Fact-0019B12CF5DA291E7BAAF6259D625381" name="us-gaap:RestructuringCharges" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2081-wk-Fact-8EC1D3CD405CB3948FBDF6259D04925B" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2100-wk-Fact-D060DFC2F4677C7C3680F6259D232ABE" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2119-wk-Fact-3E2223D98408E167DC0AF6259D330F8A" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2139-wk-Fact-357E14C70265B206695DF6259D62226E" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2159-wk-Fact-706898CD8DDEDD6EFB28F6259D5293BE" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,660.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2178-wk-Fact-5011C17B57A2DC15404DF6259D719D22" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,143.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2197-wk-Fact-EBDCED3DB754CB59F824F6259D04D640" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,647.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2217-wk-Fact-C07105E17E6E4660E761F6259D044EA3" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,739.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2237-wk-Fact-732697F15829DF743374F6259D62BFE9" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,955.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2256-wk-Fact-66042D97A89A9FB89976F6259D1436DA" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,213.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2275-wk-Fact-47BC4B878E25A565C497F6259D2384B6" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,458.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2295-wk-Fact-94E1F72F5617BB00F6A9F6259D330C76" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,747.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30709305e2315-wk-Fact-1D06C1D1506111B2621BF6259D239489" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">197.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30709305e2335-wk-Fact-9D3C2F37AB35BFAE8012F6259D232D43" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">34.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2355-wk-Fact-4F4E212D12754366EB0BF6259D4303AC" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30709305e2375-wk-Fact-FA4E213E25606EA300E5F6259D2321CF" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">75.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2396-wk-Fact-A5FA1624AC3C18E0C6D1F6259D233A43" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,758.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2415-wk-Fact-E146803FA0B028B19B7EF6259D62D3AD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,178.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2434-wk-Fact-49E6DBBCFF0BB450DCCCF6259D33903A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,618.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2454-wk-Fact-D0E0F6FC495E57AB1F90F6259D71917A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,672.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2474-wk-Fact-4624827AA9206BC4BEE3F6259D23D741" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">248.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2493-wk-Fact-3D9E0081242A84B1D3C1F6259D33E71A" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">263.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2512-wk-Fact-F19460D3D1147472DEE0F6259D3347E3" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">670.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2532-wk-Fact-52CAE90BDDEA71C31714F6259D233C61" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">586.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2553-wk-Fact-16DB6DC0C2ECCE76DFF2F6259D23016D" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2572-wk-Fact-B9E957A0FE13DAE7A5BAF6259D339382" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2591-wk-Fact-36F4882A823D85CA65B0F6259D812752" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2611-wk-Fact-FEE28C3EF37BA83466A6F6259D233568" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2631-wk-Fact-1AB203907EB0BAB2309FF6259D620105" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2650-wk-Fact-D31F8D4E9B3B5AE9DA2CF6259D234447" name="us-gaap:ProfitLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">915.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2669-wk-Fact-944622E77168D32541A5F6259D237440" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2689-wk-Fact-7EEB6BFCFE93B770E6D9F6259D04B1BB" name="us-gaap:ProfitLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,086.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2709-wk-Fact-E645E756D1A5928F4DB9F6259D33A16C" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2728-wk-Fact-6BC822D1781AE53D7E2FF6259D23815D" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2747-wk-Fact-696A695B9920C049841EF6259D33760E" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2767-wk-Fact-24E55A27DDA14CB9EAB6F6259D81B92E" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2792-wk-Fact-1312D56524962A9DE5E6F6259D623531" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2811-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">866.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e2830-wk-Fact-4C12FF47E79C07429E22F6259D717E32" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e2850-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,039.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3034-wk-Fact-8CF9DC39F989380845F4F6259D04BA7C" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3053-wk-Fact-FFF62E268FEFB138E8F5F6259D62495A" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3072-wk-Fact-663F92E7DEDC62E12377F6259D71A754" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3092-wk-Fact-D049B4E18AE05156BF93F6259D62E9CC" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3112-wk-Fact-2DC10E017EA507089A2CF6259D234B6D" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3131-wk-Fact-DEE3E7AA016512089B7DF6259D626513" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3150-wk-Fact-BBCE3A012795B8919988F6259D045D1F" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3170-wk-Fact-C89ABB444BDF41DB8497F6259D231165" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3349-wk-Fact-3DD915C4195E7A211C58F6259D14C30A" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3368-wk-Fact-FBB66D5A57657FD9D1A8F6259D04C4C0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3387-wk-Fact-D6A6A637EC02E81810FBF6259D2321A2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3407-wk-Fact-D23833DF65E5DC2469C7F6259D046BE6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">209.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3428-wk-Fact-735BC5DA3214A5F5DB05F6259D23547F" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3447-wk-Fact-8878D9126D3CB451B07EF6259D23E3E0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30709305e3466-wk-Fact-561BED1750D028A1FC26F6259D23DF4C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30709305e3486-wk-Fact-C1F390AE19DCE6838E36F6259D6231B8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">209.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC92569EF1C455E83BBD1BA2EAF901F0D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e981-wk-Fact-1312D56524962A9DE5E6F6259D623531" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1000-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">866.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1019-wk-Fact-4C12FF47E79C07429E22F6259D717E32" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1039-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,039.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1136-wk-Fact-31F010DDAF49859F6355F6259D6213D2" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1155-wk-Fact-21EBA31C28FC312C52FFF6259D528FC0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1174-wk-Fact-EC118FAD2A5A63553933F6259D1465FF" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30704023e1194-wk-Fact-CEE616735AA289DD6706F6259D143DA2" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1215-wk-Fact-9A3D853B99202E3E0591F6259D625AE0" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">37.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1235-wk-Fact-2F275844E1AC10A0E95BF6259D521B63" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1254-wk-Fact-D3F2372090B1308D93A8F6259D629FC6" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1275-wk-Fact-1BE8F66DB75E0AD41FDFF6259D149DC8" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1295-wk-Fact-42568F2007375561AFA4F6259D14F796" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1314-wk-Fact-F8517014170680EA6529F6259D14192A" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1333-wk-Fact-985141DDAB2748EC2C6FF6259D146776" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1353-wk-Fact-8A5556BAE3D9EDE48F6AF6259D624EA7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1373-wk-Fact-8A877CC0C0C5E6D39823F6259D623726" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1392-wk-Fact-5555D481A8C4A754976FF6259D62E9BA" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1411-wk-Fact-CFEA2E75C731BC2B8770F6259D14C4DC" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1431-wk-Fact-A2B291592654A0550463F6259D62D2ED" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1451-wk-Fact-7CC3D6792C2A3A811327F6259D14343D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30704023e1471-wk-Fact-EAADD9BCAD5FEB3BD958F6259D143FEF" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">92.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1491-wk-Fact-065A6EE1399E000692E7F6259D14A99F" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30704023e1512-wk-Fact-6D7EB6CFEE011396865BF6259D143ADA" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1533-wk-Fact-B0A137B6EC0E7C27AA1BF6259D047ABC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1553-wk-Fact-DF0CD48B7311719F5538F6259D6235D2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1572-wk-Fact-6440C377A189830524FFF6259D141ACB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1593-wk-Fact-53C30F8A2D37A0D5D15EF6259D14796F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1613-wk-Fact-CF635044ECDFF7D9358EF6259D62419B" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,461.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1632-wk-Fact-75BE0D31A8E1110952C9F6259D146358" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">908.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1651-wk-Fact-E4854635B3CE5ACCEAB5F6259D144463" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,890.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1671-wk-Fact-56593BA70A232668C9FCF6259D62D8D2" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,094.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1692-wk-Fact-339C0F36774A78B0C3A8F6259D62F894" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1712-wk-Fact-A783D33382ADC5B65D03F6259D529E46" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30704023e1731-wk-Fact-743F7539F07EAC0F6D4AF6259D62CFB8" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1752-wk-Fact-61A1688FA476ACF65A91F6259D04A00B" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1777-wk-Fact-7F19EA6B90DE71AA10B8F6259D145FDE" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,460.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1796-wk-Fact-26089E7159283A6571B4F6259D627D9F" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">957.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30704023e1815-wk-Fact-1F2AF1DB2838E69AEAE4F6259D62B9BA" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,890.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30704023e1835-wk-Fact-C00D336AEA4F71C1D663F6259D043A66" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,141.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFF6D9AE2D1545E0FABC1ACDB52244274"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br/>2018</span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e933-wk-Fact-9858208795209B691908F6259D338561" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,723.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e952-wk-Fact-035B89B271A4FAED0085F6259D2336D2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e967-wk-Fact-BD9E919248B6581338EDF6259D23452A" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,228.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e986-wk-Fact-F39650FBCA792ACA848FF6259D239419" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,313.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1006-wk-Fact-AE2BCE0E16D1839A8BD1F6259D335046" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,959.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1025-wk-Fact-B2E9AD3D8FCD7E315646F6259D33B4D0" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,958.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1045-wk-Fact-2D2F6815774616642EF5F6259D339468" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">557.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1064-wk-Fact-AC282426EDDBBB0752F5F6259D235244" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">526.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1084-wk-Fact-55C665FC64E6E531FF29F6259D33D65D" name="us-gaap:InventoryNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">776.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1103-wk-Fact-8C6C4783CB833F71AD59F6259D2325D5" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">929.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1123-wk-Fact-20DBD282A787CC7F2376F6259D339564" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">683.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1142-wk-Fact-FD99C4D258FDBA85A0FCF6259D23B706" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1162-wk-Fact-D456004BF084BBF369F8F6259D2390EE" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">980.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1181-wk-Fact-742E62FB17113F6C5D8AF6259D339468" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">687.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1201-wk-Fact-242EF5FBDE93AED05319F6259D23C964" name="us-gaap:AssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,909.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1220-wk-Fact-481F9FDB7D0076F652A0F6259D23E31B" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,640.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1241-wk-Fact-6FF948889A321B259E6BF6259D33C3E9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,309.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1260-wk-Fact-E06E408A000E8B3CF1C0F6259D23A411" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,375.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1280-wk-Fact-D36EC44E828AA961F2BFF6259D33C5F8" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,077.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1299-wk-Fact-F4F7BCB3A78942C0135CF6259D234031" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,601.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1319-wk-Fact-30F30492C0F6E625EDCEF6259D334F76" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">434.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1338-wk-Fact-04A7905E586B9B458C06F6259D23079B" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1358-wk-Fact-C44244A5766C4B25316FF6259D233F2E" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,681.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1377-wk-Fact-8B92C2F3788E45ADA189F6259D33FAEA" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1397-wk-Fact-D63D508540010D880C00F6259D336D62" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,749.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1416-wk-Fact-A45E521E0B1F5359C200F6259D335514" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,706.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1436-wk-Fact-E675740FEFD83830F0D6F6259D337D8D" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,820.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1455-wk-Fact-852AE116BCBBCB5DD576F6259D23AFCD" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,153.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1475-wk-Fact-A2969343D2188DFE88F0F6259D33058A" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,306.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1494-wk-Fact-1D309AFFBDC920B45EB5F6259D338BF8" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,690.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1519-wk-Fact-C509E254A6F3D0BD0E30F6259D33FCC0" name="us-gaap:Assets" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26,287.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1538-wk-Fact-841E6D4BAF69CAA3BCD3F6259D23066A" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,288.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1635-wk-Fact-3002001FCA74A7392C5EF6259D335EBF" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">427.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1654-wk-Fact-F4960609E3F746E03D1EF6259D33DB57" name="us-gaap:TaxesPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1675-wk-Fact-81F5E0FEA2F9FD8A80A3F6259D230796" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">377.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1694-wk-Fact-65041FE09DE05A22ECD3F6259D230B5B" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">370.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1714-wk-Fact-CC4552EDFEBE57032A88F6259D2345FA" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1733-wk-Fact-CDC634F416FB33364A38F6259D23C75B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1753-wk-Fact-D2C177CB69195CA03AC0F6259D33900E" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,318.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1772-wk-Fact-86E688319B1BFB671A79F6259D3356D0" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,861.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1792-wk-Fact-06DAF578A64F1EE86E29F6259D3390C7" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,210.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1811-wk-Fact-3E4619C2FFADD3A56095F6259D336F05" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,295.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1831-wk-Fact-33694DB63BA16DCFC663F6259D33CA9C" name="us-gaap:LongTermDebt" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,948.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1850-wk-Fact-B61A57895AE4A95E8E50F6259D333AD0" name="us-gaap:LongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1870-wk-Fact-B87FDA86BF3BFF6C4F43F6259D33859D" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,400.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1889-wk-Fact-09C88A415F4C30DE2ED3F6259D331942" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,636.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1909-wk-Fact-286D309BE212C93DDB31F6259D33E918" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">423.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1928-wk-Fact-6E52952A5B4E356B4CFEF6259D231687" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1948-wk-Fact-8904E7BA29021E7A3B2AF6259D33E1F9" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,355.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e1967-wk-Fact-D6DAB453FA1C7269FD1AF6259D233862" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,389.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e1987-wk-Fact-2BF6B1C8763D147B9C12F6259D2356E8" name="us-gaap:Liabilities" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,338.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2006-wk-Fact-A0ED1004BA8299B95E07F6259D33E998" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,257.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2026-wk-Fact-57E75B4FAD89DB341550F6259D33CB95" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q2" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2044-wk-Fact-22EB2B36C1291F28F2E3F6259D33E1DB" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e2146-wk-Fact-46D759CBC6CAD5CEF4C2F6259D33FAFE" name="us-gaap:PreferredStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2165-wk-Fact-A9E4900C1CF8D0CEF483F6259D33E8B5" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e2185-wk-Fact-88CC95E857D9A664786FF6259D23A24A" name="us-gaap:CommonStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2204-wk-Fact-940FE4B6F465D880CDB6F6259D33EE22" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e2224-wk-Fact-4F6D5DA9E5876E748A73F6259D338AC0" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2243-wk-Fact-AD555A3A6C3C3536A361F6259D237307" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30706092e2263-wk-Fact-87EBCA1CDEFC1D44DA24F6259D23F60D" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30706092e2283-wk-Fact-25428E0E08BD0DBCBF49F6259D237069" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e2304-wk-Fact-4C5BAD68AE6FF251B6D7F6259D2325D2" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2323-wk-Fact-10E50376D0702BB459F1F6259D339745" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30706092e2343-wk-Fact-3EC8896A5491BBD2B30DF6259D238D4F" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30706092e2363-wk-Fact-A8D138939EBCF140B112F6259D336881" name="us-gaap:TreasuryStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e2384-wk-Fact-F9165D79EC1E6C64E3B3F6259D234449" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2403-wk-Fact-3EECA24243F719A52619F6259D23FAB3" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30706092e2423-wk-Fact-3058F8545746CABEC0F0F6259D239701" name="us-gaap:MinorityInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30706092e2443-wk-Fact-38D6D5B30A7F46F6D3D6F6259D23D1DE" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e2464-wk-Fact-350EF309D1E351668276F6259D33E09A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,948.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2483-wk-Fact-789BB109D69636C33702F6259D33EE1B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30706092e2508-wk-Fact-594895C51C8DF09FCC1EF6259D23FCDB" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26,287.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30706092e2527-wk-Fact-2C79DCC9F95B06BC5A00F6259D3331F9" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,288.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s39665F6B88EC5736A645B3FACA079CF4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e933-wk-Fact-944622E77168D32541A5F6259D237440" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e952-wk-Fact-7EEB6BFCFE93B770E6D9F6259D04B1BB" name="us-gaap:ProfitLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,086.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and impairments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1008-wk-Fact-44F2CBB637ACA0DB4D3CF6259DB287ED" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">238.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1027-wk-Fact-5B23195358E63F5AC46DF6259D7173FA" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">340.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1047-wk-Fact-3E2223D98408E167DC0AF6259D330F8A" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1066-wk-Fact-357E14C70265B206695DF6259D62226E" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1086-wk-Fact-5AC23500DCF648E33B91F6259D1410B4" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">98.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1105-wk-Fact-258877B8B7F079945490F6259DB29E97" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1125-wk-Fact-33C2C3244E3CB3B9F4C0F6259D6216FA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1145-wk-Fact-7BA913E8E376F5770455F6259D81E7AA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on assets and liabilities held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1166-wk-Fact-4F66CF3F0610122535ABF6259DA9C591" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">113.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1185-wk-Fact-259ABC73BAF1F1557583F6259DAE64B5" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1205-wk-Fact-9B02D92D896789AE7A23F6259DAE77CF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1224-wk-Fact-E173F35E90EAD45DAF02F6259DB23B93" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">57.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized (gain) loss on strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1246-wk-Fact-5C13AB8BC4203020B7A2F6259D045AAA" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">199.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1266-wk-Fact-46A52DCF7AB25C49FE96F6259D040FEB" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1286-wk-Fact-811989D69A688E7A6407F6259D8175A3" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">91.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1305-wk-Fact-296BCED595B7BA39A244F6259DA4DB78" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1366-wk-Fact-7E146384C68136E45F3AF6259D8183FD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1386-wk-Fact-A6A4389668A031A9DEE6F6259DB05ACC" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">187.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1407-wk-Fact-CE1D097E01F71D7FD82DF6259DB29814" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">108.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1426-wk-Fact-EC4FBC0BF2E581923EF9F6259DB238CC" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1447-wk-Fact-6A249AC9F95C26024F1FF6259DB285AB" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">216.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1467-wk-Fact-AC07E3A649E3AD4868A2F6259DB2F8B6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1487-wk-Fact-F1137B215B423245CB8EF6259DA384D4" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">306.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1506-wk-Fact-520FBF07A788596EB1AEF6259DB2A879" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">183.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1526-wk-Fact-BA3276F79039815C5E05F6259DB22094" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1546-wk-Fact-48CB8B4CE3E9F2971B87F6259D0410E6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1566-wk-Fact-86E1EB45DC73F053A00AF6259DA43E96" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,423.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1585-wk-Fact-52B28BD40E9C11CEC043F6259DB2DB92" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,556.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1646-wk-Fact-3BBFC6B449A1CFB27923F6259DAB5774" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,255.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1665-wk-Fact-39E9D01E2A183C19B400F6259D913FA2" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,802.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1686-wk-Fact-EACF79C16A71EFF79158F6259DAEF6DE" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,075.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1706-wk-Fact-C5793882513CF1479582F6259D52EC37" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,774.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration paid related to Fumapharm AG acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1727-wk-Fact-0778C9D027D202449F35F6259DB24E6E" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1747-wk-Fact-5AFBE48E196DF0C227E0F6259D523832" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">900.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of Nightstar Therapeutics plc, net of cash acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1768-wk-Fact-3124DF2E8474C4DDDDA9F6259D6238B4" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">744.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1788-wk-Fact-B91AF59A43C03DF66CB2F6259D043D0B" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e1808-wk-Fact-121E1A84E9F0467367EAF6259D816AD2" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">314.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1828-wk-Fact-10AF69C49D7EBF39B2A1F6259D627763" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">381.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1849-wk-Fact-09FF21520A19F5535AE3F6259D04AD1C" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1868-wk-Fact-80BAF6C506039BC98F79F6259D919F93" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1889-wk-Fact-1ABD572F7EED73FBEB85F6259DA347D4" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1908-wk-Fact-E274BA7E39233961CB37F6259D81F917" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase of Ionis Pharmaceuticals, Inc. stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1929-wk-Fact-C90BC86347D9B5F01425F6259DA5CC5A" name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e1948-wk-Fact-72BB12C0C822A6EE1A94F6259DA6D634" name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">462.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales of strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e1969-wk-Fact-945C3371A4119A65749405F142C680F9" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e1988-wk-Fact-FDBC48289BC70FE1902E05F173F62E62" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e2008-wk-Fact-637E7A9F2A4D0DFCD00AF6259DAB4464" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e2028-wk-Fact-2B6A7C1A0FC31F3DFE9BF6259DB030E4" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e2048-wk-Fact-47576E86FA16A18AC25BF6259DB21A7F" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">128.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e2067-wk-Fact-49DCB3AD0A14B1C304C9F6259DB06534" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">198.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e2129-wk-Fact-5A2037D05EAC847D15A1F6259D0404D4" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,057.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e2149-wk-Fact-E87F4500598F8EB6AB6BF6259D23896C" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments related to issuance of stock for share-based compensation arrangements, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e2170-wk-Fact-D412D246F2D934002023F6259D23020D" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e2190-wk-Fact-A2FBD82A2D2B4FBB6D64F6259DB21592" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net distribution to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e2211-wk-Fact-735007638F8E7709E467F6259DB2321E" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e2230-wk-Fact-82BAFA95EAC5943D5002F6259DB2CB5F" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e2251-wk-Fact-62BE1B1A3471FF9FCFB7F6259DA85A87" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e2270-wk-Fact-F872F41B9811711C4AD5F6259D04DFFC" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30702021e2291-wk-Fact-17D683E535BBB8D28B1EF6259D04CDE7" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3,055.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e2311-wk-Fact-2854D5AC587C5401CB51F6259DAECDAB" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3,060.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e2332-wk-Fact-14B539946921102D5E29F6259D233837" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">496.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e2351-wk-Fact-B024C95EAA3A18372E3BF6259CF5D709" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">305.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e2372-wk-Fact-15165C6794E3C601ADF9F6259D042798" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30702021e2391-wk-Fact-3A8EA9C69AFE9C057A21F6259D91872F" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">18.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e2412-wk-Fact-035B89B271A4FAED0085F6259D2336D2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e2431-wk-Fact-D0726CCC9AAABA3300E3F6259D91BF61" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,573.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30702021e2456-wk-Fact-9858208795209B691908F6259D338561" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,723.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702021e2475-wk-Fact-0FD1CD1751C88178034FF6259D81D3DD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,250.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6FCE2BB0567D5735A8772CC606906626"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1333-wk-Fact-8AEDCCCAC6ED998A0425F6259D91E0C8" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1352-wk-Fact-78F2DA90279FE5AEF77BF6259D9134C9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1366-wk-Fact-265FB4D0FD39EAEC50A4F6259D918544" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">219.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1386-wk-Fact-DD36B8FEB979448395C3F6259D919B0A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1405-wk-Fact-EFB4FE2AB6A0B2BA722FF6259DA00828" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1424-wk-Fact-B0978DB39AF808C2D65BF6259DA0F600" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">219.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1445-wk-Fact-4D5D5A4D6043AB35ED69F6259D911CD4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17,026.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1459-wk-Fact-C909C3080446A3A873DFF6259DA2DECE" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1479-wk-Fact-C6B3C96D6C8F09B30415F6259DA08BF6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1500-wk-Fact-AC321684617C5C6FCD7FF6259D9122D0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,829.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1519-wk-Fact-9A889B24918CBE4A4E48F6259D91CF94" name="us-gaap:MinorityInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1539-wk-Fact-FF3E09A0D0D8250F1F30F6259D91B8E2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,822.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1667-wk-Fact-7F48E25C2D8A88FCA302F6259DA02A4A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1722-wk-Fact-1312D56524962A9DE5E6F6259D623531" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1741-wk-Fact-15965186792561F25285F6259D91065F" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e1760-wk-Fact-1AB203907EB0BAB2309FF6259D620105" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1872-wk-Fact-60E2875E670E58B34648F6259DA0FC1C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1949-wk-Fact-B0A137B6EC0E7C27AA1BF6259D047ABC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1969-wk-Fact-BEE672AE00F9F2AE3C72F6259D910904" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e1989-wk-Fact-5B498638056AA3B469E9F6259D913D54" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2179-wk-Fact-3BD82EDF075DD4A1021E05FA313A804E" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;font-weight:bold;"><span><ix:nonFraction id="d30726862e2198-wk-Fact-2C7FA4DD41C18093158605FA809FB587" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2217-wk-Fact-30D9B26F2FFD416774A405FAC04C99E1" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2370-wk-Fact-33837E12B336A596F45AF6259D916CFE" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2385-wk-Fact-671AC3C8104B4141CAB1F6259D91BA19" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2406-wk-Fact-258BF0CCA36E1E97C235F6259D91E17B" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2446-wk-Fact-258BF0CCA36E1E97C235F6259D91E17B" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2503-wk-Fact-D8584EF93273AFD536ACF6259DA08B39" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2519-wk-Fact-BDB790049D071CB3DEDDF6259D91DDE1" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2538-wk-Fact-C17F30AE3FC5E2D999EBF6259D91DCFA" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2579-wk-Fact-6B9123E26962C6F1A0AF05FC1DD72CDA" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">890.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2599-wk-Fact-9457B625ABAE904D395BF6259D918F98" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2613-wk-Fact-4530410A0A50823C465CF6259D91F410" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2633-wk-Fact-D0372D968E38D20CCE25F6259D910B11" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2672-wk-Fact-D0372D968E38D20CCE25F6259D910B11" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2825-wk-Fact-26FA2D5A4D1B057155CEF6259D91F6EE" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2840-wk-Fact-9F1922B19B206E3059C6F6259D91C2F6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2861-wk-Fact-16006BAAB86EE26E0BECF6259D91156A" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2901-wk-Fact-16006BAAB86EE26E0BECF6259D91156A" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2958-wk-Fact-62BBC20D65150980153AF6259D914279" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e2974-wk-Fact-0D9809BED82BCE244F7BF6259D919707" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e2993-wk-Fact-53B32DD32496D3FD1E84F6259D919721" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e3034-wk-Fact-2A20ABAA6C874B4D734CF6259D91D0FA" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,446.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3054-wk-Fact-8E99CA55BE058AD1A460F6259D91F1D0" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3068-wk-Fact-E7563C6B4E8B5FCF73F8F6259D916948" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3088-wk-Fact-77DB4CFA8ADC0DA2FFCEF6259DA03798" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3127-wk-Fact-77DB4CFA8ADC0DA2FFCEF6259DA03798" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3183-wk-Fact-36A781025B181E50B300F6259D919393" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3198-wk-Fact-B74429AA331254E22DACF6259DA03625" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3217-wk-Fact-70798AA0741D3D9C4F07F6259D910C6A" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3313-wk-Fact-F88BFEDCDEE87A8551C7F6259D9108D3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3352-wk-Fact-F88BFEDCDEE87A8551C7F6259D9108D3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3409-wk-Fact-34F440E9427A9F98FF41F6259D919863" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3424-wk-Fact-9B9CE0D646325EC4B44DF6259D91B958" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3443-wk-Fact-05D872447A9C48EB2CE6F6259D9160F2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e3483-wk-Fact-E8760DB2AC2CE296CE40F6259D914506" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e3539-wk-Fact-5D236078B2DDFD54AF04F6259D91A035" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e3579-wk-Fact-5D236078B2DDFD54AF04F6259D91A035" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3672-wk-Fact-304D893FCCE6CF6D8262F6259DA06F21" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3768-wk-Fact-2F9B9B9362F6591CA2CAF6259D91EEEC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3807-wk-Fact-2F9B9B9362F6591CA2CAF6259D91EEEC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3828-wk-Fact-86DA1107A93832F987E2F6259D91BE79" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3847-wk-Fact-FD82CFB218471BBFD5C0F6259D914AAB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3861-wk-Fact-828169BA47450A2D9681F6259D91B99D" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">208.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3881-wk-Fact-6A6CFF7A1707929F1941F6259D913D01" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3900-wk-Fact-0B5F9B4AA79527B0AED1F6259D910349" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e3919-wk-Fact-A4ACCC09EDDEEBB0C677F6259D91303D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3940-wk-Fact-6C624D4E4D288826896BF6259DA04799" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e3954-wk-Fact-2DAF3EC225BA959E096AF6259D910E5F" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e3974-wk-Fact-2543C14234EA7EE57EDAF6259D91596B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e3995-wk-Fact-F9165D79EC1E6C64E3B3F6259D234449" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e4014-wk-Fact-38105AE509650C0560E9F6259D91B450" name="us-gaap:MinorityInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4034-wk-Fact-350EF309D1E351668276F6259D33E09A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,948.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4620-wk-Fact-4F73C12BCF81417956A0F6259D04CD5F" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4639-wk-Fact-16E958E401A81F41BE8AF6259D04582C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4653-wk-Fact-D2DC72858D2341D80CC5F6259DB2C09B" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">221.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4673-wk-Fact-B606DED3B831B788F98DF6259D04A779" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4692-wk-Fact-60B278C7EF7D83481573F6259D04234E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e4711-wk-Fact-6AB9425D8D9CEA3D5737F6259DAEE5F8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4732-wk-Fact-F47816D5E6E302778F0FF6259DB20E2F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e4746-wk-Fact-D5C61DB273185395656BF6259D041931" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e4766-wk-Fact-F6CDF1A85E7E49C5B348F6259CF56267" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4787-wk-Fact-3EECA24243F719A52619F6259D23FAB3" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e4806-wk-Fact-FEADC5B9A888AB7F69AEF6259DB284C3" name="us-gaap:MinorityInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4826-wk-Fact-789BB109D69636C33702F6259D33EE1B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e4954-wk-Fact-90A05C6538A4EBE89B5BF6259CF55F19" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5009-wk-Fact-4C12FF47E79C07429E22F6259D717E32" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5028-wk-Fact-9C79FAACF13B1A1BB808F6259DB2DDDB" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5047-wk-Fact-944622E77168D32541A5F6259D237440" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5159-wk-Fact-82649A38A45C5B1921D2F6259DB298DB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5236-wk-Fact-6440C377A189830524FFF6259D141ACB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5256-wk-Fact-B78E974EB37E5FCD876AF6259D04D247" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5276-wk-Fact-D699D6494F09F608A74FF6259DB287FC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5466-wk-Fact-12B2FBB381D51EB6498DF6259DB12CD8" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5485-wk-Fact-45C654E443D1A330F8AFF6259D04437C" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5504-wk-Fact-E3DF2615133ABD39B57F06024488F56A" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5657-wk-Fact-8A681E458F6A1AF132D5F6259DAF6858" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5672-wk-Fact-DF9990FF76891556F1C6F6259D042EE6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5693-wk-Fact-C542395F43978DB06702F6259CF503F8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5733-wk-Fact-C542395F43978DB06702F6259CF503F8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2019 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5790-wk-Fact-32BD861548B4F7CE440CF6259DAD804F" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5806-wk-Fact-D0979F1DB23FB7AFECA3F6259DAE1FA1" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5825-wk-Fact-53F2DD622C86C229690F060317721034" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e5866-wk-Fact-E39D79CB47C390ED59F50603535B0B88" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">890.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5886-wk-Fact-DAE9CD94DC695670A17FF6259D04D8D0" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5900-wk-Fact-C6752FFBCE4685F604C6F6259D049D76" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5920-wk-Fact-3F052CD7E127577DE279F6259DADCA5C" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e5959-wk-Fact-3F052CD7E127577DE279F6259DADCA5C" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6112-wk-Fact-3193AECB8B5BB6AA0578F6259D047E6C" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6127-wk-Fact-EE6C74FD144058E4D7CAF6259DAE3F5F" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6148-wk-Fact-04DA92EA014F41249E7CF6259DB29883" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6188-wk-Fact-04DA92EA014F41249E7CF6259DB29883" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6245-wk-Fact-C67A5272D8EAFE0719DFF6259CF546B7" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6261-wk-Fact-BEE66AC2B2F2F5FA9011F6259D044D00" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6280-wk-Fact-946FE61C9F1F02B1349AF6259DB0003D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6321-wk-Fact-B39896C99FB9806DBD00F6259D04ECEC" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,036.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6341-wk-Fact-6BA2BA8DCC5845717A64F6259DB23619" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6355-wk-Fact-E30819332005F239E569F6259D04ADED" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6375-wk-Fact-8090F551CB6E2BB85698F6259DAFAECA" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6414-wk-Fact-8090F551CB6E2BB85698F6259DAFAECA" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6470-wk-Fact-3D1C5C0B12B057F212E9F6259DAB0559" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6485-wk-Fact-7B416A67A0D15C554311F6259DB22D06" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6504-wk-Fact-F17453F573794EB13BB6F6259DAE1375" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6600-wk-Fact-748BE9C1C9997A79115EF6259DAAC81F" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6639-wk-Fact-748BE9C1C9997A79115EF6259DAAC81F" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6696-wk-Fact-07DEE5AED5C9F639D574F6259DB2783E" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6711-wk-Fact-BCDACC46965B6FE2CC13F6259D04DE00" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6730-wk-Fact-7C14DC0D51A06CC91613F6259DAF7DE0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6770-wk-Fact-8388E739A34C48D4EEECF6259D0478EC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6826-wk-Fact-3DB85A03F32772D893BAF6259DB2DD0A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e6866-wk-Fact-3DB85A03F32772D893BAF6259DB2DD0A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e6959-wk-Fact-3B2B855F590FA03FA5A1F6259DB21104" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">104.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7055-wk-Fact-5F8098A6D71AA9DED587F6259DB2FF18" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">104.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7094-wk-Fact-5F8098A6D71AA9DED587F6259DB2FF18" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">104.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7115-wk-Fact-86DA1107A93832F987E2F6259D91BE79" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7134-wk-Fact-FD82CFB218471BBFD5C0F6259D914AAB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7148-wk-Fact-828169BA47450A2D9681F6259D91B99D" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">208.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7168-wk-Fact-6A6CFF7A1707929F1941F6259D913D01" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7187-wk-Fact-0B5F9B4AA79527B0AED1F6259D910349" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e7206-wk-Fact-A4ACCC09EDDEEBB0C677F6259D91303D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7227-wk-Fact-6C624D4E4D288826896BF6259DA04799" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e7241-wk-Fact-2DAF3EC225BA959E096AF6259D910E5F" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e7261-wk-Fact-2543C14234EA7EE57EDAF6259D91596B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7282-wk-Fact-F9165D79EC1E6C64E3B3F6259D234449" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d30726862e7301-wk-Fact-38105AE509650C0560E9F6259D91B450" name="us-gaap:MinorityInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;"><span><ix:nonFraction id="d30726862e7321-wk-Fact-350EF309D1E351668276F6259D33E09A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,948.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.85549132947978%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e7906-wk-Fact-469F14039ECAA58477E1F6259D14413F" name="us-gaap:SharesIssued" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e7925-wk-Fact-DDB6D05DD80A5F1927EAF6259D148C84" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e7939-wk-Fact-24A2922441497D423306F6259D14EB77" name="us-gaap:SharesIssued" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">211.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e7959-wk-Fact-75207C351D5DBDCC1AC6F6259D33B796" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e7978-wk-Fact-BAF3FA97D242C14EFB6AF6259D33886C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e7997-wk-Fact-3AC2CA216EB0291D010AF6259D1496EC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">303.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8018-wk-Fact-C0D46F05CFC091A6CB92F6259D14C913" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17,334.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e8032-wk-Fact-43DCF260367B061C4193F6259D14618B" name="us-gaap:SharesIssued" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e8052-wk-Fact-D81D2A005CC591DC4D88F6259D1498B9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8073-wk-Fact-DD4E5BD66E506EFCF2D7F6259D041496" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,053.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e8092-wk-Fact-139E1B5F311AB72C4B63F6259D143FEF" name="us-gaap:MinorityInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8112-wk-Fact-159F678EBC9216DEC44DF6259D14FACD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,037.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8240-wk-Fact-15DA6E605A3687B29F4AF6259D14E0A1" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">866.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8295-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">866.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8314-wk-Fact-C082D9D953E004F72AB9F6259D049E24" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8333-wk-Fact-D31F8D4E9B3B5AE9DA2CF6259D234447" name="us-gaap:ProfitLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">915.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8445-wk-Fact-C7FB7A24FAD6C1C6B012F6259D04047E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8521-wk-Fact-DF0CD48B7311719F5538F6259D6235D2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e8540-wk-Fact-AF6D7C0E8BB4EDABCFD8F6259D338042" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8560-wk-Fact-343A034419566D2C42F1F6259D145B37" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8749-wk-Fact-5A4B611500FBF05A440BF6259D14AC3C" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8768-wk-Fact-5DAB3175E22DBA3D7F6BF6259D14C722" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8787-wk-Fact-B82FA5FBE0FEACE69B8CF6259D140E64" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e8976-wk-Fact-A3821D1499AA1624EC9EF6259D33686D" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e8995-wk-Fact-7EDE810494586A885D6EF6259D331DE8" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9015-wk-Fact-815ABD218F4EC9F5CC95F6259D14479F" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9169-wk-Fact-A74DED1771EBF88F3407F6259D33BF59" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9184-wk-Fact-3EFADEE5717D1CE08590F6259D14A9FE" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9205-wk-Fact-8681B68B25387CAA73EEF6259D041211" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9245-wk-Fact-8681B68B25387CAA73EEF6259D041211" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9302-wk-Fact-70E425B827F22FEE7FB7F6259D14047B" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9318-wk-Fact-D135EC83C3D3DAF446AEF6259D140D3A" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9337-wk-Fact-2228ADF4B8BFBBD7E005F6259D14E757" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9378-wk-Fact-3F90D06FAA36269AEC8AF6259D14ED72" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,701.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9398-wk-Fact-FE6AA58A3AEDB58D5B4FF6259D14BCBF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9412-wk-Fact-CDC7E6ED7AE18E26C91CF6259D141F25" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9432-wk-Fact-57B2973BC7249266C5FAF6259D147B1C" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9471-wk-Fact-57B2973BC7249266C5FAF6259D147B1C" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9527-wk-Fact-1311F4C831EABF673484F6259D04668D" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9542-wk-Fact-74191E6483010B2F6048F6259D1400C2" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9561-wk-Fact-99EA8C3DD7459D6DCA91F6259D14FD46" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9657-wk-Fact-E91BC9D403E44A4F8696F6259D045585" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9696-wk-Fact-E91BC9D403E44A4F8696F6259D045585" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9752-wk-Fact-AAD20B47A23762B26A96F6259D044CF6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e9767-wk-Fact-ED3FEF56915E66B8D663F6259D04ED22" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9786-wk-Fact-B95326CA180F617BB6E7F6259D330DD1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9883-wk-Fact-1B5A25A8815C45D29B38F6259D04D375" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e9923-wk-Fact-1B5A25A8815C45D29B38F6259D04D375" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10017-wk-Fact-36F280EAF4AF8E610633F6259D33A275" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10113-wk-Fact-42A3012150808C3F39DEF6259D338233" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10152-wk-Fact-42A3012150808C3F39DEF6259D338233" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10173-wk-Fact-7E4AFAF29A6A13E19429F6259D23E69E" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10192-wk-Fact-BDD8095E4C25819E96C8F6259D62EC21" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10206-wk-Fact-77D4C7AA68C9FCD18E55F6259D621573" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10226-wk-Fact-7A39446017330B28FC40F6259D23881C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10245-wk-Fact-22BD166B27DE4C5889DFF6259D23EC21" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e10264-wk-Fact-1DA142A0CEE1EF433869F6259D239641" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">261.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10285-wk-Fact-6C7CE6CC1C5D4B37EC7FF6259D23D3D1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,499.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e10299-wk-Fact-75A37E368FA1706A9E02F6259D33F79D" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e10319-wk-Fact-44FC93C019D1025E17E7F6259D2332E1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10340-wk-Fact-6356A98F4EFF910483A3F6259D711129" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,260.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e10359-wk-Fact-D516332F4A10A5B32C86F6259D33F9C9" name="us-gaap:MinorityInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10379-wk-Fact-747D31A616D2468659E0F6259D334920" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,253.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.71098265895954%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10961-wk-Fact-A7A04EBA72156A666193F6259D23DA89" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10980-wk-Fact-E9620FAFC318B07009E8F6259D432BA0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e10994-wk-Fact-5CF3D755765F9CAFD380F6259D2364FE" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">211.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11014-wk-Fact-5442AD5444B1616E79F0F6259D231562" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11033-wk-Fact-1B0A29BE65ECA39CB03FF6259D3363C1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e11052-wk-Fact-9522A1ABDB21458FDCF0F6259D7148DD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11073-wk-Fact-DE382E793ECA727E3D63F6259D710E30" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,810.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e11087-wk-Fact-0C1A3B125CBA5D77D179F6259D6204ED" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e11107-wk-Fact-A1426A742491D326361DF6259D33B325" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11128-wk-Fact-E27E94BBB0312023C81FF6259D234635" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,612.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e11147-wk-Fact-4ADD76E2EEC9FAE436EBF6259D62412E" name="us-gaap:MinorityInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11167-wk-Fact-FD437C5C3CF17E129331F6259D33A7C4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,598.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11295-wk-Fact-6FC514C6BCCC38D75A12F6259D330D99" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,039.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11350-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,039.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11369-wk-Fact-8A71D408127E2980EC5FF6259D2310CD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11388-wk-Fact-7EEB6BFCFE93B770E6D9F6259D04B1BB" name="us-gaap:ProfitLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,086.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11500-wk-Fact-35CE8F4B84A326B668F1F6259D71A480" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11576-wk-Fact-53C30F8A2D37A0D5D15EF6259D14796F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e11595-wk-Fact-1A4B4B1D5651FEEBE677F6259D43E994" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11615-wk-Fact-992826AEE2E0FDF5FF64F6259D626D71" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11804-wk-Fact-BFCD0FA3E624B63D05BBF6259D621426" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11823-wk-Fact-4AE50635D050D932282EF6259D620345" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e11842-wk-Fact-4BE2BA7048BEBC870C64F6259D235341" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12031-wk-Fact-AAADB3CCE69022E94741F6259D6265AB" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12050-wk-Fact-E5D9A242A5B77C1AF2D7F6259D23F251" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12070-wk-Fact-AD38E45116455405AD85F6259D6234F8" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12224-wk-Fact-CD765C5CA3AF84E508DCF6259D23CDEC" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12239-wk-Fact-67B2AEBB6D23F1FC7C44F6259D33382A" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12260-wk-Fact-8E5E9C50951166E93477F6259D6277D3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12300-wk-Fact-8E5E9C50951166E93477F6259D6277D3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12357-wk-Fact-6E3F446653CD7AE7FB00F6259D231BB2" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12373-wk-Fact-70CF889F9489D3B48DE3F6259D23D344" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12392-wk-Fact-62C0DAFD7C9C9E14F8D1F6259D337DD6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">171.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12433-wk-Fact-9875D57954B191E8CD39F6259D23CD57" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,828.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12453-wk-Fact-4EFEBF9D880145C225F0F6259D23685E" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12467-wk-Fact-3233CBAA1466C0144100F6259D3381A9" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,000.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12487-wk-Fact-AFC9E6982476E9F92D6DF6259D23566B" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12526-wk-Fact-AFC9E6982476E9F92D6DF6259D23566B" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12582-wk-Fact-C8A2946CF0E49E9EDC48F6259D6274CD" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12597-wk-Fact-8AE10BE6F4518152FDA8F6259D23BE68" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12616-wk-Fact-14A3235CD76CC4AC35C8F6259D621BB0" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12712-wk-Fact-F4CF71B29FD49F9ED47BF6259D23D5C5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12751-wk-Fact-F4CF71B29FD49F9ED47BF6259D23D5C5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12807-wk-Fact-222072075FA43AF83FA5F6259D33D0C3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e12822-wk-Fact-90A4AD348B3A53348FBDF6259D626F42" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12841-wk-Fact-7E5224FB116200B997A7F6259D23F997" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12938-wk-Fact-82D5B3A8D98390E7AE2BF6259D71454A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e12978-wk-Fact-82D5B3A8D98390E7AE2BF6259D71454A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13072-wk-Fact-398CD92BDDF1BE089C1FF6259D62A2A9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13168-wk-Fact-199309FCE7E06B5F33D8F6259D622E7F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13207-wk-Fact-199309FCE7E06B5F33D8F6259D622E7F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Adoption of new accounting guidance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13319-wk-Fact-81C5C6B23E1F4963B8F5F6259D330DCA" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13339-wk-Fact-16AB48D237D4C4FF50BDF6259D23358C" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">478.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13394-wk-Fact-FD3FFB85487DB5E0E5AEF6259D814863" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">479.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13433-wk-Fact-FD3FFB85487DB5E0E5AEF6259D814863" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">479.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13454-wk-Fact-7E4AFAF29A6A13E19429F6259D23E69E" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13473-wk-Fact-BDD8095E4C25819E96C8F6259D62EC21" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13487-wk-Fact-77D4C7AA68C9FCD18E55F6259D621573" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">201.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13507-wk-Fact-7A39446017330B28FC40F6259D23881C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13526-wk-Fact-22BD166B27DE4C5889DFF6259D23EC21" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e13545-wk-Fact-1DA142A0CEE1EF433869F6259D239641" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">261.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13566-wk-Fact-6C7CE6CC1C5D4B37EC7FF6259D23D3D1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,499.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e13580-wk-Fact-75A37E368FA1706A9E02F6259D33F79D" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e13600-wk-Fact-44FC93C019D1025E17E7F6259D2332E1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13621-wk-Fact-6356A98F4EFF910483A3F6259D711129" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,260.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30726862e13640-wk-Fact-D516332F4A10A5B32C86F6259D33F9C9" name="us-gaap:MinorityInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30726862e13660-wk-Fact-747D31A616D2468659E0F6259D334920" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,253.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><a id="s004DACDB857F5FD18D6DEDB4B841E237"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</span></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><a id="sA5EE167161955359BAE0EDE0BF0A0FC2"></a></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-0-wk-Fact-5795A675490FD26B96AEF6259D810B9B" continuedAt="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-1" continuedAt="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-2"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:BusinessOverviewPolicyTextBlock" id="TextSelection-083878DC3CF1AF1726CBF6259DC298D4-0-wk-Fact-6022472C73F4EA28C56DF6259D81CE5A" continuedAt="TextSelection-083878DC3CF1AF1726CBF6259DC298D4-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-083878DC3CF1AF1726CBF6259DC298D4-1"></ix:continuation>Basis of Presentation</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-0D1F7E4DFE911849DC7AF6259DC247CB-0-wk-Fact-A2825F6364A8C5C7DA49F6259D81792C" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702019e881-wk-Fact-5C318F41468C42C49296F6259D81CEB8" name="us-gaap:NumberOfReportableSegments" contextRef="FD2019Q2YTD" unitRef="segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-2" continuedAt="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-3"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-325A95F190583038761AF6259DC25987-0-wk-Fact-B9C2A4AD2A2A2CFB94CAF6259D91195A" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30702019e905-wk-Fact-384EAE8AFCD3050BB9AFF6259D818C53" name="biib:InterestInSubsidiary" contextRef="FD2019Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:UseOfEstimates" id="TextSelection-C8081AC41C2C157AFAAFF6259DC21F7D-0-wk-Fact-758CA885EC43D4A73A33F6259D81CA89" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock" id="TextSelection-859C317D0F3023AB73DAF6259DC24581-0-wk-Fact-B88BCD9633B7E29ED463F6259D811D8D" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-6CB55BDFD20724ED6839F6259DC295EE-0-wk-Fact-0503B7805CB00E0AE59CF6259D81DAD7" continuedAt="TextSelection-6CB55BDFD20724ED6839F6259DC295EE-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-6CB55BDFD20724ED6839F6259DC295EE-1" continuedAt="TextSelection-6CB55BDFD20724ED6839F6259DC295EE-2"><ix:continuation id="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-3" continuedAt="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-4"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30702019e1023-wk-Fact-C559458B0AE3EA029A42F6259D81ADBC" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">463.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30702019e1027-wk-Fact-E4E44AA717202EBE7AFCF6259D81C14E" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">526.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-6CB55BDFD20724ED6839F6259DC295EE-2"><ix:continuation id="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-4"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC5B87D1F9CC057388590A945B1DFAAB7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-BFB6947E29C1388D4C07F6259DC26D2F-0-wk-Fact-93A728AA12924A07E0F3F6259D81BEF7" continuedAt="TextSelection-BFB6947E29C1388D4C07F6259DC26D2F-1" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BFB6947E29C1388D4C07F6259DC26D2F-1" continuedAt="TextSelection-BFB6947E29C1388D4C07F6259DC26D2F-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no approved treatments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e787-wk-Fact-15D8B185F4558A73008BF6259D81099E" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e791-wk-Fact-F46BDA50B9BDDDB80675F6259D8156FF" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">847.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e795-wk-Fact-1A5F6B0102BDD4C2ABB60636F077DE69" name="us-gaap:OtherPaymentsToAcquireBusinesses" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is  attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e799-wk-Fact-C0201D93BDBADF80404A063B637B73C9" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e803-wk-Fact-346FB69BEC327DF67093063C1F48987D" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e808-wk-Fact-6EF9E2940AF1E8B32EA5063CCD0AA244" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-E1273B518436295D0407F6259DC2432D-0-wk-Fact-E1E7D0A0025A349A6A2AF6259D813834" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30700581e863-wk-Fact-CEF22BC1B1C39D57B6F2063DD613FDBD" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30700581e878-wk-Fact-A98656F318698D0F5F8A063DD6209074" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30700581e898-wk-Fact-882BC58AAE3F5F88E247063DD62A09C3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30700581e918-wk-Fact-81CF457602F010BC4D59063DD61C2F08" name="us-gaap:Goodwill" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30700581e938-wk-Fact-0FA964BD34D415FC3E22063DD6252E56" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30700581e959-wk-Fact-4CEBE1935541B2FC5EB1063DD6178F59" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30700581e984-wk-Fact-1A9DA871CE7E13DA12DFF6259D2371EF" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">852.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the in-process research and development (IPR&amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30700581e996-wk-Fact-8F1A586ED010B46BD75F065A9584D9D1" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">12.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e1000-wk-Fact-1B9D5CFA253798631949065F0ADA7A20" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">480.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e1004-wk-Fact-6FBB55B9968AE3D79F810660C3496502" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30700581e1011-wk-Fact-4E6FA7A7BE37DBEBB4A006623ADEA639" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management&#8217;s analysis related to certain matters, such </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-BFB6947E29C1388D4C07F6259DC26D2F-2"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">as finalizing our assessment of the IPR&amp;D programs acquired and preparing and submitting certain income tax and non-income tax filings and returns. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our financial position.</span></div></ix:continuation><div><a id="s12492FC12EE6517987E31BB6872C092D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="TextSelection-ACE05C47ED409D91D735F6259DC2CF00-0-wk-Fact-046F4F53520CAC49EAB7F6259D818494" continuedAt="TextSelection-ACE05C47ED409D91D735F6259DC2CF00-1" escape="true">Divestitures</ix:nonNumeric></span></div><ix:continuation id="TextSelection-ACE05C47ED409D91D735F6259DC2CF00-1" continuedAt="TextSelection-ACE05C47ED409D91D735F6259DC2CF00-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e783-wk-Fact-46EFC128053751FC2172F6259D43F6DF" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">890.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e790-wk-Fact-752E4E0ED4666ED74E00F6259D2395B2" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock" id="TextSelection-0FA3340258B557DC3A85F6259DC20842-0-wk-Fact-1612E5B7ED45276DC0FAF6259D81B2B1" continuedAt="TextSelection-0FA3340258B557DC3A85F6259DC20842-1" escape="true">The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0FA3340258B557DC3A85F6259DC20842-1"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e877-wk-Fact-772C51D00284A1513CB1F6259D23E93B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" contextRef="FI2019Q2_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e892-wk-Fact-9CC2BD390BD3FCDC0482F6259D33BD90" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">641.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e912-wk-Fact-68222E790FDC7DC9CFFAF6259D23A1D0" name="biib:DisposalGroupOperatingLeaseAssets" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e932-wk-Fact-5BC5E181CF6FC316A83AF6259D2318A3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e952-wk-Fact-1D39CC68F771EC8D6C45F6259D238BAE" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance on disposal group on assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30711147e972-wk-Fact-EE29E49B328C5B31F85DF6259D522627" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">113.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e998-wk-Fact-D755FA7DE530909918EEF6259D237867" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">683.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e1061-wk-Fact-DC6D9DEC35981EDE395EF6259D334000" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e1076-wk-Fact-DDDB96CD794214BD65D9F6259D23A37D" name="biib:DisposalGroupOperatingleaseliabilities" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e1096-wk-Fact-8E042DF4EA4562866591F6259D23FE2B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30711147e1121-wk-Fact-EFE6EC19270F9E01911FF6259D235ACC" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-ACE05C47ED409D91D735F6259DC2CF00-2"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e1142-wk-Fact-90085B380DEE5DDFD8F2F6259D52C3AB" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e1146-wk-Fact-EE29E49B328C5B31F85DF6259D522627" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">113.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e1150-wk-Fact-538E11EDC3F7D473FD3A0669832E0024" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease to our original estimate as of March 31, 2019, reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e1155-wk-Fact-7F019D09C65D9FDF9B20F6259D52CEF9" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e1159-wk-Fact-752E4E0ED4666ED74E00F6259D2395B2" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30711147e1163-wk-Fact-136D8A2DB49CECD79C24F6259D52E80E" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse commitment, as discussed above.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proposed transaction remains subject to certain closing conditions. We expect to complete the proposed transaction in the third quarter of 2019. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="s96658E2EA672556D94E748EEAD7AE535"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-0-wk-Fact-7749EC42B44D80928B06F6259D81A5B1" continuedAt="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-1" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-1" continuedAt="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-57E12AA4AD8789AEA4C9F6259DC218A8-0-wk-Fact-C7163F13C8B95BFE1B6AF6259DA2098E" continuedAt="TextSelection-57E12AA4AD8789AEA4C9F6259DC218A8-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1341-wk-Fact-81FB72216292E686B55BF6259D7188DE" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">869.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1360-wk-Fact-E9AC7D38A07AEB01ECD5F6259D14322E" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">280.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1379-wk-Fact-91AEF89F21871044B72DF6259D14ECEA" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,150.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1399-wk-Fact-4EEB4BF2CE7931ECBCBEF6259D71ECEC" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">825.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1418-wk-Fact-47B2D795B2C5A1B633D2F6259D140FDF" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1438-wk-Fact-9A8FC1978340B2686226F6259D14513B" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,086.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1453-wk-Fact-8CCC75F6B0781326B29EF6259D14E6A2" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">379.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1472-wk-Fact-09EBD3182193F0373811F6259D14C775" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1491-wk-Fact-B7E57EA2387C8E03A328F6259D717901" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">554.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1511-wk-Fact-A4F925BAF89757FEF4EFF6259D14F5F1" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">444.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1530-wk-Fact-56C778E4CE9B44FB5C71F6259D14D009" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">180.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1549-wk-Fact-8E443015FBDD69A55EA1F6259D7113D9" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">625.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1570-wk-Fact-7872D4D74FBE82183CEEF6259D14D7D2" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">264.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1589-wk-Fact-79AE164ED87A54F2A62DF6259D1497AE" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">211.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1608-wk-Fact-4D2E74D0B2798EC5338AF6259D711CF0" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">475.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1628-wk-Fact-52E2E8050F02935A4582F6259D14CEC3" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">265.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1647-wk-Fact-5E98303451FB860FCAE6F6259D71A66B" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">201.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1666-wk-Fact-EEDA61B06196E7928A15F6259D14F2FC" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">467.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1687-wk-Fact-8B1A46E99A63E080B1E1F6259D14D762" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1706-wk-Fact-C064B5575B953EC03631F6259D71FF8A" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1725-wk-Fact-90C6D03D78FB16AD4508F6259D146864" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1745-wk-Fact-146D5C873CF04D08CB09F6259D1497DC" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1764-wk-Fact-F88D5F9F05E7BFB253EEF6259D1429AD" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1783-wk-Fact-1F68043F220B63D3B2F6F6259D145AED" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1804-wk-Fact-D2C93812953C70ADCC5CF6259D14B856" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,513.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1823-wk-Fact-FF2FA97FDBE842FE16CCF6259D147644" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">690.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e1842-wk-Fact-45DC92DA922C409480ECF6259D148382" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,204.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1862-wk-Fact-B16B983B90DD0814312DF6259D148C01" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,536.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1881-wk-Fact-6F5EA0FF7D7ED3EEFD7DF6259D14541C" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">666.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e1900-wk-Fact-DAFFB41F902E483857D1F6259D711323" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,202.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2166-wk-Fact-DFA8A651C72D9A6B942CF6259D1418DD" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2185-wk-Fact-E94F520DF0D826D86EC5F6259D14EBE8" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">257.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2204-wk-Fact-AE73E333F705A05D8817F6259D147947" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">488.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2224-wk-Fact-8496B14BC426126A12CEF6259D14E6D8" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">205.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2243-wk-Fact-9C09BD7064A8577961E6F6259D1480F7" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">216.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2262-wk-Fact-D65F0235CE05D09F2A7EF6259D147B33" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">422.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2527-wk-Fact-FA8A2BAE4A974F96BDDFF6259D146BEF" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2546-wk-Fact-5FC5B516950978F4178CF6259D141313" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2565-wk-Fact-08847A66A01F50B11866F6259D14870E" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2585-wk-Fact-2048B48A179DAE44BB6CF6259D146ACD" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2604-wk-Fact-3B64D4289E65ABB45D76F6259D712FC7" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2623-wk-Fact-155481EC85308175F3AAF6259D1415D3" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2644-wk-Fact-31B94762E4F7B79483EDF6259D71A7D2" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2663-wk-Fact-C162F4A1E7044F1626D9F6259D149CB0" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2682-wk-Fact-87EBD07876C82386EAD6066D37F9A91A" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2702-wk-Fact-A82A09F05AC42E0A3FEDF6259D14919E" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2721-wk-Fact-8E17015DD7FC21CD30B7F6259D1412C1" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2740-wk-Fact-F459D01B7380E2C04184066DA807B079" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2761-wk-Fact-2FD644B3F3B51B3908D9F6259D143EAA" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2780-wk-Fact-30386F0630EAF2D73028F6259D71DCF3" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2799-wk-Fact-53973CF3E5D2A278A7DBF6259D144F64" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2819-wk-Fact-9274106D7011C9854AA1F6259D148616" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2838-wk-Fact-2A718D30B914A6602288F6259D1435BC" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2857-wk-Fact-20503103CFFAD67C6160F6259D714A88" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2878-wk-Fact-07E1A5970172AEAE6D58F6259D14CCF0" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2897-wk-Fact-59BDF5967BFBA8373037F6259D71D542" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e2916-wk-Fact-2F03D5C2C308CC6A4245F6259D14514E" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2936-wk-Fact-8ADF700AF36D092D5F4DF6259D141187" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2955-wk-Fact-B811B5F8E7796A46E4D2F6259D144DE4" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e2974-wk-Fact-55261E1123EFF447F567F6259D140B33" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e3241-wk-Fact-9BF1FBEF7231A3A83767F6259D14DC9E" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e3260-wk-Fact-DCB378AA7B9AE57BF4CAF6259D14F296" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e3279-wk-Fact-081CEAA76EE94875CB83F6259D14A29B" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e3299-wk-Fact-E39BAE16523827156DE2F6259D71944C" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e3318-wk-Fact-EFDD0C40706B00508522F6259D14003A" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e3337-wk-Fact-418C55BF288D562036B3F6259D1474AF" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e3363-wk-Fact-6499A5A1F645D47C9A67F6259D71B5B1" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,744.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e3382-wk-Fact-4C9FF429CDEFF01B635EF6259D140569" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,135.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e3401-wk-Fact-C3F1908781ECB2F108F9F6259D62D489" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,880.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e3421-wk-Fact-AF41D42B035080F44111F6259D14CB18" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,741.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e3440-wk-Fact-C319A772368453B5E72CF6259D146BBB" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,015.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e3460-wk-Fact-2B45585D36E41B2DB864F6259D23ADFD" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,757.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-2" continuedAt="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-3"><ix:continuation id="TextSelection-57E12AA4AD8789AEA4C9F6259DC218A8-1"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4019-wk-Fact-47C77708B856C496FA90F6259DAFA4C6" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,587.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4038-wk-Fact-2B53AFFC8D3C33F1CBA3F6259D047F6D" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">561.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4057-wk-Fact-45F612077F5A8F11AB66F6259D04E4A9" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,149.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4077-wk-Fact-8A68743F9EADC51C9565F6259D0459C0" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,554.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4096-wk-Fact-AEC1505CF4AA2D7F20EFF6259DB223FB" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">519.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4116-wk-Fact-AFF4EBDCC82A5BC29008F6259D042831" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,073.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4131-wk-Fact-8A2A78DB7A9EA91C741DF6259DB01152" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">707.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4150-wk-Fact-98E74DB402BAA220E6C8F6259D040101" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">348.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4169-wk-Fact-AD0AA839E32A5FB88E35F6259D0487AD" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,055.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4189-wk-Fact-30CAAAC724A6E1F86C78F6259DB20083" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">816.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4208-wk-Fact-7EF5C05B56145C2AC449F6259D04208D" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">359.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4227-wk-Fact-BB304E20F0087B52AAEFF6259CF54804" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,175.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4248-wk-Fact-D0FA133AA1CFD639A6FAF6259D042C19" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">509.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4267-wk-Fact-FC3A827BEE59E6253160F6259D047347" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">426.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4286-wk-Fact-BBD5E1AF4D8EE02F98A2F6259D04C923" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">935.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4306-wk-Fact-3AB212B870B2ED659BD9F6259CF5D1F1" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">515.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4325-wk-Fact-4E55158B65F38CF178E0F6259D04F657" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">414.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4344-wk-Fact-4B76965910CF9CA9B2BBF6259D0486F5" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">929.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4365-wk-Fact-D8018242BEABA2F8A3D4F6259DB23F91" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4384-wk-Fact-9E14C1F194C71A40E0FEF6259DB12078" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4403-wk-Fact-15359F4F50A35787B53DF6259D04F6FC" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4423-wk-Fact-559AB257F0859FE98E1CF6259D04A06D" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4442-wk-Fact-6F942811F6E0CF93EE71F6259D04BF07" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4461-wk-Fact-989D4DE74F68BD370D23F6259D045DC8" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4482-wk-Fact-250A0DE76B823D622E60F6259DB2D26E" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4501-wk-Fact-31B61DA8DFB21D29C453F6259DB2ABC6" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4520-wk-Fact-8348FB26B4F7C30C57D2F6259DB2405C" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4540-wk-Fact-018D5D2F82E77ECE6EBFF6259D04DA74" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4559-wk-Fact-F7F95C1D865685DDFA93F6259D047E35" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4578-wk-Fact-29524DB7113B14E2AA87F6259D045330" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4599-wk-Fact-142F6EAA2D143FEE0439F6259DB204EE" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,803.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4618-wk-Fact-51CC373CE64B8E7A760AF6259D04FE41" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,383.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4637-wk-Fact-7B163BA5F835D720F26FF6259D049210" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,187.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4657-wk-Fact-71D40CF366898DC6A671F6259CF56076" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,885.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4676-wk-Fact-C9AA8FE4DD4D40E4C151F6259D0430C3" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,341.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e4695-wk-Fact-820DFD41FB565DA6E5D1F6259DB24EDD" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,227.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4963-wk-Fact-4CB6B7669741D8791157F6259D04115A" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">453.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e4982-wk-Fact-7B66565BD011BAB22F85F6259D041064" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">552.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5001-wk-Fact-50F237B84AC227EDFD62F6259DB25FE1" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,006.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5021-wk-Fact-77D266FFC916C5E4DA59F6259D04D0BB" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">393.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5040-wk-Fact-E79C8FAA6D876455197CF6259D04F664" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">392.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5059-wk-Fact-7C6FFE07A275B2989878F6259DB2718D" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">786.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5326-wk-Fact-A6FE922C63A54D025EEBF6259DB27124" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5345-wk-Fact-1392A4F3BA3963F875FAF6259D049826" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5364-wk-Fact-6D805CBD6DDD780AA0EEF6259DB2687F" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5384-wk-Fact-BB638F6BEE9198B157A4F6259DB2CBDB" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5403-wk-Fact-4A41922045AF042F70E2F6259D049B76" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">236.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5422-wk-Fact-5AB96724C2616287DAF9F6259D0460F5" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">236.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5443-wk-Fact-73253260B589F1CAD313F6259DB266FC" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5462-wk-Fact-7795ED022CF801DF9DC8F6259D0491C7" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5481-wk-Fact-2EA28AD9B372CCB805DC066EB47E03E9" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5501-wk-Fact-9256AB9804C4101F7327F6259D042249" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5520-wk-Fact-99B62F8D355D759A4B9EF6259D04CD8D" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5539-wk-Fact-FE388B9B0891F57A981B066EE4931C72" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5560-wk-Fact-4F07654D54AA3B1C827AF6259D045EBE" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5579-wk-Fact-A47948DC0912515B3240F6259DAF1323" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5598-wk-Fact-AFE12B14B5F046D946BDF6259DB22D7A" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5618-wk-Fact-3E8DE411ECB19241DE0CF6259D041080" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5637-wk-Fact-6C5D2EBB823DD92B4AE5F6259CF59868" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5656-wk-Fact-C72A81913DC78F182FEBF6259D045A4C" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5677-wk-Fact-8E57A52365F7A000D0B9F6259D04DBCF" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5696-wk-Fact-FE972358FD466C0F7766F6259D042210" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">358.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e5715-wk-Fact-44353DD72BC13C0DD89EF6259DB1C7FE" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">358.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5735-wk-Fact-4C3C9D5567FAA88E0059F6259DB15C77" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5754-wk-Fact-0A70BEC3DEEA936B1DBAF6259DB21B20" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">254.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e5773-wk-Fact-3C255406811C3CEDFCCBF6259D045AFA" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">254.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6040-wk-Fact-2E84ED9D1FEF72BF78F3F6259D04C858" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6059-wk-Fact-DF6E50827B3EF7639D70F6259D04453D" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6078-wk-Fact-FF94B2A6BF07CAD3DCFDF6259DB269F4" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6098-wk-Fact-0DD452C0CF6C3C9090F9F6259D044318" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6117-wk-Fact-BA0665F3EEDB0C8098AEF6259D04B618" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6136-wk-Fact-C471FE00E334D212C773F6259D040339" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6163-wk-Fact-FFF155C081A1B02826F2F6259D043036" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,257.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6182-wk-Fact-7AA73261CFAC30E41E0FF6259D04F040" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,302.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6201-wk-Fact-AF0A6B5FA115FD6CFF39F6259D1417AF" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,560.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6221-wk-Fact-DA93FA9B85AD9BB6744FF6259D041B2B" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,279.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6240-wk-Fact-24564DA590B243C1DC14F6259D048451" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,001.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6260-wk-Fact-C04EBFA41990DA29BFA8F6259D52D55F" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,281.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6276-wk-Fact-4EF889880D25502BBBF8F6259D81E5FD" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6280-wk-Fact-9A7945088451B8278871F6259DA2A679" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">18.2</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6292-wk-Fact-267A1D8E541BF764EC87F6259D812BEF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6297-wk-Fact-A47FD9637CC5C1BB2BF8F6259D81D36D" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">16.3</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6312-wk-Fact-12DE8D784D22C901519AF6259D812A93" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">32.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6316-wk-Fact-57F7DEC4BB03B3C10E46F6259D810B14" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.6</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6328-wk-Fact-D7CEADACFC634DCD0EC6F6259D81300E" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">33.2</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e6333-wk-Fact-08634AF63AFF4AFFE764F6259D813307" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">17.3</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="TextSelection-EE62B1AE759D04E07A56F6259DC21F80-0-wk-Fact-945BBD1D9D4A2FAF31F4F6259D819C6F" escape="true"><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6480-wk-Fact-32CA86FF20F8660C5FD4F6259D330CA6" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6499-wk-Fact-204088D903D7439A7EA9F6259D33D8F5" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">888.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6518-wk-Fact-8FD5D45BBD1278A8AF15F6259D33AC75" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6538-wk-Fact-63399ADB4FB449F0D728F6259D43BE17" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,051.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6553-wk-Fact-7E77D31860E9844B5408F6259D334031" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">308.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6572-wk-Fact-E4F2EB0DCA86D270ACC1F6259D3347C2" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,391.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6591-wk-Fact-878B41A9906C25499AFEF6259D3360BD" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6611-wk-Fact-EDD2105C4E2122A6B1FCF6259D33ADDA" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,710.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6631-wk-Fact-E183E4D34D4F167F6984F6259D333ED6" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6651-wk-Fact-FBAC4DC61EFD61A86D6EF6259D33B265" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6671-wk-Fact-33E73A4C47F786FDCD35F6259D33E34B" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6692-wk-Fact-4FAC708444742DACAF48F6259D338976" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6713-wk-Fact-620B143845EC65A2EA49F6259D332C40" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6733-wk-Fact-688F0C291EF49904A209F6259D33ED89" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">827.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6753-wk-Fact-6E43026B342D1BF26E49F6259D33EFE2" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6774-wk-Fact-8B7427C8075A8D2D30B1F6259D33A6E6" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,017.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6795-wk-Fact-ABACAA696C27EBDFA71CF6259D33CD5D" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6815-wk-Fact-B0B1172FA2A9BC6C06C5F6259D339351" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">505.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6835-wk-Fact-FFAC713B85AEE9AEB8A7F6259D33F23A" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e6856-wk-Fact-FA21E3F6769FA6AB47FBF6259D334D3A" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">639.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6882-wk-Fact-822EB7DEE8DB6192BD4BF6259D33BDAD" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6901-wk-Fact-442F8132847B9EAFD548F6259D331DAB" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">905.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6920-wk-Fact-08C12B957E0CDC496163F6259D3388F3" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e6940-wk-Fact-4A297960FBEB60C1CF10F6259D33A629" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,062.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="TextSelection-F0DD8BCEB421203AF994F6259DC27D36-0-wk-Fact-47687C9AE448926A79ACF6259D813621" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7040-wk-Fact-FDEE08D5EB349F05B66CF6259D4311E0" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">199.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7059-wk-Fact-1F97C77CDB99BBFE3BA0F6259D434B75" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7074-wk-Fact-664C6114E7A93753808DF6259D5202EB" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">863.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7093-wk-Fact-2332C6EB86868144FE27F6259D430E8C" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">874.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7118-wk-Fact-4A297960FBEB60C1CF10F6259D33A629" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,062.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7137-wk-Fact-63399ADB4FB449F0D728F6259D43BE17" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,051.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="TextSelection-73C1775D69369635245DF6259DC2DACF-0-wk-Fact-A5C712DB98040A54B690F6259D816371" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7359-wk-Fact-7DECC4F6C2FEA4925F63F6259D81BB73" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">377.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7378-wk-Fact-8CC966398D52F1AF1D65F6259D8134CA" name="biib:ShareOfCoPromotionProfits" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">359.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7397-wk-Fact-C142F4A8D970B81D58D8F6259D81A395" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">768.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7417-wk-Fact-4B96DEAB241EC04E4B06F6259D81C6A2" name="biib:ShareOfCoPromotionProfits" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">708.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7432-wk-Fact-73761669D7215D054E4BF6259D811849" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">199.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7451-wk-Fact-F1AF98AD1024576459F4F6259D8185B5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7470-wk-Fact-FFE26A4CA65381EA295BF6259D81965E" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">325.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7490-wk-Fact-7446CB6773DD014EA3A0F6259D818CEE" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">225.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7515-wk-Fact-5B9EC13DF76E0C64D4C9F6259D71CF78" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7534-wk-Fact-09FB62AF2F4874DE36DDF6259D330ABD" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">490.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7553-wk-Fact-2EBAB557DC84FE08A211F6259D622116" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,093.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7573-wk-Fact-2091EADF344F99481D24F6259D621286" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">933.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:OtherrevenuesTableTextBlock" id="TextSelection-D1CBDFFCCF56483F90B9F6259DC2B557-0-wk-Fact-E2F9EE5C5F6984AA550AF6259D81B9DF" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e7884-wk-Fact-3CCE4C6E7F03BB18B3B3F6259D5242B4" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30743146e7904-wk-Fact-FAA697E758908811AAD8F6259D529979" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30743146e7924-wk-Fact-EE25AFD9C764122DEC99F6259D52FB97" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30743146e7945-wk-Fact-9284769667647B848009F6259D52B257" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7961-wk-Fact-EF4EA71EF902CA03BC44F6259D5251AE" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e7980-wk-Fact-70498F47F0A907BAC4B9F6259D523014" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e7999-wk-Fact-E2248DBE1FF929F9333EF6259D525BC7" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e8019-wk-Fact-DF62E636750373112917F6259D52F8BA" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e8117-wk-Fact-72B2AF762786D499F545F6259D52C7D9" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e8136-wk-Fact-60394CA173CE6CD2DB78F6259D52FE1B" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e8155-wk-Fact-B66D7F1EC0D5017C0393F6259D527B4D" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e8175-wk-Fact-B18F299500A9FB259A7DF6259D52A275" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e8195-wk-Fact-E08F00601211B6F5AAADF6259D525024" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e8214-wk-Fact-E1478BCD82606A068B0BF6259D71BB8F" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e8233-wk-Fact-F627DF65E314112AF99CF6259D523A5D" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">369.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e8253-wk-Fact-E0476FADCA4DA83E9CD3F6259D52964E" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">219.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e8278-wk-Fact-CC0CC7DC660BF5C38699F6259D334216" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e8297-wk-Fact-7F5F6340692D7DDE0318F6259D814253" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30743146e8316-wk-Fact-67EF5E7D2920FD15A8F6F6259D6276B9" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">452.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30743146e8336-wk-Fact-18A0A15D9AE9D88D7F55F6259D235B1F" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">273.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30743146e8359-wk-Fact-33EE9637A600AB8233E5F6259D81A815" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30743146e8363-wk-Fact-CD868EEEBE689806D26AF6259DA21FDD" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">241.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30743146e8367-wk-Fact-85679E797E24A7A6E7F6F6259D8197A5" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30743146e8372-wk-Fact-C5E01CC71F4883F56AF3F6259D818136" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><a id="s53983EDAC7FE572DB0C4AE6C4F3DC34B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-7A81D1BFE407E6284C27F6259DC2E5EC-0-wk-Fact-848C4565D25B6730AD54F6259D911FBB" continuedAt="TextSelection-7A81D1BFE407E6284C27F6259DC2E5EC-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7A81D1BFE407E6284C27F6259DC2E5EC-1"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-B2341BA6B4AF8947A98AF6259DC2B3A7-0-wk-Fact-ACCBA893D584DFDFA1C1F6259D71088F" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30715280e865-wk-Fact-86139E79C0CAFA15C552F6259D81D860" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">205.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30715280e884-wk-Fact-3C6BD89798D140C3B8B1F6259D43D57E" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">196.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30715280e899-wk-Fact-2381935E0EFB8C0412D7F6259D434427" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">427.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30715280e918-wk-Fact-B803963A1A14069361C4F6259D43FDA3" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">606.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30715280e938-wk-Fact-859323E926FF4F6FB830F6259D4309E9" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">144.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30715280e957-wk-Fact-299E58E623BA9A6D08BCF6259D4317FA" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30715280e982-wk-Fact-3E2CEEE02EE1AA0C05D3F6259D9169FE" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">776.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30715280e1001-wk-Fact-9181D14105DE5410A84AF6259D431780" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30715280e1103-wk-Fact-55C665FC64E6E531FF29F6259D33D65D" name="us-gaap:InventoryNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">776.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30715280e1122-wk-Fact-8C6C4783CB833F71AD59F6259D2325D5" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">929.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30715280e1137-wk-Fact-1C2B5E76F76A6337A79DF6259D7155B9" name="us-gaap:InventoryNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30715280e1156-wk-Fact-456048EAFFAFF27385A4F6259D4376B9" name="us-gaap:InventoryNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30715280e1181-wk-Fact-3E2CEEE02EE1AA0C05D3F6259D9169FE" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">776.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30715280e1200-wk-Fact-9181D14105DE5410A84AF6259D431780" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we sold to Bioverativ most of the remaining hemophilia-related inventory on hand with a cost basis totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30715280e1220-wk-Fact-E1B3C73CB703A6BD4210F6259D91B21E" name="biib:InventorysoldtoBioverativcost" contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30715280e1233-wk-Fact-46EFC128053751FC2172F6259D43F6DF" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">890.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. As a result, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30715280e1237-wk-Fact-772C51D00284A1513CB1F6259D23E93B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" contextRef="FI2019Q2_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of work in process inventory was reclassified to assets held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred. In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBA449FD18E9058D3854B839A116A35DF"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-12BB1477257559D94BD8F6259DC24028-0-wk-Fact-D96926CAFD7855E9A54DF6259D71363E" continuedAt="TextSelection-12BB1477257559D94BD8F6259DC24028-1" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="TextSelection-12BB1477257559D94BD8F6259DC24028-1" continuedAt="TextSelection-12BB1477257559D94BD8F6259DC24028-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="TextSelection-2AF584EEF22EBB27741FF6259DC28B3B-0-wk-Fact-8BB5E502E15FE3C6A986F6259D7153BC" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1130-wk-Fact-994AE09CC631B6B907DEF6259D817BD1" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">543.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30722939e1149-wk-Fact-C16CEF01B386A6026447F6259D917F00" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1170-wk-Fact-03DF73FC86DFB50D44A1F6259D91BF50" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1189-wk-Fact-532E64959D73AD11A406F6259D144586" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">543.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30722939e1208-wk-Fact-97D971AC6A8F78DDA9ADF6259D9176D0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">542.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1229-wk-Fact-FD14907E23F8EFBDB645F6259D916C1C" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1257-wk-Fact-6C0806524480AC621679F6259D710FCA" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,005.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30722939e1276-wk-Fact-BA2E2DA8D2356A1A4BA0F6259D7155F0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,754.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1297-wk-Fact-286EF2EAD80FDE81B3DEF6259D91A5B7" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">251.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1316-wk-Fact-EB6CE9B71175A11302B9F6259D91F072" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,005.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30722939e1335-wk-Fact-4063D7E18EFD3AEEA951F6259D91BD10" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,734.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1356-wk-Fact-EDAF46D75F2E8FACC5F7F6259D91B664" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">270.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1386-wk-Fact-7226ABB795932687EAC7F6259D71008D" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,175.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1405-wk-Fact-E82B21AE7932A7892D1AF6259D811A3E" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1425-wk-Fact-7226ABB795932687EAC7F6259D71008D" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,175.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1444-wk-Fact-2EE64B696FC270FDBA39F6259D71CEAB" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1463-wk-Fact-1869D2AC0D4E2508517CF6259D710C12" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1483-wk-Fact-2EE64B696FC270FDBA39F6259D71CEAB" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1516-wk-Fact-3FB0BDE5AE83E9249197F6259D918875" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1535-wk-Fact-548F9B1C1D749871C066F6259D71A5AE" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1555-wk-Fact-3FB0BDE5AE83E9249197F6259D918875" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1574-wk-Fact-86BB5650A09FCE953479F6259D81BA6D" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1593-wk-Fact-80F471F5457EE70103BFF6259D91A068" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1613-wk-Fact-86BB5650A09FCE953479F6259D81BA6D" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1646-wk-Fact-2D2A27A171B0A04C280EF6259D9189F7" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,638.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30722939e1665-wk-Fact-210CEAE74230A1E120DDF6259D040494" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,449.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1686-wk-Fact-8147DBAFFF35D7B477D2F6259D91297E" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,189.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1705-wk-Fact-17D11B736CFEDA6E54C8F6259D9182E7" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,638.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30722939e1724-wk-Fact-E0B7CC09E3505ECBB5A4F6259D91B30B" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,330.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1745-wk-Fact-B2EF4B089202E2295B10F6259D71AB51" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,308.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1780-wk-Fact-ED3E9AC768467F96C658F6259D91D549" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,426.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30722939e1799-wk-Fact-F807D5F02EAF0C37D617F6259DB25919" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,745.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e1820-wk-Fact-C44244A5766C4B25316FF6259D233F2E" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,681.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1839-wk-Fact-475618DC56CE76F74122F6259D91B2BB" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,727.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30722939e1858-wk-Fact-61C718BBC07A6EABB63AF6259D918768" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,607.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e1879-wk-Fact-8B92C2F3788E45ADA189F6259D33FAEA" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,120.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30722939e1907-wk-Fact-B3BD168EB3801729A63FF6259D621F86" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$138.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30722939e1915-wk-Fact-7779EF5CE57D18E76221F6259D624E02" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30722939e1920-wk-Fact-3A52F769615790191266F6259D23382B" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">211.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. The decrease in amortization and impairment of acquired intangible assets was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no impairment charges.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30722939e1946-wk-Fact-5865D5167C6731FB71C4F6259D71F434" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">246.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of NST on June 7, 2019, we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30722939e1956-wk-Fact-882BC58AAE3F5F88E247063DD62A09C3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30722939e1974-wk-Fact-48F1CDCDD335C672AA30F6259D71D1A5" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,933.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the net book value of the TECFIDERA asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30722939e1982-wk-Fact-E6D590D6A07A5D550192F6259D715122" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our TECFIDERA license rights, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-12BB1477257559D94BD8F6259DC24028-2" continuedAt="TextSelection-12BB1477257559D94BD8F6259DC24028-3"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of 2019. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-71B85E910893DAE87276F6259DC2D305-0-wk-Fact-6B738CD867B94EC6ED0DF6259D710BF5" continuedAt="TextSelection-71B85E910893DAE87276F6259DC2D305-1" escape="true">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-71B85E910893DAE87276F6259DC2D305-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2069-wk-Fact-452E8867A439219D3171F6259D4343A3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">130.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2084-wk-Fact-2AFA437E0CFA9474DE07F6259D43B5A8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">255.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2104-wk-Fact-614BE69D44D6A09F12C2F6259D4334A4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2124-wk-Fact-4545196938FCCCACA0ACF6259D439D86" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2144-wk-Fact-F636552FD8A2F319B246F6259D4334A0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2164-wk-Fact-2AC87C200C218923F95AF6259D4333DE" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-B8A95F4196AD4074EED7F6259DC27451-0-wk-Fact-4EEF552E83305E3B6487F6259D71DFFA" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2247-wk-Fact-A45E521E0B1F5359C200F6259D335514" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,706.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2262-wk-Fact-81CF457602F010BC4D59063DD61C2F08" name="us-gaap:Goodwill" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reclassification of goodwill to assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30722939e2282-wk-Fact-5BC5E181CF6FC316A83AF6259D2318A3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30722939e2303-wk-Fact-CAFDCCC552573C3AAEBCF6259D91B8D1" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30722939e2329-wk-Fact-D63D508540010D880C00F6259D336D62" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,749.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The reclassification of goodwill to assets held for sale relates to an allocation based upon the relative fair value of the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our Hiller&#248;d, Denmark manufacturing operations meeting the criteria to be classified as held for sale due to the proposed divestiture, goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30722939e2370-wk-Fact-2FA1F9D964B8AB9FC3A8F6259D713CF6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="FI2019Q2" unitRef="usd" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-12BB1477257559D94BD8F6259DC24028-3">Other includes changes related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><a id="s69AD866EF60D5D3DB0082BD12681B139"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-29F610442C231145A7D3F6259DC2EE8E-0-wk-Fact-CED09210624284EF1067F6259DB19B02" continuedAt="TextSelection-29F610442C231145A7D3F6259DC2EE8E-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-29F610442C231145A7D3F6259DC2EE8E-1" continuedAt="TextSelection-29F610442C231145A7D3F6259DC2EE8E-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-9E6A6BCA7252AFE7AB65F6259DC2D5C8-0-wk-Fact-6E5EE5CE855E8B713387F6259DB168EC" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1021-wk-Fact-40FC6302DAB5019D304DF6259D43FAC4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,120.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1040-wk-Fact-CC9BCB3132F32264AD04F6259D339EA3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1059-wk-Fact-CE34FC526B278B0DAA7AF6259D332F1E" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,120.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1079-wk-Fact-A2668FE25BD6C6AEE336F6259D330545" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1176-wk-Fact-E5D2BEE0C78D4660DDACF6259D438BDD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,687.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1195-wk-Fact-2F4266E65D5B09BDA91CF6259D43D67F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1214-wk-Fact-416CE8D1E601DA138F86F6259D43227A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,687.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1234-wk-Fact-0825230FABBA91AA1733F6259D33F026" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1254-wk-Fact-34E41CBA0C06B38C0F60F6259D43442E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">604.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1273-wk-Fact-4524B0F9E4C395C897C1F6259D43DE8B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1292-wk-Fact-919537CE190B196632CAF6259D33D1E6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">604.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1312-wk-Fact-C55F0AFB8C2FA9B8E08AF6259D43BB3F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1332-wk-Fact-581F5D00974B7915ADE2F6259D4388DA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">246.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1351-wk-Fact-D81CF2727CF5C9056081F6259D33834C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1370-wk-Fact-A6E5F27E1AD9EE617856F6259D43A3DD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">246.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1390-wk-Fact-A3DA2CFB8BDA16F9E0B0F6259D431D2C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1410-wk-Fact-25C4ABEDDC1D7880A3FFF6259D43848E" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1429-wk-Fact-9693C37F6F7414D7864CF6259D33E756" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1448-wk-Fact-7B2F2892CC6E20620131F6259D43C6C1" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">333.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1468-wk-Fact-B33E5086C5A6E14DAEF1F6259D43CCEB" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1488-wk-Fact-03F5B0455AA183131E72F6259D43BE85" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1507-wk-Fact-FBC83B20A0F855C13DFBF6259D436335" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1526-wk-Fact-C2698E5726FF779DD5E7F6259D43CD91" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1546-wk-Fact-120D97D619F04009C015F6259D43A337" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1566-wk-Fact-33F9FA209E4438A2C705F6259D437F9D" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1585-wk-Fact-535DF14A1E3B2A5A4882F6259D3324D8" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1604-wk-Fact-2D3512B598DD529CCE31F6259D43906F" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1624-wk-Fact-82193BAD0D6A225F8465F6259D43892A" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1649-wk-Fact-1360F7F880C22EB0C9FDF6259D43DBFC" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,286.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1668-wk-Fact-66EE3015EE4D6A08E3DEF6259D43B7D0" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">176.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1687-wk-Fact-64B3C2E1A044BD18CE37F6259D33C61E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,109.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1707-wk-Fact-19FDDFC8373972EEA7D1F6259D43ECA9" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1810-wk-Fact-2DC400AFAA63C6B56354F6259D43DC6B" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1829-wk-Fact-D06AAE3FC68A73DDE4ECF6259D43D189" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1848-wk-Fact-CFF9331EB4593C31F897F6259D437FE6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1868-wk-Fact-3A4B226C43561E28F992F6259D435662" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1883-wk-Fact-6F21BF6933C48630897EF6259D6267DF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1902-wk-Fact-19D96FE7753EF0372F81F6259D43FBC3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1921-wk-Fact-0CC369BCB1078159803BF6259D33717B" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1941-wk-Fact-8E953F369AE23405D904F6259D33D116" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1966-wk-Fact-53FB5128E6E086860D7AF6259D436203" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">418.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e1985-wk-Fact-B98A597463543F8EA4F0F6259D432702" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e2004-wk-Fact-E1D705F708CAB53A3733F6259D3336F7" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e2024-wk-Fact-B20F10BC97DB233199C7F6259D432DEA" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2259-wk-Fact-D50FBD03024064FED0CCF6259DAD1827" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2278-wk-Fact-DF8295B44D9F1AC1563EF6259DA9EE19" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2297-wk-Fact-0E48A92119B6BE5A8DCDF6259DA52FF8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2317-wk-Fact-13D1EF7FB1E29B895F9BF6259DABF825" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2414-wk-Fact-CC8335F0EDC96EB59D99F6259DA89576" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,459.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2433-wk-Fact-53E7143F7EBFD279EC6CF6259DA9B91F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2452-wk-Fact-07AAF3B70ECB39450747F6259DADD029" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,459.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2472-wk-Fact-15F365DA6104495626D1F6259DA46B56" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2492-wk-Fact-A0A95EB89646EF0EF423F6259DAAAD70" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">969.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2511-wk-Fact-44B8162048B15717D557F6259DACC52D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2530-wk-Fact-EA9174FC2025E87595DFF6259DAD1070" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">969.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2550-wk-Fact-4447D2328DB7F335E023F6259DA459CA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2570-wk-Fact-851F28B4C38DBF4E468EF6259DAAD5C1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2589-wk-Fact-FD4852C1A660656A22B8F6259DB2B4E1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2608-wk-Fact-A2BAC8900A1887D43996F6259DAD38D5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2628-wk-Fact-E9570EFF6182D86C1E80F6259DAC0A76" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2648-wk-Fact-1FE3030580E2EC290D6DF6259DAC352C" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2667-wk-Fact-0E6900FCD699047E6A23F6259DA570C3" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2686-wk-Fact-36AF9404359B419DD4FEF6259DABA207" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">563.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2706-wk-Fact-6BDBCB127A130A834489F6259DA6CE43" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2726-wk-Fact-0793612D5875F14AFFE1F6259DA97068" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2745-wk-Fact-02AC6F0396FB23C6ADEBF6259DA8A048" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2764-wk-Fact-827B5508239835AD4BEFF6259DA7CDE7" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2784-wk-Fact-6F1041C6272927D4C7CCF6259DAB47B3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2804-wk-Fact-5AE9BB4560B65232094FF6259DAA4F7A" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2823-wk-Fact-8A9AB1B1EAEEC8D68779F6259DAB7A35" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2842-wk-Fact-125A58F8F5948BA5EF3FF6259DADF3BA" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2862-wk-Fact-89AE92DF17A85B9796ECF6259DA6E93B" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2887-wk-Fact-AB5EA34C12795E13F7C9F6259DABA835" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,102.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2906-wk-Fact-ED0566593DECCBE62AEEF6259DAFD1AA" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2925-wk-Fact-E6AB31BCEEB643A085CEF6259DAA257E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,050.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e2945-wk-Fact-5292E62F6CF9FF640340F6259DA71636" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3048-wk-Fact-3FB7B352C73C49600C25F6259DAC7B6A" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3067-wk-Fact-EED7B70E3BC79BDE1181F6259DACAE59" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3086-wk-Fact-3F85244626B6D3344164F6259DA535EE" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3106-wk-Fact-426C00A6A73A12B46826F6259DA591C9" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3121-wk-Fact-D42F123F970F720ADC31F6259D62EEC1" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3140-wk-Fact-D33D938EA4AA77D0B800F6259DAC064D" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3159-wk-Fact-E4ABA679F5AA15A87E37F6259DA54D49" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3179-wk-Fact-A99860ED200D69AA8889F6259DA4429F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3204-wk-Fact-671514CA5F76C68B29D7F6259DAABB18" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">434.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3223-wk-Fact-AF98BFE2187C849F86E7F6259DA4DDFA" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3242-wk-Fact-32529D5A372F335C8C1CF6259DA532E7" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3262-wk-Fact-C2DF03F9580244D292DEF6259DAD6FCC" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3282-wk-Fact-BC651C80D3E50690D757F6259DB1E809" name="us-gaap:AssetImpairmentCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3294-wk-Fact-75E090FD2E5109D73CE9F6259D04C8D9" name="us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" contextRef="FD2019Q2YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our agreement with Ionis, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing services and our option </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-29F610442C231145A7D3F6259DC2EE8E-2"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pricing valuation model, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="TextSelection-7E803F3F2BE7DF99CD51F6259DC272C8-0-wk-Fact-AFC9C15E92A2F500EC5EF6259DB14099" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3557-wk-Fact-6995D65BDFE168D4199DF6259D62C531" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,507.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3576-wk-Fact-533BC3DA10002AA23F40F6259D62B816" name="us-gaap:NotesPayable" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3595-wk-Fact-4BBF37D36635C1F03750F6259D62D2D0" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,489.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3615-wk-Fact-A47EDDBE23389EAB4630F6259D622BF0" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,480.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3630-wk-Fact-6D8818DEB40B59DC25E2F6259D62B819" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,032.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3649-wk-Fact-936A17991A934FD0D2E8F6259D6243AB" name="us-gaap:NotesPayable" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">996.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3668-wk-Fact-E210481F074B2FFDC498F6259D62BD1F" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,000.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3688-wk-Fact-C41C0CA74AF223E91C81F6259D62E26A" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">995.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3708-wk-Fact-CE7A88ABF1CAF68598C6F6259D62EA0D" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,867.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3727-wk-Fact-112B91E1E3C555E384BDF6259D622A23" name="us-gaap:NotesPayable" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,738.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3746-wk-Fact-856843DF474B36B7478FF6259D62866B" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,745.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3766-wk-Fact-E18FDA6303655172D9E0F6259D62CA57" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,737.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3786-wk-Fact-12A420DD242B145FD257F6259D6200BE" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,953.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3805-wk-Fact-452DACC9F6884F3B4495F6259D6274BB" name="us-gaap:NotesPayable" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3824-wk-Fact-D4387C793E1B38B75326F6259D62C353" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,802.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3844-wk-Fact-94AAFD48A42FB3DBCF03F6259D620DE7" name="us-gaap:NotesPayable" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3869-wk-Fact-CB2F20886598B99758C2F6259D62F6E9" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,360.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e3888-wk-Fact-0727F0899F440E476D36F6259D623077" name="us-gaap:NotesPayable" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,948.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3907-wk-Fact-9792732673FD2702D132F6259D62EE06" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,037.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e3927-wk-Fact-09B9F415B98D31814295F6259D62E96A" name="us-gaap:NotesPayable" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,936.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-1A2EC7D2B719CCAEE003F6259DC21E1D-0-wk-Fact-E88B4E4950BC850DB2C1F6259DB2A619" continuedAt="TextSelection-1A2EC7D2B719CCAEE003F6259DC21E1D-1" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1A2EC7D2B719CCAEE003F6259DC21E1D-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e4172-wk-Fact-A1E437BDCEE9167EAA5FF6259D62030F" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e4191-wk-Fact-81E5E276D86A7DDF2382F6259D62B8B6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">498.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e4210-wk-Fact-D42F123F970F720ADC31F6259D62EEC1" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e4230-wk-Fact-D677736E015852AC6F47F6259D629C56" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">523.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30733449e4245-wk-Fact-6ACFF58C36896C0429A5F6259D7118EC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e4265-wk-Fact-5D3F92B3D26D4145CC8DF6259D71B2D9" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30733449e4284-wk-Fact-33C2C3244E3CB3B9F4C0F6259D6216FA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30733449e4305-wk-Fact-7BA913E8E376F5770455F6259D81E7AA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e4326-wk-Fact-9C963564D325247874B0F6259D624EE3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e4345-wk-Fact-F5D3137F6CD013B5DD0EF6259D622B7B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e4364-wk-Fact-B0F11047D6F98621538DF6259D6272C7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30733449e4384-wk-Fact-E487A22CF92D251C51FEF6259D62AE0A" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e4410-wk-Fact-6F21BF6933C48630897EF6259D6267DF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e4429-wk-Fact-A224857E428533CE4514F6259D622CB7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">499.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30733449e4448-wk-Fact-6F21BF6933C48630897EF6259D6267DF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30733449e4468-wk-Fact-A224857E428533CE4514F6259D622CB7" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">499.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30733449e4496-wk-Fact-A2620FE041BD1D7A71D1F6259DB0DB43" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">255.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30733449e4500-wk-Fact-864C9CD2E38C4A89A38BF6259DB1D37F" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">265.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and expected timing of achieving certain development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to an increase in interest rates used to revalue our contingent consideration liabilities, the passage of time and a milestone payment.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC08BA1201F085F23A9B7AC3CB7A8A336"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="TextSelection-1E47C018002B2B8EF10EF6259DC2278E-0-wk-Fact-398ACC0D67FD72A80707F6259D23515F" continuedAt="TextSelection-1E47C018002B2B8EF10EF6259DC2278E-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1E47C018002B2B8EF10EF6259DC2278E-1" continuedAt="TextSelection-1E47C018002B2B8EF10EF6259DC2278E-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-FDACD11091F6D9130302F6259DC28B9B-0-wk-Fact-4E9C3A1B65016ECCA67CF6259D62DA71" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e862-wk-Fact-83EF32994E216ADAA9AFF6259D81212B" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">338.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e881-wk-Fact-24381720F328FA9D28D7F6259D43B803" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">231.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e896-wk-Fact-38502867D524AB46E6B5F6259DA6F5C6" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e915-wk-Fact-0773FF878E42FBA74E80F6259D814223" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e935-wk-Fact-7D25EDF458AF49D16AC9F6259DA5A6BC" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">405.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e954-wk-Fact-073CA92425F991AC074EF6259DA7C18E" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">279.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e974-wk-Fact-9C056F4178A50877CEB6F6259D91B95B" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">279.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e993-wk-Fact-084DEEEB4B7A9236665CF6259D2306B3" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">194.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1018-wk-Fact-51B97519F97A453073FAF6259CF5F3C8" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,120.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e1037-wk-Fact-0FDD60946C90FDE18158F6259DA5B3C1" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="TextSelection-4AF73C82A726295EB1DFF6259DC2CC82-0-wk-Fact-E8B99641E4C80C823C6AF6259D6226A6" continuedAt="TextSelection-4AF73C82A726295EB1DFF6259DC2CC82-1" escape="true">The following tables summarize our marketable debt and equity securities:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4AF73C82A726295EB1DFF6259DC2CC82-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1283-wk-Fact-1E618DE8D28AABB67E8AF6259D434BAC" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">933.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1302-wk-Fact-333BE0A532608DF4AE65F6259D43E4D4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1321-wk-Fact-0D9970D0FB1217C54DF1F6259D438707" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1341-wk-Fact-FD6D703CBAAEE1974ACBF6259D435D5A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">934.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1356-wk-Fact-46F86312FA2D96013D47F6259D43A9D9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">748.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1375-wk-Fact-CF75BA0566D7FF4A42A8F6259D43AE40" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e1394-wk-Fact-937E3B263A2BC1C4FA18F6259D437E50" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1415-wk-Fact-C59BFC500BD5A3776629F6259D435ECF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">753.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1517-wk-Fact-5B54275B3AA7CC12D5B2F6259D43B22D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">293.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1536-wk-Fact-AD523F87478B207DBDE3F6259D43B8EC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1555-wk-Fact-A7B51A535158CFA44B7EF6259D437F21" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1575-wk-Fact-13114AECF35C02ED11E9F6259D439178" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">294.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1595-wk-Fact-19132C779D9DCE37519FF6259D43943C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1614-wk-Fact-16B736FA83E3E2CCFEFFF6259D4379C8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e1633-wk-Fact-6892D2D90EDE5AF0F662F6259D4340F0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1654-wk-Fact-BE1E31D9C0640C29E588F6259D439946" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">310.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1756-wk-Fact-218BD74E810F1DDD98C2F6259D43BF82" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1775-wk-Fact-C7642E78602450C6A151F6259D43AC99" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1794-wk-Fact-2D7D9E6A3853CD0E54A4F6259D43D797" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1814-wk-Fact-5646483E484977998315F6259D43B861" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1834-wk-Fact-453EA6405FE05386A7EFF6259D4360AE" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1853-wk-Fact-C1E0868547A29126B888F6259D438F3D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e1872-wk-Fact-1F1423BE035BEFDB9F42F6259D435C2D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1893-wk-Fact-70681206B8E1D76BD665F6259D435A75" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">245.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1918-wk-Fact-11FC085268A7E6F3298BF6259D43F4FB" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,530.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1937-wk-Fact-3E17448BAD55E8CB3A41F6259D43343B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e1956-wk-Fact-776FED99612EB753E31CF6259D43A33B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e1977-wk-Fact-9C666B722CF40A00AADAF6259D43F8B5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,538.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2080-wk-Fact-38D8FADCF1CBA86496F51ACA06DF635A" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2099-wk-Fact-276FB041F2CD683B58141ACAF3B48B65" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2118-wk-Fact-38ED66DDDDF02CCB2CE91ACBD27F2784" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2138-wk-Fact-C68764E52A51CF8CD2931ACC8520E598" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">164.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2153-wk-Fact-BDD175DDBF492C4EB9A61ACA08662910" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">111.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2172-wk-Fact-F6D7BCFF1A5C296BEDB41ACAF5F39A4F" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">247.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e2191-wk-Fact-E851B9A58749AEAD00221ACBD4E80E90" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2212-wk-Fact-8E857985B7C9BFB6ADAC1ACC87145C8A" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">345.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable equity securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2237-wk-Fact-528FCC83ADAD2BD79606F6259D43197F" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">229.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2256-wk-Fact-37FBF1D6FDA889E88CC1F6259D4327FA" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">294.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e2275-wk-Fact-5B46C0702CB86AECF4A2F6259D43191D" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e2296-wk-Fact-8E0E78E8FDDB9E3ED272F6259D43F33E" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2522-wk-Fact-D8916DD078A30E330F01F6259D52C98C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,608.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2541-wk-Fact-D2FF231EF725489DF48EF6259D52CDC3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e2560-wk-Fact-CC51B839DAE8E6CC4343F6259D52CC54" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2581-wk-Fact-D69A5A16CB1FE70F1720F6259D71D808" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,607.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2596-wk-Fact-333FFE87232494F1144FF6259D7146AB" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">854.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2615-wk-Fact-F714705C3EF402F62700F6259D81E2B4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e2634-wk-Fact-B179B8D15942147162F4F6259D71789D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2655-wk-Fact-2639EF62961F57F543CBF6259D33E797" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">851.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2757-wk-Fact-121D8F15CED75446CAD0F6259D526C03" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">706.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2776-wk-Fact-99A83F699A6EF73BE693F6259D81FE08" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e2795-wk-Fact-3F9BE657BAD8E0DBF521F6259D432B54" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2816-wk-Fact-451F1C7F3A56124FB3E4F6259D52DE5F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">705.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2836-wk-Fact-BC978F1687E197DE33BFF6259D52A6A8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">264.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2855-wk-Fact-4F5BBDC86940FB26B1DEF6259D52BC5A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e2874-wk-Fact-161B3217E95841F65CA1F6259D529E63" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2895-wk-Fact-4AF1F4E06671448DBFF4F6259D52EB38" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">263.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e2997-wk-Fact-B76831409D9B07443DB1F6259D626ABC" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3016-wk-Fact-58E8144C47C83AB9ECC2F6259D52A755" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3035-wk-Fact-4D3363D3D8C1A8BEC222F6259D622251" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3055-wk-Fact-36A04079F34E1694AADEF6259D52F662" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3075-wk-Fact-70E72719B240030EC842F6259D52DE50" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3094-wk-Fact-C1C2D85DD01DA86F4FE1F6259D52AF99" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e3113-wk-Fact-6A3BF689510B817F6D5AF6259D232EAC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3134-wk-Fact-33CDE00A5BFC0C5C1049F6259D52ADDA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3159-wk-Fact-8AB89748537748F9EE62F6259DA63BC9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,694.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3178-wk-Fact-74E3037FA34A2F282FADF6259D52184E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e3197-wk-Fact-B1D9EDC635EAF6662BACF6259D52C1DD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3218-wk-Fact-ECE4B4B7B25669EFAD09F6259D528B7A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,689.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3239-wk-Fact-13622D3512E39D8DE583F6259D52B892" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">496.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3258-wk-Fact-C1134F383614E9A89962F6259D713012" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e3277-wk-Fact-ABC03C45AFA82AF4C05EF6259D524A5C" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3298-wk-Fact-7E9D0B6B17462E7685E9F6259D5200BA" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1E47C018002B2B8EF10EF6259DC2278E-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-E16423A2140C911779ADF6259DC20B8A-0-wk-Fact-017E0D05ECA999086E44F6259D62F99C" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3540-wk-Fact-0F8D13A445EC76789C02F6259DA70C87" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,227.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3559-wk-Fact-96134C8B66DBAE4E28D3F6259DA888B9" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,228.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3578-wk-Fact-4158C8A7FE9AF38322F0F6259DA739A8" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,314.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3598-wk-Fact-5857CF598ED04A72AEAFF6259DA81D2F" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,313.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3613-wk-Fact-60BF20812CDFFFC225E5F6259DA6EEBD" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,196.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3632-wk-Fact-BDD27EAB52586E91D35BF6259DAA9DEA" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,202.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3651-wk-Fact-8050626D8CB91B7E4666F6259DAA43DB" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,235.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3671-wk-Fact-5BDE8CE254024466F5D1F6259DA75139" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,232.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3691-wk-Fact-E359CD17808F735C258DF6259DAA69D0" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3710-wk-Fact-EA68F0D8A8C68A38FBDFF6259DA6EF4E" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3729-wk-Fact-DE45DE3D01F9271975A9F6259DA81654" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3749-wk-Fact-12D2385F2717D0D9E312F6259DA8BCF4" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3774-wk-Fact-11FC085268A7E6F3298BF6259D43F4FB" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,530.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e3793-wk-Fact-5016EC3E39ABB4216FE6F6259DA6F24E" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,538.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3812-wk-Fact-8AB89748537748F9EE62F6259DA63BC9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,694.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e3832-wk-Fact-45D3E700AB947924DA81F6259DA98634" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,689.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30735065e3860-wk-Fact-0BF3EE7718C4269F5148F6259D52D88D" name="biib:AverageMaturityOfMarketableSecurities" contextRef="FD2019Q2YTD" format="ixt-sec:durmonth">14</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30735065e3864-wk-Fact-F557FB6CBB25E0D41606F6259D52B48B" name="biib:AverageMaturityOfMarketableSecurities" contextRef="FD2018Q4YTD" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-C4DEFD4D7B358B959688F6259DC20055-0-wk-Fact-3518713C16072C8582EDF6259D623172" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e4084-wk-Fact-4F052B38E1A6FE29968CF6259D62A6BB" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,766.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e4103-wk-Fact-7908B14AD4F8157D583FF6259D629241" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,733.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e4122-wk-Fact-3BBFC6B449A1CFB27923F6259DAB5774" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,255.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e4142-wk-Fact-39E9D01E2A183C19B400F6259D913FA2" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,802.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e4162-wk-Fact-DF713B93EE8F46833199F6259D623B01" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e4181-wk-Fact-F3CFF23636F703F287A8F6259D621573" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30735065e4200-wk-Fact-783D633AFE3A9001EF15F6259D62DA65" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30735065e4220-wk-Fact-98B4D0F45588E7AFD833F6259D62EFF5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e4240-wk-Fact-1A8B6C0B73D259EB851EF6259D629D66" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e4260-wk-Fact-4C81FE7258A8731ABE0BF6259D62EBB4" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30735065e4280-wk-Fact-B206C7BE50F3A77877EEF6259D62EAA5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30735065e4301-wk-Fact-85DE14D75ECACBD6583CF6259D622BC4" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30735065e4329-wk-Fact-123D77F4DA6E1BFA2BFFF6259D719A61" name="biib:StrategicInvestmentPortfolio" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">569.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30735065e4333-wk-Fact-43F74E541074D49F708D06820C482862" name="biib:StrategicInvestmentPortfolio" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">164.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reflected as a component of other current assets in our condensed consolidated balance sheet, with the remaining balance included in investments and other assets. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30735065e4341-wk-Fact-B6F030A3A98B5B7F3C73F6259D71C61A" name="biib:StrategicInvestmentPortfolio" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is included in investments and other assets in our condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our Ionis stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the six months ended June 30, 2019, primarily reflects the sale of a portion of our investment in Ionis common stock for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30735065e4358-wk-Fact-FBAEDAA30A625EAED6230684E388662A" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">213.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as the sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3A004BCD981956E2AD02EA8AD8E51B40"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-0-wk-Fact-9221F44ADDD1374C227FF6259D628A83" continuedAt="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-1" escape="true">Derivative Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-1" continuedAt="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30746986e800-wk-Fact-921074DE09AC0CA4662EF6259D8187D6" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durmonth">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30746986e804-wk-Fact-90C2619FE7C6A7C1C625F6259D62B3F4" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">18</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30746986e808-wk-Fact-9EE78370E4A9E230F24BF6259D91C69E" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durmonth">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30746986e813-wk-Fact-7710EEB842807DA6BDFCF6259D81C9D6" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="TextSelection-A456820D6C6129341666F6259DD27A20-0-wk-Fact-9C5ABCED398875757E91F6259D815CAA" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e939-wk-Fact-59851215DA6ADA2EBD54F6259D04F93D" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,111.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e958-wk-Fact-66C72C7169F15F4E627EF6259D6232BB" name="invest:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,701.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e973-wk-Fact-526D74107BBD68654E93F6259D04269F" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">117.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e992-wk-Fact-5D3E0862959FC7302D5EF6259D52D0D6" name="invest:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e1012-wk-Fact-60E4966620A612E9B26FF6259D4313AB" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e1031-wk-Fact-7C583A0A566A0162D22BF6259D521FD5" name="invest:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e1051-wk-Fact-9A1615E0E7306E86FA1AF6259D71A66D" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e1070-wk-Fact-370B6E40E55C22AE31BBF6259D7155AE" name="invest:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">98.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e1090-wk-Fact-E63FD1EA7B4FE887DDADF6259DB21572" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e1109-wk-Fact-D08FF9E3E629DA83E7B3F6259D528606" name="invest:DerivativeNotionalAmount" contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">92.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e1134-wk-Fact-4BC54498CC48377ACAAAF6259D81F0DE" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,402.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e1153-wk-Fact-EE3E33C38F232D81A318F6259D6265E8" name="invest:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,239.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e1173-wk-Fact-254FFC36EED61AE148AEF6259D62C6D0" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e1177-wk-Fact-177E5B31FAFD347919D3F6259D81AF21" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e1189-wk-Fact-254FFC36EED61AE148AEF6259D62C6D0" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30746986e1194-wk-Fact-90C2619FE7C6A7C1C625F6259D62B3F4" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durmonth">18</ix:nonNumeric> months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e1198-wk-Fact-710891EF77B8B3C1E2970687CA5A7042" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30746986e1202-wk-Fact-08A142B6AFB8B26F2A37068D90B4E75F" name="us-gaap:DerivativeRemainingMaturity1" contextRef="FD2019Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" format="ixt-sec:durmonth">12</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-EF5DE23EA7CCDD43A169F6259DC296D6-0-wk-Fact-095B7D8F955A2D815762F6259D62E1FC" continuedAt="TextSelection-EF5DE23EA7CCDD43A169F6259DC296D6-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e1569-wk-Fact-D8B19999FDA32A3B238CF6259D624E31" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30746986e1588-wk-Fact-DE3F49734CB8DB08EF6AF6259D625B20" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e1619-wk-Fact-250CDE12804D6CD28FEEF6259D622A8C" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e1638-wk-Fact-38522A2195C8511FDF3CF6259D62914F" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30746986e1663-wk-Fact-080ED99D5462DFCE9C6DF6259D628FEF" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30746986e1683-wk-Fact-02339D1A21B79B0E602FF6259D621D50" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30746986e1714-wk-Fact-F0617BC51D0EDFD13A0CF6259D62908D" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30746986e1734-wk-Fact-A214194935854E83F864F6259D626DFA" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-2" continuedAt="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-3"><ix:continuation id="TextSelection-EF5DE23EA7CCDD43A169F6259DC296D6-1" continuedAt="TextSelection-EF5DE23EA7CCDD43A169F6259DC296D6-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e2086-wk-Fact-D6A8FEB1FB887AFB09700691BD2A7FF9" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30746986e2105-wk-Fact-EA572E7AF6A01CE66845F6259D71343A" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e2136-wk-Fact-A834CD1A743B41BF0275F6259D23138E" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2155-wk-Fact-6A37EFDE82448747E008F6259D047DD0" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30746986e2180-wk-Fact-22F3253B7EB6DFE500310691BD1A836F" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2200-wk-Fact-E479455483780C8B710AF6259D717DFB" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30746986e2230-wk-Fact-573598D7E20CA5564EE0F6259D71356F" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30746986e2250-wk-Fact-F580132D144611875BA4F6259D813B5A" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-EF5DE23EA7CCDD43A169F6259DC296D6-2"></ix:continuation>Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2275-wk-Fact-ADB46811B1B17938C579F6259D81AC42" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2279-wk-Fact-0A43F1185C062C87BDBEF6259D62574F" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">675.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2283-wk-Fact-ADB46811B1B17938C579F6259D81AC42" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2287-wk-Fact-ADB46811B1B17938C579F6259D81AC42" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and December&#160;31, 2018, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2296-wk-Fact-6F6A179CB1E663FB4CA1F6259D71CBB7" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2300-wk-Fact-19C6D2468E4FE65578B9F6259D62B8F9" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2304-wk-Fact-ADB46811B1B17938C579F6259D81AC42" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2319-wk-Fact-0E8D44ADE3BB672596F8F6259D81B710" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2323-wk-Fact-6EDF670AD27ED3D62C34F6259D81C455" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2327-wk-Fact-17D1AF9D526AF59A8697F6259D62566B" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2331-wk-Fact-05ACF1EDB334962654D2F6259D62BBCF" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30746986e2342-wk-Fact-73733D18B05449FF3C85F6259D819E7A" name="us-gaap:DerivativeTermOfContract" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" format="ixt-sec:durwordsen">four months</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2346-wk-Fact-909083BE32D596435A33F6259D9121FB" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2350-wk-Fact-1D239D2206F85D264DABF6259D9194C5" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2363-wk-Fact-89B2D21CE7404F19AE00F6259D81787D" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2019Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e2367-wk-Fact-47857C7F3BA4771A9DC1F6259D815A77" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-075AF5D8F266C965C926F6259DC2876D-0-wk-Fact-61BE2846E276FDBE5FA6F6259D810D28" continuedAt="TextSelection-075AF5D8F266C965C926F6259DC2876D-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e2901-wk-Fact-3DA3FFD54087E843325FF6259D627A11" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2920-wk-Fact-304ECEEC2C90C36D78A1F6259D330E07" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e2950-wk-Fact-C236E5B439BE3D5CECEEF6259D71DBB1" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e2969-wk-Fact-72D5DF082D48E6FCCB0BF6259D52C309" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e2999-wk-Fact-197CCB6228958F801136F6259D332EA3" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e3018-wk-Fact-3CEFE635FA79715F91BCF6259D23D1B1" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-3"><ix:continuation id="TextSelection-075AF5D8F266C965C926F6259DC2876D-1" continuedAt="TextSelection-075AF5D8F266C965C926F6259DC2876D-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e3540-wk-Fact-18DEC2D7E8D0E62FC87EF6259D71F3BC" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e3559-wk-Fact-56403951DCB833E01216F6259D71A1C4" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e3589-wk-Fact-627EE73898D62802268FF6259D71757B" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e3608-wk-Fact-61264814CA0C0D6E8CFCF6259D7166BE" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e3638-wk-Fact-33F027FF62BF5D153D96F6259D71EE47" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e3657-wk-Fact-71AB2632680A50DB28F0F6259D71E93B" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-075AF5D8F266C965C926F6259DC2876D-2"></ix:continuation>For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e3683-wk-Fact-8716DF20665A9DA71B9DF6259D62D09A" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">934.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e3687-wk-Fact-4FEA25650C3D111DDFBCF6259D62760A" name="invest:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">735.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e3699-wk-Fact-20221B93786627B4F9E7F6259D620116" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e3704-wk-Fact-E60DBCAA50DC236250A4F6259D62AD09" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, related to these contracts were recognized as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e3716-wk-Fact-D28CED96013096720CB3F6259D62301C" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30746986e3720-wk-Fact-D52428CDAD87D45D7FC7F6259D62CB4E" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be materially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-77657BA7565CB86B44E3F6259DD272D3-0-wk-Fact-000E62AA9EE763F5F7DCF6259D62EA0E" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e3901-wk-Fact-4D0E6292891C1D996D0CF6259CF5F1A9" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e3920-wk-Fact-97EF2A63882816110592F6259CF5CC59" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e3955-wk-Fact-3372FFDCC4E225DEF5CBF6259D14B69C" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e3974-wk-Fact-5EDFA62D4E0CD3159033F6259D042A6C" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e4009-wk-Fact-4BC7638579EEE683A5BA0698DE86A7EA" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e4028-wk-Fact-B0125C3991FD1FA6B0EB0698E3667F34" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e4119-wk-Fact-6F6A179CB1E663FB4CA1F6259D71CBB7" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e4138-wk-Fact-19C6D2468E4FE65578B9F6259D62B8F9" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e4229-wk-Fact-E107F55EECABB4192F01F6259D044B0E" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e4248-wk-Fact-080CAE81AC109A66F62DF6259D1420D2" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30746986e4283-wk-Fact-C016C61F4484467046F8F6259D04D2B3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30746986e4302-wk-Fact-4C411F622053B093E786F6259D04F2E0" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s2FD2B0FFF68055E2A516E9FC8C25B76B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-4D48BF0C5ABD06B58031F6259DD2089F-0-wk-Fact-96F4FD2233CD2456F39EF6259D913000" continuedAt="TextSelection-4D48BF0C5ABD06B58031F6259DD2089F-1" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4D48BF0C5ABD06B58031F6259DD2089F-1" continuedAt="TextSelection-4D48BF0C5ABD06B58031F6259DD2089F-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e783-wk-Fact-AE1A9DBB29CFBEB92EDDF6259D33EB3D" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,886.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e787-wk-Fact-0B70B559E666F6DFBFC6F6259D62EA43" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,797.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e814-wk-Fact-9C54F97E22CD5D4C4129F6259D81D526" name="us-gaap:Depreciation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e818-wk-Fact-DC28A760BD29D72322A9F6259D81CEFC" name="us-gaap:Depreciation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">99.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e822-wk-Fact-8C4A8D2B43C234370C81F6259D91C13E" name="us-gaap:Depreciation" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e826-wk-Fact-C6E91CE216F599163984F6259D915756" name="us-gaap:Depreciation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-4D48BF0C5ABD06B58031F6259DD2089F-2"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e847-wk-Fact-26CC5617A8BA7C794BCEF6259D62F39C" name="us-gaap:ConstructionInProgressGross" contextRef="FI2019Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e851-wk-Fact-C29D09488DFF0C8A94EDF6259D527FC3" name="us-gaap:ConstructionInProgressGross" contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.6</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e860-wk-Fact-A54DEFAC6CF2335F33DBF6259D43EA69" name="us-gaap:OtherCommitment" contextRef="FI2019Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e870-wk-Fact-9CC2BD390BD3FCDC0482F6259D33BD90" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">641.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment, which is primarily comprised of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e874-wk-Fact-1EB8DB73B34AD8F49F68F6259D33398B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">318.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30726225e878-wk-Fact-45F64D2867591F233ABAF6259D91FB1C" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">290.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment, was reclassified to assets held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Additionally, we ceased recording depreciation on these assets as depreciation is not recorded during the period in which a long-lived asset or disposal group is classified as held for sale, even if the asset or disposal group continues to generate revenue during the period. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><a id="s56E7B1AC84DA59BC85658A3C1FE337EE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-5B3736B2C2A90FC38FDDF6259DD2C60E-0-wk-Fact-F0BB0091E7C9C0BAD678F6259CF511C2" continuedAt="TextSelection-5B3736B2C2A90FC38FDDF6259DD2C60E-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5B3736B2C2A90FC38FDDF6259DD2C60E-1" continuedAt="TextSelection-5B3736B2C2A90FC38FDDF6259DD2C60E-2"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30750655e783-wk-Fact-5A9425D0AA001FE21AE4F6259CF52E44" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30750655e787-wk-Fact-34EA79FE0AB36C8CBDC7F6259CF5FEC6" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">nine years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30750655e791-wk-Fact-515B77CA63F47DCCBC6DF6259D0410E2" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30750655e795-wk-Fact-5F03D5B2BA0E4FA0484FF6259CF51CF5" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">six years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30750655e802-wk-Fact-5A9425D0AA001FE21AE4F6259CF52E44" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30750655e806-wk-Fact-34EA79FE0AB36C8CBDC7F6259CF5FEC6" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">nine years</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. <ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:LesseeLeaseTableTableTextBlock" id="TextSelection-3653D8B04750A998B55FF6259DD20086-0-wk-Fact-5502341294A2692E07FEF6259CF5FBB9" continuedAt="TextSelection-3653D8B04750A998B55FF6259DD20086-1" escape="true">The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3653D8B04750A998B55FF6259DD20086-1"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:41%;"></td><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e916-wk-Fact-982A881E359388C90474F6259D23AB24" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">434.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1008-wk-Fact-4210CC62A7B5C7E4F915F6259D14FCEC" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1033-wk-Fact-B6E9AE5FE872EF2AF1E3F6259D716AF3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">423.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1068-wk-Fact-07F8B45417E3FDA5651BF6259D14C1A2" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">495.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-0A677035A751416D56B6F6259DD2D868-0-wk-Fact-93A7BE1C2E333B61A0E3F6259D04E4AF" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:35%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1227-wk-Fact-9E232E66145FB5ADB331F6259D14B25D" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1246-wk-Fact-DEE20885A3D98DD187CAF6259D233DD0" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1271-wk-Fact-96B807E854375A785A41F6259D2309C7" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1290-wk-Fact-952DD864E02E1362C476F6259D2302BA" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30750655e1320-wk-Fact-D7E291807C774BC359C1F6259D235E32" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30750655e1340-wk-Fact-19E6DA66E5CACE79DCF2F6259D14B4C0" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30750655e1371-wk-Fact-C3716E88A12DD4BAB25EF6259D23FBC1" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30750655e1391-wk-Fact-F688F33D501E6BE1A9C9F6259D144EC7" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1427-wk-Fact-5F5BF9B8E9F21213BA3FF6259D14539A" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1446-wk-Fact-52EF3BA127F788901F6DF6259D23634B" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-5B3736B2C2A90FC38FDDF6259DD2C60E-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-0FA8BE529936E6E0F9DCF6259DD232A1-0-wk-Fact-87D2786518C53A8246EAF6259CF5BD4A" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1510-wk-Fact-F72F476448A2B5FEBF3DF6259D23FC65" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1525-wk-Fact-3C6F3BC39E6645E9FF34F6259D23D18D" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1545-wk-Fact-1B67D0481758C721397DF6259D230675" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1565-wk-Fact-9135633810B7E55DADFEF6259D23776F" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1585-wk-Fact-ABCBF8200419AA35650FF6259D2361D7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1605-wk-Fact-B732E32787DA67D0CB10F6259D23E10B" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1625-wk-Fact-9F15F84CEF38F6A3C045F6259D23CFA8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">147.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1650-wk-Fact-80FE15569FC7CA5E93A7F6259D2396A3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">560.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1665-wk-Fact-C9B079B508F89A2331C9F6259D238EA5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e1690-wk-Fact-07F8B45417E3FDA5651BF6259D14C1A2" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">495.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-65279FDFE0FCECA80623F6259DD27600-0-wk-Fact-43F14451B7F202D36083F6259CF51251" continuedAt="TextSelection-65279FDFE0FCECA80623F6259DD27600-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e1901-wk-Fact-77D1E72684827B19B951F6259D810AC6" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e1920-wk-Fact-3A1E898190DAD5DC1FF9F6259D819569" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e1939-wk-Fact-B3768A01D5772792E720F6259D817CBC" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e1959-wk-Fact-743E90644AC23CA3624CF6259D81C028" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e1978-wk-Fact-1EEFAD447BC64C8C4C6EF6259D8151CB" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e1998-wk-Fact-6FA8A0FADAE5BA1151FCF6259D811947" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2017-wk-Fact-F5F8B2577B9BB0A66845F6259D816A3E" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">601.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30750655e2034-wk-Fact-4C17B5B1AE8E509E84D6F6259D81EE96" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30750655e2054-wk-Fact-05711542E37DCA138910F6259D81A584" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30750655e2074-wk-Fact-69914606D236DC951180F6259D814CCC" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30750655e2095-wk-Fact-2B5A513BA2A6549524F4F6259D8188BA" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30750655e2115-wk-Fact-1593F794B286FBDAAF6CF6259D8123FD" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30750655e2135-wk-Fact-CE62D962E49D4A53D672F6259D81BCF9" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30750655e2156-wk-Fact-D08C277F7913D93983C9F6259D81C569" name="us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2182-wk-Fact-34A1BEEDE557E3ABDDC4F6259D81367B" name="biib:NetMinimumLeasePaymentsWithInOneYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2201-wk-Fact-92037651648184F79D28F6259D81BFF9" name="biib:NetMinimumLeasePaymentsWithInTwoYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2220-wk-Fact-E85C9C4E1D7F86053D27F6259D816504" name="biib:NetMinimumLeasePaymentsWithInThreeYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2240-wk-Fact-2DE186413A5AE7A3EDF3F6259D8179A2" name="biib:NetMinimumLeasePaymentsWithInFourYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2259-wk-Fact-93366D1D94898F25416CF6259D819EA9" name="biib:NetMinimumLeasePaymentsWithInFiveYear" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2279-wk-Fact-C66CB034FE659D94B67CF6259D81C79A" name="biib:NetMinimumLeasePaymentsThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">156.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30750655e2298-wk-Fact-2B6175FFE3FECFE79CB3F6259D813CD7" name="biib:NetMinimumLeasePayments" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">418.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-65279FDFE0FCECA80623F6259DD27600-1" continuedAt="TextSelection-65279FDFE0FCECA80623F6259DD27600-2"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><ix:continuation id="TextSelection-65279FDFE0FCECA80623F6259DD27600-2">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.</ix:continuation> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" id="TextSelection-57020AC20623390E8D5CF6259DD20E0D-0-wk-Fact-2B435090103F08C70EDCF6259CF573D8" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:83%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonNumeric id="d30750655e2362-wk-Fact-27F2C70AF03DD83C8EA9F6259D6200DD" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q2" format="ixt-sec:duryear">7.4</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e2377-wk-Fact-BA0B44F116CE4BE43632F6259D621481" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q2" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock" id="TextSelection-2524C326173CCB1B4317F6259DD2F644-0-wk-Fact-7EC28A33B1F294432ADFF6259CF54FCC" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e2505-wk-Fact-0820543F82216E37B40FF6259D434628" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e2524-wk-Fact-9E48CBC7E90E3A9F5A65F6259D43B85A" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e2544-wk-Fact-2C4AA462F3A36B74EB32F6259D434C75" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30750655e2563-wk-Fact-1FAF694030210BDAA572F6259D43E490" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30750655e2579-wk-Fact-68222E790FDC7DC9CFFAF6259D23A1D0" name="biib:DisposalGroupOperatingLeaseAssets" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease assets and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30750655e2583-wk-Fact-E3C36D505E12C7919E77F6259D710ECB" name="biib:DisposalGroupOperatingleaseliabilities" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease liabilities were reclassified to assets and liabilities held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><a id="s669B54340A5E554AADDCD536A05B8A69"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-8D93770C6B588FCA1026F6259DD2E1D5-0-wk-Fact-632A585B3210540DA298F6259D4310A8" continuedAt="TextSelection-8D93770C6B588FCA1026F6259DD2E1D5-1" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8D93770C6B588FCA1026F6259DD2E1D5-1" continuedAt="TextSelection-8D93770C6B588FCA1026F6259DD2E1D5-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e783-wk-Fact-450C6BB453BC2A393D67F6259D522B61" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e787-wk-Fact-702D6C363B8C3451B42C06A0CA6A9A3B" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e791-wk-Fact-104EDE293B9EB3F37E8C06A10D41F600" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e804-wk-Fact-C6D6204832EC1946EEF106A213DC12F9" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.1</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e815-wk-Fact-E27D322FD36422E59026F6259D91CD4E" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e819-wk-Fact-FB18DD1158E76EAF820FF6259D81978A" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e823-wk-Fact-07C31B8D47FD34F4777EF6259D718213" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e827-wk-Fact-EEC7A3B95A27ED74A03CF6259D81B4D8" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e831-wk-Fact-B452EBBD67A787F99B19F6259D91DD1B" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.1</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e847-wk-Fact-A1CAEC14013E4D37E760F6259D235A37" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e851-wk-Fact-2574FB36243025E2558CF6259D915398" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e855-wk-Fact-72B7F4F56DA6C53650B5F6259D915B9D" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e859-wk-Fact-612932E491E4B5924E17F6259D62D954" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">2.75</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30752799e863-wk-Fact-C37C7EFD0C2471B0EE4BF6259D71AC64" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-1D9FC69F3BDF3D3A5FC8F6259DD2B2D2-0-wk-Fact-8174D75856F21282A834F6259D235A88" continuedAt="TextSelection-1D9FC69F3BDF3D3A5FC8F6259DD2B2D2-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1080-wk-Fact-ADAD6EAF783AAA6DC31FF6259D5213AB" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1100-wk-Fact-FC5B281E9AFF12527CA8F6259D81796B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1120-wk-Fact-90F66A6A0023934CC896F6259D62490E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1139-wk-Fact-0B976B1C523735E1B684F6259D9121DA" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1159-wk-Fact-8A74AE3068D3E11E16A0F6259D2369F1" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">243.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1180-wk-Fact-25428E0E08BD0DBCBF49F6259D237069" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1201-wk-Fact-BCDCAD15C56559C893F0F6259DA019F8" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1220-wk-Fact-5A8F69C5B829D9959D41F6259D91BC3B" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1239-wk-Fact-DAF55FA0993E0C67D86DF6259D91085A" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1259-wk-Fact-D0C2BEA3ECC8970D56CEF6259D525441" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1278-wk-Fact-5D00FFEBFF5E608D3B4AF6259D7166CD" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1299-wk-Fact-C40C14A4E80539644F81F6259DB0C35B" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1324-wk-Fact-8516F1A9EE6955349DA4F6259D235160" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1344-wk-Fact-09416282FE8E7D7A78A1F6259D81002E" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1364-wk-Fact-45A3AD63EE8849B0E70BF6259DA2E036" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1385-wk-Fact-C1453C765A3B8FCB8AE8F6259D810456" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1404-wk-Fact-732C500BF7DB64117BD0F6259D719E33" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1424-wk-Fact-12D7A870B0AA76EF89B2F6259D91BD6E" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1450-wk-Fact-EA456DFD5D71EAB1E825F6259D712B6F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1469-wk-Fact-D3E7357D4C0D542413DEF6259D23B45A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1489-wk-Fact-073D69E9BDEDFFB6C4B9F6259D23DF14" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1509-wk-Fact-BD5E0D2B27ECD97C91EFF6259D23B557" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1528-wk-Fact-DDF70D4AA8EEED8BB109F6259D52859F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1549-wk-Fact-6440C377A189830524FFF6259D141ACB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1580-wk-Fact-F78C597B811F3ACBAB68F6259D62B795" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1599-wk-Fact-B7EA0D5BADFB9000B640F6259D7198BF" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e1619-wk-Fact-6A82326B82C74DA096D4F6259D7104A4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1638-wk-Fact-D19E725CCD93D61241EEF6259D810AA9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">30.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1658-wk-Fact-EFF9D6F37C700BBF7618F6259DA32B0B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">271.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e1679-wk-Fact-87EBCA1CDEFC1D44DA24F6259D23F60D" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8D93770C6B588FCA1026F6259DD2E1D5-2"><ix:continuation id="TextSelection-1D9FC69F3BDF3D3A5FC8F6259DD2B2D2-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e1869-wk-Fact-01B19C1DF7ADFE57E42BF6259DB2F08F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e1889-wk-Fact-1BB4DC2321646B7EFAD9F6259D52ABA6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e1910-wk-Fact-45CAD75D0FF879CAED84F6259DB2CB00" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e1929-wk-Fact-92321B7093899203F92AF6259DB283EE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e1949-wk-Fact-DDFE6D7EDECEFB585DBCF6259DB2884C" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">175.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e1970-wk-Fact-99C1C50DD8DB7C11A500F6259D5211F8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">318.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e1991-wk-Fact-422E6C0280067FFA32EAF6259D52C65D" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2010-wk-Fact-204D1DB54A0BC27A56A7F6259D526F69" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2029-wk-Fact-259606EB02EB31D92BFCF6259DB25584" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2049-wk-Fact-60984DD5D42426B1E05FF6259DB227A5" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2068-wk-Fact-43373B31E41DD6018769F6259D520D54" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2088-wk-Fact-7E3A54DF26E4A28CF038F6259D5299E2" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2113-wk-Fact-1831EB7B43F8278C7B0BF6259DB27DB4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2133-wk-Fact-F44BB06922597EC06AA5F6259D522963" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2153-wk-Fact-BF0D8D57B03E92A4BCE1F6259DB2CF87" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="0" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2173-wk-Fact-581602670694F1D9E1C7F6259DB298A3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2193-wk-Fact-7EE365DC620985BBD001F6259DB2D710" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">175.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2214-wk-Fact-A7F837E84505ABD156C1F6259D5222C2" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I2018Q1ASUadoptiondate" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">316.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2240-wk-Fact-6B81E61DC8BED74F4803F6259D52EEB3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2260-wk-Fact-D8607F8BABCDF72405AAF6259DB24DC3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2279-wk-Fact-2201DDACCC9DB6E55930F6259D52EB58" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2299-wk-Fact-D125AB16E26F804670B9F6259D520872" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2318-wk-Fact-A1BCDF905A48808FD718F6259D52C542" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2339-wk-Fact-B0B68B47669DB5C6447CF6259D524DAE" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2364-wk-Fact-A14F4DAEEFB1E93D5901F6259D52FD18" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2383-wk-Fact-34F8DD378CA4F3D4DC89F6259D522FB7" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2402-wk-Fact-3DB3638E7962168E96F3F6259DB243EA" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2422-wk-Fact-C629B55FF06C66AF067AF6259D52D1B8" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2441-wk-Fact-412652A46E39A22FB0F8F6259DB24ECA" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2461-wk-Fact-BDE8E4AD7799A66C3352F6259DB29B99" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2486-wk-Fact-841DD78D4FD8A0C046E5F6259DB272A1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2506-wk-Fact-D5CD60B7A9EF86753EDAF6259D52D393" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2525-wk-Fact-20145C544EF5FE89B5CCF6259D52CDF0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2545-wk-Fact-E66C211CF5BD18C17BA2F6259DB22167" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2564-wk-Fact-F91518CDB16D99DF9692F6259D52CFDE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2585-wk-Fact-53C30F8A2D37A0D5D15EF6259D14796F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2615-wk-Fact-D87D6FAE2DA719DE4CCEF6259D526687" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2635-wk-Fact-2D37A11FED790152DFEEF6259D522100" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e2656-wk-Fact-5C68895A5EA184375E5AF6259DB2A50E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2675-wk-Fact-6D95DA49B1445DCBEDA2F6259CF51FB3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2695-wk-Fact-C868416D4A782CC006BFF6259DB2FC6B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">222.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e2716-wk-Fact-83E86FCB8C749BA72D4AF6259D52BBB8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">261.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="TextSelection-F68A1210F1D29B7CCA35F6259DD2F342-0-wk-Fact-9110668B775DAEFC3D34F6259D91A9C1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:26%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3066-wk-Fact-929E6FB0C9BE16FA899EF6259D430DEB" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3085-wk-Fact-A44A323FFD19AE400171F6259D4336DB" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3105-wk-Fact-745ED82F1020C79A7A4AF6259D43522C" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e3124-wk-Fact-225DEB74D58B2320CF00F6259D43E864" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e3150-wk-Fact-D0E46A0091D5540E4B10F6259D43D48A" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3170-wk-Fact-25309EF474A47A95FA68F6259D437F08" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e3190-wk-Fact-2905F5B8B3771C126304F6259D437F59" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3210-wk-Fact-782F6ED1C983D39CDA58F6259D43CBD0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3332-wk-Fact-F34E93E0FC7D210FB8A6F6259D43EA52" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e3351-wk-Fact-1F9AB92FD2974CB1EBAFF6259D43377D" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3372-wk-Fact-EA7F6DB0F62074C2B86CF6259D436F7B" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e3391-wk-Fact-7409598BF096162277F5F6259D431FAB" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e3422-wk-Fact-7FF3E3FE85174AF00881F6259D43EFB3" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e3442-wk-Fact-9892DD34CCFCB0ACB404F6259D43BF96" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e3463-wk-Fact-49886C073FEE81B3938DF6259D4359CB" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3483-wk-Fact-FE813EA5B094346E0479F6259D43EA2D" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3513-wk-Fact-DB41B5791EBF8152193BF6259D71AE67" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3532-wk-Fact-D8F2912412FF5F37873FF6259D43AA93" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3552-wk-Fact-2D7D8B5C5001EAC9DFC2F6259D43EBF3" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3571-wk-Fact-DA1FD042F985D48A87BCF6259D43F423" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e3601-wk-Fact-C54F0AB6B0E0FEB1EA37F6259D52E0C0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3621-wk-Fact-B0E30E485AEC49D72D59F6259D239A7F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30752799e3641-wk-Fact-C3C11D290F5C44D79F9DF6259D43A9AB" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3661-wk-Fact-1B478B3D548035826487F6259D43F61B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3784-wk-Fact-27E58A78074D44046961F6259D43B269" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3803-wk-Fact-8EE98904607C99892B96F6259D43C1C6" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3823-wk-Fact-FC9226F136D6FF28217CF6259D4362D7" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3842-wk-Fact-ED80EC3356CF997826A8F6259D434FF5" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3872-wk-Fact-4AB868BB19612DFF4BBFF6259D4330FA" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3891-wk-Fact-0FA7DFF75D62A6E4DB37F6259D435BA0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e3911-wk-Fact-E162D32271D89E0FCB5EF6259D433FA7" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30752799e3930-wk-Fact-BD7D1B8A758FB192EAC7F6259D430189" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e4057-wk-Fact-F369B9825F0087789A55F6259D4396C9" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e4076-wk-Fact-C82173C565F5C57CCE10F6259D43EAB4" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30752799e4097-wk-Fact-0B520EACEB247263A4ECF6259D434DC4" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30752799e4116-wk-Fact-2EEEEAE3EC85135BE24AF6259D4330F2" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><a id="s071AF11D0A085B7F8F98D600069BDF17"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-3C7A393C829A07CED889F6259DD2F88F-0-wk-Fact-967381669694E08A0CA1F6259D5298B0" continuedAt="TextSelection-3C7A393C829A07CED889F6259DD2F88F-1" escape="true">Earnings&#160;per Share</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3C7A393C829A07CED889F6259DD2F88F-1"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-5095988AFE556107F3D4F6259DD22B30-0-wk-Fact-C6B9E0AE10E76ED031B8F6259DA488C7" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1077-wk-Fact-1312D56524962A9DE5E6F6259D623531" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1096-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">866.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1115-wk-Fact-4C12FF47E79C07429E22F6259D717E32" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1135-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,039.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1232-wk-Fact-3DD915C4195E7A211C58F6259D14C30A" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1251-wk-Fact-FBB66D5A57657FD9D1A8F6259D04C4C0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1270-wk-Fact-D6A6A637EC02E81810FBF6259D2321A2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1290-wk-Fact-D23833DF65E5DC2469C7F6259D046BE6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">209.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1392-wk-Fact-5751B324E1913CDED278F6259D7191E7" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1411-wk-Fact-DD5FEEB703C2CF84CB26F6259D71BB37" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1430-wk-Fact-6F27A6F556636AF6971DF6259D714029" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1450-wk-Fact-C34E8235B209E8F68F20F6259D711F31" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1470-wk-Fact-276CE15A2F68BFE86E6DF6259D71EBBA" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1489-wk-Fact-D22682380E513186FE97F6259D714514" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1508-wk-Fact-DF604FE47373CC8539C5F6259D71F0FF" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1528-wk-Fact-610E82D6140287132ACEF6259D7161CE" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1548-wk-Fact-97A42FB55654AECFC72AF6259D71DF5B" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1567-wk-Fact-5D1AF68264A36DB2C56CF6259D712577" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1586-wk-Fact-1105087E5AA3A2AA5C86F6259D71C48E" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1606-wk-Fact-4DE99D56D14618FD4E65F6259D7103E1" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1626-wk-Fact-DEE4D28431B34CD3CD6FF6259D71F3C0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1645-wk-Fact-9AAEFA125707B196A12EF6259D71AABE" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1664-wk-Fact-EFD4021373DBDE8E18F0F6259D71326D" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1684-wk-Fact-D9883D123D12914434E3F6259D710965" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1705-wk-Fact-EFA4D44B853EFAD7DA09F6259D7181DC" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1724-wk-Fact-D7E80FCE415B2EFB6107F6259D718566" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1743-wk-Fact-5713D77DEF68FCC5468AF6259D712709" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1763-wk-Fact-0055ED568A2706062425F6259D71D1A3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1783-wk-Fact-735BC5DA3214A5F5DB05F6259D23547F" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1802-wk-Fact-8878D9126D3CB451B07EF6259D23E3E0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">207.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30753987e1821-wk-Fact-561BED1750D028A1FC26F6259D23DF4C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30753987e1841-wk-Fact-C1F390AE19DCE6838E36F6259D6231B8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">209.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:continuation><div><a id="s738F4210B89D5D489999AA195896323C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-39F693B8604FD1EC2A94F6259DD220A1-0-wk-Fact-5D43C1EFBF331FA09AD1F6259DA71F23" continuedAt="TextSelection-39F693B8604FD1EC2A94F6259DD220A1-1" escape="true">Share-based Payments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-39F693B8604FD1EC2A94F6259DD220A1-1" continuedAt="TextSelection-39F693B8604FD1EC2A94F6259DD220A1-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-A5FF4B96F4FC3CEF8608F6259DD2D7EF-0-wk-Fact-4FA46E31CE608B634C47F6259DA786FA" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e998-wk-Fact-B511B8B9DB992AB4246BF6259D71DC3F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1017-wk-Fact-C68EEDE73D3B9F227A9FF6259DB214BC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1036-wk-Fact-173985EB2A1D14502DD4F6259D040D9D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1056-wk-Fact-9DEE8E331C091123F5EFF6259CF56F0E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1071-wk-Fact-E2BB6BB3885C8EA92F17F6259CF5B85E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1090-wk-Fact-8A5E0019CD8669E3CF46F6259CF59531" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1109-wk-Fact-E72295CA19D419E852A7F6259D719F5A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1129-wk-Fact-EDD003F48046F334FC44F6259D714360" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1149-wk-Fact-5A4E58142BF025B63C0DF6259CF56418" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1168-wk-Fact-741AC17027968767B1BFF6259DB2BDF1" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1187-wk-Fact-69717924EA814EF78A97F6259CF55E82" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1207-wk-Fact-BABEC81DE8B988E1008EF6259CF54E25" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757294e1227-wk-Fact-334611AA556B9EF1852EF6259DB2004C" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757294e1247-wk-Fact-6F1F12EB33D46D3F5C6AF6259CF51578" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757294e1267-wk-Fact-44ABA89604925E034C5DF6259D04B937" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757294e1288-wk-Fact-68730807DCA596141992F6259CF5F060" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1309-wk-Fact-3D20C17CD05B4C585BFCF6259DB2A441" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1328-wk-Fact-5F1156F1E986547E3849F6259CF5C5DB" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1347-wk-Fact-181CBD06A256337A3813F6259CF54DEB" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1367-wk-Fact-B7A1CB31B7389051850CF6259CF587BA" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757294e1387-wk-Fact-5324F451FE0938CFC7CCF6259DB2FF0C" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757294e1407-wk-Fact-B446EA1442B396E5186CF6259CF59DD9" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757294e1427-wk-Fact-EF691CCA86EE7FA06775F6259D716DF3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757294e1448-wk-Fact-17FB14B47FA6E090A05AF6259CF5B8B1" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1474-wk-Fact-3325DA0BAD38DD2B6182F6259DB22542" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1493-wk-Fact-FFA01D15009BBD0CDA18F6259D714C33" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1512-wk-Fact-4E7CE436AD553471A032F6259CF57F11" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1532-wk-Fact-5DB1A62BBF7E25466143F6259D71AE8C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-39F693B8604FD1EC2A94F6259DD220A1-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="TextSelection-7E5389B698B143C6797CF6259DD204B7-0-wk-Fact-BB7F8F76DA548D70A59CF6259DA764A6" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1761-wk-Fact-71B86506C4B2C3D4B16BF6259DB29D27" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1780-wk-Fact-A4E67E4FEEA23E1B9234F6259DB2EC63" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1799-wk-Fact-9D669B86B819253848DCF6259DB29172" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1819-wk-Fact-EDD22506E9133AE680CEF6259DB2D0F9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1834-wk-Fact-7A4C87C3FEDA0BC316E2F6259DB23EED" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1853-wk-Fact-9DB68F2272A9B9C82B0CF6259DB278BD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1872-wk-Fact-C1B8DCB3E99D38829DEEF6259DB23580" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1892-wk-Fact-E7476342D221A9C9239FF6259DB27F31" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1912-wk-Fact-14051AAC2EDCAEEE369FF6259DB2AAD4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757294e1931-wk-Fact-7F2B7959BCBE0DDC8027F6259DB20518" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757294e1951-wk-Fact-C34451D0F296F161A8A8F6259CF5FF55" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e1972-wk-Fact-46BB34011B7100B3C43AF6259DB24ACE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e1992-wk-Fact-B3F7F677881F1A14FFFFF6259DB2C1EA" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2011-wk-Fact-9402CCB39DEE7D7327B8F6259DB27E6A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2030-wk-Fact-56861D01F6791F2A7D6DF6259DB2C65F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2050-wk-Fact-1E93843C56D5F71F7F07F6259DB24C6C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2070-wk-Fact-8D95D9461642651A68D9F6259DB2B3E5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2089-wk-Fact-9BE68D97FB17CD39817BF6259DB28975" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2108-wk-Fact-6595F186D034052637FEF6259DB2C931" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2128-wk-Fact-61A18A823E386CD10BD2F6259DB2B1A3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2148-wk-Fact-E4D03D8B70BCB333F95AF6259DB20A7C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2167-wk-Fact-92ABF63EC7DBABC1BBE3F6259DB2B9FD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2186-wk-Fact-4124F5B5277754A53009F6259DB2C56B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2206-wk-Fact-6C9D33A95EE09BCF8FC9F6259DB29606" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2226-wk-Fact-DE80FADC9813280B4600F6259DB24043" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2245-wk-Fact-4A89E407E15788498D51F6259DB27670" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2264-wk-Fact-72EB6F30B48A080F9D1EF6259DB2268E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2284-wk-Fact-CE94966F68B92871737DF6259DB2C3BE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2304-wk-Fact-73B6240E0F150233C17806A6B3B86785" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2323-wk-Fact-810677FF1DBA4AFC142306A744FA4814" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2342-wk-Fact-BF7E2C58CA3FD825FF0806A6F0D5139B" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2362-wk-Fact-05DD6C6914B68219BECB06A71D653261" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2382-wk-Fact-5A4E58142BF025B63C0DF6259CF56418" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2401-wk-Fact-741AC17027968767B1BFF6259DB2BDF1" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2420-wk-Fact-69717924EA814EF78A97F6259CF55E82" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2440-wk-Fact-BABEC81DE8B988E1008EF6259CF54E25" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757294e2461-wk-Fact-334611AA556B9EF1852EF6259DB2004C" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757294e2481-wk-Fact-6F1F12EB33D46D3F5C6AF6259CF51578" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757294e2501-wk-Fact-44ABA89604925E034C5DF6259D04B937" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757294e2522-wk-Fact-68730807DCA596141992F6259CF5F060" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2548-wk-Fact-3D20C17CD05B4C585BFCF6259DB2A441" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2567-wk-Fact-5F1156F1E986547E3849F6259CF5C5DB" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757294e2586-wk-Fact-181CBD06A256337A3813F6259CF54DEB" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757294e2606-wk-Fact-B7A1CB31B7389051850CF6259CF587BA" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock option expense reflects the accelerated vesting of stock options previously granted to NST employees as a result of our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><a id="s615386F9FE6C5DF0AEB4D9FD4C19E392"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-64BC892B7BEBA480B6A1F6259DD2B36E-0-wk-Fact-B3C22834AF8782ADD1C8F6259D81070D" continuedAt="TextSelection-64BC892B7BEBA480B6A1F6259DD2B36E-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-64BC892B7BEBA480B6A1F6259DD2B36E-1" continuedAt="TextSelection-64BC892B7BEBA480B6A1F6259DD2B36E-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-4BFD5B727F0CAA25CA95F6259DD278A0-0-wk-Fact-0F6C0E6914CA0171626AF6259D814314" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e949-wk-Fact-3129734233234053B136F6259D5227B6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e964-wk-Fact-2C0BC2F9B66A1FDEEE80F6259D52AE43" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q2QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e979-wk-Fact-6C5AF0BD23463090B391F6259D528E6A" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e994-wk-Fact-696B5E69B182628278BDF6259D527E08" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1011-wk-Fact-4E8710AC21A61BA4AFDAF6259D528D96" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1025-wk-Fact-F6A051F2DC84440D4092F6259D52E014" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1039-wk-Fact-2D3320B987BB105D05E3F6259D5284CB" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1053-wk-Fact-B5968F98BB4D29AAAD82F6259D52F205" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757297e1069-wk-Fact-1159262E6C993C878A07F6259D52544D" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757297e1084-wk-Fact-960BF2355277623A3F39F6259D43E663" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757297e1099-wk-Fact-474A0309103CFF646A06F6259D523649" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757297e1114-wk-Fact-CA2C6198D1D69E1F071CF6259D5209FA" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757297e1131-wk-Fact-EDD50968240707E44116F6259D523E7F" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757297e1146-wk-Fact-B4EDA84EC6AE13807677F6259D52698D" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757297e1161-wk-Fact-B529321409CEC8C5FADAF6259D528F09" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30757297e1176-wk-Fact-515A7582A8B40A48CC33F6259D5275A6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1193-wk-Fact-D0EA032A9698AE2EB130F6259D5251A9" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1207-wk-Fact-E7094419BEDB8E6DF5C8F6259D52B736" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1221-wk-Fact-93ABC2F87F6826D88105F6259D527AD7" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1235-wk-Fact-86BB758115D20A5C65C0F6259D522F55" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark assets held for sale</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1251-wk-Fact-0BCE2F82D21F82DF6491F6259D529843" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1265-wk-Fact-29DBE4D92E44432007C8F6259D520443" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2018Q2QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1279-wk-Fact-BD359459777F687D2EFEF6259D52B7C1" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1293-wk-Fact-3ECC1875EEC0103E3010F6259D5202DA" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2018Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757297e1309-wk-Fact-09085D269CB60D14FFBD0AFCDFD932FF" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1324-wk-Fact-179EC99B1E6A4C42B85D0AFCF8538E3E" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30757297e1338-wk-Fact-C554B8F2915A3F58F14C0AFD23842EA0" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1353-wk-Fact-35AA6450D6444697D03D0AFD4A068A2A" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Global Intangible Low-Taxed Income (GILTI)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1369-wk-Fact-29DF6566572B77E71458F6259D5249B2" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1383-wk-Fact-FCD7756E26FF4B117EBCF6259D525948" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1397-wk-Fact-910DD8DDDCA5C292D29FF6259D526D77" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1411-wk-Fact-4B2E0CAD7F029A6BDA14F6259D52E1C2" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1427-wk-Fact-BA526238642074CAB62DF6259D5214B4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1441-wk-Fact-43215CC2D71811F74D23F6259D5261F1" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1455-wk-Fact-AB18D69523007EDF7386F6259D52ACF4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1469-wk-Fact-F9397001DD1BEC67E4A5F6259D52954A" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1486-wk-Fact-0DC1184F605DA119ABBEF6259D435DC8" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1500-wk-Fact-B2E9EB0DE005DAC90FDCF6259D526C10" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1514-wk-Fact-57590215743E3537C1A9F6259D523D23" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1528-wk-Fact-5EE9221660A7DA339FC7F6259D43251D" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1544-wk-Fact-3122850EB26C228709AEF6259D52427F" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1559-wk-Fact-1373B3EEAA9CDD259B93F6259D5207A1" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">22.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30757297e1574-wk-Fact-A913B4916E069B6ED3EBF6259D5274AB" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30757297e1589-wk-Fact-B70CA1DAEBBC197DBBD3F6259D52B180" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property (the effective tax rate decrease from this internal reorganization is not expected to recur post 2019) and a higher effective tax rate in 2018 resulting from the sale of </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-64BC892B7BEBA480B6A1F6259DD2B36E-2"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights, offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30757297e1644-wk-Fact-136D8A2DB49CECD79C24F6259D52E80E" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the proposed divestiture of our subsidiary that owns our Hiller&#248;d, Denmark manufacturing operations and a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Specifically in regard to the Hiller&#248;d, Denmark manufacturing operations, although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of the operations as held for sale and results in a taxable gain in certain jurisdictions.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, we have recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30757297e1654-wk-Fact-034A54F7FF85212C41E30B05048EBCC6" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q2_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">856.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30757297e1658-wk-Fact-25C48B4196ADDBC807F50B09EDDF023D" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2019Q2_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">685.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the second quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">International Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30757297e1684-wk-Fact-938A76F2A87DCA09A17BF6259D810706" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes on certain payments made by our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. We continue to dispute the assessments for all of these periods and believe that the tax positions taken related to these payments are valid. Any amount refunded by SKAT associated with this withholding tax receivable will be paid to our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. This withholding tax receivable from SKAT will be included within the assets that will be transferred to FUJIFILM as part of the proposed transaction. Under the share purchase agreement, FUJIFILM is required to remit any future proceeds refunded by SKAT to us. We have assessed the collectability of the receivable from FUJIFILM and regard it as a contingent gain, which does not meet the probable threshold for recognition under ASC 450, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Contingencies</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and therefore we have recorded a pre-tax charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30757297e1698-wk-Fact-938A76F2A87DCA09A17BF6259D810706" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to write the asset down to zero as a component of the loss on assets and liabilities held for sale in the first quarter of 2019. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also reclassified </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30757297e1705-wk-Fact-8E042DF4EA4562866591F6259D23FE2B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our deferred tax liability to liabilities held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2FFBED0817B6580DAFCD693DF61F5F05"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="TextSelection-08A0F941C8D9D117A569F6259DD2D98B-0-wk-Fact-194E8CFCA052AFE3BC44F6259D71EB9C" continuedAt="TextSelection-08A0F941C8D9D117A569F6259DD2D98B-1" escape="true">Other Consolidated Financial Statement Detail</ix:nonNumeric></span></div><ix:continuation id="TextSelection-08A0F941C8D9D117A569F6259DD2D98B-1"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-63E8B8B76EC01146AAD9F6259DD2D521-0-wk-Fact-D6F75DBF8E447F3A2599F6259D71D97D" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e998-wk-Fact-7B1F227E752840C88A53F6259D71547C" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1017-wk-Fact-D89A01DB704AD746B883F6259D711FC9" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1036-wk-Fact-39EC78C59DF6AD63B127F6259D71E76A" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1056-wk-Fact-EA4CEB60D496492F5DCAF6259D815F57" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1071-wk-Fact-64D9F3FABBF968274AB0F6259D712D23" name="us-gaap:InterestExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1091-wk-Fact-0EF6A5DB586DDB76CDF4F6259D811DE1" name="us-gaap:InterestExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1111-wk-Fact-6B3128268D1C8D4DB812F6259D049EB7" name="us-gaap:InterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">95.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1132-wk-Fact-B278C072A6A9C28EF030F6259CF564A4" name="us-gaap:InterestExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1153-wk-Fact-8E99235A2CC1D5A93A01F6259D816689" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">173.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1173-wk-Fact-BBB18990A1AFF862C253F6259D712F9F" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1192-wk-Fact-E30C9356B86057918D76F6259D71AC5C" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">203.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1212-wk-Fact-30B55D02939A4B0B6C6EF6259D717527" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1233-wk-Fact-FC83FDC95D5EEDDB779BF6259D7160DB" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1252-wk-Fact-AC91782429339CA025E9F6259D8155BD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1272-wk-Fact-86806CFE64829CF1A527F6259CF5F362" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1293-wk-Fact-56D1732C64F58A67C1FAF6259D716CC4" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">14.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1314-wk-Fact-0C5EACAFA0AF436D3711F6259D71B9D1" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1334-wk-Fact-B1BF54109021D9418DD7F6259CF598A0" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1354-wk-Fact-3D7E99AC2A832675CF6EF6259CF5CB1B" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1375-wk-Fact-6E283E3ED149479B9713F6259D81F5B4" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1401-wk-Fact-1D06C1D1506111B2621BF6259D239489" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">197.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1421-wk-Fact-9D3C2F37AB35BFAE8012F6259D232D43" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">34.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1441-wk-Fact-4F4E212D12754366EB0BF6259D4303AC" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1461-wk-Fact-FA4E213E25606EA300E5F6259D2321CF" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">75.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:GainLossOnInvestmentsTextBlock" id="TextSelection-3D2122A9D883D927DC2AF6259DD2E979-0-wk-Fact-1F24EBAAB139C92E8424F6259D712D06" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1642-wk-Fact-71E0469F4F0FD027D67A0B12EF971E94" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">174.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1657-wk-Fact-C6D86EAD6671B23741E50B12EF7C0BAF" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1671-wk-Fact-D1197F618C868111F2500B12EF8396B5" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">201.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1685-wk-Fact-1981B1CBA79744C7D78B0B12EF801144" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1702-wk-Fact-0303B95ABFC854ED921D0B12EF9ABF60" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1717-wk-Fact-CE6A529AF66C2DF92FF80B12EF75657A" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1731-wk-Fact-052752627D18DA599FF70B12EF915131" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">42.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1745-wk-Fact-07EEEDAD692AD242AB360B12EF875DD3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(<ix:nonFraction id="d30759021e1762-wk-Fact-68B07F7CE298C8F992E70B12EF796C95" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">131.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1777-wk-Fact-96B711CDA63E5815DDB50B12EF8D0D4F" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1791-wk-Fact-709B5E9F291C74336B780B12EF8A0249" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d30759021e1805-wk-Fact-CB3BEB0ED6EB66DF602E0B12EF93AC72" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-FA2997BC103FC4DCA272F6259DD2B28E-0-wk-Fact-BD8B4FBCD5E7DD20CA41F6259D71BAF6" escape="true"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1904-wk-Fact-664C6114E7A93753808DF6259D5202EB" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">863.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1923-wk-Fact-2332C6EB86868144FE27F6259D430E8C" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">874.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1938-wk-Fact-BDB45425303197E19B55F6259D23AD36" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">212.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1957-wk-Fact-385A15F813D79734575EF6259D14C483" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">224.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e1977-wk-Fact-C448841029E726782A07F6259D23DB6D" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">199.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e1996-wk-Fact-4D37744F7DD45A710BFDF6259D145524" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">320.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e2016-wk-Fact-F072CB58416A848352BDF6259D149516" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">146.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e2035-wk-Fact-B2D68BC015F832171A36F6259D23BE1E" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">444.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e2055-wk-Fact-3B172870604FD6AC85B2F6259D239B5B" name="biib:Collaborationexpensesaccrual" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">130.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e2074-wk-Fact-083EC9609C074F899B35F6259D14E070" name="biib:Collaborationexpensesaccrual" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e2094-wk-Fact-3D8839FA287DF987E38FF6259D141D69" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e2113-wk-Fact-0270E61648E7F621DF42F6259D2310ED" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e2133-wk-Fact-B208E5442234260D9F45F6259D04BCCB" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">727.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e2152-wk-Fact-5BBFFDAEFB6203BCE239F6259D144157" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">609.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30759021e2177-wk-Fact-D2C177CB69195CA03AC0F6259D33900E" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,318.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30759021e2196-wk-Fact-86E688319B1BFB671A79F6259D3356D0" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,861.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30759021e2222-wk-Fact-8904E7BA29021E7A3B2AF6259D33E1F9" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,355.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30759021e2226-wk-Fact-D6DAB453FA1C7269FD1AF6259D233862" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,389.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30759021e2238-wk-Fact-6800B1C121373EA4E3F7F6259D71ED08" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">801.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30759021e2243-wk-Fact-FD770021538CE8280A58F6259D71F2A2" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">791.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA40A91EA422A5197B0FADCE4D3583807"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-0-wk-Fact-CB802719E78997CC585BF6259D912C31" continuedAt="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-1" escape="true">Collaborative and Other Relationships</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-1" continuedAt="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="TextSelection-20982A016CA37C7CF820F6259DD2B489-0-wk-Fact-7942CE727AE0140E1B96F6259D912194" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1034-wk-Fact-EFBAE164A05731242AFEF6259D52AB11" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1053-wk-Fact-D5FC18004BCAD44EAD42F6259D52F44B" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1072-wk-Fact-312F99746438C5864125F6259D5263D0" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1092-wk-Fact-635F0E6560F3E961612FF6259D52193B" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">111.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1112-wk-Fact-724D7FD84A0F56B423F4F6259D52DB47" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1131-wk-Fact-B26F8769EE06E40D8D85F6259D52C635" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1150-wk-Fact-1D34AF37A6B9BCAE9149F6259D529A2D" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1170-wk-Fact-D8C38730C8E4B9AC2F2BF6259D52D5ED" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1186-wk-Fact-F421E1E50AA6DD8AA475F6259D916078" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1190-wk-Fact-A821BE56FC23499C31B0F6259D9170C2" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. As a result of this decision, in the first quarter of 2019, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1198-wk-Fact-83205B9699764B97F7AAF6259D915357" name="us-gaap:LossOnContractTermination" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1202-wk-Fact-A821BE56FC23499C31B0F6259D9170C2" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense incurred was shared in proportion to the same region-based profit split that would have been utilized to co-promote aducanumab had it been commercialized. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-2" continuedAt="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="TextSelection-9018276EF046E8B18FF0F6259DD294C0-0-wk-Fact-93B6936ECA0BFDEA3BD1F6259D91A2FA" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1419-wk-Fact-213C39BAD38692D371C6F6259D33495E" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1438-wk-Fact-A82C59C4E524F51874A4F6259D33BF15" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1457-wk-Fact-015E973F5550CFDA02E9F6259D81A496" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">165.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1477-wk-Fact-86DE013B087972C41DBCF6259D339577" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">140.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1497-wk-Fact-17177575544A41FA2140F6259D812E39" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1516-wk-Fact-D38D2488E59142089F85F6259D335085" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1535-wk-Fact-ABCA7EB95E9A185D9F60F6259D43ADA7" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1555-wk-Fact-7C38B092914F973E2FBBF6259D818184" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">128.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1657-wk-Fact-8E40E958D4FEB901CB27F6259D8118B2" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1676-wk-Fact-2D866D0E22166719F666F6259D333785" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1695-wk-Fact-D1A97C0A13E0E78D8D59F6259D33D86C" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1715-wk-Fact-9259C2C83704AD3CCA83F6259D3379B9" name="biib:Expenseincurredbythecollaboration" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1735-wk-Fact-5C7797C2E1BDC9A5F401F6259D81D12A" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1754-wk-Fact-8A25906FD682CBF1A0B8F6259D330E7B" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span><ix:nonFraction id="d30760591e1773-wk-Fact-1CEF2789422C2D278F3FF6259D33AD41" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1793-wk-Fact-84AA08E595A60102F325F6259D819E7B" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1821-wk-Fact-9E44D095667D0875E991F6259D910110" name="biib:AdditionalMilestonePayment" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1828-wk-Fact-B0ACC52BA0217BEB96C2F6259D91F3F7" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1832-wk-Fact-C4E2F8273F4FFAE7630AF6259D91971E" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1836-wk-Fact-013E61936C5D6F2AD48EF6259D9168CB" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1850-wk-Fact-0E8D44ADE3BB672596F8F6259D81B710" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1854-wk-Fact-6EDF670AD27ED3D62C34F6259D81C455" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1858-wk-Fact-17D1AF9D526AF59A8697F6259D62566B" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1862-wk-Fact-05ACF1EDB334962654D2F6259D62BBCF" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1871-wk-Fact-6EDF670AD27ED3D62C34F6259D81C455" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-3"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1884-wk-Fact-A1C9A0EF6B15869E8097F6259D917925" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">675</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1888-wk-Fact-86BE074DB9124A6EC150F6259D91EA91" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1892-wk-Fact-6214B49FB662B79E45AFF6259D9173B1" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">615</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1896-wk-Fact-676B1E9E911356443709F6259D915A14" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1900-wk-Fact-35E266ED5B6DCD88D558F6259D9185D8" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30760591e1905-wk-Fact-53FC9B3E9926AD7E0E43F6259D915D7A" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" format="ixt-sec:duryear">1.5</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d30760591e1909-wk-Fact-46BE2F2E0767988A3EC5F6259D91B219" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1927-wk-Fact-6FDCA9B3A57BCD5C3FB6F6259D91FB2E" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1931-wk-Fact-0D7B85985912B02305FE0B0EE4736EC4" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These losses reflect our share of income totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1935-wk-Fact-C1B6B774626649B67411F6259D913CCA" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1940-wk-Fact-121A575DA28DEF6851440B0F9EE158B3" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1944-wk-Fact-5C1F8D0A38C0D0D9B08FF6259D919526" name="us-gaap:AdjustmentForAmortization" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1948-wk-Fact-BD9485F2F7CA73557FA80B0FCB5F4116" name="us-gaap:AdjustmentForAmortization" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">36.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1963-wk-Fact-022EF5AA31A512FA766FF6259DA0F1BF" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">712.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1967-wk-Fact-BDECDBD4AEDE0731C1B2F6259D91A881" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1971-wk-Fact-ED996A004E1BA124DD15F6259D91563C" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e1976-wk-Fact-97B393475AC97FAB6F5AF6259D916AE2" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">680.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e1989-wk-Fact-D1C95822DD79876FD44CF6259D91B75F" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2001-wk-Fact-0D1D967ABD4E7CC22D15F6259D91D37D" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2005-wk-Fact-9B4572A2385BED806239F6259D914536" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d30760591e2010-wk-Fact-D1C95822DD79876FD44CF6259D91B75F" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2014-wk-Fact-897D11EC5297DB0EA599F6259D918288" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2018-wk-Fact-A690747F2BD9651F331BF6259D91BD71" name="biib:Collaborationprofitlosssharing" contextRef="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2037-wk-Fact-D822364BEF5FD2CC97F0F6259D91EC80" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2041-wk-Fact-A7172E6749013B78F8B9F6259D91C37F" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2045-wk-Fact-98E22AB6B2061E8F5867F6259D91B53B" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30760591e2050-wk-Fact-4C8CB41E2610218203F0F6259DA08900" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></ix:continuation><div><a id="s154C949CF9B15C79B245105B5ED29428"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="TextSelection-0E5AB135A3E395E4CD69F6259DD280B8-0-wk-Fact-3A49E0BC89EF164213B1F6259D717CB1" continuedAt="TextSelection-0E5AB135A3E395E4CD69F6259DD280B8-1" escape="true">Investments in Variable Interest Entities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0E5AB135A3E395E4CD69F6259DD280B8-1" continuedAt="TextSelection-0E5AB135A3E395E4CD69F6259DD280B8-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0E5AB135A3E395E4CD69F6259DD280B8-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, of aducanumab.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30759200e837-wk-Fact-A46C2E6294E147EFEADDF6259D7170C0" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30759200e841-wk-Fact-8F87BC379A3BBA28D7A2F6259D71E1B1" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></ix:continuation><div><a id="sFEE545DF4D1C576B90A9F1A8B256FF5F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-0-wk-Fact-DF3EABB533CDFA95F10EF6259D04CA76" continuedAt="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-1" escape="true">Litigation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-1" continuedAt="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-2"><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-2" continuedAt="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-3"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#8216;510 Patent), which was issued in June 2018 and expires in May 2035. A hearing has been scheduled for late 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing in the proceeding in Germany has been set for March 2020. No hearing has been set in the proceeding in Italy.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the &#8216;510 Patent. Fresenius Kabi counterclaimed for infringement, damages and injunctive relief. In July 2019 the United Kingdom Patents Court entered a consent order in which it declared that the United Kingdom counterpart of the '510 Patent is invalid, ordered the patent revoked and dismissed Fresenius Kabi's counterclaims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent. A trial is scheduled in the Dutch matter for October 2019. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. declined to intervene. The case alleges agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-3" continuedAt="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-4"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">an award of damages, interest and attorneys' fees. In June 2019 the U.S. Court of Appeals for the First Circuit affirmed the judgment below dismissing the complaint with prejudice.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial date has not been set in the Delaware action against Banner Life Sciences LLC. A trial date has been set for December 2019 in the other Delaware actions, and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for June 2020. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#8216;263 Patent expires in February 2023.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-4"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d30761196e925-wk-Fact-48DAF5B6C31320BDCEE0F6259D0464FE" name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="FD2019Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8A5B83111CBC5D448F1E323F88567F3D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy (PSP), Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the E.U. For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">future sales of our existing products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapies, biosimilars of existing products, other products approved under abbreviated regulatory pathways and other technologies. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures as well as the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the competition and pricing risks that could negatively impact our product sales, please read Item 3.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Quantitative and Qualitative Disclosures About Market Risk </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Brexit</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of the future relationship between the U.K. and the E.U. upon exit, which is expected to occur in October 2019.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The potential impact on our results of operations and liquidity resulting from Brexit remains unclear. The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the ultimate resolution of the Brexit negotiations. The final outcome of these negotiations may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not, however, expect Brexit to have a material impact on our consolidated results of operations as 3.3% and 3.5% of our total product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and 3.3% and 3.4% for the prior year comparative periods, respectively, were derived from U.K. sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have implemented measures to meet E.U. legal requirements and continue to modify our business operations to prepare for the U.K.'s separation from the E.U. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Therefore, we will continue to monitor developments in this area and assess any potential impact on our business and results of operations.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><a id="s57336D8E21D65F248CC983C40A4BE963"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</span></div><div style="line-height:120%;text-align:justify;"><img src="financialhighlights.jpg" alt="financialhighlights.jpg" style="height:426px;width:317px;"></img></div><div><a id="s218AD02D9D6655C6B2543FF55DA00CCD"></a></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.85</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 87.8% over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.18</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our net income and diluted earnings per share attributable to Biogen Inc. for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,616.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 7.8% over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,356.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,880.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 4.5% over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,757.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a 45.4% increase in revenues from our biosimilar products and a 15.5% increase in revenues from SPINRAZA. These increases were partially offset by the unfavorable impact of foreign currency exchange, net of gains recognized related to the settlement of certain cash flow hedge instruments under our foreign currency hedging program, of $24.6 million.</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$576.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 17.5% over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$490.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a 61.8% increase in royalty revenues on sales of OCREVUS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$160.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 47.3% over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$108.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to higher contract manufacturing revenues. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1,660.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">22.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,143.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily due to a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">50.6%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in research and development in relation to the prior year recognition of a $486.2 million net charge to research and development expense upon the closing of a 10-year exclusive agreement with Ionis Pharmaceuticals, Inc. (Ionis) to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases (the 2018 Ionis Agreement), a decrease in acquired in-process research and development (IPR&amp;D) in relation to the prior year acquisitions of BIIB104 from Pfizer Inc. (Pfizer) and BIIB100 from Karyopharm Therapeutics Inc. (Karyopharm) and a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">34.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in amortization and impairment of acquired intangible assets. These decreases were partially offset by a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">13.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in selling, general and administrative expenses and a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">13.1%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in cost of sales. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. was favorably impacted by a decrease in our effective tax rate to 14.1% for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from 22.4% for the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due in part to an internal reorganization of certain intellectual property rights in the second quarter of 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Condition, Liquidity and Capital Resources:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$4.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$4.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately 6.5 million shares of our common stock at a cost of approximately $1.5 billion during the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of 2019 under a program </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">authorized by our Board of Directors in August 2018 to repurchase up to $3.5 billion of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase Program was completed as of June 30, 2019.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately 3.9 million shares of our common stock at a cost of approximately $909.9 million during the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of 2019 under a program authorized by our Board of Directors in March 2019 to repurchase up to $5.0 billion of our common stock (2019 Share Repurchase Program).</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions, Divestitures, Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. In connection with this agreement, we made an upfront payment of $74.0 million to Skyhawk.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Skyhawk, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa (XLRP), which is a rare inherited retinal disease with no approved treatments.</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.50</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled $847.6 million. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. The proposed transaction remains subject to certain closing conditions. We expect to complete the proposed transaction in the third quarter of 2019. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB098 (diroximel fumarate)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 we and Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of RMS. The NDA has been assigned a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. If approved, we intend to market diroximel fumarate under the brand name VUMERITY, which has been conditionally accepted by the FDA and will be confirmed upon approval.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab (AB mAb)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we and Eisai Co., Ltd. (Eisai) announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. We continue to analyze the data from&#160;the ENGAGE and EMERGE trials and plan to share results of these trials following the completion of our analysis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Share Repurchase Program</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. </span></div></div></div><div><a id="s10F93A896EC85CF588438D8036CE3439"></a></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,744.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,741.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,257.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,279.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,135.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,015.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,302.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,001.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,880.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">79.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,757.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,560.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">78.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,281.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">576.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">490.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,093.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">108.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">452.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">273.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,616.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,356.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,106.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,487.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</span></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,150.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,086.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,149.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,073.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">554.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">625.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,055.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,175.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">475.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">935.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">929.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,204.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,202.5</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,187.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">75.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,227.6</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">488.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">422.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,006.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">786.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">244.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">83.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">184.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">358.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">254.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,880.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,757.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,560.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,281.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="sEFE7D729C1CD57A791E3F6E438AC980C"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of 5.3% in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by higher rates in discounts and allowances. U.S. TECFIDERA revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, benefited from a lower decrease in channel inventory levels as compared to the same period in the prior year.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of 2.1% in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by a decrease in unit sales volume of 3% and higher rates in discounts and allowances.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 7.4% and 8.2%, respectively, in rest of world TECFIDERA revenues were primarily due to increases in unit sales volumes of 15% in both periods, primarily related to our European and Japanese markets, partially offset by pricing reductions in certain European countries. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate an increase in TECFIDERA demand on a global basis in 2019, compared to 2018, </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">notwithstanding increasing competition from additional treatments for MS. We expect volume growth in our international markets to exceed volume declines in the U.S. We also expect price reductions in certain European countries.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</span></div><div style="line-height:120%;text-align:left;"><img src="interferon.jpg" alt="interferon.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases of 14.6% and 13.4%, respectively, in U.S. Interferon revenues were primarily due to decreases in Interferon unit sales volumes of 13% in both periods, which were primarily attributable to patients transitioning to other MS therapies and higher rates in discounts and allowances, partially offset by price increases. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases of 3.4% and 3.2%, respectively, in rest of world Interferon revenues were primarily due to pricing reductions in certain European countries, partially offset by increases in Interferon unit sales volumes of 5% and 16%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that Interferon revenues will continue to decline in both the U.S. and international markets in 2019, compared to 2018, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases of 0.5% and 1.2%, respectively, in U.S. TYSABRI revenues were primarily due to decreases in unit sales volumes of 4% and 6%, respectively, partially offset by price increases.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 4.6% and 3.0%, respectively, in rest of world TYSABRI revenues were primarily due to increases in unit sales volumes of 2% and 4%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate TYSABRI demand to be stable on a global basis in 2019, compared to 2018, with expected volume declines in the U.S. due to increasing competition from additional treatments for MS, including OCREVUS, to be offset by volume growth in our international markets.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;text-align:left;"><img src="spinraza.jpg" alt="spinraza.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 12.0% and 15.2%, respectively, in U.S. SPINRAZA revenues were primarily due to increases in unit sales volumes of 13% and 15%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 18.8% and 40.8%, respectively, in rest of world SPINRAZA revenues were primarily due to increases in unit sales volumes of 47% and 66%, respectively, partially offset by the unfavorable impact of foreign currency exchange of $14.0 million and $27.1 million, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world SPINRAZA revenues were favorably impacted by approximately $14.0 million as we reached a price reimbursement agreement in France, which resulted in the recognition of additional revenues in relation to sales for the period from August 2017, the date upon which we began to sell SPINRAZA in France, until December 2018 as we had a change in the estimated amount of revenues for which we determined that a significant reversal was not probable. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world SPINRAZA revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the three months ended March 31, 2019, were also unfavorably impacted by $10.4 million due to the timing of shipments occurring in the first quarter of 2019 in advance of expected commercialization activities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will moderate in 2019, compared to 2018, primarily due to a lower rate of new patient starts combined with the impact of loading dose </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">dynamics as patients transition to dosing once every four months.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face competition from a new gene therapy product, which was approved in the U.S. in May 2019 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market. Future sales of SPINRAZA may be adversely affected by the commercialization of these competing products.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BENEPALI, IMRALDI and FLIXABI</span></div><div style="line-height:120%;"><img src="biosimilars.jpg" alt="biosimilars.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of 45.4% and 41.1%, respectively, in biosimilar revenues were primarily due to the launch of IMRALDI in the fourth quarter of 2018, partially offset by the unfavorable impact of foreign currency exchange of $7.6 million and $17.2 million, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2019 we expect strong revenue growth for our biosimilar business, primarily driven by the continued launch of IMRALDI.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">condensed consolidated financial statements included in this report.</span></div><div><a id="sACA7671CC85E54C0A0AB31A4EAC51743"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;"><img src="anticd20.jpg" alt="anticd20.jpg" style="height:346px;width:317px;"></img></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,165.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,141.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">158.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,006.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">952.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">377.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,391.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,238.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">331.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">342.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,060.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,895.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">768.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">708.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in U.S.&#160;product revenues, net were primarily due to increased net sales of RITUXAN in the U.S. of 1.8% and 6.5%, respectively. These increases in net sales of RITUXAN in the U.S. reflect selling price increases, partially offset by higher discounts and allowances. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, for the six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net sales of RITUXAN in the U.S. reflects an increase in unit sales volume of 3%.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in U.S.&#160;product revenues, net also reflects increases in GAZYVA unit sales volume of 7% and 9%, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in collaboration costs and expenses were primarily due to lower selling and marketing costs on RITUXAN and lower Branded Pharmaceutical Drug Fee expenses for RITUXAN and GAZYVA.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, may compete with RITUXAN. In 2018 the FDA approved a rituximab biosimilar in the U.S. A biosimilar of RITUXAN could come to market in the U.S. in the fourth quarter of 2019, which may adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which would, in turn, adversely affect our co-promotion profits in the U.S. in future years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in other revenues from anti-CD20 therapeutic programs were primarily due to sales </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled $182.7 million and $294.3 million, respectively, compared to $112.9 million and $189.6 million, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">OCREVUS royalty revenues are based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the following quarter. Royalty revenues recognized on sales of OCREVUS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect the favorable impact of an approximately $17 million change in estimate related to sales in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></div></div><div><a id="sB45F12BB7B555009A183F71786727B58"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">52.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">107.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">375.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">83.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">108.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">452.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">273.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships primarily include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, which we expect to occur in the third quarter of 2019, FUJIFILM will assume responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis; and we will no longer recognize revenues earned under our technical development services and manufacturing agreements with Samsung Bioepis. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized $52.2 million and $77.0 million, respectively, in revenues related to the services described above provided to Samsung Bioepis, compared to $14.7 million and $32.6 million, respectively, in the prior year comparative periods. Revenue recognized related to these services totaled $96.4 million for the year ended&#160;December&#160;31, 2018.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</span></div><div style="line-height:120%;"><img src="otherrevenues.jpg" alt="otherrevenues.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in other royalty and corporate revenues were primarily due to higher contract manufacturing revenues, partially offset by the reduction in royalty revenues due to the expiration of certain of our patents.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other royalty and corporate revenues was also due to $241.3 million in revenues recognized under the manufacturing and supply agreement with Bioverativ Inc. (Bioverativ) entered into in connection with the spin-off of our hemophilia business, compared to $94.6 million recognized in the prior year comparative period. The increase in Bioverativ revenues over the prior year comparative period was due to sales of the remaining hemophilia inventory on hand.</span></div><div><a id="sC9F020E7C698546BB73691F13154C9D9"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:left;"><img src="reservesdiscountsandallow.jpg" alt="reservesdiscountsandallow.jpg" style="height:372px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 23.1% in both periods, compared to 23.2% and 23.7%, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in discounts were primarily due to changes in wholesaler invoicing in certain European markets. </span></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in contractual adjustments were primarily due to higher managed care rebates and governmental rebates in the U.S. as well as higher governmental rebates and allowances in the rest of world, due in part to increases in SPINRAZA sales volumes worldwide, partially offset by decreases in Medicaid rebates in the U.S.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves were relatively consistent.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read Note 4, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><a id="sDA5D6EE6404D5AF1A197D37B405B16BA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">476.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">421.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,078.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">867.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">484.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">981.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,048.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,477.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">587.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">516.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,155.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,017.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">70.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">107.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">138.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">63.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">121.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss on assets and liabilities held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">113.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,660.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,143.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,647.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,739.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA9BDA88CDF255B138443A9DC0649EF49"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="costofsales.jpg" alt="costofsales.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in product cost of sales were primarily due to higher contract manufacturing shipments, increased sales of our biosimilar products and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons. These increases were partially offset by lower product cost of sales associated with our MS products.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was also due to the sale to Bioverativ of most of the remaining hemophilia-related inventory on hand with a cost basis totaling $173.5 million in the first quarter of 2019, pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in royalty cost of sales were primarily due to a decrease in royalties payable on sales of TYSABRI resulting from the expiration of certain third party royalties, partially offset by increased royalties payable on higher sales of SPINRAZA and IMRALDI.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sDA40B5BF59055129A413E513276E7872"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;"><img src="rdpercentofrev.jpg" alt="rdpercentofrev.jpg" style="height:366px;width:317px;"></img></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;"><img src="rd.jpg" alt="rd.jpg" style="height:622px;width:317px;"></img></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represent costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in research and development expense were primarily due to decreases in milestone and upfront expenses. These decreases were partially offset by increases in costs incurred in connection with our early stage programs. The decrease in milestone and upfront expenses was primarily related to the closing of the 2018 Ionis Agreement, as discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was due to a decrease in costs incurred in connection with our late stage programs.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in milestone and upfront expenses were primarily due to the prior year recognition of a $486.2 million net charge to research and development expense upon the closing of the 2018 Ionis Agreement, which was a new 10-year exclusive agreement with Ionis to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Milestone and upfront expenses for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflected the recognition of a $38.5 million charge to research and development expense upon entering into our collaboration and research development services agreement with Skyhawk.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in spending associated with our late stage programs was primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the discontinuation of the global Phase 3 trials of aducanumab, net of Eisai reimbursement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lower spend related to the development of diroximel fumarate (BIIB098) in MS pursuant to our license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lower spend related to the development of elenbecestat (E2609) in AD pursuant to our collaboration arrangement with Eisai. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This decrease was partially offset by an increase in spending related to the development of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BAN2401 (A&#946; mAb) in early AD pursuant to our collaboration arrangement with Eisai, which was advanced to a late stage program in the first quarter of 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB093 (glibenclamide IV) in large hemispheric infarction (LHI), which was advanced to a late stage program in the third quarter of 2018; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB067 (tofersen) in ALS, which was advanced to a late stage program in the first quarter of 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, of aducanumab. As a result of this decision, in the first quarter of 2019, we accrued approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early AD. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in spending related to our early stage programs were primarily due to the development of: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB092 (gosuranemab) in PSP pursuant to our license agreement with Bristol-Myers Squibb Company; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB054 (&#945;-synuclein mAb) in Parkinson's disease; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB104 (AMPA) in cognitive impairment associated with schizophrenia (CIAS).</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These increases were partially offset by a decrease in costs associated with: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the development of BIIB074 (vixotrigine) in trigeminal neuralgia (TGN);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the advancement of BIIB093 in LHI to a late stage program in the third quarter of 2018;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the advancement of tofersen in ALS to a late stage program in the first quarter of 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our decision in October 2018 to discontinue development of vixotrigine for the treatment of painful lumbosacral radiculopathy; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our decision in December 2018 to discontinue development of BIIB087, an investigational AAV-based gene therapy for the treatment of X-linked retinoschisis, and BIIB088, an investigational AAV-based gene therapy for the treatment of XLRP, upon the termination of our collaboration agreement with Applied Genetic Technologies Corporation.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</span></div><div style="line-height:120%;"><img src="sga.jpg" alt="sga.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in selling, general and administrative expense were primarily due to acquisition related charges incurred in connection with our recent acquisition of NST totaling $33.4 million, including $18.4 million of stock-based compensation expense associated with the accelerated vesting of stock options previously granted to NST employees for post-combination services performed, an increase in legal and patent fees and an increase in commercialization costs, primarily related to SPINRAZA, as we continued to expand into new international markets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expense for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflects a decrease in operational spending associated with our pre-commercialization costs related to our AD programs following the discontinuation of the global Phase 3 trials of aducanumab in March 2019. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expense for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflects an increase in corporate giving, partially offset by a decrease in operational spend on ZINBRYTA subsequent to the voluntary worldwide withdrawal of ZINBRYTA for RMS, which we and AbbVie Inc. announced in March 2018. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="s6B3254BDF7B950D8BD3F0D51129DDB47"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="amortofintangibles.jpg" alt="amortofintangibles.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of 2019. The results of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA analyses were impacted by changes in the estimated timing and impact of other alternative MS formulations, including OCREVUS. The outcome of this most recent analysis resulted in a net overall decrease in our expected rate of amortization for acquired intangible assets, which was primarily related to higher expected lifetime revenues of TYSABRI. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, decreased primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expected lifetime revenues of TYSABRI. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no impairment charges.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon many variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and Company data regarding the productivity of clinical research and the development process. Changes in our estimates and prioritization of these items may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For example, we have an IPR&amp;D asset related to the development of vixotrigine in TGN. The TGN program has experienced numerous delays in development in the periods since we acquired the TGN program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">indication, for which we also have an IPR&amp;D asset. Data from that trial may affect the economic value of vixotrigine and the IPR&amp;D assets for one or both programs could be impaired if assumptions used in determining their fair value change.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of our acquired intangible assets, please read Note 6, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="sFB6BBD1B087051148F01E3E2690C99A1"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</span></div><div style="line-height:120%;"><img src="collabprofitshare.jpg" alt="collabprofitshare.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing primarily includes our partner's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$121.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. The increases in profit-sharing expense were primarily due to increased collaboration profits resulting from increased biosimilar sales.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFAEE0D4565095E6D8A0EEFC400B64A56"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss on Assets and Liabilities Held For Sale</span></div><div style="line-height:120%;"><img src="lossonassetheldforsale.jpg" alt="lossonassetheldforsale.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$890.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&#248;d facility to produce commercial </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale and were reclassified to assets and liabilities held for sale in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$174.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects a $2.3 million decrease to our original estimate as of March 31, 2019, reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$61.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse purchase commitment, as discussed above.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proposed transaction remains subject to certain closing conditions. We expect to complete the proposed transaction in the third quarter of 2019. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div><a id="sBBBF75CAEF1C5B919587AC1BBCED87ED"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div style="line-height:120%;"><img src="gainlossonfvremeasure.jpg" alt="gainlossonfvremeasure.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in the fair value remeasurement of contingent consideration for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were primarily due to changes in the probability and expected timing of achieving certain development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sEDE7C1C7D46155B1BC5850AEF5238E3B"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></div><div style="line-height:120%;"><img src="acquiredinprocessrd.jpg" alt="acquiredinprocessrd.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB104 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 from Pfizer. BIIB104 is a first-in-class, Phase 2b AMPA receptor potentiator for CIAS. In connection with the closing of this transaction, we made an upfront payment of $75.0 million to Pfizer, which was recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB104 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB100 Acquisition</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 from Kayropharm. BIIB100 is a Phase 1 investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. In connection with the closing of this transaction, we made an upfront payment of $10.0 million to Karyopharm, which was recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB100 has not yet reached technological feasibility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB104 and BIIB100, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><a id="s98B6C3A8D8675CC19EC9BB458C8D1C03"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;"><img src="oie.jpg" alt="oie.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net losses totaling $173.4 million recognized on our investments related to our holdings in equity and debt securities, compared to net gains totaling $5.3 million in the prior year comparative period. The net losses recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflect a decrease in the fair value in our investment in Ionis common stock from March 31, 2019, and a loss recognized on our sale of a portion of our investment in Ionis common stock during the second quarter of 2019 reflecting a decrease in fair value of the shares sold from March 31, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from the sale of a portion of our shares of Ionis common stock in the second quarter of 2019 totaled approximately $213.3 million. The original cost basis of these shares upon acquisition in June 2018 totaled approximately $173.6 million.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net gains totaling $203.0 million recognized on our investments related to our holdings in equity and debt securities, compared to net losses totaling $9.1 million in the prior year comparative period. The net gains recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily reflect an increase in the fair value in our investment in Ionis common stock from December 31, 2018, partially offset by the loss recognized on our sale of a portion of our investment in Ionis common stock during the second quarter of 2019 reflecting a decrease in fair value of the shares sold from March 31, 2019. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflects an increase in the fair value of an investment in a non-marketable equity security from December 31, 2018, that was realized for a net gain of approximately $87.7 million upon sale in the second quarter of 2019. </span></div><div><a id="s1ADF465F9EB35127A55B13BE6A94C30C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</span></div><div style="line-height:120%;"><img src="incometaxprovision.jpg" alt="incometaxprovision.jpg" style="height:350px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property (the effective tax rate decrease from this internal reorganization is not expected to recur post 2019) and a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights, offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$61.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the proposed divestiture of our </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">subsidiary that owns our Hiller&#248;d, Denmark manufacturing operations and a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Specifically in regard to the Hiller&#248;d, Denmark manufacturing operations, although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of the operations as held for sale and results in a taxable gain in certain jurisdictions.&#160; </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s2A7C8F3FAADA594996E2050E96CEEDC4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;"><img src="equityinlossofinvestee.jpg" alt="equityinlossofinvestee.jpg" style="height:213px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately 49.9%.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, losses reflect our share of income totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><a id="s97B93CEE55975807BB407089D3170E73"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,723.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,224.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,228.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,313.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,309.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,375.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,261.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,913.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,948.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,948.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,936.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,909.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,640.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,210.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,295.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,698.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,345.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s4B73670102A15CFC97E8284709AB46C1"></a></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.4 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities, net of</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$295.1 million in total payments for income taxes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million upfront payment </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">made to Skyhawk upon entering into a collaboration and research and development services agreement; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$45.0 million upfront payment made to C4 Therapeutics (C4T) upon entering into a collaborative research and license agreement; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$744.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made for our acquisition of NST, net of cash acquired;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$314.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$309.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in proceeds received on sales of strategic investments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the final contingent payment made to former shareholders of Fumapharm AG and holders of their rights.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2.6 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities, net of:</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million upfront payment </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">made to Ionis upon the closing of the 2018 Ionis Agreement and a $162.1 million charge reflecting the premium paid for the purchase of Ionis common stock; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$472.0 million in total payments for income taxes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$900.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$462.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made to Ionis reflecting the fair value of the common stock purchased upon the closing of the 2018 Ionis Agreement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$381.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million in upfront payments made for our acquisitions of BIIB100 and BIIB104.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned from our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read Item 3. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1A. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$909.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which was a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock that was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.75 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately $4.3 billion compared to approximately $4.9 billion as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net decrease in cash, cash equivalents and marketable securities at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash used for share repurchases, cash used for our acquisition of NST, net purchases of property, plant and equipment, contingent payments made to former shareholders of Fumapharm AG and holders of their rights and upfront payments made to Skyhawk and C4T, partially offset by cash flows from operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets in our condensed consolidated balance sheet as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and December 31, 2018, includes the carrying value of our investment in Samsung Bioepis of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$615.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. Investments and other assets, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and December 31, 2018, also includes an asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$333.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$563.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, reflecting the fair value of the long-term portion of our investment in Ionis common stock, which is subject to certain holding period restrictions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report. For additional information on our collaboration arrangements with Skyhawk and Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis and C4T, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These Senior Notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital is defined as current assets less current liabilities. The change in working capital at </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects an increase in total current assets of approximately $268.9 million and a decrease in total current liabilities of approximately $84.3 million.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in total current assets was primarily driven by the reclassification of assets associated with the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, a reclassification of a portion of our investment in Ionis common stock and an increase in prepaid taxes, partially offset by a decrease in net cash, cash equivalents and marketable securities, as described above, and a decrease in inventory resulting from the sale of hemophilia-related inventory to Bioverativ.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in current liabilities was primarily due to a reduction in accrued expenses and other, partially offset by an increase in income taxes payable and a reclassification of deferred tax liabilities to liabilities held for sale in relation to our proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations. The net decrease in accrued expenses and other was primarily related to a decrease in the accrual of contingent payments related to FUMADERM and TECFIDERA, a decrease in the accrual for employee compensation and benefits and the $45.0 million upfront payment made to C4T, which was accrued as of December 31, 2018.</span></div></div></div><div><a id="s761F76DEB1C9569EBE78D8E796925F4F"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,423.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,556.4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">128.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,055.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,060.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s6432960651B85EFDBDC93A16526EA7E1"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">non-cash operating items such as depreciation and amortization, impairment charges, </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operating activities increased primarily due to higher net income and the $375.0 million upfront payment made to Ionis upon the closing of the 2018 Ionis Agreement and a $162.1 million charge reflecting the premium paid for the purchase of Ionis common stock in the prior year comparative period, partially offset by the changes in working capital, as discussed above. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows provided by investing activities was primarily due to a decrease in net proceeds related to marketable securities and the cash used for our acquisition of NST. These amounts were partially offset by a decrease in contingent payments made to former shareholders of Fumapharm AG and holders of their rights, the $462.9 million payment made to Ionis reflecting the fair value of the common stock purchased upon the closing of the 2018 Ionis Agreement in the prior year comparative period and the proceeds received in the second quarter of 2019 on sales of strategic investments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in financing activities was primarily due to the net distribution to noncontrolling interests reflecting the payment made to Neurimmune SubOne AG in 2018 in exchange for a 5% reduction in royalty rates payable, offset by an increase in cash used for share repurchases. </span></div><div><a id="sCA5BE09A808D5155B959203A28B8FA5A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no material changes in our contractual obligations since </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11% and 15%, which are recognized as cost of sales in our condensed consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. (Convergence), Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $1.0 billion in remaining milestones related to these acquisitions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately $6.7 billion, including approximately $1.0 billion in </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">development milestones, approximately $1.5 billion in regulatory milestones and approximately $4.2 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately $198.0 million of milestone payments during the remainder of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $45.0 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $474.0 million in cancellable future commitments based on existing CRO contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately $122.4 million of liabilities associated with uncertain tax positions.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of both </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of $697.0 million under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to a $87.0 million carryforward of taxes paid in relation to the company's 2017 tax return. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div><a id="sF1F2C2AF403659CFBE8585888A413762"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s882C4591E4AF5C85B04E4577D1BF757E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our 2018 Form&#160;10-K. Except as discussed above, there have been no material changes to these critical accounting estimates since our 2018 Form&#160;10-K.</span></div><div><a id="sA9D938BBC4F85A6497B0638E2E1D02EA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia and Central and South America. In addition, we recognize our share of pre-tax co-</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">promotion profits on RITUXAN in Canada. As a result, our condensed consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone, Japanese yen and South Korean won.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $330.0 million and $290.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Hedge Program</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of exercising our option to increase our ownership percentage in Samsung Bioepis to approximately 49.9%. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four months</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement would result in a hypothetical decrease in fair value of approximately $62.0 million and $64.0 million, respectively. The estimated fair value was </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $18.0 million and $19.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of certain drugs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars and other products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">receivable and greater collection risk in certain countries. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div><div><a id="sB63B8B10076F5943ACAB8B5A267EE1DD"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><a id="sADFDF881245F540E91E2A9CCDE9F4188"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div><a id="sF1A1B5903B425193955D10B7CD35853E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal proceedings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our unaudited condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div><a id="sE3216EF0B9ED55D59E0F3C1191AAA0C9"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the European Commission and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets. In addition to risks associated with new product launches and the other factors described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of a new gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA, and other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors' reimbursement policies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. Under the Drug Price </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a manufacturer may file an Abbreviated New Drug Application, seeking approval of a generic copy of an approved innovator product, or a NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which may be for a new or improved version of the original innovator product. The manufacturers are allowed to rely on the safety and efficacy data of the innovator&#8217;s product, may not need to conduct clinical trials, can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, especially a small molecule product, the major portion of revenues for that product may be dramatically reduced in a very short period of time. If we cannot prevent others from exploiting our inventions, we will not derive the expected benefit from them. Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of uncertainty and risk. Only a small number of research and development programs result in the commercialization of a product. Furthermore, the development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining regulatory approval from the FDA and other regulatory agencies that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and, even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, may limit the scope of the approval or may deny approval altogether. Consequently, it may be difficult to predict the time and cost of product development of novel approaches for the treatment of diseases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing and research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways.&#160;Generic versions of drugs, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or generic or biosimilars of our MS products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the SMA market, we face competition from a gene therapy product that was approved in the U.S. in May 2019 for the treatment of SMA. Future sales of SPINRAZA may be adversely affected by the commercialization of this competing product.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives, external opportunities, which may include the acquisition, partnering and in-licensing </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of products, technologies and companies or the entry into strategic alliances and collaborations, or the disposition of certain of our assets or operations. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement. Furthermore, if we decide to dispose of certain of our assets or operations, we are not certain that we will be able to identify a suitable counterparty or if we will be able to reach agreement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data to operate our business. Our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data. A breakdown, invasion, corruption, destruction or breach of our technology systems and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products, or generic or biosimilar versions of our marketed products, may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships, including joint venture partners, for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships, including joint venture partners, subjects us to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators, joint venture partners or other third parties, and the underlying agreement with our collaborators, joint venture partners or other third parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships, joint ventures and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators, joint venture partners or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, and could adversely impact our ability to conduct business, our operating results and our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, or revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements and/or joint ventures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. If we, or our vendors or donation recipients, are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Further, certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we partner or collaborate with or acquire in emerging markets.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and other products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">diverse data privacy and protection requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.'s decision to voluntarily depart from the E.U., known as Brexit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, due to the long lead times necessary for the expansion of manufacturing capacity, in 2015 we made the decision to expand our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required. In addition, we have made and expect to make significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, cyber-attacks and numerous other factors.   </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. In addition, if the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations is completed, we will be dependent on FUJIFILM for the manufacture of biosimilar products. If Samsung Bioepis, FUJIFILM or other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand. In addition, if the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations is completed, we will be dependent on FUJIFILM for the manufacture of biosimilar products. FUJIFILM may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success   and/or the success of Samsung Bioepis in this business area; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Legal and Regulatory Requirements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Any improper conduct or actions on the part of Samsung Bioepis or our joint venture partner, Samsung BioLogics, could damage our reputation and be distracting to management. In particular, Samsung BioLogics is currently subject to an ongoing criminal investigation, which may impact the operations of Samsung Bioepis and its business or divert the attention of the Samsung Bioepis management team from its ongoing operations and business.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">failure to meet certain contractual commitments, including, for example, the minimum batch production commitment guarantees we have provided as part of the proposed transaction with FUJIFILM.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws, including the Tax Cuts and Jobs Act of 2017 (2017 Tax Act) and the Swiss Federal Act on Tax Reform and AHV Financing (TRAF). Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income and includes base erosion prevention measures on non-U.S. earnings. These changes became effective in 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The TRAF will result in significant changes to the Swiss cantonal income tax system. These changes include the elimination of historic favorable cantonal tax regimes, the introduction of a patent box regime and the introduction of a research and development super deduction. The TRAF also provides for transitional rules to lessen the immediate impact of the elimination of the favorable cantonal tax regimes. These changes will become effective on January 1, 2020. In response to the TRAF, each canton must enact cantonal tax reform to comply with the framework provided by the TRAF and are also expected to lower the statutory tax rate to compensate for the elimination of the historic favorable cantonal tax regimes. We will account for the impact of the TRAF and the specific cantonal tax reform changes in the period in which Zug, the canton in which we operate, enacts the cantonal tax reform, which we expect to occur in the second half of 2019. Upon the enactment, we will be required to remeasure our Swiss deferred tax </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">assets and liabilities, to account for the elimination of the historic favorable cantonal tax regimes, the impact of the transitional rules and the change in the statutory cantonal tax rate. This remeasurement of our Swiss deferred tax assets and liabilities could have a significant impact on our income tax provision in the period of enactment.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes share repurchase programs, including, most recently, our 2019 Share Repurchase Program. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of shares. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our 2019 Share Repurchase Program could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption in the past, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><a id="s162E89A1CF495921871071633C2717AD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2018 Share Repurchase Program during the second quarter of 2019:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($ in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,083,096</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">235.99</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,083,096</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,000.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">May 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,300,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">229.57</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,300,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57,582</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">223.42</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57,582</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,440,678</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">231.59</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2019 Share Repurchase Program during the second quarter of 2019:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($ in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,000.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">May 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,000.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,942,418</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">230.81</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,942,418</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,090.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,942,418</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">230.81</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$909.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which was a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock that was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.1 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div><a id="s7586889C4F855BC8BA9BBA38CBBE5AF7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAA7097922C1755E290A45B883F904D26"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1*+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019630xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2*+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019630xex102.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3*+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019630xex103.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4*+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019630xex104.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective June 19, 2019.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019630xex311.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019630xex312.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2019630xex321.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2019, formatted in XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF5DEF489EED05DA18092129BE52C8FC9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s4EFD59117A4E5773AB2E94F1F94FE283"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, and</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July&#160;23, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>biib-2019630xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sbb7404a1b8854b47ab03776b88f53089"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit 10.1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MARKET STOCK UNIT AWARD AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GRANTED UNDER</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BIOGEN INC. 2017 OMNIBUS EQUITY PLAN</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant of Market Stock</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account (the &#8220;Grant Date&#8221;), the number of market stock units (the &#8220;Granted MSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan. No MSU shall be paid unless vested in accordance with this Agreement. The Participant&#8217;s rights to the Granted MSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vesting</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:10pt;">The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion. Except as provided in Section 2.C. or 2.D. below, no portion of any Award shall become eligible to vest on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate. If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:10pt;">(i) The Award will become eligible to vest in in three equal installments on each of the first, second and third anniversaries of the Grant Date (each a &#8220;Vesting Date&#8221; and collectively, the &#8220;Vesting Period&#8221;).</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">On each Vesting Date, the number of MSUs that become eligible to vest on such Vesting Date will vest based upon the change in the Company&#8217;s share price between the Vesting Date and the Grant Date. The calculation of the number of Granted MSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account. In the event and to the extent that a number of the Granted MSUs then eligible to vest do not vest on the applicable Vesting Date in accordance with this Agreement and the LTI Overview, such Granted MSUs shall be immediately forfeited. In the event and to the extent that the target is exceeded based on the calculation described in the LTI Overview, an additional number of Granted MSUs will vest. In no event shall the number of Granted MSUs that vest on the applicable Vesting Date exceed 200% of the Granted MSUs that became eligible to vest on such Vesting Date.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:10pt;">In the event of a Corporate Change in Control, subject to the Participant&#8217;s continued employment with the Company and its Affiliates through the date of such Corporate Change in Control: </font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">the Committee shall determine the extent to which all then outstanding and unvested Granted MSUs would vest based solely on the Company&#8217;s share price in connection with the Corporate Change in Control (determined as if the date of the Corporate Change in Control were the Vesting Date for such Granted MSUs, and not, for the avoidance of doubt, taking into account the Company&#8217;s share price during any trailing thirty (30)-day period) and, that number of the </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">Granted MSUs that does not vest based on such share price in accordance with this Agreement and the LTI Overview shall be immediately forfeited; </font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:10pt;">to the extent the acquiring or surviving entity assumes, continues or substitutes for any then outstanding Granted MSUs (determined after giving effect to clause (i) above) in connection with the Corporate Change in Control, the Granted MSUs (including any Granted MSUs that had become vested by their terms on Vesting Dates prior to the Corporate Change of Control and that remain outstanding) shall remain outstanding and shall vest, subject to the Participant&#8217;s continued employment with the acquiring or surviving entity, on the applicable Vesting Date or, if earlier, upon an Involuntary Employment Action as described in Section 10.C. of the Plan or the Participant&#8217;s termination of employment on account of death or Disability;  </font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:10pt;">to the extent the acquiring or surviving entity does not assume, continue or substitute for any then outstanding Granted MSUs (determined after giving effect to clause (i) above) in connection with the Corporate Change in Control, the Granted MSUs (including any Granted MSUs that had become vested by their terms on Vesting Dates prior to the Corporate Change of Control and that remain outstanding) shall vest in full as of immediately prior to the Corporate Change in Control; and</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:10pt;">notwithstanding clause (iii) or (iv) above, with respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the latest Vesting Date described in Section 2.B. above, to the extent required to avoid adverse tax results under Section 409A, all then outstanding and unvested Granted MSUs (determined after giving effect to clause (i) above) (including any Granted MSUs that had become vested by their terms on Vesting Dates prior to the Corporate Change of Control and that remain outstanding) shall vest in full as of immediately prior to the Corporate Change in Control.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">D.</font><font style="font-family:inherit;font-size:10pt;">Except as otherwise provided in the Plan or Section 2.C. above, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability will, to the extent not vested previously, become eligible to vest as of the date of such termination of employment, and such Granted MSUs then eligible to vest will vest in accordance with Section 2.B.(ii) with the date of the termination of employment serving as the applicable Vesting Date; and</font></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:10pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will remain outstanding and will remain eligible to vest over the remainder of the Vesting Period as set forth in Section 2.B.(i) without regard to the service requirement specified in Section 2.A., with respect to fifty percent (50%) of the number of Granted MSUs covered by such unvested portion and with respect to an additional ten percent (10%) of the number of Granted MSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Granted MSUs, and such Granted MSUs that become eligible to vest will vest in accordance with Section 2.B.(ii). For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">E.</font><font style="font-family:inherit;font-size:10pt;">Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delivery of Award</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:10pt;">With respect to a Participant who is not and does not prior to the latest Vesting Date described in Section 2.A. above become eligible for Retirement, within 30 days following the date on which a Granted MSU becomes vested, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) (or, in the case of an assumption or substitution described in Section 2.C.(ii) above, common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award) in satisfaction of each vested MSU.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:10pt;">With respect to a Participant who is or becomes eligible for Retirement at any time during the Vesting Period, to the extent required to avoid adverse tax results under Section 409A and notwithstanding anything to the contrary in this Agreement,  the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock (or, in the case of an assumption or substitution described in Section 2.C.(ii) above, common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award) in satisfaction of each vested MSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the applicable Vesting Date or (ii) the date on which a Corporate Change in Control occurs.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:10pt;">If you are a &#8220;specified employee&#8221; (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability. The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A. For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(ii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(ii), as applicable.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares. Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers to the Participant shares of Common Stock. Furthermore, the Participant is not entitled to vote any Common Stock by reason of the granting of the Award or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unfunded Status</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates. The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Withholding</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awards will be subject to income tax withholding and reporting as required under local law. If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant a number of shares of Common Stock equal in value to the statutory minimum amount required to be withheld. A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities. The number of shares to be withheld will be calculated using the closing sales price of a share of Common Stock (or, in the case of an assumption or substitution described in Section 2.C.(ii) above, common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award) on the applicable Vesting Date. Shares (net of the number withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan. The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment. If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Provisions of the Plan</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control. A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No Right to Employment</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>biib-2019630xex102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sccf2060334fd48d78a269f59cfd631dd"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit 10.2</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PERFORMANCE STOCK UNITS AWARD AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GRANTED UNDER </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BIOGEN INC. 2017 OMNIBUS EQUITY PLAN</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grant of Performance Stock Units</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">(the &#8220;Grant Date&#8221;), the number of performance stock units (the &#8220;Granted PSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No Granted PSUs shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the Granted PSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting  </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.&#160;&#160;&#160;&#160;The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion.  Except as provided in Section 2.C. or 2.D. below, no portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate.  If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.&#160;&#160;&#160;&#160;The Award will become eligible to vest upon achievement of the Granted PSUs goals (&#8220;Performance Goals&#8221;), as adopted by the Committee in the first calendar quarter of the year in which the Award is granted and communicated.  The calculation of the number of Granted PSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account.  Granted PSUs that become eligible to vest upon the achievement of the Performance Goals are referred to as the &#8220;Eligible PSUs.&#8221;  In the event and to the extent that the Performance Goals are not satisfied, such Granted PSUs shall not become eligible to vest and shall be immediately forfeited upon the Committee&#8217;s determination that such Performance Goals have not been satisfied (or deemed satisfied).  As specified in the Performance Goals, in the event and to the extent that the Performance Goals are exceeded, an additional number of Granted PSUs will become eligible to vest.  In no event shall the number of Eligible PSUs exceed 200% of the number of Granted PSUs.  All Eligible PSUs shall vest on (i) the later of</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">the third anniversary of the Grant Date or the date of the Committee&#8217;s determination of the degree to which the Annual Performance Goals have been satisfied (which shall occur not later than March 1 immediately following the end of the year to which the Annual Performance Goals relate), (ii) in the event of a </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Corporation Change in Control, the date or dates described in Section 2.C. below,</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">or (iii) in the event of a termination of the Participant&#8217;s employment with the Company and its Affiliates on account of death, Disability or Retirement, the date or dates described in Section 2.D below (the &#8220;Vesting Date&#8221;). </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.&#160;&#160;&#160;&#160;In the event of a Corporate Change in Control, subject to the Participant&#8217;s continued employment with the Company and its Affiliates through the date of such Corporate Change in Control: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;if the applicable performance period relating to the Performance Goals has ended prior to the date of such Corporate Change in Control, the Committee shall determine the extent to which the Performance Goals were achieved, if not yet determined, and the Granted PSUs that are eligible to vest based on the achievement of such Performance Goals shall become Eligible PSUs as of immediately prior to such Corporate Change in Control based on the level of achievement so determined; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) &#160;&#160;&#160;&#160;if the applicable performance period relating to the Performance Goals has not ended prior to the date of such Corporate Change in Control, any outstanding Granted PSUs shall become Eligible PSUs as of immediately prior to such Corporate Change in Control assuming that the Performance Goals are achieved at target; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)&#160;&#160;&#160;&#160;to the extent the acquiring or surviving entity assumes, continues or substitutes for Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) in connection with the Corporate Change in Control, the Eligible PSUs shall remain outstanding and, subject to the Participant&#8217;s continued employment with the acquiring or surviving entity, shall vest in full upon the third anniversary of the Grant Date or, if earlier, upon an Involuntary Employment Action as described in Section 10.C. of the Plan or the Participant&#8217;s termination of employment on account of death or Disability; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iv) &#160;&#160;&#160;&#160;to the extent the acquiring or surviving entity does not assume, continue or substitute for the Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) in connection with the Corporate Change in Control, the Eligible PSUs shall vest in full as of immediately prior to the Corporate Change in Control; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(v)&#160;&#160;&#160;&#160;notwithstanding clause (iii) or (iv) above, with respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the latest Vesting Date described in Section 2.B.(i) above, to the extent required to avoid adverse tax results under Section 409A, the Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) shall vest in full as of immediately prior to the Corporate Change in Control.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">D.&#160;&#160;&#160;&#160;Except as otherwise provided in the Plan or Section 2.C. above, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability will, to the extent not vested previously, become fully vested upon the later of (a) the date of death or Disability of the Participant or (b) the date of the determination of the Eligible PSUs based on the achievement of the Performance Goals and the Committee&#8217;s determination </font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">thereof (including under Section 2.C. above, in which case the Eligible PSUs (determined after giving effect to Section 2.C. above) will vest as of immediately prior to the Corporate Change in Control), even if such determination occurs following the date of death or Disability of the Participant; and</font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the later of (a) the date of Retirement or (b) the date of the determination of the Eligible PSUs based on the achievement of the Performance Goals and the Committee&#8217;s determination thereof (including under Section 2.C. above, and with the Eligible PSUs determined after giving effect to Section 2.C. above), and in either case, with respect to fifty percent (50%) of the number of Eligible PSUs covered by such unvested portion and for an additional ten percent (10%) of the number of Eligible PSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Eligible PSUs of the Award.  For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">D.&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delivery of Award </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is not and does not prior to the latest Vesting Date described in Section 2.B.(i) above become eligible for Retirement, within 30 days following the date on which Eligible PSUs become vested, with respect to, and in satisfaction of, such vested Eligible PSUs (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan), the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested Eligible PSU (or, in the case of an assumption or substitution described in Section 2.C.(iii) above, of the common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award).  </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the latest Vesting Date described in Section 2.B.(i) above, to the extent required to avoid adverse tax results under Section 409A, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock (or, in the case of an assumption or substitution described in Section 2.C.(iii) above, of the common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award) in satisfaction of each vested Eligible PSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Eligible PSU otherwise would have vested under Section 2.B.(i) of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A) and/or the date the Eligible PSU vests under </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">Section 2.B.(iii) of this Agreement, subject to Section 3.C. of this Agreement or (iii) the date on which a Corporate Change in Control occurs.  </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:11pt;">If you are a &#8220;specified employee&#8221; (as defined in Section 409A), to the extent required to avoid adverse tax results under Section 409A, you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability.  The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">prior to the date on which the Company delivers to the Participant shares of Common Stock.  Furthermore, the Participant is not entitled to vote any Common Stock or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.  </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unfunded Status</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates.  The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholding </font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant an amount of cash equal in value to the statutory minimum amount required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities.  The amount of cash to be withheld will be calculated using the closing sales price of a share of Common Stock (or, in the case of an assumption or substitution described in Section 2.C.(iii) above, of the common stock of the acquiring or surviving entity or such other cash or property payable under the assumed or substituted award) on the applicable vesting date.  The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Provisions of the Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Right to Employment</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Executive Officer </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>biib-2019630xex103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s991c89bc65804f00a8e0cf140be0f6b2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit 10.3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PERFORMANCE STOCK UNITS AWARD AGREEMENT (CASH SETTLED)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GRANTED UNDER </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BIOGEN INC. 2017 OMNIBUS EQUIT PLAN</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant of Performance Stock Units (Cash Settled)</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">(the &#8220;Grant Date&#8221;) the number of cash-settled performance stock units (the &#8220;Granted PSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No PSUs shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the Granted PSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vesting  </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A.&#160;&#160;&#160;&#160;The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion.  Except as provided in Section 2.C. or 2.D. below, no portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate.  If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B.&#160;&#160;&#160;&#160;The Award will become eligible to vest upon achievement of each of three annual performance goals (the &#8220;Annual Performance Goals&#8221;), as adopted by the Committee in the first calendar quarter of each of the three years beginning on the first year in which the Award is granted and communicated.  The calculation of the number of Granted PSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account.  Granted PSUs that become eligible to vest upon the achievement of each of the Annual Performance Goals are referred to as the &#8220;Eligible PSUs.&#8221;  In the event and to the extent that the any of the Annual Performance Goals are not satisfied (or deemed satisfied in accordance with Section 2.C. below), such Granted PSUs connected to such unachieved Annual Performance Goals shall not become eligible to vest and shall be immediately forfeited upon the Committee&#8217;s determination that such Annual Performance Goals have not been satisfied (or deemed satisfied).  As specified in each of the Annual Performance Goals, in the event and to the extent that the Annual Performance Goals are exceeded, an additional number of Granted PSUs will become eligible to vest.  In no event shall the number of Eligible PSUs exceed 200% of the number of Granted PSUs.  All Eligible PSUs shall vest on (i) the later of</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">the third anniversary of the Grant Date or the date of the Committee&#8217;s determination of the degree to which the Annual Performance Goals have been satisfied (which shall occur not later than March 1 immediately following the end of the year to which the Annual Performance Goals relate)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:10pt;">(ii) in the event of a Corporate Change in Control, the date or dates described in Section 2.C. below, or (iii) in the event of a termination of the Participant&#8217;s employment with the Company and its Affiliates on account of death, Disability or Retirement, the date or dates described in Section 2.D. below (the &#8220;Vesting Date&#8221;). </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C.&#160;&#160;&#160;&#160;In the event of a Corporate Change in Control, subject to the Participant&#8217;s continued employment with the Company and its Affiliates through the date of such Corporate Change in Control: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;the Committee shall determine the extent to which the Annual Performance Goals relating to the year prior to the year in which the Corporate Change in Control occurs are achieved, if not yet determined, and the Granted PSUs that are eligible to vest based on the achievement of such Annual Performance Goals shall become Eligible PSUs based on the level of achievement so determined as of immediately prior to such Corporate Change in Control; </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) &#160;&#160;&#160;&#160;any outstanding Granted PSUs that are eligible to vest based on the achievement of Annual Performance Goals relating to a year in which the Corporate Change in Control occurs or a year after the Corporate Change in Control occurs shall become Eligible PSUs as of immediately prior to such Corporate Change in Control assuming that the Annual Performance Goals are achieved at target; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;to the extent the acquiring or surviving entity assumes, continues or substitutes for Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) in connection with the Corporate Change in Control, the Eligible PSUs (including any Granted PSUs that had become Eligible PSUs by their terms prior to the Corporate Change in Control) shall remain outstanding and, subject to the Participant&#8217;s continued employment with the acquiring or surviving entity, shall vest in full upon the third anniversary of the Grant Date or, if earlier, upon an Involuntary Employment Action as described in Section 10.C. of the Plan or the Participant&#8217;s termination of employment on account of death or Disability; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv) &#160;&#160;&#160;&#160;to the extent the acquiring or surviving entity does not assume, continue or substitute for the Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) in connection with the Corporate Change in Control, the Eligible PSUs (including any Granted PSUs that had become Eligible PSUs by their terms prior to the Corporate Change in Control) shall vest in full as of immediately prior to the Corporate Change in Control; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(v)&#160;&#160;&#160;&#160;notwithstanding clause (iii) or (iv) above, with respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the latest Vesting Date described in Section 2.B. above, to the extent required to avoid adverse tax results under Section 409A, the Eligible PSUs (determined after giving effect to clauses (i) and (ii) above) shall vest in full as of immediately prior to the Corporate Change in Control.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D.&#160;&#160;&#160;&#160;Except as otherwise provided in the Plan or Section 2.C. above, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability, to the extent not vested previously, will become fully vested as follows: (1) with respect to any Eligible PSUs for which the achievement of Annual Performance Goals has been determined as of the date of such termination on account of death or Disability, upon the date of such termination; and (2) with respect to any Eligible PSUs for which the achievement of Annual Performance Goals has not been determined on the date of such termination, upon the date of the determination of the Eligible PSUs based on the achievement of the applicable Annual Performance Goals and the Committee&#8217;s determination thereof (including under Section 2.C. above, in which case the Eligible PSUs (determined after giving effect to Section 2.C. above) will vest as of immediately prior to the Corporate Change in Control), even if such determination occurs following the date of death or Disability of the Participant; and</font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested as follows: (1) with respect to any Eligible PSUs for which the achievement of Annual Performance Goals has been determined as of the date of such Retirement, upon the date of Retirement and, (2) with respect to any Eligible PSUs for which the achievement of Annual Performance Goals has not been determined on the date of such Retirement, upon the date of the determination of the Eligible PSUs based on the achievement of the applicable Annual Performance Goals and the Committee determination thereof (including under Section 2.C. above, and with the Eligible PSUs determined after giving effect to Section 2.C. above), in each case, with respect to fifty percent (50%) of the number of Eligible PSUs covered by such unvested portion and for an additional ten percent (10%) of the number of Eligible PSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Eligible PSUs of the Award.  For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">E.&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delivery of Award </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:10pt;">With respect to a Participant who is not and does not prior to the latest Vesting Date described in Section 2.B. above become eligible for Retirement, within 30 days following the date on which an Eligible PSU becomes vested, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, the cash value of one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested Eligible PSU.  For purposes of this Agreement, the cash value of a share of Common Stock (&#8220;Cash Value&#8221;) will be equal to the 30 calendar-day average of the BIIB closing stock price ending on the applicable Vesting Date (or, in the case of an assumption or substitution described in Section 2.C.(iii) above, common stock of the acquiring or surviving entity).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:10pt;">With respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the latest Vesting Date described in Section 2.B. above, to the extent required to avoid adverse tax results under Section 409A and notwithstanding anything to the contrary in this Agreement, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, the Cash Value in satisfaction of each vested Eligible PSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Eligible PSU otherwise would have vested under Section 2.B.(i) of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A) and/or the date the Eligible PSU vests under Section 2.B(iii) of this Agreement, subject to Section 3.C. of this Agreement or (iii) the date on which a Corporate Change in Control occurs.  </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:10pt;">If you are a &#8220;specified employee&#8221; (as defined in Section 409A), to the extent required to avoid adverse tax results under Section 409A, you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability.  The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock that are used to calculate the Cash Value to be delivered to the Participant in satisfaction of any vested Eligible PSUs or with respect to any other aspect of the Award.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate.  Furthermore, the Participant is not entitled to vote any Common Stock or to receive or be credited with any dividends declared and payable on any share of Common Stock by reason of the granting of the Award.  </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unfunded Status</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates.  The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Withholding </font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant an amount of cash equal in value to the statutory minimum amount required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities.  The amount of cash to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date.  The Cash Value (net of the cash withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan.  The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Provisions of the Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No Right to Employment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>biib-2019630xex104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s55859855f82c4e12b3c1bc4a240a680c"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:32px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit 10.4</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severance Plan for U.S. Executive Vice Presidents</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As an Executive Vice President, you are entitled to severance benefits in the event your employment is terminated by Biogen other than For Cause or for reason of death or Disability (as these terms are defined in the Biogen Inc. 2017 Omnibus Equity Plan, as amended from time to time, or any successor plan there to (&#8220;OEP&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Your severance benefits are comprised of (i) a lump sum payment (as calculated below), (ii) upon completion of the appropriate forms, continuation of your participation in Biogen&#8217;s group medical and dental insurance plans, to the same extent permitted by COBRA and to the same extent such insurance is then provided to regular employees of Biogen, including payment by you of a portion of the insurance premiums (i.e., the &#8220;Insurance Benefit&#8221;) and (iii) the reasonable cost of up to 12 months of executive-level outplacement services from a recognized provider of such services selected by Biogen, at the expense of Biogen (upon receipt of appropriate documentation).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The lump sum severance payment is calculated as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[12 + (A x 2)] x B = lump sum payment</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">where:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A is the number of full years of service with Biogen (but A x 2 may not exceed 9), and B is the monthly equivalent of your target annual cash compensation at the time of your termination (i.e., one-twelfth of the sum of your then annual base salary plus target annual bonus).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The following are examples of how the lump sum payment and Insurance Benefit Period are determined:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">If your employment with Biogen is terminated after 10 months of employment, you will receive a lump sum payment equal to 12 months of your target annual cash compensation and continue to participate in Biogen&#8217;s group medical and dental plans for 12 months, unless you become eligible to participate in another employer&#8217;s medical and dental plans before that date. COBRA continuation of medical and dental benefits is available, at your own expense, for an additional six months after this 12-month Insurance Benefit Period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">If your employment with Biogen is terminated after five years, you will receive a lump sum payment equal to 21 months [12+9] of your target annual cash compensation and continue to participate in Biogen&#8217;s group medical and dental plans for 18 months, unless you become eligible to participate in another employer&#8217;s medical and dental plans before that date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adopted October 13, 2008&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">&#32;of 7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revised June 19. 2019&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If at any time within two years following a Corporate Transaction or Corporate Change in Control (as these terms are defined in Biogen&#8217;s OEP) your employment is terminated by Biogen or the succeeding corporate entity, other than For Cause or for reason of death or Disability (as these terms are defined in Biogen&#8217;s OEP), or you experience an Involuntary Employment Action (defined below) and as a result you terminate your employment with Biogen or the succeeding corporate entity, then, regardless of the length of your service with Biogen and the succeeding corporate entity, and in lieu of the formula set forth above, you will receive a lump sum payment equivalent to 24 months of your target annual cash compensation at the time of your termination or at the time of a Corporate Transaction or Corporate Change in Control, whichever is higher. In addition, you will be entitled to continue participating in Biogen&#8217;s group medical and dental plans for 24 months, unless you become eligible to participate in another employer&#8217;s medical and dental plans before that date. The term &#8220;Involuntary Employment Action&#8221; shall have the definition set forth in Biogen&#8217;s OEP, provided, however, that the term &#8220;Corporate Transaction&#8221; used in that definition shall be deemed to mean either a Corporate Transaction or Change in Control, as the case may be, and provided also that prior to your termination of employment you have notified the Chief Legal Counsel or the Head of Human Resources of Biogen in writing of the basis for your Involuntary Employment Action, you have given such notice within one year of the circumstances giving rise to your Involuntary Employment Action and Biogen does not cure such circumstances within 30 days after the date of your notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Delivery of Benefits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payment and provision of all the benefits provided under this arrangement are conditioned on your execution and delivery of all necessary forms and an irrevocable general release in favor of Biogen, in form and substance reasonably acceptable to Biogen, with respect to any and all claims relating to your employment and the termination of your employment with Biogen. If you retire or voluntarily terminate your employment with Biogen, or Biogen terminates your employment For Cause or for reason of death or Disability (as these terms are defined in Biogen&#8217;s OEP), or you do not provide the requisite general release, you will not be eligible to receive the severance benefits described above.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If all other conditions of this arrangement are met, a lump sum payment (less applicable taxes and other mandatory deductions as required by law) will be paid to you following the termination of your employment, no later than the first to occur of: a) 90 days following your termination of your employment with Biogen and b) March 15 of the year following the calendar year in which termination of employment occurs, unless you are a &#8220;specified employee&#8221; as defined in Section 409A of the Internal Revenue Code of 1986, as amended (i.e., &#8220;Section 409A&#8221;). (If all preconditions to payment, including the delivery of an irrevocable general release, are not satisfied prior to the earlier of these two dates, payment to you may be delayed and you may incur additional tax liabilities under Section 409A.) If you are a &#8220;specified employee&#8221;, to the extent required by Section 409A, payment will not be made to you before the date which is six months after you &#8220;separate from service&#8221; (or, if earlier, your date of death or Disability) unless the payment qualifies as excepted welfare benefits under Section 409A, does not constitute a &#8220;deferral of compensation&#8221; under Section 409A or is otherwise not subject to the requirements of Section 409A.  Each payment made under this arrangement shall be treated as a </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adopted October 13, 2008&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;">&#32;of 7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revised June 19. 2019&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">separate payment and the right to receive a series of installment payments under this arrangement shall be treated as a right to a series of separate payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Insurance Benefit will be paid on a monthly basis and will continue until the earlier of (i) the date you become eligible to participate in the medical and dental insurance plan of another employer or (ii) the date that is [12 + (A x 2)] months, but not more than 21 months (or 24 months in the case of a Corporate Transaction or Change in Control), following the termination of your employment with Biogen (the &#8220;Insurance Benefit Period&#8221;). You will have the right, at your own expense, to continue your participation in Biogen&#8217;s group medical and dental insurance plans at the expiration of the Insurance Benefit Period, pursuant to the provisions of COBRA, but only for an 18-month period that will be deemed to have commenced at the start of your severance.  You will only be entitled to receive the Insurance Benefit if you timely and properly elect continuation coverage under COBRA. If Biogen determines in its sole discretion that it cannot provide the Insurance Benefit without the possibility of violating applicable law (including, without limitation, the Patient Protection and Affordable Care Act) or it or you incurring additional taxes, including but not limited to under Section 105(h) of the Internal Revenue Code, Biogen will in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that Biogen Idec would have otherwise paid under this arrangement in respect of the Insurance Benefit (which amount will be based on the premium for the first month of COBRA coverage) for the Insurance Benefit Period in equal installments in accordance with Biogen&#8217;s normal payroll practices.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen shall administer and shall have the discretionary authority to adopt rules for the management and operation of this arrangement, to interpret the provisions of the arrangement and to construe the terms of the severance arrangement in its sole discretion. The decision of Biogen, or the duly authorized delegate, is final and conclusive for all purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The severance arrangement may be amended, modified, suspended or terminated by Biogen at any time; provided that the severance arrangement may not be amended or terminated without your written consent for a period of two years following a Corporate Transaction or a Change in Control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This arrangement is unfunded. This arrangement will benefit and bind Biogen and its successors and permitted assigns and you and your heirs, executors and legal representatives. You do not have any right to transfer or assign your benefits under this arrangement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This arrangement shall be construed, administered and enforced according to the laws of the State of Delaware, except to the extent that such laws are preempted by the federal laws of the United States of America.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adopted October 13, 2008&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;of 7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revised June 19. 2019&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Additional Summary Plan Description Information</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.71794871794873%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:20%;"></td><td style="width:80%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This document describes 3 Plan which is subject to the Employee Retirement Income Security Act of 1974 (ERISA). This document constitutes the Summary Plan Description (SPD) and Plan Document. Benefit determinations are controlled exclusively by this SPD and Plan Document.</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Name of Plan</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Severance Plan for U. S. Executive Vice Presidents</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Name and Address of Employer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen Inc.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">225 Binney Street, Cambridge</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Massachusetts 02142</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Plan Identification Number</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employer IRS Identification #: 04-3002117 Plan #: 523</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Type of Welfare Plan</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Severance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ERISA Plan Year Ends</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">December 31</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Type of Administration</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Plan is administered by the Plan Administrator</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Plan Administrator, Name, Address, and Telephone Number</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen Inc. is the Plan Administrator and named fiduciary of the Plan, with authority to delegate its duties.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen Inc.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">225 Binney Street</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cambridge, Massachusetts  02142</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(617) 679-3400</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agent for Service of Legal Process on the Plan</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen Inc.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">225 Binney Street</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cambridge, Massachusetts 02142</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Funding</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Plan is unfunded</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Appeal Procedures</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You have 180 days from your effective date of termination to file an appeal. Requests for appeals should be sent to the address specified in the claim denial. A decision on review will be made not later than 45 days following receipt of the written request for review. If the Plan Administrator determines that special circumstances require an extension of time for a decision on review, the review period may be extended by an additional 45 days (90 days in total). The Plan Administrator will notify you in writing if an additional 45 day extension is needed.</font></div><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If an extension is necessary due to your failure to submit the information necessary to decide the appeal, the notice of extension will specifically describe the required information, and you will be afforded at least 45 days to provide the specified information. If you deliver the requested</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adopted October 13, 2008&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">&#32;of 7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revised June 19. 2019&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.71794871794873%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:20%;"></td><td style="width:80%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">information within the time specified, the 45 day extension of the appeal period will begin after you have provided that information. If you fail to deliver the requested information within the time specified, the Plan Administrator may decide your appeal without that information.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You will have the opportunity to submit written comments, documents, or other information in support of your appeal. You will have access to all relevant documents as defined by applicable U.S. Department of Labor regulations. The review of the adverse benefit determination will take into account all new information, whether or not presented or available at the initial determination. No deference will be afforded to the initial determination.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The review will be conducted by the Plan Administrator and will be made by a person different from the person who made the initial determination and such person will not be the original decision maker&#8217;s subordinate.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A notice that your request on appeal is denied will contain the following information:</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l   </font><font style="font-family:inherit;font-size:12pt;">The specific reason(s) for the determination;</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l   </font><font style="font-family:inherit;font-size:12pt;">A reference to the specific Plan provision(s) on which the</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;determination is based;</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l   </font><font style="font-family:inherit;font-size:12pt;">A statement disclosing any internal rule, guidelines, protocol or</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;similar criterion relied on in making the adverse determination (or</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a statement that such information will be provided free of charge</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;upon request);</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l   </font><font style="font-family:inherit;font-size:12pt;">A statement describing your right to bring a lawsuit under Section</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;502(a) of ERISA if you disagree with the decision;</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l   </font><font style="font-family:inherit;font-size:12pt;">The statement that you are entitled to receive upon request, and</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;without charge, reasonable access to or copies of all documents,</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;records or other information relevant to the determination; and</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l   </font><font style="font-family:inherit;font-size:12pt;">The statement that &#8220;You or your plan may have other voluntary</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;alternative dispute resolution options, such as mediation. One way</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to find out what may be available is to contact your local U.S.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Department of Labor Office and your State insurance regulatory</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;agency&#8221;.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notice of the determination may be provided in written or electronic form. Electronic notices will be provided in a form that complies with any applicable legal requirements.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Unless there are special circumstances, this administrative appeal process must be completed before you begin any legal action regarding your claim.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Your Rights Under ERISA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As a participant in this Plan, you are entitled to certain rights and protections under the Employee Retirement Income Security Act of 1974 (ERISA). ERISA provides that all Plan participants shall be entitled to:</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l   </font><font style="font-family:inherit;font-size:12pt;">Receive Information About Your Plan and Benefits</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adopted October 13, 2008&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">&#32;of 7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revised June 19. 2019&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.71794871794873%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:20%;"></td><td style="width:80%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">Examine, without charge, at the Plan Administrator&#8217;s office</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and at other specified locations, all documents governing the</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Plan, including a copy of the latest annual report (Form</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5500 Series), if any, filed by the Plan with the U.S.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Department of Labor and available at the Public Disclosure</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Room of the Employee Benefits Security Administration.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">Obtain, upon written request to the Plan Administrator,</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;copies of documents governing the operation of the Plan,</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;including copies of the latest annual report (Form 5500</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Series), if any, and updated Summary Plan Description.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">The Plan Administrator may make a reasonable charge for</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the copies.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">Receive a summary of the Plan&#8217;s annual financial report, if</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any. The Plan Administrator is required by law to furnish</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;each participant with a copy of this summary annual report.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">l   </font><font style="font-family:inherit;font-size:12pt;">Prudent Actions by Plan Fiduciaries</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">In addition to creating rights for Plan participants, ERISA</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;imposes duties upon the people who are responsible for the</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;operation of the employee benefit plan. The people who</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;operate your Plan, called &#8220;fiduciaries&#8221; of the Plan, have a</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;duty to do so prudently and in the interest of you and other</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Plan participants and beneficiaries. No one, including your</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Employer or any other person, may fire you or otherwise</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;discriminate against you in any way to prevent you from</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;obtaining a benefit or exercising your rights under ERISA.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l    </font><font style="font-family:inherit;font-size:12pt;">Enforce Your Rights</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">If your claim for a benefit is denied or ignored, in whole or</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in part, you have a right to know why this was done, to</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;obtain copies of documents relating to the decision without</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;charge, and to appeal any denial, all within certain time</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;schedules.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">Under ERISA, there are steps you can take to enforce the</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;above rights. For instance, if you request a copy of Plan</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;documents or the latest annual report from the Plan and do</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not receive them within 30 days, you may file suit in a</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;federal court. In such a case, the court may require the Plan</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Administrator to provide the materials and pay you up to</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$110 a day until you receive the materials, unless the</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;materials were not sent because of reasons beyond the</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;control of the Plan Administrator.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adopted October 13, 2008&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;">&#32;of 7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revised June 19. 2019&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.71794871794873%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:20%;"></td><td style="width:80%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">If you have a claim for benefits that is denied or ignored, in</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;whole or in part, you may file suit in a state or federal court.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If it should happen that Plan fiduciaries misuse the Plan&#8217;s</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;money, or if you are discriminated against for asserting your</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;rights, you may seek assistance from the U.S. Department of</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Labor, or you may file suit in a federal court. The court will</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;decide who should pay court costs and legal fees.  If you are</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;successful, the court may order the person you have sued to</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pay these costs and fees. If you lose, the court may order you</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to pay these costs and fees, if, for example, it finds your</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;claim is frivolous.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">l    </font><font style="font-family:inherit;font-size:12pt;">Assistance with Your Questions</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:Wingdings;font-size:10pt;">&#160;&#160;&#160;&#161;   </font><font style="font-family:inherit;font-size:12pt;">If you have any questions about your Plan, you should</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;contact the Plan Administrator. If you have any questions</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;about this statement or about your rights under ERISA, or if</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;you need assistance in obtaining documents from the Plan</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Administrator, you should contact the nearest office of the</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Employee Benefits Security Administration, U.S.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Department of Labor, listed in your telephone directory or</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Division of Technical Assistance and Inquiries,</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Employee Benefits Security Administration, U.S.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Department of Labor, 200 Constitution Avenue N.W.,</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Washington, D.C. 20210. You may also obtain certain</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;publications about your rights and responsibilities under</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ERISA by calling the publications hotline of the Employee</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Benefits Security Administration.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other Rights</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Plan Administrator, as fiduciary for the Plan, is entitled to legal and equitable relief to enforce its right to recover any overpayments to you under this Plan. This right of recovery is enforceable but will not exceed the benefits paid you. You agree that the Plan Administrator has a lien over such sources of income until any overpayments have been recovered in full.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Discretionary Acts</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Plan Administrator has discretionary authority to interpret the Plan and to make benefit determinations under the Plan. The Plan Administrator may act directly or through its employees and agents or further delegate their authority through contracts, letters or other documentation or procedures to other affiliates, persons or entities.</font></div><div style="padding-bottom:4px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Once you are deemed to have exhausted your appeal rights under the Plan, you have the right to seek court review under Section 502(a) of ERISA of any benefit determinations with which you disagree. The court will determine the standard of review it will apply in evaluating those decisions.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adopted October 13, 2008&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;">&#32;of 7</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revised June 19. 2019&#160;&#160;&#160;&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>biib-2019630xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s14AE1DE6525456648E83C7D73D9EDFE3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: July&#160;23, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>biib-2019630xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5E49702D95E45E29B155FB5A9BB7E31B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey D. Capello, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: July 23, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>biib-2019630xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7656B6A5973E542B889130980D8190CB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: July&#160;23, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: July&#160;23, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer and Chief Accounting Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>biib-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20190630" xmlns:biib="http://www.biogenidec.com/20190630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2106100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetails" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails">
        <link:definition>2406402 - Disclosure - Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2406403 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2134100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2334301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement">
        <link:definition>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2123100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2423402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2323301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetails" roleURI="http://www.biogenidec.com/role/DivestituresDetails">
        <link:definition>2414402 - Disclosure - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetailsTextual" roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual">
        <link:definition>2414403 - Disclosure - Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestitures" roleURI="http://www.biogenidec.com/role/DivestituresDivestitures">
        <link:definition>2114100 - Disclosure - Divestitures Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresTables" roleURI="http://www.biogenidec.com/role/DivestituresTables">
        <link:definition>2314301 - Disclosure - Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2130100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2430402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2330301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2129100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2421402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2421403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2421404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2421405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2321301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2122100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2422402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2422403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2422404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2422405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2422406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2322301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2132100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2432402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2432403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2332301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2120100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2119100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2419402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual">
        <link:definition>2419403 - Disclosure - Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2319301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2135100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>2128100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.biogenidec.com/role/LeasesDetails">
        <link:definition>2428402 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual">
        <link:definition>2428403 - Disclosure - Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.biogenidec.com/role/LeasesTables">
        <link:definition>2328301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2136100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2436401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2133100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails">
        <link:definition>2418406 - Disclosure - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2424401 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProposedDivestitureOfDenmarkManufacturingOperationsDetails" roleURI="http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails">
        <link:definition>2419404 - Disclosure - Proposed Divestiture of Denmark Manufacturing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails">
        <link:definition>2418402 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2418407 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenues" roleURI="http://www.biogenidec.com/role/RevenuesRevenues">
        <link:definition>2118100 - Disclosure - Revenues Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2318301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2131100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2431402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2431403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2331301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2429402 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables">
        <link:definition>2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramMember" name="A2016ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2018ShareRepurchaseProgramMember" name="A2018ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2019ShareRepurchaseProgramMember" name="A2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AcquisitionsAbstract" name="AcquisitionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" name="AssetsandLiabilitiesHeldForSalePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB111Member" name="BIIB111Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB112Member" name="BIIB112Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredTaxAssetLiabilityTypeAxis" name="DeferredTaxAssetLiabilityTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredTaxAssetLiabilityTypeDomain" name="DeferredTaxAssetLiabilityTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenmarkManufacturingOperationsMember" name="DenmarkManufacturingOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityAxis" name="DerivativeMaturityAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityDomain" name="DerivativeMaturityDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DisposalGroupOperatingLeaseAssets" name="DisposalGroupOperatingLeaseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_DisposalGroupOperatingleaseliabilities" name="DisposalGroupOperatingleaseliabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DivestituresAbstract" name="DivestituresAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_E2609andBAN2401Member" name="E2609andBAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveTaxRateReconciliationGILTItax" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Expenseincurredbythecollaboration" name="Expenseincurredbythecollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expensereflectedwithinstatementsofincome" name="Expensereflectedwithinstatementsofincome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IMRALDIMember" name="IMRALDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InventoryAbstract" name="InventoryAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventorysoldtoBioverativcost" name="InventorysoldtoBioverativcost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LesseeLeaseTableTableTextBlock" name="LesseeLeaseTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LongtermoperatingleaseliabilitiesMember" name="LongtermoperatingleaseliabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MSProductRevenuesMember" name="MSProductRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NightstarMember" name="NightstarMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OperatingleaseassetsMember" name="OperatingleaseassetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" name="OperatingleasesupplementalcashflowdisclosureTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" name="OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherrevenuesAbstract" name="OtherrevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PostacquisitionequitycompensationMember" name="PostacquisitionequitycompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetAxis" name="ResearchanddevelopmentassetAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetDomain" name="ResearchanddevelopmentassetDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReserveforCashDiscountsMember" name="ReserveforCashDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_Revenuesfromanticd20therapeuticprogramsMember" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShorttermderivativeMember" name="ShorttermderivativeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SkyhawkTherapeuticsMember" name="SkyhawkTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_WorkinprocessMember" name="WorkinprocessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>biib-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20190630.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20190630.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20190630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190630.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190630.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190630.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetails" xlink:href="biib-20190630.xsd#DivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20190630.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190630.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresTables" xlink:href="biib-20190630.xsd#DivestituresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20190630.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190630.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190630.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190630.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20190630.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190630.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190630.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:href="biib-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190630.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:href="biib-20190630.xsd#LeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:href="biib-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190630.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20190630.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20190630.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20190630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190630.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190630.xsd#ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190630.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190630.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190630.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20190630.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20190630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190630.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190630.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20190630.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190630.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190630.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190630.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190630.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20190630.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20190630.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_362cfa30-ad95-8907-5736-6d156ad185ef" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_362cfa30-ad95-8907-5736-6d156ad185ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_f3e9b844-fd8f-c7ab-57bd-f53052c6dc0d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_f3e9b844-fd8f-c7ab-57bd-f53052c6dc0d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_93dd97fc-33af-32aa-9307-74029660459f" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_93dd97fc-33af-32aa-9307-74029660459f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_483713d8-e500-be9d-d173-6b5e26416fef" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_483713d8-e500-be9d-d173-6b5e26416fef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fb2eba1d-18a1-c88e-44d1-389c4fe84127" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fb2eba1d-18a1-c88e-44d1-389c4fe84127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="arc" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fb2eba1d-18a1-c88e-44d1-389c4fe84127" xlink:type="arc" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="arc" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_68ab4f27-d74b-d0bc-abda-f625b11860e1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_68ab4f27-d74b-d0bc-abda-f625b11860e1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9F3325E0F11F9E0FAFA50AFCD3C2B8CB" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9F3325E0F11F9E0FAFA50AFCD3C2B8CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1614e10d-239d-dd27-f21f-6bf70cc45577" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_4644c36b-2591-5821-1391-f625b166fb31" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1614e10d-239d-dd27-f21f-6bf70cc45577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_1b3378b2-4516-3e25-8b78-2fea6fcc17f4" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_8d3a9604-12a6-9f8a-2166-f625b1186579" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_1b3378b2-4516-3e25-8b78-2fea6fcc17f4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_9457929d-79a2-8c41-ff57-afe7f61ce807" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_c8e43ccd-2663-8a3a-34ae-f625b157f11e" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_9457929d-79a2-8c41-ff57-afe7f61ce807" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2e5128aa-6caf-7804-0014-2a8148a0b9de" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_ee837b39-c135-31a6-5f3f-f625b0ab8a62" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2e5128aa-6caf-7804-0014-2a8148a0b9de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_12928cf4-7bc8-1112-408f-6e02bd1f135d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_e87c6669-8f1b-0b93-4ac0-f625b0f97077" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_12928cf4-7bc8-1112-408f-6e02bd1f135d" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_d4de5958-df21-732d-46e4-0fb9b9ce81e1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f67e4a70-063a-7e63-7c03-f625b0ca3e13" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_d4de5958-df21-732d-46e4-0fb9b9ce81e1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_59c79d0c-ed63-b2bc-685a-f7e81a18ac39" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_828e5d61-3893-c6ba-834e-f625b0ab217a" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_59c79d0c-ed63-b2bc-685a-f7e81a18ac39" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:to="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>biib-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20190630.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20190630.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20190630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190630.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190630.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190630.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetails" xlink:href="biib-20190630.xsd#DivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20190630.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190630.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresTables" xlink:href="biib-20190630.xsd#DivestituresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20190630.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190630.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190630.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190630.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20190630.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190630.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190630.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:href="biib-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190630.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:href="biib-20190630.xsd#LeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:href="biib-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190630.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20190630.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20190630.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20190630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190630.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190630.xsd#ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190630.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190630.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190630.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20190630.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20190630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190630.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190630.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20190630.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190630.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190630.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190630.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190630.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20190630.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20190630.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_E7BF2320D38A8EDD66B60B174D0D5CEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_E7BF2320D38A8EDD66B60B174D0D5CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_118970C36F68F3047F0A0B174D0D641F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_118970C36F68F3047F0A0B174D0D641F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_118970C36F68F3047F0A0B174D0D641F" xlink:to="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_118970C36F68F3047F0A0B174D0D641F" xlink:to="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93A1814C1FD9F599D91B0B174D0EC934" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93A1814C1FD9F599D91B0B174D0EC934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5420DF1CAB8F1B5E7A940B174D0ECDD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5420DF1CAB8F1B5E7A940B174D0ECDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_449A11954160AB0AA1C80B174D0EF0DA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_449A11954160AB0AA1C80B174D0EF0DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43DDBEBA0138ACD8B9130B174D10289B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43DDBEBA0138ACD8B9130B174D10289B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4A81DD49FB20A7ECEA790B174D105EBE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4A81DD49FB20A7ECEA790B174D105EBE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_32C223FE45DCC29C1AC70B174E65B963" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_32C223FE45DCC29C1AC70B174E65B963" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3C6B8576605BBECEB1C50B174E652A13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_32C223FE45DCC29C1AC70B174E65B963" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3C6B8576605BBECEB1C50B174E652A13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3C6B8576605BBECEB1C50B174E652A13" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3C6B8576605BBECEB1C50B174E652A13" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_C411DB83A716F91C59B50B174E668DA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343" xlink:to="loc_biib_NightstarMember_C411DB83A716F91C59B50B174E668DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0451B2F74B0EA5A64C00B174E679E91" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0451B2F74B0EA5A64C00B174E679E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:to="loc_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:to="loc_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:to="loc_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4E66BC7E39100F9AC7550B174E5D0837" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4E66BC7E39100F9AC7550B174E5D0837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4E66BC7E39100F9AC7550B174E5D0837" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4E66BC7E39100F9AC7550B174E5D0837" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:to="loc_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_58B666E7BC93AB79CC3B0B174C552F8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_58B666E7BC93AB79CC3B0B174C552F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_58B666E7BC93AB79CC3B0B174C552F8E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_58B666E7BC93AB79CC3B0B174C552F8E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9841D2D3FFA4E036EE5D0B174C569657" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9841D2D3FFA4E036EE5D0B174C569657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1D02FAEDC435442CF6A20B174C56EA2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1D02FAEDC435442CF6A20B174C56EA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:to="loc_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:to="loc_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7A14A859BDE0AB1919BE0B174C574FC8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="loc_srt_ProductOrServiceAxis_7A14A859BDE0AB1919BE0B174C574FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7A14A859BDE0AB1919BE0B174C574FC8" xlink:to="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7A14A859BDE0AB1919BE0B174C574FC8" xlink:to="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:to="loc_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:to="loc_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9040A36CDD4F27EA8F120B174C47B36F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9040A36CDD4F27EA8F120B174C47B36F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9040A36CDD4F27EA8F120B174C47B36F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9040A36CDD4F27EA8F120B174C47B36F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1415E1421A0D3DA2626B0B174C497DCE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1415E1421A0D3DA2626B0B174C497DCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1415E1421A0D3DA2626B0B174C497DCE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1415E1421A0D3DA2626B0B174C497DCE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9D49243DBFF30A2CB6220B174C49ABB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9D49243DBFF30A2CB6220B174C49ABB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45ABD65CDF0556A091B80B174C4ADFCF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45ABD65CDF0556A091B80B174C4ADFCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45ABD65CDF0556A091B80B174C4ADFCF" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45ABD65CDF0556A091B80B174C4ADFCF" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_628DC344FEF6E805F7070B174C4A3157" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_628DC344FEF6E805F7070B174C4A3157" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E509D8FA388FB103CD500B174C4BA64C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E509D8FA388FB103CD500B174C4BA64C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B10ED37EC9C50BEE3CF50B174C4B11B7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B10ED37EC9C50BEE3CF50B174C4B11B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_96C194A9EB0CD6CAC5EC0B174C4D2DFD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_Collaborationprofitlosssharing_96C194A9EB0CD6CAC5EC0B174C4D2DFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_AF87BA8C68BE59E7963A0B174C4D5BAD" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_Revenues_AF87BA8C68BE59E7963A0B174C4D5BAD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:to="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:to="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:to="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:to="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DFAC17DE80F932B01313170B397A4931" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_NetIncomeLoss_DFAC17DE80F932B01313170B397A4931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_96AF9A36D34673A6A951F6291A44368A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8AA2CE196565791F3240F6291A44A46A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_96AF9A36D34673A6A951F6291A44368A" xlink:to="loc_us-gaap_StatementTable_8AA2CE196565791F3240F6291A44A46A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8AA2CE196565791F3240F6291A44A46A" xlink:to="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:to="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:to="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:to="loc_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:to="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:to="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:to="loc_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:to="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:to="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A32350E1F2F6726E70ED1756F226BF5F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A32350E1F2F6726E70ED1756F226BF5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A32350E1F2F6726E70ED1756F226BF5F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A32350E1F2F6726E70ED1756F226BF5F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:to="loc_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:to="loc_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:to="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:to="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:to="loc_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:to="loc_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:to="loc_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:to="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:to="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:to="loc_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:to="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:to="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:to="loc_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:to="loc_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_EE74FC8929009276770D0B174E4D5583" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_EE74FC8929009276770D0B174E4D5583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EE74FC8929009276770D0B174E4D5583" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EE74FC8929009276770D0B174E4D5583" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9D4003F2EFB83432C65E0B174E448827" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9D4003F2EFB83432C65E0B174E448827" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9D4003F2EFB83432C65E0B174E448827" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9D4003F2EFB83432C65E0B174E448827" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_D10943AD7B6503C817350B174E458CE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_D10943AD7B6503C817350B174E458CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_FD6A3D83A4461909A6010B174E46440D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_FD6A3D83A4461909A6010B174E46440D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:to="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:to="loc_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D6A24931624C85803D9FF625F8EEA30A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:to="loc_us-gaap_DebtInstrumentAxis_D6A24931624C85803D9FF625F8EEA30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_D6A24931624C85803D9FF625F8EEA30A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_D6A24931624C85803D9FF625F8EEA30A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB7CDC30928910C15E88F625F8EE59FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB7CDC30928910C15E88F625F8EE59FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6556D19F630D04DEA74CF625F8EE5015" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6556D19F630D04DEA74CF625F8EE5015" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A58BB25EC7E3A9C64F9DF625F8EE2F0B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A58BB25EC7E3A9C64F9DF625F8EE2F0B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_66023A34561B18E5FC21F625F8EE45E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_66023A34561B18E5FC21F625F8EE45E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="loc_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="loc_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_448E882A7125E215FDC0F625F8DF3AEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_448E882A7125E215FDC0F625F8DF3AEF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3F0304E371930F620F2BF625F8DF2CF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_448E882A7125E215FDC0F625F8DF3AEF" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3F0304E371930F620F2BF625F8DF2CF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3F0304E371930F620F2BF625F8DF2CF5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3F0304E371930F620F2BF625F8DF2CF5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_84BAD964745FE7E8BCEEF625F8DFFA79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_84BAD964745FE7E8BCEEF625F8DFFA79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1101D9F0467AC18E17ECF625F94C3598" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:to="loc_us-gaap_DebtInstrumentAxis_1101D9F0467AC18E17ECF625F94C3598" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1101D9F0467AC18E17ECF625F94C3598" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1101D9F0467AC18E17ECF625F94C3598" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4543F640FEADE8B8EB49F625F94CCBF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4543F640FEADE8B8EB49F625F94CCBF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DF44E5F2A74564BB903FF625F94C6030" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DF44E5F2A74564BB903FF625F94C6030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:to="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_EDB87F2AB2734E0054441ACA4BF8CD3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_EDB87F2AB2734E0054441ACA4BF8CD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EDB87F2AB2734E0054441ACA4BF8CD3F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EDB87F2AB2734E0054441ACA4BF8CD3F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E26F596AD2AAE8DEA05E1ACA85AA2BEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_E26F596AD2AAE8DEA05E1ACA85AA2BEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0F025EAADA4DDB5601061ACACCD15132" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0F025EAADA4DDB5601061ACACCD15132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C2D005B539440C6F128C1ACA0D612F1B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C2D005B539440C6F128C1ACA0D612F1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C2D005B539440C6F128C1ACA0D612F1B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C2D005B539440C6F128C1ACA0D612F1B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2D630AF18C05275B77FC1ACA0D61B7AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2D630AF18C05275B77FC1ACA0D61B7AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2EC015530BACC93486E51B1B924F7A29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2EC015530BACC93486E51B1B924F7A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2EC015530BACC93486E51B1B924F7A29" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2EC015530BACC93486E51B1B924F7A29" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_B7FB8CD6EDF95DB161B51B1B924F4F93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_B7FB8CD6EDF95DB161B51B1B924F4F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9" xlink:to="loc_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:to="loc_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:to="loc_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_A1969B6EA547B73E48E11B1B924FFA86" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_A1969B6EA547B73E48E11B1B924FFA86" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:to="loc_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D62BE674077C0FF47BEF0B01B6C61B70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D62BE674077C0FF47BEF0B01B6C61B70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D62BE674077C0FF47BEF0B01B6C61B70" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D62BE674077C0FF47BEF0B01B6C61B70" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_5F3B5961B043720FD9370B01B6C61BD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_5F3B5961B043720FD9370B01B6C61BD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_13DDF1008CA068D7757E0B01B6C63049" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_13DDF1008CA068D7757E0B01B6C63049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_13DDF1008CA068D7757E0B01B6C63049" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_13DDF1008CA068D7757E0B01B6C63049" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8" xlink:to="loc_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D4B34543F3A31B29642E0B01B6C67B27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D4B34543F3A31B29642E0B01B6C67B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F3F6401FACE1D2F8F410067AD570CDD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F3F6401FACE1D2F8F410067AD570CDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F3F6401FACE1D2F8F410067AD570CDD6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F3F6401FACE1D2F8F410067AD570CDD6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_44AFCB5405DAF1A78CBC067AD59CC8D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D" xlink:to="loc_biib_NightstarMember_44AFCB5405DAF1A78CBC067AD59CC8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_72C9F550CEC875B147860672E6B2A281" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_72C9F550CEC875B147860672E6B2A281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:to="loc_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_99CCE21AAE95D55120320672E6B34626" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_99CCE21AAE95D55120320672E6B34626" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:to="loc_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_12058DA79C9CF78A5FC40672E6B35C5D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_srt_ProductOrServiceAxis_12058DA79C9CF78A5FC40672E6B35C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_12058DA79C9CF78A5FC40672E6B35C5D" xlink:to="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_12058DA79C9CF78A5FC40672E6B35C5D" xlink:to="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:to="loc_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:to="loc_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:to="loc_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1CE5FB255F00CBAFCFF30672E6B46C75" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_srt_RangeAxis_1CE5FB255F00CBAFCFF30672E6B46C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1CE5FB255F00CBAFCFF30672E6B46C75" xlink:to="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1CE5FB255F00CBAFCFF30672E6B46C75" xlink:to="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:to="loc_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:to="loc_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_E85764B6992734CA886A0672E6B7A934" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_E85764B6992734CA886A0672E6B7A934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_39D2D96F52F4BF4EAB44067AD50AB1DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_39D2D96F52F4BF4EAB44067AD50AB1DE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71805DC94F7E99A2B4480672E66A69E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71805DC94F7E99A2B4480672E66A69E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71805DC94F7E99A2B4480672E66A69E5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71805DC94F7E99A2B4480672E66A69E5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_B054B84DF192CFA591BB0672E66A5D4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B" xlink:to="loc_biib_NightstarMember_B054B84DF192CFA591BB0672E66A5D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7E4A7F0DC63919EBA50B0672E66BF919" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7E4A7F0DC63919EBA50B0672E66BF919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7E4A7F0DC63919EBA50B0672E66BF919" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7E4A7F0DC63919EBA50B0672E66BF919" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_090BB12F24884C9EF7ED0672E66B173C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_090BB12F24884C9EF7ED0672E66B173C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:to="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:to="loc_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F" xlink:to="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F" xlink:to="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972" xlink:to="loc_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:to="loc_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DE7B13A28752AC5BD4D70672E5CD7FFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DE7B13A28752AC5BD4D70672E5CD7FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DE7B13A28752AC5BD4D70672E5CD7FFC" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DE7B13A28752AC5BD4D70672E5CD7FFC" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:to="loc_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4B0760A756922F31FC210672E5CEC36B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4B0760A756922F31FC210672E5CEC36B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_0E51BC1C67B8B4F399ED0672E5CE72DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_0E51BC1C67B8B4F399ED0672E5CE72DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0EF80B66332EFC5B2CC90672E5CFF9C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0EF80B66332EFC5B2CC90672E5CFF9C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0EF80B66332EFC5B2CC90672E5CFF9C6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0EF80B66332EFC5B2CC90672E5CFF9C6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A7F4E9C34C8D29AB5C40672E5CF61EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A7F4E9C34C8D29AB5C40672E5CF61EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_91CE3FB25D4B3D0A80040672E5CFCB95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_91CE3FB25D4B3D0A80040672E5CFCB95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_913EFDCC00D3A18CB83B0672E5CF2AF5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_913EFDCC00D3A18CB83B0672E5CF2AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9DC59FFCDA6353076EE00672E5D05DAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9DC59FFCDA6353076EE00672E5D05DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_46E309F51C178FE090440672E5D02181" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_46E309F51C178FE090440672E5D02181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23830DA29C903F89710B0B174D24B345" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23830DA29C903F89710B0B174D24B345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23830DA29C903F89710B0B174D24B345" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23830DA29C903F89710B0B174D24B345" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_A07A27E5B3094DFC71FC0B174D255246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_A07A27E5B3094DFC71FC0B174D255246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C99C20DF6E9B135383030B174D257D81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:to="loc_srt_RangeAxis_C99C20DF6E9B135383030B174D257D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_C99C20DF6E9B135383030B174D257D81" xlink:to="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_C99C20DF6E9B135383030B174D257D81" xlink:to="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0F8F0655BB80C925975E0B174D260044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:to="loc_srt_MinimumMember_0F8F0655BB80C925975E0B174D260044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E7DE0DE4DBB8B73551160B174D2695A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:to="loc_srt_MaximumMember_E7DE0DE4DBB8B73551160B174D2695A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_CF8B46924A95AC9836BD0B174D274740" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_CF8B46924A95AC9836BD0B174D274740" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_97CC20FBEE4DFAF6A43E0B174D2765BE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_97CC20FBEE4DFAF6A43E0B174D2765BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_0D94758BE592352CB5740B87D975BFA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:to="loc_country_BR_0D94758BE592352CB5740B87D975BFA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7F32EC4D9DCF41E45B2C170B379E04B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_415A49569F24999ACC32170B379E2EED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7F32EC4D9DCF41E45B2C170B379E04B8" xlink:to="loc_us-gaap_StatementTable_415A49569F24999ACC32170B379E2EED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B48656F1299F0C016E34170B379E9C92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_415A49569F24999ACC32170B379E2EED" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_B48656F1299F0C016E34170B379E9C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B48656F1299F0C016E34170B379E9C92" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B48656F1299F0C016E34170B379E9C92" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_171709EBFAD92E22CA6E170B379E6168" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_171709EBFAD92E22CA6E170B379E6168" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_DA93685B43A375AD256F0B174E1A1A2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_DA93685B43A375AD256F0B174E1A1A2F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_387BD35E163AA08108780B174E179375" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:to="loc_us-gaap_TypeOfArrangementAxis_387BD35E163AA08108780B174E179375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_387BD35E163AA08108780B174E179375" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_387BD35E163AA08108780B174E179375" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_84233EBE9AB0FF8E7FB40B174E170DC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_84233EBE9AB0FF8E7FB40B174E170DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_79CF5DC0CAE3ACAFAF400B174E186358" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:to="loc_srt_ProductOrServiceAxis_79CF5DC0CAE3ACAFAF400B174E186358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_79CF5DC0CAE3ACAFAF400B174E186358" xlink:to="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_79CF5DC0CAE3ACAFAF400B174E186358" xlink:to="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:to="loc_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:to="loc_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_882BB8526C62019952160B174E188C16" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_882BB8526C62019952160B174E188C16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_06CB75A2E8682A375B890B174E199CF8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:to="loc_srt_MajorCustomersAxis_06CB75A2E8682A375B890B174E199CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_06CB75A2E8682A375B890B174E199CF8" xlink:to="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_06CB75A2E8682A375B890B174E199CF8" xlink:to="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:to="loc_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_A6D73E81B1424AD925400B174E1A4A39" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_A6D73E81B1424AD925400B174E1A4A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_513D8609BECC670DAA080B174E1A1980" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_DA93685B43A375AD256F0B174E1A1A2F" xlink:to="loc_us-gaap_Revenues_513D8609BECC670DAA080B174E1A1980" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:to="loc_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:to="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:to="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:to="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:to="loc_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:to="loc_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D1CDAED267CAA857300B174DFA989B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D1CDAED267CAA857300B174DFA989B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D1CDAED267CAA857300B174DFA989B" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D1CDAED267CAA857300B174DFA989B" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_5E921FCE8E4BA6AF6D350B174DFAA358" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_5E921FCE8E4BA6AF6D350B174DFAA358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DE90553434E12083A0F80B174DFB566E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DE90553434E12083A0F80B174DFB566E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60F2B9078F6304CBB9C31756F1C8A140" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60F2B9078F6304CBB9C31756F1C8A140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60F2B9078F6304CBB9C31756F1C8A140" xlink:to="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60F2B9078F6304CBB9C31756F1C8A140" xlink:to="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8DD06F2A02DCAF34EA181756F1C86832" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_NetIncomeLoss_8DD06F2A02DCAF34EA181756F1C86832" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:to="loc_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:to="loc_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_78039ABE2D2C4FADE79D0B174E26A718" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CF9E428F7B276BC54F960B174E250DB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_78039ABE2D2C4FADE79D0B174E26A718" xlink:to="loc_us-gaap_StatementTable_CF9E428F7B276BC54F960B174E250DB0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_786BB36E1989FAAC0DE30B174E25DA42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_CF9E428F7B276BC54F960B174E250DB0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_786BB36E1989FAAC0DE30B174E25DA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_786BB36E1989FAAC0DE30B174E25DA42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_786BB36E1989FAAC0DE30B174E25DA42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:to="loc_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78039ABE2D2C4FADE79D0B174E26A718" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_AA4F4AB5C516328ADCD4170B39299353" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AA4F4AB5C516328ADCD4170B39299353" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E7E54EAD481FEB2E31CA170B39228666" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:to="loc_srt_ProductOrServiceAxis_E7E54EAD481FEB2E31CA170B39228666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_E7E54EAD481FEB2E31CA170B39228666" xlink:to="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_E7E54EAD481FEB2E31CA170B39228666" xlink:to="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_4ED0016DE85811A6E3CC170B39228A76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_TecfideraMember_4ED0016DE85811A6E3CC170B39228A76" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F84D448889CB02D9644A170B3922862A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_TysabriProductMember_F84D448889CB02D9644A170B3922862A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_537E2492F7B6BAE7D6B9170B392892B8" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_us-gaap_ProductMember_537E2492F7B6BAE7D6B9170B392892B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:to="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:to="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:to="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D70DCD898CA8A1E24985170B39291327" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:to="loc_country_US_D70DCD898CA8A1E24985170B39291327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:to="loc_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AA4F4AB5C516328ADCD4170B39299353" xlink:to="loc_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:to="loc_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8" xlink:to="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8" xlink:to="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_372DD6272618074397AE0B174E1067F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_372DD6272618074397AE0B174E1067F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_C1E3A47BDFF136DE9DD40B174E10B4B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:to="loc_srt_MajorCustomersAxis_C1E3A47BDFF136DE9DD40B174E10B4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_C1E3A47BDFF136DE9DD40B174E10B4B1" xlink:to="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_C1E3A47BDFF136DE9DD40B174E10B4B1" xlink:to="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:to="loc_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:to="loc_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_8D29FF91EB8BF1AC86630B174E1110F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:to="loc_biib_BioverativMember_8D29FF91EB8BF1AC86630B174E1110F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:to="loc_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_084FAFDBEB848DEA34AE0B174E1F5B73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:to="loc_srt_ProductOrServiceAxis_084FAFDBEB848DEA34AE0B174E1F5B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_084FAFDBEB848DEA34AE0B174E1F5B73" xlink:to="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_084FAFDBEB848DEA34AE0B174E1F5B73" xlink:to="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_BDCFAACF6E17D5ADE0E90B174E1F3EF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_BDCFAACF6E17D5ADE0E90B174E1F3EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:to="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:to="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:to="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:to="loc_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="loc_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="loc_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:to="loc_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_C59737DBB14908D8B04707255AACCFAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE" xlink:to="loc_biib_NightstarMember_C59737DBB14908D8B04707255AACCFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:to="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_1565AAC5E50546A3F8E707255AACDEEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_MarketStockUnitsMember_1565AAC5E50546A3F8E707255AACDEEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_8BB5062B8EB27477417607255AAC53FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_8BB5062B8EB27477417607255AAC53FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_62D3EF5CE4B4AE47D42F07255AACC049" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_62D3EF5CE4B4AE47D42F07255AACC049" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0A1427BC0E649CA13CEA07255AAC850B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0A1427BC0E649CA13CEA07255AAC850B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_2B2754BD6B359768E77507255AAC7CB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_2B2754BD6B359768E77507255AAC7CB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5B5B47710242C2D7FD9D07255AAC98AB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5B5B47710242C2D7FD9D07255AAC98AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3D64A997BBFBF6D3264E07255AACAE6E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3D64A997BBFBF6D3264E07255AACAE6E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9A7B9099D5A6B7196FD30B174D18A4AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9A7B9099D5A6B7196FD30B174D18A4AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9A7B9099D5A6B7196FD30B174D18A4AB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9A7B9099D5A6B7196FD30B174D18A4AB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F1D1D51E371863F193670B174D18A4C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_F1D1D51E371863F193670B174D18A4C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_CE32531EF7F5135223180B174D18A1B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_CE32531EF7F5135223180B174D18A1B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_6C4F1928E8B69A2802390B174D190B34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_6C4F1928E8B69A2802390B174D190B34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_43491C4D7669099F3D510B174E706CAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:to="loc_us-gaap_StatementTable_43491C4D7669099F3D510B174E706CAC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_3DB49C89C64BD7C1A37C0B174E71EE67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_43491C4D7669099F3D510B174E706CAC" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_3DB49C89C64BD7C1A37C0B174E71EE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_3DB49C89C64BD7C1A37C0B174E71EE67" xlink:to="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_3DB49C89C64BD7C1A37C0B174E71EE67" xlink:to="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:to="loc_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>biib-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D" xlink:to="lab_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D" xlink:type="arc" />
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C_terseLabel_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities held for sale</link:label>
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C_label_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held For Sale [Policy Text Block]</link:label>
    <link:label id="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C_documentation_en-US" xlink:label="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held For Sale [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" xlink:label="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:to="lab_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_73548E245ED85E173C31F625F92D85AD_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_73548E245ED85E173C31F625F92D85AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_73548E245ED85E173C31F625F92D85AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_73548E245ED85E173C31F625F92D85AD" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_73548E245ED85E173C31F625F92D85AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:type="arc" />
    <link:label id="lab_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668_label_en-US" xlink:label="lab_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668" xlink:to="lab_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7F208AB7E63E6C04C6320B174D537E94_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7F208AB7E63E6C04C6320B174D537E94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7F208AB7E63E6C04C6320B174D537E94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7F208AB7E63E6C04C6320B174D537E94" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7F208AB7E63E6C04C6320B174D537E94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C_label_en-US" xlink:label="lab_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:to="lab_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:to="lab_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:to="lab_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:to="lab_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290_label_en-US" xlink:label="lab_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:to="lab_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:to="lab_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:to="lab_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_DF8D27870D6F0338575FF625F8C0C7D7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_DF8D27870D6F0338575FF625F8C0C7D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DF8D27870D6F0338575FF625F8C0C7D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DF8D27870D6F0338575FF625F8C0C7D7" xlink:to="lab_us-gaap_EarningsPerShareAbstract_DF8D27870D6F0338575FF625F8C0C7D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C41ACE0F44681F9F0C17F625F8A0C7D7_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C41ACE0F44681F9F0C17F625F8A0C7D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C41ACE0F44681F9F0C17F625F8A0C7D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C41ACE0F44681F9F0C17F625F8A0C7D7" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C41ACE0F44681F9F0C17F625F8A0C7D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25_label_en-US" xlink:label="lab_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:to="lab_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:to="lab_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:to="lab_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:to="lab_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7A020EACFC6913E1CF1BF625F8DFCF99_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7A020EACFC6913E1CF1BF625F8DFCF99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A020EACFC6913E1CF1BF625F8DFCF99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A020EACFC6913E1CF1BF625F8DFCF99" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7A020EACFC6913E1CF1BF625F8DFCF99" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:to="lab_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C_label_en-US" xlink:label="lab_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C" xlink:to="lab_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB" xlink:to="lab_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5_label_en-US" xlink:label="lab_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="lab_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_7E303BA12292E06178051A8B31975164_terseLabel_en-US" xlink:label="lab_dei_DocumentType_7E303BA12292E06178051A8B31975164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_7E303BA12292E06178051A8B31975164_label_en-US" xlink:label="lab_dei_DocumentType_7E303BA12292E06178051A8B31975164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7E303BA12292E06178051A8B31975164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_7E303BA12292E06178051A8B31975164" xlink:to="lab_dei_DocumentType_7E303BA12292E06178051A8B31975164" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B" xlink:to="lab_dei_DocumentQuarterlyReport_4A3961AD2F087A133D9A1A8B3197806B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733" xlink:to="lab_dei_DocumentPeriodEndDate_4C8D627708EFB95A18CB1A8B31975733" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801" xlink:to="lab_dei_DocumentTransitionReport_9300D37270521FF9425F1A8B31976801" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862_label_en-US" xlink:label="lab_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862" xlink:to="lab_dei_EntityFileNumber_D37C363615D23E34583E1A8B31973862" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50_label_en-US" xlink:label="lab_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50" xlink:to="lab_dei_EntityRegistrantName_B4CEB1130623FEBBAC341A8B31978E50" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B" xlink:to="lab_dei_EntityCentralIndexKey_DCE00533299F5546B3431A8B3197FD1B" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305" xlink:to="lab_dei_CurrentFiscalYearEndDate_C5DEB0FB0B42718211181A8B31979305" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259" xlink:to="lab_dei_DocumentFiscalYearFocus_2796CA1629204807A2041A8B31977259" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC" xlink:to="lab_dei_DocumentFiscalPeriodFocus_6957BBCB1BEE601657B21A8B3197D9FC" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2_label_en-US" xlink:label="lab_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2" xlink:to="lab_dei_AmendmentFlag_C8C46B8774826E9673DE1A8B3197BBF2" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513" xlink:to="lab_dei_EntityIncorporationStateCountryCode_EBAC3D548524FD01534B1A8B31975513" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14" xlink:to="lab_dei_EntityTaxIdentificationNumber_D86AD68FB58FB268E0E41A8B31972A14" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF" xlink:to="lab_dei_EntityAddressAddressLine1_958B9394A305FD4899881A8B3197D7CF" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB" xlink:to="lab_dei_EntityAddressCityOrTown_47666A9C181DD41ED2A91A8B319728AB" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E" xlink:to="lab_dei_EntityAddressStateOrProvince_1E5EBD14933D7DDD85581A8B31970B8E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF" xlink:to="lab_dei_EntityAddressPostalZipCode_DEEC1A963E3EE1C605081A8B3197BCCF" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F_label_en-US" xlink:label="lab_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F" xlink:to="lab_dei_CityAreaCode_2153D7974F5C7AACCFA71A8B3197E22F" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A" xlink:to="lab_dei_LocalPhoneNumber_35B140C1A6775EB2BE021A8B31978B5A" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C_label_en-US" xlink:label="lab_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C" xlink:to="lab_dei_Security12bTitle_C36ED970E146750146A91A8B3197C90C" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2_label_en-US" xlink:label="lab_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2" xlink:to="lab_dei_TradingSymbol_98F226DE26D004D8AB991A8B3197CEF2" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89_label_en-US" xlink:label="lab_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89" xlink:to="lab_dei_SecurityExchangeName_EA2F1424BA3533D4F5871A8B31970A89" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA" xlink:to="lab_dei_EntityCurrentReportingStatus_1726CFCF84EEDA949FBB1A8B31979CEA" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3" xlink:to="lab_dei_EntityInteractiveDataCurrent_A13D6109578D5A16050B1A8B3197CDD3" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755_label_en-US" xlink:label="lab_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755" xlink:to="lab_dei_EntityFilerCategory_8C11F5DC978278511CE21A8B31972755" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798" xlink:to="lab_dei_EntitySmallBusiness_F3170D4E00B3665716B01A8B31978798" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103" xlink:to="lab_dei_EntityEmergingGrowthCompany_CA05675345A624E1172D1A8B31979103" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9_label_en-US" xlink:label="lab_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9" xlink:to="lab_dei_EntityShellCompany_BCDBAA421B16BB587AE91A8B319767F9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_123A190734ED9CD3173D1A8B31970D54" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0_terseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_FD4BB25BCCF40A79232E170B39745336_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_FD4BB25BCCF40A79232E170B39745336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_FD4BB25BCCF40A79232E170B39745336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_FD4BB25BCCF40A79232E170B39745336" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_FD4BB25BCCF40A79232E170B39745336" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F_label_en-US" xlink:label="lab_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="lab_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD_terseLabel_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD_label_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:to="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:label id="lab_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D_label_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:to="lab_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:to="lab_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:type="arc" />
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9_terseLabel_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9_label_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9_documentation_en-US" xlink:label="lab_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:to="lab_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:type="arc" />
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:to="lab_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="lab_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:to="lab_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:to="lab_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:to="lab_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:to="lab_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:to="lab_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:to="lab_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="lab_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E_label_en-US" xlink:label="lab_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:to="lab_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:to="lab_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:to="lab_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:to="lab_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, decrease from distributions to noncontrolling interest holders</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting guidance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:to="lab_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_309A7FB6311FF124E85D170B397CD3DE_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_309A7FB6311FF124E85D170B397CD3DE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_309A7FB6311FF124E85D170B397CD3DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_309A7FB6311FF124E85D170B397CD3DE" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_309A7FB6311FF124E85D170B397CD3DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0B356C1319863DF609FD170B397C4625_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0B356C1319863DF609FD170B397C4625" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0B356C1319863DF609FD170B397C4625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0B356C1319863DF609FD170B397C4625" xlink:to="lab_us-gaap_StockholdersEquity_0B356C1319863DF609FD170B397C4625" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_A820BEE320F848CFD6F4170B397C2B14_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_A820BEE320F848CFD6F4170B397C2B14" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A820BEE320F848CFD6F4170B397C2B14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_A820BEE320F848CFD6F4170B397C2B14" xlink:to="lab_us-gaap_MinorityInterest_A820BEE320F848CFD6F4170B397C2B14" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_23BE54B83A92FB935BF8170B397C884C_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_23BE54B83A92FB935BF8170B397C884C" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_23BE54B83A92FB935BF8170B397C884C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_23BE54B83A92FB935BF8170B397C884C" xlink:to="lab_us-gaap_SharesIssued_23BE54B83A92FB935BF8170B397C884C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30775B844692EEAF707CF625F847D85B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30775B844692EEAF707CF625F847D85B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30775B844692EEAF707CF625F847D85B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30775B844692EEAF707CF625F847D85B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30775B844692EEAF707CF625F847D85B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7BCF1B1A15703CC423B81756F226E44B_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7BCF1B1A15703CC423B81756F226E44B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7BCF1B1A15703CC423B81756F226E44B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7BCF1B1A15703CC423B81756F226E44B" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7BCF1B1A15703CC423B81756F226E44B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:to="lab_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:to="lab_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:type="arc" />
    <link:label id="lab_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:to="lab_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:to="lab_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C_label_en-US" xlink:label="lab_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:to="lab_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="lab_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:type="arc" />
    <link:label id="lab_currency_EUR_51C51AEE7313C1CB56251756F22662D2_verboseLabel_en-US" xlink:label="lab_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_51C51AEE7313C1CB56251756F22662D2_label_en-US" xlink:label="lab_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:to="lab_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:type="arc" />
    <link:label id="lab_currency_GBP_5735681D34BDB36D55491756F22660D7_terseLabel_en-US" xlink:label="lab_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_5735681D34BDB36D55491756F22660D7_label_en-US" xlink:label="lab_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:to="lab_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:type="arc" />
    <link:label id="lab_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2_terseLabel_en-US" xlink:label="lab_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2_label_en-US" xlink:label="lab_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:to="lab_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:type="arc" />
    <link:label id="lab_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB_terseLabel_en-US" xlink:label="lab_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB_label_en-US" xlink:label="lab_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:to="lab_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:type="arc" />
    <link:label id="lab_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92_verboseLabel_en-US" xlink:label="lab_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92_label_en-US" xlink:label="lab_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:to="lab_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_423557A44366CA778D121756F2264922_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_423557A44366CA778D121756F2264922_label_en-US" xlink:label="lab_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:to="lab_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:to="lab_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:to="lab_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:to="lab_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:to="lab_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:to="lab_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:to="lab_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:to="lab_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:to="lab_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:to="lab_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8_label_en-US" xlink:label="lab_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:to="lab_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD_terseLabel_en-US" xlink:label="lab_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD_label_en-US" xlink:label="lab_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:to="lab_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4_label_en-US" xlink:label="lab_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:to="lab_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_A24F889EB155A122B9931756F236C348_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_A24F889EB155A122B9931756F236C348_label_en-US" xlink:label="lab_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:to="lab_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:to="lab_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on reclassification of cash flow hedges, effective portion</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:to="lab_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:type="arc" />
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:type="arc" />
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:type="arc" />
    <link:label id="lab_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041" xlink:to="lab_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:type="arc" />
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84_terseLabel_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84_label_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84_documentation_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:to="lab_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:to="lab_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:to="lab_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:type="arc" />
    <link:label id="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88_label_en-US" xlink:label="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88_documentation_en-US" xlink:label="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:to="lab_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:type="arc" />
    <link:label id="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4_label_en-US" xlink:label="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4_documentation_en-US" xlink:label="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:to="lab_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:type="arc" />
    <link:label id="lab_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8_terseLabel_en-US" xlink:label="lab_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8_label_en-US" xlink:label="lab_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8_documentation_en-US" xlink:label="lab_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:to="lab_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for pre-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of post-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:type="arc" />
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, in-process research and development, discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="lab_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:to="lab_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:to="lab_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8_label_en-US" xlink:label="lab_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:to="lab_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:type="arc" />
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B_label_en-US" xlink:label="lab_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B" xlink:to="lab_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:to="lab_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4" xlink:to="lab_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF" xlink:to="lab_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764" xlink:to="lab_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_BDA1C5682F8AA0E582E2F6291A4488CE_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_BDA1C5682F8AA0E582E2F6291A4488CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_BDA1C5682F8AA0E582E2F6291A4488CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_BDA1C5682F8AA0E582E2F6291A4488CE" xlink:to="lab_us-gaap_ProfitLoss_BDA1C5682F8AA0E582E2F6291A4488CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_F75ACB32F526BBA66055F6291A44AC9C_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_F75ACB32F526BBA66055F6291A44AC9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_F75ACB32F526BBA66055F6291A44AC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_F75ACB32F526BBA66055F6291A44AC9C" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_F75ACB32F526BBA66055F6291A44AC9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0B25A106C2A8DAA1E131F6291A44C7FD_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0B25A106C2A8DAA1E131F6291A44C7FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0B25A106C2A8DAA1E131F6291A44C7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0B25A106C2A8DAA1E131F6291A44C7FD" xlink:to="lab_us-gaap_NetIncomeLoss_0B25A106C2A8DAA1E131F6291A44C7FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:to="lab_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F" xlink:to="lab_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3" xlink:to="lab_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4F7D90CC48F01770F0C1F6291A44CD3E_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4F7D90CC48F01770F0C1F6291A44CD3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4F7D90CC48F01770F0C1F6291A44CD3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4F7D90CC48F01770F0C1F6291A44CD3E" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4F7D90CC48F01770F0C1F6291A44CD3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61489023C2CAFB6916C6F6291A44A43D_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61489023C2CAFB6916C6F6291A44A43D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61489023C2CAFB6916C6F6291A44A43D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61489023C2CAFB6916C6F6291A44A43D" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61489023C2CAFB6916C6F6291A44A43D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_5150974D2899C8CF54181B1B9368E1F1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_5150974D2899C8CF54181B1B9368E1F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5150974D2899C8CF54181B1B9368E1F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_5150974D2899C8CF54181B1B9368E1F1" xlink:to="lab_us-gaap_ProfitLoss_5150974D2899C8CF54181B1B9368E1F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1" xlink:to="lab_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8A3C917A0651D8ECF7171B1B936834DD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8A3C917A0651D8ECF7171B1B936834DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8A3C917A0651D8ECF7171B1B936834DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8A3C917A0651D8ECF7171B1B936834DD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8A3C917A0651D8ECF7171B1B936834DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Nightstar Therapeutics plc, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of Ionis Pharmaceuticals, Inc. stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2A04D11F2CC4DB197CE1B1B9378C9AE_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2A04D11F2CC4DB197CE1B1B9378C9AE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2A04D11F2CC4DB197CE1B1B9378C9AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2A04D11F2CC4DB197CE1B1B9378C9AE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2A04D11F2CC4DB197CE1B1B9378C9AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:to="lab_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945" xlink:to="lab_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:to="lab_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:to="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:type="arc" />
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6_terseLabel_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6_label_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6_documentation_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:to="lab_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:type="arc" />
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:to="lab_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Lived Assets and Liabilities Held-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:type="arc" />
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E_terseLabel_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E_label_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating Lease Assets</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E_documentation_en-US" xlink:label="lab_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating Lease Assets</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:to="lab_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:type="arc" />
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF_terseLabel_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF_label_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating lease liabilities</link:label>
    <link:label id="lab_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF_documentation_en-US" xlink:label="lab_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Operating lease liabilities</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:to="lab_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:to="lab_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:to="lab_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:to="lab_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:to="lab_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:to="lab_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B261B8492E0E9E950CFC0B87D96F6354_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B261B8492E0E9E950CFC0B87D96F6354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B261B8492E0E9E950CFC0B87D96F6354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B261B8492E0E9E950CFC0B87D96F6354" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B261B8492E0E9E950CFC0B87D96F6354" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_B99B47C6A1C91CDE5B0B0B87D9744B03" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_4360FAAD6375E391BB860B87D974992C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_9EC866EF82BE718C929A0B87D97483F1" xlink:type="arc" />
    <link:label id="lab_country_BR_0D94758BE592352CB5740B87D975BFA8_terseLabel_en-US" xlink:label="lab_country_BR_0D94758BE592352CB5740B87D975BFA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_0D94758BE592352CB5740B87D975BFA8_label_en-US" xlink:label="lab_country_BR_0D94758BE592352CB5740B87D975BFA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_0D94758BE592352CB5740B87D975BFA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_0D94758BE592352CB5740B87D975BFA8" xlink:to="lab_country_BR_0D94758BE592352CB5740B87D975BFA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_F73114E8E097C30101F30B87D9753804" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_6D60B544F6E913D1C86E0B87D9754D53" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:to="lab_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation inputs</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:to="lab_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:type="arc" />
    <link:label id="lab_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB_label_en-US" xlink:label="lab_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB_documentation_en-US" xlink:label="lab_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InventoryAbstract" xlink:label="loc_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB" xlink:to="lab_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:to="lab_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE_label_en-US" xlink:label="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE_documentation_en-US" xlink:label="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:to="lab_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:to="lab_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:type="arc" />
    <link:label id="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A_terseLabel_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A_label_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:label id="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A_documentation_en-US" xlink:label="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory sold to Bioverativ, cost</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:to="lab_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_6E4BDBB15F48BE5FCED70B174D245D05_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_6E4BDBB15F48BE5FCED70B174D245D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_6E4BDBB15F48BE5FCED70B174D245D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_6E4BDBB15F48BE5FCED70B174D245D05" xlink:to="lab_us-gaap_LeasesAbstract_6E4BDBB15F48BE5FCED70B174D245D05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_70F96BD057E900DA55AC0B174E2481F9_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract_70F96BD057E900DA55AC0B174E2481F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_70F96BD057E900DA55AC0B174E2481F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_70F96BD057E900DA55AC0B174E2481F9" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract_70F96BD057E900DA55AC0B174E2481F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:to="lab_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_845C704675E5463829D4F625FA274E87_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_845C704675E5463829D4F625FA274E87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_845C704675E5463829D4F625FA274E87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845C704675E5463829D4F625FA274E87" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_845C704675E5463829D4F625FA274E87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2" xlink:type="arc" />
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267_terseLabel_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of operating leases</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267_label_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267_documentation_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:to="lab_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD_label_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD_documentation_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:to="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78_terseLabel_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78_label_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78_documentation_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:to="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration expected to be received for sale of Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on assets and liabilities held for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum batch production for Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E" xlink:to="lab_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F_label_en-US" xlink:label="lab_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F" xlink:to="lab_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4F219219F6A54F208E68170B37A1AAB6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_4F219219F6A54F208E68170B37A1AAB6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4F219219F6A54F208E68170B37A1AAB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4F219219F6A54F208E68170B37A1AAB6" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_4F219219F6A54F208E68170B37A1AAB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Net gains (losses) recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_93BF7B102672F9A5E7B7170B37A1FDF0_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_93BF7B102672F9A5E7B7170B37A1FDF0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_93BF7B102672F9A5E7B7170B37A1FDF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_93BF7B102672F9A5E7B7170B37A1FDF0" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_93BF7B102672F9A5E7B7170B37A1FDF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:to="lab_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:to="lab_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="lab_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50_label_en-US" xlink:label="lab_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:to="lab_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:to="lab_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_64C79288857FC6CB238FF625F8DF35A0_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_64C79288857FC6CB238FF625F8DF35A0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_64C79288857FC6CB238FF625F8DF35A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_64C79288857FC6CB238FF625F8DF35A0" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_64C79288857FC6CB238FF625F8DF35A0" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:type="arc" />
    <link:label id="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:to="lab_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:to="lab_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_9C20D5FE8071D1D67BC50B174D20853B_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9C20D5FE8071D1D67BC50B174D20853B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9C20D5FE8071D1D67BC50B174D20853B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9C20D5FE8071D1D67BC50B174D20853B" xlink:to="lab_us-gaap_EquityAbstract_9C20D5FE8071D1D67BC50B174D20853B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="lab_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="lab_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E79B61A6D4F73FAE8D2E1513BDB53A7B_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E79B61A6D4F73FAE8D2E1513BDB53A7B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E79B61A6D4F73FAE8D2E1513BDB53A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E79B61A6D4F73FAE8D2E1513BDB53A7B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E79B61A6D4F73FAE8D2E1513BDB53A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_2E71B119F7688CC5E09C1513BDB567DD_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_2E71B119F7688CC5E09C1513BDB567DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2E71B119F7688CC5E09C1513BDB567DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_2E71B119F7688CC5E09C1513BDB567DD" xlink:to="lab_us-gaap_InventoryNet_2E71B119F7688CC5E09C1513BDB567DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2" xlink:to="lab_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3" xlink:to="lab_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF_label_en-US" xlink:label="lab_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF" xlink:to="lab_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413_label_en-US" xlink:label="lab_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413" xlink:to="lab_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2" xlink:to="lab_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858" xlink:to="lab_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_1A826AD085D64D51788D1513BDB93439_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1A826AD085D64D51788D1513BDB93439" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1A826AD085D64D51788D1513BDB93439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1A826AD085D64D51788D1513BDB93439" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1A826AD085D64D51788D1513BDB93439" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2" xlink:to="lab_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F" xlink:to="lab_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47_label_en-US" xlink:label="lab_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47" xlink:to="lab_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="lab_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2" xlink:to="lab_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48" xlink:to="lab_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765" xlink:to="lab_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE" xlink:to="lab_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_744D51C05F98F8B2DE861513BDBD8E7E_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_744D51C05F98F8B2DE861513BDBD8E7E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_744D51C05F98F8B2DE861513BDBD8E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_744D51C05F98F8B2DE861513BDBD8E7E" xlink:to="lab_us-gaap_StockholdersEquity_744D51C05F98F8B2DE861513BDBD8E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_A7FA6B663DB7B6DA2BA71513BDBD0705_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_A7FA6B663DB7B6DA2BA71513BDBD0705" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A7FA6B663DB7B6DA2BA71513BDBD0705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_A7FA6B663DB7B6DA2BA71513BDBD0705" xlink:to="lab_us-gaap_MinorityInterest_A7FA6B663DB7B6DA2BA71513BDBD0705" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3525A470FF07F26A409A1513BDBD8ABA_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3525A470FF07F26A409A1513BDBD8ABA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3525A470FF07F26A409A1513BDBD8ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3525A470FF07F26A409A1513BDBD8ABA" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3525A470FF07F26A409A1513BDBD8ABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:to="lab_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:to="lab_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3_label_en-US" xlink:label="lab_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3_documentation_en-US" xlink:label="lab_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:to="lab_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:type="arc" />
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:to="lab_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:type="arc" />
    <link:label id="lab_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:to="lab_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994_label_en-US" xlink:label="lab_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994_documentation_en-US" xlink:label="lab_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:to="lab_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:to="lab_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:type="arc" />
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:to="lab_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment to Skyhawk</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:to="lab_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06" xlink:type="arc" />
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:to="lab_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:to="lab_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:to="lab_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:to="lab_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:type="arc" />
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Our share of Samsung Bioepis gains (losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:to="lab_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:to="lab_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732" xlink:to="lab_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:to="lab_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:to="lab_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6_label_en-US" xlink:label="lab_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6_documentation_en-US" xlink:label="lab_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:to="lab_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA_label_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA" xlink:to="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:to="lab_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="lab_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80" xlink:to="lab_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:type="arc" />
    <link:label id="lab_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020_label_en-US" xlink:label="lab_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:to="lab_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory expected to be sold to FUJIFILM</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:to="lab_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:to="lab_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_D6F57B90376909FDBD390672E66C54CF_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_D6F57B90376909FDBD390672E66C54CF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D6F57B90376909FDBD390672E66C54CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_D6F57B90376909FDBD390672E66C54CF" xlink:to="lab_us-gaap_Goodwill_D6F57B90376909FDBD390672E66C54CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_122CE5D1605154A146760672E66C2237_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_122CE5D1605154A146760672E66C2237" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_122CE5D1605154A146760672E66C2237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_122CE5D1605154A146760672E66C2237" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_122CE5D1605154A146760672E66C2237" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_7165D24780A54F60FE510672E66C54A8_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_7165D24780A54F60FE510672E66C54A8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7165D24780A54F60FE510672E66C54A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_7165D24780A54F60FE510672E66C54A8" xlink:to="lab_us-gaap_Goodwill_7165D24780A54F60FE510672E66C54A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:to="lab_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F_verboseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of new accounting principle in period of adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:to="lab_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:to="lab_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8_label_en-US" xlink:label="lab_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8_documentation_en-US" xlink:label="lab_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:to="lab_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC_label_en-US" xlink:label="lab_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:to="lab_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37_label_en-US" xlink:label="lab_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37_documentation_en-US" xlink:label="lab_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:to="lab_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:to="lab_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:to="lab_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5_label_en-US" xlink:label="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:to="lab_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14_label_en-US" xlink:label="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:to="lab_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A_netLabel_en-US" xlink:label="lab_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:to="lab_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:to="lab_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:type="arc" />
    <link:label id="lab_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D_label_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D_documentation_en-US" xlink:label="lab_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:to="lab_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:to="lab_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:to="lab_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Income Statement, Sublease Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:to="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_FCAB26A43F0E075D33E30672E5D1902B_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_FCAB26A43F0E075D33E30672E5D1902B" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net lease cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_FCAB26A43F0E075D33E30672E5D1902B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_FCAB26A43F0E075D33E30672E5D1902B" xlink:to="lab_us-gaap_OperatingLeaseCost_FCAB26A43F0E075D33E30672E5D1902B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments 2019 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 842 - Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 940 - Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments, thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Minimum lease payments total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2019</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2021</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2022</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, 2023</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income, thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A_terseLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Sublease income total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments 2019</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2021</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2022</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, 2023</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments, thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">ASC 840 - Net minimum lease payments total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:to="lab_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:to="lab_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark assets held for sale</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal reorganization of certain intellectual property rights</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:to="lab_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:to="lab_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:to="lab_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NST stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:to="lab_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:to="lab_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:to="lab_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:to="lab_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:to="lab_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:to="lab_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:to="lab_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:to="lab_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:to="lab_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:to="lab_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:to="lab_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A_label_en-US" xlink:label="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A_documentation_en-US" xlink:label="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:to="lab_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8_label_en-US" xlink:label="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:to="lab_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:to="lab_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:type="arc" />
    <link:label id="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:to="lab_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6_label_en-US" xlink:label="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:to="lab_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8_label_en-US" xlink:label="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:to="lab_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:type="arc" />
    <link:label id="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14_label_en-US" xlink:label="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14_documentation_en-US" xlink:label="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:to="lab_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92_label_en-US" xlink:label="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:to="lab_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762_label_en-US" xlink:label="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:to="lab_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684_label_en-US" xlink:label="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:to="lab_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:to="lab_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:to="lab_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:type="arc" />
    <link:label id="lab_country_US_D70DCD898CA8A1E24985170B39291327_terseLabel_en-US" xlink:label="lab_country_US_D70DCD898CA8A1E24985170B39291327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_D70DCD898CA8A1E24985170B39291327_label_en-US" xlink:label="lab_country_US_D70DCD898CA8A1E24985170B39291327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D70DCD898CA8A1E24985170B39291327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_D70DCD898CA8A1E24985170B39291327" xlink:to="lab_country_US_D70DCD898CA8A1E24985170B39291327" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F_label_en-US" xlink:label="lab_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:to="lab_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:to="lab_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual Property</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:to="lab_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:to="lab_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset recorded on transfer of intellectual property</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability recorded on transfer of intellectual property</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payment, including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>biib-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20190630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20190630.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20190630.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20190630.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20190630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20190630.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20190630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20190630.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20190630.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20190630.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetails" xlink:href="biib-20190630.xsd#DivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20190630.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20190630.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresTables" xlink:href="biib-20190630.xsd#DivestituresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20190630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20190630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20190630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20190630.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20190630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20190630.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20190630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20190630.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20190630.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20190630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20190630.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20190630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20190630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20190630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20190630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20190630.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20190630.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20190630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20190630.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20190630.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:href="biib-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetails" xlink:href="biib-20190630.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:href="biib-20190630.xsd#LeasesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:href="biib-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20190630.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20190630.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20190630.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20190630.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20190630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20190630.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:href="biib-20190630.xsd#ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20190630.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20190630.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20190630.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20190630.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20190630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20190630.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20190630.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20190630.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20190630.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20190630.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20190630.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20190630.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20190630.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20190630.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20190630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E9468C1ED210FD0077FF0B174D0C5886" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E9468C1ED210FD0077FF0B174D0C5886" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C02CA3C176C0C0585A290B174D0CA685" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_E7BF2320D38A8EDD66B60B174D0D5CEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_2474980E466680FCF6EE0B174D0D21FB" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_E7BF2320D38A8EDD66B60B174D0D5CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_118970C36F68F3047F0A0B174D0D641F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_118970C36F68F3047F0A0B174D0D641F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_118970C36F68F3047F0A0B174D0D641F" xlink:to="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93A1814C1FD9F599D91B0B174D0EC934" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93A1814C1FD9F599D91B0B174D0EC934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5420DF1CAB8F1B5E7A940B174D0ECDD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5420DF1CAB8F1B5E7A940B174D0ECDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_449A11954160AB0AA1C80B174D0EF0DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_449A11954160AB0AA1C80B174D0EF0DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_CC7D7141A4364F6AB0D20B174D0EB537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_15E8F0BEE9187F0290230B174D0D8228" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_F46D8CC3C0E9B754B0350B174D0E51B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_B783BC9D08C445EAE58C0B174D0C398C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71F0E21B9289464ACDD10B174D0F440F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3099FCABDFCB49F0CA160B174D0F6C1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C6EBF545D38BF8AD3640B174D0FF918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C7939C9B71A3AEEB589A0B174D10C83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_169011691BFED543F9B40B174D10D4B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43DDBEBA0138ACD8B9130B174D10289B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43DDBEBA0138ACD8B9130B174D10289B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8A53AFB9AE271205147B0B174D10FC08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4A81DD49FB20A7ECEA790B174D105EBE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60B7FE89BD8259DBE89C0B174D0FD3C0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4A81DD49FB20A7ECEA790B174D105EBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7238CBF7E0C952ABC9770B174D1DDB83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7238CBF7E0C952ABC9770B174D1DDB83" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_C8FCFDF23D66355FD54C0B174D1D5918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7238CBF7E0C952ABC9770B174D1DDB83" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_2314EA83F4628924F42D0B174D1D9B06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C7281D8D6CFC56628248F625F8916F23" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_81C183220A76CEEA0932F625F89129A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_5703F0DD7A897FA095180B174E65DA73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_32C223FE45DCC29C1AC70B174E65B963" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_5703F0DD7A897FA095180B174E65DA73" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_32C223FE45DCC29C1AC70B174E65B963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3C6B8576605BBECEB1C50B174E652A13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_32C223FE45DCC29C1AC70B174E65B963" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3C6B8576605BBECEB1C50B174E652A13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3C6B8576605BBECEB1C50B174E652A13" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_C411DB83A716F91C59B50B174E668DA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A2C15F04F1C9F78B3BB10B174E665343" xlink:to="loc_biib_NightstarMember_C411DB83A716F91C59B50B174E668DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_32C223FE45DCC29C1AC70B174E65B963" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_03C708D3CFAC395085960B174E667388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_0772C67B6F0563D368540B174E67C78E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0451B2F74B0EA5A64C00B174E679E91" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0451B2F74B0EA5A64C00B174E679E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_Goodwill_E9343DF70B8AACEB89070B174E67BECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_D80083BF0B42CD954E3D0B174E67AF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_9D2F862E9BE26C7852A60B174E679393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_741CDD381396C969147F0B174E6628C6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E5705B357DA7434CF5580B174E67164A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_9E0336B40EFF3211910D0B174E5B9041" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_403E24C63C29F37DE8F10B3375330A7C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_C4CB69B0909DFBC984140B33753A5609" xlink:to="loc_biib_PostacquisitionequitycompensationMember_A0DEA3DFF395C9D979210B337583FF84" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_26CB678EDBA9594FF2810B174E5CA44C" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:to="loc_biib_BIIB111Member_21259AE5EF977EF1D5320B174E5C7A88" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_2205462ADC2B2F3CA2AC0B174E5C8470" xlink:to="loc_biib_BIIB112Member_3A991FD180E54F0572670B174E5D9EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4E66BC7E39100F9AC7550B174E5D0837" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4E66BC7E39100F9AC7550B174E5D0837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4E66BC7E39100F9AC7550B174E5D0837" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97485E9D64527F96CA960B174E5D6DAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D051117957744EC8E2240B174E5DBC47" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8D38D897B4E6D990BB090B174E5EB73E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7E50C5E12F114D08990F0B174E5E96D8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CBFB98033A6291DA409D0B174E5E8E08" xlink:to="loc_biib_NightstarMember_3DADC22800384B2BB8AB0B174E5E60D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E72BFC46C70EC03C6A0F0B174E5CF38D" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_210856A818BCB37F92400B174E5F0E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_48EB33E16E701E8D7DB60B174E5FF11C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_218E928A9BA6C1E1FD450B174E5FFBF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFBC4B5D4DCFB516D2A20B174E5FDBEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_7B80423349615629BD980B174E5FE33C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC8E3450900CF9626D700B174E60951E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ECDF521950E3F4BF2720B174E5F0492" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_D7766DA620BF4843F7D50B174E604EFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30775B844692EEAF707CF625F847D85B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_30775B844692EEAF707CF625F847D85B" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4DE607C659CC606A69D7F625F847DB7A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2CF598F7051C78F1DA150B174C55D225" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2CF598F7051C78F1DA150B174C55D225" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_58B666E7BC93AB79CC3B0B174C552F8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_58B666E7BC93AB79CC3B0B174C552F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_58B666E7BC93AB79CC3B0B174C552F8E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9841D2D3FFA4E036EE5D0B174C569657" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9841D2D3FFA4E036EE5D0B174C569657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1D02FAEDC435442CF6A20B174C56EA2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56208C6DDD4D6106F8290B174C56D69C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1D02FAEDC435442CF6A20B174C56EA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_22F8789DBA9B1E6CC7100B174C564163" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2CD2D19E4C99344F5D7E0B174C57C8B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:to="loc_biib_EisaiMember_D4FC269CCF081C6EA28F0B174C570CD3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7892E6FD16E73388B3BD0B174C5664D0" xlink:to="loc_biib_SkyhawkTherapeuticsMember_EC14C7B44DCE09B9165A0B174C574FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7A14A859BDE0AB1919BE0B174C574FC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="loc_srt_ProductOrServiceAxis_7A14A859BDE0AB1919BE0B174C574FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7A14A859BDE0AB1919BE0B174C574FC8" xlink:to="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:to="loc_biib_E2609andBAN2401Member_3F6C4A24D971A23341830B174C58B135" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B7CC51A02FE072E56B870B174C582FF0" xlink:to="loc_biib_AducanumabMember_2C4AFA04B209AA3E79890B174C581994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4A4FFBC7C28BB3472C80B174C55408C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_Expenseincurredbythecollaboration_62281F16FC656319CFAC0B174C58062A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_A263824570354B414A950B174C598D60" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6F04E3AC8BF9455822F80B174C596D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_us-gaap_LossOnContractTermination_9F6AE932A395ED45C9760B174C599A7E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_AdditionalMilestonePayment_9583469DC4935F2D1B420B174C59A228" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_78ADEF7C6D60940354070B174C5912A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_23617F4351995A80F39E0B174C59BC86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C81921F8FB64337AF9370B174C580C14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_6A290BF40EF2A39D15C90B174C5A36C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92759EC47B3C7262F1780B174C4698F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92759EC47B3C7262F1780B174C4698F0" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9040A36CDD4F27EA8F120B174C47B36F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9040A36CDD4F27EA8F120B174C47B36F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9040A36CDD4F27EA8F120B174C47B36F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_us-gaap_InventoriesMember_8D1B0828DA229D528D9D0B174C485A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_14AE52B82742EF5545F00B174C48882B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4BBB07AB9F11AA1FCECD0B174C49E5F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_98B38479476070B54C650B174C474A88" xlink:to="loc_biib_DeferredtaxliabilityMember_3D31C31F1450ABDAEA100B174C49A307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1415E1421A0D3DA2626B0B174C497DCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1415E1421A0D3DA2626B0B174C497DCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1415E1421A0D3DA2626B0B174C497DCE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9D49243DBFF30A2CB6220B174C49ABB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55113CDFF2D9B053135E0B174C496F29" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9D49243DBFF30A2CB6220B174C49ABB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45ABD65CDF0556A091B80B174C4ADFCF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45ABD65CDF0556A091B80B174C4ADFCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45ABD65CDF0556A091B80B174C4ADFCF" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_628DC344FEF6E805F7070B174C4A3157" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0CB680C8810ED75EA6B60B174C4A939C" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_628DC344FEF6E805F7070B174C4A3157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9EC268D25B3160F4D7D30B174C47E618" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E509D8FA388FB103CD500B174C4BA64C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_E509D8FA388FB103CD500B174C4BA64C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_F0617AAEE9BADC23D2D30B174C4B0B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B10ED37EC9C50BEE3CF50B174C4B11B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_B10ED37EC9C50BEE3CF50B174C4B11B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_F520D6861813167602910B174C4B4F0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_A117FEAC628228A0EDA30B174C4B99AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_4065A156405A1010337E0B174C4C914E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_044D86DEE1016FB33F790B174C4C6C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_AdjustmentForAmortization_9D49CF5A36BD1C21E8400B174C4CC25E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_EquityMethodInvestments_E9E3298E0D02A95BC27A0B174C4CF9B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_139E2A7E59F25965BE5D0B174C4C6764" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_96C194A9EB0CD6CAC5EC0B174C4D2DFD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_biib_Collaborationprofitlosssharing_96C194A9EB0CD6CAC5EC0B174C4D2DFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_AF87BA8C68BE59E7963A0B174C4D5BAD" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_178FEB514DF5105BD8ED0B174C4AD9D1" xlink:to="loc_us-gaap_Revenues_AF87BA8C68BE59E7963A0B174C4D5BAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67303B5B082BD9A772CB0B174C5EEBCA" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67303B5B082BD9A772CB0B174C5EEBCA" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_EDCBCC06FF09B0F00BE80B174C5F1D6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67303B5B082BD9A772CB0B174C5EEBCA" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4C430B9710F56EAD66430B174C5F3235" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D554C70653C84833D2EA1513BDB59B5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D554C70653C84833D2EA1513BDB59B5B" xlink:to="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E79B61A6D4F73FAE8D2E1513BDB53A7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E79B61A6D4F73FAE8D2E1513BDB53A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3CEBF459CFEF1C1AB5391513BDB53C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_DE24ED6DB88ACB98773C1513BDB57691" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_B2E936E35882D715627E1513BDB5106E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2E71B119F7688CC5E09C1513BDB567DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_us-gaap_InventoryNet_2E71B119F7688CC5E09C1513BDB567DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_BD1727E29E8946DE66B21513BDB5FB67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_us-gaap_OtherAssetsCurrent_DB8905BB1F195645EA111513BDB58EB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6A401ABC0612BDAAE6701513BDB5CD17" xlink:to="loc_us-gaap_AssetsCurrent_9530D69DFC8E796287BD1513BDB57FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_24ED002F5E94159B0E901513BDB5E003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_EE9CDFEA7056397C279A1513BDB574AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8DCF9331D62BE057D4E31513BDB5E36D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8DCF9331D62BE057D4E31513BDB5E36D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_AAF7D8F28A996E66A3E01513BDB9B05C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_Goodwill_41A6EC7FF0DFCD55DEDC1513BDB928DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E193C1F863530A028C0D1513BDB99D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_88D37744CA4402235DA11513BDB92D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4A6059B8FE65456739931513BDB5AD47" xlink:to="loc_us-gaap_Assets_66C5210EF3DF1BC4CAD41513BDB9D413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D554C70653C84833D2EA1513BDB59B5B" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:to="loc_us-gaap_TaxesPayableCurrent_3781B78B2F42E37B2B041513BDB95EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:to="loc_us-gaap_AccountsPayableCurrent_1E420DD84D17E459D8081513BDB97858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_94AA3D701C952F7EA2231513BDB98AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1A826AD085D64D51788D1513BDB93439" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1A826AD085D64D51788D1513BDB93439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7DFF5F9DCE10484B95BF1513BDB94C4A" xlink:to="loc_us-gaap_LiabilitiesCurrent_2B918480AF640A693DFA1513BDB955A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_LongTermDebt_99725B064547432FBBD51513BDB9936F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F097885405AA8484E1271513BDB94818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4FEB350E5A31942642C61513BDB9C460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_D250718CAD30EBB5C2F01513BDB92A23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_Liabilities_9D3DA530592199A452101513BDB93C47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1D7159DFA19051CDD9BC1513BDB9C48D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="loc_us-gaap_PreferredStockValue_719C01B200A1E6C6E5DB1513BDB9C9D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="loc_us-gaap_CommonStockValue_49C476A69AA0571AE3531513BDBD7C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="loc_us-gaap_AdditionalPaidInCapital_864BE4F047F8DA22C4E91513BDBDE765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D8304D4AF62410E4E1971513BDBD5518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EFABA105A25B2751DB971513BDBD927B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="loc_us-gaap_TreasuryStockValue_B78224B80F25AB79A1621513BDBDACEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_744D51C05F98F8B2DE861513BDBD8E7E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BC6BA0663FA8F461A0D71513BDB9FA2E" xlink:to="loc_us-gaap_StockholdersEquity_744D51C05F98F8B2DE861513BDBD8E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A7FA6B663DB7B6DA2BA71513BDBD0705" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:to="loc_us-gaap_MinorityInterest_A7FA6B663DB7B6DA2BA71513BDBD0705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3525A470FF07F26A409A1513BDBD8ABA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC976B7603839CB59C811513BDB92DF1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3525A470FF07F26A409A1513BDBD8ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C19D8F1CD9D32C6E156F1513BDB9F2C2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1D64B7DA1878658477401513BDBDE928" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BA3612186BD55573C8DF625F9E8F439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BE64E64FFB32509986D5F625F9E88370" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDDD92C3FEC106B745C9F625F9E8598C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_FD4BB25BCCF40A79232E170B39745336" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_FD4BB25BCCF40A79232E170B39745336" xlink:to="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_B6B21EC16D9B49486DC0170B39745BDD" xlink:to="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_6E45BB0808950182163D170B3974D210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_38A87275C3657A3D40CE170B3974E44D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_EA6E229CDA4923FFE2D3170B39743187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_40530431559DB0719CEB170B39748275" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_F9F7474402FC524075C4170B397454F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_A4C56F8558D365DF138D170B3974031D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4DEE506D4E20CC21F3DE170B3974455C" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_C2943E037033E85B087C170B3974652B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0CBAF9A906FEAAE5E2FF170B39749ABF" xlink:to="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_PreferredStockMember_004E75C50C28C0A32000170B3974AC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_CommonStockMember_C24DB2268697DF8515F9170B3974E87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1768726B424B72A936CA170B3974E4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32FE6D61EF901C541598170B397433E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_RetainedEarningsMember_55F4268F93AC9EC8A281170B39740859" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_TreasuryStockMember_904A8109732780D9FA2A170B3974353C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_F7168BC396E6F1A9D1FF170B39747474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_162F02E9099629E71234170B3974F4F5" xlink:to="loc_us-gaap_ParentMember_C342F475A786F13160C7170B39741A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57B36FCCE7FE7278C7D3170B3974921F" xlink:to="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05C3DB283D3044F8D0BD170B39740079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_SharesIssued_C8424FFC146CB897FB7B170B3974D00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquity_91F26F5638855E580DD6170B397ABB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_MinorityInterest_47297DA331DE1EB4E37D170B397A5FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DFAC17DE80F932B01313170B397A4931" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_NetIncomeLoss_DFAC17DE80F932B01313170B397A4931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1C188E44F108FFF61958170B397ABB68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_ProfitLoss_286D6668CE9CDBA5F3F9170B397A3E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90E1BAE0792EB2B640FF170B397BF898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0457F0650439F22956D7170B397B741C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_1E9348CC56261C75BEB1170B397B3C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_11127BC2A9963B08F658170B397B4C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_64F65A2AD06E5EF6D745170B397B5B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_AA7C1DD60895139DDE5E170B397B8236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_77E67F651F358736E34A170B397BE89C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7A8D4ACBDF10961EC08D170B397CAB3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_82396EFEB69719F6AF31170B397C6AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_E14333C1B07028F9DB94170B397C87FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E62230E44AA3B7F8421D170B397CCD10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3D8370DAF94DEF47D743170B397C6D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_FE933E2E4C4BDAAFBD77170B397CCBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquityOther_D71BA7AFFAD1A6AFC54C170B397C6282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_309A7FB6311FF124E85D170B397CD3DE" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_309A7FB6311FF124E85D170B397CD3DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0B356C1319863DF609FD170B397C4625" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_StockholdersEquity_0B356C1319863DF609FD170B397C4625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A820BEE320F848CFD6F4170B397C2B14" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_MinorityInterest_A820BEE320F848CFD6F4170B397C2B14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_23BE54B83A92FB935BF8170B397C884C" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AC7DBF1827510071808D170B39740798" xlink:to="loc_us-gaap_SharesIssued_23BE54B83A92FB935BF8170B397C884C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5150974D2899C8CF54181B1B9368E1F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:to="loc_us-gaap_ProfitLoss_5150974D2899C8CF54181B1B9368E1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_066FCD3096CC15D8915B1B1B9368A2D3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_C46F142B28EDDAD77D6F1B1B93682EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6BD888D2CD766984BBC31B1B9368DE8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6BD888D2CD766984BBC31B1B9368DE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_ShareBasedCompensation_80A59403D91866552AF81B1B936868A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8A3C917A0651D8ECF7171B1B936834DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8A3C917A0651D8ECF7171B1B936834DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_F6F5A976D8F03564C2131B1B9368916E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_DBD5FE7AAD1CAC8745001B1B9368954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E321320C899A6DA500F11B1B936831EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_73A9C74478232FFDF0661B1B9368E6E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_F70FD2DD2114D4BAAD481B1B93688B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0D9AD3BF90EEE53DEB611B1B9368B870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDC9C28B5ED7A7DB7A8D1B1B9368BA12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A8DA2C8174E51D47531B1B93689D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_D1388A673F061A91BBB71B1B93681D78" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9ADBBF83CE191BED64F71B1B936871E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5A530B5B156A8CF2FFA81B1B9368D4E5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5180A506A14E94FC68311B1B9368825B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4D0123DF714F4FF94EAA1B1B9368A498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13899931877026F70D811B1B93682F91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4CB913959B51F9D685E21B1B936823AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4CCC1B3653F49F4F3A721B1B93684FAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7C692908C3EC53EB66A61B1B9368C0B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_C7B3E54393C1F9BDFC621B1B936844A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2807A4803BACE49F52ED1B1B9368609F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_11238FD1ED75B97DB3B21B1B93680EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_209762F7001AF893B0A61B1B936877A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7F0ABEB7EF284CB164491B1B937876CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_610C089A0A6CA16C33371B1B9368084A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_E015C260D53179CC4CC41B1B9378745F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B1753892E241B5E58A6C1B1B93781971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_B94C212F9D5CFC9962601B1B93788395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_D845BC54A7BDAC12C0491B1B93782F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E19AB8DA992088942AA71B1B93784F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EEAD3B5A0D87D81D47B61B1B93783713" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B748DB08863E96768DE31B1B9378FA2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_D10EB942B09340DCD4E61B1B9378002E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_FC64358EDDADC9CA86821B1B9378D52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE85A51241FC99C760281B1B9378C1EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2A04D11F2CC4DB197CE1B1B9378C9AE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_71AB24E5796B0B3769121B1B936891A4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F2A04D11F2CC4DB197CE1B1B9378C9AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_883389E396899439FE161512B9407F66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B" xlink:to="loc_us-gaap_NetIncomeLoss_883389E396899439FE161512B9407F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A444A0F5BDD2F76931141512B93F064B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58E0501297A6AE0DD0B81512B94047A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_85488C040319A6665F121512B940ECD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_DF8D91465E05BF03A0E61512B9400BA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_DF8D91465E05BF03A0E61512B9400BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_054E4D4E4BEFCA89063A1512B9405B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_A79C265460DE0BA7E03D1512B940EEB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_68689E8C3E6816A84A021512B940C0CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_531EDD490A23C25F863A1512B940120B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_32E0E09AA0029DD0C3151512B940B9C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0A9124EFD31ADF9AB7911512B940EF79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4418B6A42D594CEE416B1512B940BA96" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8AA2CE196565791F3240F6291A44A46A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_StatementTable_8AA2CE196565791F3240F6291A44A46A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8AA2CE196565791F3240F6291A44A46A" xlink:to="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0CE428A1D235A3961384F6291A444CC5" xlink:to="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:to="loc_us-gaap_ProductMember_8E46477483521818B16AF6291A449EB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_D84103F04D2727F9F245F6291A44E8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A424927E93C409172AE1F6291A448C05" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9C16FF2A69E9C9FD1686F6291A449929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_96AF9A36D34673A6A951F6291A44368A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8AA2CE196565791F3240F6291A44A46A" xlink:to="loc_us-gaap_StatementLineItems_96AF9A36D34673A6A951F6291A44368A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_Revenues_CDA009AD3E8113780AF2F6291A44002B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_A591A3974D35C0ED7A04F6291A44C36A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_54E9336F79A3015C7F05F6291A44E43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6A1304C341DB95AAC3BBF6291A44FBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4AD8DBE64CB9BE590184F6291A446E91" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_biib_Collaborationprofitlosssharing_F429F893E62D65F5D2FCF6291A44687D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_F69714FDE4CF27460D0BF6291A4402F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_797C0D04F459EBBF3CA9F6291A44187D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_RestructuringCharges_57FF58EE9C8290CE3940F6291A443AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_4CEDAD7C4804BBBCC35EF6291A446BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2D445F9AA34DB3D7A95DF6291A44707F" xlink:to="loc_us-gaap_CostsAndExpenses_4255D9CFE3EC118E0527F6291A44F3CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_OperatingIncomeLoss_9321A823A0B4B74550DFF6291A44D764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8E52A97F6122D02D2CBAF6291A4472AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_EA33794D9A3268BD99C4F6291A44DD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_400C1103FC9C0BA03719F6291A44A84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A5401F192B48033809B8F6291A44C080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_BDA1C5682F8AA0E582E2F6291A4488CE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_ProfitLoss_BDA1C5682F8AA0E582E2F6291A4488CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_F75ACB32F526BBA66055F6291A44AC9C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_F75ACB32F526BBA66055F6291A44AC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0B25A106C2A8DAA1E131F6291A44C7FD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_NetIncomeLoss_0B25A106C2A8DAA1E131F6291A44C7FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:to="loc_us-gaap_EarningsPerShareBasic_F47748713F03B70B0210F6291A44F70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_569D721AE299DF5AB6F9F6291A448F26" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C505EFF296001945C5E5F6291A448BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9E5F1B5E45B6E8F3399BF6291A441321" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4AB2F330F32349B99E79F6291A44B9D3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9E5F1B5E45B6E8F3399BF6291A441321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4F7D90CC48F01770F0C1F6291A44CD3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9E5F1B5E45B6E8F3399BF6291A441321" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4F7D90CC48F01770F0C1F6291A44CD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61489023C2CAFB6916C6F6291A44A43D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9E5F1B5E45B6E8F3399BF6291A441321" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61489023C2CAFB6916C6F6291A44A43D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3016769EC1ED701D78671A889736B260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_DocumentType_3016769EC1ED701D78671A889736B260" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_B0A822A0E9F6E27CE2E81A889736C078" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_DocumentQuarterlyReport_B0A822A0E9F6E27CE2E81A889736C078" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_87E515773784FF9A915A1A8897456432" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_DocumentPeriodEndDate_87E515773784FF9A915A1A8897456432" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_39210DF80D05D275E78F1A889745D716" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_DocumentTransitionReport_39210DF80D05D275E78F1A889745D716" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_7C4ED35281A6F5C3454E1A889745E458" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityFileNumber_7C4ED35281A6F5C3454E1A889745E458" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B1B05C290C8FF8E15E2A1A8897451E25" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityRegistrantName_B1B05C290C8FF8E15E2A1A8897451E25" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_535D62ADB5590C696D1D1A8897452755" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityCentralIndexKey_535D62ADB5590C696D1D1A8897452755" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7A537F6A53591AE4493A1A889745913B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_CurrentFiscalYearEndDate_7A537F6A53591AE4493A1A889745913B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_BA98F1959B7D24C2154A1A889745EE0E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_DocumentFiscalYearFocus_BA98F1959B7D24C2154A1A889745EE0E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_46D275E9CDC7920444711A8897452068" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_46D275E9CDC7920444711A8897452068" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_009F89E5317C4B53B2A91A889745E724" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_AmendmentFlag_009F89E5317C4B53B2A91A889745E724" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1C7690B5F1066564402D1A88974552C9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1C7690B5F1066564402D1A88974552C9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_34605C6B0C335328C9BF1A889745BEB4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityTaxIdentificationNumber_34605C6B0C335328C9BF1A889745BEB4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_876324D94BE0DEBA8DCA1A889745D8CC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityAddressAddressLine1_876324D94BE0DEBA8DCA1A889745D8CC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_A662779C9A6DA88C75471A88974535FB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityAddressCityOrTown_A662779C9A6DA88C75471A88974535FB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_150DA706F1F511667DDF1A88974562C7" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityAddressStateOrProvince_150DA706F1F511667DDF1A88974562C7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_62A354EF42898113EC0B1A889745D708" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityAddressPostalZipCode_62A354EF42898113EC0B1A889745D708" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_7F93D7FF67A1E57ED3F51A889745989C" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_CityAreaCode_7F93D7FF67A1E57ED3F51A889745989C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_5706F511BA4832A577F51A8897453B2A" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_LocalPhoneNumber_5706F511BA4832A577F51A8897453B2A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_DEBFE82B58682936A0381A8897452BFD" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_Security12bTitle_DEBFE82B58682936A0381A8897452BFD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_75CB6CDFC2E8A9B461C71A889745FDDB" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_TradingSymbol_75CB6CDFC2E8A9B461C71A889745FDDB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_4BADACC5F1B62168C84C1A8897450096" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_SecurityExchangeName_4BADACC5F1B62168C84C1A8897450096" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1C967EF020DCDD8B57B81A889745EF27" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityCurrentReportingStatus_1C967EF020DCDD8B57B81A889745EF27" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_CC5073F4E5361DA6F7211A889745AD7B" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityInteractiveDataCurrent_CC5073F4E5361DA6F7211A889745AD7B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_41CA45F48167EB41C5701A88974565D7" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityFilerCategory_41CA45F48167EB41C5701A88974565D7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_7B3A6AACDD33E6DB75801A88974507CF" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntitySmallBusiness_7B3A6AACDD33E6DB75801A88974507CF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9459F83D5A62E96C84F51A8897453719" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityEmergingGrowthCompany_9459F83D5A62E96C84F51A8897453719" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_8D8809B3C4DDEEB8154A1A889745DF10" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityShellCompany_8D8809B3C4DDEEB8154A1A889745DF10" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4C88D93B57C11F0E95D61A88974540BD" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_DCD50E13755C8EB0491E1A8B319751C5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4C88D93B57C11F0E95D61A88974540BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_F6482257EA7D96BF3566F625F91D0EB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_F6482257EA7D96BF3566F625F91D0EB3" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_FED1430924421951C455F625F91DD32A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7BCF1B1A15703CC423B81756F226E44B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7BCF1B1A15703CC423B81756F226E44B" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_C548FEE726DF758C3ED31756F22630D1" xlink:to="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_A7572E2E2A4299E8D7721756F226DE1A" xlink:to="loc_biib_ShorttermderivativeMember_07E8728709D2942C4C061756F2262AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D3FAD8E44518AB94CCDA1756F2267E22" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5E6FC8409DB172B9C7FE1756F226D3DC" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_CA9945CC06C8D039A7261756F226329B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_BE2D8B0D4FE21DF9DCDC1756F2266647" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0B3688C320D211BB71AE1756F2268D0C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9E40386F34DFEDA09F451756F2264B15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_3BF7E7466ED6AFC7A05E1756F2264A3C" xlink:to="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_EUR_51C51AEE7313C1CB56251756F22662D2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_GBP_5735681D34BDB36D55491756F22660D7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_CHF_A149D5B670CC9AAC53D51756F2265EE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_JPY_05D7EB0DA70C7C74B2D41756F226F9CB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_128CE6CDB9F579DD35781756F2265F0F" xlink:to="loc_currency_CAD_7A58B3B2F2B5F7A300181756F2264F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A32350E1F2F6726E70ED1756F226BF5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A32350E1F2F6726E70ED1756F226BF5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A32350E1F2F6726E70ED1756F226BF5F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:to="loc_us-gaap_SalesMember_423557A44366CA778D121756F2264922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:to="loc_us-gaap_OperatingExpenseMember_DA679BCFCDC21ED0C99E1756F22634DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5B2380453D94587B4181756F226ADC5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_D253E897EB5FFE1AE0B01756F226272C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43747193A2500E8ED1F01756F226DB87" xlink:to="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:to="loc_biib_CashflowsrevenueMember_EC047D6EE13A0C4DD7341756F226FED0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:to="loc_biib_CashflowsoperatingexpensesMember_D2D2648B7722C2B7AFE71756F226740C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92B41CFF929C617959551756F22651D5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1F5F41F19A949A6193721756F2260E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E5DCFA51C979ECDA25FF1756F226ECDB" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7E64FFC6D6D1F3FCCFDD1756F2262117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_96A626C8EE78353D58351756F22613BD" xlink:to="loc_us-gaap_InterestRateSwapMember_E33BBB75003138D260121756F226EC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8F38C08D95F56DC815671756F226C052" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_0AB4C9A3D228C961F09F1756F22617E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_D97D975F9023C984F6551756F2260235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7286EDFF29403E24D7841756F2267619" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_C8DEE15F7DF353FE854A1756F226F5FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_359B3134B1BA0DAFD29A1756F2263F9A" xlink:to="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_348F8E1706FCC65067B11756F226C9F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_A38874180FA790EDB2E81756F226C24D" xlink:to="loc_us-gaap_NondesignatedMember_E0B99F78968CADB85E411756F236913B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9640F5BD469BE4FFFBFB1756F236FCF8" xlink:to="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:to="loc_srt_MinimumMember_D9247451BF694C9686F41756F236B2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B6007A0DAC3AA7B4C26E1756F236F0FD" xlink:to="loc_srt_MaximumMember_A24F889EB155A122B9931756F236C348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_6605709DC602AEA4AA041756F2265A45" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_EA10F2D554183A6D3EF71756F2364F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_invest_DerivativeNotionalAmount_BD94C740A67E4F4C339C1756F2367C1D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9A2D0B07F839A70A3C301756F2367246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_C81504234BE7F93E51741756F2366110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_587A9D7638BBF90811471756F236A79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1F55915BB5D610264CB41756F2368750" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_702C5517C90FE80B6CEB1756F236EC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5F0B1624B4B25C9A2BB61756F236A10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_95E7D72D0B28E26C062C1756F23675D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeTermOfContract_B4F46A96EFB65FE4F8811756F2369361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_64A922E6DDA7A3213A2F1756F2364D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_B5A64E98F80E05E667301756F236D576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_531D83517CA3E013D2FD1756F23652C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_4034D27844E8CCF64D151756F2361710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_B27930E67072FB3BE3371756F2367058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B2BDEB05E02934B1E3AC1756F236265E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A6DD92D8B6A354A0CCA31756F2363971" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3E81178836591A1F05FA1756F2361916" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECC7FE7648594FA0B2F2F625F9AA0CCE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECC7FE7648594FA0B2F2F625F9AA0CCE" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_592BACB0DCB822DAD398F625F9AA87E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECC7FE7648594FA0B2F2F625F9AA0CCE" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_08CFCD615BB81FB9F862F625F9AACC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECC7FE7648594FA0B2F2F625F9AA0CCE" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F7A9166E380FA9436395F625F9AA9BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECC7FE7648594FA0B2F2F625F9AA0CCE" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1486227BF72D48D1026FF625F9AA792F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_4E3E2127F6438E275DA20B174E4C5EAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_4E3E2127F6438E275DA20B174E4C5EAD" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_EE74FC8929009276770D0B174E4D5583" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_EE74FC8929009276770D0B174E4D5583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EE74FC8929009276770D0B174E4D5583" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F33203A710F9388ED42E0B174E4D185C" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_455FF0E63AE60C732C7B0B174E4D1EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9BFAD5A7381F40E332BA0B174E4E7FF3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4E2D09A9383D1BE223E80B174E4EB26A" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_F0E9DEC7CC5EE9F277A30B174E4E0480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_8DA0D66650C35FD637800B174E4D928E" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_AB418E42557EEAFAD83C0B174E4F3EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_E29FC4EF8F6EED780E4D0B174E4FBCE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_9B13D48C5D1E6CEA30F60B174E4F405E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BD4F7C65CB20FAB240740B174E4FE1D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_38CC6669E9223379DE720B174E4F937F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_CBBC6BA2AEFC124598890B174E50EACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_534E321CDE78A4F41CA30B174E507725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_1B4DEE1748B4310E4B100B174E50919F" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_B69046F1B90B8E2C4CE00B174E5062CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_195916D88505A10580570B174E507477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_1C8B88CBD48590F700960B174E4E49E4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_02E4E296B726A8D989D80B174E50DCF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_7EB6FE30486AA58C3A2B0B174E440234" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_7EB6FE30486AA58C3A2B0B174E440234" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9D4003F2EFB83432C65E0B174E448827" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9D4003F2EFB83432C65E0B174E448827" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9D4003F2EFB83432C65E0B174E448827" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_D10943AD7B6503C817350B174E458CE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27DE44DB08468C286E0A0B174E459DDD" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_D10943AD7B6503C817350B174E458CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_36CE0FE85A777AC80A930B174E4488B1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_EF8C322EAA8563C4D2B30B174E45CFAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_E88120394C30967A1FCB0B174E46AF80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_FD6A3D83A4461909A6010B174E46440D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_FD6A3D83A4461909A6010B174E46440D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_AABD3BA1F09B88DA7A270B174E46F928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_991C7F1205A28966B59D0B174E468CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3477D10C631C5823DA0D0B174E45B2FD" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_00B2D8002A2A89BE38440B174E46115A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_144B591102B1A637D13EF625F9BAB668" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_93C15B8B1BF553CF96E1F625F9BA755C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresTables" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_DAF93F3F8621E4C6FB6D0B174E543BCF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_DAF93F3F8621E4C6FB6D0B174E543BCF" xlink:to="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_92E2CB999CB66C125CBC0B174E54F9EA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_D932FEA8B5B4E9CAC1D3F625F9D9A14E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_D932FEA8B5B4E9CAC1D3F625F9D9A14E" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_CEB5809B5F8764DA1DF9F625F9D9CF1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_D454E988010A628BB768F625FA37D711" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_D454E988010A628BB768F625FA37D711" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6878ED6F57BF8B7AAF3EF625FA370C35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_A7A1CE76904E69BBA99AF625FA374FDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_B56CB1D30D38B685B847F625FA370B75" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_MarketStockUnitsMember_48C233A35E71027B4855F625FA377E0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_EB5BCCAC462B9FAB8036F625FA372AE4" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_4DCDDB3DDA74CD98E703F625FA37BFB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_999A8683968BE1ADF63AF625FA378D1B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0F7E9633D49233EC8D6EF625FA37A81E" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:to="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_AEF1FB5DAEA6B8F8669AF625FA37B0C1" xlink:to="loc_us-gaap_NetIncomeLoss_F328724F45B49DCAC0FEF625FA37FDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_A7BB8444B1FBB12BCB54F625FA37C99B" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52C93A576A742E1CDF4EF625FA37E050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_BED8089C95349B5BE5D0F625FA375480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_33B4175C33CC34C8DD5BF625FA376DDC" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_E814DE393CE7EC4D9FEFF625FA37FF46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5E87F4700811548B278CF625FA37BEB3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E4549A30D3EE64C3C1CBF625FA37A775" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DF8D27870D6F0338575FF625F8C0C7D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DF8D27870D6F0338575FF625F8C0C7D7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8EF3C37A8BAC762CD266F625F8C07137" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9C20D5FE8071D1D67BC50B174D20853B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9C20D5FE8071D1D67BC50B174D20853B" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_82DDE41EF0CA30DDB8CF0B174D20E86A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1AC8CA1F24C388C7A431F625F8403078" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1AC8CA1F24C388C7A431F625F8403078" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8006544E473A464B801CF625F8400FFA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_73548E245ED85E173C31F625F92D85AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_73548E245ED85E173C31F625F92D85AD" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09C2D2D447363AED232DF625F92DBFB9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_BC268A55384A32D8F4CBF625F92D401A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_A7F21CF32C3EC1B6896FF625F92DBB90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2BD861DC9A6AB75CCD70F625F92D2808" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7E788BF32DA5656B26D7F625F92DA7D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08BA65079D09C1A3F90AF625F92D40A2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DDB5DA2779F4C7C99BA5F625F92DA59B" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_D4183FB5D2284E825CFBF625F92D1A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_94898891E62DB9BDA835F625F92D7F46" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3ACF61C2823FBBCA436EF625F92D83F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F3801991FFA54A835B2DF625F92D34EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_804727CC1D10A318EE50F625F92DEA54" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3A972D63B17E77244EB9F625F92D6064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CDA71AD8AF1C1220C457F625F92DBC3F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2031BEF65CA5FC99F03EF625F92DFDBA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_127BA897BF0212870696F625F93D5B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48D8511A98EFAFDE632CF625F93DD37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_CD11161F5B5687412DF9F625F93D1009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_581C17B622D7C371577CF625F93D4132" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_85F9B9C4172A872D61A7F625F93DC825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_E057E0C747FCAA872537F625F92D792B" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6F72685AEB2259E7521AF625F93D7259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_9DB8EA0D869EED7CB4F1F625F92D4F80" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_E26A279B47ADF569F0C0F625F93DA61A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_61FC5ABDC027283AE7C1F625F93D8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_958B8A432A23B009D81CF625F93D68F5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4F585F9DB3E0B250070EF625F93D7A62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_85C6221FF06B764A6C14F625F8EE0BCA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85C6221FF06B764A6C14F625F8EE0BCA" xlink:to="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D6A24931624C85803D9FF625F8EEA30A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:to="loc_us-gaap_DebtInstrumentAxis_D6A24931624C85803D9FF625F8EEA30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_D6A24931624C85803D9FF625F8EEA30A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB7CDC30928910C15E88F625F8EE59FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_BB7CDC30928910C15E88F625F8EE59FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6556D19F630D04DEA74CF625F8EE5015" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6556D19F630D04DEA74CF625F8EE5015" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A58BB25EC7E3A9C64F9DF625F8EE2F0B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A58BB25EC7E3A9C64F9DF625F8EE2F0B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_66023A34561B18E5FC21F625F8EE45E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2BB76BC7AB9104D8D626F625F8EEDB48" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_66023A34561B18E5FC21F625F8EE45E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_E017CCAF8206FA9DB988F625F8EEAF41" xlink:to="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_B1E636DE6A957A765E81F625F8FED3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="loc_us-gaap_NotesPayable_EDDE2C045AFF03F85050F625F8FE4B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FA53C29AEF63FD034098F625F8EECE36" xlink:to="loc_us-gaap_DebtInstrumentFairValue_B5939FED14D09C5E78C0F625F8FE4687" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9A829699B083A694A08CF625F8DF6F6B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_448E882A7125E215FDC0F625F8DF3AEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9A829699B083A694A08CF625F8DF6F6B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_448E882A7125E215FDC0F625F8DF3AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3F0304E371930F620F2BF625F8DF2CF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_448E882A7125E215FDC0F625F8DF3AEF" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3F0304E371930F620F2BF625F8DF2CF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3F0304E371930F620F2BF625F8DF2CF5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_84BAD964745FE7E8BCEEF625F8DFFA79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_C5701AD4BA082B5CF0ABF625F8DFE9B7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_84BAD964745FE7E8BCEEF625F8DFFA79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_448E882A7125E215FDC0F625F8DF3AEF" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4B2579896DC1BF98F64FF625F8DF25A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD074A2F395357569626F625F8DF2B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_93040BA85EF2D4C62F17F625F8DFB984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_64C79288857FC6CB238FF625F8DF35A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_DA797FF1C498FEBCC48EF625F8DF1E92" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_64C79288857FC6CB238FF625F8DF35A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E0CDD8BAF9D5C59A247AF625F93D0987" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E0CDD8BAF9D5C59A247AF625F93D0987" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1101D9F0467AC18E17ECF625F94C3598" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:to="loc_us-gaap_DebtInstrumentAxis_1101D9F0467AC18E17ECF625F94C3598" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1101D9F0467AC18E17ECF625F94C3598" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4543F640FEADE8B8EB49F625F94CCBF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4543F640FEADE8B8EB49F625F94CCBF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D2D566FCB5C54F879AC9F625F94C8037" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_C8F538B899F8FB2C6764F625F94C000B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8348CA2D292F7AF88EF3F625F94C7D6A" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_4FD02D85BA552938B3BFF625F94C79B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_41A8C4196760157EDDB5F625F93DE313" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_AssetImpairmentCharges_8535A800DF8AAA66CCFDF625F94C249D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions" xlink:label="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions_99BCDF40B10F82148EADF625F94C45D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DF44E5F2A74564BB903FF625F94C6030" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DF44E5F2A74564BB903FF625F94C6030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_BAD01B3BEBEF1BD472ECF625F94CC7C3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DF93DB9631D5EAF80032F625F94CA50B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D4F506A13A4B17608ACBF625FA46FAD8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D4F506A13A4B17608ACBF625FA46FAD8" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7A75EDE4636416CC2063F625FA467E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D4F506A13A4B17608ACBF625FA46FAD8" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_584C78C5F477F6436422F625FA46A19F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D4F506A13A4B17608ACBF625FA46FAD8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_505899C83948B9C8A9D3F625FA467563" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7E5DBBE10515B50ADFF8F625FA08A1F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7E5DBBE10515B50ADFF8F625FA08A1F7" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_4A4963A4EA3CCDB9AB41F625FA08A2EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_13CDF338E0F53300CBF2F625F96B79F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_13CDF338E0F53300CBF2F625F96B79F5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:to="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_6CB0E893B09D4F21DFE9F625F96B1684" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_CommercialPaperMember_610F993A79C04B94C6ACF625F96B7EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_A2AEE48AB60BB469C87EF625F96BD525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4E5F998E6294093612B6F625F96B7E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06B7D384EA87815C957CF625F96B6A6D" xlink:to="loc_us-gaap_DebtSecuritiesMember_E456C486F820FE9E25B9F625F96BD623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_C5990B67F68FA391334AF625F96B0EEB" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_794FB088EFB1E454298BF625F96BFD26" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_83F62890AB6E25EDBB29F625F96B79BA" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_410463003007228CEA20F625F96B74C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2FE5FAFDC2A0672995111ACA0D41733A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2FE5FAFDC2A0672995111ACA0D41733A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_EDB87F2AB2734E0054441ACA4BF8CD3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_EDB87F2AB2734E0054441ACA4BF8CD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EDB87F2AB2734E0054441ACA4BF8CD3F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E26F596AD2AAE8DEA05E1ACA85AA2BEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_E26F596AD2AAE8DEA05E1ACA85AA2BEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0F025EAADA4DDB5601061ACACCD15132" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CCF9B9220F631EE2C1931ACA4DEB2D0E" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0F025EAADA4DDB5601061ACACCD15132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C2D005B539440C6F128C1ACA0D612F1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C2D005B539440C6F128C1ACA0D612F1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C2D005B539440C6F128C1ACA0D612F1B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_EC1864ABE19DD23652DD1ACA0D61B945" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_A19DC90BE7EB805567391ACA0D616D6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_D4D8AD2DB6010316B1161ACA0D6132EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_BD1E88E54EF14F63BFC91ACA0D616F60" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6A4B678A85656B271EEB1ACA0D61A82A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_6C1402DD68DA6A8DE85B1ACA0D61C23B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B5FB8894A4E0C4BA9ECB1ACA0D61248D" xlink:to="loc_us-gaap_EquitySecuritiesMember_EF8570A5195EB98F32771ACA0D61CF26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_79D65CC1237F8A678AC91ACA0D52FDA8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2D630AF18C05275B77FC1ACA0D61B7AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2D630AF18C05275B77FC1ACA0D61B7AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D1A256EBCF266EF2A34F1ACA0D615A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C763DD48A10D7FDCAC71ACA0D61BEE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F99113DDB3769289F831ACA0D61ADBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_256DC2D983E4571E5D851ACA0D617989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FAC69F453767D5B38B421ACA0D613DAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_DE0A7FA67FB6177071A01ACA0D615206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_AC05F8C507B1D784E82C1ACA0D61D8B4" xlink:to="loc_us-gaap_AvailableForSaleSecurities_6AC24401085E257F79AE1ACA0D61A7C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_F5FBC1AECC50572CE03BF625F86B85AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_F5FBC1AECC50572CE03BF625F86B85AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_D803D15F97B67006A1C8F625F86B5970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1EE278C2F45314BFB4EFF625F86BC9BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_B55EAB78832069DB68D2F625F86BE123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E15B3D8B2DF3CF6936B2F625F86C98C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_CEFBF01D0CB68C27432FF625F86C2BD9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3B1153BF26EF904FE2BEF625F86C5508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7B6C0E633A8D701A9E34F625F86C8C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_D53FBF0CF20F12FF04F6F625F86B9B39" xlink:to="loc_us-gaap_AvailableForSaleSecurities_5A7400E8A7BA82CEFEECF625F86CEA80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C32003BC02EF31799E95F625F89130B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C32003BC02EF31799E95F625F89130B5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A7636F768C00F90384EAF625F8917D1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C32003BC02EF31799E95F625F89130B5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8CA529BDF9E3487D3E3BF625F8911360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C32003BC02EF31799E95F625F89130B5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_B217D8EE9103EC9D8C9AF625F8916290" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8BB6F0FDBA56BB9C1FBBF625F90E828E" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_0D6EF4F9F78EA4F72E93F625F90EF386" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_6E8FA2DBE01853224EC71B1B924FF019" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2EC015530BACC93486E51B1B924F7A29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2EC015530BACC93486E51B1B924F7A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2EC015530BACC93486E51B1B924F7A29" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_B7FB8CD6EDF95DB161B51B1B924F4F93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_B7FB8CD6EDF95DB161B51B1B924F4F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E640B795EBDE184F5E511B1B924F597C" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_128C5676BA9FA330921F1B1B924F7D6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1D5AE64D266D5BE73C6E1B1B924F8799" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E3747736DF22CC82E411B1B924FC0A9" xlink:to="loc_biib_IonisPharmaceuticalsMember_62FE365D154B4059010A1B1B924F7672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4997A06B800EF6BD47A21B1B924FE1F6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_C0F513C62DE645BA5DF71B1B924F7A23" xlink:to="loc_biib_StrategicInvestmentsMember_6F13B21FC1B0F62793741B1B924FFD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DFA86CCEC79CF1179A151B1B924F6D8E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:to="loc_biib_StrategicInvestmentPortfolio_00470BF55C388AD909991B1B924FD06F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_A1969B6EA547B73E48E11B1B924FFA86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A78E3B7A156B2E350C1C1B1B924FE230" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_A1969B6EA547B73E48E11B1B924FFA86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_653A1D2CA51F32582F89F625F861106C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_653A1D2CA51F32582F89F625F861106C" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5513F063E5D304678664F625F86194B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_653A1D2CA51F32582F89F625F861106C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_B430C6BD853D18E7C1C6F625F8627072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_653A1D2CA51F32582F89F625F861106C" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1249308F9E49BD12ECFCF625F862D0DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_653A1D2CA51F32582F89F625F861106C" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_C3A8ECDE0B5EE92DB772F625F862BC5D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_82D7F0C9614F953C192DF625F94C31F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_82D7F0C9614F953C192DF625F94C31F5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_046E6F20D0C5ADAA85ADF625F94CD51E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CE0D156DB9E0E38F1E7F0AFCE3C84C80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE0D156DB9E0E38F1E7F0AFCE3C84C80" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1C26E07C38C2780F07710AFCE3CB381F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F5F117F9629FFC06DD40AFCE3CC9DCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_91EB8DBFD4FF0142C8FD0AFCE3CC5C0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_F900E337922F9E7BC88B0AFCE3CCD994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_243F73DAE7F5375F23090AFCE3CDEB88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_CD16767EF2BE4A57D59C0AFCE3CD92E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_8D4EBE911B994514A6B30AFCE3EF4025" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_82B87CA456E844A4D8230AFCE3CD51C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5D476E92F2320A0416320AFCE3CD96D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9CF6DE7D3C4878C398B80AFCE3CD69EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_485AA5912BC577EA71210AFCE3CA7AF9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DCF1DF4E98D858B94F2A0AFCE3CEAF34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0E199F38C634740C16D70B01B6C611FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0E199F38C634740C16D70B01B6C611FE" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredTaxAssetLiabilityTypeAxis" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DeferredTaxAssetLiabilityTypeDomain" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_C1A9D9B072BBF168A5480B084992742A" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_A87202AFE712E66DD02A0B084992F758" xlink:to="loc_us-gaap_IntellectualPropertyMember_BAB2BB9BD369BA259E3A0B0889C8E52C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D62BE674077C0FF47BEF0B01B6C61B70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D62BE674077C0FF47BEF0B01B6C61B70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D62BE674077C0FF47BEF0B01B6C61B70" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_5F3B5961B043720FD9370B01B6C61BD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_32DC5FECC578F7ADF33B0B01B6C634F3" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_5F3B5961B043720FD9370B01B6C61BD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_13DDF1008CA068D7757E0B01B6C63049" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_13DDF1008CA068D7757E0B01B6C63049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_13DDF1008CA068D7757E0B01B6C63049" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7699C0694355CB48E7DA0B01B6C677E8" xlink:to="loc_us-gaap_ForeignCountryMember_50BDE2D3B282E11DFCA00B01B6C6222B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_329BE0828C52F1AB84480B01B6C67574" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D4B34543F3A31B29642E0B01B6C67B27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_D4B34543F3A31B29642E0B01B6C67B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_454FB33A84500E504D4D0B05048D0C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3F11E39F790682177A8E0B09EDCF0935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_D0499608DA9A0E19F8B90B01B6C6CAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DCA1C5F97B5464CF53510B01B6C6AEA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1BAED1DC7F9B4E363F420B01B6C6E57B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_845C704675E5463829D4F625FA274E87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845C704675E5463829D4F625FA274E87" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_032F1AA23E68F82AFB71F625FA27C2F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2A3B85B985F781D1FD7AF625FA27B272" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4E0FA8FA893FC1204A27F625FA27D6ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F3F6401FACE1D2F8F410067AD570CDD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F3F6401FACE1D2F8F410067AD570CDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F3F6401FACE1D2F8F410067AD570CDD6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_44AFCB5405DAF1A78CBC067AD59CC8D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4CE09043E87899E731C3067AD575836D" xlink:to="loc_biib_NightstarMember_44AFCB5405DAF1A78CBC067AD59CC8D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7314FDC0523C93EEB09E0672E6B1638D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_72C9F550CEC875B147860672E6B2A281" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_72C9F550CEC875B147860672E6B2A281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6900242E5AE9930CC1750672E6B21739" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_578CD500488A894297290672E6B25657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EAA69729CBBF9DA572450672E6B2DEED" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:to="loc_biib_OutLicensedPatentsMember_2EDE62B2D696D1CD8BC00672E6B376BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_99CCE21AAE95D55120320672E6B34626" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_99CCE21AAE95D55120320672E6B34626" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_819E4FF29698D699433E0672E6B39EA4" xlink:to="loc_biib_InLicensedPatentsMember_E002D78A1BC65C27A6780672E6B3F1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_12058DA79C9CF78A5FC40672E6B35C5D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_srt_ProductOrServiceAxis_12058DA79C9CF78A5FC40672E6B35C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_12058DA79C9CF78A5FC40672E6B35C5D" xlink:to="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:to="loc_biib_AVONEXMember_329580AAA2D5AE85D7530672E6B4BEA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:to="loc_biib_TysabriProductMember_158CC421E37FC69C96D30672E6B49BFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2E4A5BF112D767D867F70672E6B4C395" xlink:to="loc_biib_TecfideraMember_28936C6AE277363372C70672E6B41D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1CE5FB255F00CBAFCFF30672E6B46C75" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_srt_RangeAxis_1CE5FB255F00CBAFCFF30672E6B46C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1CE5FB255F00CBAFCFF30672E6B46C75" xlink:to="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:to="loc_srt_MinimumMember_AC49B730AAC9044341ED0672E6B5634D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CB0009B01C36CE09F2150672E6B5D029" xlink:to="loc_srt_MaximumMember_7DA46688801CDE4F1E060672E6B551F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A649F625675D1CD72BA50672E6B19A36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D9E5B129DC079D0524D60672E6B67CAA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_008BE92DDAB5692420C40672E6B68097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_548F47735C53EF423C850672E6B65041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9959E51871B61D9AFF150672E6B65F14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_589B7FA1198F5CBB020E0672E6B7C2A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7B4D369EC66B23C6986A0672E6B778FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_B18E48BCDCDB459FA5C80672E6B74B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_DA1633C2BAA8D44F0E020672E6B6235C" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A3732524D1E445B6D0800672E6B77403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_E85764B6992734CA886A0672E6B7A934" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_E85764B6992734CA886A0672E6B7A934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_39D2D96F52F4BF4EAB44067AD50AB1DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE3818338C78E0F44BB90672E6B611D8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_39D2D96F52F4BF4EAB44067AD50AB1DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_6E90843F5A69B06A78C30672E6B76DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_11BE70DDA6713EAEC7840672E6B8E89B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7FA01185B4F9422AB36A0672E6B8ADEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_63F6CB60031F6E55C6950672E6B88D33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B5E5448C0CCD49B5BE090672E6B91B70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_152F877BF9DE8F37A82D0672E6B93603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_420E10375AC0D414E9170672E6B125A8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_A2E19ED276E517F682BD0672E6B95828" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3D4C2E273326555C447C0672E669913A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3D4C2E273326555C447C0672E669913A" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71805DC94F7E99A2B4480672E66A69E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71805DC94F7E99A2B4480672E66A69E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71805DC94F7E99A2B4480672E66A69E5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_B054B84DF192CFA591BB0672E66A5D4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC2F082B88DAF2B425360672E66A823B" xlink:to="loc_biib_NightstarMember_B054B84DF192CFA591BB0672E66A5D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7E4A7F0DC63919EBA50B0672E66BF919" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7E4A7F0DC63919EBA50B0672E66BF919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7E4A7F0DC63919EBA50B0672E66BF919" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_090BB12F24884C9EF7ED0672E66B173C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2B6C7E2D64DBEBC545A00672E66BFB88" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_090BB12F24884C9EF7ED0672E66B173C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_CF0102465B28C6C2ADC00672E66A0921" xlink:to="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_E58352348461528784260672E66B5927" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0EBFFAEB11B44BAB4146067C9812E30C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3D4C2E273326555C447C0672E669913A" xlink:to="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D6F57B90376909FDBD390672E66C54CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:to="loc_us-gaap_Goodwill_D6F57B90376909FDBD390672E66C54CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_122CE5D1605154A146760672E66C2237" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_122CE5D1605154A146760672E66C2237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_0DC718F7B33E4B1580B10672E66C3ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7165D24780A54F60FE510672E66C54A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_E4F12CABBEF2B382E8EE0672E66C15A0" xlink:to="loc_us-gaap_Goodwill_7165D24780A54F60FE510672E66C54A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39C7265BA374A87271D3F625F90EC78C" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39C7265BA374A87271D3F625F90EC78C" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_9DB1F9AAF1D5CFFF525EF625F90E92D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39C7265BA374A87271D3F625F90EC78C" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_09E90CA10671752D7F31F625F90E98A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39C7265BA374A87271D3F625F90EC78C" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_D5F371F84539AAA0BD83F625F90E06E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4160B30856B30DDFCFFAF625F8916E63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4160B30856B30DDFCFFAF625F8916E63" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9F30950BD23FFC2D1036F625F89192F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:to="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_432808602657332DFC2EF625F9D9DD1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C136F98D847AEF679F9BF625F9D9D834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0A6BD98A7C0B27A953FFF625F9D91459" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_ED481536880CE97B764AF625F9D94BC0" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_9CC4D76ADB23144E3720F625F9D93FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:to="loc_us-gaap_InventoryNet_64D4FAA5471CEBFB6A5BF625F9D94B3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_027E47835A7F9FF05EE1F625F9D92637" xlink:to="loc_us-gaap_InventoryNoncurrent_92F3DAABE6A9E4BC8C7DF625F9D9CAEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_InventoryAbstract" xlink:label="loc_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InventoryAbstract_3A445B435B66E8946FDE0B174DFEEDEB" xlink:to="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:to="loc_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_F1B62765F245116C615D0B174DFF6C4F" xlink:to="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E7E28E16EFEE9A947AC0B174DFF7972" xlink:to="loc_biib_BioverativMember_A6B58CCDF87B732FC35A0B174DFF41AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_CDDD5E22FEB1158588120B174DFFDEBB" xlink:to="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InventorysoldtoBioverativcost" xlink:label="loc_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_D039BDE2FD81B6D907BF0B174E009B25" xlink:to="loc_biib_InventorysoldtoBioverativcost_32A08A8EB7D18D6074190B174E00DA2A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7DB39F836D8FD52B3B5CF625FA17EC5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7DB39F836D8FD52B3B5CF625FA17EC5C" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8DA26B4EE9808C225F90F625FA1780BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_EF228E064150A7E854F2F625FA460906" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_EF228E064150A7E854F2F625FA460906" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_D3C30E8DFD4C3425E8E2F625FA464AB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_49A65B89D2A5FD5D1CD8F625F97B7BB2" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_A47CD274464A56FE7261F625F97B36B0" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_4D821C35AE33DF570C79F625F97B3902" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_8F5BD708A1DE62879BD60B174D4E9516" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8F5BD708A1DE62879BD60B174D4E9516" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ABE16AAF790F9DBEAB7F0B174D4F2F1A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2D6E852448DB5FF1CA2B0672E5CDF8FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2D6E852448DB5FF1CA2B0672E5CDF8FF" xlink:to="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DE7B13A28752AC5BD4D70672E5CD7FFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DE7B13A28752AC5BD4D70672E5CD7FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DE7B13A28752AC5BD4D70672E5CD7FFC" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OperatingleaseassetsMember" xlink:label="loc_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:to="loc_biib_OperatingleaseassetsMember_52E8B23D3CCB7B01751A0672E5CE933D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4B0760A756922F31FC210672E5CEC36B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4B0760A756922F31FC210672E5CEC36B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_LongtermoperatingleaseliabilitiesMember" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_0E51BC1C67B8B4F399ED0672E5CE72DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6BB139FD5C34FD7916FF0672E5CE04E5" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_0E51BC1C67B8B4F399ED0672E5CE72DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0EF80B66332EFC5B2CC90672E5CFF9C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0EF80B66332EFC5B2CC90672E5CFF9C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0EF80B66332EFC5B2CC90672E5CFF9C6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A7F4E9C34C8D29AB5C40672E5CF61EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A7F4E9C34C8D29AB5C40672E5CF61EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_91CE3FB25D4B3D0A80040672E5CFCB95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_91CE3FB25D4B3D0A80040672E5CFCB95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_913EFDCC00D3A18CB83B0672E5CF2AF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88A1AD5F37F340686E230672E5CF6D38" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_913EFDCC00D3A18CB83B0672E5CF2AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0AEED210062F2FCAB4A10672E5CD9386" xlink:to="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9DC59FFCDA6353076EE00672E5D05DAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9DC59FFCDA6353076EE00672E5D05DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46FB460E775C2E8E718D0672E5D0EF7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_46E309F51C178FE090440672E5D02181" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_46E309F51C178FE090440672E5D02181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseLiability_AB3A767BF9FB7BBE485C0672E5D082A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseCost_3C27FC82BC9F391B1EB90672E5D04ED0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_552A3262296A4C9D4CCF0672E5D1FFA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_FCAB26A43F0E075D33E30672E5D1902B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseCost_FCAB26A43F0E075D33E30672E5D1902B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_B3A466806EEABEB7BA330672E5D16FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ACCD1954738AFE8CA7520672E5D10FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_F6DB571288EF77EDFA720672E5D23A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_C3C3DFDD68E93126B1910672E5D25D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_25F39761256EF5398F380672E5D25317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5CBEA86CF04B6E9856A10672E5D245CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4F568870CA9233616D180672E5D26623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_C2C7035BC43A52A81D590672E5D2B250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_75A82C99DDE34F3C106F0672E5D247F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4A199445C2E480880BE40672E5D34BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5AB86A281848550210E60672E5D3DFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1CE638FE993EA24E9DE10672E5D34273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E27E4EF2420639C898BA0672E5D3A5B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_86631094B85CD04FEA5A0672E5D3161C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_C42D9909CC97454D4ECB0672E5D45ACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_530A26F1BDE4ABBD79120672E5D494C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_313E7F68461A0C640E880672E5D40097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_0D97393A7B226DEEBEE70672E5D499FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_7E52619CB03E43851F710672E5D5B644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7262DBD74A784E4A76F80672E5D51E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_E4126DECF521D9A3A7250672E5D5E97D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B41383A2C3B3A5123F2E0672E5D5C459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_582D896477C2CA2F4B9A0672E5D53C6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_12C528624AC4E21DFA270672E5D5C6A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_002FA7C7C920C8AE696E0672E5D51A12" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_443BD1F2934C0FC7A7800672E5D62388" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_841FEF95004077F680620672E5D642BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_E64B4E9227A11A99B94D0672E5D6A39E" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_DA3186B486F9079810690672E5D6D96D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_biib_NetMinimumLeasePayments_A8973C87BF46A6FEFC430672E5D6F7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8954E263CB31F17E2E5E0672E5D6A7B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_EDC240753F8327CDEED90672E5D71A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_OperatingLeasePayments_044669C79E1346E2649B0672E5D724BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777CFE2199DF167E4F810672E5D09050" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9122F9C0F1D078679E120672E5D7813D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_6E4BDBB15F48BE5FCED70B174D245D05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6E4BDBB15F48BE5FCED70B174D245D05" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23830DA29C903F89710B0B174D24B345" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23830DA29C903F89710B0B174D24B345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23830DA29C903F89710B0B174D24B345" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_A07A27E5B3094DFC71FC0B174D255246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_142839C11CC802AD047C0B174D2569B1" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_A07A27E5B3094DFC71FC0B174D255246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_C99C20DF6E9B135383030B174D257D81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:to="loc_srt_RangeAxis_C99C20DF6E9B135383030B174D257D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_C99C20DF6E9B135383030B174D257D81" xlink:to="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0F8F0655BB80C925975E0B174D260044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:to="loc_srt_MinimumMember_0F8F0655BB80C925975E0B174D260044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E7DE0DE4DBB8B73551160B174D2695A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BE2F9139CB465EEAEB760B174D260298" xlink:to="loc_srt_MaximumMember_E7DE0DE4DBB8B73551160B174D2695A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_91A7F89DC83F632643D00B174D24BC87" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_930D13B7584D6776C4B40B174D267D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7E155D0A9293497DEC2F0B174D27C655" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingLeaseAssets" xlink:label="loc_biib_DisposalGroupOperatingLeaseAssets_CF8B46924A95AC9836BD0B174D274740" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_biib_DisposalGroupOperatingLeaseAssets_CF8B46924A95AC9836BD0B174D274740" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DisposalGroupOperatingleaseliabilities" xlink:label="loc_biib_DisposalGroupOperatingleaseliabilities_97CC20FBEE4DFAF6A43E0B174D2765BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_121D4C155BA64B65E1040B174D26B63F" xlink:to="loc_biib_DisposalGroupOperatingleaseliabilities_97CC20FBEE4DFAF6A43E0B174D2765BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_LesseeLeaseTableTableTextBlock" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47" xlink:to="loc_biib_LesseeLeaseTableTableTextBlock_F92352EF26F37FA030890B174D4A6267" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_A216867161ED55D35E120B174D4BDD0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64FF9E8178DDB7B71C720B174D4B040E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_CA632ED53396415ACC100B174D4B506B" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47" xlink:to="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_D8B55E542EDE35AB12680B174D4B4DBD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_B640C59AB7B8BB68332A0B174D4ABB47" xlink:to="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_BAF45553D363B0BC9F1D0B174D4BAF78" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D40F01B88FE079F27B09F625F7EE8708" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D40F01B88FE079F27B09F625F7EE8708" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_29F9D3E414228223C57CF625F7EE5056" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B261B8492E0E9E950CFC0B87D96F6354" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_0C5A38943DD9295B628C0B174C2F4F74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B261B8492E0E9E950CFC0B87D96F6354" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_0C5A38943DD9295B628C0B174C2F4F74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CCC58C3BCFB5E302A2B00B174C31518F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0C5A38943DD9295B628C0B174C2F4F74" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_CCC58C3BCFB5E302A2B00B174C31518F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_48ADC95478615E4D51430B174C316F6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CCC58C3BCFB5E302A2B00B174C31518F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_48ADC95478615E4D51430B174C316F6C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_BFBE3D7C55636B866E160B174C32CA35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_48ADC95478615E4D51430B174C316F6C" xlink:to="loc_country_BR_BFBE3D7C55636B866E160B174C32CA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_AF1AA73AF0CE7B7280960B174C329A57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_0C5A38943DD9295B628C0B174C2F4F74" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_AF1AA73AF0CE7B7280960B174C329A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_A117CAB97E1157A9EF4D0B174C325E2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_AF1AA73AF0CE7B7280960B174C329A57" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_A117CAB97E1157A9EF4D0B174C325E2E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BEDD295F3C98A420EC5BF625FA08908A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BEDD295F3C98A420EC5BF625FA08908A" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_76568887C94C9D329C1FF625FA08A304" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69B316D33D7038C67C04170B379EF453" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_415A49569F24999ACC32170B379E2EED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69B316D33D7038C67C04170B379EF453" xlink:to="loc_us-gaap_StatementTable_415A49569F24999ACC32170B379E2EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B48656F1299F0C016E34170B379E9C92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_415A49569F24999ACC32170B379E2EED" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_B48656F1299F0C016E34170B379E9C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B48656F1299F0C016E34170B379E9C92" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_171709EBFAD92E22CA6E170B379E6168" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2A5F98A3E157710C9BEB170B379EA453" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_171709EBFAD92E22CA6E170B379E6168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7F32EC4D9DCF41E45B2C170B379E04B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_415A49569F24999ACC32170B379E2EED" xlink:to="loc_us-gaap_StatementLineItems_7F32EC4D9DCF41E45B2C170B379E04B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69B316D33D7038C67C04170B379EF453" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:to="loc_us-gaap_InvestmentIncomeInterest_FC677B78159D29D89EC6170B37A0706E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:to="loc_us-gaap_InterestExpense_B43FB23CD1AE40684A28170B37A02A9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_5DBF28872C78997DF473170B37A0D0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9761E34DB00375108588170B37A0DDDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1B8680F4D9426EA39430170B37A113AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4F219219F6A54F208E68170B37A1AAB6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_39BD01D5F3109C4B9BE6170B37A02175" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4F219219F6A54F208E68170B37A1AAB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69B316D33D7038C67C04170B379EF453" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_F21CD51A732F984595A1170B37A156AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_13D6BA3DE7F2D9108D21170B37A1DB1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_8C2914B3B1658827B56A170B37A187F0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F5FA5D58CB90AC9CE7F4170B37A17398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69B316D33D7038C67C04170B379EF453" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_93BF7B102672F9A5E7B7170B37A1FDF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_93BF7B102672F9A5E7B7170B37A1FDF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_F7AB5CBC63AECC60C16B170B37A1020B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_DF89B733D64F323A0003170B37A1D264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_C249E5844E347D5C2CE0170B37A1930A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_biib_Collaborationexpensesaccrual_A86C87267918BA4E6829170B37A1AD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B6D9059F3BEFD5278B6A170B37A1DC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C3240E5D0CE59E3C75B2170B37A1A202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6AA9C7F6DBF3492896E6170B37A18029" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_CC87F5D271A5B44D8C7E170B37A15DCB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01D34669C358CD5001C1F625F9D96C99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01D34669C358CD5001C1F625F9D96C99" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_FCF537717EA3CFDAE5C3F625F9D97EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01D34669C358CD5001C1F625F9D96C99" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_41EC6DC9BD49EA7DAD4AF625F9D94C96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01D34669C358CD5001C1F625F9D96C99" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8538AFB23B4307F92F53F625F9D9F501" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D7207CF3B785FAFE8A8D0B174C66F526" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_943A20096DD0CD45471E0B174C6724D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D7207CF3B785FAFE8A8D0B174C66F526" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_943A20096DD0CD45471E0B174C6724D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D7207CF3B785FAFE8A8D0B174C66F526" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_CFBCB416A5701D9A87520B174C676E63" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_FF756887D2ABD452512B0B174E16D732" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_387BD35E163AA08108780B174E179375" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:to="loc_us-gaap_TypeOfArrangementAxis_387BD35E163AA08108780B174E179375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_387BD35E163AA08108780B174E179375" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_84233EBE9AB0FF8E7FB40B174E170DC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3878C814665A9FD5B8D40B174E17D6B5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_84233EBE9AB0FF8E7FB40B174E170DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_79CF5DC0CAE3ACAFAF400B174E186358" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:to="loc_srt_ProductOrServiceAxis_79CF5DC0CAE3ACAFAF400B174E186358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_79CF5DC0CAE3ACAFAF400B174E186358" xlink:to="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:to="loc_us-gaap_RoyaltyMember_75658A37E3B9D46ED5B40B174E185AC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:to="loc_biib_OthercorporaterevenuesMember_D456DFFE8934B75A81950B174E18CAEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_882BB8526C62019952160B174E188C16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CDDEC51B4DB196A5FB550B174E18706B" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_882BB8526C62019952160B174E188C16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_06CB75A2E8682A375B890B174E199CF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:to="loc_srt_MajorCustomersAxis_06CB75A2E8682A375B890B174E199CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_06CB75A2E8682A375B890B174E199CF8" xlink:to="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:to="loc_biib_AbbVieMember_F77CFB8F28AEB4673F2B0B174E19C3F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_A6D73E81B1424AD925400B174E1A4A39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_438DF97A48879CB5550F0B174E193C17" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_A6D73E81B1424AD925400B174E1A4A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_DA93685B43A375AD256F0B174E1A1A2F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_F4A00C9A3134298BA55A0B174E175102" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_DA93685B43A375AD256F0B174E1A1A2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_513D8609BECC670DAA080B174E1A1980" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_DA93685B43A375AD256F0B174E1A1A2F" xlink:to="loc_us-gaap_Revenues_513D8609BECC670DAA080B174E1A1980" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7F208AB7E63E6C04C6320B174D537E94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7F208AB7E63E6C04C6320B174D537E94" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_CC571746BBF071801B260B174D53FB54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:to="loc_us-gaap_BuildingMember_4BDB65E2A4148AF2AD280B174D54A54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9A3C33B8B05D1D5175080B174D534AF4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6BF4C792DCFABAA8F25C0B174D5493A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:to="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_4D2991801079EBF18B650B174D54D812" xlink:to="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_05DEB92677F1492680190B174D54AF70" xlink:to="loc_biib_SolothurnSwitzerlandMember_E6FBA33408C7BEA17B020B174D559BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D4E71005C589A7E2341B0B174D53449B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4DD88789D9EDF89C28280B174D55629B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_Depreciation_35826876DB55EC68D6270B174D550290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_ConstructionInProgressGross_6B873F4E71E932C8B1B00B174D557056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_OtherCommitment_2BCD369D8AC2099049700B174D5670F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB7412554D0FBE9A5AD20B174D55CCA1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1AB3BEF9AFA608D727330B174D564DAC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B4BA7161E1AF2D69E736F625F7FAC5EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B4BA7161E1AF2D69E736F625F7FAC5EE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_FA725034CC66667154A3F625F7FA19B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_5B23342E3C8CD6A72E490B174DF98EB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_5B23342E3C8CD6A72E490B174DF98EB3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_06EB2C16D747157E59BF0B174DF9EE9E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_648E6789BE19CB4B87830B174DF9B41C" xlink:to="loc_biib_WorkinprocessMember_8E966096FF428FB204100B174DFAB020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D1CDAED267CAA857300B174DFA989B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D1CDAED267CAA857300B174DFA989B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D1CDAED267CAA857300B174DFA989B" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_5E921FCE8E4BA6AF6D350B174DFAA358" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08D6CD6392D3E091698F0B174DFA35CA" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_5E921FCE8E4BA6AF6D350B174DFAA358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1C39808AD0967C166F0B0B174DF9A111" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DE90553434E12083A0F80B174DFB566E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DE90553434E12083A0F80B174DFB566E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9BB5691C62F8E7159DBB0B174DFB9411" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0C6B572C74D8B4D38C890B174DFB5262" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_F72766A5721291B1A58E1756F1B9A55D" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60F2B9078F6304CBB9C31756F1C8A140" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60F2B9078F6304CBB9C31756F1C8A140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60F2B9078F6304CBB9C31756F1C8A140" xlink:to="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_32D8F0A0AFB863C236F91756F1C8AC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9AA7FEFDDB7D63A4DE211756F1C87F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D60EBB49EF7134D70B8B1756F1C8F487" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_C6AD4E7928569049A1641756F1C8250C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_7525BEE49972446E9C421756F1C801C8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_484545AF5751EEFBBFB81756F1C899EE" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5723ADCB62D0AEB681461756F1C822F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_1FF96E3DE2FF42E82AA31756F1B98061" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5372F8F065816E865A381756F1C8B896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5A88B7BF661B6B47EC3A1756F1C8F715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_Revenues_7341E87BDAD9A711916C1756F1C842F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_OperatingExpenses_04C56A5C1DF3354F91EA1756F1C8A97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8DD06F2A02DCAF34EA181756F1C86832" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_B8A30D3F0F2E65FDA9431756F1C83A3A" xlink:to="loc_us-gaap_NetIncomeLoss_8DD06F2A02DCAF34EA181756F1C86832" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_4BA151B0A4CF992C65380B174E2A4720" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_4BA151B0A4CF992C65380B174E2A4720" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86E3B5FF51F69455C9350B174E2B6912" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:to="loc_biib_ReserveforCashDiscountsMember_87B764787E41906F4CF00B174E2B2E64" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:to="loc_biib_ContractualAdjustmentsMember_D32E4B5D9B2EBC126A0D0B174E2CD881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_9A3ABD3D558AC59B73AC0B174E2BC7C1" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_1CE016F0B3E86B9ED4430B174E2C3006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_DC3E6A316EC9867D16610B174E2AEB8A" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_C35D7D11C558F02601AA0B174E2C4FB2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_0DF0591B2750EB059C9A0B174E2C0833" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00B09FF208485CDC3BD30B174E2CB5ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_C2E25B8281E2676C44300B174E2D22B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_60E012EA5997AD07F7330B174E2D712B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_E935FEAA3FE7F7BC00A30B174E2C10D1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_48CE93976C03FA2FB21D0B174E2DFE79" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_70F96BD057E900DA55AC0B174E2481F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CF9E428F7B276BC54F960B174E250DB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_70F96BD057E900DA55AC0B174E2481F9" xlink:to="loc_us-gaap_StatementTable_CF9E428F7B276BC54F960B174E250DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_786BB36E1989FAAC0DE30B174E25DA42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CF9E428F7B276BC54F960B174E250DB0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_786BB36E1989FAAC0DE30B174E25DA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_786BB36E1989FAAC0DE30B174E25DA42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:to="loc_us-gaap_AccountsReceivableMember_6D5D110172A75466B1B40B174E261D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_230219D6B4B40D8690B40B174E25D865" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0B87F82F929522B2C0110B174E26FC0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_78039ABE2D2C4FADE79D0B174E26A718" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CF9E428F7B276BC54F960B174E250DB0" xlink:to="loc_us-gaap_StatementLineItems_78039ABE2D2C4FADE79D0B174E26A718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78039ABE2D2C4FADE79D0B174E26A718" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4CE78E292B52E637275F0B174E26AF97" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_F21C260993948A492182170B39226C78" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E7E54EAD481FEB2E31CA170B39228666" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:to="loc_srt_ProductOrServiceAxis_E7E54EAD481FEB2E31CA170B39228666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_E7E54EAD481FEB2E31CA170B39228666" xlink:to="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_4ED0016DE85811A6E3CC170B39228A76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_TecfideraMember_4ED0016DE85811A6E3CC170B39228A76" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_InterferonMember_8D03345FE500189574BA170B3922ED3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_F84D448889CB02D9644A170B3922862A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_TysabriProductMember_F84D448889CB02D9644A170B3922862A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_FAMPYRAMember_1F5D3FD72A5448187EA1170B392262F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_ZINBRYTAMember_6A650E3E1EA6231BDB61170B3922EB01" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_MSProductRevenuesMember_B25BC7719DD0AB11A30A170B3922C636" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_SPINRAZAMember_61A39BE1BB93441F8069170B3922A0D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_BENEPALIMember_AD3E2AD75EABF5D96D79170B392241A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_IMRALDIMember_80383B3F5B7A306E2521170B39289C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_FLIXABIMember_656E2DE5C34BDE05852C170B39220D92" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_BiosimilarsMember_474DD1A9C634705F21F9170B3928E762" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_biib_FUMADERMMember_B06E974F4CA74671ADC7170B39287684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_537E2492F7B6BAE7D6B9170B392892B8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81D4532915CD57C309D7170B392209F9" xlink:to="loc_us-gaap_ProductMember_537E2492F7B6BAE7D6B9170B392892B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:to="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_07D9E303443E5936E9FA170B39289485" xlink:to="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D70DCD898CA8A1E24985170B39291327" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:to="loc_country_US_D70DCD898CA8A1E24985170B39291327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_AB93F6C938CDC3DA6AB1170B3928EADE" xlink:to="loc_us-gaap_NonUsMember_E70DC56CB3BA236196E6170B3929A60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_AA4F4AB5C516328ADCD4170B39299353" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1C6188999FD8887902AF170B3922129F" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_AA4F4AB5C516328ADCD4170B39299353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_AA4F4AB5C516328ADCD4170B39299353" xlink:to="loc_us-gaap_Revenues_806ADA7C70FAA1269203170B3929D0CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20525F1AB82E2508418F0B174E0FBC64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20525F1AB82E2508418F0B174E0FBC64" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:to="loc_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_E91E9B3DB13452947A280B174E0FACC8" xlink:to="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_372DD6272618074397AE0B174E1067F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F44AA7926E9406A34D330B174E107CDE" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_372DD6272618074397AE0B174E1067F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_C1E3A47BDFF136DE9DD40B174E10B4B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:to="loc_srt_MajorCustomersAxis_C1E3A47BDFF136DE9DD40B174E10B4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_C1E3A47BDFF136DE9DD40B174E10B4B1" xlink:to="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:to="loc_biib_DistributorOneMember_CDD059522B38A9BA3F340B174E1135C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:to="loc_biib_DistributorTwoMember_106B344276CB007E612B0B174E11BA14" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_8D29FF91EB8BF1AC86630B174E1110F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DBCC994472EB96CA18850B174E117222" xlink:to="loc_biib_BioverativMember_8D29FF91EB8BF1AC86630B174E1110F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06F275A4CCAC10A6D87D0B174E0F84A6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:to="loc_us-gaap_Revenues_A9BE5CCE6376E07205940B174E12D01A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9E8ED4BA179205678AF80B174E120ED2" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_AEBC734FD5B5F92EA0150B174E12A21D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C150E8B94B9B34DCC7430B174E1F4121" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C150E8B94B9B34DCC7430B174E1F4121" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_084FAFDBEB848DEA34AE0B174E1F5B73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:to="loc_srt_ProductOrServiceAxis_084FAFDBEB848DEA34AE0B174E1F5B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_084FAFDBEB848DEA34AE0B174E1F5B73" xlink:to="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_BDCFAACF6E17D5ADE0E90B174E1F3EF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AD0F83F004ED6CDE50C30B174E1F3FC9" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_BDCFAACF6E17D5ADE0E90B174E1F3EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:to="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_61DDEE6EEB4AEA774FD40B174E2050AA" xlink:to="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B495FAE59B6A6F4F9B260B174E2013BD" xlink:to="loc_biib_RocheGroupGenentechMember_C75E24377D50DED8DC7B0B174E200F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A030F85A97199D89CB680B174E1FE7B2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="loc_biib_ShareOfCoPromotionProfits_407F908728047C3BF6EF0B174E21CD48" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_2742BC722674BA3E0A190B174E2193D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0A2771EBA7BCFBC293E70B174E214C92" xlink:to="loc_us-gaap_Revenues_74BCD82AB1EB061302CB0B174E210D2E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A020EACFC6913E1CF1BF625F8DFCF99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A020EACFC6913E1CF1BF625F8DFCF99" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_424050648C34D457D217F625F8DF291D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B27ECF36D1EEA6638B6E0B174E3CE31A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B27ECF36D1EEA6638B6E0B174E3CE31A" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_A235114261E0E68FB79C0B174E3D8657" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B27ECF36D1EEA6638B6E0B174E3CE31A" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F5F01A886AFA16FB91C80B174E3D3FEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B27ECF36D1EEA6638B6E0B174E3CE31A" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4DD4E2BE9D8F4C1FECFE0B174E3DC979" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B27ECF36D1EEA6638B6E0B174E3CE31A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_52C3ACEC0447199B02730B174E3D8D52" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B27ECF36D1EEA6638B6E0B174E3CE31A" xlink:to="loc_biib_OtherrevenuesTableTextBlock_E5B3D19A7451721666660B174E3DAD7A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD31CAA7C55BECE28987F625F8EEDF0E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD31CAA7C55BECE28987F625F8EEDF0E" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CE032412FC84BA3C9770F625F8EE737B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C41ACE0F44681F9F0C17F625F8A0C7D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C41ACE0F44681F9F0C17F625F8A0C7D7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2F3B0B770C54F989081BF625F8A0405F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6143C375F3833E5AA73CF625F8A0CE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_A679EE2820CDB19C5D57F625F8A0B5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C7B24E279AB02B0591B2F625F8A0D967" xlink:to="loc_us-gaap_ParentMember_4EA9C5F2EA032FAC04B7F625F8A05A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6A9CF12EC221CC290478F625F8A0385B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F8ADCECC3DDC5DBD328FF625F8A09F58" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72987C366AD3EDB0FB90F625F8A0C4C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8588D70D8C2C905B95F9F625F8A0862D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F7110BA6AA0D1E6CB628F625F8A0AA90" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_155D30C35C482CD83AA3F625F8A03021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_8BECC3281CCBB968998FF625F8A04CBE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_C816A96FE6A5C691E3A5F625F8A09D3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE43989299142234183407255AAC98FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE43989299142234183407255AAC98FC" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_917E89F9955F557ABC4507255AAC09CC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_C59737DBB14908D8B04707255AACCFAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1525A01723E45EF56CCC07255AAC2FAE" xlink:to="loc_biib_NightstarMember_C59737DBB14908D8B04707255AACCFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:to="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C064F7FD9EC30987825007255AAC9784" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_1565AAC5E50546A3F8E707255AACDEEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_MarketStockUnitsMember_1565AAC5E50546A3F8E707255AACDEEA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_8BB5062B8EB27477417607255AAC53FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_8BB5062B8EB27477417607255AAC53FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_CashSettledPerformanceSharesMember_92FA1C5B42181126B72207255AAC62D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_us-gaap_PerformanceSharesMember_6C84934F7CC93508FFF307255AACCE4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_62D3EF5CE4B4AE47D42F07255AACC049" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_62D3EF5CE4B4AE47D42F07255AACC049" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_8E29128F996F9F28826507255AACE3EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_36458E4A1833C8734D3707255AACE9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9697ED24D7C23D20D42807255AAC4233" xlink:to="loc_us-gaap_EmployeeStockOptionMember_455A6DBCDF62F1E6005507255AAC606E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4647F170BAA28FA07D6B07255AAC2303" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3EC8851D703EB4CDB88F07255AAC4DAE" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0A1427BC0E649CA13CEA07255AAC850B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0A1427BC0E649CA13CEA07255AAC850B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_2B2754BD6B359768E77507255AAC7CB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_2B2754BD6B359768E77507255AAC7CB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_AFC7D2DCCBE02463E7D207255AAC6269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5B5B47710242C2D7FD9D07255AAC98AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5B5B47710242C2D7FD9D07255AAC98AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3D64A997BBFBF6D3264E07255AACAE6E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_BD3576F103120E69A98407255AACA3A0" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_3D64A997BBFBF6D3264E07255AACAE6E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6CFE1E9BB116751753D3F625F8CF41B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6CFE1E9BB116751753D3F625F8CF41B9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E850C3F57F7C10E876E5F625F8CF19DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6CFE1E9BB116751753D3F625F8CF41B9" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8077C56AC3CD541CFC9AF625F8CF9AF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8B27662EE49BBA197C610B174D16A66C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8B27662EE49BBA197C610B174D16A66C" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9A7B9099D5A6B7196FD30B174D18A4AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9A7B9099D5A6B7196FD30B174D18A4AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9A7B9099D5A6B7196FD30B174D18A4AB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2019ShareRepurchaseProgramMember" xlink:label="loc_biib_A2019ShareRepurchaseProgramMember_F1D1D51E371863F193670B174D18A4C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:to="loc_biib_A2019ShareRepurchaseProgramMember_F1D1D51E371863F193670B174D18A4C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_CE32531EF7F5135223180B174D18A1B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_CE32531EF7F5135223180B174D18A1B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_6C4F1928E8B69A2802390B174D190B34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C9DDAA337DF5BDEA6C840B174D1808A2" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_6C4F1928E8B69A2802390B174D190B34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AD6AA8D8C7C5ABB29FC20B174D17C0CC" xlink:to="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_B9AFC2CE9EB7D5D3F37D0B174D19CCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_24E7CDC2EB733EC7718E0B174D192EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1831DDEDED7C7D7FFC400B174D195C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3F27FDA833D56CD66FDB0B174D190BA8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37C9951D2EC647A65D8A0B174D191760" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended">
    <link:loc xlink:href="biib-20190630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_25C82693AC50CF8600B70B174E6AE04F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_25C82693AC50CF8600B70B174E6AE04F" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_E897200CE046A6D668380B174E6AD3BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4974649005941E87DAD7F625FA27627D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4974649005941E87DAD7F625FA27627D" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E747EF79B9AAC9A778D5F625FA27E020" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2967B0C47874985A45C60B174E70E85A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_43491C4D7669099F3D510B174E706CAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2967B0C47874985A45C60B174E70E85A" xlink:to="loc_us-gaap_StatementTable_43491C4D7669099F3D510B174E706CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_3DB49C89C64BD7C1A37C0B174E71EE67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43491C4D7669099F3D510B174E706CAC" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_3DB49C89C64BD7C1A37C0B174E71EE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_3DB49C89C64BD7C1A37C0B174E71EE67" xlink:to="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_674A1DA3C6B22AB088270B174E71A77D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_9A6B262EFFEA12CB8E1B0B174E7297E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43491C4D7669099F3D510B174E706CAC" xlink:to="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE004A2E60CA6D63631C0B174E72A807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DEC4246A915E94A7AF180B174E72F6FA" xlink:to="loc_us-gaap_OperatingLeaseLiability_122AD58CFF91CB64DC1D0B174E729A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2967B0C47874985A45C60B174E70E85A" xlink:to="loc_us-gaap_NumberOfReportableSegments_167B33BC3CDD0DFBAF030B174E72C945" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2967B0C47874985A45C60B174E70E85A" xlink:to="loc_biib_InterestInSubsidiary_1A8809CF8A9C5B17B5A70B174E725259" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:type="locator" />
    <link:loc xlink:href="biib-20190630.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_A71C5D185C713BC5BFC9F625F93DFB7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C21287AF0F4735D0B476F625F93D8005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3094E29A6C0F31B4DBE8F625F93DA8AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:to="loc_us-gaap_UseOfEstimates_C1D29CEC5CA8C8D5C9FCF625F93DE63D" xlink:type="arc" />
    <link:loc xlink:href="biib-20190630.xsd#biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock" xlink:label="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:to="loc_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock_61BB17F1E674276DB9A8F625F93DC35C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A6B12314B043FB3ACB5AF625F93DBE66" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3B3DD9815E69BE85B836F625F93DF114" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>acquiredinprocessrd.jpg
<TEXT>
begin 644 acquiredinprocessrd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M_P##;6OBEK=QXSOKW6],O-)TN7P]H5U:Z=/I6G:]=7&KS6UM-96MHT]_!]/
MA@&'0@$?0C-?B#_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4
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MJ_W%_P"9AU_T'_43H WJ*Q/^$?T__GKJ_P#X4/B#_P"6='_"/Z?_ ,]=7_\
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M^$?T_P#YZZO_ .%#X@_^6= &W16)_P (_I__ #UU?_PH?$'_ ,LZ/^$?T_\
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MKXCOM0M%\3^!/ASX@^*&F>(?B7-XNTP>(H6U+Q1I-]K/[$CI^)_F?U]1V/%
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M^%[O0M3\91^$]/\ $UQ:Z?\ M /ZGN3W/K_+H.@XH _$'_@I/_RDD_X(4_\
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M?]"[K7_?S0O_ )=T?VK>?]"[K7_?S0O_ )=T ;5%8O\ :MY_T+NM?]_-"_\
MEW1_:MY_T+NM?]_-"_\ EW0!M45B_P!JWG_0NZU_W\T+_P"7=']JWG_0NZU_
MW\T+_P"7= 'D7QZ_Y 6A?]AE_P#T@N:^7J^D_C?>3W.B:(LNF7]@%U=V#W;Z
M<RR'[#<#8@LK^\<-@[LNB)A2 ^["GYLK^:O$C_DK,=_UXP/_ *B4@"BBBOA
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M_P!!%?B'_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$4 /HHHH
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M!X1\>O\ D!:%_P!AE_\ T@N:^7J^H?CU_P @+0O^PR__ *07-?+U?S5XD?\
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M4?V!GW_0DSC_ ,-F-_\ E'G^?9@?T"? C_D6-5_[#TW_ *;].KVZOP(^%/\
MP7\_X)!>&-"O[+5_VUO!L%Q/JTEU&H^&_P >B#"UG9Q!OG^$L9^_"XX4CCKG
M(KU#_B(@_P""-O\ T>YX._\ #;?'C_YU%?TKP=1K8?AK**.(HU:%:GAK3I5J
M<Z56#]I-VG3FHS@[:VE%.VM@/VGJ*>5(899I98X8XHWDDFE94BBCC4N\DKLR
M*L<:@O(Q9=J!CN&,C\7?^(B#_@C;_P!'N>#O_#;?'C_YU%'_ !$0?\$;?^CW
M/!W_ (;;X\?_ #J*^E \0^&_[6/[36CI\5O!7Q,^,/C&S^*'Q!^+GP)\,>'/
M$TV@?!3QI\$?#?@GXD^.OV3OAI\1_C!^S)X[\$VT\3^"_"<7QWT:Z\)^$?C9
MI&H7"77Q%^&GBG5?^$@N;7XF07WZE_LJ^+_'LGC+]IGX-^,_%WB+XFZ?\"/B
MIX2\,^$/B9XJMO#L'B;5=#\;_!CX=_$^?PAXMN?"VB>&]&U;Q3X$U7Q7>6<F
ML6VA:9<WOA;5O""ZQ%>:]!JVK:A^2OA?_@K-_P &YG@F'XKV?ACXR?LZZ):?
M':]N;OXKV%M\ ?BM'9^/C=:5I^EW.FZU8O\ !HV]WH\EKI4=VWAZ&)-'749=
M5UY;!=6U/5=0N?4/AM_P7._X(5_!_P +V_@OX9?M6?##P3X8MKN]U!=)T#X4
M?'2R@GU+4YS<ZGJM](/A0]UJ6K:E<'S]1U;4;B[U*_FQ+=W4SA2 #]Y:*_%C
M_B(@_P""-O\ T>YX._\ #;?'C_YU%'_$1!_P1M_Z/<\'?^&V^/'_ ,ZB@#]H
M+K_CVN/^N$W_ *+:OSM7H/H/Y5\V3_\ !P]_P1N>"9!^VYX.W/%(J_\ %MOC
MQRS(P4?\DH[D@'TZX/2OC@?\%P_^"4>!_P 9F>"^@_YIQ\?_ /YT%?C_ (IY
M=F&.J9&\%@<9C%2CF2J/"X6OB%3Y_P"SN3VGL83Y.?DGR\UN;EE:_*[!^K=%
M?E+_ ,/P_P#@E'_T>9X+_P##<?'_ /\ G04U_P#@N-_P2@C4O)^V?X(C11EG
MD^'?Q\CC4>KR2?")41?]IF SQG)%?DO]@9]_T),W_P##9C?_ )1Y_GV8'ZN4
M5^4O_#\/_@E'_P!'F>"Q]?AO\?P?Q'_"H.*/^'X?_!*/_H\SP7_X;CX__P#S
MH*/[ S[_ *$F<?\ ALQO_P H\_S[,#]E?AE_R/GAO_K[N/\ T@NZ^W:_FX\#
M_P#!=?\ X)+Z+XLT35+_ /;0\&16=I<RO/(/AO\ 'TE$>TN8@?F^$2+]^11@
ML,YZU^N/[(/_  43_8T_;T?Q_'^R7\;]&^,;_"X>&3X\&D^&O'OA[_A'AXQ_
MMS_A&S.?&WA/PP+O^U/^$<UKR_[--[Y'V%_M?V?S;?SOW#PPP6,P638ZGC<)
MBL'4GFE6I&GBL/5P\Y0>#P,5.,:T(2<7*$H\R37-&2O=,#[6HHHK]* ****
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MM9CJ$,-OHGB[0;E+^6V6RN7NGMX)I+BUN(X_J+(&,D#/3W^E&0.IZ\#W/I0
MSRU]!_WRO_Q-'EKZ#_OE?_B:?_3K0"",@@CU'(H ;L Z<?@O_P 31M'^0O\
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M6&_U_4;>V6RM;[7]7N'N=8URZL[%(["QGU:_O'L;"..RLS!:QI",;XY?LS_
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MH&N>.[KXD>.X+"UU/0[GQ5K'BSPSXA\,V6B:+J^K1Z#I.M^"=,O;ZVO],O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>amortofintangibles.jpg
<TEXT>
begin 644 amortofintangibles.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M_P##;6OBEK=QXSOKW6],O-)TN7P]H5U:Z=/I6G:]=7&KS6UM-96MHT]_!]/
MA@&'0@$?0C-?B#_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4
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M1_ZN/_<7_P!!% &'_P (SI/_ #SN_P#P:ZO_ /)]'_",Z3_SSN__  :ZO_\
M)];]% &!_P (SI/_ #SN_P#P:ZO_ /)]'_",Z3_SSN__  :ZO_\ )];]% &!
M_P (SI/_ #SN_P#P:ZO_ /)]'_",Z3_SSN__  :ZO_\ )];]% &!_P (SI/_
M #SN_P#P:ZO_ /)]'_",Z3_SSN__  :ZO_\ )];]% &!_P (SI/_ #SN_P#P
M:ZO_ /)]'_",Z3_SSN__  :ZO_\ )];]% &!_P (SI/_ #SN_P#P:ZO_ /)]
M'_",Z3_SSN__  :ZO_\ )];]% &!_P (SI/_ #SN_P#P:ZO_ /)]'_",Z3_S
MSN__  :ZO_\ )];]% &!_P (SI/_ #SN_P#P:ZO_ /)]'_",Z3_SSN__  :Z
MO_\ )];]% &!_P (SI/_ #SN_P#P:ZO_ /)]'_",Z3_SSN__  :ZO_\ )];]
M% &!_P (SI/_ #SN_P#P:ZO_ /)]'_",Z3_SSN__  :ZO_\ )];]% '-7'AO
M2EM[@B.[R()B/^)KJQY\MNQOR#]".:_.#QSH&I^*O!^O^'-(U71=&U'6M/\
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MY'SPW_U]W'_I!=U]NU^W>$__ "(\P_[&];_U"R_IL(****_4P"BBB@ HHHH
M**** "BBB@#\0/\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_$/
M_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"* 'T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 077_'M<?]<)O_1;5^=J
M]!]!_*OT2NO^/:X_ZX3?^BVK\[5Z#Z#^5?B?B[_%R#_#FO\ [S %HHHK\; *
M*** .[^&7_(^>&_^ONX_](+NOMVOB+X9?\CYX;_Z^[C_ -(+NOMVOWWPF_Y$
M>8?]C>M_ZA9> 4445^I@%%%% !1110 4444 %%<M/XX\&6WB"'PG<>+/#4'B
MFX17M_#<VO:3%X@G1U#(T.B27BZI*'4AE,=HP92"I((KJ?\ /I_.@#\0/^"D
M_P#RDD_X(4_]G6_M0?\ K'/Q!K]NXR/+CZ_<7L?[H]J_$#_@I9#'/_P4A_X(
M51S(LB']J_\ :<<HPRI:+]CWQ_*A([[716P<@XP01D5^T,?A?0/+3_B60?<7
M^*;T'_32@#H<CW_(_P"%&1[_ )'_  K!_P"$6T#_ *!D'_?4O_QRC_A%M _Z
M!D'_ 'U+_P#'* -[(]_R/^%&1[_D?\*P?^$6T#_H&0?]]2__ !RC_A%M _Z!
MD'_?4O\ \<H WLCW_(_X49'O^1_PK!_X1;0/^@9!_P!]2_\ QRC_ (1;0/\
MH&0?]]2__'* -[(]_P C_A1D>_Y'_"L'_A%M _Z!D'_?4O\ \<H_X1;0/^@9
M!_WU+_\ '* -[(]_R/\ A1D>_P"1_P *P?\ A%M _P"@9!_WU+_\<H_X1;0/
M^@9!_P!]2_\ QR@#>R/?\C_A1D>_Y'_"L'_A%M _Z!D'_?4O_P <H_X1;0/^
M@9!_WU+_ /'* -[(]_R/^%&1[_D?\*P?^$6T#_H&0?\ ?4O_ ,<H_P"$6T#_
M *!D'_?4O_QR@#>R/?\ (_X49'O^1_PK!_X1;0/^@9!_WU+_ /'*/^$6T#_H
M&0?]]2__ !R@#>R/?\C_ (49'O\ D?\ "L'_ (1;0/\ H&0?]]2__'*/^$6T
M#_H&0?\ ?4O_ ,<H WLCW_(_X49'O^1_PK!_X1;0/^@9!_WU+_\ '*/^$6T#
M_H&0?]]2_P#QR@#7NB/LUQU_U$W8_P#/-O:OSN7H/H/Y5]Z7'AC05M[AAIL
M(@E(.Z7@^6W_ $TKX+'('T%?B?B[_%R#_#FO_O, 6BBBOQL HHHH [OX9?\
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M%&DWVL_L2.GXG^9_7U'8\4 ?B#_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\
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MC\3^'(N472S5.&LT\'33BKI7DGB;QUDEK;5I;M!;S73KWM_G^#/M"N$^)O\
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M1117XV 4444 =W\,O^1\\-_]?=Q_Z07=?;M?$/PS('COPV20!]KGY)P.;"[
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M^)+77-:CGU?XG0:YH?A9M'U7P_XV%EXR\2_"73]%@_H0^/7_ " M"_[#+_\
MI!<U\O>ON #[@$, ?4!E5@#D!E5NJ@C^>..,=/+N-<=B(0C4?U/#TG"3DHM5
M<#3AK;=)M-IJ]D^5PJ<E2#3M_7_ ?]>6A^7>KVNE+^U[^U#IWPK\'_&'PCX_
M^-_[*NL?"JV^,VI?!GX^2>"KG]HB/QC\7[_0;R[^-.M^#9O"%GX5\&Z1K7A>
M]\+ZYI^OV'PWT.P,=CX.%I?SW&GRS_"C0KC1=5TOQ_X*_9I\6>"O#_P5_8$U
M#X:?$7X8>*OA"GA63XH_&WP9?>#_ !A\.OA=H6F7FG)#\6[SP/<^$/B1;6_Q
M(T&/Q%X:U.3XMZ?;>&/%>JZAXAU:&Q_3[)QC)QC&,G&/3Z4T #H . .!C@9P
M/H,G'U/K7QCS63AR>RE).C0I2=2M*3DJ-)4'S<L8<T?9)*E&7,\/-<].2;L%
M^VGX=OU6^[ZGR]\*M(U'X&?!GX5^";+PA?>(_BMX_P!%U_Q%XAO+7POJ%CX-
MU/\ : U_P%JOQ4\;ZY\8O$OAK2YH?AKX5\2^.8;KP=9>(;O3I5LH_P#A&/ V
M@V<MU:Z-IZ_.'[%OP^_:&\"?M!?M':A\:OA+HGAJX\?_  R_9NU_Q;\5](^*
M8\?6OQ,^,6GS_&N7QI>::J?#'P1;RVD,7B2UTZ#2;6^DB^%GA#0OAWX*6VU*
MWU"SO-/_ $QHK'^T)^RQU-TJ<I9@H^WJR=3G4H8F.)BZ?).$8P3A%>SE&<6X
MQF_AC%%_Z_#??Y;'TY\$]+TR^\-ZG+>Z=87DB:Y+&LEU:6]PZH+"P8(KS1NR
MH&9FV@@98G&2:Z[XC:+H]KX(\13VVDZ9;SQV(:.:"PM898V^T0#*21Q*ZG!(
MRK X)%<_\"/^18U7_L/3?^F_3J[/XF_\B'XF_P"O!?\ TI@K^@,G_P"3<O\
M[)_,O_4?% MUZK\SXC/4_4_SI*5NI^I_G25_-X@HHHH *]M^"%C97VM:W'>V
M=K>(FE6[HEU;Q7"(YO"I95F1PK$  L "0,9Q7B5>[_ ;_D.:[_V"+?\ ]+6K
MZO@;_DK,D_[":O\ ZB8@:VEZ?JCZ#N?#^@"WN"-#T@$0RD$:;9 @A&(((@R"
M#T-? @Z#Z"OT2NO^/:X_ZX3?^BVK\[5Z#Z#^5?<^+O\ %R#_  YK_P"\P0M%
M%%?C8!1110!VWPX@AN?&_AZ"XABN()+J<20S1I+%(!8W3 /'(&1@& 8!@0"
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M  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\
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M)_$C_DK,=_UXP/\ ZB4A!1117P@!1110!]5? C_D6-5_[#TW_IOTZNS^)O\
MR(?B;_KP7_TI@KC/@1_R+&J_]AZ;_P!-^G5V?Q-_Y$/Q-_UX+_Z4P5_2&3_\
MFY?_ &3^9?\ J/BAQW7JOS/B-NI^I_G24K=3]3_.DK^;Q!1110 5[O\  ;_D
M.:[_ -@BW_\ 2UJ\(KW?X#?\AS7?^P1;_P#I:U?5\#?\E9DG_835_P#43$#6
MTO3]4?35U_Q[7'_7";_T6U?G:O0?0?RK]$KK_CVN/^N$W_HMJ_.U>@^@_E7W
M/B[_ !<@_P .:_\ O,$+1117XV 4444 =W\,O^1\\-_]?=Q_Z07=?;M?$7PR
M_P"1\\-_]?=Q_P"D%W7V[7[[X3?\B/,/^QO6_P#4++P"BBBOU, HHHH ****
M "BBB@ HHHH _#__ (*4LJ?\%(_^"%)9E4?\-7?M/+EB -S_ +'?Q 55R<#+
M,0JCJ6( R2!7Z$?&J>&X\3Z<\$T4R#P_9J6BD210PO-0)4LA8 @$'&<X(/>O
MSU_X*5QQR_\ !2'_ ((5)(B2(?VKOVGF*.JNI*?L=_$!U)5@1E7564XRK ,,
M$ C]"/C1:VUIXFTZ.UMX+>-M LW*011PH7-W?J6*QJJEB%4%B,D #.  /SSQ
M/_Y):I_V'X+_ -+F!^>W[8GP%\3_ +1GP@N_AUX:O/A3*;C5=)OM1\+?&OX:
MQ?$CX=^*K:RUG1[Y$U!+75-$\3^%=9T2.RO+O1/$'A?4TN+D7FI>'M4M);+6
M(]1T>_X)_9WOO!FH?LQ)-\0+[Q9HG[-G@OXK:-9C7K*\.K>)/&7C[3M \-^'
M?%L<ESJNL'3+#P%X+/CSP=X<T?4-4UW4].\.>*-.TX^(-3ET[4=1U'Z<HK^?
MHX_%1PT,)&HE0ISQ,XP]G3OS8JA+#5G*?+S2;HSG"+;;BI:/W*7([O\ KUNO
MQ^_[[_%^E?LO^+=+\1^&M'7QUX/G^"?PZ^/GC;]IWX=>%I?".OGXA6_Q.\5Z
MA\1/%6B>%?%7B<^)6\-WWPR\"?$;XG^*/&>E3:-H-CXSUVUB\.^$]4N;*TT2
M[UG7CXC_  M_:N\7^*/V:O%&E>+?V7?MOP0N)O%_B<:_X:^.=G:^+/B-XG^$
MGC3X4^.CX:T_1/$=\OAOP&8?&ESK_A"SU._UCQ3;W-A::;XBU*^MS)='[0HJ
MGF.)E452;I3FJ=6G>5&D[JO&K&M*5HKFJ5E6J>TJ2O.3DFW>,'%"CJ/J/YU]
ML_#V^LHO!/AF.6\M8W72K<,DEQ"CJ1NR&5G!!'H17Q,.H^H_G7VI\/\ 2M,G
M\%>&I9M/L997TJW9Y)+.VDD=CNRS.\3,Q/<DDU^C>$W_ ".LQ_[%<O\ U+PP
M^B]7^G_ .$^.EU:W&AZ&L%S!.5UARPAFCE*C[#<C)",Q R0,GC) KYEKZ6^.
M5A96FB:&UK:6MLS:PZLT%O#"S+]AN#M8Q(A*Y ."2,@'J!CYIKQO$C_DK,=_
MUXP/_J)2$%%%%?" %%%% 'U%\#KNUM_#.J+/<V\+'796"S31QL5.GZ> P#LI
M()!&0,9!'8UV/Q)OK*7P-XDCBO+661K !4CN(G=C]H@.%57+$XYX!KB_@A86
M-WX:U1[JSM;AUUR55>>V@F95%A8$*&EC<A<L3@'&22!DG/7_ !(TO3;?P/XC
MF@T^RAE2Q!22*TMXY$/VB 95TB5E."1D$<$U_2&3_P#)N7_V3^9?^F,5^@X[
MKU7YGQD>I^I_G24IZGZG^=)7\WB"BBB@ KW+X%SP0:WKC3S10J=)MP&ED2-2
M?MI. 7903@@X'/->&U[?\#K2UN]:UQ+JV@N572;=E6>&*958WI!95E5P"0 "
M0,XXKZO@;_DK,D_[":O_ *B8FPUM+T_5'TM<ZCIYMK@"_LB3!+@"Z@)/[MNW
MF5^?(Z#Z"OT N=&TD6]P1IFG B";!%C: @^6W((ASD5^?XZ#Z"ON?%W^+D'^
M'-?_ 'F"%HHHK\; **** .X^&LB1>.?#LDKI&BW<Y9W8(B@V-V 69B ,D@<G
MJ0*^VH;FVN-WV>X@GV8W^3+'+MW9QNV,VW.#C.,X..AKXD^&T44_CCP[%-''
M-$]U.'CE19(W L;I@&1P58!@" 0<$ ]0*^V+:RL[/?\ 9;6VMO,V[_L\$,&_
M;G;O\I$W;=S;=V<9.,9.?WWPF_Y$>8?]C>M_ZA9>!9HHHK]3 **** "BBB@
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M_P#7W<?^D%W7V[7[[X3?\B/,/^QO6_\ 4++P"BBBOU, HHHH **** "BBB@
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M!GW_ $),X_\ #9C?_E'G^?9@?JVO4?4?SK[C^'7_ "(WAC_L$V_\FK^<(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>anticd20.jpg
<TEXT>
begin 644 anticd20.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: 3T# 2(  A$! Q$!_\0
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M75O&4?A?QQ\6_AO9^#;CQ_::3JFG>*_"NL7_ (8\::!%X7\?>-UU^X_8ZR\
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MHHH **** /Q _P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(K\/\
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MWQ"^)'PW\?N?"WAN=1;0>%UUV.6^\$WED%O? ]OK_CW4W-OY[X1D^#5UX_\
M'^NZ-\'/ 47[+VD_$_4+KQW\2?'.B>([N\O_  3<:%IT%A\+/@U9:MJ$?B'P
MUXPUS5+;Q+KWP^TW0;JY^($%MKGAZ\\=ZEI'A+P=JTLOQ_+\??CC)XD\1>,$
M^+WQ)M?%'BZ/3X?%&N:?XT\0:;J&OP:2_F:3;:K-I]_;?;+72Y<S:;:2JUMI
M\[//9PPS.[LVR^/OQVTTWYT[XT_%BP.JZK=Z]J?V/XA^+;8:CKE_:V=C?:S>
MB'5D6YU:]LM/L+.\U&8/>75K8V=O/-)#:P)'_1V'X.SVGE]+"5\?1K5J>687
M+WB89GFM&<W%8>-:O**I3H_6L)3HJ&45H4J>$PF*=;,I99*KBYX>E_&^,\2N
M%:V;5LPPN4XK#X:KGF/SA8.KDF0XF%/VLL3.AAH3=>E76 S"MB)5.(,-4KUL
M?F&"6&R>.=4\/@*>)K_4&O\ A7PIXD^#$^B>$]%'A3Q!X*_9T\$?%;Q0_BC]
MG;PWHG]M0)JND1ZS?:=\<[G47\:7FJ^)[G7K&?PQJB:);^$O%EK$_A32;Y)Y
MHC-9^!GP^T*TT+X#:3JGPGT3QW=_&7]HGQ7\)OB[+XH\,ZK>:_X,\-Z3;?#N
MWL-"T&^\RUN?AQK<>@^+O%/Q';Q+;QV>L2_V#:/<W+^'= UC3[GXJN?B!X\O
M/"UOX&N_&WB^Z\$VET;VT\'7/B?7)_"MM>FXFN_M=OX=EOWT>&X%U<7%RLL=
MDKK<SSW"%9II)&O)\4_B='/XMND^(_CU+GQ^''CNY3QCXC2X\;"6.:*0>+IE
MU)9/$GF17$\4AUEKTO%//"Q,4TJ/Z4^&<XE@<5@89E24*V/Q6,C)RJTZC5;"
M?5:/M:^$I86M4='$5'FL'.<Z]/%8/"8?ZW4A)XFAXE'COAN.:8'-:F1XEUL+
ME. RZ<8QP]:A%X?,(X[$K#87,*^.P]&GB,'060S5.-/#5<!F68XK^SZ$XQP>
M)^SO^":=K9V/_!0WX V6G7JZEI]G\0O%UI8:BH 74+&U\%^.;>SOU"Y7%]:Q
MQ78V_)B;Y<+BO[A$^XO^ZO\ (5_#5_P2[_Y/W_9L_P"QOU[_ -5]XRP .P'8
M5_<JGW%_W5_D*_C+Z6B<>.N'8RDYRCPAA4YNUY-9OFZ<G9)7D]79)7>B2T/]
M(_V?LHS\+.+YQA&E&?B'F$HTX.3C3C+A_AQJ$7)RDXQ3Y4Y-NRU;8ZBBBOY8
M/[Q"BBB@ HHHH *1L;6R,C!R/48Y'XTM1S21PQ232R1Q111O)))*ZI%&B*7=
MY'8A4C106=F(55!)( )H _&+Q!X ^'/CS]JSXUV-KHWAFR6R^-/PTTWQ;X;^
M(?[5VE> ]9FOCJ7P"^,'B;7O WP5M?@QXVOCX5^,&O?#7X4/J0U3X@Z7JOQ'
MO/A2^DZ&? 6AZIKLGB']H ,#\3^/)R>@Y/4C'!R*_%/XG6OCF^_:DU_5=/TR
M?5/%]]\=_@O>_"R_TK2/V3[K]G&Y^"\B?#2;Q1J'Q2\0^([2?XU?\+$6RE\<
M7<<D.HQ^/&\0)\/'^#EI<^%Y;LWO[6#..??^9ZXXSZXXSG% 'X@_\%)_^4DG
M_!"G_LZW]J#_ -8Y^(-?MVA B0G@"-2?H%!-?B#_ ,%*Y8X?^"D/_!"J261(
MHQ^U=^T\"\CJB O^QY\0$0%G(4%G9549RS$*,D@']J4UW1?+0?VQI8.Q1G^T
M++(.T<X,_;WH ^2=*_;2\*Z[^T=XS^ .A_#GXBZSIGP]T_5%\:?%W3;?PW<>
M"/#?BK1;!-6U/PMK&BGQ"GQ#L88-/N+".'QA-X/'A"\U?4;32[7598IDU%N7
M^!G[:/BOX_\ P_\ 'GC?P1^SGXBN+[PKH/@_6=!\$P?'#]F[7?%GB6[\90)J
M=EX;U>V\,_$_6+/X9^([+P_<6FMWFF?$>[\/2/'.]E8F\O;>:)?+/%W[&.M>
M,_VW=,_:=U/XI_"6S\/:#H,$>BZWH?@"QT/]H!O)FUV%?A7XA^(.E>)[/PSX
MM^#T]IK(75K'Q+X.U/5];T*UL_"5XR75G#XR'8_![]F?Q=X"\6W7C[6/B!^S
MUX>\4>&/V>-7_9T^&-I\#?A1:_"[P@FE76MZ/XETOQMXW\.OXNUV.>\T'6?#
M^GGPAX$\.SV/AKP-9ZMXYCTW4=4;Q:/[( #3O^"A%I)X'M]?UOX"_$+0O&&L
M_$GXF?#_ ,*^!I_'7P0EM/$&F_!JULE^*'Q+;XH3?$>Q^%.@_#?P9XENI/A]
MJ6MZ]XMLKZZ^(,,/AO2-*U)]2TZZN/M;P_\ $G1M4^&-A\5?$-AK/PWT*3PD
MWC'7[#XCVUGX;UCP3IMKITNIZS%XO1;^_P!*TZ70+:WNGU6\L]6U'1C!:R7^
MG:KJ&F26U]/\'>(_V+]&A^'G[).G^$/$7P<\0>/_ -D[X<W_ ,-M)MOC#X8;
MQ?\ "OQYI7B[PCX,T+Q]J7B'PUINOZ7J-OXFU'Q'X&T/QMHWB1[C5I[345UB
MRO+&XD\02ZOINQI_[(]Q+^S]HO[)OB'XV:9!\#M,^'7A/39-4^'EM%X(^*$?
MQ"T#XIR?$&\L]"NM3UKQIX$T7X#'2H-)\%:)\(+SPAK[V7@^Q?PEK'B77O#L
MSV;@'TS^S7^T1X<_::\ ZO\ $#PSX7\8^$+#2/B/\2?AS)H_CO3['2O$+W7P
MZ\7:CX7?69M,LM0U%M.L/$D%G;>(-'L-2DM=>LM+U*UM?$.EZ/K<-]I=K]!U
M\6?L??L_']ESPW\6- USX]^)/C)+\2?CQ\5/C';:IXXU'PB+S0K;XB>([G7$
MT: >']"\.6[71,YN]?N! ;.]UV6\O-*M-(L)H],@^O?[>T3_ *"^E_\ @QLO
M_C] &M163_;VB?\ 07TO_P &-E_\?KR_QW^T5\!_AAXB\!^$OB+\8?AMX)\3
M?%#5KG0OA]H?B?QGX?T;4O%VJVEE=W]Q9Z);7U_#)=/'#92Q"3"P27\EGI4<
MKZIJ.GV5T >S45Y[>_%KX8:;XY\/_#._^('@VS^(?BOPYXF\7^&O!-QXDTB+
MQ1KOA;P9?:-IOBSQ#I>BO=B_O-&\.ZAXBT.RUC48H6M;"ZU6R@GD628*//?#
MO[6?[,/BWP[X[\7>&/V@O@UKWA;X8(9?B'XBTKXD>$KW1?!EMNN$BOO$6I0Z
MJUIIFFW;VEU'8:G<2KIVHRVMU%I]U=26\RH ?0E%>=^!/B[\+OBAX5TOQQ\.
MOB%X,\;>$-:%R-+\1^&?$ND:QI%Y)8W4MCJ%O%>V=W+$+O3K^"XL-2LY#'=Z
M??V]Q97L$%U!+"AHWQ<^%_B'Q7XU\"Z%\0?!NK^,OAQ_PBX\?>%].\1Z3=ZY
MX-/C;2;C7O""^)=.ANFN='?Q+HMK<ZMHB7J0OJ.G0O>6RR6X$A /1*_,O_@L
MC_RC)_;!_P"R7Q?^I=X8K]'O[>T3_H+Z7_X,;+_X_7YH_P#!8K5M,NO^"9O[
M8$-MJ-C<2GX7PXB@O+::0Y\8>%EX2.5F/S,!P.I ZD ^QP]_R/\ (_\ L<99
M_P"IM \'BG_DF>(O^Q'FW_J!7/\ .FD_UDG^^W_H1IE/D_UDG^^W_H1IE?V.
MM$O1'\&A1113 *_I>_X-DO\ DY/]I?\ [(7X._\ 5D35_-#7]*W_  ;-7=M:
M?M(?M+R75Q!;1_\ "B_!WSSS10IQ\2)!]Z5T7JZCKU91U89^1X]_Y)#//^P>
MA_ZFX4^Z\-/^2ZX>_P"PJO\ ^H6*/[*/%\AB\*^)9  2F@:TX!S@E-+NVP<<
MX.,''/I7^7C'\=]=,<9_L'1.8XS_ *_4^Z*?^>WO_C7^GMXQUS1G\)>)U75M
M,8_\(YKQPNH6;' TB]).!,3@ $GC@<GBO\I:/_51?]<H_P#T!:^6\!\]S;)J
M7%"RO'5<&L14R=UO9PHR]HZ4<S]G?VM.I;E]I.W+:_,[WLK?3?2;X.X9XJJ\
M&2XARC#YH\#3X@6$=>IB:?L%B)9*Z_+]7KT;^T^KT;\_-;D7+:[O[M_PO;7?
M^@#HG_?_ %3_ ./4?\+VUW_H Z)_W_U3_P"/5X917] _Z[\5_P#0[Q/_ (*P
MOE_U#^2/Y7_XA#X:_P#1)8#_ ,*,R\O^HWR_JRM[G_PO;7?^@#HG_?\ U3_X
M]1_PO;7?^@#HG_?_ %3_ ./5X911_KOQ7_T.\3_X*POE_P!0_D@_XA#X:_\
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M *B_-?U<^;_XFB\ ?^CFY#K;_EWF76W_ % >?X,^PO@O8?%KPYJ7QW\9Z?\
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M4-/M_P!#A_4_S_K7XKV7B[3Y/BK=_%#Q3XQ_9?\ "/B?Q'XN\):U\1- \/\
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MG/)>"G3PV/RFIA_:YEAZ$LYGAZCY<.IUZ6)HU8YU&OB:.+6!Q4XYHOJ3X]>
MK2V_:;^+_@#P'HFFZ+H]C\8O$'A;P]I4%P-.\.^'K2[\4G1]$L;C5-4NI+?1
M=%M)KJVM/[0UG4?*M+91+>7DC(\C>U?M2_ S1/A=\'O@Y?\ AWPKI5JFF>.?
MBW\/?$7Q$M==T+4]2^*%[H5I\.[_ $_Q7<V^E^(M7%KHUWJNH^,XO!VGVUM
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M3V]G?P1QWEI;SCSH+:>*&;]Y&U?Z,J?<7_=7^0K\9\7G?/\ +GWR>D]4T_\
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MPN/<I8G#IQPF,J*E0KRC[5R4)3E%2O&\>:/,ES1O\145]TW_ .SI\&+7X_\
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M'_K'/Q!K\+?^#DDX_;G^&IXX_9=\"GD9'_)1_BMU!X(]J_=+_@I/_P I)/\
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M&EY>?D_O\CQO^(.<$_\ 0-F'_APK?Y'^;7_PPO\ \%)_^D97[;?_ (;WP?\
M_-[1_P ,+_\ !2?_ *1E?MM_^&]\'_\ S>U_J'^3%_SRC_[X7_"CR8O^>4?_
M 'PO^%'_ !%+B[_H(P7_ (0TO+S\G]_D'_$'."?^@;,/_#A6_P OZN_*W\@O
M_!(O]HC]J;_@G]\!/B%\*_BU_P $C_\ @J!XIU_Q;\7]0^(.GWOPY^$/P;U/
M1X-'O/!?@[PVEK>S^)?CUX5O(]26]\.7<SPP6%Q;?99K9Q>&5I88_I_]O3]O
M;X__ +57[(/QX_9\\"_\$?O^"KVA^+_BCX-C\.Z!JOBWX,? NT\-V=\NO:+J
M9DUB[T?]HS6M3M[3[-I]PHDL])U"8SM#'Y C=YHOZ6_)B_YY1_\ ?"_X4>3%
M_P \H_\ OA?\*^0KYSCL3F_]N59TWF'UNCC>=4XQI^WH2ISIOV7P\J=.-X[-
M774^ZPV09=A,B_U=HPJK+/J5? <DJLI5?J^(A4A47MOBYW&I*T]T[/H?Y>3_
M +#'_!2=F9A_P3*_;;^9B?\ DGO@_N2?^A]IO_#"_P#P4G_Z1E?MM_\ AO?!
M_P#\WM?ZA_DQ?\\H_P#OA?\ "CR8O^>4?_?"_P"%?7_\11XN_P"@C!?^$-+R
M\_)_?Y'PW_$'."/^@;'_ /APK?Y?U?TM_EFZU^R+_P % O#FJ>$=%US_ ()R
M?MF:7JOCW7[OPOX.L+OP%X0CN?$7B"Q\,>(?&EYI.F(/';>=>6_A7PIXCUV2
M-C&HT[1KZ8.6B"-T?_#"_P#P4G_Z1E?MM_\ AO?!_P#\WM?Z4?Q2^$UUX_\
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MFI?L3?"3X8ZIXH6[\<>'["\U;1-<U/0--\*W7@CX5V'A^77CKFJ_'&_N9=-
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MJ:SXSMK3Q?K,"PZKXHL[/7;R_M8?L:@ IK,%ZY]@%+$_0*">.YQQWIU?FO\
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M3:^'/$VG0M%]>?\ !,?5[YK?]HCPJ]W\.=7T/P]\1?"=[X:UG]G#Q7KWC?\
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M7DV*OF.1QO?<V,C/)S-10!%-##<1M%/%'-$V-T<L:21MM(8;D=64X(!&0<$
MCD"HTL[6-&CCMX4C=S*\:11HCR$J2[HBJCOE5.]@6#*K @J"+-%  !@8';\3
M^)/)/J3R>]%%% !1110 4444 %%%% !1110 4444 %%%% !112$A1DYQ[*S'
M\E!/Z4 +12!@<8SSGJK \8Z@@$'G@'!(Y&12].M !11UZ4$X]>3C@$_RZ#W/
M% !1103@9Y_ $G\ADT %%%% !112$@8SGDX& 3^> <#W.![T +1110 4444
M%%%% !12%@N,[N?16;H,\[0<?CC)X'/%+0 44$X_0=">IQV_4] .3Q10 44F
M><<]^QQQ[XP/;/7M2T %%&?KTST/^<^W6D+ #)SCV4D_]\@%L^V,B@!:*0$,
M,C/X@@_B" 0?8@&EH **** "BBB@ HHHH **** $8[1GW4?]],%_3.:_F+\8
M?\'+?PU\(^+O%OA*;]D[XEWTOA3Q7XG\*RWT/Q-\"PPWLOAG7]1T&6\AAETH
MRQ17<FG-<1Q2$R1)*L;LS*6/].4GW1_OQ_\ HQ:_RK_C0K'XR?&'"L?^+N_%
M7L?^BB>)O:OT[PVX;RCB&KFT<VPTL3'"T\'*BE7KT>1U98A5/X%6FY<RIP^+
MF2MHE=W_ "'Q8XKSSA>ADD\DQ<<++&U<?'$.6&PV(YU0C@W226)HU5"SK5'[
MBBY7]ZZ21_:=^R%_P7P\!?M;?M(?"S]G72/V;?'W@K4?B?JNLZ7:^*=7\?\
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M,:]XG\ ^(_$NJ_"KX8_LR^(OB)\(_P!H73_#-AH]Y\4?%&H_$CQSI?A[5_\
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M?B<^!_@]=7OQ;\46'A!_^$)UN^\.:G<^%[R7P3>V4@^=/ ^H>/\ ]I']I/\
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MN_#6O_L45#=1TZ<D?CP1R.QZCG!&32D C!Z<<9(Z=N,<=B.A&000<4 ?F_\
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MZ]\4BS\0:_'XP^)?CC4/"?@A_&OBZRC\)>'+V/P;HR^'O /AEY]9DU/[ HH
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biogenlogostandardrgbr.jpg
<TEXT>
begin 644 biogenlogostandardrgbr.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(                  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
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M P,# P,# P,# P,# P,# P,# P,#_\  $0@!(@-A P$1  (1 0,1 ?_$ /P
M 0 " P$  P$!           )"@8'" 4#! L" 0$!  $% 0$!
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M'ZB B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MT7Y,^[+$^JD]O*I$!%2D] 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M?^4%['_SK-%_OB8]_A@S#]5O,;Z$R7XA_P"\L3_69R^^F<=^.9^^G\H+V/\
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M7BKZXL)02R1D3W,< 2"0X"AH01Y0L3R&N]&8J\?C\ED[*"^B(#XWRM:YI(!
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M:]A+7-/:"""ND5M<P7EM'>6K@^VE8U['#<YK@'-<.P@@A>N/!>Z B B B B
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M("*^5Z3_ -7KVT_-C*/I$S$<S^=WO3S'KH_81+HOR9]V6)]5)[>52("*E)Z
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MKO/EQ*VKKF),Z=*<X/I;:;4L^/ AX75U:V-N^[O9(X;2-M7/>X,8T#I<YQ
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M76F&G'WW&V666UNO/.K2VTTTVDUN...+,D(;0@C,S,R(B+DQ^M:7$-:"7$T
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MJ$7&PY#KB#6E2XK<_"HJ%<$KA;J.2X/DI_\ #7BA?\QQ>N'HV5C-*#]D[@@
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MIZ5+IZ^3(>4G867H2;K[T=;KADA)$7)GX$1#FSSKO;V+FCEXXII6L$T= 'N
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MS_NR9G]*FF!K;XH_=_9_YQ%_AKM;#>&G_OJ[_P IE_Q%JKA T,6\" B B B
MBHN>L=]8_P!QG^J+Z"-8#I)R"]TN)_O7^,N%SRYY^]/*?W;_  ENHR!,*B9
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MH9N?(,T.\(-Q*/>3[_0D_<$B8[Q5861H_.V)NH7=/<RQRCS!XAZ-M*]E3O6
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M?_T8[(_Q=#$"^)#W92_VR#^45.'A[]X\7]DG_DA75AST6^R B B B B B B
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M8>2XI./:+I+RIR+<GRZQ%PT@\%FR$^6"L!]FNXQ'"D% 1 1 1 1 1 1 1 1
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M+D=S2OGAL>)EC;TF22&,#[N0$[^@$GH&PJAO.='+.R;Q/RD;W=4<<TA/W$9
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MF,EZ.;M?,O*^8;FO\7=4I*XZW[C)(A2W&'4J0_7ULM!^TN84Y\:U9I/0TUI
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MP<;G+7#G]R[?G<:-7XAG%E+*.DS6C;) *GBV;W0U)[8R[:>!H51,;U+2A 1
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MN=0C>_E5RFLM VWYQOBV?4\T='O'Q(FFA,<5=^T#CD.UU-@:W896A":F1 1
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MR%A>9.?)W\#YX(;R"R%M>,B:Y\C(W6Q[ZV<X,<(B>)H=1K@1M6R/YP-VU?\
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M2 ]RRAV.!DXAMHTD44IZ8Y+Z]U*]KQ:.LK$G;+<UB%.ML9'>NJ/BD,X3LJX
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M^ ;^C<7PQ36IQ&5MV@?/&W,3G'I+',<&>8.;)\)W=-B\:H+:% 1 1 1 1 1
M1 14FO6?[9L1[>>[%%QKZKAT.&[HQ-G8;6/UT9,.LH<J*UL:;+8-5%:23$>N
MG2H3-DEM!I0R[/<:;0VTAM(Z(>'W6%]JK1!@RCW2Y#'SF O<:N?'PM?$7$[2
MX F.IVD,!)+B2M!.?&D[+3&L^_QC&QV-_")N!HHUDG$YL@:-P:2 ^@V O(
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M.2U'*TALTC((SV1@OD/:"7QBO6TCK5D,:DK:= 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M@[231TA <X !K6R1B)%*B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MC$DL>V1H>P@L(J"-H(["H\<US'%CP0\':#L(\H7PCZ7R@(@(@(@(@(NA]/\
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MV]MO=3:YY^ND>:O>[J+B:#8*"@6[1CJOZ B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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'@(@(@(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biosimilars.jpg
<TEXT>
begin 644 biosimilars.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M/K;4/A+I,FD>!/"-SKGA;X=:9H>D0:UH,&J^!#X!N;S5O[0ZC]K[_@GQX/\
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M"C[=H^HI$-:M?&W@SXX>-M,U>%KZQGT/41I&NZ%=07NGLD_-1?\ !/+PM9^
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M\R%O+U.$\Q:@FV\C_@F7)J?4M+TW6;&XTS5["RU33KM!'=6&HVL%]97,8=9
MEQ:74<UO.@=$<++&ZAU5@-R@@ _FHT#XH7&K?!/Q==?&7X]_$_P_XI^'W[)G
MB'6OV.-;B^-7C2U'C[X^^&?C7^U?X1\2:[\&M<LO$-A>?M5/I.J>%_V>_!GP
M;F\;CQUXA^)OP6U[P!XAUWP[=WGQK\80:I^]6F?$/1O$GPJ\96GC#XE^&?A_
MXW\">!;2Q^.^J>&/%GA=;SX"^+]7^%VD^-]:NM9O-;34]'\*7GAS0?$-GXWT
MB;QAITFFCP[-HWB&_LKO0[H&?VN?2=,NOL!N=/LK@Z5<)=Z89[6"8Z==QP36
ML=U8&2-C97,=M<3V\<]J894MYI(4<1.R'.M/"?AJQF\47%KHFFQS>-;U=1\6
M2&UCE;Q#>)H>F^&8YM6$PD6]$?A_1],T>.*96A33[*&V6,1A@P!_/WHOQ.\&
M:SX;\=^,_P!GKX\^)Y_V0?$'C']D7P3\1-2O?VFM<^('Q'U+X<WOQDU)/C=^
MU;J-]>>/?$/Q"^"'@;XE^&-6\)?#W7O&=QJ7@+7=<\&#QO\ %^_T?P;9:'X4
M\47^G\:?B3I/A7]E+]JBX\-?M7>(? GP(^'_ .T;H>G?LR>)T^.>GV,GQ/T"
MP\&? 37?&OPV\/\ Q@\8W]WXV\8?"[P!\9-1^*>EI9^#_&[R:AIVEZG\+K_6
MI_A]X:N- O?WDT/P!X&\,OJ$GASP=X5T&358O(U231?#FBZ2^HP[I&\F_?3K
M&V:\B+2RDQ7)E0F20E?G;,NI^!O!FM:?IFDZQX2\,ZKI>BA%T?3M2\/Z/?V&
ME+' +6-=-LKNRFM;!8[8"W06D4(6 >4N(_EH _"[]LWXO:\OQ,^(WBKX5?%#
M2?B-\0/$WA3X,ZO^Q1=_#O\ :DM-%M_ .N7FLRZ%>:%)\ _#WB5+CXWP_%[Q
MO9ZBH\0^'O#'Q+T+QQH,M_\ #?X@7OPT\-?#V3Q!=_:__!0;]J?QS^SMI7@/
M2OAKXB\,:%XR\5Z-\4/%UC!XQT7P4=&UVP^&%IX5GET5?%GQ&^,'PG\,Z;>W
MU_XKTN!?"^A)XV^)OBW2Y=1O_!GANTL/"_BCQ%I7Z"V/A7PSIBZ,FG>']#L$
M\.PW5MH"V6D:=:+HEO?!5O;?2%M[:(:9!>*B+=0V(MX[D*HG60 "M&]TW3]1
M-H=0L;.^-A>P:C8_;+6"Z^QZA;!Q;WUKY\<GV>\@$D@ANH=EQ$)'$<BAVR ?
MC#X._;O_ &DO$1T?XKMI/PZO/A[JOQD^ 7PJL?@MI'A?6SX\U:3XZ_L'_!K]
MIGR;;XB7OB>"UM_$6C_$GQ]<^&O#%DW@J>WUG0+G['K(M]2DL=1L.W_89^./
MCCXX?M%>)O%/BKXR^!?BC;^(?V*/V9O'=YI/PLL]6T+P1\._&/C7XH?'[4O$
M?@F?0+SQGXOAB\3^';9=)T*[OM4.C>/I-*T_2[?QMI5K<Q:;N_61-)TN,*L>
MFV"*EQ;7:*EE;*$NK.VBL[2Y4+$ L]M:006MO,,2P6\,4$3I%&B*MII>FV#S
MR6.GV-F]S/<W-P]K:6ULT]S>7#W=W<3-#%&TL]U=.]S<RR%I)[AVFE9Y6+D
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M$:X_8[^(!;="DUNSY4,HQ,FTD,=P7:W[31V_B+8G_$VTC[B_\P&[]!Z>(,4
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M;+&^TR[$%S$LT0NM.U.VL]1L+@(X$UG?VEM>6T@:&Y@BF1XU /Q/_P""D_\
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M=6\56&A2>'X9[/7-4$5N ?J*#GUZD<@CH<=P./0]".02*6OS _X)7>(-6O\
MX/\ QIT75_!_QN\)CPS^UM^TU9VL_P >;C2[WQAK8U/XK:]K%[=S:G8>,_&(
MO[N'4[N\&N^5<6&C6.N7-YI_A>T/AVVL"GZ>>9'_ ,]$_P"^E_QH ?13/,C_
M .>B?]]+_C1YD?\ ST3_ +Z7_&@!]%,\R/\ YZ)_WTO^-'F1_P#/1/\ OI?\
M: 'T4SS(_P#GHG_?2_XT>9'_ ,]$_P"^E_QH ?7YJ_\ !8.66#_@FM^US+!+
M+!*GPRB*2PR20RH?^$N\+C*2Q,DB'!(RK X)&>:_2?S(_P#GHG_?2_XU^:7_
M  6'=#_P32_:[ =2?^%8Q<!@3_R-_A?L#FNO ?[_ (+_ +"\-_Z>@<69?\B[
M'_\ 8%BO_3%0_P \636M9\R3_B<:O]]O^8KJ/]X_]/-,_MK6?^@QJ_\ X-=1
M_P#DFL^3_62?[[?^A&F5^NJ4K+5[+JS\2Y(?RQ_\!7^1I_VUK/\ T&-7_P#!
MKJ/_ ,DT?VUK/_08U?\ \&NH_P#R36913N^[^]AR0_EC_P" K_(T_P"VM9_Z
M#&K_ /@UU'_Y)K^D?_@VHO[Z\_:/_:36[OKV[5/@?X/9$NKRZN51C\1) 619
MY9%5B."R@$C@DBOYI:_I._X-H"%_:0_:5+$*/^%'>#^20!_R467UQ7DYZW_9
M&.U?\.GU_P"G](]GAZ,5G6 :C%-596:237[JHNW8_L8\27<ECX?UR\B5'DM=
M'U2Y19-VQGM["XF17VE6VLT8#8(.TG!!P1_ LG_!9W]H1HH\_"[X+_-&A($'
MCL#YD!(!_P"$LR!SQSD>N>:_O=\821GPIXEPZ?\ (OZW_&O_ $"KSWK_ "HH
M_P#51?\ 7*+_ -%K7!P)F>/RZ&9_4L54PWMI8/VOL^7W_9K$\E^:,OAYYVM;
MXGY'?XCY+E>;3R=YE@J6+=".8>Q=1S3IJH\%SVY)Q^+V<+WO\*Z7O]^3?\%!
M/B+<?%F;XO3^"?#UQJHE@U?3/"%YXX^*NH?#?0/&UM=>*KNV^(>@^#=1\6WE
MI8>*K&;QEKUSI5J;B;PCHNK7]WK^E>%[76KNXO&H^ O^"@WQS\"V_P 6;2;4
M+SQS9_&A/%,_C.U\=>(3=(NO^,?#6D^#]:\7:#/X3\/>#KW1O$A\-Z'IFFV4
MR7=QI%D+;[7%HOV]WNC\*45]?''XR,N>.(G&7/5J.T::3G6@Z=5M*%GSPE*#
M5K*$I12478^$ED>4SAR5,#2J15*C07M'4G*-'#SC4HTXRE-RC&%2*FN5IN:4
MY-R2:_2;5?\ @IM\5=8\'^$/AW=?#;X=1_#WPIX-U/X>7G@6RU3QY9>&/'?@
M;5/AI=_"N7PK\0[&#Q"L_B'2+3PY=F^TV*SN]%FL?$MO9ZW%.6MEM6H^!?\
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M:/\ P6(_Y1I?M=_]DQB_]2_PM77@/]^P7_87AO\ T] XLR_Y%V/_ .P+%?\
MIBH?YV$G^LD_WV_]"-,I\G^LD_WV_P#0C3*_7([+T7Y'XH%%%%, K^D;_@VI
MLK*^_:._:3CO;.UO$3X'^#V1+JWAN%5C\19 659D<*2 ,D $X'H*_FYK^D__
M (-G_P#DY']I7_LAW@[_ -6++7DY[_R*,=_U[I_^GZ)[/#W_ ".<!_U]E_Z:
MJ']>WC#P_H*^%?$I71-'!'A_6\$:999'_$JO.A\CBO\ *WC_ -5%_P!<H_\
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MA\;:=J>M^'(_"NHZK]AUN2]\2>%_$]GIK^'[/0M,_07_ (-H1C]I+]I<<<?
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MM=2#J/"5</[1)\G-4IS@I6>MDY7:WLC^%&3_ %DG^^W_ *$:97]CQ_X-6/\
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M^/\ HN/_  4"_P#$K)__ )@:/];<-_T"5_\ P.G_ %W_ *>A_J7BO^@W#_\
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MPK.I7E64H1E%)2I48<KYM;ITV[]FC[5HHHKR#W HHHH **** "BBB@ HHHH
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M\1?C=XCO/^$#\(3?"*P^&WBCQYX-^*/@B>Q\1^+;>/Q[\6?AKKWPQ\=IXO\
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M/B6YU3PE\%M/OO$'PX\/ZH8K_5M1\<MHOA5?#WZX0K.MO$LK0M<B)1*\22)
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M^F5?6\,83"XE8WZS0I5N1X90]K",^7F]OS*/,G;FY5>V]EV/B^+L9B\(\O\
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M_"?@_P #^ _"K?&+7?A]X.\%?$O2/C5H7A/P?H?@Z318(+W1M6@\1^D_$/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>collabprofitshare.jpg
<TEXT>
begin 644 collabprofitshare.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MI^(K;PS<2^,+SX?^)W\-Z;X?OIKNSNI_$][J%NG]@Z?I#R:U=WT2#3();E%
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M[SP;HGBW2OB)\,O$7Q!LO!NE^+M*@T;5?$.O>$_&_B#3_AW8Z_K4MGX_>QT
M>+H_N"YT+1;RUN;&[TC3+FRO+"+2KRTN-/M)K6ZTR 3"'3KFWDA:&XL(A<3B
M.SF1[:,32[(E\Q]U];:W6W6U6&);98A L"HHA6$)Y8A6( ((A&!&(PNP1_(%
MV<4 ?SO?#CQQ'+>_\*S^)GQ L-#_ &61^V->Z/\ $77/AS^TW\0_B%^SSH.F
M:U^R,?$_PO\ A9X<_:;\1:EX.\<Q>$->^+FDW?B7XH>&=2O_  WH6@_%G6/
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M?%+6[CQG?7NMZ9>:3I<OA[0KJUTZ?2M.UZZN-7FMK::RM;1I[^#Z>!# ,.A
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M9?C,-C:4)NG.IAJT*T(U%&,W"4J<I)249QDXMW2DFUJA6:W5@HHHKM ****
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MOC;P)/X3T[XM>.-3;4-+?2O$">(-%^%(T*#QF]KX_P!4O]%T73/<_@YX5M/
MOPH^'7@RP\#Q_#6R\+>$=(T.W\ Q^+(/'I\*)8Q-&VEW'CFWCBC\97[2F34-
M5\4E!/K^K7U]JEXTE[=7,LGI-%>=4Q+G0AAXT:-*$9^TE*G[;VE6=I).LYUI
MPGR*4E32A'V:E/DY75K.H7_K^M?76WD?57P(_P"18U7_ +#TW_IOTZNS^)O_
M "(?B;_KP7_TI@KC/@1_R+&J_P#8>F_]-^G5V?Q-_P"1#\3?]>"_^E,%?T/D
M_P#R;E_]D_F7_J/B@CNO5?F?$;=3]3_.DI6ZGZG^=)7\WB"BBB@ KW?X#?\
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M%ZS_ /2S4*_//_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]#/C?\ \C3IO_8O6?\
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M^4O_  _#_P""4?\ T>9X+_\ #<?'_P#^=!1_P_#_ ."4?_1YG@O_ ,-Q\?\
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M .CS/!?_ (;CX_\ _P Z"C^P,^_Z$F<?^&S&_P#RCS_/LP/V5^&7_(^>&_\
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M<WAOXL_M$^+?V5?V&?$&O^/?C1>Z5X_T_64_:+^+'P0^'WAKQ/\ 'F_U/3=
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M=^'?P\-O^T7\8?@_\<?BG\,=%^-_Q,B\0Z!XA@3X'^+_  QX8^'_ (C^(/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>costofsales.jpg
<TEXT>
begin 644 costofsales.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M/$/Q!\'_  Y_9RLK;PS)JWPO\4?&"[\>6>B^(UU3XCW/@GP/XCOKNTTC2=2
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M?%+6[CQG?7NMZ9>:3I<OA[0KJUTZ?2M.UZZN-7FMK::RM;1I[^#Z>!# ,.A
M(^A&:_$'_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"* 'T444
M %%%% !1110 4444 %%%% !1110 5#//!:PR3W,T5O!$-TDTTB0Q1J2!N>61
ME1!D@99@,D#.2*FKYY_:N ;]GCXJ!@&!\.+D, 0?^)IIQY!R#SZBNW+L(L?F
M& P+FZ2QN-PN$=51YW36(KPHN:AS1YG#GYN7FCS6MS*]SS<XQ[RK*,TS14E7
M>79=C<<J+G[-5GA,-4KJDZBC-P51T^5SY)<M[\LK6? Z'^R)^QOX6T_XMZ9X
M4^&'PV\(VWQQU&WU+XDR>#KJ/P=J&M/:Q:"EO8V>L^%-3T76O#NC0W'AW3]3
MCT3PUJ.D:4NL/J.K"T^WZMJ4]R?#W]DS]E+X3Z?\/=%^&_AK1?".@_"_XDO\
M6/!N@V/C37+_ $K1_&O_  KOQ9\+H;^RMM?\2ZP;&RMO"/C7Q!9PZ+I\EIHW
MVB[%\]@]VGFM_.W^T)\;=)^ O@ZS\2W/AE/%&K:[K+Z!X;T637O#7@O2[W58
MM,OM;GCU;QAXIGM=$T.,Z7IE\=.A87NJ:YJ@M=(T;3+RYGE>UR_B3\=;SX:6
M>EZSK'P?\01:'+9:+=ZW_:WC'X9:#XJMK[6M;_L1_"?@7P6VO:KJ'Q<\<:&S
MVNJZQH'A"_AM;C2=0TIO#.L^)-4U*'2H_P!8J^%^64)UJ=7B2M&6&A2J8CER
M>K4C2A6NZ;G.GBY17,H3DU?FA!J<U&#C)_@E#QQSG$TL+6H\&X:4,;5K4<+S
M<1T*4J]2@Z4:L:<*V!IS=I58PC+E4:E3FI4W*I%PC_3-X/\ V??V7/ $/Q M
MO!GP_P#AGX<MOBAI=]H/C>WTM;"W@UGPYJ/]J/=^%TA^VM'I/A66XUS7+Y?"
MVA+I7AV'4]:U?5(-,BU'4[VZGU/'7P8_9W^)/A#PMX&\9^%_!.L>&_ T=E%X
M*M1J"Z=>^#TL-*70;?\ X1;7-(U33_$'AX_V&O\ 8UPVD:K9O>:2\FG7K7-G
M+)"_\OVG?M$:'J7QAU#X26_A&-KFP^)6K_"62Z3QCX0F\:_\)/HNAMX@G\1S
M_!N(GQU9?"6]L1"=)^*%RRZ;?P7VE:P-)A\/ZK9:K)T_PU^,WAWXH^-?BGX5
M\/Z'<IIOPV?P6;#Q9+-I\^E>/;/Q='XN@?6/#-K;QFZBT33=<\$Z_HEKJ5W*
M\?B/[)_;.E(NCSV-S>.GX7975G&G3XFG.<J]7#1BLJDG*M0I^UK15\8O=A33
M;J_PFY1A&HYRA&2K>..=8>E.O6X*I0I4\+A\;.I_;T)1CA\56AAZ$FX9?+]Y
M4JSY50_WA)3G*E&G3J2A_1O)^S3^R3+IEUHA^%OPD71+OX=^&OA3-HD=AH\.
MC#P%X.\7ZE\0/"F@0:3#<1Z=:)X=\<ZMJ'C'1]2M+:#6K#Q1/_;UOJ::I%!=
M1>G_  B^&OPD^$GAVX\'_"+0/#?AO1Y]3N_$6K6NA7"WE[K&NZC':VM[XB\1
MZI<WFH:WX@UV]M[&QL[G7=?U#4=4N+6PL;.2\:VLK6&'^6*U^.NGW/BVQTX^
M!=0A^'VL?%;5_@7HGQ2.M>')+'4/BKHDNLZ?<Z0_@Y0OB"R\+7WB;P[KG@?1
M/&;W,\6H^,-.-E-H=AHU]INOW?[#?\$[TC'Q ^(11(USX,TKE(U0D?V\Q )5
M02.<X->=G/AUA,MR;,<UP^=U,6\!&#=&67/#JHYU:%--5)8J3=.4:O/3K4Z=
M2E47\.4DFU[/#GC!C\ZXCR?(<7PS2R]9M4J06)CG$<7*BJ="O5DI4:>"@E6C
M.@Z=7#U:M&O1<KU:<7RQ?ZVT445^5'[J%%)D8SD8]<\?G2T %%)N7.,C/ID9
M_+K2T %%%% !1110 4444 %%%% !1110 4444 ?B!_P4G_Y22?\ !"G_ +.M
M_:@_]8Y^(-?MY'_JX_\ <7_T$5^'_P#P4L$Q_P""D'_!"GR#&)/^&K_VG.90
M[($_X8]\?^;PC*Q;RM_EC<!YFW=\N17[01IXH\N/]YH/W%_Y9:E_='_3Q0!T
M=%<_L\4?\]-!_P"_6I?_ "11L\4?\]-!_P"_6I?_ "10!T%%<_L\4?\ /30?
M^_6I?_)%&SQ1_P ]-!_[]:E_\D4 =!17/[/%'_/30?\ OUJ7_P D4;/%'_/3
M0?\ OUJ7_P D4 =!17/[/%'_ #TT'_OUJ7_R11L\4?\ /30?^_6I?_)% '04
M5S^SQ1_STT'_ +]:E_\ )%&SQ1_STT'_ +]:E_\ )% '045S^SQ1_P ]-!_[
M]:E_\D4;/%'_ #TT'_OUJ7_R10!T%?/7[5O_ ";S\4_^Q<7_ -.FG5[+L\4?
M\]-!_P"_6I?_ "17@7[4:Z\/V?\ XH_;'T@V_P#PCJ^8+:.^$Q']J:;]PRS-
M&#U^\I].F:]CA[_D?Y'_ -CC+/\ U-H'SO%__))\3_\ 9/YS_P"J[$G\XGQ^
M^%^N_%_X<:UX'T'Q5I/AJ;5$:&\MO%'@G0_B%X*\1V3R0,^D^+?#&L"&>XM(
M)(8]1TV]T;5-,U"RU.WB$YU#3;B\L9/)_$/[*MUJG@'2/A/8_$/23\/K#0!H
M47_"2_"+PKKWC?P5<2ZMJNJZAXF^"'BNTUC1$^$VNW0U*WT_0H1IGBO3OA[8
M:!X;B\&I:P:/'9W'V"W4_4_SI*_K*OEN#Q-6K6K4ISJ5J$<-4:Q&)@I4(RE+
MV2A3JPC&$I/FFHI*<E&<KS2D?P-AL[S+!X>AAL-6ITZ6'Q,\923PF#J2CB9Q
MA#VSJ5</4G*<(P4:<I2;A&4X1:A)Q/D'4?V3K#5_&T_B#4/%.EC2Y_B-XF^)
M3Z_IO@==(_:#FN?%8UR/4? =Q^T-8>*HM?\ ^%;PV&MGP_::5:^&K75(O!^D
MZ'X434(8=*M]4%WP)^R[+\(M:^(WB'X5_%GX@6FI>+? /PF\ ^$[3XGZ[XC^
M+?AOP/I_PM.K6UO.?#^M>(]+AUXSZ)JLFB>'XOM6COX1M#>K:3W\.HW5LWUC
M141RG+X356&&4*JG.I&K&I556$ZE*5&3IU/:>T@O9R:BH248R4:D4JD8R5U,
M_P WJTW1J8QSH2I4Z,J$J.'="=.E7IXF$:E'V/LZK]M2A*4JL9RJ1YJ51RI3
MG"7SM;? 26W\561_X3%)/A3HWQGUC]H+0?AT_A>$ZW8_$G5]3USQ&EI=>/&U
MMDO? >C^-O$FK^/=(T%/"-GKD?B*:TL;OQ/<^'M-M]-D_8[_ ()X #X@?$(#
M@#P9I0 ]AKI K\^J^^O^"?POSX\^(/\ 9[6:R_\ "':7N^V+.T97^WN-OD.C
MAOO9))'08ZU\[QGAZ.&X1SU48.*G1H-KGG.UL7A8QC#GE+V=*"5H4:?+2IJ_
MLX1N[_9>&F,Q.,\0N%7B*BFZ6*Q,8M4Z5.]\!C93G/V4(>UKU9/FJXBKSUZT
MK.I4ERQM^NU>,?M":W\0?#WP<\=:G\*;WPG8?$6/2[:U\'S^,]0T_2]%DUS4
M]7TW2[2RBN]8GMM$&OZE]M?3O"-OKL\6@WOBZZT*QUMQI-S>9]'V^*!UET'_
M +]ZE_\ )%<WXCT2'QCH6J^%_%NG_#WQ3X:URRFT[6_#OB/31KFA:QI]P-MQ
M8:KI&IO=:?J-E.H"S6EY;S02KPZ' K^6TF]DWZ)O\C^Y7*,=Y)7VNTK_ '^J
M^\_"_P"'/[67[1WBGX,_L_\ P_\ #WC#]I[XB?&#4?B7XKC^,7@/1_ O[-'A
M+]L=?AGI_P &['QKH&K>%_$WCNZ3]E'6?!]IX@\3^"M9UWQU=ZGX:U36_#?B
MS1O!>@74OC?2M3LO$&I;_MC?M._$/P=)X@L/%/Q;TC3_ (#_ +,G@WXR?%[7
M?A?\//@?IVIP>([[X@_M#>%?B'<_%+P[\<(=(C\777P<7]G_ %+P7XW^$?PC
MA^&NI>(_'EE\4+W2?$/AS3T^%-K=?I3I'[$W[-6@?"OPY\%]$^#GPATKX?>$
M=7N?$'AS3=/M=6T_5M*\0WUFNFZCXBM_%FF:I8^*U\0ZII*1Z+JNMC6EU+5-
M#A@T6_N+C2H(K--[7OV2OV?/$NG> M&UGX,? R[T7X9Z<FB^"]%7PU]DT?2?
M#ZWL.IGPS)I5C<VNGZMX6EU>VM]:N?#&N6VI^'[O6X(=:N=-FU2-+P/DG_++
M_P !?^1/M(?SP_\  E_GYK[SR?1;?Q_XB_;:TJR\%_M(_&W6?AUX?^&T/QW^
M*/P_U=/A#+\,4TOXK/XE\%_!/X<>'["W^$^F_$?2[+4;SPIX^^(]]?:AX[N-
M?TN/P/X=TBZFU"R\77_V7@_VJ?C)\;--\7_M877@'XJ7WPFL/V/?V5O!O[0G
MAOPZOAGP;K.B?&'Q/K\'QT\07\'Q+N/%/A[5M8?X8K9_!NT\!6MGX!U;P;K]
MKK6M^*]8D\1RZE8^%X-/^^].\)Z?I'BOQ/XXTW3_  /9>+?&=EX;T[Q3X@@C
MO5U+7;'PA'JT7AFUU"?[8?.AT6/7M86Q3:HB&HW6=QDR/$)?V0?V>I]*^&&A
MS_![X,7&D?!O3;71/AS87.DWUQ;^'M!LM2MM:L_#VR;47.K^'K37;*QU^VT#
MQ =7T>'7]/T_7([%=6L+.\A.2?\ ++_P%_Y![2'\\/\ P)?Y^:^\^I?#.K3Z
M_P"'=!URZTN]T.YUG1M+U6?1=2V_VAI$VI6%O>RZ7?!/D^V:=).UG=;?E\^"
M3'&*W*Y=)]>9@D=YX99F)VHAOF9CR3A1=$D]2< GJ36Q8C5!YO\ :36#?<\G
M["MRN/O>9YGVB23.?DV;,8^;=GC"::W37JK?F4FI:IIKNFGY]/)IFA1112&%
M%%% !1110 445%.KO!,L<I@D:*14F5$D:)V1@LHCD#(YC8APC@JQ4*P*D@@$
MFY>?F7@X/(X/H?0^U+7XX_$KXY_#+PG\5KGP0-9_:T\5>+M#^*D7@KQY\0],
M_:"U+PQ8^$K(:S^SWX/F\:Z?\(M/\26O@G6=('Q%_:8^'?A/2/"'_"I;(>*1
MHWCK6='T_5]*T'3?^$H_8#3+:YL]-L+2]U"?5KRUL[>VNM5NH;.VNM2N((DB
MFO[FWTZVL]/AN+R1&N)H[&SM+-)9&6UM;> 1PH ?B=_P4G_Y22?\$*?^SK?V
MH/\ UCGX@U^WD?\ JX_]Q?\ T$5^(?\ P4G_ .4DG_!"G_LZW]J#_P!8Y^(-
M?MY'_JX_]Q?_ $$4 /HHHH **** "BBB@ HHHH **** "BBB@ KYZ_:M_P"3
M>?BG_P!BXO\ Z=-.KZ%KYZ_:M_Y-Y^*?_8N+_P"G33J]CA[_ )'^1_\ 8XRS
M_P!3:!\[Q?\ \DGQ/_V3^<_^J[$'X*MU/U/\Z2E;J?J?YTE?V ?YXA1110 5
M^@W_  3Q_P"2@?$+_L3=*_\ 3\:_/FOT&_X)X_\ )0/B%_V)NE?^GXU\GQU_
MR26=_P#8/1_]3,,?H'A7_P G!X8_[#,1_P"J_&'ZLZO_ ,@O4?\ KPO?_26:
MOY=O'7C?1?AQX-\0>.?$DEZN@^&-.CU#4OL$<,]XT4MW9Z?!%;I=W=C9(\]]
M?6L!N=1U#3M+L8Y'O]6U'3M+M;R_MOZB=7_Y!>I?]>%[_P"DLU?S#>(],O\
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MO_\ @FO/_B* -^BL#_A((O\ H%:__P"":\_^(H_X2"+_ *!6O_\ @FO/_B*
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M/AQXTA^(G@7PMXWM]/GTJ#Q/H]KJ\6G7,\5S/9I=!B()9X56*5TV\O&H4YX
MKRLVX8SS(Z-/$9I@)82C6J^QIS=;#55*IR2GRVHUJDE[L9.[2CI:]VK^[D/&
MW#'$^(K83(\TAC\1AZ'UFM3CAL;0<*//3I\[EB<-1@_?J0C:,G+6]K)L[7 ]
M!^0KXP^-G[9&D_"+X]_"[]GO2/A5X\^*7C/Q[8Q^(]=B\&:AX%LKKPAX*N](
M^)M[8>([+1/%WBOP[K'Q N3>_"SQ)'JN@^"K;4K[1-)MQ?7\@U?5?!_AOQ9]
MH5^=7[:O[$/B;]KCQ=\*+EOB%X*T3P/X.U+4[G5M.\3?";1O%?CSP5=WW@KX
M@>'!X_\ @#\1(-2T/6_A]\3Q>^*= N[35=:;Q+HWAW5_"/A;QOX?TZTUKP]>
M:3XL\$^J/9?$7[6W@G0OVE='_9K@\-^*]>UJX^'/Q'\<^(O%F@6,&JZ#X8U?
MX?Z;X!\1+\.9]/LY+CQ'K?CW7_!WC_2O%]EHF@Z7>/8:)<Z"^IM#=>+_  U;
M7O#^&?VV(I=1\1:#\2?@!\;?AGXMM/AAI7QE\&^!7T31/B+XX\;^!M<\6V'@
M.PT^+PQ\,M8\3WWA?XA6?B[6-"T?Q!X/\4&PL="&M1ZG/XJGTC0?&U_X4\ZC
M_P""=5OX7_:3\&_M'_#KX]?&#3+_ ,*:G^TMXON/A_XS\5:CXR\"Z[XY_:#/
MAB]EFO[19-'U8>"](U;P[%)?>$O[5DEN]*LO"^BZ)K7AW3_"NG0->^!_[._[
M8OPNL?BQXE\5?%C]FGXB?''XC:+X86X^+FH_"#XPVESJVNZ%K;R1:9KF@R_'
M2^MM"^$_A_P[JGB6T^'WPK^'ESX5TOPOKFL77B34]0\2Z]K7B_5_$P!]6_#?
MX]>#O'O[.?@G]IC4X+SP'X%\6?![1/C5J-OXF:SGU#P=X6U3P?#XUOX=?DT*
M?5-/FO/#VDO.NJR:-=ZE8R36<[:;=7UNT$TOG/P*_:JA^+WBZU\$^)/A/X\^
M#_B#Q5\,K+XX?#&R\;W'A:_?Q]\(KW5=,T:?7H_^$4UK6AX8\3>&K_7_  HG
MC/P/X@,&IZ!'XR\,O!?:N]QJT6C>=?!C]F#XV>&/V9?AK^RW\7/B/\(/&/@+
MPUX+U7X*_$&7P;\+_''AC4?'_P #G^">H?#C2-+TNYUOXK>)#X+\?_\ "5W-
MIXCUSQ.R>)="OO#5O<^%]-\+Z3J5W%XFL^Q^!?[-/Q \"^/?#7Q#^+_Q8TKX
MHZ[\,/@LW[/GPJET#P+/X&%KX$O]9\):YXM\5>._MOBWQ@?$?Q*\<W?P]^'\
M>NW^@_\ "*^$[%/#$TFB^&K7^W;F&Q /LO ]!^0KA/B: / ?B;  _P! ';_I
MY@KO*X3XF_\ (A^)O^O!?_2F"O)S_P#Y$6=?]BG,?_4.L..Z]5^9\0RHDJRQ
M2(DD4JM'+%*B212QE@QCECD5HY(RRJQ1U92RJ2,J")UN+E/."7-R@N-QN EQ
M,HN2V[<;@*X$Y;>^XR[]V]]V=[9B;J?J?YTE?R+_ %_7W+[A$IGG:);=KB=K
M=#N2W::5K=&!8[D@+F)&RS'<J Y9CG+-E$EEC*-'++&8RQC,<LB&,N,.8RK
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M%R=J@D LV!D@9R11_P 1]\(?^BTPW_AJX@\O^I1Y_P!:7?\ Q"7Q$_Z)JO\
M^%^4>7_4P\_ZLS%_94_Y.%^%W_8;U#_U&M<K][%  & !P/Y5^1_[/WP&U'PK
M\9/ ?B";Q+IU[%I>J7D[VL.FWL$LPDT35;4*DLL[QH0UP')92,*0.2*_7 <
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MPU26SMI=1L;*]?4K.ROI(4>[M+749+/3I+^WMIS)##>2:?8O=1HLS6EN7,2
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MW'>V=K>(FE6[HEU;Q7"(YO"I95F1PK$  L "0,9Q7B5>[_ ;_D.:[_V"+?\
M]+6KZO@;_DK,D_[":O\ ZB8@:VEZ?JCZ#N?#^@"WN"-#T@$0RD$:;9 @A&((
M(@R"#T-? @Z#Z"OT2NO^/:X_ZX3?^BVK\[5Z#Z#^5?<^+O\ %R#_  YK_P"\
MP0M%%%?C8!1110!VWPX@AN?&_AZ"XABN()+J<20S1I+%(!8W3 /'(&1@& 8!
M@0" >H%?:UIIVGV'F?8;&SLO-V^;]DM8+;S-F[9YGDHF_9N;;NSMW-C&3GXN
M^&7_ "/GAO\ Z^[C_P!(+NOMVOWWPF_Y$>8?]C>M_P"H67@%%%%?J8!1110
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M20V7_!13XE6T;RE50RND6@JK.41%W$$[549P*FNO^")OAB^MY;2]_P""E_\
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M,59H+NRO(I[6YA9E5C%-$Z$JI*Y QS_V7EG_ $+L!_X28?\ ^5^2^X=WW?\
M7_#+[C\0E_X(3_#)MQ'_  4/_P""OX'F2  ?\%!_B'@*LC*H^;P^Q^Z!U9CZ
MD]:=_P .)?AE_P!)$/\ @L!_XL(^(7_S/5^YG^?SZT4?V7EG_0NP'_A)A_\
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M73_%_C4S1WWQ#\41:O:#Q5-I/AM9='MI]%EO]5 /L2BBB@#Y&^-/[7O@_P"
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M/$OC?PM\"_B!/XR\(^,='\4:WX.L_&>NVV@^+].T9K'6?A]X@\7^$?A_XO\
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MKVRN8UF2.54N+6>*9%ECCD"N Z(P*C2H **** "BBB@ HHHH **** "BBB@
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MQ3X2DGM/%%Q<^)IF\3KN0?L._&NS\=>+?C78_M&>"[;XW^/?$OQ*N/$>M3_
M0:K\.M/\%_%OX/\ [-'PO\2^'/"_P^U/XHS7EOK/AW4/V8O!_BSP9XA\3>+O
M%-C(NJ:WX<\:^'?%.FWB2V_Z;T4 ?.WP;^">M_"+Q]\=]:B\7:9KW@GXP^-]
M ^)FG:)-X8FT[Q9X;\9Q_#KP3\./%R7_ (CM-??P_KGAS6++X=>&]8T'3=.\
M%>&+GPY?WFOV4MWJ^F2Z1#IGT3110 5^7G_!197;4?A-M1VQ9>,\[49L?O\
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>equityinlossofinvestee.jpg
<TEXT>
begin 644 equityinlossofinvestee.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #5 3T# 2(  A$! Q$!_\0
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M5%UN/3+7P_H]OIR:RKHZZLEC#91VBZFKQQNNH+"+Q616$P*@CJP,<?Y_S[T
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MZ5]Q?^7^V]!_TTH WJ*Q/^$E\/?]!O2O_ ^V_P#CE'_"2^'O^@WI7_@?;?\
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M))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!% &/]F\0_P#07TK_ ,$5S_\
M+ZC[-XA_Z"^E?^"*Y_\ E]6W10!B?9O$/_07TK_P17/_ ,OJ/LWB'_H+Z5_X
M(KG_ .7U;=% &)]F\0_]!?2O_!%<_P#R^H^S>(?^@OI7_@BN?_E]6W10!B?9
MO$/_ $%]*_\ !%<__+ZC[-XA_P"@OI7_ ((KG_Y?5MT4 8GV;Q#_ -!?2O\
MP17/_P OJ/LWB'_H+Z5_X(KG_P"7U;=% &)]F\0_]!?2O_!%<_\ R^H^S>(?
M^@OI7_@BN?\ Y?5MT4 8GV;Q#_T%]*_\$5S_ /+ZN*^(L&M)X(\1-=:EIT\
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M =+@,<<^E7<TJ+\V%>:/6;=)& QEEAB!/1!7W'A*K9UF/_8K?_J5AA=%ZO\
M)'I-%8OD^(O^@CHO_@EOO_E_1Y/B+_H(Z+_X);[_ .7]?OHC:HK%\GQ%_P!!
M'1?_  2WW_R_I/*\0XS_ &EHF/7^QK['/3G^W^] &W16+Y/B+_H(Z+_X);[_
M .7]'D^(O^@CHO\ X);[_P"7] &U7"?$W_D0_$W_ %X+_P"E,%=#Y/B+_H(Z
M+_X);[_Y?UQ7Q&BUI?!'B,W5]I<L L1YD=OI=W!,X^T0<)-)K%RD9S@[F@E&
M!C;SD>3G_P#R(LZ_[%.8_P#J'6&MUZK\SXW;J?J?YTE*>ISZFDK^11!1110
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MV.RGL]F-V_S/.O[[S-WR[=OE;<-G?N&T NT444 %%%% !1110 4444 %%%%
M'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?H9\;_P#D:=-_[%ZS_P#2S4*_)W_@
MLY\;_A=^S1^V'_P1B^/OQP\5P^ OA!\-?VHOVB[_ ,=>.+W2]=U73?#EGK7[
M*GC'PYIEQ?6WA[2]8U1EO-:U2PL(5M["=S+<!V5((IYHLOXH_P#!>;_@D;XE
MUZRO=*_;8\"36\.CVUI(Q\ ?'3B>.YO)'7]W\*)%X65#]X'GH!C/P?B-A<3C
M.&IT<)AJ^*K/&X.2I8:C4KU7&,Y<TE3I1G-J/5I674#]$:*_*7_A^)_P2@_Z
M/2\!_P#A ?'C_P"=)1_P_$_X)0?]'I> _P#P@/CQ_P#.DK\ _L'/?^A)G'_A
MLQW_ ,H\U]X[>GWK^NOY]F?JU17Y2#_@N-_P2>)8+^VIX!8JVUPO@/XZL4?
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M1U&:UL;12EO(QENIXH@5 +!BM?41= <%E!]"P!_+.:4,IS@@XX."#@^AQTH
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M6FJZ?J6K>/=6L5TO4O%NJP6NJ1:9J6O7NF1P:=<:C>V$\\ME;6EJS>3:6R1
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MXB?#W]J'Q_\ LU:O\3_&_P :?!6G_ ;P#\8M)\2_$E?"MYX]\ Z[KOQ$\?>
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M&-(XHT10*VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>financialhighlights.jpg
<TEXT>
begin 644 financialhighlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSXT?%KP]\$?ASXB^(?B*W
MU#5$TFWBM]#\,:'%%<^)O&WBO4YDT_PMX&\*64TD,-[XF\6ZY/9Z)H\%Q/;6
M4=S=?;-3N['2K2^OK;S-OVIO",/[+WP]_:@G\.>)Y=&^)O@KX.>)?"'@/3%T
M?4_&NM^(OCLW@_3OAQ\/M.QJEKX=N/$NN^)_''A_PQ'>2ZU:>'+:[N9=3OM8
MM-#MKG4(I_VC_P!F;1OVC;7P6;_XC_%KX;ZQ\/-1\4:WX4U?X7^,QX9:+6O%
M/@S6/ MS>ZQ87.E:QINL-9Z!K^LVFF2SVD5]I(U;4Y=+O;2>\ED/S5X<_8P^
M*WAS]GSX'?LH0?&&#4_ WP/^#?PGDT+XM>)/#LNO_$H_M)? KXD_#GQQ\*_%
M26Y\1Z=I-S\*=)3P3?:;K/P[NK"#5[[PY>:3H-EX_MI;:]U"0 [N/]N 3L/
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M0U^XE?AWX_\ ^5B#]G#_ +1-_M)?^M2?"&OW$H **** "BBB@ HHHH ****
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M:Z:""6X2WG:.9K=?/5#$RN?WH_X27P]_T&]*_P# ^V_^.4 ;=%8G_"2^'O\
MH-Z5_P"!]M_\<H_X27P]_P!!O2O_  /MO_CE &W7P#_P48_;;A_8:^!=K\0-
M.\-6OC'QYXO\3VO@KX?^'M3N+JST)]9ET^^UF_U?Q'=V6+U=%T71],N[F2TL
M'COM4OY=/TR&>RBNKC4;+[C_ .$E\/?]!O2O_ ^V_P#CE?!__!0O]DOP3^W+
M\#8OAR/B!HW@OQKX5\1VWC3X?>*KEDU/2[+7K>POM)N]-U[3;>[M[F[T+7-(
MU*\L;M[.:.^T^Z%CJML+HV+Z?>?3\%OAV/%612XL4WPZLPHO-5#VS7U?6SJK
M#_[0\.JOLWB5A_W[P_M51O4Y4_F^+UG[X9SI<+N*S]X&K_9CDZ2?UB\;^R=?
M]PL0Z7M%AG7_ '*Q'LG5:I\S/QA_93_X+N?&+4OC%X8\+?M-^'?AM<?#'QEK
M]GHE_P"*_!6A:UX9UGX?/JLWV.QUF:UN-?\ $%IX@\.V=[/;#6[>6.VU>UTW
MS]2LKN]GM?[-N_WY'[97PFU*!I?!6@_&[XELI(#?#_\ 9Z^-6N:=*P;"^5XB
MNO!&E>%G20!VCF.N+ PC8>:&**_X,_LD?\$3/&?@;XX^"OB)^T3\7/A#<>"?
MAUXJTGQA9>%?AUKNM:[JOC/5O#5_#JV@VFI:EK&B^&K;P[H*ZM:6-[J:Q1:I
MJFHVMO+I<0TW[2VH1?T\CQ'X=P1_;>E$$DD&_MR,DDG@RG')SCH.W05^G^+V
M(\)HYY@)<%8%8N"P*_M%Y)C?J&3JNJG[B/LJV78EU<2Z-_K+P57#48Q]BI.>
M)>(<?S;PHH>*,LFQT>,<8\++Z[;+UG&#6-S=T?91]M)U*6/PZI4%526'CC*6
M(JR;JN,8894%+YK;]H/XO:S )?!7['OQNNE)"B[\?^)?@I\-+$L?,4,UO>_$
MK7_$Z1!U7>Q\,EUC+2)'(?(2X)/$7[:VOPH^E_"[]G3X=I(0-_BKXN_$'XAZ
MG NU3OFT?PK\+/!^F.^&(:*'Q:R"2-E6X>-DF/TJ/$GAT=-;TD?2^M1_[4I?
M^$E\/?\ 0;TK_P #[;_XY7Y*LVP4+>QX>RB$HN\*E6IF^)J+:W/"MFDL)4>E
MW?"<C_D2T?ZFLJQDU^^S_-III<].G#*</"^GP3HY9'%06G3$N6M^:Y\TS_#O
M]KS7Q&^L_M)_#;P<&XEM?AE^SR&N(E 7)AU?XE_%+QW \K,F0TOAWRU5Y5\E
MBT+P.E_9B\1:R\4OC3]J?]I_Q,1S<6FE>,O!?PMT^4EW9EB'P@^'O@75X(V1
MB@5=;:5!@QS(R1&+Z4_X27P]_P!!O2O_  /MO_CE'_"2^'O^@WI7_@?;?_'*
M/]8<RC;V*RW"RCI&IA,ER?"UXKHHXFA@:>)TMI)UG+O)O4/[ R]W]K+,,2I6
MYX8K-\VQ-&;7\V'KXVIAVGU7LN771)'S6_[$O[.%_,ESXI\&:Y\1KH!3+<?%
M?XE_%+XI_:7!#.\UKX^\:>(-./FNH:2*.RCMR<@0A#MKU3PK\ O@9X%D6;P3
M\&OA5X0F10BS>&?AYX0T.<* ZX,^F:-;3,2))-S-(68R2%B2[9] _P"$E\/?
M]!O2O_ ^V_\ CE'_  DOA[_H-Z5_X'VW_P <K"OGN=XJFZ6)SC-,12:M[*MC
M\55IV[*G.K*"6BT44K:6L;4,DR;#357#Y3EM"JFG[6E@<-3J777VD*497\[W
MW[LV0H'3(]@QQ^6<?ABEVJ#D  ^N!G\ZQ?\ A)?#W_0;TK_P/MO_ (Y1_P )
M+X>_Z#>E?^!]M_\ '*\H].R[?UI_DON-NN'\6?#+X<>/;BPNO''@'P5XRN=*
MW?V7<>*_"F@>(Y]-W.)&^P3:SI][)9[I ';[,T0+@.1NYK=_X27P]_T&]*_\
M#[;_ ..4?\)+X>_Z#>E?^!]M_P#'*TI5JV'J*K0JU*-6-U&I2G*G-*2<9)2@
MU))IM-7U3:>C(JT:5>#IUZ5.M3=FZ=6$:D&TU)-QFG%V:35UHTFM4:\,,5O%
M%!!%'#!#&D4,,2+'%%%&H2...- J1QQHJHB(JHB*%4!0 )*Q/^$E\/?]!O2O
M_ ^V_P#CE'_"2^'O^@WI7_@?;?\ QRLVVVVW=O5M[M]V:))*R5DM$ELEV-NB
ML3_A)?#W_0;TK_P/MO\ XY1_PDOA[_H-Z5_X'VW_ ,<H VZ*Q/\ A)?#W_0;
MTK_P/MO_ (Y5VSU/3M1\S[!?6EYY.WS?LUQ%/Y>_=LW^6S;=VQMN<9VG'0T
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MLJ>,_&W["_C!OB;XC\#:_P#&'5]&^.G[4?A7P'\6$M=+U#PY'\?OB9JOP_\
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M110!^'?C_P#Y6(/V</\ M$W^TE_ZU)\(:_<2OP[\?_\ *Q!^SA_VB;_:2_\
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M*ST^!+6PM+:RMH_N6]K!';PIZ[8XE1 3W(&2>3DU:KZ?ZGB\1KC,;.,/^@?
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M*A/FC"<$_K4*L9I8>=/V=6I[5KWB;P[X6L'U3Q+KFD>'].0D-?:UJ-IIEIN
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M8T6.*-%1%55 #+RQL]0A^SW]I;7L&]7\B[MX;F'>F=C^5.DB;E))5MNY>Q%
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M^I^--"T[3M'T;Q1J>H6TL1U+7=,TC2-*TJRU&^2XN8--TZRL$<6EM#"O1_\
M#+_[.ZW/Q.O8?@O\-K2^^,]AJ.E_%/4+#PGI.G:CXZT_6+B2\U>S\0W^GV]M
M>7D&K:A--JFJ1B>,:EJ\\VKWWVC4Y9+MO=Z* /D[P[^PG^QWX3\%:_\ #GP]
M^S=\(=+\"^)];TOQ-K7A2W\'::VB7?B313J;:5XACL9TFCL==L9-9U>6#5].
M^R:BLVJZE,;EI+ZZ:7Z5\,^&/#G@OP_HWA/PCH.C>%_#'AW3K72-!\.^'M,L
MM%T/1=*L8E@LM-TG2=.@MK#3K"TA58K:TM((H(8U"QHHK<HH **** "BBB@
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MG+CL%[+DY:G-?VGM.>*]Q1?-^5'[0G_!3OPOX"^"'Q3\8^ OA%^TG#XU\/\
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M-MB/LFF6TDEMI\%K [1D ]4HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIOF)NV[TW9QMW#=
MGTQG.: '444?UZ4 %%%% !1110 444 @\@@CGD<]#@_D>#[T %%%% !1110
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M-,T[4M0DN+VPM)X>8\!_L??LY^ -'\6:38_"CP/KLWQ T[Q'HGQ#U[Q5X/\
M"6L^(OB%H'BGQ;X@\::KX?\ '.J'0K=O%.BOK7B742NGZO%=0RP+:"]%W<VR
M7) /A>;]O[]HF\TJ.PT?X">'--\5^'_A_P#M7_$3Q5=?$]_BC\*-+UWPY^R^
M?V>-4AU/PEX/\3^#O^%D:,GQ*TSXW7.A6^G^,]&M;WP9XC\-W=_,WBOP^=/D
MU[L/$7_!0_Q#X3\;R:OXG^%\.@? ^;P!9>)_"^JW(\<:MXO^(.J7_P"S9/\
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M1Z1JOA^'Q;:)I>EVJV_B"WT'6]7T.UU6()=VFC:G?:7:R0V-S+;L ?GOI/\
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M38:OJ6I>#)_A9K$NBQ>%&L;?QUJ_B;PWX*CN_#MQ'+XKU'ME_;M^*A\1A?\
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M#VE#7_\ A)9O!]K\/9M?_M<6OV_^V9? EC9>#)-2\_[8_A:TM]!:4Z9#';*
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gainlossonfvremeasure.jpg
<TEXT>
begin 644 gainlossonfvremeasure.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OSO^)O[:VK^$/VNIOV9--F_9=\,V^C^"/@]XZU+5/CI^TG=?"KX@>+=.^)
MNO\ Q2LM7MOA/\.+?X9>*8_&L_@[1/A9J.H7,MQXHT:WO-1U.UT^Z?2;.VGU
M0_HA7SEJW[,_@;Q)X]^//C/Q1)=:[9_M ?"3P)\'/%GAR>*"VM;/POX,LOB_
MIER=,U2V*ZI#=>(M,^,>NV5^XEC-JEG:O9L&FN,@'GUK_P % /V6[S14UV'Q
MOXF$%YK7PZT30M-N/A'\8+/Q+XME^,-KXIN_A%JG@GPG=^!(/$WC3PS\4D\%
M>*8/A_XK\+:3JWASQ7J&AZAIFD:G<:A;O;BI^TG^VOX8_9V\8V/P]NOA[\1/
M%7BC7/V;?VC?VB]$U&P\*^)K?X>PZ=^SSH7A[6=1\,^+OB%;^']3T'P;?>(7
M\0VUC#?ZM*L&AW+Z7;:K +_Q5X4LM7Y3P1^P=%H?B?P%XV\<?&WQQ\3/%OPU
MU+X.:=X5U?6_#G@K1/*^'/P)TSXI67@?PCJ5GX<TRQM]0UO4=0^+&NZ_XU\;
M8M[S7=5L-'CTK1?#6E6C:;)ZC^TE^RQ:_M!ZEX>U1?'FK>";G3_A7\?O@AX@
MCLM"T?7;7Q'\,?VB?"WA[1?&6F>7J+VT^C:]IFM^"/!'B7P[X@L;J06TFC:A
MH^HZ7J6F:Y<"V ,+PW^WK^SOKW@ZU\3MX@\2Q:M-<_#O2D\"6/PQ^+&J^/M;
MUWXG^"]1\>>#[7P!X&@\"1>,_B7HNO\ AKP_XNUK0O%W@CP[K'A?5M$\%^,=
M;@U1=-\+Z]/I_;_$CX[ZHW[-VM?'_P#9WL/ ?Q6@LO"%_P"/='L_&'B[Q+\/
MM UGPYH%G?ZGXCMIM7TSP%XU\0:)XDLK72M0T]-"U3PA#=67B.WET3Q"NAW%
MK>FW^=/C%_P3:^&GQ@U.V\1:YKUIJ6N:#8_ =/"5CXY^&W@3XG> K+5?@?X*
M^-WPZ@N_$OP_\86=UH_BVP\6>$?CQXLM-3L);C2+S0]2L=$USPSK>F:C9-))
M]0^$_P!G;PEX+_9Q'[-OAZ:WTGPL/AYXD\!"^T+PKX,\(Q1#Q9I^LV^M:Q8^
M$O!&A>&?!6CSW&H:]J.K#3=%T+3M,6YF(,+L\T\H!\A?#O\ X*,V^GWGA/3/
MVG/!_A;X27'C']GCX7?M(VFK_#GQ#\2?C)X8\/\ @OXL>,]6\)Z1_P )MJD'
MP<\*S^"]*\,+9:9<^-O'WB>STCP'H-QK5O;SZY]FB:_?Z(O?VX_V<;2?7+*V
M\4^*]>U+0?B3XL^$4FC>$?A-\6O&6N:S\0_A_=>)+;XB>'?"&B>%O!&KZKXV
M?X>#PIJ]UX]U'PE::UI'@^R.EW7B#4+!=>T--0X'Q+^P5X/\2^"_%7@R?QWX
MEMK;Q3^QM\/OV-Y[V'3=(>YM?#'P_O?$][9^,(4D_=/KVH/XGG2ZL)#_ &9$
MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M_P##;6OBEK=QXSOKW6],O-)TN7P]H5U:Z=/I6G:]=7&KS6UM-96MHT]_!]/
MA@&'0@$?0C-?B#_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4
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MJ?YTE?R*(**** "O=_@-_P AS7?^P1;_ /I:U>$5[O\  ;_D.:[_ -@BW_\
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M_P"@AH?_ ()[_P#^7E?O@C<HK#\GQ+_T$-#_ /!/?_\ R\H\GQ+_ -!#0_\
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M?\CK,?\ L5R_]2\,/HO5_E$[2BBBOWP04444 %%%% !7"?$W_D0_$W_7@O\
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M.4889X6G&3BN>T*7*D[W;C>3;;87W\_7R?5^04445^AB"BBB@ HHHH ****
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M*Y__ (1?1O\ GUD_\#M1_P#DRC_A%]&_Y]9/_ [4?_DR@#H**Y__ (1?1O\
MGUD_\#M1_P#DRC_A%]&_Y]9/_ [4?_DR@#H**Y__ (1?1O\ GUD_\#M1_P#D
MRC_A%]&_Y]9/_ [4?_DR@#H**Y__ (1?1O\ GUD_\#M1_P#DRC_A%]&_Y]9/
M_ [4?_DR@#H**Y__ (1?1O\ GUD_\#M1_P#DRC_A%]&_Y]9/_ [4?_DR@#H*
M*Y__ (1?1O\ GUD_\#M1_P#DRC_A%]&_Y]9/_ [4?_DR@#H**Y__ (1?1O\
MGUD_\#M1_P#DRM"QTNRTWS?LD31^=L\S=/<S9\O=MQ]HFEVXWMG9MSGYLX&
M#0HHHH **** "BBB@ HHHH **** /Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&
MOT,^-_\ R-.F_P#8O6?_ *6:A7YY_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^
MAGQO_P"1ITW_ +%ZS_\ 2S4*_//$_P#Y):I_V'X+_P!+F!XU1117\Y %%%%
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M^"'@SP5<>,+Z2U^$MT%N/$&IPW&FJ;HVVHW$/A:*\O+.W2YMFE_1'P;_ ,'
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MOB1X[@L+74]#N?%6L>+/#/B'PS9:)HNKZM'H.DZWX)TR]OK:_P!,O]7TR_\
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MG2M.AMK#3M.L;:..WM+*SMX;:WAC2*&-$4*-J@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>incometaxprovision.jpg
<TEXT>
begin 644 incometaxprovision.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %> 3T# 2(  A$! Q$!_\0
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M[\<[R+Q=\6M(UF&Q.D>)?BM:ZA=VMG\2M.AA.[PWJ,'PZ'A?X2OHFG%](N?
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M&CWK6_\ ;%AXY\$_&GQMH>M0IJ&FWFBW4FEZUH=]!>Z>%EYH?\$\_!UK\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5/ VKZ'J<>M^"Y].TVU^(&DZ^L)\8^%;_0K6YOP#Z)\9_M#_  O\&_"7P_\
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MBC^;+_\ PC?E_P!/O)_?Y"NNWX^G^3^_R/K3_A>7@W_GVU[_ , ;7_Y84?\
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M$\,_]@X?^CIJY'XZ?\BA9?\ 8?LO_2/4:Z[X:?\ (B>&?^P</_1TU<C\=/\
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M#+]EWPC\)O'WBOXA^&?B9^T+J6H^.O%'B/QGXQ\/^,OB]-XM\'>)O$/B..>
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M<TJ*'8 _%/\ X*6R-%_P4@_X(5.D,MPP_:N_:= BA,0D;=^QYX_4D&>6&(!
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MU&P4:Y9N)KM],:)B+2_ C L]2O)=[ DC,03"MEP=H;O_ (:?\B)X9_[!P_\
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M?$O7-0\4^&KK2]'U3PO^_ Z=^_7ZG\QZ'J1@GF@#\0?^"D__ "DD_P""%/\
MV=;^U!_ZQS\0:_;R/_5Q_P"XO_H(K\0_^"D__*23_@A3_P!G6_M0?^L<_$&O
MUR\8?$JQ\%WMCIUUI=Y?/=Z>EZLMM-;QHB^;)!Y;"9E8MF(MD<8('7-<.8YE
M@LJPTL9F&(CAL-"4(2JRC4FE*I+E@K4X3E[STTC9=6@/3:*\%_X7UI'_ $+^
MJ<8S_I-CQG. ?WG!.UL#OM;&<'"#X^:,20- U,D=0+JP)'..1YO'/'UKY_\
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M_P#2/4:Z[X:?\B)X9_[!P_\ 1TU<C\=/^10LO^P_9?\ I'J-?TIFG_)NI?\
M9-X'_P!1<./[?_;WZGR=1117\UDA1110 5[A\!_^1EUC_L!G_P!+[2O#Z]P^
M _\ R,NL?]@,_P#I?:5]5P1_R5>2_P#85+_TQ6 ^J****_J8 HHHH **** "
MBBD;!!!R!@Y(ZXQVQSGTH ^?OC#XN\%>!;O0O%UGX.\%>._C!-XC\/\ P_\
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MW$-P\<J 'XK?%71[Z']L3QEXIB^$^GM\2)OCU\$-*\+_  ^M_P!GOXUZY?\
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M_#/X&>)_A[X@\,WWQ,^(2>*/B?IVFWGBOXX_%*V'VK0KF^\/?#[7;.TTS7_
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M?]ECN,_]#'3O^'8__!4G_I-G<?\ BM?]EC_YHZ7_ !"KB3_H*R;_ ,*L9_\
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M:625@9)'9M.OBO\ X=C_ /!4G_I-G<?^*U_V6/\ YHZ/^'8__!4G_I-G<?\
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M1110 4444 %%%% !1110!^>G[2'A/XU?"#XP^)/VP?@CX'T;XR7NH? #P_\
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MPI_:BA^./QG\0_!CP/\ "/Q%X:^._P"RY\)_@BOC+Q]\3=:\,/\ ##Q=\/\
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M?#?V'0/B/\/3/XAT.&XUW2_%6B:A%IB26VG6.J7_ &OB']@WXKZI8?$O08/
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MWOP^\1_$+]DOXZ^.?'_B*ZLVT?\ 9T\%>&/A'X<^)'@7Q9_PC?AG3O#/PO\
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>interferon.jpg
<TEXT>
begin 644 interferon.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M\8O#FM'Q-\#_  )\,M,\2?#&T\$^)]!UMTA\&^'?'=I;#6])U6P748M/NKH
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M_P"#'2._ '_'YU)X [FM^HIU=H95C6-Y#&X1)MWDLY4A5EVAF,3-@2!024+
M*QX(!\Q_#W]L+X!_%?4?B7I7PZ^)/@?Q9??!ZYO+?XE1Z=XR\.QQ>%H=/TZP
MU.^UBYO+V^M+&]\+V<&HQ6]UXOTJYO\ PO;ZG;:GI4VKQZAIE[;Q>I?#_P"*
MOA_XK>"/"OQ)^&TMGXV\ ^.="T[Q/X.\7Z!K.EW6A^)O#NL0)=:3K>CW4EQ
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MA9]I;?!#XMSZ8GB'QM\(/VG/%G@73OC[XD\1_"WX6:5^UTMC^TE\+OAIXB^
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M_P"_4?\ \31_Q+]A_P#HJ:W3_F30\K_\S3U^_P"X_P"(YXC_ *)JC_X=I_\
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M_P $*?\ LZW]J#_UCGX@U^WD?^KC_P!Q?_010 ^BBB@ HHHH **** "BBB@
MHHHH **** "O./BY\1;7X2_#CQ9\1;W2[K6K7PIIHU*;2[*X@M;J\0W=M:>5
M#<7(,$39N0^Z4;=J$=2*]'KYC_;+_P"38OC#_P!BNG_IXTNO6R#"4,?GN2X'
M$Q<\-C,VRW"8B"E*#G0Q&,HT:L5.#C.+E3G)*491E&]XM-)GE9[BJV!R3.,;
MAI*&(PF5X_$T)N,9J%:AA:M6E)QFI0ERSC%\LHRB[6DFFT?*!_X*@^$ 2/\
MA4?BT\_]#%X?YQ_VR]J3_AZ#X0_Z)'XM]?\ D8O#_P!/^>5?CH>I^I_G25_7
M:\'^ ;)_V/5V7_,SS/R_ZB_+\?6_\L?\15XX_P"AM2_\-V7?_,OE^?=G[&_\
M/0O"'_1(_%O_ (47A_\ ^-4?\/0O"'_1(_%O_A1>'_\ XU7XY44_^(/< _\
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M;_2],MKK4=2MO$,VF-8V-G?75SY<5C>-!PUKK'@W_A7/A?3-:\>76IZIHWQ
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M3QZ_+?&O_DUO&'_8#A/_ %:Y>?IG@Y_R<WA'_L.Q/_JLQQ_5CXL_Y%?Q'_V
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MSK?VH/\ UCGX@UG?\%)C_P 7T\+G_JENA'T_YF+Q5^(J[_P4LBCG_P""D/\
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M\>[OQ!J^D_!+X8Q>!O"6H?$?4O!&G?&+Q3<?#OX0^"O"GB2^N_BKH@\3^#?
MEK8_#3PGHMU?Z+X1^&,&C>)+^":UO'E\0^*-=U&5X;#1K%+>\'Q)#&XBC2I8
M6,:<ZE;VM2IBHJ>'PM/"QQ2Q-6E&C*--PYZ5#&8>K5I5L'7KX=352G5513B^
M'I8.A5J5,1*52%.BZ=.GAI.%?$5,4\*\/3J2JQE-3Y:E?"8BG2J4<71H5W!P
MG2=-_('^&?PSC/TR",^O%?T#_P#!O/\ \G!?M"?]D:\+?^IX]?!VL>"/#B>
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M$KEO#GQ6\6:O>?"/5O"&EV]\/$">)1Y6HZW=K>>#])T>74]'OM0;PO7OV;?
M?A[5_P!K/P_=_$S7)/$_[/>@^(-7\+>$F\&SV>K:ZGAK7?A[I6NWGCG5+EET
M'1++29_&]SX=M[7PS-J]]XH\0Z)=ZWI;Z;X,:PU#5ZWCS]L;Q9\0]1\5V7B+
MX:?"74/A9XI73O,^"MUH?B&+P3I]YI6MZGXEL]?MM5T+Q/X>\;2>*CK^N:W>
MWNMS>)/*U&VU)M,NM-:SL]/6UQK7]JK7)-;^)?B+Q/\ "KX2^-M8^*GAFV\"
M>(;C6X/B3I=O8?#K3['P3IND> ?#VG^$OB3X=M=-T'1K+X>^%;?3[^Y74?%1
MCL91?>(KTW=PS_T!@,)QS1ITI8[$SK..$P"='#3P+JRJT:N4RK0J5<5-TFZU
M&EFL<3&*56E+$1Y,VS+VE&65?A6.Q7!=6I..#PT*2EBL=)5:\,<J4:56EF<:
M4H4L/3C42I5:N62PTFW3JQP\G4RS+G3K0S/L?%_[*]AX,^#0\8:@OQ#O/&R?
M"/P/\9;JXTJY^%]YX,T_1?'MQHEUINF7W@D^(H/C-%X;T_P_X@TQ=8^-$6DW
M'@:Q\;ROX4;1GL$/B,<S\)/@5X \5:#\*+KX@^)O&VB:Q^T#\5O$'PC^&,GA
M/3O#M[HOAB_\/3>#M#F\8?$*'6G&IZMHMUXT\>^']#3P]X7ETG5K?1[/7_$3
M:M/-#IFBWG%7G[0WBJ]\)WGAY_"WP^BU_4/AW;_!V\^)L>AZO)\2)OA%92VJ
MV/P\.J77B*XT :=:Z18:;X3_ .$A'AD>-;GP9IUGX9N_$D]FDLDVOX>_:;\2
M^%;F2?0_A[\)+6#2?'^J?%'X7Z=+X9UZZT[X(>.M8T_2M.O=9^%]O/XM9H[9
M_P"P/#^J1Z%XXE\;:#%XB\/Z)XA73SJ=BTL_I+#<6?4<11J5U/%SQE>K"O1G
M0H-4?JGL\/3I>TEB5"G',IT<6G**YL#AL10J855*E.CB.#ZQPM]=H58491PT
M,)AZ<J%:G6KIU5BXU*\ZGLUAW.H\NA6PEE+W<9B,/7IXB4*<ZM#W[_@E[I]W
MI'_!1K]F_2=01([_ $CXC^,-(U"*-_-CBO\ 2O ?Q TZ^CCE 42QQW=M,D<H
M51(BK)M4-@?WC(<HO7[J]01V]Z_@K_X):(+S_@H1^S']L+W;3^.O$,UQ)<.T
MTMQ.WP\\<7$D]Q(Y+S32W \^:60EI969W+,S$_WBZ?I>GZ:K?8;6.V\Y8_,\
MO=\^P'9G<S?=W-C&.IK^1?I2<RXUR!2:<EPGAN9I-)R_M;-[M)MM*^R;;[M[
MO^J?HT<O^I^><J:7^M&)LFTVE_9.3V3:2N^[LC1HHHK^9C^C@HHHH **** "
MBBB@!,#.<#/3..<>F:6BB@#\0/\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K\J/\
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M_P!3TE/&7B7Q7J=AH^D>()[GP;H\":JT=_9^&!KT\<=UK,L%O_;7_P $S/\
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M4N7&8B$>9M\L(Y9CE&,;MVC%:**T2T2/ZL?%G_(K^(_^P#K/_IMNJ_S1(_\
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M;_L#RG_U6X8****_<#\7"BBB@#^N_P#X-\O^34_BY_V<+K'_ *K;X<U]O?\
M!5O_ )1Y_M3?]DZB_P#4I\.5\0_\&^9Q^RG\7.O_ "<+K'8G_FFWPY]*^WO^
M"K9S_P $]/VIL9_Y)U%V(_YFGPYZBO\ .[BO_E(9_P#9?\/?^IN5G]]<,?\
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MQ-:2BI5L1@L-7JR44E%.I5I2FU%12BF[)*RT/YM/^(77]@__ *.#_P""B/\
MXEUJG_S$U\WZ9_P;F_L;WG[6_C/X(R_'_P#;\'@S0/V<_AK\4;%T_:MU==;/
MBCQ9\5?BWX/U47&H?\(FRRZ8-&\$Z+]DLQ:)Y%V;V;S9#<8B_K;K/72-*359
MM=33=/36KC3[?29]76RMEU2?2[.YNKVTTZ;4!$+R6PM;R^O;JWLWF:V@N;RZ
MGBB26XF=]_\ 6/B'_H?9U_X=<?Y?]1'DC'^P,BT_X1,HTV_X3<%Y?]./)'\X
MG_$+K^P?_P!'!_\ !1'_ ,2ZU3_YB:/^(77]@_\ Z.#_ ."B/_B76J?_ #$U
M_2711_K'Q#_T/LZ_\.N/\O\ I_Y(/[ R+_H291_X;<%Y?]./)'X,?#K_ (-_
M_@?\'](O/#_PF_;Q_P""L_PRT+4=2?6=0T;P'^WMXW\*Z7?:O):VUC)JEW8Z
M-X8M+>>_>SL[.T>ZDC:9K>UMX2Y2%%7=\6_\$*/AKX_\.:MX.\=?\%$?^"P/
MC/PEK]L++7/#'BC_ (*#_$+7- UBS$T5P+74]*U#P[/97MN)X(9O)N(9(_-B
MC?;N0$?N517G3Q>*J8GZY4Q.(GB_:1J_6IUJDL3[6#3A5]O*3J^T@XQ<9\_-
M%Q3332.^&&PU/#_5*>'H0POLY4OJT:-..']E--2I^Q453]G)2DI0Y>62;333
M9_-I_P 0NW["!Z_M!_\ !1'_ ,2ZU3_YB:/^(77]@_\ Z.#_ ."B/_B76J?_
M #$U_2717H_ZQ\0_]#[.O_#KC_+_ *?^2.#^P,B_Z$F4?^&W!>7_ $X\D?R:
M?&#_ (-POV,_ WQ)_96\)Z)^T#^W^=+^,GQO\3_#WQ@;[]J[5;FZ7P_I'[-W
MQY^*UHVCSCPC$+#4/^$I^&_AY9KIHKD/I1U&R\I3>">#Z _XA=?V#_\ HX/_
M (*(_P#B76J?_,37]'MWI>FW]QIEW?:?8WEWHM[+J.CW-U:6]S<:5J$VG7VD
M37VFS31O+87DNE:GJ6FR75H\,\FGW][9/(;:[N(I+U'^L?$/_0^SK3_J:X_R
M_P"HCR0?V!D7_0DRC_PVX+R_Z<>2/YM/^(77]@__ *.#_P""B/\ XEUJG_S$
MUZ+\./\ @W5_9H^#NHZEJ_PD_;/_ ."IOPPU;6+&+3-7U/P%^W'XL\*W^IZ=
M;W'VR"PO[K1O"=I-=6<-WFYBMYG>*.<F55#DFOZ!J*RKYWG6*I3P^)SC-,10
MJ)1J4*^88NM1J).,DITZE:4)I2C&24HNSBGNKFM')\HPU6%?#Y5EN'K4VW3K
M4<!A:56FW'E;A4ITHSBW&\6XR3:;6S=_Q4E_X(I^';B*6"?_ (*:?\%FYH)H
MY(9H9?\ @HU\39(I8I4:.2*1&T(JZ2(S(ZL"&5B",&OE_P#XA=?V#Q@#]H+_
M (*(@   ?\-=:IP!P /^*)Z <"OZ2Z*PPF99CE_M/J&/QN!]KR>U^IXNOAO:
M^SYN3VGL*D.?DYI<G-?EYI6MS.^V*R_ 8YP>-P.#QCI<WLGBL-0Q'L^=Q<_9
M^VA/DYG"'-RVYN6-[V1_-I_Q"Z_L'_\ 1P?_  41_P#$NM4_^8FOFW]K_P#X
M-S?V./@;^S1\9?BSX*_: _;\?Q5X%\%WFO:$NM_M6ZMJ.E&_@O;"%/MUDOA*
MS-Q!Y=Q*&C^T1Y)4[@0"/ZW:SM6TC2M>TZ[TC7-,T_6-)OX3;WVF:K96VHZ?
M>P,59H+NRO(I[6YA9E5C%-$Z$JI*Y QV?ZQ\0K_F?9UI_P!37']+?]1'DON.
M3^P,B_Z$F4=O^1;@O+_IQY(_G$7_ (-=_P!@]]S?\-!?\%$ /,E  _:ZU4 *
MLCJHY\%,> !U9CZD]:7_ (A=?V#_ /HX/_@HC_XEUJG_ ,Q-?TE_Y_/K11_K
M'Q#_ -#[.O\ PZX_R_Z?^2#^P,B_Z$F4?^&W!>7_ $X\D?SK^$O^#:7]CSP!
MXCTGQCX%_:I_X*7^#?%N@SR76A^)_#'[9_B#1->T>YFMI[*6XTS5=/\ !T%Y
M932V=U=6DDEO,CO;7$\+$QRNI_5+]D']BFP_9!;Q\UC^T]^VE^T7_P )\/#(
MD7]KK]I#Q/\ ']/"/_",_P!M[#X!7Q'8V0\*G7/[;;_A)?L?F?VS_9>B>?L_
MLR+=]K45P8O'8W'SC5QV,Q6-JP@J<*F+Q%;$U(4TW)0C.M.<HP4I2ERIJ/-*
M3M=MOMPV#P>"A*G@L)AL)3E+GE3PM"EAX2GRQCSRA2A"+GRQC%R:<FHI7LD%
M%%%<ITA1110 4444 %%%% !1110 4444 ?#?QD_;9TSX6>)_BS8:+\)_'7Q)
M\&_LV^&M#\7_ +2_CKPS?>%["T^%VBZ]X>G\:"UTC0->U2PUSXD>)?#OP]AC
M^)7BWP]X9ABETOP3?Z5)I5WX@\5ZI9>$IMF\_:YFTGXI^$_"FN_!GX@Z)\+_
M !_\4H_@GX$^,]]?>%5TGQ7\0;KPUJ_BC2;[2?!$6K2>-KGX8>(K?0=7TKP[
M\28+">TU/4[%]6.B6W@&6W\<3>)?M0?LK?%J]O?CKJGP-UM[GP9^V$_@;P=^
MU)X#L-!\-2_$^/PS;> +SX.^)_B'\!_&OB_X@^!/!6@>-M0^&EOX0\*:[I?Q
M M?$6GVNC>'1XP\%F/Q=IB^%O&':^'?V9OV@M-_:=T_XO^(_B=\#?%WPP\'W
MUYH/PA^']]\(/B/9>(/@K\++CPY%X>DT7P)JT7QQN?!4GQ/UJ"%[?Q7\9=>\
M!ZGXBU3PW?7G@G1+#PMX2ENM(O0#Z2\;_&H^ _%NIZ'J/PY^)&K^'],^&<GC
M\^+_  EX4U;Q?::AJ[>+]/\ "6G_  [TC1/#UE?ZYJ?C35'U&'5;2S@MQ:Q:
M6LM[?W%E96]U>V_@>E?MM)XQ^%?[-OB_X??!OQEXC^(_[4.C:UKW@7X0:AXC
M\%^'=4\/Z7X1THZQXXN_'/C.?5-0\'Z;'X5CDT_2;A?#UWXIGU;Q#K.F6FB0
MW^C?VGX@TSZ^\>6WCJ[\(ZW!\-M5\)Z+XZ>UC_X1S5/'&@ZSXG\)6>H)=6\A
MDUO0/#_B3PEK.IV;6Z7$8@L/$>E3B9X93<M'')#+^;?AK]A+XRQ_LS_"[X$^
M/?B5^SSXTUSX)^+K35OA[XJF^ OQ,T[3$T-=%UW3KP7<&E?M&:3\0/#WC*2Z
M\0WZ?\))X#^)7AO3=4\*R:EX'\3>'-;T3Q#J;( ??7P.^,7AGX]_##PW\4O"
M=MJ=AI>OOKNGW>CZTMBNL^'?$OA'Q-K7@KQIX6U=M*OM4TB75?"GC+PYKWAS
M4;C1M5U31KJ\TN:YTG4]0TZ:VO)O6:\3_9T^".A_LZ?!KP5\'O#UZVIV/A2W
MU>>ZU+^R]-T*'4]?\4>(M8\8^*]4L_#^C10Z1X=T_4O%'B'6+W3?#VEH=/T'
M3I[71[.2:"QCFD]LH *^</C9\?KWX:^+/A]\+O OPXU[XN_%_P")NF^-/$OA
MOP1HVM:!X5L;+P5\.&\+P^-_&GBGQ;XFGCTO0M%TS4_&W@SPWI\,5MJFKZWX
MF\5Z/8V>G)ID6NZUHGT?7R)^T?\ !?XF:YXG\)?M"?L\Z]X0T7]H7X2_#WXM
M>!_"NE?$7P[<>(?AU\1/"7Q-_P"$,U_5_ 7B[^R/$'A+Q'H)G\:?##P#K6A>
M+=(\0J-!N=/U"#4M&UG3-7NXK< \NUO]OR"+X7_\+J\)_L]_&/Q-\,/"/P_\
M6_$CXV^(;V7P+X0E^$]A\./%GC7P1\4/ IMO$7B>*T\>_%OX;^(/ASXX'BWP
M3X/U2XT^UTS0K>]L_%=Y/XK\#V'B;["\7?$*Y\.7'PQ72?!WB;Q?9_$7QSIW
MA.ZU#1+0K!X*TG4?"?BKQ.OC3Q3'=I%/9^'K>3PY::'<%HX[F+5O$6D02(C/
M(@_-7_AB_P#:1UKP'\&/#.A?$_P5IGPWT&VUOXG_ !(^"G[2?PHO_&>L>/\
M]I'Q[\5_$OQC\9>/OBMJ?P%_:%\/^!_$GARR\6^([G4/"OP8T^_\1_#?0=8\
MG5M5U;QX^B>$1X<_6Z)9U@C65H6N1$OFO%&\<#3[!YCI&\LDBQ-+N94>:1PI
M"M([ N0#X>3]N_P.OPA_:?\ C1??#7XN:+X9_9D\7)X8U;2/$/A>#PWXQ\86
M5UX ^&_C_2O%^G^&/$&H:7>^"_">IZ9\2]*G>_\ B@_@NZ\.:#8:EXO\:V/A
M?P] ]Q'ZK^S?^T/!\?\ 2O&CR>%)/"NN?#_Q1;^%?$$6G>*_#7Q%\&WUY?:!
MI?B:SG\*?$;P9/<>&O$:0Z9K%I;ZW8*+#6O#NKI+8ZKID4$VEW^I?+%M^QW^
MTGXMM?VH=!^+'QS^#%UX:_:5\5^#_B%J%I\./@E\0?#ESIOB;P)H7P4\'V'A
M+Q+'XG^/'BFQ\<?!OQQX.^#8\-?%SP(\?A[5/&^@>-?%.@6_BK0],NE4>Z_L
MG_LL']F^;XHZE_:'P^TW_A:.N^'=;E^&OP-^&TWP9^ W@R[\/:)-HUSJW@[X
M92>+?&JZ?XO\:F:.^^(?BB+5[0>*IM)\-K+H]M/HLM_JH!]B4444 ?(WQI_:
M]\'_  '\?WOP_P#''A?Q*NHZQ\*I?'_PAN=,^PWB_&KQ?I_BZS\%:S\%?!%H
MTL-S_P +3M-:\5?#*33M&OQ'::YI'CZ/6;&\&G>$/&<^C?.OC/\ ;^^*_P .
MM>_::T_QG^R??V.B?LO_  LL/BIXMUS3?CEX&U637-+\7:=XYN/AKINA:0/#
MEI<+?>*M1\!ZGINJRZC<6UKX66XM;Z:35H?.C3['^-/P*TWXQ>+/V</%-]>Z
M=9S?L]_'5/C9I\5]H%OK4^J7<?PA^+?PL&F:==S7-N_AV\Q\41JXUN".\E$6
MCOIGV3&H_:[3P[XW_L:ZA\6;/]LP:;\1;+P[J'[57P+^&'PCTJ6^\(SZS9>
MM2^&47Q1-GXCU"VMO$ND3^*K'5;KXAV[W.B6MWX;N+>WT>:*'6&EU".>Q /3
M_@Y^T/JWCGQUXI^#WQ.^&.K?!WXP^%?"'A_XAOX7NO%'ASQUX>\3> _$FLZ]
MX;M?$G@[QEX::"'4UTGQ+X<U+P_XHT;6-$\/:]H-])H]U+IUSHOB'0]6ON.^
M)?[8UE\*?!MIXJ\3_!KXO_:=2^/=U\%;#1['PYYD<>D0?&O1?@Y!\7==\2W;
M67A?PW\/-2/B'1O%VAG5-47Q)XHT?4+;3O"&A^(M:>2UAZ+X.? CX@:'\5?%
MGQZ^./CWPAX[^*GB+P'X<^%VBVOPY\"ZS\// /@GP'H'B+7O%UW9Z7I/B/QU
M\0_$>L>(?%GBC7O[2\2:[J_B)+1++0_#.CZ%H.D)8:M?Z_3_ &Q_@I\9?C[\
M.=+^'GPF^(/PR^'EO-XM\&^*/%.I_$3X<>+?B++=_P#"O?'_ (,^)'AFST"V
M\+_$WX;KI?VG7/!Z6.N7&HRZN9M*OG&G1V%W )Y@#F/B]^VQHGPG\8_$>PG^
M&_BKQ!\-?@,_@2/]H;XL6>L^$],T?X7O\1;;3=4T8VOAO6=4M/$OC>+0/#FL
MZ-XM\;RZ#;1#2/#^KV:>'5\8^)(M2\.:?]O@AAD>I'XJ2I_4'GOUK\SOC7^P
M/K?[1?BK0_$?Q5\4?!MO[?\ !7@+PM\:9_"_P:\3:;XH\3#P?K\VOW]EX+U^
M[^,%SHMAH.K-<W6G>&F^*G@OXM^+?A-#J?B74OAMXIT?6_$(OM*_3%1M&,YY
M)/U8EC^&3P.PP,F@!:\'^./QZT'X!M\-=8\;Z5>V_P /?&WQ$TKX<>)_B,+J
MTM_#?PMU#Q58W\'@?7O'3W.Q['PGXG\:PZ-\._[>CD^S:)XF\6^&9=76#1KJ
M^U+3O>*\$_:D^!EA^TS^SK\:/V?]3U"PTFQ^+_PY\3^ 9]5U308/%%AI8\0Z
M?)9QZC<^'[FZL8=72QE:.Z%B]Y:B9XD N(6"R* ?+$O[<GQ0U?XB?L_^%O _
M[+>L:]X3_:5M/%.O_#7QGK_Q;\)^"[MO!O@Z6WU/5?%&O^#-0\/:CK>D1ZEX
M$U/0O'/AK2#<7&JZE8:U;:7J<&A:K!=Q0]!\#/VYKSXIZA\*+CQE\$/$_P ,
M/ O[0GB7QOX6^!?Q G\9>$?&.C^*-;\'6?C/7;;0?%^G:,UCK/P^\0>+_"/P
M_P#%_B7PM:WEIK>C7:^']0T&^\0Z?XDFT72]8^AO''P1_P"$O^./P!^,47B&
M/2X?@A:?%JT_X1M=(^T?\)"OQ.\,:#X<B\K4EO[=-(70QHGVG9_9]^+]9Q;J
M;,0^9)\K_ +]BGXI_#\? ?PS\5OC-X'\;?#+]E_Q9XT\;?"/PSX%^$^L^!]>
MUOQ5XBTOQ_X7\.:]\4/%'B+XE^/(M7_X0SPC\3?&%I9Z+X0T+PE8:OXDO[/Q
M'J5Q]FTBQT&@#ZN\;?&]O FH_%&'4OAG\3M:TKX=^"/ASXITG4O!WA6]\5S_
M !(UOXAZ[XZ\/Q>!/ ^E:8AGNO$?AZ]\)Z/+XFN]3N--\.^'M,\:Z'KOB/6=
M#\/6NL:Q9?._C']O3P_X=^$W[+7Q%T[X>:G<:G^U=X'L?'?@S0_%OCGP!\.?
M#?A?3S\.-+^)^KZ1XU^*'BK5HO!-GXEM- U)[?1=!T>XUJ^\576F:[J&D1CP
MOX=\1>(](^P/B;I_Q#U3P/KNG?"G6O!?A[QS=P6]OHNK_$'PSKOC#PE:(]W
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MXP^!?PO^+?@?QE\,/B7^T%XC^(/ASX=V-L=+^)/@/Q!'\.O"^B^+]3\6:/\
M$[P#<:EX?N?!&JZ5KUI!HVMZM;>'[Z/5;/6++7]$T*+2YKQP#[HHKX=\<_\
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MZQB*6&AR0G.G%_O*T.:\U:-VKM6?Z#45^!(_X*&?M)D@'4O!&,C/_%&Q^O\
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MA".?[-KQUB7Q$N@OXN.F1>%!HQ\7R2CP7')XZ\U-!:V_X0-&\<B?_A$E.M
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M;4H+F^\.7]_IOB/3FN_#6MV4<CZ+J5^D$LH /K&BBB@ HHHH **** "BBB@
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>lossonassetheldforsale.jpg
<TEXT>
begin 644 lossonassetheldforsale.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MI^(K;PS<2^,+SX?^)W\-Z;X?OIKNSNI_$][J%NG]@Z?I#R:U=WT2#3();E%
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M[SP;HGBW2OB)\,O$7Q!LO!NE^+M*@T;5?$.O>$_&_B#3_AW8Z_K4MGX_>QT
M>+H_N"YT+1;RUN;&[TC3+FRO+"+2KRTN-/M)K6ZTR 3"'3KFWDA:&XL(A<3B
M.SF1[:,32[(E\Q]U];:W6W6U6&);98A L"HHA6$)Y8A6( ((A&!&(PNP1_(%
MV<4 ?SO?#CQQ'+>_\*S^)GQ L-#_ &61^V->Z/\ $77/AS^TW\0_B%^SSH.F
M:U^R,?$_PO\ A9X<_:;\1:EX.\<Q>$->^+FDW?B7XH>&=2O_  WH6@_%G6/
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M?%+6[CQG?7NMZ9>:3I<OA[0KJUTZ?2M.UZZN-7FMK::RM;1I[^#Z>!# ,.A
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MGR3;HK$^S>(O^@MI'_@AN_\ YH*/LWB+_H+:1_X(;O\ ^:"@#;HK$^S>(O\
MH+:1_P""&[_^:"C[-XB_Z"VD?^"&[_\ F@H VZ*Q/LWB+_H+:1_X(;O_ .:"
MKMG'J,?F?;[NSNL[?*^RV$UCLQNW[_-U"_\ ,W97;M\K9M;._<-H!>HHHH *
M*** "BBB@ HHHH **** /Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7
M'_N+_P"@BOQ#_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(H ?11
M10 4444 %%%% !1110 4444 %%%% !7"?$W_ )$/Q-_UX+_Z4P5W=<)\3?\
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M_P!G6_M0?^L<_$&OV\C_ -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\
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M[T/_ .75;=% &)_:UW_T+NM_]]Z'_P#+JC^UKO\ Z%W6_P#OO0__ )=5MT4
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MZW_WWH?_ ,NJVZ* ,3^UKO\ Z%W6_P#OO0__ )=4?VM=_P#0NZW_ -]Z'_\
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M&_Y*S)/^PFK_ .HF(&MI>GZH^H:***_J404444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_
M -!%?B'_ ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!% #Z***
M"BBB@ HHHH **** "BBB@ HHHH *X3XF_P#(A^)O^O!?_2F"N[KA/B;_ ,B'
MXF_Z\%_]*8*\G/\ _D19U_V*<Q_]0ZPX[KU7YGQ&W4_4_P Z2E;J?J?YTE?R
M*(**** "O=_@-_R'-=_[!%O_ .EK5X17N_P&_P"0YKO_ &"+?_TM:OJ^!O\
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M 44 @]"#@X..Q]/K10 4444 %%%% !1110 4444 %%%% !1110!^('_!2?\
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M3=1T*ZU/PCJNM:K-H&HM9BXT];TI&W^BZ>UI[9D>O7I[T9&<9&<9QWQZX]*
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M(W13PTC,.WH1[^M/VC_(7_XFG?Y_S^1I,C&<C'KGCGIS0 FT?Y"__$TH&/\
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M\4>$O%.DWNA>(_#NMV<5_I&M:/J4+6U_INI64X:*ZLKN!VBN() 4DC8JPP:
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M1]-@2UT_2])TK3H;:PT[3K&VCCM[2RL[>&VMX8TBAC1%"C:H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>oie.jpg
<TEXT>
begin 644 oie.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
MO_BAXBN?C]8^/-;^*7Q-M/!7B^/P]\!?A)\!5\3SZ1KNL?LY>);F#Q-!J_@W
MX9Z)HOPZN/AMI7PIL]5\8^*?&'Q<M=(]-T;Q5\+],_X:F\/?!7]JO7/#7[*(
M_9N^$'B75/C5!\?AXL'@_P"-_B?Q)\4K;6/#_A'XM_%75_&<7A?QM\7/AM9>
M#KOQW::7JEAXG\)ZO?\ AGQMX>M_"_CSQPFO7'[$6'P[\!:7KA\3:;X*\(Z?
MXC+7+G7['PSH=GK6^]22.[;^UK:PBU#==)-*EPWVG=.LLBREP[ W;OP;X2U#
M2;K0;[PQX>O=#O;U]2O-'N]$TNYTJZU"2[^WR7]SIT]I)93WLE]_IDEW+ ]P
M]W_I+2&;YZ /YW/B+\;;_P"*7P1_8.'@#XT?"3Q1:V/[%E_XA\:W'QM_:X\<
M_ 3X)>(_BG:^ O@U:6&I)\<OA/J^I^)_%7[2'PT\0FYOM1\ ^*I[C2='\(^-
M=9\9ZWKWA#Q6_AK5=1_=C]F;Q5/XY_9U^!/C&ZN/&UY=>)_@_P##;7+J]^)6
MEV>B?$*_NM2\':/=7-_XWTG39[K3-/\ %5_/))>ZY;:7=76EIJ-Q.=.N;BR:
M"9_0[7P%X(L=-31[+P?X6M-)CU5=<CTNU\.Z-;Z<FM(Z.NKI80V*6BZHKQQN
MNHK"+Q616$X*@CK0,<?Y_P ^] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?,'QI_:T^&7P(^,_P"RO\"O&=AXON_&7[7WQ \<?#?X777A_2M,OM T[7OA
M_P##;6OBEK=QXSOKW6],O-)TN7P]H5U:Z=/I6G:]=7&KS6UM-96MHT]_!]/
MA@&'0@$?0C-?B#_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4
M/HHHH **** "BBB@ HHHH **** "BBB@ IKND:L\CK&BC+.[!%4=,LS$ #/<
MFG5PGQ. /@+Q," 1]@7@\C_CY@KCS#%/ X#'8U055X/!XG%*FY<BJ/#T9U5!
MSY9<JGR<O-RRY;WY7:S:5VEW=CL/M]C_ ,_MI_X$P_\ Q='V^Q_Y_;3_ ,"8
M?_BZ_%3]J_\ :6TC]ESX>Z?XQN?"C>,]<\2>(&\+>$/#LWBKPM\/]$U#6X='
MU'Q%<Q:]X\\97EGX?\.0_P!B:/J1TFW(U'6_$FM"ST+0-'OKF>YELM'Q!^T+
M;^&_B!\!OASJOPC^*FEZQ\;]6O\ 1[J_UC2]"M/#GPOU&U\"?$CQS9Z'XM\4
M6.L:MX=\2^*]6@^&.NVEEX>^'6J>*%M]-DLO%^L:KI/A[4-#?7/RB'B?F,Z-
M.O'ARFZ57ZPZ<O[6BG)82"J8B2@\&I\M..CDXJ,IOV5-RJ6@%O7[K=O/S_+O
MI^S7V^Q_Y_;3_P "8?\ XNC[?8_\_MI_X$P__%U^"L7[9V@Q?%?XK>!=8T+X
M<:+X5^#]S\7F\3Z[/^T)X/O?BU<Z)\%?"ESXF\8>)-&_9NLO"$GC"_TW_0;^
M&QM5\7#59=)LY/%,ME'I3QQ-Z;\*OCY?>._&%AX!\;_"O5/A'XO\3?"'2?C]
MX"T;4_''@OQT_BOX2:OKNF^&VU>ZG\(ND?AKQ/H6LZ[X=M/$7AN<:OI$8\06
M,WAOQIXHBM-8;3:J>)N9TH.=3ANE&*I0K:YO3<G3FKJ48+".<^6*YJL81<Z,
M7SUHTXN+"R[_ -:7Z^OK;3?3]G?M]C_S^VG_ ($P_P#Q=2Q7-O.2L-Q#,RC+
M"*6.0J"< D(Q(!/&3QFOP^T[]J*SO/&>AV-S\-=9TSX4^+_CYXI_9=\&?&.[
M\6^$V@\0?''PA<^+M+U'0'^&Z[/%>E>&-2\2^ _%OA+P_P"*IK^[U&]UG2$O
M]5\(:#X4U;3/$DWZ2? 0)_;FNLH W:/;'( &0;TD9X!Z>M>AD_B%B\RSC+LJ
MQ&24\(L?.<56CF,<0Z?)3JSE>$,+%*I&5)PJ49SIU:<G:<(NR"VE_P"MTN_G
M_73ZCHHHK]1$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^('_!
M2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 017XA_\ !2?_ )22?\$*
M?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!% #Z*** "BBB@ HHHH **** "BBB@ H
MHHH *X3XF_\ (A^)O^O!?_2F"N[KA/B;_P B'XF_Z\%_]*8*\G/_ /D19U_V
M*<Q_]0ZPX[KU7YGY+?M4?!7Q/\?OA%XA^&_A;QOHG@^YUI&@O[/QG\//#GQ2
M^'?B[3Y);9GT/QSX/UY(;JXL;2:WBU?1M2\/:OI&JZ=K-K$MR=4TB\O].D\:
MUC]E+XMZ%IW[-GACX.?&?X;>'?"/[->OZCXQT"U^)'P.\1>,M7U[Q1K/A[XM
M^%-0MR?!?QI^&_AWPG\/['0OBWJ%IX/\ Z!H;Q^#+3P_X=T&PUR\\/:=%95]
MY-U/U/\ .DK^4J688JC1AAZ<Z:HPJ5:JA+#X>:<ZU)T*CFYTI2G>E*4(\[?(
MIRY;:6$[?T_)]&NQ\KZY^SWXO\5>.-&U#Q+\4O#]S\-_#'QD?X^>'?">D?!?
MPKHGCB/XB)X;U[P]I=IK_P 1(=<GT?Q+X1T7_A(KVY>2]^'$/C_QCI=OIW@W
MQ_XX\1>'(=276?-/A)^Q?J/P8D\7>*? _C/X6>&OBA??#S3?A;X$U_PI\ ?[
M \!^$O"T/C/2/%^OWVM?#J[^*GB&X\1Z]XI_L:QTQ-(T;QCX,^&OP_L=/TZS
M^&_@/P_I[:Q::O\ >=%4LSQL:;HQK1C2E&G&=..'PT83C3FYQ4XQHI3O)OVG
M-?VT6X5>>'NA?OK;O?R\_+^M+?&-S^QWH&I_M&Q_'75K_P "-8Z7\4!\8M%T
MC0OA-;>'_'UYXUL]!O=!\/1^-?B)#XSO=!\0:;X;6^74I-;T/X8^$OB-X^O-
M(\,6'Q(\;>)-%\.QV.I?J)\!0%UO7 .@T>V ^@O2!7A->[_ ;_D.:[_V"+?_
M -+6KZ/@[%5\3Q9P_P"WJ.:H5)T:2Y8Q4*4,+B>6*4(Q3M?XG>322;:22+_%
MZ?K$^H:***_IX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X>?
M\%+1,?\ @I!_P0J$#Q1R_P##5W[3N'FC:6,+_P ,>>/S)F-)868F/<$Q(H5R
MK-N4%3^T<<7B;RT_T_0ON+_S"=0]!_U&J_&#_@I/_P I)/\ @A3_ -G6_M0?
M^L<_$&OV\C_U<?\ N+_Z"* ,7RO$W_/_ *%_X*=0_P#EU1Y7B;_G_P!"_P#!
M3J'_ ,NJW:* ,+RO$W_/_H7_ (*=0_\ EU1Y7B;_ )_]"_\ !3J'_P NJW:*
M ,+RO$W_ #_Z%_X*=0_^75'E>)O^?_0O_!3J'_RZK=HH PO*\3?\_P#H7_@I
MU#_Y=4>5XF_Y_P#0O_!3J'_RZK=HH PO*\3?\_\ H7_@IU#_ .75'E>)O^?_
M $+_ ,%.H?\ RZK=HH PO*\3?\_^A?\ @IU#_P"75'E>)O\ G_T+_P %.H?_
M "ZK=HH PO*\3?\ /_H7_@IU#_Y=5Q?Q%CUT>"?$1O+S29+<6(\U+;3;R&9E
M^T0<1RRZK/&AS@Y:&08&-O.1ZC7"?$W_ )$/Q-_UX+_Z4P5Y.?\ _(BSK_L4
MYC_ZAUAK=>J/B,]3GU-)2MU/U/\ .DK^11!1110 5[7\$EU!M9UL:?-9P2#2
MK<NUY;3W2,GVPX"K!=V;(P;)+%W!&!M!^:O%*]W^ W_(<UW_ +!%O_Z6M7U?
M W_)69)_V$U?_43$C6TO3]4?0GE>)O\ G_T+_P %.H?_ "ZH\KQ-_P _^A?^
M"G4/_EU6[17]2B,+RO$W_/\ Z%_X*=0_^75'E>)O^?\ T+_P4ZA_\NJW:* ,
M+RO$W_/_ *%_X*=0_P#EU1Y7B;_G_P!"_P#!3J'_ ,NJW:* ,+RO$W_/_H7_
M (*=0_\ EU5ZR34U\S^T;BPGSL\G[%:7%KMQN\SS//O;S?GY-FWR]N&SNR-M
M^B@ HHHH **** "BBB@ HHHH **Y:?QQX,MO$$/A.X\6>&H/%-PBO;^&YM>T
MF+Q!.CJ&1H=$DO%U24.I#*8[1@RD%20174_Y]/YT ?B!_P %)_\ E))_P0I_
M[.M_:@_]8Y^(-?MY'_JX_P#<7_T$5^(?_!2?_E))_P $*?\ LZW]J#_UCGX@
MU^WD?^KC_P!Q?_010 ^BBB@ HHHH **** "BBB@ HHHH **** "N$^)O_(A^
M)O\ KP7_ -*8*[NN$^)O_(A^)O\ KP7_ -*8*\G/_P#D19U_V*<Q_P#4.L..
MZ]5^9\1MU/U/\Z2E;J?J?YTE?R*(**** "O=_@-_R'-=_P"P1;_^EK5X17N_
MP&_Y#FN_]@BW_P#2UJ^KX&_Y*S)/^PFK_P"HF(&MI>GZH^H:***_J404444
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M_P!!%?B'_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$4 /HHHH
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MO9V0'*?\+-^('_0V:A_X ^'O_E)1_P +-^('_0V:A_X ^'O_ )25PM%?@_\
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MI7AGPGHVD>!O W@O3[^T\1^'+3X96OA3Q%'XOTF'6-4\2ZI'J6L6E[P>O?\
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M_!"G_LZW]J#_ -8Y^(-?H9\;_P#D:=-_[%ZS_P#2S4*_//$__DEJG_8?@O\
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MC_A%]&_Y]9/_  .U'_Y,KH** .?_ .$7T;_GUD_\#M1_^3*/^$7T;_GUD_\
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MC,@C1HX:OBW_ &E@)U*.'I5JM1T8U7[67+AZ5:JHJ#?-.%*HXWNHR=HMK?\
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M ,Z2C_B(6_X(\?\ 1Z/AG_PUGQ__ /G24 ?M!17XO_\ $0M_P1X_Z/1\,_\
MAK/C_P#_ #I*/^(A;_@CQ_T>CX9_\-9\?_\ YTE '[045^+K?\'#/_!'1"BO
M^VKX51I&*1*_PP^/B-*X5G*1*WPF#2N(T>0I&&81QR2$!$=@[_B(6_X(\?\
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M2P$L'[2_A/6=<U1_A[IM_P"*;GX6_$G]JGX>:)X5^#?AZ>>X_P"$?T/3-%\
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G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>otherrevenues.jpg
<TEXT>
begin 644 otherrevenues.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M/K;4/A+I,FD>!/"-SKGA;X=:9H>D0:UH,&J^!#X!N;S5O[0ZC]K[_@GQX/\
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M"C[=H^HI$-:M?&W@SXX>-M,U>%KZQGT/41I&NZ%=07NGLD_-1?\ !/+PM9^
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M\R%O+U.$\Q:@FV\C_@F7)J?4M+TW6;&XTS5["RU33KM!'=6&HVL%]97,8=9
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MR6.GV-F]S/<W-P]K:6ULT]S>7#W=W<3-#%&TL]U=.]S<RR%I)[AVFE9Y6+D
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M##XE(_AKXE:%JVE^(-1T#6M)MP_B+14O[;Q%H:0M87FH6'R]\=OAQ^T3XO\
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M'2/_ )-K?HH P/[4U;_H7+O_ ,&.D?\ R;1_:FK?]"Y=_P#@QTC_ .3:WZ*
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M/;)Q]:;_ ,+T\,8(_L;6\$Y(\O3,$^I']H\GZU\L44?\1/XH_FR[_P (W_\
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MYL8H(EX^])(JYP,Y(!]0KA/B;_R(?B;_ *\%_P#2F"O)S_\ Y$6=?]BG,?\
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MA=X:^*&H>![7PI:)J?PXTOQ[IW@:S\7_ !ATV*#2/!'@CPM%K.KZ]-I_''X
M_M'6G[/O[-O@KX'_  =F_:'^!WP;'[+NN_#Z#Q1KGBGX$?$!OBW9?M5^"?$O
MCOQMK_[/WC7X+ZMK7@/PWX!\):4VA_"?3)+VUL_@M\/O$OCS5YM*U*'POX0N
M;;]Q?^%T^"?[VK^O_(-ER?J?,R?\^E+_ ,+J\$_WM7_\%DG_ ,<KSO\ 6_A?
M_H?99_X54_\ ,+/L_N9\^:'\.;CQG^V=J_C?Q3\,[70O#_P6^$G@Z^\ ZZ_A
M+3AI_B+XT?&B^\>V_P 4O$FE^,!I=K<:]K'P]^'_ (6\,>"++4H)([FPL_B?
MXW@NX8EU^)1\!?M/^'_B)\5OB#X[^,MA\,OB;K6B?%;]E;X9Z)^SCX$\5?L;
MQ?$V]U3XB:!XK^+>J^-O@9\>/#?Q*\-:E>? /P=XXU#7/AGK/BK5=1N?@M>:
M_86\%U?_ !:TJ;X6Z+:VO[ ?\+J\$_WM7_\ !9)_\<I/^%T^"#U.K'C'.ER'
MCTYDZ<"C_6_A?_H?99_X54_\PL^S^YGI>D&^;2].;4[:WL]1:QM&O[2TG>ZM
M;6]:WC-W;VUU)'#)<V\%P98H+B2*)YXD25XT9RHT:\WT;XJ>%-=U2STBP;4C
M>7TCQ0":P>*+<D4DS;Y"Y"C9$V"0<G [UZ17JX#,\OS2E.MEV,P^-I0J.E.I
MAZD:D8U%&,W!N+=I*,X2:[23ZBLUNK!1117< 4444 %%%% !2'H>=O!Y]..O
M/''6EI#T.>1@Y'7MZ'@_C0!^(?Q7\,>*?&?[5_BVPM_C_K&K0^$/CS\/M=\(
MVOA30?VH/%B_#7Q1XBU3]FN_\2:+XGE\ ^!M<^"WAK6?A_\ "GX>>)?#'@WP
MW?\ B&/1=8LOVD/&GBSXK0>&FEU*3Q=^WB].<GD]?J>.0,@= <<@ U^)/C;X
MIQ^!?VH_BUKGAWQAK?A3P]:_M/\ P0^'?CCX4VG[2^F^&_B7X\\7^.M/^%&D
M6_C/X>?LVO\ !C7+/5_"VIV7BK1OMT;>/]-\1_$SP[X9\6^)(=2TJ;1M+MM4
M_;8'(S]??OV/&1Z'N,&@#\//^"ET\%M_P4?_ ."%D]S-%!#'^U;^T]OEF=8X
MTW?L=_$!%W.Q"KN=E49(RS =37[31^)?#WEI_P 3S2ON+_R_VWH/^FE?B]_P
M4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JT_W%_D* ,?_ (27P]_T&]*_\#[;
M_P".4?\ "2^'O^@WI7_@?;?_ !RMNB@#$_X27P]_T&]*_P# ^V_^.4?\)+X>
M_P"@WI7_ ('VW_QRMNB@#$_X27P]_P!!O2O_  /MO_CE'_"2^'O^@WI7_@?;
M?_'*VZ* ,3_A)?#W_0;TK_P/MO\ XY1_PDOA[_H-Z5_X'VW_ ,<K;HH Q/\
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M?#[4-1LM"M_$M_K,&HVYB\,3VGB"Y /MGS(_^>B?]]+_ (T>9'_ST3_OI?\
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MK,D_[":O_J)B!K:7I^J/J&ZDC^S7'[Q/]1+_ !K_ ,\V]Z_/ $!020 %R2>
M !R2>P%??=SX>T 6\Y&AZ."(92"-,LL@A&((_<=0>1[U^4OQ]U/6-'^#'Q"U
M'P_\1_#_ ,(M=@T.U32?B9XKN)+'PWX.O;O7=&LDU/6M7CTO6SX<LKJ.YET8
M^+WT;5H?!4^JP^,;C3;Z#09+67[WQ9INKB>&Z46E*K+,J:;4FE*I/*X)M0C*
M;2NFU&,I/51C)V31[ >"0>""5(/!##DJ0<$$ $D$9QS29!Q@@YY'/4>H]:_%
MK]G?XR_#_5_V9_!]G\6?C3^T1HZ>"/']OX7G^'WA;]HS2?B#XT^/OC'Q=\/;
M3Q/X,^&'PB^/G@:\\+_$GQ3I^C6E]-XTUKP;J'BCP[K?P_\ $IGF^,VM^'OA
M3HVGP#W:\U7XQ^!+'_@G;+\6?VE($UZ^^+'A?P9\5_"FE>*OA^ND_$:?7/AK
M^T+K<NH^/OB%;M:77Q(M/#%AH/@WPW)/H5KX>\#>(OB#X<UCXB7L.KWFIZ)8
M:'^8U\EJ4*E6E*O!3IU*\(J=*K'VRI4JU9.DX*I&HW&E'G<9.C3=>@E7FW55
M)I7_ .&?7;RWT^3\K_I?D>HZD=>X )'U ()'8$'O3@K$9 )'J 2*_*&S^(GQ
M4T7]I'X?Z./$7C?Q/XV\6_MJ>-OAYXLGL/CGX/\ $OP,U/\ 9H?0OB'KMAX5
M\+_ S2/&6KZ_X0\;_"#P?8^"=4\9WNK_  V\(>)O"GC31]>\0>*?B5XHT+XA
M^&-$\0>U_M(Z#X.^+_B+]G'1_"/Q&^(UIKWQU\4W&CZ'XV^#7[1'Q1\(^&;'
MX0?#'0M9^+'Q6\8Z%IGPO\?Z5X#\5:]?:78Z=\/= \1ZCIVN);:CX]TV\N)K
MNW\.65A64\L=*KAX3KITZ]"==U:4555.%-5I5)2@JD7R1A0JU4VU5E3A*U%3
M3IHM^.WX;W\G>_\ 2_2SX9D#QWX<)( %W<$DD #_ $"[ZD\5]N*RMG:RMCKM
M(.,],X/%?$'PZA@N_'&@0W%O!+;S7=SYEK)&)K<J;*[<1F.?S-\:$+L\TNWR
MJS,SC=7VK::=I]AYGV&QL[+S=OF_9+6"V\S9NV>9Y*)OV;FV[L[=S8QDU^T>
M$W_(BS#_ +&]7_U"P%[_ (?B(N4445^I@%%%% !1110 5'-#%<1203Q1S031
MO%-#*BR12Q2*4DCDC<%7C=&*NC JRDJP()%244 ?-LW[*_PT>X\NWUKXPZ9X
M;,,L+> ]'^._QCTCP%Y4K,3:P>&-.\;6UI8Z6%9H_P"P=-DL?#YA9H&TEH6,
M9^@]+TO3M$TVPT?2+*VTW2]+L[;3].T^RA2WM+*RLX4M[6UMH(P$A@@AC2**
M- %5% '2K]% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MV@S$@Z9C49QG^$=
MN_TK\1/^"D__ "DD_P""%/\ V=;^U!_ZQS\0:_4KXC_$?7_".LV6FZ7#IDEO
M-I%M>.UY;SRR^;)<74+ -%=P*$V0)A=A(8L2Q! 'DYUG."R'!/,,>ZJPZJTJ
M+]C3]I/GJMJ/NWCIH[N^@'QOK_[%?Q2UK]NJP_:<MO$/PF\.:#I&GZ==)XT\
M&>&O%G@WXY^*[33;W5U3X-_$2;1O%#?#SQYX"OM.O;"RU+QIXK\,ZUXBB\.Z
M3H^B:#X>T7Q)I%EXZCPM#_9<_:S\7V?[05E\49_V=/!EW\1OCW\,?VK/AIK_
M ,/?$?Q5\?/X5^,7P97]GE?!?ASQ;X?\5^"?A]'K_@'5Y?@1YGBV_P!*U_3-
M>?3_ !/=:5HVG6=S9V^N+]2_\+Q\8_\ /MH7_@%=_P#RPH_X7CXQ_P"?;0O_
M  "N_P#Y85\C_P 1/X8_FQ__ (2>G_3SS?W>8_FOQ_R_JS\K^+W?['WQ(\;>
M%/C%??$'Q+X!M?B#^TE\:/V=_$WQ>T?PM!XHN/ -A\#O@EX@^'EOJGP>T"^U
M6.SU[Q%<^-O WA3Q98:]XDUW2-'M=2O/B'JFCS:)::!I=DTGO7[0?PM^)7QC
MT3QQ\/8K#X/:C\-M7\"^'+[P[;^,C\4;?Q-#\8O#OQ M_%%IJ,VL_#_Q)X3U
M3POHNF:;H^B:CX-\9^"]>L?B%X(^(=M;>+=/%]#HUGIMWF_\+Q\8_P#/MH7_
M (!7?_RPH_X7CXQ_Y]M"_P# *[_^6%'_ !$_AC^;'_\ A)Z?]//-_=YA\U^/
M^7]6?E?._9#_ &:-4^ =I\5?$_B_4]/U+XB_&WQQI'C3Q@-*\0^._&EGIB>&
M/ OAKX=>&]*E\??$_4=0^(/Q#U:+1/#$=_K/C/Q2-,N;^]U)M*TGP_X?\-Z)
MHFEV_P!C5\ECXX>,21_HVA=1_P N5W_\L*^D_"6JW.N>&]&U>\6%;K4+&*YG
M6!62$2/G<(T=Y&5>. SL?>O;R+B_*.(L16PN7/$NK0H?6)^VH>RC[-3A3=I<
M\KRYZB5K;7=PMU_KI_F=#7B_[0NL_$_0/A!XPU'X-0:#=?$ORM&L/"EMXANM
M(M+:YO=8\2:-H]S;Z5_PD6KZ!X<O?%T^F7]_'X$T?Q'KNB^'==\<-X=T77M5
MT[1[^]NX?:*YCQGX+\)?$3PQK'@OQWX:T3Q?X3\06HLM:\.^(],M-7T?4[99
MHKB..\L+Z*:WE\FY@@NK>0H);:[@@N[:2&Y@AE3ZD1^*OP4_:?\ CW\0/A#\
M!=+U;XO_ +1-M&ESK>D_'[XH:+^R%HFM_M#^ ?'-_P##3X7^,?@E\/\ QE\/
M_#GACXK^")O"'Q0L/&?BCQE'\=O"/PTO?#.M:9IO@/P2S>$_$7B34_$<_+^'
M_P!NO]ICXG^#H?'5S-\3OAMH_P %OV:?A7\:/C!J7PT^$/P:\6:--+XI\3_&
M6V\4?$7XA:#\4/&UMJ^O?"^R\,_!B6]3X7?L[^+H_B=:W.H>-YK;QKJ3:+X(
ML]?_ $]TG]@_]E'0OA9X0^#FC_"#1M,\$^![V74] 73=7\4:3XG75;S18/#F
ML:IJ7CK1]=TWQOK=]XC\/VUKH/B>75_$%XGB30K2TT36HKW2;.TLH.R\9_LE
M?LW_ ! D\$-XJ^#W@O4+;X>:%I/A/PQI-O83Z/X?A\&:#-!<Z#X%U;PWH=UI
MF@>*/ 6AW5O'=Z-X%\5Z9KGA'2KOS+JPT6WGFFDD5UW7]?\ #K[P/GK_ (*#
M_MBZ#^S5\'TTW2?BOX%^$OQ1^+GA'XH2?"WQ[X_NM MO#_A*W\"^!+GQ/KOC
MZ"P\62VVA>*]8T66]\+Z'X+\%W+7?_"4^//&'A.TU'3+GPM#XIN+#Z:_9B^*
M%O\ &G]GCX)_%:W\3:+XQ;Q[\+? OB6_\2^'KO2[[1]5UO4O#6FR^(IK.XT7
M&E_NO$']J6MQ!9)%!9W=O<60A@:W:&/I-/\ @M\,=,T7XE^';7PG9G1/C#X@
M\5>*?B/IMU=ZKJ%MXFUSQMHUGX?\47EPNH:A=-9)JVCV%M8S66DMI^GPQ(S6
MEK;RS3R2]MX:\-Z'X.\.Z%X3\,Z;;:-X=\,Z-I?A_0=)LPZVNF:-HMC;Z9I>
MGVPD>20065C:V]M%YDCOY<2[W=LL2Z[K^O\ AU]X&W7"?$W_ )$/Q-_UX+_Z
M4P5W=<)\3?\ D0_$W_7@O_I3!7E9]_R(LZ_[%.8_^H=8<=UZK\SXC;J?J?YT
ME*W4_4_SI*_D404444 %>[_ ;_D.:[_V"+?_ -+6KPBO=_@-_P AS7?^P1;_
M /I:U?5\#?\ )69)_P!A-7_U$Q UM+T_5'TU=?\ 'M<?]<)O_1;5^=HP5P0K
M J59759$='4I)')'(K1RQ2HS1S0R*\4T3O%*CQNRG]$KK_CVN/\ KA-_Z+:O
MSM7H/H/Y5]SXN_Q<@_PYK_[S!'E-U\!O@9?^%/#7@34O@I\(-6\$^#$O$\(>
M$-;^&/@?7O#/A9=2.=2/AW1-;T+4=/T:34B!_:4VGP03:B%07LDXC0+6U;]G
MG]GW7[71+'7O@%\"]=LO#.E#0?#5EK?P:^&6L6?AO0EO+K4%T/P]::EX5NK?
M0M%&H7U]?C2=)BL].%]>WEX+;[3=W$LGL%%?D'UBO>_MZU^:4K^UG?FFVYRO
MS7YI-MREO)MMMW8'-V'@SP;I7B"\\6Z7X.\(Z9XMU'3;/1M1\6:;X5\/Z?XJ
MU#1].6%=/TC4/$MEIL&NWVE6*6]LEGIEWJ$UC:I;6R06\:6UNL4VE^%/"VAV
MN@66B>%_#6BV7A2SN].\*V6C>'M&TFS\+Z=J$<<.H:?X9M=.L;:W\/6%_#%%
M#?66C1V-K>111QW,,J1HJ[U%0ZDWO.;T2UDWI&+BEOLHR<4ME%M+1L#N_AE_
MR/GAO_K[N/\ T@NZ^W:^(OAE_P CYX;_ .ONX_\ 2"[K[=K][\)O^1'F'_8W
MK?\ J%EX!1117ZF 4444 %%%% !1110 4444 ?B!_P %)_\ E))_P0I_[.M_
M:@_]8Y^(-?H9\</^1ITW_L7K/_TMU&OSN_X*70QW'_!1_P#X(60R^9L?]JW]
MI[=Y4TUO)\O['?Q 8;9K>2*9/F49V.NX95MR,RG]!_C+:6]CXDT^.#SQ&=!M
M96-Q=W=XX8W=^#B6]GN)50*HPBN$&"P7<S%OSSQ/_P"26J?]A^"_]+F!Y)17
M@%M^TQ\+;WXV7WP%LY/&%WXNTRVNH]1\0VO@'Q?<_#/3_$UA)G4/ %_\28-(
MD\*6'C;3K)H[_4-.O-0@TVR,T.BW6L1>*)%T$TM!_:Q^ OBCX?\ Q+^*GAWQ
MM+K7P^^%7C5_AYXB\3:;X=\17=KK7BU[7P5/I6F_#RUATU]2^)$7BJZ^(?@_
M1? ^H>#[+4]/\;ZYK5K9>%;G5H)(;V;^?'@<8E%_5<1:<:,HOV4[2CB9<F':
M?+9^WFG&DMZC344[,+?Y'T917R[=_M:?#^*VL8-,\"?'OQ+XSN/&_B3X>:K\
M)/#GP>U*[^+_ (0\3^$O!NE_$'78O&O@K4]9T:'0-(A\&:]X<\0Z=XB77-0T
M+Q!IOB70)O#M_JOV\B#U_P 2_$[PYX*^'+?$[QE8^+?"^BQ:?H5U<^']3\)Z
MM=_$&VU3Q-J&F:)H7@YO GA]-<UJ[\>:EXBUG3/#-KX4TE=2O9?$%Y'IZ2LB
MR7*3/"8F#IQG0J1E5DH4H.+YZDI2<8J$/BESR3C!Q34WI%L=GV\M=#T1>H^H
M_G7W'\.O^1'\,?\ 8)M_Y&OS2^&?Q7\*_%.#Q*= MO%.B:UX'\2CP?XZ\%^/
M/"^H^"_'/@KQ*^BZ1XFM-+\2>'-2,K6XU7PUKVB^(M"U33KW5-"UW1-3M;_2
M-5O$%REO^BW@'1+"Y\&>')Y3J DETNW=Q%K.L6\>X@YV0P7\<,:^B1QH@[**
M_3O"F$Z>>YG"I&4)QRMWC)6:YL5A91=GTE%J47M*+4DVFF#V7J_T.5^/#NFA
M:$49TSK+@E&92<V%SP2I!/T/%?,'G3?\]IO^_LG_ ,57T;\;M,M+#1=%>W-V
M6DU=T;[3J.HWJA18W#?*E[=7"(V0,NBJY'R[MI(/QG\3OB/X9^$?@/Q%\1O&
M#WZ>'?#,.F/?+I5K#>ZG<W.N:]I'A;1-.L+>ZO--L3=ZKXAU[2-+@GU/4]*T
M>R>]%]K6K:5I%M>ZC:^/XBQJ5.+\73IJ4ISI9?"$(WO*<\-1C&*2WE*322W;
M:0KOO_7])'?^=-_SVF_[^R?_ !5'G3?\]IO^_LG_ ,57Q[9?M4>)-0^ >B_'
MNW_9M^)]GILNA:AXI\8^&O%WCGX,_#V?P3X3TWPU;^*IO&B>+O%/C:/P9XX\
M&W.FSRK8ZUX-U6_N&N]/U2RO],T[4+&:Q%75?VQ]*T#0KWQ%KWP5^,&EZ;X$
M^%7P_P#C%^T*TA^'LD_[-WA/XD:5JGB#1;3Q[:2>-;6]\7>)M&\,:)J_B_QI
MX?\ AA:^*KSPIX3T^;5;LW%_+9Z)=?(++L<Y2A&FI2A5E1DHXC#R<:D9QI\K
M2K.W-4G3A3>U6=2E"DYRJTE-Z^?WV[?\!^FNR/LSSIO^>TW_ ']D_P#BJ/.F
M_P">TW_?V3_XJO"?V@?C_P"#OV<_ C^._%ND>,O$UJ^H66GV.C_#_P .77B7
M4KQ;C4=,LKW6+J]!M?#WAWPOH5IJD.L:UXF\4:SHVEQV"I::9)JOB"_TG1+_
M -XN(6MKBXMG*L]M<3VSLN=K/;RO"[+N ;:S(2NX X(R <BN65.M&G3K2C.-
M*K*I&E-W49RH^S]IR]U#VD$VM+MQ3;C)(N^_]:?Y+[O0^IO@4SMX8U4NSN?[
M>F +LS'_ )!^G< L2<<]/>NQ^)O_ "(?B;_KP7_TI@KSOX*:7:7WAO4Y;@W@
M=-;E0?9M2U*R4K]@L&&Z.SN[>-F!8_.R%R"%+%54#KOB+HMC:^"?$5Q$=0,D
M5B&03:QJ]S%DW$(^>"XOI8)!@GY9(W7.#C(%?T9E'_)N=[O_ %?S*_\ X(Q7
MZ6!;KU7YGQRW4_4_SI*5NI^I_G25_-P@HHHH *]W^ W_ "'-=_[!%O\ ^EK5
MX17M?P2L;>_UG6H[@W 6/2K=U-M>WED^3>,IW/97%N[KCHCLR@\@ \U]7P-_
MR5F2?]A-7_U$Q UM+T_5'U-=?\>UQ_UPE_\ 1;5^=J]!]!_*OO>X\/::MO.P
M;4R1#*0#KVND<(QY!U+!'J#UKX('0?05]SXO?Q.'_P##FM_ORW]+"%HHHK\;
M **** .[^&7_ "/GAO\ Z^[C_P!(+NOMVOASX<P1W/C;P_!+YGER74ZMY4TU
MO)@6-TPV3V\D4T9R!S'(I(RI)4D'[5LM.MK#S/LYNCYNW?\ :;^_OON;MNS[
M;<W'E_>.[R]F[C=G:N/WWPF_Y$68=_[7J_\ J%@/^ !>HHHK]3 **** "BBB
M@ HHHH **** /Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OT,^.'/BC3AQSX=L
M^HR/^/S4.H[CVK\\_P#@I/\ \I)/^"%/_9UO[4'_ *QS\0:_0SXW_P#(TZ;_
M -B]9_\ I9J%?GGB?_R2U3_L/P7_ *7,#\C-0_9K^,1_;<7X[>&A\/? _@F;
M3+.Z\6>+?!'B[XB>'_$GQ<T.VU._2Y^$?Q8^$+"^^&OBW7M8T\:'9WOQCO[E
MGTW0M T36-$T6R\:Z<MC6)I_P0_:<\96/Q_M/&/@'X2?#74?&O[1GPL_:K^%
MFK:=\;]2^)^D6GC;X,Q?L[CPO\-O'6AV'P=\$WUOX6\0R?!35(=6\5:#<W\F
M@:=K^G?V=X7U&_TD++^E-%?@W]KXF]-N%!SHX?#X:G4<:CG&GAJL*U/_ )>\
MLKU*<'*,XRIJ,>2G"$934G?\-OP_KUU9^=NM?LR^-?%7B[Q1\9/B+\"OV<?B
M[XF\=_$31M=U+X(^//B+XQF\(^#/"/@_X.Z+\(O",6C_ ! _X5Q?>&/&?BN]
M2RUK6_B$OBSX.-HESI^L:)I_@BYTO7O ]CJ^M^C^&?"?[5?P7^ 6A_#'X<:7
M\'OBEXZ\$?!S2],\*^*OB)\2_'WA[1K_ .)UWX]U1+OPSJMO-X3\3>))/A7\
M-_AEJ%A!X-\0:AXAF\:>-KCPUI?A+Q%:^&(KV[\56OV7145,SKU84J56G1J4
MJ,J+A2E[9TXPP\7"C24?;>[3A3E.G+E:G6C+FKSJU(TYP+_U]W]=NR1\X?LQ
M>!?''@?PEXH;XG>%K/1OB-XN\;W7B_QOXJ3XH:?\5=7^)VOW>B:)I+^+]:U'
M1_AQ\+]#\(P:=IFCZ9X.\)?#CP[X=/AKP3X,\.:)I6BW+QBXEN/US^'7_(C>
M&/\ L$V_\FKX<7J/J/YU]Q_#K_D1O#'_ &";?^35^D>%M65?/\TJS48RGEC;
MC'FY(VQ.%BHP4I3E&"22C'F:A&T8VBHQ0]EZO\HGGGQZ_P"0%H7_ &&7_P#2
M"YKXN^('AS5?%W@W7_#6BZQHVA:CK%G':17_ (D\%Z1\1O#,D'VRUFO])\3^
M!-=N++3?%7AGQ!IT5WX?\0Z/)J&F7<VD:I>2Z7JNF:K#97T'VC\>O^0%H7_8
M9?\ ](+FOEZO#\19RI\7XN<;<T*6 G&\8S7-'"T6KPFI0DKI7C*,HR6DDTVA
M'YQ?!7]AO7_AW^S#8? 76O&?A"T7Q!\3_@=X\^(/A?P/X<UW3?A)IWA7X::W
M\,=4\>?#3X=^']6\0:SJ>GVGQ87X;O?>,=9NKJSTC6?$_BKQ#J8\):/I]W-8
MW'>?M1_L@R_M)^(]8GNM1^'NC^'O'_P_M/AI\2]3O=%^)A^(5]X9BUO6]3O(
M+2+PO\2/#_PL^)"?8]?U.'P58?&[P)XKL?A/XDO+_P 9^&1K,FH7'AQ?N'KT
MHR/45\J\XS#ZR\6J_+7=6K6YXTZ:M4K*BIR2Y=;K#T/BYK^S2ES*4U)W?D]+
M?+3_ "_RU/D+]HSX2_M!_&'X,_$OX1>%/%?P$T*W\=>)KK3])U#Q-X;^*[P>
M&_A)IFH>$=<\%:1=VN@>(9YO$/Q&L-6T#4;?Q#KK3:3X7O=*O-,?2M'L]1LK
MV2]^I/#TOBV?1K"X\>'PJWC*X2>X\1GP.NO)X1_M&XO+F9AH"^*&?Q"+!;=X
M%_XFS&Z-R+A@%A,*C9HKCGB)U*,*#C34*=2I5CRTXQESU84X5&Y))M3C1I73
MNDX)I)N5R_ITZ=OZU/JKX$?\BQJO_8>F_P#3?IU=G\3?^1#\3?\ 7@O_ *4P
M5QGP(_Y%C5?^P]-_Z;].KL_B;_R(?B;_ *\%_P#2F"OZ)R?_ )-R_P#LG\R_
M]1\4$=UZK\SXC;J?J?YTE*W4_4_SI*_F\04444 %>[_ ;_D.:[_V"+?_ -+6
MKPBO=_@-_P AS7?^P1;_ /I:U?5\#?\ )69)_P!A-7_U$Q UM+T_5'TU=?\
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MR7=J)GC4"XA8+(OO5% '@GCCX)'QC\<O@%\8X_$2:9%\$;7XMVQ\.#2?M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>,-4TOQ3X3^$EG\3_$4WP]M-*^'OA77;B_T_P7>^,M>\0W/A:[F\2\M\/O\
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M.OX?&'P]\6_#3Q'I/B/PQI?C'P%K-P#H7BV:_P!&U31O%VCW^F:SI=D)VO\
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MBBB@ HHHH **** "BBB@ I"JMC<JMCID X^F:6B@!GEQ_P#/-/\ OE?\*>
M,   = . /PHHI62V27R ****8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>rd.jpg
<TEXT>
begin 644 rd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )N 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OSO^)G[:VK^$/VNIOV9--F_9>\,V^D>"/@]XYU'5/CI^TG=?"KX@>+=.^)
MNO\ Q2LM7MOA/\-[?X8^*8_&L_@[1/A9J.H7,MQXHT:"\U'4[73[I])L[>?5
M#^B%?.6K?LS^!?$OC[X\>,_%#W.NV?[0'PD\"?!SQ7X<GA@MK:R\+^#++XOZ
M9='3-4MBNJ0W/B+3/C'KME?NLL1M4L[9[-PT]Q0!Y]:_\% /V6[S14UV'QOX
MF$%YK7PZT30M-N/A)\8+3Q+XMD^,-KXIN_A%JG@GPG=^!(/$WC3PS\4D\%>*
M8/A_XK\+:5JWASQ7J&AZAIFD:G<:A;O;BI^TG^VQX8_9V\8V/P]N_A[\1/%7
MBC7/V;?VC?VB]$U&P\*>)[?X>PZ=^SSH7A_6=1\,^+OB';^']3T#P;?>(7\0
M6UC%?:M*L&AW+Z7;:K +_P 5>%++5^3\$?L'1:'XG\!>-O&_QM\<?$SQ;\-=
M2^#>G>%=7UOPYX*T7ROAS\"=,^*5EX(\(ZE9^'-,L;?4-;U*_P#BQKNO^-?&
M^+>[UW5K#1TTK1?#>E6C:9)ZE^TE^RQ:_M!ZEX>U1?'FK>";C3_A7\?O@AX@
MCLM"T?7;7Q'\,?VB?"WA[1?&6F"/47MI]&U_3-<\$>"/$OAWQ#8W,@MI-&U#
M1]1TO4M-UVX%J 87AO\ ;U_9WU[P=;>)F\0>)8M6FN?AWI2>!+'X9?%C5?'V
MMZ[\3_!>H^//!]KX \#P>!(_&?Q+T77_  WX?\7:UH7B_P $>'=8\+:MHG@O
MQCK<&JKIOA?7I]/[CXD?'?5&_9NUKX__ +.]AX#^*T%EX0O_ ![H]GXP\7^)
M/A[H&L^'= L[_4_$=M/J^F> O&WB#1/$EE:Z5J&GIH6J>$(;NS\1V\NB>(5T
M.XM;TV_SE\8O^";/PU^,&I6WB+7->L]2UW0;'X#)X2LO'/PV\"?$[P%9:K\#
M_!7QN^'4-WXE^'WC"SN=(\6Z?XM\(_'CQ9::GI\MQI%YH>I6.B:YX:UO3=1L
MFDD^HO"?[.WA+P7^SB/V;?#TUOI/A8?#SQ)X"%]H7A7P9X1BB'BS3]9M]:UB
MQ\)>"-"\,^"M'GN-0U[4=6&FZ+H6G:8MS,0879YIY0#Y"^'?_!1FWT^\\):9
M^TYX/\+_  DN/&/[/'PN_:0M-7^'/B'XD_&3PQH'@SXL>--6\)Z./&VJ0?!S
MPK/X*TKPRMGIESXV\?>)[/2? >@W.M6]M-KGV:)K]_HB]_;C_9QM)]<LK;Q3
MXKU[4M!^)/BSX12:-X1^$WQ:\9:YK/Q#^']UXDMOB)X=\(:)X6\$:OJOC9_A
MX/"FKW7CW4?"5IK6D>#[(Z7=>(-0L%U[0TU#@/$O[!7@_P 2^"_%/@R?QWXE
MMK;Q3^QM\/\ ]C>XO8=-TAKFU\,?#^]\3WMGXP@23]T^O:@_B>=+JPD/]F1+
M:PF'EY*YOXN?\$XOAA\5/#_A*VU+4=&O_$O@7XQ_M%_%OPQJGQ ^%GP_^+7A
M>)_VF_'/B7QIX^\/ZG\.O&]A>>'=273I==LE\)^(H9+#Q%H]_P"&M)OY+N]T
M^\\1:#K8![[9?MD?LZ:IXN\*>#=(^((UJ]\96O@"XT?7M%\,>,M7\ 07'Q8T
MBVU_X6:-K_Q+T_P]<?#_ ,+>)?B1HM[I^I^"/#'B7Q)I/B#Q)::KH;Z=ITK^
M(- 35.F^+'[2?PE^".I:9I_Q(U;Q%HD-_:V6H7GB"T^'WQ!\0>#/"NE:CK">
M'['6?'OCCP[X7U7PAX!T>ZUJ2.PBU'QAK>C6V[SKMV33K2]O;;Y#\.?\$OO@
M/X.^,O@SXJ^'++P7##X:?X.:K=Z;JGP%^ FJ^(?^$F^!'@OPWX%\":CX*\<G
MX?VM_P#"31)]*\'>%KS7_"GP\TG1=*AUW0;75? <GP_GO-:75.I_:^_X)\^#
M_P!K_P 2R:QXQ\<WVFZ5??#>V^'EWH=]X%\ >/$\//I/B75/%NE>-?A9J/C;
M2=3N/A5XZU#4]42P\;^)_#,3:IXN\/:!X0TY+K0K_P *Z1K, !ZE%^W5^R\V
MI^.]-N/B2^EI\.(/C/+XIUO7/!GC[0_"<5Q^SQXDO_"?QJTC1O&.J>%[7POX
MJ\0_#K6=/E3Q!X<\+:MK.O)82VNJV>G7>G745P=#X)?M2:1\;]:_:"L=#\%>
M,=+L/@9XF\(^'%@U_P -^+/"OCCQ'/XG^#/@CXNO!>_#CQWX9\'^*?">LVB>
M,H="M-&U>V9]3,-IJD5S#!J4<,/DOC;_ ()]_#_Q_P"&K?PKK?CGQA;Z9#XL
M_;#\7&?2K?1K/5(M3_:Z\=^)OB%J%S87-S:WMO;7?PU\2Z_:WW@ZXN+#4+74
M9]#L5\16&H6EQ?65Q[+\%_V>=2^&LGQGU[Q;\4_$OQ$\<?'G6] \0^./%BZ/
MHW@.6SU/0/AEX:^%=F/"6F^%@J^'H(M#\+:;?6N;N_U&UUF2[OO[2F\R&.W
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MN=7O]!L_#OAS0P#J=<_X*,_ "SU?X1:+X9M?BAXXO?BU\;O!/P5MK70/@_\
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M]M>0M%H]DBRS6>FBVM;J\U"Y@EU"Z][H **** "BBB@ HHHH **** "BBB@
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M>+/B/\7?A7X9TFYU#4O$.EVK^'M%@\;?$?Q3I4]_=>#] TZT\/>(?$>E_?\
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M$LA:2>XD>>5GE=G(!^!/Q9^)NA7?COXYW_[$_P"T9XF\>_&?X:^ _P!L&_\
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M-);PYH=W;V$^E:?K]Y<ZM+:VTEA!:M-?0?0HU;56 8>'+O! (_XF.D=",_\
M/[7XP?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!% &'_:FK?\
M0N7?_@QTC_Y-H_M35O\ H7+O_P &.D?_ ";6_10!@?VIJW_0N7?_ (,=(_\
MDVC^U-6_Z%R[_P#!CI'_ ,FUOT4 8']J:M_T+EW_ .#'2/\ Y-H_M35O^A<N
M_P#P8Z1_\FUOT4 8']J:M_T+EW_X,=(_^3:/[4U;_H7+O_P8Z1_\FUOT4 8'
M]J:M_P!"Y=_^#'2/_DVC^U-6_P"A<N__  8Z1_\ )M;]% &!_:FK?]"Y=_\
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MI<E03_Q3/@_J1_V * /M+X>?LR?M3?#'3?CQ-HG[3UYK/BOXV>*HO'Z:U=?
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MHS*W['#D#Z"@!:*** "BBB@ HHHH **** "BBB@#\0/^"D__ "DD_P""%/\
MV=;^U!_ZQS\0:_;R/_5Q_P"XO_H(K\0_^"D__*23_@A3_P!G6_M0?^L<_$&O
MV\C_ -7'_N+_ .@B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &=J__ ""]2_Z\+W_TEFK^79/N+_NK_(5_43J__(+U+_KPO?\
MTEFK^79/N+_NK_(4 .HHHH **** /HO]DG_DXWX4_P#8=U'_ -1G7J_H,7H/
MH/Y5_/G^R3_R<;\*?^P[J/\ ZC.O5_08O0?0?RH 6BBB@ HHHH **** "BBB
M@ HHHH _$#_@I/\ \I)/^"%/_9UO[4'_ *QS\0:_;R/_ %<?^XO_ *"*_$/_
M (*3_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@B@!]%%% !1110 4444
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MSVT'_OQJ7_R77044 <_L\4?\]M!_[\:E_P#)=&SQ1_SVT'_OQJ7_ ,EUT%%
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M _\ :3V#Y$?D_8H[E,?>W^9]HEESGY-FS;CYMV>,?@'^R3_R<;\*?^P[J/\
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M_P#A']3M?MMM<:OHFOV]AJWA^YCM@7O]-UJTL=0TQTE@U*VM;B&:*/\ ,_\
M9D_9<_:=_9Q\9_M#^.=,\#?"BS\/ZWJ%W=^#?@#X'^-'Q%T[X,_$[Q;<67P,
M&D_$K1/#GC;PUXNT7]E^V\*IX,^(5C8>$?!VD^*+K6IO%2:9K^I7ND> OA_K
M]YZ7^SO\-?VDO"/[*GPC_9?^+OPB\#Z;YUKJ?P+^(OB+P'\:M4\4P:3\*+_X
M1^/I[_XI:)>7'PF\,.?$#>-5\.^#;#P7J-M:)]EUR7Q*/$S3:8FC7H!]*_"+
M]KKX-?&C5K[2?"]]XHTAQX+7XH>&;[QUX*\2^!-)^(7PD>\@T]?BO\/=4\3V
M%A:>*O "WEWIXNM:M9(9].LM9\-:QJ=A9:'XL\+:GK/$:;^WQ\ ?$'@#PEX^
M\(3^/O&J_$+XD_$GX5_#SP=X4^'/BG5/B#XX\3_";4O$=GXVGT#P@;.WU ^&
MM,T_PMJGB2/Q7JSZ3H%UX;ET?4X;TMKVBVM]\LS_ +#_ .T1\6/"?@CP/\3O
M'O@;X20?!;]F^Z_9E\+>+OA3YWC^Z^+VA^)O%'P,O_B/KGCCP;XR\+>%-%\(
M>#/'G@KX"Z+X*U+X966I^)[^"V\=^-8H/&R6VE:)>ZOYS_P[O_:%?X<VWA;X
MM>*?!/[2ND:;^UO^TQ^T"WP_M_%GB3]EF]U"U^+&M:K/\-_$.C_&3X0>'=3\
M;^%?$GA&'7O&&I:]X2TAM)T/65^(%[X>N/$E]H_@G0[370#].]8_:;^&.G?
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MX3U.Y\3Z+I6D_$Y/%,W@6UT1] U^\U(Z/X6O)YOB#HMW?:5\0+GPS?Z/X?\
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M,'P5I(!DBDC!/_"0,< NJ@G'.!SCF@#];=7_ .07J7_7A>_^DLU?R[)]Q?\
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M^?Z* /H#_AJK]HK_ **WXH_[]:%_\IJ/^&JOVBO^BM^*/^_6A?\ RFKY_HH
M_<7]ASXA^-OB1\-?$^L>.O$FH>)]3L_'5WIEK>ZBMHLT%A'X?T&Z2U06=K:1
M^6MQ=7$H+1L^Z5LN5VJ/ICXF?\B+XD_Z\!_Z56U?&G_!.;_DD?C'_LI%[_ZB
M_AFOLOXF?\B+XD_Z\!_Z56U 'Q6W4_4_SI*5NI^I_G24 %%%% !7N7P+_P"0
MYKG_ &";;_TOKPVO<O@7_P AS7/^P3;?^E] 'TK>HLEG=(ZAD>VG5E.<,K1.
MK X(."I(.#WK\IU^"OPJVK_Q0^B]!WU#T_Z_J_5JZ_X]KC_KA-_Z+:OSU7H/
MH/Y4 >8?\*6^%7_0CZ+_ .5#_P"3J/\ A2WPJ_Z$?1?_ "H?_)U>H44 >7_\
M*6^%7_0CZ+_Y4/\ Y.H_X4M\*O\ H1]%_P#*A_\ )U>H44 0?!_X6?#S0OB9
MX1U;2/">E:?J5C?W,MI>0?;/.@D?2M0@9X_,NY$RT4LB'<C#:YXS@C]%^E?$
M_P -?^1[\-_]?D__ *;[ROMB@ HHHH **** "BBB@ HHJ*>*.>&6"6-98IHI
M(I(GY21)$9'C;_9=6*M[$T >07_[1/P!TOQ._@K4_C;\)-.\8QW@TY_"M]\1
M_!UIXA346D6)-.DTBXUF.^BU!W=1'820I>2'.R!L&O9 <C(Z'D5^2OQ$\5?M
M86?Q1UGX3_#KX(:7H_P6\$_%;P?9)H%M\$K35/ 'Q,^&7C76_@#X3T?P[_PE
M<\\VB16<>BZ[^TW\3/B;XGT7P_82?#$^ ?ASX7UD3G61%X^_5S3-.L-'TZPT
MG2[.VT[3-,M+?3].T^SA2VM+&PLXDM[.TM;>)4BM[:VMXXX8((D2.&)%BC14
M55 !^)7_  4M1Y/^"D'_  0J1)I(&/[5W[3I$L2Q,ZA?V//'[, )HY8_G4&-
MBT;$*Q*[7"L/VECTO4?+3_BI-5^XO_+KH/H/^H/7XO?\%)_^4DG_  0I_P"S
MK?VH/_6.?B#7[>1_ZN/_ '%_]!% &/\ V7J/_0R:K_X"Z#_\IZ/[+U'_ *&3
M5?\ P%T'_P"4];=% &)_9>H_]#)JO_@+H/\ \IZ/[+U'_H9-5_\  70?_E/6
MW10!B?V7J/\ T,FJ_P#@+H/_ ,IZ/[+U'_H9-5_\!=!_^4];=% 'YK?\%%+2
MYM_A[\/3/JEY?AO'=R ES%IT:H?^$9U0AE^Q6-HY8 ,/G=E(<_+D*1^2%?K]
M_P %(/\ DG?P[_['RY_]1C5J_(&@ HHHH **** /V"_X)Y6=U<?";Q>T&JWM
M@H^(UXICMH=-D1B/#/APF1C>V%U)O8,JX614 083<68_8WQ$L+V'P5XADEUO
M4;I%L06@FM](2*0?:;<;7:WTR"8#G/[N5&R!SC(/R3_P3F_Y)'XQ_P"RD7O_
M *B_AFOLOXF?\B+XD_Z\!_Z56U 'Q6>I^II*P/%?BSPMX&T#5/%OC;Q+X?\
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MAPD;LH E%+@[6?:VQ2 S[3L4L"55GQM#,%8JI()"L0"%.)#!<*R(UO<*\O\
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M?P/XM\92>$5O$_9$\,2"00Q(()!!YY!'(/N*;M7IM7   &!T4Y ^@/('8]*
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M!-]7 D @$@-@, 2 P!R P'! (! .>0#U I/J2?J<]. .>P' '8<#B@#]DO\
M@G-_R2/QC_V4B]_]1?PS7V7\3/\ D1?$G_7@/_2JVKXT_P""<W_)(_&/_92+
MW_U%_#-?9?Q,_P"1%\2?]> _]*K:@#XK;J?J?YTE*W4_4_SI* "BBB@ KW+X
M%_\ (<US_L$VW_I?7AM>Y? O_D.:Y_V";;_TOH ^E[K_ (]KC_KA-_Z+:OSU
M7H/H/Y5^A5U_Q[7'_7";_P!%M7YZKT'T'\J %HHHH **** .X^&O_(]^&_\
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M._-S2CO[16M?9^5_U.R/4?F*,CU'YBORS_X6W\3NO_"?>*<>O]J/_P#$4?\
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M_P#"+Z+_ ,^C?^!=_P#_ "71_P (OHO_ #Z-_P"!=_\ _)=?G99_MH_$-?\
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M6\,ZFQ&)YI0,F->0 >,9 )S^25?K]_P4@_Y)W\._^Q\N?_48U:OR!H ****
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MR1L<[1U/OCDY_//;SG;SZXY_/%?HS_P3>!_X6-\1N#_R)&D#D?\ 4QL:_4O
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MNH#%&*YP2*^3_P#A#O"'_0I^&/\ PG](_P#D.@#\F=R_WT_[[7_&C<O]]/\
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M+2CE^6U%'EP]*E%^_5G+F<7)\UF[))+1117"?LH4444 %%%% !1110 4444
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MV/Q1^#.E?%C0K?1=;U'Q7X?N+"\AO])\1^!?%^K>$/$VD3K=6-S=+::EI%Y
MEQ;:BFGV]O>66IV]]9_NX+ZW@@U2QL+VVYK4OV:/ >HV5MHB_P#"9Z;X/&DV
M&A:SX TKXB^)+?P-XQTG3=1O-5MK7QKH5U>WLNN2W.H7][<^(-0AU#3-3\9F
M[N(?'%[XEM)#;5_+F2Y!])O#Y'EV&S/A#Z2<LVIXS,%CL52R'CC$WP%>KE\X
MSISQKQ%.KCHX:CB</E[J4/J="M.?M,)AYNKF>-_.Z7'N11HTXSXIPSJJ4^>4
M<WH.].3I-6<\3).?*G&&G+%N[C%N4Y^AK^TM^US%^T##X,C^,7@75_ MMH6L
M^.O%7AR+X*6.F^(O"GA6_O+_ ,-?#W11X_7QYJ5IJ_B7Q!XHT_6KIKEO!%C:
MR^&_!_B*[-G:3WFDDUOC5^UY^U?\/0_B7P_XJ^'D_AV"^\%:#X7\#ZGX<?4_
MB#\:/&/B;6ELM4\'^&;W39M+L?!>HZ=IDB7GAZ?^PO'8U!K36=>\51>&_!VC
MW=VM^V^'UA:>)?&OB^WCNX_$'C^P\,:;X@OAJ0!^R^#].US3=!72T50-+>U3
MQ%J]V[0%A+J5T;[8DH(;QR[_ &6]/N?%?AGQK'\5_P!H.R\1>%/!.A> =,O8
M/BO87K/H>CHBZA=7;>(/"&NW!\0^-VCCE^)'B.PN=.U3QS)' FL3-;6MI;P>
M?@.&_I8/,,)7QW#/TA/JV"RG!8>="7#G'T5F.+4:>*QL:_U-4J="53$5,1E<
M,S^KXC&0RR-+%TZ<,UA3Q=*(<>9.ZD'/BO!<L*4(M?VK1]^7NRFGRXA)-R;I
MJIR2DJ=II>T7,ON5_C]\6$G>-/%WFQI,\:2C1M VRQK(520 ::1B10' #$8;
M@GK7[B?LYZC=>(O@=\+];UEHKW5-3\'Z7>7UTUM;Q&>XE$IDD,<,4<2;B =L
M:*H[ 5_/$-.NMX;RXQE]VU9$"C+9VJ"Q(4=%&3@ #)K^A/\ 9<C:+]GSX1(^
M R^"-'5@"#@A9<\CCO7ZK]&[(/'K*.*,\K>+&6>*F!R>IP^Z675./*'%-++I
MYG_:& DH8-YZEAGC?JL,1*U%^V]@JS7[OG/I>#.(<)G&.Q5##YU1S.5+!^UE
M2I8^&+=./M:,/:.$:L^5>\H\]DKRM?6Q\L_\%((HH_AW\.O+CC3_ (KRZ^XB
MKU\,:IG[H'7 SZX'H*_$_P"(/AV;Q9X,U_PY!I'A/7WU:WM8&T/QT-87PIJT
M,&IV%[/8ZM=>'S_;NEF:&UD_LS7=(CN=1\.ZTNFZ_:V5]+IJV<_[A?\ !12"
M.?X?_#U9 Q"^.;HC:Q4Y_P"$9U4=1]:_)'^SK?G[X !8DRX554%F9F. J(H+
M.S$*B@LQ"@D>WXH?0[\8?%GCZOXC<&8W@NAE6(CE*P,<ZSO-<#CX8G)\-AL-
M4E4HX+(\9"G#ZSAI2I2IXOG=/EG^[EI'XSCKCK)L@XFQ.!QD,>\31IX.JWA\
M/2J4_?P]*K"TY8FE)NS5_=5G=)]3\_OAM\"_BY9?LX6OPE\9ZM$HUWQ%\,++
M4O"&K^/=?^(C>!OA%8WO@@?%CP-9^/M?L+;5O$,OBNQT;QA+9Z*4?1="MO%U
MQX5T;5;G2XEG7L?CU\&=?^)&MZS?^'O 7P]NM?UWP;IGA[PS\6]4\=>+O#7B
MSX.>(-,U'Q!?6/BW2/#6F:9?V&K3^'YM=;5/"]SX1U#PMXDN;U+GPUXHU!O"
M=Q!/;?5I\1>!AX=L?&#>+_"\?A'4TLY--\63^*M#MO"^H1ZA(8;!['Q%<:A%
MHUV+Z96ALQ!?2-=3(\, DE1D%77O%WPY\*:CIVC^*O'G@GPMJ^L+$^CZ3XG\
M;^&/#NJZND]R+*!])TS6M6L+_5$FO&6SA?3[>Y66[9;6,M<,(S\]+Z#_ -)=
M9I5SF.9^$]"M6QN,S)PP_$W$N%P[KYF\ME.4Y8;(Z-?$4YRRG 3:Q.(KK'3I
M5)YB\=+$8IU?G/\ B*F3NLY+"9PJCJUFZ<<!%/VD72]M%QCCE-NG[.G[2,W+
M76LI.4K^'>)M$^*LGQ!\+_%30_"?A'5-7^'>H?%+P9I7A34/'\NBP^./AOXY
M3X>ZEI?C*7Q$G@O4[;P5XSL_$_@:UDU/PB=*UG3SX>DU&&R\1/J$VG6X[#X-
M^ KGX8?##P?X&O\ 4+?5=3T2TU2XUC4+)+F+3;C7?$OB/6_&&O+I$%Y_I5OH
MEMK7B'4+/0X+@)/%H]M8K-%!+OAC]INK;3[&"XNKZXCL;6T7?=W5[=QV=K:(
M94@#W5S<O%!;(9Y8H T\D:F>6.$$R2(K3'3H%)5A*K*2&5G8%2#@@@@$$$$$
M$ @C!YKR,5^S\^D7BLMH94\7X5T<+AYT)Q]CQ#Q"JLUAJF:5<+"I*KPY57)0
MK9WF]2#A"$YO&SA6G5I8;!4\+R2\5>'94HP]CF:@FK-8.CJX<\DKO&M>ZZ\Y
M.VO[Q*3<534?UP_X)S112?"+QB9(XW/_  LF]&716X'A?PT0/F!X!)(],GU-
M?9OQ+@@3P)XE9(8D86"X98T5A_I,'0@ BOD3_@GC D'PF\8*F[!^(EXWS,6.
M?^$:\- ]>V,5]@?$W_D0_$W_ %X+_P"E,%?T[PYP-G7AKX7T>!>(JF!JYUPW
MPYF. S">65ZV)P$J_L<77OAJ]?#X2M4I\E:'O3PU)\W,N6R3?]#\(YA0S7AW
M*,PPRJ*ABL,JE-5HQA44?:3C[\8RG%/392DK=3XC/4_4_P Z2HKJX@M(+B[N
MYX;6TM8S/=75S+';VMK '2,SW-S,R06\(DDCC,LTB1B22--V]T!GD22*58)8
MWBG>:6W2"5&BG>XMXVEN+>.&0++)<6\2--<0(C36\*M+,B1JS#^>/^#^"3?W
M)IOLFNY]"-HH[ ]FW;3_ 'MI4/M_O;"Z!]N=I= V"R@H"&WX(/E32VTNTAO*
MN8"HGMI=I/E7-N707%M)MG@+H)HT+KD 6O=/@3'')K>NB1$<?V1;G#JK#/VT
M\X8$9X'Y#TKPO^(I_P M%A2Y:/(\Q;:25H([EH_OK;23JT$=PRB"2=6A21I5
M9![O\!O^0YKO_8(M_P#TM:OJ^!O^2LR3_L)J_P#J)B!K:7I^J/I.ZMK;[-<?
MZ/!_J)O^64?_ #S;_9K\]!T'T%?HE=?\>UQ_UPF_]%M7YC^,?&7AKX?>%=9\
M:>,-3_L?PUX>M(;O5M0%G?ZE-$ES?6>EV5O9Z7I5K>ZKJVI:GJNH:?I&D:1I
M5E>:GJVKZA8Z9I]K<7EW#$WW7BW&4ZW#T(1<IS_M.,8Q3E*4I/+%&,8J[<I-
MI))-MM)*XCIZ*^5O#7[7?@#Q9X&\%>,-%^'_ .T!=Z[X^U?5-"\._"./X)^*
MH?C!/J&AZ(GB;6YIO"^JG2=$BT#2O#L]GJUQXO?Q4OA2<ZA8:'I^L7OBRY3P
M]6S9?M:_ 75+[X$:7I/C*YU75OVC[EX/AAI%EX;\0G5GAAL/&-U>:AXVT^YT
M^UN/AO86&H^ O%GA*[;QJND7K>.M&OO!UA8WVLV&IP:?^2RR_'1<E+"8A.+J
M*2]E-\OLE4E4;:37)&-&M+GOR.-&JXR:IS<79_UKV_S1](45X=X8^.ECXO\
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MA+BJ*PF)Q>(IRJ99F=6"6,IX2%6G"C_9T/9Q4L)3J)JI+WYUG)2YU[/]*_\
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MKX U74=&,^N_!'2(-5M+GQ9?:MK5K\'M&M_ OA_P5\'-&US6X=4\7^&?W-^
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M8&8X!)PJVY)P 2<#@ D\ U(O[._Q,D3S(['1Y(^\D>LQO&.,G+I:E1@$$Y/
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M4Z,*?##E+"T<1)/(\;S1J8B=*-"@O^,@]FW5C5HU8U)581]G5O*,9QE!+_B
M_ __ #]SWU^OX6W2W_,N\OGKYW]\7]GWXC9'^CZ#U'_,?M_7_KWK]H?@!H][
MX?\ @Q\-M%U)8EOM-\*:;:72P3">$31*X<1S*%$BC(PX4 ^@KY-F0QW,\9.X
MQW,T9;:$W%)G0ML4E4R1G8K,J9VJQ4 G[>^'7_(C>&/^P3;_ ,FK7(_&3B[Q
M(KU<JXAI9-3PN"H?VA1>6X+$X:JZZG3P]JDZ^.Q2E3<*TWRJ$'S<KYK)I_5<
M)^''#W!F,Q&/R>>92KXK#/!U5C<31KTU2]K1K-PC3PM"2FYTHZN37+=<MW<\
M\^/7_("T+_L,R?\ I!<U^8_Q1_:?\,_#/XL>!/@Y#X#^*'Q&\7>+;:VUK7(/
MAKX;L/$+> ?".HZ=\1+O2/%6MZ9<ZUIFN:_;ZA<_"_QA$VC^"-,\2:Y8:9HF
MIZW>64:PZ7I^M_IQ\>O^0%H7_89?_P!(+FOQG_:__9&\8_M+>,?A+JFD>*?A
MGX?T;P5J6ISOXCUWX>ZG<?&/X5WEYX/\>:0/''P-^)OA/Q;X4UNS\13:OK_A
MG48/"_B66X\*:5XE\*:'XR==7L[?7/!^N_C_ !M'!SXVQL<?4]EA_J=#W[U+
M1J+ 0=-\M-<TVII-0YZ:E)*\I:4JGWR_KIU7G_G^J^B_#?Q\\#^*_C+\1_@E
MH]KXJ;Q!\+?!NF>,O$WB;4/#E]H_@2[AOO%GB#P;J&C^%O$.JBTD\6:AX8U?
MP[=)XGU+0["Z\*Z=)<0:=:^(M1UBWU;3],YGP5^U3\,?'7@7XG_$?2]/^(ME
MX5^%OQ"N?AQ>G5/AQXKA\4^+M7_L+P)KV@WW@;X?6UA=^.]7T[QO#\1O#%MX
M'AU'P]HVM:VU[%J%SI&E:-/#J+<Y!\//VCD_:KUWXS37W[/LGPUU3X9Z;\'K
M;2?MOQ@;XF0>$?#OCGQC\0M$UV>4Z''X*/BFYUCQ1%I>K:7;7$7AZVTRTGO-
M*N6NY8;)<#X5^ /VOO -]^T'K^IW/[)VH:]\8/B)<?%?0H=,U;]H6+2])\4:
MGX2^%WP]U/0O$5W>^'EU2Z\,CPQ\/[W5;?4M*B?7+CQ'JMM87EFFB175TWQ?
ML<!RR:FF_J^"G%?6TG[5SIQQ=-OV#2FXJ<HS:Y**2]RJW%H_K^OZMVV/I#X5
M?$O0_B[\*?AY\8-"L]6T;PW\2/ ?AWXAZ5I_B6&SL]<TC1O$FC0:Y;VGB"WL
M+W4K"TU33[2?R]5AL]1U"TM[F&=+>]NHD69^;^"GQV\&_'O3?'.L^"-.\86&
ME^!?B-JGPWN+CQGX7U#P?>:[>:=X6\&^,(/$NB:%K0@\00^$]=T/QQHM[X=O
M/$.EZ#J^I6;'4)-$L[.XLI;GS/\ 9R^&O[0WP?\ @W\#?A-XHUCX!7\7PJT2
MR\!^(=2\)VGQ8G?Q/X%\+_#:71O"%_HC>(?[*/AWQK/\08-+O_%*7UIK?AL>
M!8]0L="V^)Y[6[MI_P!GGX>?M!^!?&7QPUOXNWGP#O='^,'Q)U#XMQI\*KOX
MN7&NZ-XHU'P9\-/ <FB7+?$'2+#3KWPZNE_#TZJ=325=;DU;5!:FT6Q@:=\Z
MM+"1_M#DJQDH24L$U5E[T/K/)R.#@G.;H)5+N45%))ISE:!I_37ET^_\#]5_
M@1_R+&J_]AZ;_P!-^G5V?Q-_Y$/Q-_UX+_Z4P5QGP(_Y%C5?^P]-_P"F_3JX
M+]M[XNW?P&_93^-?Q=L=!M/$]WX%\)IK$&@WVH7&EVFI.VM:38_9Y]0M;>[N
M+5 MZTOF16\K;HPNW#$C^C^#\JQV?<'Y9D>5T5B,SSG 5,JR[#RJTJ$:^.S&
M57!X2BZU>=.A157$5J<'5K5*=*FI<]2<8)R7)C<=ALLP6+S'&5'2P> PU?&X
MJJH3J.GAL+2G7KS5.G&=2;A3A*2A3A*<K<L8N32?B;=3]3_.DK^?]O\ @M?X
MR#,!^SGX-.&(_P"2D>),GG'_ $+'4TDG_!:_QE"D4DW[.?@V&.:#[5#)+\2/
M$D4<UKY\]K]IADD\,*DMM]JMKFU^T1L\/VFVN;;S//MYHXU_Q)O](;3_ (PC
M"ZM)?\99P?KL]/\ A>[-_<S\I_XCQX7?]%#6T5W_ ,(N>Z+35_\ ";HM4?T
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MQ!IOAJ[UK2-%\+ZE=IXITSPW<:M");+0FN;3^?+]BWP+^V_\&/BS)XE\:?\
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M  53_8IRH'C[QEU  _X59XS Z\?\N? K]POV=?B!X7^*GP/^&'Q$\%7EU?\
MA3QCX1TS7=!O+W3[K2KJYTV]5VMY9].O52ZLY6"G=!.HD3HPK_/3_P"&9_\
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MJL'AWP]JTBPVDUU=--;?8]4M"MR'56E,L6S,1)YO_@JW_P H\_VIO^R=1?\
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M9WGA)/$_A7X8ZI:^&]3\.^!/&2Z+HOB&[OOAM!X9\0ZG\7;+5Y3^+S?LS?\
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M1@I?YB <%OF(SS5A$2,;4544=%4;5 ]%4<*.^  ,DGJ2: '4444 ?F;^V?\
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MA^WGT3XS^%/B3XAM]4\3^*?&_@?5]3\,:IX<N_$/AC]H*]\.?#;P-HEUJ?\
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MYSS^VS^V#X8TKX*Z7HWCWX<>,KGQ1\.-2^(ND>.=?\?_  C70_C5\7]?^/\
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M]^OOR:6BM1C=H/=N_P#$P^]UZ'\O[O\ #BEVCW_[Z;N,=,X_^OSU.:6B@!
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ME[KIANY+%]>\1CP9)\/_  +>:5XV\::!J5M^87[,W[2G[8,-[^RK\!H;W0?
M>F6WP3_8M\$>']"\67V@67BOQ[X,\<?LU^!-6^+?QKM_ OB3P!XI^*GB?Q)\
M.O&VL>*=,T:;1O%>C?#GPOJ_PPO?#?QFL99O$4VKV0!_1C17\_?C+]NK]KF\
M\'_#36UDTKX9^'G\0Z[\"_C9X^UT^!/AMIW@[]H/X!?#^Z;XH66E>*_BSX,\
M:^!+;0_B;\:-6O\ PCX4CU?1IXO$6@_"#5]&^'^HZ7XI\<Z5K"=O:?'7XR^'
M=8N_$GCOQWI7P&C^+WCG]DW2OV@?C)IWA^36?!OP/@UG]BO4O&^IW7A9?BKH
MK^'_  OI/B[XO:/X?^'5CXL^)OA:?2O#9\2Q6?B'14\4:IH\EN ?N;17X/Q?
MMK?M*72?#W^UO'VG^'/B;-X&_9)\2>$?@F?A%!I<_P"TOJ7Q5_:/^-/PP\7I
M;P^(K6[\5^"E\6_!/P-X9^,-MX4T74K#Q+\&QJQ\8>-+N_\ A[HFN:1>XD_[
M4/[:D/POU_Q]#\7+>XO8/V1/CS^U586,OP8\(O:IXF_9[^-$OA7P_P##5$M]
M.M[R?P?\5/ ^KV*^.A+(WCI-7T:+6OASXE\&V=_>:.H!^_=%?@'XZ_;9_;3T
M[Q=^V-%I<G@;P]J7PK\(_MLW/A[X:ZE>>&M;\1>!_#GP8\(>*KO]G+XK6OPZ
MT[P$?B#/)\1M4T?PAXDUK4_B'X]NOAEX[\->.CI?PUL]-U_0X[/4?1_'/Q!^
M/NC_ +2OPH\(_$/]J'Q;X4\ ?!S]M3X<Z1XJ\8Z=X1^&_@_P[X^\(_'/]CCX
MJ>)]'^'OQ'^T^$KW0CX4A^-^GZ)\./ -Q!+I^M?:OB#X<L]4UO7?B?H?@_QK
M" ?MK17YX_&GXX>./#?[6/A7X9W7Q>M?@SX/_P"$9^">M?#W09OA7_PL";]I
M;Q=X[^,7BCP;\5_ MO>+;S:W"?AEX*T?PC?R6W@"]T36_!K_ !"B^+'C^\U+
MX9^%M3T>?XQL/VQOVG]2\-^,]2T[XI>$(/&5Q\'?B5XM^,7@_P 4_"^XT_0_
MV'?B=X6^/'P\\#>%?AQKOB'PYX7\0ZO!+XH^'_B/XB0V^L_%70O'=LVK_#^T
M_:":T@^ EUJ^B1@'[N45^"W@O]H;XR>+_B?\%OB:G[1OC71=&B^ O[?WP\\+
MZ'XW\)_#G7O@U\=?C7\.O$?PB\2?"G4VO/@?X>U5/C=,W@W4?$6M:-XA^ $W
MA'7?'FE?"?QQIW@;P#X1O9OB3X7U;[>_X)]?'_QA\;/"OQ&L?&GC"\^).I^"
M/$'A6W'Q!L8/AMK7@/5W\2^#-.U?5-'\%_$KX3Z?X5\*^,8O#^NP:H-0T75_
MAUX"^(?P^@U+1_#7CO3=8U$VWB/5 #]"Z*** "BBB@ HHHH **** "BBB@ H
MHHH \Q\<?#6'QKJ5GJ,FL3:<;2R^Q"*.SCN5D'GR3^87>>(J<R;=H!&%SGG%
M<4?@';$$?\)1=<@C_D%P=QC_ )^Z^@Z* *FGV@L+"RL0YE%E:6UH)2H4R"VA
M2$.5!(4N$W%02 3@$XS5NBB@ INT>_0C[S< ]<#.!^&,#@< "G44 )CZ_F>W
MX\_CU[T!0.F?Q9CT)/<G'7\L#H *6B@ IH4 8^;''\;=CD<[LCWQU'!R.*=1
M0 W:./O<<?>;L<\\\\^N>..AQ2[1[\_[1[G/'/'X=N.@Q2T4 )M&<\Y/^T<=
M,=,XZ>WOUI:** $"@=,]NK,>GU)H*@\\\>C$>_.",^V<XYQU-+10 A /7/'H
M2/U!''MTZ'J!1M&<\YX_B;'''(S@^^1SQGH*6B@!NT>XZ]&(/(QU!!QZ#H,#
M'084J#QSQC^)@>/<'/U]>^:6B@#G;3PEX<L/$VM^,;/2;:W\3^)-*\.Z'KFL
MQ^:+S4])\)S^(+GP[8W3&0QM!I,_BGQ!+:A8U;=JMUYK2 H$Z''U].I_Q_7K
M2T4 )M&<\\Y_B;'/7C.!T].#DCDFC'?GKGJ?ITSC'/3IGGJ!2T4 (0"0><CT
M) _$ @'\0>_K2;1SUYX^\W'.>.>/PQQ@= !3J* $VCW[_P 3=^O?\O[O;%
M'3/XDGH,=R?_ *YY/-+10 4444 %%%% !1110 4444 %%%% !1110!Y+X_\
MCI\)_A;JEEHOC[QIIOAK5-0T_P#M2SL[RWU.:2>P^TS6?VE6LK"ZC"?:8)8M
MKNLFY"=FW!/!G]L+]FQ06/Q7T(!06)^Q>(. H))_Y _8 FO@3_@HTV/BSX'Y
MQ_Q;KUQ_S-&L5^>DS_N9OF_Y8R_Q?],V]Z /ZC]-U&RUC3K#5M-N$NM/U.RM
M=1L+J,.J7-G>P1W5K.BR*D@2:"6.10Z(X# ,JMD"[7"?"[GX:?#S_L1O"/\
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MVMK>-88+>"&-5CBAAB1(XHD54CC544!0 )Z** "DP/\ )/;_ #SZ\9S@4M%
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>rdpercentofrev.jpg
<TEXT>
begin 644 rdpercentofrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N 3T# 2(  A$! Q$!_\0
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M>^.?#WAC5/"'@+2+G6I8["/4/%^MZ/!DRW;E-.M+V]MOD3PY_P $O_@-X/\
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M-T[5[*XTW5;&SU/3KM/+NK#4+:"]LKF/<K".XM;J.6WG0,JL$EC=0RJV-P!
M!_-7HOQ);5?@AXEO/C)\<_B;H/BGP!^R)K.L?L;ZY%\8_&4)\>_'[PQ\:?VH
MO"7B/Q%\&-=M/$=GJ/[3EQ8ZSX6_9[\(_!V?QJ/%_B?XD_!+Q%X$US7O#D\O
MQI\86VH_O-IOQ#T7Q)\+?&MEXO\ B7X8\ >-_ /@>TL/COJGAGQ;X76Y^ _B
M_5_A;I'CG6;O5[[7$U/1O"MUX<T'Q%9^-]'N/&&GOIJ^'I='\07UE=:'=+Y_
MM4^DZ7='3VN=/LKAM*G6ZTQI[6"8Z==)#);)<V!DC8V=PEO-+;I/;&*58)9(
M5<1.RFA:>%/#EC/XGN;71M/CG\:7R:CXKD-M'*=?O(]#TSPS'-J@F$BW8CT#
M1M,TA(I0T"6%E#;K$$#!@#^?C0?B9X$UCPS\0?%W[/7QYUZ;]D/7?%7[(/@[
MXBWD_P"TUKGQ!^)6I?#2_P#C#J"?&K]K'5+JX\?Z[X_^!_@;XF^%-5\,> =;
M\83ZCX&U[Q%X.C\<_%W5=%\)VNB>%/$=YI?&OXE:#X1_9,_:HG\.?M5:_P"
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M&EFN+F22XGED+233N\TK/*S.0#\!/BQ\3?#U]X]^.=[^Q-^T7XD\=_&CX:^
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M , DD  GH#D\9R,9]:3S(\ ^8F#D [UP2.H!S@X[U^#GP#_:YC_:)T__ (*
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M]% &!_:FK_\ 0NW/_@RTK_Y*H_M35_\ H7;G_P &6E?_ "56_10!@?VIJ_\
MT+MS_P"#+2O_ )*H_M35_P#H7;G_ ,&6E?\ R56_10!@?VIJ_P#T+MS_ .#+
M2O\ Y*H_M35_^A=N?_!EI7_R56_10!@?VIJ__0NW/_@RTK_Y*H_M35_^A=N?
M_!EI7_R56_10!@?VIJ__ $+MS_X,M*_^2J/[4U?_ *%VY_\ !EI7_P E5OT4
M 8']J:O_ -"[<_\ @RTK_P"2J/[4U?\ Z%VY_P#!EI7_ ,E5OT4 8']J:O\
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M< _'+_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(K\0_P#@I/\
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M117]3 %%%% !1110 4C?=;J>#TR#T[$<Y^G-+2'H><<'GT]^>..M 'X\>)?
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M4DG_  0I_P"SK?VH/_6.?B#7[=QD>7'U^XO8_P!T>U?B!_P4LABG_P""D/\
MP0JCF19(S^U?^TZQ1QE2T?['OC^1"0>#M=%8 \$@9!'%?M%'X8T#RT_XE5K]
MQ?X6]!_M4 =!D>_Y'_"C(]_R/^%87_"+^'_^@5:_]\M_\51_PB_A_P#Z!5K_
M -\M_P#%4 ;N1[_D?\*,CW_(_P"%87_"+^'_ /H%6O\ WRW_ ,51_P (OX?_
M .@5:_\ ?+?_ !5 &[D>_P"1_P *,CW_ "/^%87_  B_A_\ Z!5K_P!\M_\
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M7RY*5'%5:=.'-/"2G+EA"*YI2E)V3DV]1O3[E^*N?0W_  OVX_Z%>'_P;O\
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MM_\ ;WZGR=1117\UDA1110 5[A\!_P#D9=8_[ 9_]+[2O#Z]P^ __(RZQ_V
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M2ATAK+P]X_\ @KXRUZVL=%T3Q)\!-)UOQ5^SU^TEX0U"/P_\'=,\'Z-K&O\
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MX'/&<#FD_P"%R:&<?Z;I9&,C,?B4@J<<G.@$,.F"<X['FFN*.''_ ,S[*/\
MPXX/K;_I]Y_@PY6^G]:?YK^DS\]_^":/ASQ!X6\<_'FR-OX4\4^#[KPA\"X-
M+^*_PM_9B\5_L9_"W5/$'AJR\=^'O$/@J'X"^+7OQ<_$71)8HO$GC+XG>'?$
M&K6&K:+XI\&_#S4='\'3?#?3=,OOUTKQ0?&31!TO-+.><F+Q,V1VY.@$XYX&
M<<\5V6@>*+_Q/9/J&BQZ-=6D=S):/))<:S;$3Q)'(Z>7<:+&Y 2:,[@I4DD
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M-/TZV=FM-+\:^)K=-,\1_$98$*"XTNTB\*^#)+CSG?1-425II/U"_9VTC2-
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MKGQ'T?PU\1;OQ=J6I>&O#.E^'?3?@;^SY\0?@S>^*_%MMK/P^U'QO\8?BAX
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ME1XLP.(Q-6IB<PXCR'+X*G3\I5>,.'K+$TO]>,JA&*^M86.!RKB[#P27OXK
MMX+A[/VKRJUZ^75.&<11HPA0P60YOBY\TOEC6?@S^U7JO[8OP+^-L^A_!?6O
M B?%GQE=7>LZEJ?Q+TGXA_"'X!ZA^SSXU\&>%O 6O^'?['O?"]GKMOXC\6Z_
MK&M/X:UG6K/Q-\7O$RSZ[/9^$M'TR;2.4_:;^''QO^-'B.X^(/AGP-^U5\)'
M\5_LR^)O@]IVD_!P? NY\9>(]:U+XB^-+[4/AI^U;I_C;X@3^'K'X+7EK9>&
MO$'@O5OAQK6DZY'H/Q+^)2:U\2_".LR:9H4.I^TY^W;\8?@)J_A#0)_@?H_A
M[6=5TC5;S6(_%NJW/B/P]?S66HPV=MJ'@#Q5X3U;2HM:T*:)I1>1ZSH^CZYI
MMWY5M>Z?"75I?F>T_P""L'Q?GNK2";X:?"B&"6ZMHI9=WC)1#%+/&DTH+>(R
MJF.-GDW,"JE<L"H(K]]X*^A%])7C;AO)...&>&>#LPR7&X+$0RO&T>-N&,51
MQ&#P./QF%J3I3P.;8O XNG.M0J^PKX:M7HUJ-.G5H3O4<W^,<3?3"\#^#^(,
M;POGF<Y[@\XRZIAZ6+PM;A//\/4H5<3A\/B84ZM+&8'#8G#U52Q%-5J6(H4:
MM*?M(5(1<;'T_P"(O@9\;/#/BSPMX_\ AWX&;3=2^'F@Z MIX1TJ[T_QMX*3
MXN^+/!'C[QEXDU+X5^&/%NLZ/'H_P2\"?%KQG=>#-.U/7+^?Q=I$'Q.^*7CO
M1!:)X&\$WND_J'"9"D)F2*.8QQ&>."1Y;>.<HIGCMY9%226WCEWI!+(B22PJ
MDCHCLR+X(/VB?"&N/+!\+_#'Q&^,\RNR"\^'O@Z[3PGO7<!YWQ"\92^$_!&S
M<F#-8ZUJ6!AD1^E.%S^TMXK*BVTKX4_!?3I3_KM9O]5^,OC6.(E<8TO1?^$-
M\"65UM+$K+KOB*WC? (F R?YHQG G%+5!\5K)>!XX:+57_7#,Z.39W2HU%&4
M:U7A.<\9QWC</*?-.%;+^&<="]27)[LDC]M7'>1XJRR)9CQ7-NU*?#& K9IE
MM>:Y5*BN)?W'"6'K1VE3QV?X22=T[6=OU9^&I \">&?7^SEX&2>9IAG R<>_
M2OG']IW]H'X)^"](M?#?B/XG>$;3Q4NN6KKX/L-2_P"$A\:RJEK?HQ@\&>&8
M]9\52@.RQ[TT<QB0A&=6(!P_ O[*FE^-?!^A77QC^+GQH^+EM>:<OG^%K[QI
M/\.?AT )9P+<> OA)'X+T_4;( G-KXIO_$YDW$7$TZX4=]XR^%7PS^$W@.UT
M[X8> /!WP^LY-<L$GA\'>&](\.FZVV>HG?>3:5:6T][,Q)9YKN6>:1F9G=F9
MB?W_ #/!\ Y7X>R6.S;/>+)T^'<'&I0X;P]+AK+<1'ZMADJN"X@XBP699G&-
MKR4,;P+AYR32DJ<KJ.:QG'F9U/\ 9,HR/A?#3DW#$9_BZW$.:4TG_#Q.09%7
MP&61E)VM5PW&N)C!7O3FTD_A+_A;GCWQ(%7X;? 7QYJ-O+_J?$GQ5O--^#/A
MDH=I6X33M877?B'>P,&+JD7@BUDD4?*RD@UY+\>O!/[1?C#X)?%J/6O''AFR
M>X^'OBA+3X9?![X?W>NW?B2XDT^00>'KSQCXVGU'Q!J OF(@DC\,>%?#U].2
M5M)X6.3]9^+[;QC>^%O$=I\/;[P_IGCV\T:_M_!^J>*]*U+7?#6F^([B%HM-
MU/7M$T>[L-5UK3M/F?[;/I%E?V,VJ- EB][9PW$MS%\.>%_&_P 8=<TGXO74
M?[3VAVGP ^'GBWP@P_; \5?##X;:-JVJ>'=.\+^*6^.6A?#]+#2(/@CX@TWP
M?\0X? /A[1/B_>>#=9T"(ZK\0? FAV/Q'\6>%='UYOQ/ACQ!H<,YUD^?<*\%
M<%99/(,YRG,E4SC!X[BS-LRAE^8X3$T:&)Q'$BSO)L'BZTZ:@LPX7X?X>S*#
MC5Q& ITZE&\.+.. J_$F49KE?$/%W$F,AFV6X_+Y4LOQ-+AS+\%/'82KA:E7
M#4>'J>6YGB\/!57)9?G^=YUA:R3I8A5:<I)_A6?V</VA,G_BQGQ=/_=._%G_
M ,JJ_<;_ ()F^"?&7@/X&^,-(\;^%/$?@_5+GXIZIJ%MIOB?1=1T*^N+"3PM
MX6MX[V&TU*WMIY+5Y[>>%;A$:)I894#ED8#T)?BY\</#W[#WCCXR^*QHFC?%
MO0? _P 3=6\$:I\2/!NL>!],U]H_$_B+2?V?]?\ B'\-])%YJG@[Q7\4?#K>
M ]4U'X8Z<B7L'B_Q/;^&XM+T9[F?0M(^9M#_ &C?VFTTSXHC5!\5O#7_  J.
MR\&^.]=T3]H[X1_!GX8?'ZR\.>)_"NO75MJOB;PEX,NV^%^N? /5_'NB7_@G
M3?$7PTU35/B\_B?0O$G@NVC;4[319-1_K'Z0/TX^./I&^&N9>&^;\"<(<.8"
M>?Y5C:F:Y=G&;XG$O$9-BZ=2G3HTL705"=&O4Q%*$IR<9KVD%&*E)(_GOP4^
MAOPSX*<<X?CK*N,L]SO%X;+LQRU8''X#+\/AY0S&BJ-2JZF'FZO-2BG*"2Y9
M/XG9'ZU5[A\!_P#D9=8_[ 9_]+[2OA/]GCXI3?%7P;>ZYJVI;_$TVL7FNZEX
M7.AWNBCP)X=\6WNHW_@#PI9W-]IVGGQC8:5X:T\Z9<_$.S-_I?C#Q=I?C&XT
MB_?2;.PMK;[L^ __ ",NL?\ 8#/_ *7VE?P]P=1GA^,,HHU%:I3QDHR5FM50
MJNZYDFXM-.,K6E%J46XM-_V*?5%%%%?U" 4444 %%%% !6=JZW3Z5J26*/)>
MMI]ZMI''>+I\CW36LHMTCOWM[I;)VF**EVUM<+;,1.T$PC,;:-(>AZ'@\'H?
MK[4 ?BP?%?BGP-\=/#?PXUOX\>))-9TGQ7\,;+Q!X6\2?M]^%;SQ':ZAXAM?
M"NM7?A_7OAY8?LU/<W<LK:O):V&A77B/0[SQGHKZ=J<$VA6GB*T>U_:@?U/O
MW_S].E?FK8^&_C'X7_:,^*]U;Z3^U%H?@SQA\9?"_B72_P#A2WA;]DW3_@EK
M>C2^%? NCZKKGC&;XAWNO?&:^UZ]O-)U"U^)6NZ=_8+:AI%CI7_"%:/;ZA9W
M-[>?I5_]?KCU]OT[XZ\T ?B!_P %)_\ E))_P0I_[.M_:@_]8Y^(-?HI\=/^
M1AT/_L )_P"EUU7YU_\ !2?_ )22?\$*?^SK?VH/_6.?B#7Z*?'3_D8=#_[
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M#7PGB/1K5^%\33H4JE:H\5@FH4H2J3:6(BVU&"<K):MVTZ@>445#]IM/^?\
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M0?H11D=<C&<9SWSC'USQ]: *OV"Q_P"?*T_\!H?_ (BC[!8_\^5I_P" T/\
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M\)SZ7X,&OR6UWI^KVNG^$O$?D>()X-(OK.\U1%FL5N[8NDR?FUIWQ(_:??\
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M[F.6VNK2ZMY9(+FVN(I()X9'BFC>-V4@'Y3ZSK/Q'^'GQ4^,O[/VH_M=>/\
M3/AAH/P.^$/Q[\4?&[Q_;_#K6OB3\++?4OBQX]\(>-?"%AXHM_!'AOPKH\/Q
MOT#PM%=> KW4_#'B+5? NHZ/XY_X031;FVU/PA8^%/J3]E$_&K7O@KXE/Q'U
MSQM&^J^,?B)%\%O$'Q.T&RT3XR1?!VXG%M\,M:^*WA^VT;P[!9>-"OV[5K?3
MM5T'1O%</A.3PI:_$73+/XA)XLB7%T3_ ()Z_LJZ3H/Q,\"7WPL\)>)_A/\
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M3:RU2>SDNQ=^%["PL[/PYJ$LLNHZ#;01PZ3=V:#%>\T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %12S0P+O
MGFBA3(7?+(D:[CG"[G*C)P<#.3@XJ6O'/CB ?!D&0"/[=L#@@$9$%[V->9G.
M8/*LJQ^91I*N\'AJE=47-TU4<%?E<U&;BGW4)6[,#U;^TM._Y_[+_P "H/\
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MSHOA?]H3Q/K/@/0_B?X'^+OCJY\3>*_"NF_"8:Q\6?"WA>/X)^-?"_AWQ_\
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M['0M-A\:^)K66P:/6/%UO8^%_#=K;>);P2:W;0Z!HR6]]%_9MF88;O\ 9V^
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MZ5I.F06MAI]E;K\L-M:V\4,8SM09.=ZB@ HHHH **** "BBB@ HHHH ****
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M%-4%U8:;+Y#XL_X*/>+?#/B7XT^%[CX;>$])U7X5?#[X8?%2PL_&/C%O#?\
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MLOA#Q4=(;54T34Y-'U)CHFMZ?K]C]GU"**9X -0TRU,H$;>;")(6PLA(_:^
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ME_X4\#7/PD^(WPQM=1\#_P#"8ZIH'A^$> /$WB'X>>.KC15U:QO+K1_ S?\
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MQ;V][%#XST"3XEZWX-M]1\,J-1T[6852ZU&QN]&M+W !Z7<_L?\ [-]_XO\
M"OBV_P#A+X%OQX"\(^&_!G@'PK?>"_"5SX*\"6/A/Q;?^--!U/P7X?ET P>'
M-;L==OS-%J&DS6Z*EK8,D"7-LER?49?A!\)I@$F^&W@:51#\2K<"3PKH\BB#
MXR:P=?\ BU"2UD0(OB9KN=8\=H2%\5ZG_IVM?;;@^97XA_#C]B#]L3P?;_$#
MQ=K&H>*O%?QK\ 66J_$K0]8OM>^#GA3P1^TY\<O!7QVT+XM?#N75=>\+:E>?
M$G6;'Q+X/T3Q-\)HO$7QHM_ <OPI\(?$W7O VFZ3XH\(6]K?:5WEW^Q7^U ?
MC]\)_&>L^(/&>J:3#:_LZ^)H_$/A6\^#5ZOP>\>:;\5_$_Q7_:H$NO?$C49/
M'/A^Q^*6O>*;NVE;X2^%O&L/Q+\%Q0?"OQI%X9\-Z+HNKD _5EOV:OV=I/%#
M>-7^!GPE;Q@?"/\ P@3>)V^'/A8Z\W@K_A'G\'_\(M_:QTG[:VACPG+)X6_L
MX3^2/#<CZ#M&D,UF=7Q%\!O@EXKT;4_#OB;X2_#O7M#UG0O _A;5-)U3P9H=
M_87_ (>^&.I:CK/PXT:YMIK&2.33/ .KZQJFJ^#+; B\,:EJ-[?:-]BNKF65
MOQ[L/V$_VA/"?PY\#S^#_##V/C__ (59X\UGXO6C?$^W%S\0_B/X+_;=_9]_
M:#^#?A#4-8N=?O+"]O)/A=X9^,G@CP)KM[*WASP%IWB9O"NIZEH_A^_%L.9^
M,O[(G[8OQ9\1^*_&M_X5\7:+X1\7?%C]I;Q-I'PET;Q1\"/%OB3PYJ'Q&\#?
MLV>'O@I\5M3G\?\ B^/P!X9\1>!+'X=?%#2I-=\"Z[XF\;_![Q+XF?Q'\--/
M\>1:E<ZHX!^VWQ,^"WP>^-%KH^G_ !=^%W@#XGV7A[46U?0K3Q]X-T+Q=:Z1
MJ4D/V>:]TZ/7M/OH;2>YM<VEV8 BWEJ3:7:SVY,1X[XD?LO? _XH^'K[P[XB
M\ >&[>+4=7U#6[G5-*\/^'K?6VOM>\1^&/$OBXC4+O2+XF'QU<^#]"T_QO$\
M4B^)=&M(]-U O%#:FW^(?!'[.GQT\&?MI:!\3$\+:KXJTFXN]-M?B-\8?B)X
MJ\#:Z-1\'6?[.^D^![I/ /B#PIKO@GXK:5K.J?$O0=(UG4_@9XY^%'C/X$6F
MI:GXW^*O@_Q7X3\7ZSI6EZ9^KXSCGKWQTS0!\_ZA^RA^S%JOA/P_X#U/]GKX
M*ZAX)\*:[J?B?PSX1O?AAX+N?#>@>(=;N)KO6]9TG19M%?3['4-:GN)WUFY@
MMTEU<321ZDUW&[(?19/A=\-YKR34)? ?@^2_F\:Z7\2);U_#FDM=2?$#1/#>
MG>#M'\;/.;7S&\5:5X3TC2_#6GZ\6_M*ST+3K+2H+A+&VAA3NZ* /GBR_9(_
M9;TWPCXH\ :=^SK\$M/\$>-M1T[5_%OA*Q^&'@RT\.^(=4T6=[K1+_5=(M]'
MCLKJ[T*ZDDN="F:$/HEP[S:2;*21V;T.^^$7PKU+X</\'=0^&_@2\^$[Z+!X
M<;X:7'A/09/ 8T"U>.2UT9/"1L!H4>F6LD,,MK9QV"0VTT,,T"1S11R+Z)10
M!\\:A^R1^RUJVBZ+X;U/]G3X(:AX?\.ZU<^(]"T6\^%O@JXTO2->OK'2=,U#
M5]/L9=%:WMK_ %/3M!T2PU6XCC#ZM9Z3IUOJ?VN.SMUC]$^('PC^%GQ7T_1-
M)^)WPY\#_$+2_#>M67B/P_IWC3PMHGB6RT37].CDALM8TJVUBRNXM/U&WMYI
M[5+JU6*4VEQ<6;E[6>:%_0Z* ,7PYX;\/^#]!TCPMX4T/2?#7AKP_I]KI.A>
M']!T^TTG1=&TNRB6&ST[2],L8H+.PL;2%5BMK2UAB@@B58XHU10!M444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !_G_/I^%%%% !1110 4FT9SSR0
M?O-CCIQG 'J ,'N#2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>reservesdiscountsandallow.jpg
<TEXT>
begin 644 reservesdiscountsandallow.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %T 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OSS^)/[:NK>$OVN;G]F73G_9@\-6VB^!O@_P"/-3U7XY_M*W/PJ^('BO3?
MB;XA^)VFZK;_  G^&MO\+O%:^-YO!^E?#*]O;J:Y\5:);WFI:M9Z;.VEVT$V
MI-^AE?-6M?LO^ O%7Q ^/?C7Q<T_B*Q_:!^$7@'X->*/#=U:64%OIOACP5;?
M%RQNY-'UF!!K-M>>)+'XNZM;7\B7$7V(:98RV#))-=%@#B+;]O\ _96NM&AU
MM/'^O)!?:M\.](T73KCX4_%ZT\2^*I/B_:^*+OX2:GX+\)7?@2#Q/XT\-?%%
M/!GB>W^'WBSPMI&K^&_%FH:-?Z7I&IW&I0/:K4_:2_;7\+_L[^++3P%=_#OX
MD>+/$^L_LV_M%?M%Z)J&F^$O$L'P]@T_]GS1O#>JZAX9\8_$&'0M1T/P7>^(
MF\1V]G%J.JL;70;@Z9;:U%#?^+/"%EK?(>"OV#ET3Q3X!\<^-OCAXZ^)/C#X
M:ZG\'M/\,:SK/AOP3H@_X5O\#=+^*EGX,\'ZG9>'=-L[:^US5M1^+6O:_P".
M?'$8M;O7]2T[1(=+T7PWI=G+I\_J7[2?[+$'[0EYHU_%X_U?P+=6OPF^/?P,
MUXV'A_0O$$&N_#/]H?P]X5TSQE8Q1ZP(Y-$\0Z=K/@'P5KWA_P 16,\OV9=.
MU71K_3=0T_79C: &+X9_;U_9S\0^$+;Q&?$WB*'6);CP!I8\!V7PS^+&J^/]
M:UOXF>$-5\<>#;?P!X%MO :>-?B9H?B7PUX=\5Z[X>\8>!_#FL>%]6T#PAXN
MUR/4XM.\+>()]-[CXC?'?46_9PUKX_\ [/5CX$^*]O9>#[_Q[H]GXM\8>)/A
M]H&L^'=!LK_4_$-O+K&F> /&^OZ+XBLK;2]0L%T/4_"$-U9^(;:?1=?&B7%K
M>&W^:OC/_P $U/AO\9M3M_$7B+Q+'JFNZ!I_P%3P=9^-_AUX%^)7@73=9^!_
M@GXY?#E-1\1> O%=G-I7BVS\7^$?CYXNMM3TZXNM+GT+5K#0M<\-ZMI][:3_
M &CZG\+?L[>%?!W[.#?LW:!<PZ5X:?X>^)_ AU+0_"G@OPDD3>+[#6H=;UNQ
M\)>"]"\-^"=)N+C4M?U'5QIND:'8::+J4B2*5Y)[B8 ^1/A]_P %&['3KWPE
MIO[3GA#PQ\()?&/[._PN_:0M=9^'WB/XC_&3PQX?\&_%?Q9K/A?2CXVU2W^#
M?A.?P5H_AA[#3'\:^/O$UGI7@/0;K7[""?7?LJ37X^BKO]N#]G"WN=:L+7Q9
MXHU_4M#^)/BOX13:1X1^$WQ<\9:UJWQ#\ 77B6V^(?ASPEHWA7P/K&J>-I_A
MV/">L77CV]\(VFM:7X/LO[+NM?OK%=>T-=1\X\2_L#^%O$G@GQ9X)E^(OBJT
MMO%?[&'P\_8TN+^#2M":YM/#GP]O/%=Y:>-X8Y$\F3Q#J1\57$5WILP.CPI;
M1?9T!EFSSGQ<_P"";_PR^*WA_P )6NK:MI>I>)/ GQC_ &C?BSX8U+X@?##P
M%\5?"L:_M.?$'Q%X]\>>&-5^'?C&SFT#4[?3+K6=.'A7Q!!-I_B+2K_PQI.H
M3WE[97OB+1-: /H*P_;'_9RU7Q9X6\'Z/\18M;O/&%KX"N-'U[0_#/C+6? $
M-S\5=+M]<^%^BZ]\3--\.W/P]\+>)OB+H]Y8ZCX(\+^)O$VD^(?$EMJ>BG3=
M-FDU_08]3Z3XL_M+?"#X'ZEI6G?$S7->T"/4X+.]N-=M_A_\0M?\'>&=,U#4
MI-%L=8\=^./#GA;5O!_P_P!'N=73[#'JGC/6]$M PENI)$T^TO;RV^0?#?\
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M5/!DWAKX@Z]+,OQ \9Z3\,=%TGX::U!X'L+?XWW3_%77=&^& _X59:>(Y_\
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M#!I]AHEG=6Y@T.Q433V6EK;6=W>ZC<P2ZA<^^4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Q+^VS\1+#PWX<^"_@O2_'-OX?\
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MX/N_BE8WITK5+^#XG:F?%?P^U;Q)K?P\LO'$VF>'?KG]F7XT^-O$7[$'PO\
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M?QAXIMO@UJ'B6T^)U_\ ";1/&NBZM\,[CXAZ?I5W+)XZL)_L_A>;P0/^$XH
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MBL#^W3_T!]=_\%I_^/T?VZ?^@/KO_@M/_P ?H WZ*P/[=/\ T!]=_P#!:?\
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MYSL"BBB@ HHHH **** "BBB@#\0/^"D__*23_@A3_P!G6_M0?^L<_$&OV[C
M\N/@?<7L/[HK\1/^"D__ "DD_P""%/\ V=;^U!_ZQS\0:_;R/_5Q_P"XO_H(
MH =@>@_(48'H/R%+10 F!Z#\A1@>@_(4M% "8'H/R%&!Z#\A2T4 )@>@_(48
M'H/R%+10 F!Z#\A1@>@_(4M% "8'H/R%&!Z#\A2T4 )@>@_(5\X?M= ?\,W_
M !9X'_(M+V_ZBVFU](5\X?M=?\FW_%G_ +%I/_3MIE '\^[=3]3_ #I*5NI^
MI_G24 %%%% !7Z+?\$X #\1?B/D9_P"*)TG_ -2!J_.FOT6_X)P?\E&^(_\
MV).D_P#J0-0!^N&K@?V7J/ _X\+WL/\ GUFK^7=/N+_NK_(5_43J_P#R"]2_
MZ\+W_P!)9J_EV3[B_P"ZO\A0 ZBBB@ HHHH ^B_V2?\ DXWX4_\ 8=U'_P!1
MG7J_H,4  8 ' _E7\^?[)/\ R<;\*?\ L.ZC_P"HSKU?T&+T'T'\J %HHHH
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M ,%ME_\ &*/[ T/_ * VE?\ @MLO_C%:]']>E &1_8&A_P#0&TK_ ,%ME_\
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M]G_:>F2L+NP>YBANXH9RT:X,/Q.^'%SXSN?AU!X[\)3>/+-)WNO"$>NV#:_
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MYJ]E\2(?@[8>%? ^B^(_#^J_"F.TU+=X?^)FIZQJT%]X:\)65[^LK.B#+LJ
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M%Z#Z#^5?SY_LD_\ )QWPI_[#NH?^HSKU?T&+T'T'\J %HHHH **** "BBB@
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MU%)13G4IRDTDDDF[):+0\*U/X&P:Y\8M'^*VO?$+Q_KMEX;FL=:\+^ =7O\
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M&<_#+1>#T/\ Q4'BCCO_ "H _-D?$KX>'Q\OPL'C?PJ?B2^CIKZ>!?[=T_\
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M"ZJ'7/QM^S_XL^&>C?#_ %6:T\6Z#I>C_%/XD?$S4M!\*_#@>*+SPA\*#;^
M;;Q+K7@#PSKNF^'+.VT>X\/>%?#>I>/M:US3K'0?"EQX^U_7(OA[;R-/HMIJ
M/+?LI:S\&/%OCSQ1XI^"<NC>$O"=M\-= \(6'P]L;77-.\6^*K32O$LM\OQG
M^+&F:K86QL_%EX;J+PYX;36KO4_B3<Z-J6N:S\1[VVU+6;#P[X? /Z@_^"<W
M_)(_&/\ V4B]_P#47\,U[O\ M=?\FW_%G_L6D_\ 3MIE>$?\$YO^21^,?^RD
M7O\ ZB_AFO=_VNO^3;_BS_V+2?\ IVTR@#^?=NI^I_G24K=3]3_.DH ****
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M?B&6PC@U%_'G@;X8:MHEOIWCWX77=C=165BWA7Q9J/BEC;:IXEO+6SL=-O=
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M->D_M<> ?CMIWQ[TCQ1X%M?B5\>O'/CC1/$/PB\.:7XN@T+XA?#S0_A_X%\
MZ+XEL?%5U-JFA>&O#.AZ?X,T6\?3-+N?!^DV=QXA^Q:_KVOZU-=_K]\!?^0Y
MKN>3_9%MD],_Z:>U>SPE2PE+BSAKZKB%B.=2GB6N=<F)=''1G349TJ4HQ5.-
M)Q3YY23]HW%34(EK)ZWT_6/^=OD?35U_Q[7'_7";_P!%M7Y:?$KXB>&OA)X
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M&.Q.88?&8_%8C%T/J]3ZW/#."@ITIKDC0PU#EY?90A"*?)"FN2,%%141N_\
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M_D?R$V7_  4K_P"";EG^T)?_ +0#?\%(?B9=2ZEX:M? MS\+YOV8O&47P_\
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MI(O_  Q?[3__ ,Y"OZ8]H]6_[[?_ .*HVCU;_OM__BJ^&_XA/D/_ $,,X_\
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M /!P-_P2+DAFC'[6R O%(@)^ _[3N,LA SCX*$XR>< GT!KXV'_!:[_@F"
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M7D'Q9UOX@>))=/\ #5SKNH:7X%M-.M+ZRT*;Q0)P#[CR!C) ST]_I1D#J>O
M]SZ5^)-U\7_VC/'O[/7A;QWH/[2GBW4?CI>7'QN^#_[._P .O@[\//AQ]C_:
M-^+OP<^./Q9^%^@_'CXGPZSX<\30?\*.\8>&/#7P[\4?$,^'V^&OPV^'FAZQ
MXP\0V?BR[O/$OPQMO#WZT>+_  U\0?$,WPMNM \=CP7_ ,(QXZTWQ)\1+#3]
M(M]2M/'_ (6@\)>+-)U'P*LNI(UUH]A>>)M8\/>(HM5MRFIQ)X9ALV;9?72L
M >G9'//3K[=^?PYH!!&001ZCD5^1/B?XP?M3?#_X%?\ !0&;6OBYI7B+XT^
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MN@W'BOQ!XP\->)?#%CHFBZWJJ^'=)USP+I-[?V=_IFHZQIM_^9?C#XY?M/\
MB3X"?\$Z+#X?:M\7OB;\2/B_^S9'\7?C3X/^"UW\&? 'QZ\>6?A_X1?#&_N_
MB3I_CCXR:+I_P4\->%=,^)_CCP]I7CGPS:_\(IK_ (EUGXC^$3X-(\,^'?%G
MAG50#]LJ*^;OV0?B;JWQB_9H^#/Q%\0^)[/QAXG\0^"=./B[7K/P[>>$Q<^,
MM)EN=!\86EWX<O;+39M(U72/$^E:MHNMV<>F:99IK6G:@^G:=8:<]I9P?2-
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M;#PQJ^@Z5XUT;X67[>+;S1_"_@_X:?'>Y\+Z[X\L-9T[Q!HOC=6U'0M(UO\
M2($, 1@@@$$<C!&>#QQ^ KP_0OV9?V<_#'B#PCXM\._ ;X.Z)XK\ Z+;>'/
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M?0^AH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?Q$/@3PP?'%Q?:5IMSHVFWTOBK^R_P"VWO;+1KNYT>WO&O3<QZ3*^F>:;';
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>sga.jpg
<TEXT>
begin 644 sga.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M_P##;6OBEK=QXSOKW6],O-)TN7P]H5U:Z=/I6G:]=7&KS6UM-96MHT]_!]/
MA@&'0@$?0C-?B#_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4
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M""2.*7_AJ[]ITJ\L33( /V//'Y<&-98&.Y R*1*NQF#X8+L;]I8[;Q#Y:?\
M$WTK[B_\P*Y]!_U'J -ZBL3[-XA_Z"^E?^"*Y_\ E]1]F\0_]!?2O_!%<_\
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M404444 %>[_ ;_D.:[_V"+?_ -+6KPBO=_@-_P AS7?^P1;_ /I:U?5\#?\
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MTE"-E;7WKA\[??\ HF>_?\)'X>_Z#NC?^#2Q_P#C]'_"1^'O^@[HW_@TL?\
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M6KY<?_/-/^^5_P */+C_ .>:?]\K_A7V(C*_X2'0/^@YH_\ X,[+_P"/T?\
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M 5[;\$+ZRL=:UN2]O+6S1]*MT1[JXBMT=Q>%BJM,Z!F ()4$D YQBO$J]V^
MX#:YKH(!']D6_! (_P"/X^M?5\#?\E9DG_835_\ 43$#6TO3]4?0ESX@T V]
MP!KFD$F&4 #4K(DDHP  $^22>@KX$'0?05^A]U'']FN/D3_43?PK_P \V]J_
M/!>@^@_E7W/B[_%R#_#FO_O,$+1117XV 4444 =M\.)X;;QOX>GN)HK>".ZG
M,DTTB111@V-TH+R2%44%B%!8@$D#J17VM::CI]_YGV&^L[WRMOF_9+J"Y\O?
MNV>9Y+OLW[6V[L;MK8S@X^+OAD ?'GAO(S_I<_7_ *\+NOMP*JYVJJYZX &?
MKBOWWPF_Y$>8?]C>M_ZA9> M%%%?J8!1110 4444 %(>AQR<' _#WX_.EI#D
M D=0#CZ]NG/Y4 ?F:OPP^->B_M*?$_Q#'X9_:/7P5XM^+O@[Q1HNH?"7XB?L
MZ^ _A)<>'X?#?@S2=4O/%G@;7/%C_$+7-5%_I&J-X[UZ:R7Q#XSTI+"UTNP@
MCTS2K-?TS'^/7Z_YQ[5^<MYX_P#CHW[17CSP]XFU7]J70/"&F?$_PA8?#V'X
M4_ 'X<Z[\%]?^'][H7A&69O$7CSQ;X#\5>.#J*^))/%5I\0-:L]<\/:9I>EO
M8?\ "() ;"ZU67]&A^/4]?K_ "]/;K0!^('_  4G_P"4DG_!"G_LZW]J#_UC
MGX@U^A?QQ&?%&G# .?#MF,'H?],U'@^WK7YZ?\%)_P#E))_P0I_[.M_:@_\
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M)1@8V\Y&#\"/^18U7_L/3?\ IOTZNS^)O_(A^)O^O!?_ $I@K^D,G_Y-R_\
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M?^Q>L_\ TLU"OSS_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]#/C?_ ,C3IO\
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M(E1%_P!IF SQG)%?DO\ 8&??]"3-_P#PV8W_ .4>?Y]F!^KE%?E+_P /P_\
M@E'_ -'F>"Q]?AO\?P?Q'_"H.*/^'X?_  2C_P"CS/!?_AN/C_\ _.@H_L#/
MO^A)G'_ALQO_ ,H\_P ^S _97X9?\CYX;_Z^[C_T@NZ^W:_FX\#_ /!=?_@D
MOHOBS1-4O_VT/!D5G:7,KSR#X;_'TE$>TN8@?F^$2+]^11@L,YZU^N/[(/\
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MY]* &>6OH/\ OE?_ (FCRU]!_P!\K_\ $T_^G6@$$9!!'J.10 W8!TX_!?\
MXFC8/\A?_B:=10 SRU]!_P!\K_\ $T>6OH/^^5_^)I^1Z].3]/7]#^5-WIDC
M>N1G(W#(QUSSQCOZ4 ?.7QJ^'7BGQC\4?V1O$WA^PAN]&^%'QZ\5^.O&]Q)>
MV5HVF>&]4_9A_:%^&EE>0V]S)%/J4LOB_P ?>%]/-IIZ3W4<-[+J$D2V5E=S
MP_1GEKZ#_OE?_B:<"",@@CU!R/S%&1ZCC@\]_2@!OEKZ#_OE?_B:-BCH /\
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MN\\:SV-_I/J+^(OCU-^TO\,;3PI\7_&?B[7/$GC"T\5_&7X(3>"/">G?!CX
M_LVZOX UFZT_0_&FL6^@WGB_3_C;+XN30!X,U&Y^(,?B;XAZU<>(;]?AUI7P
MCT+5U\,_1OQ__9(^$?[0VJ^#/%OBC2;?1_B-\/M>\.:YX3^)&D^'O!6K>)[*
M+PUJ=WJMGX<U.#QMX7\6>'O$WA-KW4+_ %"'P]XET35;'1/$,UMXR\,#0_&F
MDZ1X@L6Z3^Q9^RWH/Q9U#XY:)\%O!VC_ !6U;QMJ/Q(U;QII<.I:?J>J^/-7
ML5TS4O%VJ16NI1:;J.OWNFQP:?<ZE>V$]Q+96UI;,QAM+9(@#L/''A+XTWGB
M[4/$G@'XI:'X>TFX^' \):7X0\4>#)/$_AS3/'=[XTTR_?XE7L6F:SX:US69
M=+\)+J6BV?A9/$>D:;?W<EM->WMO$)I1^<WAOXL_M$^+?V5?V&?$&O\ CWXT
M7NE>/]/UE/VB_BQ\$/A]X:\3_'F_U/3= UJ/P1?Z9X$TKP-XEM]/\*^)_%=H
MLGQ!U3X>_#?5;WPV4\/0?9/#O@34?%7B'2?U;\>^ ?"/Q/\ !^N^ ?'>B6WB
M+PCXELUL-;T2[DNX;:_M$N(+I89);&YM+N,+<6T$JM!<PR!XUP^,@_/&A_L'
M_L?^'/A[+\*='_9\^&UG\.G\36WC&'PA_8LEQHVG>)[32YM#BUO1;>[NKA]!
MOCHEU?:/-+HDNG+<Z5J.IZ==)-9ZG?P7(!-^P_\ %7QS\:?V9/AW\0?B/ND\
M7WUY\0O#^H7\UKHEE>:]9> _BCXV\ :!XKU.T\,7%UX6M]7\7^'?"^D^)]8A
M\*SOX7CU75KU?#@CT3[!&GUC67H>AZ+X8T72/#?AO2-,T#P]H&F6&BZ%H6BV
M%II6CZ+H^EVL5EIFDZ5IEA#;V6G:;IUG##:6-C9P0VMI;110011Q1JHU* "O
MAW]H/Q+\0/%/[27[/_[-?AWXE^*/@OX2^(OPR^/OQ6\3>.O \'A%?'/B/5?A
M#K/P5\/>'/AIX6U;QGHOBO3-'2]C^+.L^//$LMKX7N]9OM*\$6NGVFH6&D3^
M(EN?N*O&?CM\ ?A7^TAX!U/X=?%GPO9>(=%O8+XZ;?\ EPP>(O">K7NEWVD+
MXF\&:]Y,E_X8\3V=CJ-Y!::SICQS^1<W-C=K=Z;=WEC<@'Y9W?Q?_:.\>?L]
M>$_'N@?M'>)[WXX7A^-/PA_9\^''P=^'?P\-O^T7\8?@_P#''XI_#'1?C?\
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M]=M=+\.>)2P#ZEI6G6_B;Q!'8VLK!;4:O?F$HT[&@#Y@^"FM?$/X>?M1>/\
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>spinraza.jpg
<TEXT>
begin 644 spinraza.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M -F:S_T,4G_@JT[_ .(H_LS6?^ABD_\ !5IW_P 17044 <__ &9K/_0Q2?\
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M@?Q+\.]+LOA#\+? OQ9^)OB'XA_"SXQ_$+3);#XA:UXWLM%TS5M3^">FW8^
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M]\9_^%1K?_R=1_PLGXB_]#[XS_\ "HUO_P"3JXJBOYL_MG./^AKF7_A=BO\
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M:V38V5:K4JR69U(J52<IR45A<(U%.3;23;=MKM]Q:***_>#]$"BBB@ HHHH
M*0YP<=<''U[4M5;ZZ6RL[N\>*ZG2UMKBY:&RMIKR\E6"%YFBM+2W5Y[FYD"%
M+>WA1I9YF2*-6=U! /RFUFVU6]_:W^)/_";:!\3]#O+GXL?"6[\%WWPY_97^
M#?B7P?X]\%>"=(\*7?A#7?%7Q,\8?#;Q3\4=5U?P+XMU'QA::SXLM==T?2?A
M[8W5JW@*;2IK6^UF?]8AT].WIT_IZ>U?B%X^^%I\5?M*:KK5GX#\1_8_B/\
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M5I=^'TF\+Z?XHU]](D^*'Q T/P/+_P (#HGC/QSJ^F>%9=;M[2Z\8^*?T/\
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M /!D_P#Y7Z_T]/V:K[&_8S_Y''QE_P!BSI__ *=S7\S_ /PVI\?O^@[X9_\
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M)(8+TZ/;8'C7X=^-/'%C)YUCH_AS4_&W@=O!_P 0FT/XAZ^FC11R#6[1$O\
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MO<9_'EO^'&?GA1:*7!]#^1HP?0_D:_'CXD2BEP?0_D:,'T/Y&@#[=_X)N_\
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MV^J>&KB.WNVM)IK9IXE60P2R1%MCL#Y=_P 0RW[%_P#T<_\ \%*?_$S?$/\
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MXA_^9"C_ (AEOV+_ /HY_P#X*4_^)F^(?_F0K^C.BC^S<N_Z ,#_ .$F'_\
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M73_%_C4S1WWQ#\41:O:#Q5-I/AM9='MI]%EO]5 /L2BBB@#Y&^-/[7O@_P"
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M/$OC?PM\"_B!/XR\(^,='\4:WX.L_&>NVV@^+].T9K'6?A]X@\7^$?A_XO\
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MXTF\;7:?$;1O _\ PL?QE#X.TC2_#_@.^U&WU#3;KQGKGB#7-!M-7N?T]HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M8?#OQYX_\5^-;W6M4TOP]X4UZV7P%\3?@]\ _A%X[\!P:=X@L[NV5[I?V=?
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M_M:^)] ^'TLO[/G[.MCXJ^*W[4?Q8_9D\&Z='^TA\3KK0+74?@+#^THWQ/\
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M^,5K816_@SQ]X1\*Z[;:-;:9\+++7-%\3QK>Z9XIL?%,;6'D+I<DEW\[V?\
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MM$<GD7D"RR"&ZBV7$0DD"2*'<, ?C+X0_;I_:1\1W.C?%AM*\ W/PXU/XQ?
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MOO#'AZ]T.]O7U*\T>[T32[G2KK4)+O[?)?W.G3VDEE/>R7W^F27<L#W#W?\
MI+2&;YZ /YW/B+\;;_XI?!']@X> /C1\)/%%K8_L67_B'QK<?&W]KCQS\!/@
MEXC^*=KX"^#5I8:DGQR^$^KZGXG\5?M(?#3Q";F^U'P#XJGN-)T?PCXUUGQG
MK>O>$/%;^&M5U']/A\3-?\2?LV_L.:A!K7C^QMOC1XH_9FTKQIXB\?:?!X<^
M)-UHVH^$9?&][!XUM-'O7L-&\2>/]?\ "ND^$_%$.D7EUI\C^+M1L]*N;BUO
M;:X;[=M? 7@BQTU-'LO!_A:TTF/55UR/2[7P[HUOIR:TCHZZNEA#8I:+JBO'
M&ZZBL(O%9%83@J"+/BKPCX?\:Z2NA^)-/74=.CU70=<@C\^YMIK36?"^N:=X
ME\/:K9W=I-!=VFH:/KVDZ=JEA=V\\<T%W:QNK8W*P!^9'[:,WA?]GGX<? Z3
M7OVL/$GP[AMOVQ/AEX\&A>*OBQX7\&3?$ZT^)O[;7PY\6>,M%\1:QK$VG>)]
M=^&/PJ\*^.O$>B6G@?1=7T_PC;^#I-(MO'EIK6C:%IMK%\A?M0?&7Q'!^U=X
MS^)7A'XG:)KG@;PCXO\ V1XO!VGP_M >)/"WQTCT/Q#'X1\3>*;G]C3]G?0+
MZ?X5_M1?#WXMZ-XPT*PU#7_'D^E7GBKQ'#\5O"&B+\0+/P1X,T"+]\?$7@KP
M?XN-H?%7A;PYXE-@+I;$^(-"TG6C9K?+&EXMJ=4L[LVRW211I<K!Y8G2-%E#
MJB 6H?"_ANWET::#0=&@F\.VAT_0)8=*L(I-$L3#';M9:/)';J^EV;011PO:
MV!M[=X8TB:,QJ%H \ _9=\1:QK&@?%71-1O[O5]/\ _M!_&GP+X7U:^DO+BY
MN/#&D>+9+_3M+>\OI9Y[Y/!\^L7W@2WNWED>2V\+0I/)+<Q32-].5S?A+PCX
M>\#:'!X<\+Z>NF:1!>ZQJ0MQ/<W4DVI>(=:U#Q'KNI75U>37%W>:AK&NZMJ6
MKZE>W4\MS>:A?7-S/(\DK&NDH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*?<(92L;2L(W*QI(
M(GD8*2J+*641,[ *)-R^62'W+C< #EK'Q_X'U/\ X3$Z=XP\,7P^'NHW&D>/
M#::]I5PO@S5;32;+7KK3O%;17;+X>OK;1-2L-7N+;5S9S0:;>6]]*J6TJR'0
M\,^*?#7C30M/\3^$/$&A^*O#>K1-/I?B#PYJ^G:[HFI0)*\+S6&K:5<W>GWL
M2S121-);7,J++&\98.C*/YQ_V=/!7A_X+6?[8EMX_P#V1/BO\6O@-X6U#0I-
M4T+5OV5IC^TWJWC7PW-^S#J?PZ^#NNW_ ,,]1O\ 0/VK])U7Q NL^*_%_C73
M?#5SX)\/KX)U/Q]\2/''C71_BOXAELOTM_8W\6>$O".AZ[XEU#0?%?AWQ7^U
M;^U'KL][X$\/? 7XV?#CP'\-?&[_  3M=3@T#2+'XE_#3X;:O=^%X? ?P>_M
M+QC\=+SPAH7ACXB?&#6-8EB32=0UW2O#5B ?HW::IIM_/J5M8ZA97ESH]ZFG
M:M;VMU;W$^EZA)8V>IQV.HPQ2/)8WDFG:C87Z6UTL4[V5[9W:QFWNH)9.2U+
MXH_#71O#5YXRU?X@>"-+\(Z=K%YX>U#Q1J/BWP]8^'+'7M.UB?P]J&B7FNW6
MI0Z5:ZO8Z_;7.B7FF7%W'?6VKV\^F3P1WT4D"_CW\']1\0Z7X8_;R^%_[%_P
MW^*GAKQK\1/C=X?\>_#?6/C)\-_VD?@=!K7@[6O@O^S3\//B]\4]/^,WQQ^#
M]_:^(/B_!KVE_$6\\.2^,KO7/$7B7QQHUKK>K6U]X6MY[X^+?"KX0_%GX=_#
M#P;XD\:?L[P_#"W^#W[;'[9D7@KX2:C\-/BG^UG\.M1^'_Q@\4^)WM/'VI>&
M/AEX)LOB3I>J:;"]]8?#+XIVGA/QM;>,;'7O$W_"2S>';/XM#Q-H8!_0U/J>
MG6NFS:Q<W]G;Z3;V4FI3ZG/=00Z?!I\4!NI;Z:]DD6UBLHK96N)+N25;>.W5
MIWD6(%Q1\->)_#GC/0M-\3^$=?T7Q1X;UF#[5I'B#P[JNGZYHFJ6N]XOM.FZ
MMI5Q=Z??V_F1R1^=:7,T7F(Z;MZ,H_&S2? ?Q3T?]ACX5_LZ^*_AG\3?%7B3
MP)J?P6^.7Q-\ 0_#.[;0_$'[.D?[7=UXRUGX!Z-):R:AX#OO&OA+X.:/!I6I
M?L[Z)XFU[5$\+:+IO@)!K6D^(M*N=6^Q_P!C;PU?VOBG]J;Q_HGA'7/AY\'/
MBK\:]%\5_"?P=XD\":I\,M6N18?!_P"'7A?XC_$$?#[7=,T+Q!X-L?B'\1-$
MUG48M+\0>']"UG6;[3-3\=7NG$>,H;R[ /NBBD)P"<$X!.!U.!G ]ST%?FWH
M?[<WBW7/VU_B%^RY#\// ]C8>"_"&K:MI?A[7_B8GA3]H?QO>:-9^)-03Q5X
M'^&GB?0=*\)^+?AMXF?2M,TK0M7T7Q]//ID>I1^)_$]SI=DFK:+X? /TEHKX
MQ^!O[07Q>\4_&'Q-\$OC5\,/!?@_QCIGPF\'?&=6^&?C_4OB)I7@_2_&?B/6
M_#-I\._B/?ZIX3\)IIOC>.[T'4+SP_JVBK?^'/'>EZ5XHU#28=)@\.!]8\^'
M[9'Q ?QAH^M?\*U\)6OP!\:_M%^,_P!DOP5XTN_&>LGQX/BOX3UWQQ\/['QC
MXA\)6_A670+?X8>)_C!X"UGX;:>NG>*KCQ99BZ\.>+9K*YLM;OM'\/ 'Z'T5
M^<_P[_:!_:XU-OVCK;Q+X!_9N\2S?!+_ (0_PQ9:OX,^)/Q$\+>#Y_B1J5O9
M>(_B%I/B?Q!XT\%:A-9>&OA1\/==\->*_%&L>'M+UO4;C5+[4?!%CI3>(=%U
M!8/6?V2/VDM7_::^%7C+QI:VWPYN[GPMX_\ %_P\T'QE\.?&.I>,?A#\3CX:
MTG0[V'QKX+U^[T/1]=7PZVJZU<^%==L;O3KBZTCQ1X7\3V>FZEXBTN#3-;U$
M ^OZ*^+/V8_BW^T5\0_B%\:O"7Q>T/X'+X?^$UYX8\('Q7\'M=^(6HV]]\3[
M[2D\3^+_  @UOXWT/38[BV\&^&-:\%3:CK&G7,L:>(?$=[X7FMXM2\-:N(OM
M.@ HHHH **** "BBB@ HHHH **** /F#XT_M:?#+X$?&?]E?X%>,[#Q?=^,O
MVOOB!XX^&_PNNO#^E:9?:!IVO?#_ .&VM?%+6[CQG?7NMZ9>:3I<OA[0KJUT
MZ?2M.UZZN-7FMK::RM;1I[^#Z>!# ,.A (^A&:_#W_@I9(8O^"D/_!"EQ')*
M?^&K_P!IQ=D2AG/F?L>^/X]V&9 %3=OD8L-L:LW.,']H8]<D\N/_ (DNN_<7
M_EPB_NC_ *>Z .BHK _MR3_H"Z[_ . $7_R71_;DG_0%UW_P B_^2Z -^BL#
M^W)/^@+KO_@!%_\ )=']N2?] 77?_ "+_P"2Z -^BL#^W)/^@+KO_@!%_P#)
M=']N2?\ 0%UW_P  (O\ Y+H WZ*P/[<D_P"@+KO_ ( 1?_)=']N2?] 77?\
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M%RP<X8R-&-252%&A7<HJA7KQY''$02;DI74ERV2;T****^2/J0HHHH ****
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M)Y8(I#;RSY,%JCW5U,Z0-%9V-JC76HWLEM86H-Q<QU_5)K7_ ""-4_[!U_\
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M:=FTD[-.W5;G\Z;?M,_ L,P/Q"T_()'_ ""_$/K_ -@>D_X:9^!?_10M/_\
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MC_5&7_0>O_";T_ZB/-_=YA_K>O\ H7O_ ,*E_P#,Y_4A^QN#_P --_"'@_\
M(?U/L?\ H5?$%?T>KT'T'\J_@O\ ^"6ESJ$W_!0+]F"-;^Y!;QMKW,TUS<Q8
M'PZ\;,P>&2X57#*K+@L-I(<9* '^[_3H=0A5OMU]%>[EC\KR[);/R\!M^=MS
M<>9ORN,[-NTXSNX_C+Z1^6O*^+\EHNM[;VG#5"KS>S]G:^:9I#EMSSO;DO>Z
MWM;0_KGZ/N9+-.%<WKJC[#V?$6(I<OM/:7MEF53YK\E.U^>UK/:]]32HHHK^
M>C]Z"BBB@ HHHH *0YP<=<''U[4M5;ZZ6RL[N\>*ZG2UMKBY:&RMIKR\E6"%
MYFBM+2W5Y[FYD"%+>WA1I9YF2*-6=U! /RFUFVU6]_:W^)/_  FV@?$_0[RY
M^+'PEN_!=]\.?V5_@WXE\'^/?!7@G2/"EWX0UWQ5\3/&'PV\4_%'5=7\"^+=
M1\86FL^++77='TGX>V-U:MX"FTJ:UOM9G_6(=/3MZ=/Z>GM7XA>/OA:?%7[2
MFJZU9^ _$?V/XC_'/X#_ !B;XR:_^QA\:]7_ &@_AK_PC5C\+[JW^'G@7XS1
M:<GA#P[X.^S^'Y=%NM7U/4-$M_A9H_BSXF>&M>\&>+KI]4N[W]O0,#'U_GT^
MGI[8H _$'_@I/_RDD_X(4_\ 9UO[4'_K'/Q!KZ4_X*8^-?C7X3^#OA*#X(^-
M]2\,:SJOB_3U\0:+\//&'PX\&?'GQ9X?MKC2X5M?A#J'Q8MKSP3=2Z9K.HZ5
M>>-]/OAH]S<>%I93%XFTBQ34K?5/FO\ X*3_ /*23_@A3_V=;^U!_P"L<_$&
MOU(^./@7]G?XO>$S\,/VAM$^&/C/PM>S:5KK>$/B-)H$]J]UIET)],U:WL=7
MGCFAFM[FWDCAOK41.\?VNR:5[:XN[>72G2JUI<E&G.K-IODIPE.5EN^6*;LN
MKM9=2*E6G2CSU:D*<+I<U2481N]ES2:5WZGQYHGQD^)WC7QS_P $\/''A/XR
MZKJ/P7^+6K>._!GC'PKJ?PV\/^&O&OC[Q/H7[/OQ[\3ZMK?Q*U6TGU'2-+;P
MUXL^'FB0:;X5^&.G:%X<E\1VWB#7%\3>*O"U]X6TK2?5O^"@?B[XN^#OV:/'
MOC?X+?$NS^'.J^!SIVM:_J]EX8T_Q3XGO["QU_0%?PKH%QJMY)H7A6XULW8M
M->US4O#OB?4+?P[-?6GA_3]&UZ^T_P 5:%=^(_[/'[!'Q=UWPQXE^)7P\_9T
M\9:]X*T32O#?@[4];7P?<7/A30M$2]BTC2O#?EWL,6AV.G6^I7]I:6^F1VJ0
MV-Y<V" 6<SP&+QA^SO\ L)_$72_%6B?$;PC\"OB#H_C3XG:U\8?$NE>,;OPC
MK>FZK\1-?T+1O#&H^);NPFNTM+B_E\.^']%T?S;B&9VL],M?.>6=#.W1_9^/
M_P"@+%_^$]7_ .0\_P ^S.?Z_@O^@S"_^#Z7_P EY_GV9\Y?M;>)_BQX(^-?
MCGXTW7C#XAK^SS\ /!'P2\3>,O"_PR_:,\(?#F]L+27QGXVO?'=W?_">;P-X
MHU?XB:[J6EKX;FCT/QAXN^%>D>+/"NFRZ%X!UW5?$LU]8R4?"_QF^,+>/OA5
M\67^*OB?7[CXH_MY?'3]E#Q3^STJ>$SX%\,_#;X>:_\ M ^&=&N=!TV/P[%X
MKT[Q[X+T3X0^'OC'XH\6W?B23_A(?#^N^+;.[TV7P]<^"+?0/KBS^"W[#EC<
M?#Z\@\"_LY-??"FQL],^'5_<V?@*^U#P?I^FZM=Z_I=GHE_?RW-Y;6^D:]?W
MNNZ/$T\J:1K5W<ZMI@M-0GDN6ZU?"?[)J?$/6_BTNC_ =?B;XDTB?0M?\>A/
M 8\6ZQI-U8P:7=V.H:\'_M&ZBO=+M++2[YI9VFO=,L-/TZ[EFL=/LK> _L_'
M_P#0%B__  GJ_P#R'G^?9A]?P7_09A?_  ?2_P#DO/\ /LSYL_:PU'XQ0>.?
M#[?!7X]>,Y/B[XGMO 8^!GP \$>&_"USX"AM+7Q1"/B;\4?VA]1O=&\2ZCJ7
MPDN="OCI^L>(;S6? MEH-KIECX<^%?\ :OQD\4:/)?\ Z1KG'S=<MCK]W<=N
M<\YVXSGG.:^#M3_94_X)T:OJOAW7+[X1_LQMJ_A/PC\/_ /AO4+:T\%V%SHW
M@CX46S6?PS\(V$EA>VOD^&_ -K)+;^$-&P;#P_#/<1Z9!;K<3B3[HL;ZQU.S
MM[_3;RTU"PNXEGM;VQN(;NTN89,E9K>YMWDAFB?DK)$[(W.":RJX;$T$I5L/
M6HQD[*56E.FF[7LG**3=M;;Z/LS6EB</6;C1KT:LDN9QIU(3:6BNU%MI7:5W
MU=MSD/B5\2/"'PC\%:W\0/'6IR:5X:T%+$7=Q;Z?J.KWUQ>:MJMAH.B:3I6C
MZ1:WNJZSK>NZ]JNEZ'H>CZ99W.H:KK&I6.GV<$EQ<QJ?E!/^"A7P&LOV>?"_
M[17BVQ^*'@/0_%FJZ+H&F> O%_PS\3Z=\4IM;UJ+1KQ+>S\(1VMP=;T?3=(U
MZP\0ZWXWT#4-4\ :+X=6_P!8U/Q3:VVEZE]E^E/C=X'U+XD?"SQEX(TBQ^'V
MJ7OB+3(K+^R/BIX6G\9_#[6[1=0LKG4=!\5>'[34-,N[C2]<TZWN]):^M+E[
MO0[B\M]>M;'5)],CTN\_)OP=^Q3^UYX)_P""?^J?LSZ%;_";6O%OCX^&;8>#
M_'/QZ^+ \!? +P_HOAWP''J.D>"?&FJ_#'XM^+_&J>)?%_A#5/$]_P"&X[3P
M/X'\*WOBV\L_!-G::/I:6NJX&Q^NGQ4^*7A+X.> ];^(OC6XOX=!T632K+R-
M(TG4-=UO6-<\1:[IOA7PMX9\/:'I<%QJ.M>)/%?BK6=&\->'-'LXFN-3UK5;
M&SC*><9$^:I?V[?A@L.DZ);>!OC-??%_5/'?BCX<2?L_VW@*!?B]I?BGP7X.
MT'XB>*(M4L;OQ#:>!X=%TWP!XK\)^,+;Q3;>/+SPQX@T?Q1H \+ZOK>HZG#8
M5D?%WP#^TG\=_#]CX0UCPG\)_AMJ7A6T^"OQV\+Z]9>.?%WQ%T"U_:&^%'QX
MA^(>F?#S4)I/ OP]O->^&6I^'O!>C6>O>+;?0](\2Z?)XIO);#PM-/I6FS7?
MS#\4O^"?OQ,^-'B37OB;\7/"/P0^)DOQ!^)-SXV\:?LUWGQ3^*G@GX:Z5+X=
M^$/A;X,?"/Q!X>^/'A3X;_\ "P]1\9^ O#%I\47U66Y^&7A_P_XLC^,M[8/8
MZ?/\.O"FK:@ ?84_[<WP@N8/"%YX-T#XO?$ZP\1^ O#7Q3UZ[^&OPI\4^*V^
M&_PZ\7:]JWAC0?$_Q TR"&VUW3Y+_7O#OBJPC\*>'M*\3^/1%X1\5ZM_PB9T
M/P]J>J0>H_&C]H?PE\%]2\!^&+S0/&_COQ_\3[WQ#:^ OAU\./#\&O\ BWQ'
M!X/TJ+7/%^JPKJFJ^'_#^G:1X:TJYL[G4K_6O$&FI)+J&G:=IJ:AJNH6EC+^
M8%[_ ,$S?BQ:^%X]+36OA-\0O&'BKX&?"WX4R_$GQQKGQ&T77?V9/%WPDU3Q
MU;> _BS^SW;:%HVIZAXE\6^#/A_XO\.>#-+UG4?$7PE\=Z_?_"S0/%'BCQW=
M'QEXMTF#Z0_:D_97^*_[3TWA*W^)W@?X'?%/X??#KQY\3+C1/@YKWQ5^*7P\
MTWQIH_B'PSX9\/\ PZ^+7B'XF>"?AO?^)?!OQ6\%:?+\5- OO ?A_P /ZYX!
MU;1_B(^HIXACUK1M)^R 'WC\,_B/X2^+O@+PI\2O NH2:IX3\9Z-:ZYHEY/9
M7>FW3VET&5H;W3M0AM[[3K^TN(Y[*_L+R"*YLKVWGMIT62)J^+O^"K?_ "CS
M_:F_[)U%_P"I3X<KZ4_9D^&/B_X,_ 7X7_"WQUXN@\;>(_ WA>W\/W&M6L%Q
M#90V%G=79T'P[I\]Z!JFJZ9X,\/2:3X-TWQ!K@'B+Q+8>'[?Q#XC UW5-0%?
M-?\ P5;_ .4>?[4W_9.HO_4I\.5]5P+_ ,EOP;_V57#W_JWP9\QQM_R1O%O_
M &36>_\ JLQ1_!H_WV_WF_F:;3G^^W^\W\S3:_U=CLO1?D?Y?!1113 *_H'_
M .#>?_DX+]H3_LC7A;_U/'K^?BOZ!_\ @WG_ .3@OVA/^R->%O\ U/'K\M\:
M_P#DUO&'_8#A/_5KEY^F>#G_ "<WA'_L.Q/_ *K,<?U8^+/^17\1_P#8!UG_
M --MU7^:)'_JHO\ KE%_Z+6O]+OQ9_R*_B/_ + .L_\ IMNJ_P T2/\ U47_
M %RB_P#1:U^(_1/_ (7'7_7SAS_TG.S]B^E%_'X)_P"O?$?_ *5D(^BBBO[
M/Y1"BBB@#]!/^"5?_*0C]E[_ +';Q!_ZK;QS7]Z2?<7_ '5_D*_@M_X)5_\
M*0C]E[_L=O$'_JMO'-?WI)]Q?]U?Y"OX1^E-_P EOD7_ &2N'_\ 5OFY_;/T
M9O\ DCL[_P"RGQ/_ *J<G'4445_,I_1X4444 %%%% !63KZ[M#UA?L[7>=*U
M$?94L5U-[G-E./LZ:<\ULE^TV?*6R:X@6[+"W::(2&1=:D;[K?0^W;UH _"O
MPI\ '\*?%'P"A^ /A?;IWB?X<ZJ/$6C?\$X/ ?AJRL?M,OAW7&FM_%;?M+75
M_P"&KSP\;LV>I:Q;Z%JDWA?6=,OI+:RU9]+2.Z_=0?U/;'<_YSWZU^-4^F^"
MK7]L+XP3^*/"WP LO$.H_'[P!?:1?_$_]D[XQ_'CXF:Q;+X+^&5AI>M^%?C]
M:W^B>#?!%G]IT^33?"?A2RL=9TWX1ZCI$NM:GJ]XNNG2-(_94?AU/08[G]?4
M]SS0!^('_!2AE7_@I'_P0I+$*/\ AJ[]IY<D@#<W['?Q 51D]V8A5'4L0!R1
M63_P4D^RW/QT\+NOV:X ^%NA)Y@$4V/^*B\5-MWX;& V[;GHP..16I_P4KCC
ME_X*0_\ !"I)421#^U=^T\2DBJZDI^QW\0'4E6!!*LJLIQE6 88(!&5_P4?M
MK:T^./AB.UMX+:,_"_0W*6\,<*%_^$A\4@N4C55+$*H)QG  Z 5^M^";:XXH
MV=O^$S,?_2*9^7>,"3X-JW5_^%' ;_XZAX%%\(O!L_P1M/B%9SZYJNL#5K>/
MQ!J>A0>'=7T+P=%(5ANM'\3^'8;V+Q3IZV$;Q7C^(#%Y=W>WEA:VUH^E7D=\
ME[0?A#\.?&-YX*DT*;QEH^D>)O'.O^$K)O$5OX>DU#QAIFA>'+S6?^$J\/\
MV32[>W\.6$FK6UGX:UR?6(M:T'PK<ZS;WEYKEVFC:Y!#P-M\7O$EKX)C\#II
MWA=[191!-K#^'M/77[WP\;6"TF\*WVIP107%QI-Y! EG?71E36;O2"VB2:B-
M.VQK?UCXV>(M8UZW\2GPWX$TW5(K*[T:8:;H.I?V9>^%[_2KK1+OP9<:'J.O
MZEH]MX0DTR\GMDT32++2DMM_GVL\%QNE?^F)87B5O%Q6*G&4\3F<\)7CB82C
M0HU:$8X*G5HSI*,^6LW)5%&4:,(.,<+[2J\12_G:.(X?7U63PT7&&'RV&+H2
MP\DZU6E6YL9.G5C4;A>DN5PO&5:<^:6)]G2]A5['Q5\&?!_@?2[GQ=XETSQ1
M#HUMH/A.ZE\):9KW@[6-4&M^+]9\56ME#9_$/3-$N_".KZ1;Z'X2O]:N+C2=
M)NY[;4KFT\-7TMM<Q7MS!YGKOPNN+7XFW/PZT P:J\M]8_V3J=Y:P6$1T35=
M%LO$UIK&M!/-ATR#3?#M^FH^(I!(]OIT=GJ$D;O%$FZZ/B]KHM4T;_A'O I\
M'QZ<=-3P WAN5O!@7^V7\0_;VLFU4ZN^L_VS))>MJSZXUXZ2SZ>[MI=Q/8R8
M\_Q*\6S:G>>((K]--\57VN:CKESXOT6.71?$[C5-,ATFXT./4],N+9;;PO%9
MP(EIH%M;PVEL"T:EK;; O3@J'$-'VSKXBE5E*CB8T/:59NC"4XX7ZASTFZM6
M/U:5/&O$KZQB*LXXJC"6+QLJ*JTL,96R*LJ*HX>K2C&KAI5N6G#VLXQEB/KR
MA47LZ<GB(SPBPS^KT*5.6&K3CA,'&LZ52;XF^$/"OA37M$MO"ES?:KH>L^"O
M"'BFTU#6+.TM[NZ?7K"2:YG2U@MX5M+*>:%KG3[.;S;RSLIX;:^N)[J.61OZ
M!/V3KJS@_9N^#$;W%K"5\!Z.!&TL4>T 2J0$++C!!!&!@@CJ#7\]7C#Q]XL\
M?7&BW/BS6;W69]!T+3O#NGRWMU=7+I8Z<I599'NKBX:2^O&/G:E=@HU[<*DT
MB!E%?T'_ +*.E:9/^SC\&I9].L9I6\":.6DEL[:1V)$I)9WB9B22223R23U)
MK\D\;(8NGP?P_3QM3VN)AFT8UI^T]KSR6"Q:YG4]E04Y22C*;5&FN9R2C9)O
M]1\'I8:?%>>U,'#V>'GE4I4H>S5+EB\9@VXJFJE;EC&5XP3K3?*E>3;:7*?M
M=_M&>)/V?_"7A+7_  9IOA?7KO7_ !1/HEW#KQU">W@M8M%O=2$UN-)U"QE$
M_GV\4;&5Y(_+D(V!RK#Y#\*_MS_M0>-M)US6_#'PF^'&JZ=X?B$E[-&GB*%[
MB42V:26.DP7/BF&;6-2@BOK>\N-/TY+BYALW61D\V:T@N>]_X*:6%E9_#;X:
MM:V=K;,WQ!NU8V]O# 64^%=7)#&*-"1E5.#P2H)Z#'Y__!KQSX!T'P9XRT+Q
M]J#W^EW:K=GP7J/A*UUJWU?S=:\(RROX-\26NIZ5K7ACQ/<VNCR1WKS7<&DP
MR:?H/B4B_FT&33I_/X'X3R+'<!8'-JW#V$S3,ZF85:56=6AC<35GAUF+HR4*
M&%KT7*<*'NP<IT:,'[]6K"$7([^,N)LZP7&^-RNEGN*RW+J>!I5:=.G7PF&I
M0KRR^%6/-6Q-"MRPG6]Z:C"K4E=PI4IRDHGU]<_MV_M.6?AQ/%=Q\*?AFFC-
M8:9JSNLVKRZG;:-K=PEKHFMWWAZ'QE)XBL-$UBYEAATO5KW2H+"]DN+3R)W2
M]LWGM:I^W#^U1H\VFVMY\'_AU+>ZKJY\/6NGZ6VLZ[J47B(6T=XWAS4].T/Q
MCJ-[HWB!+.5;N71M8@L=0AMEFFE@1+6[,'Q1I7B3P1X(\-Z;J?AKQ=;^(O%V
MH?\ "'W_ (WM]:T/Q=!JEWIWA_Q#H7B!/AKX;O9]*DT&STF*?1-,&M>)K_4'
MN-<.E6EAI5IH^BVZV>I7?''C#P1XF>=--\6Z9IFHZMXUUW7=-\3:;\.M3\'3
M^#/!>KZ9K OO!_B&;PY;3:WXPU#6;_4;:*YG7^WH+4VVIWDOB"Y@\17MK']=
M'@CAV5=17!V7O"NMBH>VEE>>4ZKITJ5'V<G1>*DXI5I59^TFX_7L/%+!T8XN
M+P\_E'QEGZH.7^M>.^LJEA9NE',LFG34ZE2HZD756&2E*5*-./LX*7U.O)RQ
M566%E]8A]0:U_P %%_C]X=US5/#6L_#CX9V6NZ-J=SHVIZ=Y/B>YFMM3M)S;
M7%F'L_$]Q#<2I< Q*;66>.5\"%Y RD[7BC]O;]I7P9%;3^)/A=\+]/ANKN[T
MU9([C5M32VU?3XX9M0T/4CI'C*__ +(U^PAN8);W0]4^QZK;1RJ\MHJK(4^*
M?&'B'P<?B_XB^)FA^*+;7+6'QKIOQ!T#2#X:\0V!UF6/QE97\OAF^EU.UM(]
M)N+;2K=]0EU!HKO3)P%T^VD-VV%S_&WB'P?%X:\1:#X6UR^\2MXR^)Y^(D\]
M[H-YH;^']/M=-\16>GZ1=_;9I1J/B*ZF\47?]L7>F-/HZ0:59FVOKQ[MDM.N
MEP+PI5>66X/P<?;T:$L;&I@<VI\E:<*,L1"-6K7IPP<<+&I*HI8F->.*E&6$
MHSCB*=2W-4XTXFIQS#_C*\7+V-6JL'*&,RNJIT83J1HRE3I49SQ<L2Z:@UAY
M47AHR6*K0EAZD$_VZ_9)_:#\0?'SP'X@\4^,;#PSH.H:3XON/#]O;:$U]!:R
MV<6BZ/J23RKJM_>SFX:?4)XRT<JQ&.) (PX=F\B_X*KW5K-_P3U_:F2*YMY6
M_P"%<Q';'-&[8_X2KPVN<*Q.-S =.I ZD5C?\$U-/L;OX.>-'NK.TN77XFWR
M*]Q;03,$'A7PNP4-+&Y"@LQ"@X!)(&2<Z7_!532]-MO^">_[4LMOI]E!*/AU
M%MDAM+>*0?\ %5>&R,/'$K#D \'J >H%?ALL!@\L\9LKP& H0PN#PO&W#M/#
MT*?-R4H?VAETN6/,Y2MS2;U;=V?LSQN*S'PCS+&XZO/$XK$<'9[4KUZG+SU)
M_4<=%2ERJ,;V26B6B[G\(3_?;_>;^9IM:.IZ3JFDPZ9>:KIM_IEIKVF/KNAW
M>H6D]E;:SHBWUYIS:SI4]S''%J&E+J%A?61U"U>6U%U9W,!E#Q.!4N+>XM)I
M;:[M[BTN8&V3VUW!-:W,#[0VR>WN$BGA?:RMLEC1]K*V,,"?]+83A)1Y91E=
M22<6FKP?)-73>L)>[)?9EH[,_P Z)0G'XHRC;E;YHM64X\T'JOM1]Z/\T=5=
M:D-%=%J7@_QAHR6,FL^#O&&C1ZI<)::5)K'A/Q%I,>JW<JJT5II3ZCIEJNIW
M<RNC0VM@;BXE5T:.-E=27V_@OQI>:G?:)9^"_&EYK>F1QS:GHEIX0\2W6M:9
M#-L$,VIZ/;Z5)J>G0S&2,0RWMK!'*9(Q&S>8FZ/K&'Y>?V]+DLY<WM(<O*I*
M#=[V24Y*+=[*32>I?U>OS<GL:O.W%<OLY\UY1<HJUKWE%.26[BF]DSFJ_H$_
MX-ZY8XOV@/VA'ED2)!\&O"V6D=44?\5ZP^\Q ZLHZ]6 ZD5^" T'7CJ__"/C
M0==/B W'V,>'UT753X@-X4\P68T(69U<W9B_>BU%E]H,7[P1[/FK]_\ _@@+
MX9U/2?VBOV@],\5>&]5T>\/P4\)7*Z;XGT#4-(O#;S>/I1%<K8:W96MR;>9X
M&$5P(##*T+B.1FB;;^7^-56G+PNXNC&I!SGE^#J1BI)RE3>:Y?[Z2=W&STDE
M;S/TKP<I5%XE\)S=.:A',,5"4G&7+&:RS'>Y)VLI?W6T_+0_J:\57UDWACQ&
M%O+5C_8&M' N(B<#3+HDX#YP "2>P!)X%?YIT?\ JHO^N47_ *+6O]*CQ5HV
MD+X8\1LNEZ<I&@ZT 18V@(SIET#R(0>02#ZC@\5_FKQ_ZJ(]O*CYQQQ&I(ST
MR!AB.H4ANC G\5^B?;V/'7_7WAQ>7PYYIZ]OF?K_ -*'^/P5_P!>^(O_ $K(
M1]%(""6 *DJ=K $$JV =K $E6P0=K8."#C!&8OM-MYI@^TV_GC(,'GQ><"!N
M(,6_S 0OS$%>%R3QS7]@+7;72^G;OZ'\HDU%0Q7%O.6$%Q;SE<%A!/%,5!)
M+"-V*@D$ G&2"!4@=&4LKHRJ6#,KJ54H2'#,"5!0@AP2"A!#8(( TUNK>H;[
M:GZ"_P#!*UE7_@H/^R\695'_  F^OC+$ 9/PW\<*!DX&2Q 'J2 .2*_O.M[B
M"=!Y,\,VU5W>5(DFW(XW;&.,X.,]<''2OX*/^"54ME>?\%!OV8(EFM+Q3XVU
MXO&DL%RN%^''C=E+HK2  .JE2PP&"D'<!7]Z5G8V=FI^R6EM;>8J>9]GMX8-
M^T';O\I$W;=S;=V<9.,9.?X1^E,FN-\BNK?\8KA_7_D;YN?VS]&;7@[.[?\
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M5Z^I6=E?20H]W:6NHR6>G27]O;3F2&&\DT^Q>ZC19FM+<N8D /Q._P""D_\
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MR_9?&5V? /AB]\,#QG\4?&<'Q%^+'C.&^UZZUNV;QKXTM]!\/+J-AX7BN?[
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MYJ>GW/BKQ!IT'B71]0O]-TI)6M[:_P!/M/-?6M8T+2=4_I9_X.&O^2 _L_\
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MDX&0#C.>@K_->C_U47_7*/\ ] 6O]+OQ9_R*_B/_ + .L_\ IMNJ_P T2/\
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M<:5J$VG7VD37VFS31O+87DNE:GJ6FR75H\,\FGW][9/(;:[N(I+U'^L?$/\
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M-3T+QSX:T@W%QJNI6&M6VEZG!H6JP7<4/0? S]N:\^*>H?"BX\9?!#Q/\,/
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MYM2@N;[PY?W^F^(].:[\-:W91R/HNI7Z02R@ ^L:*** "BBB@ HHHH ****
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M#J&M^%-6T[XK:1I_@_5D@TC3_#]UX8N=>L-<_4BB@#Y"\#_LR>)/AO\ LD>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M1O <MGJ>@?#+PU\*[,>$M-\+!5\/01:'X6TV^M<W=_J-KK,EW??VE-YD,=N
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M4DES<2R%I)[B1YI6>5V<@'X$_%CXF:%=^._CG?\ [$_[1?B?Q[\9_AKX"_;
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M^"BO[.)RK7'C@X/0^#+SJ/\ MZH_X>*_LX<?Z1XXX  _XHN[X"G*@?Z5T!Y
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M' ''@R\' S@<7709./3/%'_$/^-O^B7SO_P@Q'_R']6?E<_UZX/_ .BDR?\
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M^T34=(^,GQ^^,WPIOOB)^S+X<_:0\.^.)_A%^SAI&F:3X?T;4_#6J_$GQ?\
M!#5[2V^)-KHGP]T:R\7^'O#FI?#?]ICX>>)/BW::+K6B>*K+Q6NJS^(-,T$
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M,?\ 7O.?_2LK%HHHK^C#\#"BBB@#Z4_8]GAMOVEOA)-<2QP0IK^H[Y9G6.-
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M\>._@A_PL1O#">"V\:_\)%X3_P"$G/A)-3?64\.?VU]H^W_V,NJ2/?C3_/\
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M9W  LN,YW*""R]5!!( (R@93T92,;LA@1MYPV<_=.&PW0[3@\''U7_$OL/\
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MU?QAKEO?VL?A[0[-YHHOA]XRND5;FULHKB(B>WA?=%(I(4J<JS _VS+]U?\
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MM_\ *//]J;_LG47_ *E/ARN9_P"";%QJ47P=\:"QTZ*]C/Q,O2TCWZ6I5_\
MA%?# *!&MYL@*$;=N&2V HVDG0_X*HW.K2_\$^?VI5N]+AM8?^%<Q9E74DN&
M'_%5^&@0(EM(B2%+-RZCY<9R17\LYA_R?'!?]ESP[_ZGY8?TI@_^3,XS_LC,
M]_\ 4+'G\)3_ 'V_WF_F:;7J'PG^#OQ"^.'C&/P3\-]"76M:>"6^NYKO4-/T
M71-&T^.1(/[1U[7M7N+32](LI;R:VT^VENKA9+S4KRTL;.*>XG"#67X ?%"*
MPU?4-:TWPQX-31/$6O>$KZQ^(/Q(^&_@#69/$OAC2](UG7M%TG1?%WBS2-3\
M0WFFZ=K^ASNWA^VU2UN3J^G1V-S=/>6XD_T5J9IEE"M+"ULPP5'$TZ=*I/#U
M<50IUH0K<ZI2E2E-34:CISY&XVERRM>Q_G[2RS,:U"&)HX#&5<-4G4A#$4\-
M6G1E.BH.K&-6,'!RI^TASKFO'F5]SQFBO7$^ _Q;E\#V7Q$@\%WESX9U'3]&
MUFT6TU+0;OQ1)X?\1>(%\*>'?%+^ K;5I?'D'A'7_%#Q>'=%\53^&H]!U/6K
MBUL;2_D>\LVN*_Q$^"GQ,^%,%E=>.O#D&EVE]J^J^'%N].\2>$_%5I8>*="B
MMY]=\'ZY=>$->UZW\.^,M%@N[>?5?"FNR:?KMG!+YSV)BCG>)PS3+*M98>GF
M. J5Y5:V'C0AC,/*M*OAHQGB*$:4:CG*M0A.$ZU)1<Z491E4C%-,)Y;F-.E*
MO4R_'0H1I4:\JT\)7C2C0Q$G##UG4E34%2KSC*-&HY<E647&$I--+RNOZ!_^
M#>?_ )."_:$_[(UX6_\ 4\>OQ5N?@1\5[3P"WQ,N/"@3PC'H&E^+IY5\0^%)
MO$5GX,UO5(M$T;QQJ/@:'79/'.F^"=6U>>VT_3_%M]X<M]"N9[RQ=;X6U_93
MW'[0?\&^<EW%\??VA&L[5+N7_A37A;]T]R+7_F?L<.T,PSM+MRH^YC.6&/S3
MQDQ>%Q?A9QJ\+B:&)5'#8:A6>'K4ZRI5XYIESG1J^SE+V=6"E%SISM.*DG))
M-,_1O"+"XG#>)O!JQ.'KX=UL3B*U)5Z52C[6C++<P4:U/VD8^TI2<9*-2%X2
M<9)-M-+^KOQ9_P BOXC_ .P#K/\ Z;;JO\T2/_51?]<HO_1:U_I/^*;S73X9
M\1A]%@1?[ ULEO[7B;D:7=E1M%B"2S *.0 3D\ U_F_^$?"VO^-M=T3PIX7T
MXZKX@UR1;33+ 75E8)+)%937US+<ZAJ=S9Z9IMA8V%I=ZCJ>J:E>6FG:9IMG
M=ZA?W5O:6TTJ?B_T4JD*6&X]JU9PITZ3X>J5*E22A"G3A3SR4YSG)J,80C%R
MG)M1C%-R:1^N_2>ISJXK@:G3A*I4J+B&G3IPBYSJ5)SR&,(0A%.4ISDU&,8I
MN4FDDWH8=%?3'B7]E3X@^$?%_B_PIK_BSX.Z;9^#-%TGQ!J'CN[^*&AM\/K[
M3=<\0P>$]+33/$.DQZS+)JUSXCF?2CH%]IUAK$$EM<7=S9Q6'V>ZN.%TGX&_
M$/Q#X<^*7C7PW8Z1XB\"?!^TDO/%WCW1]=M)O!UVD>H:/IZP^$-7NTLI/&-]
M+_;NFZBMAHUE+>6VB3?VSJ45A8-;S7']74L[RFM3C6IYAA949/#1C6]M!47/
M&.C'"TO:-J'MJ\L10C3H-^VE*K3CR7E%/^8:F39K2J.C4P&*C6C]8<J/LI.J
MH81598FJZ:3FJ-&-&M*I6M[*,:523GRQ;/(:*]2U[X3ZIX:\(:/XMUGQE\+;
M2;7O#>@>+=*\#_\ "<QR_$JYT'Q.S-HMY_PB$>E'RGNK)&U=[:35%G@T93J$
MB!"L;;/PZ_9_^(OQ1TJQU;PP?!MLFN^)+WP7X,TWQ3XZ\-^$]=^(WC/3M.LM
M4O\ PE\.]'UF[AN?$^NVMKJFDQR1#[#I[ZEK.CZ)!J,VN:G::;)I/-<NIX>6
M*JXS#TL-"K*C*O5J1I4O:07--*=1QC)0BI3G*+<8PA.;?)"36<<LS"I7CAJ>
M$KU<1.E&M&C2INI5]G-J,&X0YI1<I2C",9)2=2<().4X)_3/_!*O_E(1^R]_
MV.WB#_U6WCFO[TD^XO\ NK_(5_!3_P $LC-'_P %!OV8/+A+S+XXU]3#*QMR
MK#X=>-TE63?&SQ/$-Y=&CWAT,3*KGY?[QM.GU"96^W6$=EM6/RMEZEWYF0=^
M=MO!Y>W"XSNW;CC&WG^(?I3?\EOD7_9*X?\ ]6^;G]E_1F_Y([._^RGQ/_JI
MR<TJ***_F4_H\**** "BBB@ HHHH 3 SG STSCG'IFEHHH _$#_@I/\ \I)/
M^"%/_9UO[4'_ *QS\0:_.O\ X+G?%CXD>!OVN? FC^$?&&K:!ID_[/WA*_FL
M[ 67E27LOCCXB027+?:+.X?S'AMH(SAPFV-<*#DG]%/^"D__ "DD_P""%/\
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MF?\ @G-K6J^(OV&_V7M<UR^GU+5M3^$'A>[U"_N?+\^[N9(Y_,GE\J.*/>^
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M:+<V?@;Q1H6AV]SX6\;^-?$_BW4=<\1:KXDO!J7ASP?J-M\//A_:-:0Z!?\
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M.F:ND>F:[9PW>@W]W86NIRWUM_I">+/^17\1_P#8!UG_ --MU7^:)'_JHO\
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MUK6-'N+SPCX)O-1\,^'M-\):+JMMX3T..WU'4-5U.QL6U/7+HW<T4$']K_\
MP3,_Y,%_9/\ ^R,>%/\ T7<5_ DGWU_WE_F*_OM_X)F''[ W[)_7_DC'A3L3
M_P L[CT%?SM])C X?+>!>&<%A8N-"CQ'+DB^56]I@<PJSY8PC"E3ASSE[.C1
MITL/0I\M'#TJ5"G3IP_?_HYXVOF'&O$>,Q,E*O6X>]^7O-OV>.RRE%RE.4ZE
M2?)"/M*U:=2O7GS5J]6K6G4J2_-C_@X:_P"2 _L__P#9<-1_]5KXIK\'_P!E
MG]I'X<?!CX>?%?PQXXL/B%XA3Q7:6DLGPZAD\'^)/A%\4XXO$O@FZ70/%7AG
MQCH>IQ>"M7CTC1M<TV_^(&BIJ&JW/A?598=)@TKQ=H/A:^F_>#_@X9Y^ /[/
M^,_\EPU'L?\ HFOBGVK^3>OI_ W*<'G7A#E&!QRJ2P[S3,*[5*HZ<G/#9O.O
M37,KZ.=-:VYX.U2C*G7A3JP^;\:<UQ>3^*V:XW!.G&O'+<!13J052*AB,HHT
M9OE;6O+-V5^6:O3JQJ49U*4_LC1?B]\&OAE\-_#%C\'+OX@Z7\0HM0^'?C/X
MEMXG^'_AJXL?B5XL\#^,M%\<6?@3_A-K+XGS:GX2^"NBZYI-OJ%CHNE>"[GQ
M)XRUK3M.\0>.]2O;BVTC3_#_ *KXB_;%\):KK46H6WBW]HY;C4OB'X^\;:?X
MNB3X8:)XT_9^T'QSX&\4>%)_AI\&39W.H:?KO@^2^\26MWXILI[CX::=KND^
M$] 'A[3?!_BRXOO$T?YQ45^MU>$<IQ%257%>WQ=:<\7.=?$.A.O-8RG3ISIS
MJK#QG*G3A3A3I0DW;#QC@9N>7PCA%^54N*LTP\(4L-[##4:<,+"%&@JT*,/J
MDY5(3A2=>4(5*DYSJ5)QBF\1.6-AR8Z4L2_J3XI?%OP#\0=7\+:M=:K\7_$&
MM?##P!X(\,>&_''BC_A&5\<?%;7]%^(]_P")M8U?XE:L^L>([CPS::)X/UB?
MPM\.+BUO?B+KUDGAOPS!XEN[^P-Q%8Z_QZ_: T7XE^"G\*6OB[XW?%'4M2^+
M.H?%,^+?CS-X9EUKP+97WA_4-%G\ >#_ /A'-9UR&>RUNYU"WUCQCJMJ/"/A
MW5;[PUX:DT3P!HDL=[+7R)1792X>RZE/ S4:DGEU2I4PJDZ?[N57V<JBA*-*
M,Z5.5:#KNC0E2HN4Y473>$C3P]/EJ9]CZD,9!NG%8^%.GB7%5/?C2YXTW)2J
MRC4G&E-455K1JU4H1K*?UJ53$5/Z[_\ @WR_Y-3^+G_9PNL?^JV^'-?;W_!5
MO_E'G^U-_P!DZB_]2GPY7Q#_ ,&^9Q^RG\7.O_)PNL=B?^:;?#GTK[>_X*MG
M/_!/3]J;&?\ DG478C_F:?#GJ*_@KBO_ )2&?_9?\/?^IN5G]P<,?\F%_P"[
M'SS_ -0\P/X-'^^W^\W\S3:<_P!]O]YOYFFU_HA'9>B_(_@4****8!7] _\
MP;S_ /)P7[0G_9&O"W_J>/7\_%?T#_\ !O/Q^T#^T(>?^2->%NQ_Z'QZ_+?&
MO_DUO&'_ & X3_U:Y>?IG@Y_R<WA'_L.Q/\ ZK,<?U8^+/\ D5_$?_8!UG_T
MVW5?YHD?^JB_ZY1?^BUK_2Z\6$?\(OXCZ_\ (!UGL?\ H&W7M7^:+'_JHO\
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MY.ZU3L/^Q)K^DRBO1_UCXA_Z'V=?^'7'^7_3_P D<']@9%_T),H_\-N"\O\
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M6Q&"PU>K)1244ZE6E*;45%**;LDK+0_FT_XA=?V#_P#HX/\ X*(_^)=:I_\
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MFAE_X*-?$V2*6*5&CDBD1M"*NDB,R.K AE8@C!KY?_XA=?V#Q@#]H+_@HB
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MN[*\BGM;F%F56,4T3H2JDKD#'9_K'Q"O^9]G6G_4UQ_2W_41Y+[CD_L#(O\
MH291V_Y%N"\O^G'DC^<1?^#7?]@]]S?\-!?\%$ /,E  _:ZU4 *LCJHY\%,>
M !U9CZD]:7_B%U_8/_Z.#_X*(_\ B76J?_,37])?^?SZT4?ZQ\0_]#[.O_#K
MC_+_ *?^2#^P,B_Z$F4?^&W!>7_3CR1_.OX2_P"#:7]CSP!XCTGQCX%_:I_X
M*7^#?%N@SR76A^)_#'[9_B#1->T>YFMI[*6XTS5=/\'07EE-+9W5U:226\R.
M]M<3PL3'*ZG]4OV0?V*;#]D%O'S6/[3W[:7[1?\ PGP\,B1?VNOVD/$_Q_3P
MC_PC/]M[#X!7Q'8V0\*G7/[;;_A)?L?F?VS_ &7HGG[/[,BW?:U%<&+QV-Q\
MXU<=C,5C:L(*G"IB\16Q-2%--R4(SK3G*,%*4I<J:CS2D[7;;[<-@\'@H2IX
M+"8;"4Y2YY4\+0I8>$I\L8\\H4H0BY\L8Q<FG)J*5[)!1117*=(4444 %%%%
M !1110 4444 %%%% 'PW\9/VV=,^%GB?XLV&B_"?QU\2?!O[-OAK0_%_[2_C
MKPS?>%["T^%VBZ]X>G\:"UTC0->U2PUSXD>)?#OP]AC^)7BWP]X9ABETOP3?
MZ5)I5WX@\5ZI9>$IMF\_:YFTGXI^$_"FN_!GX@Z)\+_'_P 4H_@GX$^,]]?>
M%5TGQ7\0;KPUJ_BC2;[2?!$6K2>-KGX8>(K?0=7TKP[\28+">TU/4[%]6.B6
MW@&6W\<3>)?M0?LK?%J]O?CKJGP-UM[GP9^V$_@;P=^U)X#L-!\-2_$^/PS;
M> +SX.^)_B'\!_&OB_X@^!/!6@>-M0^&EOX0\*:[I?Q M?$6GVNC>'1XP\%F
M/Q=IB^%O&':^'?V9OV@M-_:=T_XO^(_B=\#?%WPP\'WUYH/PA^']]\(/B/9>
M(/@K\++CPY%X>DT7P)JT7QQN?!4GQ/UJ"%[?Q7\9=>\!ZGXBU3PW?7G@G1+#
MPMX2ENM(O0#Z2\;_ !J/@/Q;J>AZC\.?B1J_A_3/AG)X_/B_PEX4U;Q?::AJ
M[>+]/\):?\.](T3P]97^N:GXTU1]1AU6TLX+<6L6EK+>W]Q965O=7MOX'I7[
M;2>,?A7^S;XO^'WP;\9>(_B/^U#HVM:]X%^$&H>(_!?AW5/#^E^$=*.L>.+O
MQSXSGU34/!^FQ^%8Y-/TFX7P]=^*9]6\0ZSIEIHD-_HW]I^(-,^OO'EMXZN_
M".MP?#;5?">B^.GM8_\ A'-4\<:#K/B?PE9Z@EU;R&36] \/^)/"6LZG9M;I
M<1B"P\1Z5.)GAE-RT<<D,OYM^&OV$OC+'^S/\+O@3X]^)7[//C37/@GXNM-6
M^'OBJ;X"_$S3M,30UT77=.O!=P:5^T9I/Q \/>,I+KQ#?I_PDG@/XE>&]-U3
MPK)J7@?Q-X<UO1/$.IL@!]]? [XQ>&?CW\,/#?Q2\)VVIV&EZ^^NZ?=Z/K2V
M*ZSX=\2^$?$VM>"O&GA;5VTJ^U32)=5\*>,O#FO>'-1N-&U75-&NKS2YKG2=
M3U#3IK:\F]9KQ/\ 9T^".A_LZ?!KP5\'O#UZVIV/A2WU>>ZU+^R]-T*'4]?\
M4>(M8\8^*]4L_#^C10Z1X=T_4O%'B'6+W3?#VEH=/T'3I[71[.2:"QCFD]LH
M *^</C9\?KWX:^+/A]\+O OPXU[XN_%_XFZ;XT\2^&_!&C:UH'A6QLO!7PX;
MPO#XW\:>*?%OB:>/2]"T73-3\;>#/#>GPQ6VJ:OK?B;Q7H]C9Z<FF1:[K6B?
M1]?(G[1_P7^)FN>)_"7[0G[/.O>$-%_:%^$OP]^+7@?PKI7Q%\.W'B'X=?$3
MPE\3?^$,U_5_ 7B[^R/$'A+Q'H)G\:?##P#K6A>+=(\0J-!N=/U"#4M&UG3-
M7NXK< \NUO\ ;\@B^%__  NKPG^SW\8_$WPP\(_#_P 6_$CXV^(;V7P+X0E^
M$]A\./%GC7P1\4/ IMO$7B>*T\>_%OX;^(/ASXX'BWP3X/U2XT^UTS0K>]L_
M%=Y/XK\#V'B;["\7?$*Y\.7'PQ72?!WB;Q?9_$7QSIWA.ZU#1+0K!X*TG4?"
M?BKQ.OC3Q3'=I%/9^'K>3PY::'<%HX[F+5O$6D02(C/(@_-7_AB_]I'6O ?P
M8\,Z%\3_  5IGPWT&VUOXG_$CX*?M)_"B_\ &>L>/_VD?'OQ7\2_&/QEX^^*
MVI_ 7]H7P_X'\2>'++Q;XCN=0\*_!C3[_P 1_#?0=8\G5M5U;QX^B>$1X<_6
MZ)9U@C65H6N1$OFO%&\<#3[!YCI&\LDBQ-+N94>:1PI"M([ N0#X>3]N_P #
MK\(?VG_C1??#7XN:+X9_9D\7)X8U;2/$/A>#PWXQ\865UX ^&_C_ $KQ?I_A
MCQ!J&EWO@OPGJ>F?$O2IWO\ XH/X+NO#F@V&I>+_ !K8^%_#T#W$?JO[-_[0
M\'Q_TKQH\GA23PKKGP_\46_A7Q!%IWBOPU\1?!M]>7V@:7XFLY_"GQ&\&3W'
MAKQ&D.F:Q:6^MV"BPUKP[JZ2V.JZ9%!-I=_J7RQ;?L=_M)^+;7]J'0?BQ\<_
M@Q=>&OVE?%?@_P"(6H6GPX^"7Q!\.7.F^)O FA?!3P?8>$O$L?B?X\>*;'QQ
M\&_''@[X-CPU\7/ CQ^'M4\;Z!XU\4Z!;^*M#TRZ51[K^R?^RP?V;YOBCJ7]
MH?#[3?\ A:.N^'=;E^&OP-^&TWP9^ W@R[\/:)-HUSJW@[X92>+?&JZ?XO\
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M.N7&HRZN9M*OG&G1V%W )Y@#F/B]^VQHGPG\8_$>PG^&_BKQ!\-?@,_@2/\
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M8I^*?P_'P'\,_%;XS>!_&WPR_9?\6>-/&WPC\,^!?A/K/@?7M;\5>(M+\?\
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M\$Z#X=36/$NE7OB'QKK&L6GAOPYX:%_XBO[EK*Q=)<[1?VZ_!-AXP^!?PO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>biib-2019630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20190630"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20190630.xsd" xlink:type="simple"/>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2SharesOutstanding">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      id="Fact-DC2363294D15B74C4955F6259D8198BD-wk-Fact-DC2363294D15B74C4955F6259D8198BD">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact-74703AAE2BD12C30A5DBF6259D81DCFA-wk-Fact-74703AAE2BD12C30A5DBF6259D81DCFA">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <dei:AmendmentFlag
      contextRef="FD2019Q2YTD"
      id="Fact-F3D469DC9E7E1FA74315F6259D716052-wk-Fact-F3D469DC9E7E1FA74315F6259D716052">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q2YTD"
      id="Fact-5A126993C837E662020DF6259D43FB99-wk-Fact-5A126993C837E662020DF6259D43FB99">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q2YTD"
      id="Fact-35557C07B8F2FD40B118F6259D047756-wk-Fact-35557C07B8F2FD40B118F6259D047756">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q2YTD"
      id="Fact-43B941E4D3B98E65C63EF6259D04D992-wk-Fact-43B941E4D3B98E65C63EF6259D04D992">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q2YTD"
      id="Fact-F7ACC83A6C7F62AC81A9F6259CF51FF0-wk-Fact-F7ACC83A6C7F62AC81A9F6259CF51FF0">0000875045</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-5039E0EFDC14A7AF8494F6259D717262-wk-Fact-5039E0EFDC14A7AF8494F6259D717262"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-6E121E9445E85B479E08F6259D3361F6-wk-Fact-6E121E9445E85B479E08F6259D3361F6"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="INF"
      id="Fact-7A997D0B576EE901A6D2F6259D81748E-wk-Fact-7A997D0B576EE901A6D2F6259D81748E"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="INF"
      id="Fact-E92F0E3BF7CF663F4737F6259D813239-wk-Fact-E92F0E3BF7CF663F4737F6259D813239"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="INF"
      id="Fact-21E0AFF426C06BBE8D94F6259D813EDB-wk-Fact-21E0AFF426C06BBE8D94F6259D813EDB"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-73EA653E34D9526F99ECF6259D819D7D-wk-Fact-73EA653E34D9526F99ECF6259D819D7D">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-7DB894B851F66023C865F6259D812FA3-wk-Fact-7DB894B851F66023C865F6259D812FA3">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-C99BABFFE2F044AB9E5BF6259D8166FB-wk-Fact-C99BABFFE2F044AB9E5BF6259D8166FB">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-331384F6B048A2116782F6259D8150B7-wk-Fact-331384F6B048A2116782F6259D8150B7">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-FC082F7B9A11EF18F799F6259D81E61A-wk-Fact-FC082F7B9A11EF18F799F6259D81E61A">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-44726AD7F55D00805CAEF6259D816745-wk-Fact-44726AD7F55D00805CAEF6259D816745">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-03F5B983F5B60C947337F6259D337BC1-wk-Fact-03F5B983F5B60C947337F6259D337BC1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-93EB9787A98FC27070F6F6259D3306DD-wk-Fact-93EB9787A98FC27070F6F6259D3306DD"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <dei:DocumentType
      contextRef="FD2019Q2YTD"
      id="d30702571e795-wk-Fact-ECF48E61C3CED7A5F589F6259DA27745">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q2YTD"
      id="d30702571e813-wk-Fact-15C9BCDD4254055AB4D9F63C9F2517D9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q2YTD"
      id="d30702571e823-wk-Fact-7DB925690F09665D39D1F6259D8113C6">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q2YTD"
      id="d30702571e843-wk-Fact-9DB8690C64FDC5C7870AF63D3CE292E7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q2YTD"
      id="d30702571e853-wk-Fact-BD7D5E32C535B3A4D7BBF63D98B91AE4">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q2YTD"
      id="d30702571e862-wk-Fact-141FF02D24228C55769BF6259DA41D9B">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q2YTD"
      id="d30702571e884-wk-Fact-3278885681EB66F214B3F64090F9DA23">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q2YTD"
      id="d30702571e894-wk-Fact-67B3B629C144166A671AF640ADAA4BF7">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q2YTD"
      id="d30702571e919-wk-Fact-4EE423FA3CAF99DBE4F6F640DAF42912">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q2YTD"
      id="d30702571e924-wk-Fact-EE3A1931AE93AF14DDD6F641123A425A">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q2YTD"
      id="d30702571e929-wk-Fact-543D93899F4066EB758AF64150FEEE5D">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q2YTD"
      id="d30702571e934-wk-Fact-093DA0C7F16CB324B730F6417025690B">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q2YTD"
      id="d30702571e941-wk-Fact-2E13BDCE7461D9F742A4F641944DEDE6">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q2YTD"
      id="d30702571e946-wk-Fact-148BCC8FE9E5CA133214F641B5884501">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q2YTD"
      id="d30702571e1007-wk-Fact-748E8D4D42F46174182EF642017334A1">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q2YTD"
      id="d30702571e1017-wk-Fact-878F4139F49AFCBBDEDDF642152B71A0">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q2YTD"
      id="d30702571e1032-wk-Fact-2A4DA4607DF9C518772CF64244763590">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q2YTD"
      id="d30702571e1037-wk-Fact-2476BC79D90B352124CAF64286CC1989">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q2YTD"
      id="d30702571e1055-wk-Fact-70574750234C3B3FF305F642AFD14985">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q2YTD"
      id="d30702571e1090-wk-Fact-86728A13832940E24676F6452D9D9F33">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q2YTD"
      id="d30702571e1136-wk-Fact-91325945C06D36444343071C3C3327E6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q2YTD"
      id="d30702571e1162-wk-Fact-632665AEA1F68DFE7AEA071C5EDBA3BA">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q2YTD"
      id="d30702571e1172-wk-Fact-C5B7E204B0FE656A3100F646A6301759">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q2SharesOutstanding"
      decimals="INF"
      id="d30702571e1190-wk-Fact-FD165FADE2295E59F991F6259DA20922"
      unitRef="shares">184447218</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30709305e1063-wk-Fact-C3F1908781ECB2F108F9F6259D62D489"
      unitRef="usd">2880300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30709305e1082-wk-Fact-2B45585D36E41B2DB864F6259D23ADFD"
      unitRef="usd">2757500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30709305e1101-wk-Fact-AF0A6B5FA115FD6CFF39F6259D1417AF"
      unitRef="usd">5560300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30709305e1121-wk-Fact-C04EBFA41990DA29BFA8F6259D52D55F"
      unitRef="usd">5281000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30709305e1136-wk-Fact-5B9EC13DF76E0C64D4C9F6259D71CF78"
      unitRef="usd">576400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30709305e1155-wk-Fact-09FB62AF2F4874DE36DDF6259D330ABD"
      unitRef="usd">490400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30709305e1174-wk-Fact-2EBAB557DC84FE08A211F6259D622116"
      unitRef="usd">1093800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30709305e1194-wk-Fact-2091EADF344F99481D24F6259D621286"
      unitRef="usd">933600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30709305e1214-wk-Fact-CC0CC7DC660BF5C38699F6259D334216"
      unitRef="usd">160000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30709305e1233-wk-Fact-7F5F6340692D7DDE0318F6259D814253"
      unitRef="usd">108600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30709305e1252-wk-Fact-67EF5E7D2920FD15A8F6F6259D6276B9"
      unitRef="usd">452400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30709305e1272-wk-Fact-18A0A15D9AE9D88D7F55F6259D235B1F"
      unitRef="usd">273000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1292-wk-Fact-C7FDF5E25322082D0991F6259D049965"
      unitRef="usd">3616700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1311-wk-Fact-1C5290B3B3CB7DD0C9D7F6259D335955"
      unitRef="usd">3356500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1330-wk-Fact-0F0DB851024A5AA84F7FF6259D71A480"
      unitRef="usd">7106500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1350-wk-Fact-A77911B12733251103BFF6259DA238F3"
      unitRef="usd">6487600000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1452-wk-Fact-BCE188F5B8289B326622F6259D231634"
      unitRef="usd">476300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1471-wk-Fact-AEE38EC55DD969338755F6259D71A115"
      unitRef="usd">421000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1490-wk-Fact-DD4CF4890052B549F881F6259D81FC12"
      unitRef="usd">1078300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1510-wk-Fact-D02171DA0CC2696B405EF6259D23F0FE"
      unitRef="usd">867000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1530-wk-Fact-78B14F963FA10EB8E8A5F6259D04E349"
      unitRef="usd">484800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1549-wk-Fact-9769E0D3B78857CD81B0F6259D5254B1"
      unitRef="usd">981000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1568-wk-Fact-07EF1F112AE2E5AF6159F6259DB265DA"
      unitRef="usd">1048500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1588-wk-Fact-655DB4C361C2687DEA2BF6259D714A3B"
      unitRef="usd">1477700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1608-wk-Fact-3A65D7580D1256F88110F6259D71652E"
      unitRef="usd">587600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1627-wk-Fact-BA669425A7864CA9D22BF6259D7146B5"
      unitRef="usd">516200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1646-wk-Fact-81F603803BA6BB05FD07F6259D3330DE"
      unitRef="usd">1155300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1666-wk-Fact-AC7C9BCF6E9A8D9E0660F6259D044118"
      unitRef="usd">1017500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1687-wk-Fact-B3BD168EB3801729A63FF6259D621F86"
      unitRef="usd">70100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1706-wk-Fact-7779EF5CE57D18E76221F6259D624E02"
      unitRef="usd">107400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1725-wk-Fact-B5DFD812D22F420158BDF6259D237ACF"
      unitRef="usd">138300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1745-wk-Fact-3A52F769615790191266F6259D23382B"
      unitRef="usd">211300000</us-gaap:AmortizationOfIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1765-wk-Fact-9B6251B03F97D7A33E2AF6259D14531F"
      unitRef="usd">63500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1784-wk-Fact-DD8C1B21C56443052CC8F6259D04427F"
      unitRef="usd">39200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1803-wk-Fact-5E4C5FBDC495F8A1A707F6259D14AFA2"
      unitRef="usd">121600000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1823-wk-Fact-8F6BCE61193B007C0584F6259D43E3CE"
      unitRef="usd">81700000</biib:Collaborationprofitlosssharing>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1843-wk-Fact-1CB61165D41CFE0E7A0EF6259D046651"
      unitRef="usd">-2300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1863-wk-Fact-A4CB49C6CAA6798C106AF6259D331021"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1882-wk-Fact-62F4DD8F603903FB7B89F6259D715EC0"
      unitRef="usd">113200000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1902-wk-Fact-83CCF52D84FD932D2D8BF6259D43A2B6"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e1922-wk-Fact-6ACFF58C36896C0429A5F6259D7118EC"
      unitRef="usd">20000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e1942-wk-Fact-5D3F92B3D26D4145CC8DF6259D71B2D9"
      unitRef="usd">-1900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e1961-wk-Fact-33C2C3244E3CB3B9F4C0F6259D6216FA"
      unitRef="usd">8500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e1982-wk-Fact-7BA913E8E376F5770455F6259D81E7AA"
      unitRef="usd">3700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2003-wk-Fact-A4C4510A0A15FFDAB0EDF6259D71E10D"
      unitRef="usd">800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2022-wk-Fact-2C06C29C747E562ADC51F6259D230196"
      unitRef="usd">1600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2041-wk-Fact-F705CBBE3FBA002A8C29F6259D1437CC"
      unitRef="usd">1200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2061-wk-Fact-0019B12CF5DA291E7BAAF6259D625381"
      unitRef="usd">3200000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2081-wk-Fact-8EC1D3CD405CB3948FBDF6259D04925B"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2100-wk-Fact-D060DFC2F4677C7C3680F6259D232ABE"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2119-wk-Fact-3E2223D98408E167DC0AF6259D330F8A"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2139-wk-Fact-357E14C70265B206695DF6259D62226E"
      unitRef="usd">85000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2159-wk-Fact-706898CD8DDEDD6EFB28F6259D5293BE"
      unitRef="usd">1660800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2178-wk-Fact-5011C17B57A2DC15404DF6259D719D22"
      unitRef="usd">2143300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2197-wk-Fact-EBDCED3DB754CB59F824F6259D04D640"
      unitRef="usd">3647900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2217-wk-Fact-C07105E17E6E4660E761F6259D044EA3"
      unitRef="usd">3739700000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2237-wk-Fact-732697F15829DF743374F6259D62BFE9"
      unitRef="usd">1955900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2256-wk-Fact-66042D97A89A9FB89976F6259D1436DA"
      unitRef="usd">1213200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2275-wk-Fact-47BC4B878E25A565C497F6259D2384B6"
      unitRef="usd">3458600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2295-wk-Fact-94E1F72F5617BB00F6A9F6259D330C76"
      unitRef="usd">2747900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2315-wk-Fact-1D06C1D1506111B2621BF6259D239489"
      unitRef="usd">-197400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2335-wk-Fact-9D3C2F37AB35BFAE8012F6259D232D43"
      unitRef="usd">-34500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2355-wk-Fact-4F4E212D12754366EB0BF6259D4303AC"
      unitRef="usd">159900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2375-wk-Fact-FA4E213E25606EA300E5F6259D2321CF"
      unitRef="usd">-75500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2396-wk-Fact-A5FA1624AC3C18E0C6D1F6259D233A43"
      unitRef="usd">1758500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2415-wk-Fact-E146803FA0B028B19B7EF6259D62D3AD"
      unitRef="usd">1178700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2434-wk-Fact-49E6DBBCFF0BB450DCCCF6259D33903A"
      unitRef="usd">3618500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2454-wk-Fact-D0E0F6FC495E57AB1F90F6259D71917A"
      unitRef="usd">2672400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2474-wk-Fact-4624827AA9206BC4BEE3F6259D23D741"
      unitRef="usd">248100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2493-wk-Fact-3D9E0081242A84B1D3C1F6259D33E71A"
      unitRef="usd">263700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2512-wk-Fact-F19460D3D1147472DEE0F6259D3347E3"
      unitRef="usd">670600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2532-wk-Fact-52CAE90BDDEA71C31714F6259D233C61"
      unitRef="usd">586200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2553-wk-Fact-16DB6DC0C2ECCE76DFF2F6259D23016D"
      unitRef="usd">-16300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2572-wk-Fact-B9E957A0FE13DAE7A5BAF6259D339382"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2591-wk-Fact-36F4882A823D85CA65B0F6259D812752"
      unitRef="usd">-45000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2611-wk-Fact-FEE28C3EF37BA83466A6F6259D233568"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2631-wk-Fact-1AB203907EB0BAB2309FF6259D620105"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2650-wk-Fact-D31F8D4E9B3B5AE9DA2CF6259D234447"
      unitRef="usd">915000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2669-wk-Fact-944622E77168D32541A5F6259D237440"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2689-wk-Fact-7EEB6BFCFE93B770E6D9F6259D04B1BB"
      unitRef="usd">2086200000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2709-wk-Fact-E645E756D1A5928F4DB9F6259D33A16C"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2728-wk-Fact-6BC822D1781AE53D7E2FF6259D23815D"
      unitRef="usd">48400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2747-wk-Fact-696A695B9920C049841EF6259D33760E"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2767-wk-Fact-24E55A27DDA14CB9EAB6F6259D81B92E"
      unitRef="usd">46700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e2792-wk-Fact-1312D56524962A9DE5E6F6259D623531"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e2811-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF"
      unitRef="usd">866600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e2830-wk-Fact-4C12FF47E79C07429E22F6259D717E32"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e2850-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8"
      unitRef="usd">2039500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d30709305e3034-wk-Fact-8CF9DC39F989380845F4F6259D04BA7C"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d30709305e3053-wk-Fact-FFF62E268FEFB138E8F5F6259D62495A"
      unitRef="usdPerShare">4.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d30709305e3072-wk-Fact-663F92E7DEDC62E12377F6259D71A754"
      unitRef="usdPerShare">15.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d30709305e3092-wk-Fact-D049B4E18AE05156BF93F6259D62E9CC"
      unitRef="usdPerShare">9.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d30709305e3112-wk-Fact-2DC10E017EA507089A2CF6259D234B6D"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d30709305e3131-wk-Fact-DEE3E7AA016512089B7DF6259D626513"
      unitRef="usdPerShare">4.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d30709305e3150-wk-Fact-BBCE3A012795B8919988F6259D045D1F"
      unitRef="usdPerShare">14.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d30709305e3170-wk-Fact-C89ABB444BDF41DB8497F6259D231165"
      unitRef="usdPerShare">9.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e3349-wk-Fact-3DD915C4195E7A211C58F6259D14C30A"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e3368-wk-Fact-FBB66D5A57657FD9D1A8F6259D04C4C0"
      unitRef="shares">207100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e3387-wk-Fact-D6A6A637EC02E81810FBF6259D2321A2"
      unitRef="shares">193400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e3407-wk-Fact-D23833DF65E5DC2469C7F6259D046BE6"
      unitRef="shares">209200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30709305e3428-wk-Fact-735BC5DA3214A5F5DB05F6259D23547F"
      unitRef="shares">190400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30709305e3447-wk-Fact-8878D9126D3CB451B07EF6259D23E3E0"
      unitRef="shares">207300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30709305e3466-wk-Fact-561BED1750D028A1FC26F6259D23DF4C"
      unitRef="shares">193700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30709305e3486-wk-Fact-C1F390AE19DCE6838E36F6259D6231B8"
      unitRef="shares">209500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e981-wk-Fact-1312D56524962A9DE5E6F6259D623531"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1000-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF"
      unitRef="usd">866600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1019-wk-Fact-4C12FF47E79C07429E22F6259D717E32"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1039-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8"
      unitRef="usd">2039500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1136-wk-Fact-31F010DDAF49859F6355F6259D6213D2"
      unitRef="usd">3300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1155-wk-Fact-21EBA31C28FC312C52FFF6259D528FC0"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1174-wk-Fact-EC118FAD2A5A63553933F6259D1465FF"
      unitRef="usd">10200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1194-wk-Fact-CEE616735AA289DD6706F6259D143DA2"
      unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1215-wk-Fact-9A3D853B99202E3E0591F6259D625AE0"
      unitRef="usd">-37900000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1235-wk-Fact-2F275844E1AC10A0E95BF6259D521B63"
      unitRef="usd">132800000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1254-wk-Fact-D3F2372090B1308D93A8F6259D629FC6"
      unitRef="usd">-21000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1275-wk-Fact-1BE8F66DB75E0AD41FDFF6259D149DC8"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1295-wk-Fact-42568F2007375561AFA4F6259D14F796"
      unitRef="usd">11700000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1314-wk-Fact-F8517014170680EA6529F6259D14192A"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1333-wk-Fact-985141DDAB2748EC2C6FF6259D146776"
      unitRef="usd">25700000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1353-wk-Fact-8A5556BAE3D9EDE48F6AF6259D624EA7"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1373-wk-Fact-8A877CC0C0C5E6D39823F6259D623726"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1392-wk-Fact-5555D481A8C4A754976FF6259D62E9BA"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1411-wk-Fact-CFEA2E75C731BC2B8770F6259D14C4DC"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1431-wk-Fact-A2B291592654A0550463F6259D62D2ED"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1451-wk-Fact-7CC3D6792C2A3A811327F6259D14343D"
      unitRef="usd">-10300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1471-wk-Fact-EAADD9BCAD5FEB3BD958F6259D143FEF"
      unitRef="usd">-92000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1491-wk-Fact-065A6EE1399E000692E7F6259D14A99F"
      unitRef="usd">-28100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1512-wk-Fact-6D7EB6CFEE011396865BF6259D143ADA"
      unitRef="usd">-47300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1533-wk-Fact-B0A137B6EC0E7C27AA1BF6259D047ABC"
      unitRef="usd">-33100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1553-wk-Fact-DF0CD48B7311719F5538F6259D6235D2"
      unitRef="usd">42300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1572-wk-Fact-6440C377A189830524FFF6259D141ACB"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1593-wk-Fact-53C30F8A2D37A0D5D15EF6259D14796F"
      unitRef="usd">55300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1613-wk-Fact-CF635044ECDFF7D9358EF6259D62419B"
      unitRef="usd">1461000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1632-wk-Fact-75BE0D31A8E1110952C9F6259D146358"
      unitRef="usd">908900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1651-wk-Fact-E4854635B3CE5ACCEAB5F6259D144463"
      unitRef="usd">2890400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1671-wk-Fact-56593BA70A232668C9FCF6259D62D8D2"
      unitRef="usd">2094800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1692-wk-Fact-339C0F36774A78B0C3A8F6259D62F894"
      unitRef="usd">400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1712-wk-Fact-A783D33382ADC5B65D03F6259D529E46"
      unitRef="usd">-48400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1731-wk-Fact-743F7539F07EAC0F6D4AF6259D62CFB8"
      unitRef="usd">400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1752-wk-Fact-61A1688FA476ACF65A91F6259D04A00B"
      unitRef="usd">-46700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30704023e1777-wk-Fact-7F19EA6B90DE71AA10B8F6259D145FDE"
      unitRef="usd">1460600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30704023e1796-wk-Fact-26089E7159283A6571B4F6259D627D9F"
      unitRef="usd">957300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30704023e1815-wk-Fact-1F2AF1DB2838E69AEAE4F6259D62B9BA"
      unitRef="usd">2890000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30704023e1835-wk-Fact-C00D336AEA4F71C1D663F6259D043A66"
      unitRef="usd">2141500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e933-wk-Fact-9858208795209B691908F6259D338561"
      unitRef="usd">1723400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e952-wk-Fact-035B89B271A4FAED0085F6259D2336D2"
      unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e967-wk-Fact-BD9E919248B6581338EDF6259D23452A"
      unitRef="usd">1228800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e986-wk-Fact-F39650FBCA792ACA848FF6259D239419"
      unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1006-wk-Fact-AE2BCE0E16D1839A8BD1F6259D335046"
      unitRef="usd">1959600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1025-wk-Fact-B2E9AD3D8FCD7E315646F6259D33B4D0"
      unitRef="usd">1958500000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1045-wk-Fact-2D2F6815774616642EF5F6259D339468"
      unitRef="usd">557500000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1064-wk-Fact-AC282426EDDBBB0752F5F6259D235244"
      unitRef="usd">526900000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1084-wk-Fact-55C665FC64E6E531FF29F6259D33D65D"
      unitRef="usd">776700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1103-wk-Fact-8C6C4783CB833F71AD59F6259D2325D5"
      unitRef="usd">929900000</us-gaap:InventoryNet>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1123-wk-Fact-20DBD282A787CC7F2376F6259D339564"
      unitRef="usd">683400000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1142-wk-Fact-FD99C4D258FDBA85A0FCF6259D23B706"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1162-wk-Fact-D456004BF084BBF369F8F6259D2390EE"
      unitRef="usd">980400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1181-wk-Fact-742E62FB17113F6C5D8AF6259D339468"
      unitRef="usd">687600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1201-wk-Fact-242EF5FBDE93AED05319F6259D23C964"
      unitRef="usd">7909800000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1220-wk-Fact-481F9FDB7D0076F652A0F6259D23E31B"
      unitRef="usd">7640900000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1241-wk-Fact-6FF948889A321B259E6BF6259D33C3E9"
      unitRef="usd">1309300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1260-wk-Fact-E06E408A000E8B3CF1C0F6259D23A411"
      unitRef="usd">1375900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1280-wk-Fact-D36EC44E828AA961F2BFF6259D33C5F8"
      unitRef="usd">3077500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1299-wk-Fact-F4F7BCB3A78942C0135CF6259D234031"
      unitRef="usd">3601200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1319-wk-Fact-30F30492C0F6E625EDCEF6259D334F76"
      unitRef="usd">434400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1338-wk-Fact-04A7905E586B9B458C06F6259D23079B"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1358-wk-Fact-C44244A5766C4B25316FF6259D233F2E"
      unitRef="usd">3681300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1377-wk-Fact-8B92C2F3788E45ADA189F6259D33FAEA"
      unitRef="usd">3120000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1397-wk-Fact-D63D508540010D880C00F6259D336D62"
      unitRef="usd">5749200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1416-wk-Fact-A45E521E0B1F5359C200F6259D335514"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1436-wk-Fact-E675740FEFD83830F0D6F6259D337D8D"
      unitRef="usd">2820100000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1455-wk-Fact-852AE116BCBBCB5DD576F6259D23AFCD"
      unitRef="usd">2153900000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1475-wk-Fact-A2969343D2188DFE88F0F6259D33058A"
      unitRef="usd">1306000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1494-wk-Fact-1D309AFFBDC920B45EB5F6259D338BF8"
      unitRef="usd">1690600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1519-wk-Fact-C509E254A6F3D0BD0E30F6259D33FCC0"
      unitRef="usd">26287600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1538-wk-Fact-841E6D4BAF69CAA3BCD3F6259D23066A"
      unitRef="usd">25288900000</us-gaap:Assets>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1635-wk-Fact-3002001FCA74A7392C5EF6259D335EBF"
      unitRef="usd">427200000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1654-wk-Fact-F4960609E3F746E03D1EF6259D33DB57"
      unitRef="usd">63500000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1675-wk-Fact-81F5E0FEA2F9FD8A80A3F6259D230796"
      unitRef="usd">377100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1694-wk-Fact-65041FE09DE05A22ECD3F6259D230B5B"
      unitRef="usd">370500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1714-wk-Fact-CC4552EDFEBE57032A88F6259D2345FA"
      unitRef="usd">88600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1733-wk-Fact-CDC634F416FB33364A38F6259D23C75B"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1753-wk-Fact-D2C177CB69195CA03AC0F6259D33900E"
      unitRef="usd">2318000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1772-wk-Fact-86E688319B1BFB671A79F6259D3356D0"
      unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1792-wk-Fact-06DAF578A64F1EE86E29F6259D3390C7"
      unitRef="usd">3210900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1811-wk-Fact-3E4619C2FFADD3A56095F6259D336F05"
      unitRef="usd">3295200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1831-wk-Fact-33694DB63BA16DCFC663F6259D33CA9C"
      unitRef="usd">5948500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1850-wk-Fact-B61A57895AE4A95E8E50F6259D333AD0"
      unitRef="usd">5936500000</us-gaap:LongTermDebt>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1870-wk-Fact-B87FDA86BF3BFF6C4F43F6259D33859D"
      unitRef="usd">2400600000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1889-wk-Fact-09C88A415F4C30DE2ED3F6259D331942"
      unitRef="usd">1636200000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1909-wk-Fact-286D309BE212C93DDB31F6259D33E918"
      unitRef="usd">423000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1928-wk-Fact-6E52952A5B4E356B4CFEF6259D231687"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1948-wk-Fact-8904E7BA29021E7A3B2AF6259D33E1F9"
      unitRef="usd">1355800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e1967-wk-Fact-D6DAB453FA1C7269FD1AF6259D233862"
      unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e1987-wk-Fact-2BF6B1C8763D147B9C12F6259D2356E8"
      unitRef="usd">13338800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2006-wk-Fact-A0ED1004BA8299B95E07F6259D33E998"
      unitRef="usd">12257300000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q2"
      id="d30706092e2026-wk-Fact-57E75B4FAD89DB341550F6259D33CB95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d30706092e2044-wk-Fact-22EB2B36C1291F28F2E3F6259D33E1DB"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2146-wk-Fact-46D759CBC6CAD5CEF4C2F6259D33FAFE"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2165-wk-Fact-A9E4900C1CF8D0CEF483F6259D33E8B5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2185-wk-Fact-88CC95E857D9A664786FF6259D23A24A"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2204-wk-Fact-940FE4B6F465D880CDB6F6259D33EE22"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2224-wk-Fact-4F6D5DA9E5876E748A73F6259D338AC0"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2243-wk-Fact-AD555A3A6C3C3536A361F6259D237307"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2263-wk-Fact-87EBCA1CDEFC1D44DA24F6259D23F60D"
      unitRef="usd">-252900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2283-wk-Fact-25428E0E08BD0DBCBF49F6259D237069"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2304-wk-Fact-4C5BAD68AE6FF251B6D7F6259D2325D2"
      unitRef="usd">16182800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2323-wk-Fact-10E50376D0702BB459F1F6259D339745"
      unitRef="usd">16257000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2343-wk-Fact-3EC8896A5491BBD2B30DF6259D238D4F"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2363-wk-Fact-A8D138939EBCF140B112F6259D336881"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2384-wk-Fact-F9165D79EC1E6C64E3B3F6259D234449"
      unitRef="usd">12952900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2403-wk-Fact-3EECA24243F719A52619F6259D23FAB3"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2423-wk-Fact-3058F8545746CABEC0F0F6259D239701"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2443-wk-Fact-38D6D5B30A7F46F6D3D6F6259D23D1DE"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2464-wk-Fact-350EF309D1E351668276F6259D33E09A"
      unitRef="usd">12948800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2483-wk-Fact-789BB109D69636C33702F6259D33EE1B"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30706092e2508-wk-Fact-594895C51C8DF09FCC1EF6259D23FCDB"
      unitRef="usd">26287600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30706092e2527-wk-Fact-2C79DCC9F95B06BC5A00F6259D3331F9"
      unitRef="usd">25288900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e933-wk-Fact-944622E77168D32541A5F6259D237440"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e952-wk-Fact-7EEB6BFCFE93B770E6D9F6259D04B1BB"
      unitRef="usd">2086200000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1008-wk-Fact-44F2CBB637ACA0DB4D3CF6259DB287ED"
      unitRef="usd">238100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1027-wk-Fact-5B23195358E63F5AC46DF6259D7173FA"
      unitRef="usd">340400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1047-wk-Fact-3E2223D98408E167DC0AF6259D330F8A"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1066-wk-Fact-357E14C70265B206695DF6259D62226E"
      unitRef="usd">85000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1086-wk-Fact-5AC23500DCF648E33B91F6259D1410B4"
      unitRef="usd">98000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1105-wk-Fact-258877B8B7F079945490F6259DB29E97"
      unitRef="usd">81700000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1125-wk-Fact-33C2C3244E3CB3B9F4C0F6259D6216FA"
      unitRef="usd">8500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1145-wk-Fact-7BA913E8E376F5770455F6259D81E7AA"
      unitRef="usd">3700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1166-wk-Fact-4F66CF3F0610122535ABF6259DA9C591"
      unitRef="usd">-113200000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1185-wk-Fact-259ABC73BAF1F1557583F6259DAE64B5"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1205-wk-Fact-9B02D92D896789AE7A23F6259DAE77CF"
      unitRef="usd">71600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1224-wk-Fact-E173F35E90EAD45DAF02F6259DB23B93"
      unitRef="usd">-57400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1246-wk-Fact-5C13AB8BC4203020B7A2F6259D045AAA"
      unitRef="usd">199200000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1266-wk-Fact-46A52DCF7AB25C49FE96F6259D040FEB"
      unitRef="usd">-1000000.0</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1286-wk-Fact-811989D69A688E7A6407F6259D8175A3"
      unitRef="usd">-91100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1305-wk-Fact-296BCED595B7BA39A244F6259DA4DB78"
      unitRef="usd">-45100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1366-wk-Fact-7E146384C68136E45F3AF6259D8183FD"
      unitRef="usd">2900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1386-wk-Fact-A6A4389668A031A9DEE6F6259DB05ACC"
      unitRef="usd">187200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1407-wk-Fact-CE1D097E01F71D7FD82DF6259DB29814"
      unitRef="usd">-108700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1426-wk-Fact-EC4FBC0BF2E581923EF9F6259DB238CC"
      unitRef="usd">40100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1447-wk-Fact-6A249AC9F95C26024F1FF6259DB285AB"
      unitRef="usd">-216100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1467-wk-Fact-AC07E3A649E3AD4868A2F6259DB2F8B6"
      unitRef="usd">13300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1487-wk-Fact-F1137B215B423245CB8EF6259DA384D4"
      unitRef="usd">306900000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1506-wk-Fact-520FBF07A788596EB1AEF6259DB2A879"
      unitRef="usd">183400000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1526-wk-Fact-BA3276F79039815C5E05F6259DB22094"
      unitRef="usd">80300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1546-wk-Fact-48CB8B4CE3E9F2971B87F6259D0410E6"
      unitRef="usd">-8700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1566-wk-Fact-86E1EB45DC73F053A00AF6259DA43E96"
      unitRef="usd">3423500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1585-wk-Fact-52B28BD40E9C11CEC043F6259DB2DB92"
      unitRef="usd">2556400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1646-wk-Fact-3BBFC6B449A1CFB27923F6259DAB5774"
      unitRef="usd">3255800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1665-wk-Fact-39E9D01E2A183C19B400F6259D913FA2"
      unitRef="usd">6802700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1686-wk-Fact-EACF79C16A71EFF79158F6259DAEF6DE"
      unitRef="usd">2075100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1706-wk-Fact-C5793882513CF1479582F6259D52EC37"
      unitRef="usd">4774300000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1727-wk-Fact-0778C9D027D202449F35F6259DB24E6E"
      unitRef="usd">300000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1747-wk-Fact-5AFBE48E196DF0C227E0F6259D523832"
      unitRef="usd">900000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1768-wk-Fact-3124DF2E8474C4DDDDA9F6259D6238B4"
      unitRef="usd">744400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1788-wk-Fact-B91AF59A43C03DF66CB2F6259D043D0B"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1808-wk-Fact-121E1A84E9F0467367EAF6259D816AD2"
      unitRef="usd">314000000.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1828-wk-Fact-10AF69C49D7EBF39B2A1F6259D627763"
      unitRef="usd">381500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1849-wk-Fact-09FF21520A19F5535AE3F6259D04AD1C"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1868-wk-Fact-80BAF6C506039BC98F79F6259D919F93"
      unitRef="usd">85000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1889-wk-Fact-1ABD572F7EED73FBEB85F6259DA347D4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1908-wk-Fact-E274BA7E39233961CB37F6259D81F917"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1929-wk-Fact-C90BC86347D9B5F01425F6259DA5CC5A"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1948-wk-Fact-72BB12C0C822A6EE1A94F6259DA6D634"
      unitRef="usd">462900000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e1969-wk-Fact-945C3371A4119A65749405F142C680F9"
      unitRef="usd">309700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e1988-wk-Fact-FDBC48289BC70FE1902E05F173F62E62"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2008-wk-Fact-637E7A9F2A4D0DFCD00AF6259DAB4464"
      unitRef="usd">4000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2028-wk-Fact-2B6A7C1A0FC31F3DFE9BF6259DB030E4"
      unitRef="usd">-2100000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2048-wk-Fact-47576E86FA16A18AC25BF6259DB21A7F"
      unitRef="usd">128000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2067-wk-Fact-49DCB3AD0A14B1C304C9F6259DB06534"
      unitRef="usd">198100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2129-wk-Fact-5A2037D05EAC847D15A1F6259D0404D4"
      unitRef="usd">3057300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2149-wk-Fact-E87F4500598F8EB6AB6BF6259D23896C"
      unitRef="usd">3000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2170-wk-Fact-D412D246F2D934002023F6259D23020D"
      unitRef="usd">23600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2190-wk-Fact-A2FBD82A2D2B4FBB6D64F6259DB21592"
      unitRef="usd">14300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2211-wk-Fact-735007638F8E7709E467F6259DB2321E"
      unitRef="usd">-4300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2230-wk-Fact-82BAFA95EAC5943D5002F6259DB2CB5F"
      unitRef="usd">38900000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2251-wk-Fact-62BE1B1A3471FF9FCFB7F6259DA85A87"
      unitRef="usd">21600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2270-wk-Fact-F872F41B9811711C4AD5F6259D04DFFC"
      unitRef="usd">-6900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2291-wk-Fact-17D683E535BBB8D28B1EF6259D04CDE7"
      unitRef="usd">-3055000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2311-wk-Fact-2854D5AC587C5401CB51F6259DAECDAB"
      unitRef="usd">-3060100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2332-wk-Fact-14B539946921102D5E29F6259D233837"
      unitRef="usd">496500000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2351-wk-Fact-B024C95EAA3A18372E3BF6259CF5D709"
      unitRef="usd">-305600000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30702021e2372-wk-Fact-15165C6794E3C601ADF9F6259D042798"
      unitRef="usd">2300000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30702021e2391-wk-Fact-3A8EA9C69AFE9C057A21F6259D91872F"
      unitRef="usd">-18000000.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30702021e2412-wk-Fact-035B89B271A4FAED0085F6259D2336D2"
      unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-5"
      id="d30702021e2431-wk-Fact-D0726CCC9AAABA3300E3F6259D91BF61"
      unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30702021e2456-wk-Fact-9858208795209B691908F6259D338561"
      unitRef="usd">1723400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q2"
      decimals="-5"
      id="d30702021e2475-wk-Fact-0FD1CD1751C88178034FF6259D81D3DD"
      unitRef="usd">1250200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e1333-wk-Fact-8AEDCCCAC6ED998A0425F6259D91E0C8"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e1352-wk-Fact-78F2DA90279FE5AEF77BF6259D9134C9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e1366-wk-Fact-265FB4D0FD39EAEC50A4F6259D918544"
      unitRef="shares">219000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e1386-wk-Fact-DD36B8FEB979448395C3F6259D919B0A"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e1405-wk-Fact-EFB4FE2AB6A0B2BA722FF6259DA00828"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e1424-wk-Fact-B0978DB39AF808C2D65BF6259DA0F600"
      unitRef="usd">-219800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e1445-wk-Fact-4D5D5A4D6043AB35ED69F6259D911CD4"
      unitRef="usd">17026700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e1459-wk-Fact-C909C3080446A3A873DFF6259DA2DECE"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e1479-wk-Fact-C6B3C96D6C8F09B30415F6259DA08BF6"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-5"
      id="d30726862e1500-wk-Fact-AC321684617C5C6FCD7FF6259D9122D0"
      unitRef="usd">13829900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e1519-wk-Fact-9A889B24918CBE4A4E48F6259D91CF94"
      unitRef="usd">-7900000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1"
      decimals="-5"
      id="d30726862e1539-wk-Fact-FF3E09A0D0D8250F1F30F6259D91B8E2"
      unitRef="usd">13822000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e1667-wk-Fact-7F48E25C2D8A88FCA302F6259DA02A4A"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e1722-wk-Fact-1312D56524962A9DE5E6F6259D623531"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e1741-wk-Fact-15965186792561F25285F6259D91065F"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e1760-wk-Fact-1AB203907EB0BAB2309FF6259D620105"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e1872-wk-Fact-60E2875E670E58B34648F6259DA0FC1C"
      unitRef="usd">-33100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e1949-wk-Fact-B0A137B6EC0E7C27AA1BF6259D047ABC"
      unitRef="usd">-33100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e1969-wk-Fact-BEE672AE00F9F2AE3C72F6259D910904"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e1989-wk-Fact-5B498638056AA3B469E9F6259D913D54"
      unitRef="usd">-33500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30726862e2179-wk-Fact-3BD82EDF075DD4A1021E05FA313A804E"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e2198-wk-Fact-2C7FA4DD41C18093158605FA809FB587"
      unitRef="usd">4200000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e2217-wk-Fact-30D9B26F2FFD416774A405FAC04C99E1"
      unitRef="usd">4200000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e2370-wk-Fact-33837E12B336A596F45AF6259D916CFE"
      unitRef="shares">3900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e2385-wk-Fact-671AC3C8104B4141CAB1F6259D91BA19"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e2406-wk-Fact-258BF0CCA36E1E97C235F6259D91E17B"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e2446-wk-Fact-258BF0CCA36E1E97C235F6259D91E17B"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e2503-wk-Fact-D8584EF93273AFD536ACF6259DA08B39"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e2519-wk-Fact-BDB790049D071CB3DEDDF6259D91DDE1"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e2538-wk-Fact-C17F30AE3FC5E2D999EBF6259D91DCFA"
      unitRef="usd">19700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e2579-wk-Fact-6B9123E26962C6F1A0AF05FC1DD72CDA"
      unitRef="usd">890200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e2599-wk-Fact-9457B625ABAE904D395BF6259D918F98"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e2613-wk-Fact-4530410A0A50823C465CF6259D91F410"
      unitRef="usd">909900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e2633-wk-Fact-D0372D968E38D20CCE25F6259D910B11"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e2672-wk-Fact-D0372D968E38D20CCE25F6259D910B11"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e2825-wk-Fact-26FA2D5A4D1B057155CEF6259D91F6EE"
      unitRef="shares">6500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e2840-wk-Fact-9F1922B19B206E3059C6F6259D91C2F6"
      unitRef="usd">1491600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e2861-wk-Fact-16006BAAB86EE26E0BECF6259D91156A"
      unitRef="usd">1491600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e2901-wk-Fact-16006BAAB86EE26E0BECF6259D91156A"
      unitRef="usd">1491600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e2958-wk-Fact-62BBC20D65150980153AF6259D914279"
      unitRef="shares">6500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e2974-wk-Fact-0D9809BED82BCE244F7BF6259D919707"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e2993-wk-Fact-53B32DD32496D3FD1E84F6259D919721"
      unitRef="usd">44900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e3034-wk-Fact-2A20ABAA6C874B4D734CF6259D91D0FA"
      unitRef="usd">1446700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e3054-wk-Fact-8E99CA55BE058AD1A460F6259D91F1D0"
      unitRef="shares">6500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e3068-wk-Fact-E7563C6B4E8B5FCF73F8F6259D916948"
      unitRef="usd">1491600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e3088-wk-Fact-77DB4CFA8ADC0DA2FFCEF6259DA03798"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e3127-wk-Fact-77DB4CFA8ADC0DA2FFCEF6259DA03798"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e3183-wk-Fact-36A781025B181E50B300F6259D919393"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e3198-wk-Fact-B74429AA331254E22DACF6259DA03625"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e3217-wk-Fact-70798AA0741D3D9C4F07F6259D910C6A"
      unitRef="usd">9600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e3313-wk-Fact-F88BFEDCDEE87A8551C7F6259D9108D3"
      unitRef="usd">9600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e3352-wk-Fact-F88BFEDCDEE87A8551C7F6259D9108D3"
      unitRef="usd">9600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e3409-wk-Fact-34F440E9427A9F98FF41F6259D919863"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e3424-wk-Fact-9B9CE0D646325EC4B44DF6259D91B958"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e3443-wk-Fact-05D872447A9C48EB2CE6F6259D9160F2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e3483-wk-Fact-E8760DB2AC2CE296CE40F6259D914506"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e3539-wk-Fact-5D236078B2DDFD54AF04F6259D91A035"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e3579-wk-Fact-5D236078B2DDFD54AF04F6259D91A035"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e3672-wk-Fact-304D893FCCE6CF6D8262F6259DA06F21"
      unitRef="usd">55000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e3768-wk-Fact-2F9B9B9362F6591CA2CAF6259D91EEEC"
      unitRef="usd">55000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726862e3807-wk-Fact-2F9B9B9362F6591CA2CAF6259D91EEEC"
      unitRef="usd">55000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e3828-wk-Fact-86DA1107A93832F987E2F6259D91BE79"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e3847-wk-Fact-FD82CFB218471BBFD5C0F6259D914AAB"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e3861-wk-Fact-828169BA47450A2D9681F6259D91B99D"
      unitRef="shares">208600000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e3881-wk-Fact-6A6CFF7A1707929F1941F6259D913D01"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e3900-wk-Fact-0B5F9B4AA79527B0AED1F6259D910349"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e3919-wk-Fact-A4ACCC09EDDEEBB0C677F6259D91303D"
      unitRef="usd">-252900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e3940-wk-Fact-6C624D4E4D288826896BF6259DA04799"
      unitRef="usd">16182800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e3954-wk-Fact-2DAF3EC225BA959E096AF6259D910E5F"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e3974-wk-Fact-2543C14234EA7EE57EDAF6259D91596B"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30726862e3995-wk-Fact-F9165D79EC1E6C64E3B3F6259D234449"
      unitRef="usd">12952900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e4014-wk-Fact-38105AE509650C0560E9F6259D91B450"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30726862e4034-wk-Fact-350EF309D1E351668276F6259D33E09A"
      unitRef="usd">12948800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e4620-wk-Fact-4F73C12BCF81417956A0F6259D04CD5F"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e4639-wk-Fact-16E958E401A81F41BE8AF6259D04582C"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e4653-wk-Fact-D2DC72858D2341D80CC5F6259DB2C09B"
      unitRef="shares">221000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e4673-wk-Fact-B606DED3B831B788F98DF6259D04A779"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e4692-wk-Fact-60B278C7EF7D83481573F6259D04234E"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e4711-wk-Fact-6AB9425D8D9CEA3D5737F6259DAEE5F8"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e4732-wk-Fact-F47816D5E6E302778F0FF6259DB20E2F"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e4746-wk-Fact-D5C61DB273185395656BF6259D041931"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e4766-wk-Fact-F6CDF1A85E7E49C5B348F6259CF56267"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30726862e4787-wk-Fact-3EECA24243F719A52619F6259D23FAB3"
      unitRef="usd">13039600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e4806-wk-Fact-FEADC5B9A888AB7F69AEF6259DB284C3"
      unitRef="usd">-8000000.0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30726862e4826-wk-Fact-789BB109D69636C33702F6259D33EE1B"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e4954-wk-Fact-90A05C6538A4EBE89B5BF6259CF55F19"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e5009-wk-Fact-4C12FF47E79C07429E22F6259D717E32"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e5028-wk-Fact-9C79FAACF13B1A1BB808F6259DB2DDDB"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e5047-wk-Fact-944622E77168D32541A5F6259D237440"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e5159-wk-Fact-82649A38A45C5B1921D2F6259DB298DB"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e5236-wk-Fact-6440C377A189830524FFF6259D141ACB"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e5256-wk-Fact-B78E974EB37E5FCD876AF6259D04D247"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e5276-wk-Fact-D699D6494F09F608A74FF6259DB287FC"
      unitRef="usd">-12900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30726862e5466-wk-Fact-12B2FBB381D51EB6498DF6259DB12CD8"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e5485-wk-Fact-45C654E443D1A330F8AFF6259D04437C"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e5504-wk-Fact-E3DF2615133ABD39B57F06024488F56A"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e5657-wk-Fact-8A681E458F6A1AF132D5F6259DAF6858"
      unitRef="shares">3900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e5672-wk-Fact-DF9990FF76891556F1C6F6259D042EE6"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e5693-wk-Fact-C542395F43978DB06702F6259CF503F8"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e5733-wk-Fact-C542395F43978DB06702F6259CF503F8"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e5790-wk-Fact-32BD861548B4F7CE440CF6259DAD804F"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e5806-wk-Fact-D0979F1DB23FB7AFECA3F6259DAE1FA1"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e5825-wk-Fact-53F2DD622C86C229690F060317721034"
      unitRef="usd">19700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e5866-wk-Fact-E39D79CB47C390ED59F50603535B0B88"
      unitRef="usd">890200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e5886-wk-Fact-DAE9CD94DC695670A17FF6259D04D8D0"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e5900-wk-Fact-C6752FFBCE4685F604C6F6259D049D76"
      unitRef="usd">909900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e5920-wk-Fact-3F052CD7E127577DE279F6259DADCA5C"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e5959-wk-Fact-3F052CD7E127577DE279F6259DADCA5C"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e6112-wk-Fact-3193AECB8B5BB6AA0578F6259D047E6C"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e6127-wk-Fact-EE6C74FD144058E4D7CAF6259DAE3F5F"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e6148-wk-Fact-04DA92EA014F41249E7CF6259DB29883"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e6188-wk-Fact-04DA92EA014F41249E7CF6259DB29883"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e6245-wk-Fact-C67A5272D8EAFE0719DFF6259CF546B7"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e6261-wk-Fact-BEE66AC2B2F2F5FA9011F6259D044D00"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e6280-wk-Fact-946FE61C9F1F02B1349AF6259DB0003D"
      unitRef="usd">110500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e6321-wk-Fact-B39896C99FB9806DBD00F6259D04ECEC"
      unitRef="usd">2036900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e6341-wk-Fact-6BA2BA8DCC5845717A64F6259DB23619"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e6355-wk-Fact-E30819332005F239E569F6259D04ADED"
      unitRef="usd">2147400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e6375-wk-Fact-8090F551CB6E2BB85698F6259DAFAECA"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e6414-wk-Fact-8090F551CB6E2BB85698F6259DAFAECA"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e6470-wk-Fact-3D1C5C0B12B057F212E9F6259DAB0559"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e6485-wk-Fact-7B416A67A0D15C554311F6259DB22D06"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e6504-wk-Fact-F17453F573794EB13BB6F6259DAE1375"
      unitRef="usd">26200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e6600-wk-Fact-748BE9C1C9997A79115EF6259DAAC81F"
      unitRef="usd">26200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e6639-wk-Fact-748BE9C1C9997A79115EF6259DAAC81F"
      unitRef="usd">26200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e6696-wk-Fact-07DEE5AED5C9F639D574F6259DB2783E"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e6711-wk-Fact-BCDACC46965B6FE2CC13F6259D04DE00"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e6730-wk-Fact-7C14DC0D51A06CC91613F6259DAF7DE0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e6770-wk-Fact-8388E739A34C48D4EEECF6259D0478EC"
      unitRef="usd">50000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e6826-wk-Fact-3DB85A03F32772D893BAF6259DB2DD0A"
      unitRef="usd">50000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e6866-wk-Fact-3DB85A03F32772D893BAF6259DB2DD0A"
      unitRef="usd">50000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e6959-wk-Fact-3B2B855F590FA03FA5A1F6259DB21104"
      unitRef="usd">104000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e7055-wk-Fact-5F8098A6D71AA9DED587F6259DB2FF18"
      unitRef="usd">104000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726862e7094-wk-Fact-5F8098A6D71AA9DED587F6259DB2FF18"
      unitRef="usd">104000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e7115-wk-Fact-86DA1107A93832F987E2F6259D91BE79"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e7134-wk-Fact-FD82CFB218471BBFD5C0F6259D914AAB"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e7148-wk-Fact-828169BA47450A2D9681F6259D91B99D"
      unitRef="shares">208600000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e7168-wk-Fact-6A6CFF7A1707929F1941F6259D913D01"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e7187-wk-Fact-0B5F9B4AA79527B0AED1F6259D910349"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e7206-wk-Fact-A4ACCC09EDDEEBB0C677F6259D91303D"
      unitRef="usd">-252900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e7227-wk-Fact-6C624D4E4D288826896BF6259DA04799"
      unitRef="usd">16182800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e7241-wk-Fact-2DAF3EC225BA959E096AF6259D910E5F"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e7261-wk-Fact-2543C14234EA7EE57EDAF6259D91596B"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30726862e7282-wk-Fact-F9165D79EC1E6C64E3B3F6259D234449"
      unitRef="usd">12952900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e7301-wk-Fact-38105AE509650C0560E9F6259D91B450"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30726862e7321-wk-Fact-350EF309D1E351668276F6259D33E09A"
      unitRef="usd">12948800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e7906-wk-Fact-469F14039ECAA58477E1F6259D14413F"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e7925-wk-Fact-DDB6D05DD80A5F1927EAF6259D148C84"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e7939-wk-Fact-24A2922441497D423306F6259D14EB77"
      unitRef="shares">211000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e7959-wk-Fact-75207C351D5DBDCC1AC6F6259D33B796"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e7978-wk-Fact-BAF3FA97D242C14EFB6AF6259D33886C"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e7997-wk-Fact-3AC2CA216EB0291D010AF6259D1496EC"
      unitRef="usd">-303900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e8018-wk-Fact-C0D46F05CFC091A6CB92F6259D14C913"
      unitRef="usd">17334600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e8032-wk-Fact-43DCF260367B061C4193F6259D14618B"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e8052-wk-Fact-D81D2A005CC591DC4D88F6259D1498B9"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1"
      decimals="-5"
      id="d30726862e8073-wk-Fact-DD4E5BD66E506EFCF2D7F6259D041496"
      unitRef="usd">14053700000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e8092-wk-Fact-139E1B5F311AB72C4B63F6259D143FEF"
      unitRef="usd">-16200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1"
      decimals="-5"
      id="d30726862e8112-wk-Fact-159F678EBC9216DEC44DF6259D14FACD"
      unitRef="usd">14037500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e8240-wk-Fact-15DA6E605A3687B29F4AF6259D14E0A1"
      unitRef="usd">866600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e8295-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF"
      unitRef="usd">866600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e8314-wk-Fact-C082D9D953E004F72AB9F6259D049E24"
      unitRef="usd">48400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e8333-wk-Fact-D31F8D4E9B3B5AE9DA2CF6259D234447"
      unitRef="usd">915000000.0</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e8445-wk-Fact-C7FB7A24FAD6C1C6B012F6259D04047E"
      unitRef="usd">42300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e8521-wk-Fact-DF0CD48B7311719F5538F6259D6235D2"
      unitRef="usd">42300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e8540-wk-Fact-AF6D7C0E8BB4EDABCFD8F6259D338042"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e8560-wk-Fact-343A034419566D2C42F1F6259D145B37"
      unitRef="usd">41800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30726862e8749-wk-Fact-5A4B611500FBF05A440BF6259D14AC3C"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e8768-wk-Fact-5DAB3175E22DBA3D7F6BF6259D14C722"
      unitRef="usd">11100000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e8787-wk-Fact-B82FA5FBE0FEACE69B8CF6259D140E64"
      unitRef="usd">11100000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30726862e8976-wk-Fact-A3821D1499AA1624EC9EF6259D33686D"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e8995-wk-Fact-7EDE810494586A885D6EF6259D331DE8"
      unitRef="usd">-50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e9015-wk-Fact-815ABD218F4EC9F5CC95F6259D14479F"
      unitRef="usd">50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e9169-wk-Fact-A74DED1771EBF88F3407F6259D33BF59"
      unitRef="shares">9600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e9184-wk-Fact-3EFADEE5717D1CE08590F6259D14A9FE"
      unitRef="usd">2750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e9205-wk-Fact-8681B68B25387CAA73EEF6259D041211"
      unitRef="usd">2750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e9245-wk-Fact-8681B68B25387CAA73EEF6259D041211"
      unitRef="usd">2750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e9302-wk-Fact-70E425B827F22FEE7FB7F6259D14047B"
      unitRef="shares">9600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e9318-wk-Fact-D135EC83C3D3DAF446AEF6259D140D3A"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e9337-wk-Fact-2228ADF4B8BFBBD7E005F6259D14E757"
      unitRef="usd">48300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e9378-wk-Fact-3F90D06FAA36269AEC8AF6259D14ED72"
      unitRef="usd">2701700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e9398-wk-Fact-FE6AA58A3AEDB58D5B4FF6259D14BCBF"
      unitRef="shares">9600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e9412-wk-Fact-CDC7E6ED7AE18E26C91CF6259D141F25"
      unitRef="usd">2750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e9432-wk-Fact-57B2973BC7249266C5FAF6259D147B1C"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e9471-wk-Fact-57B2973BC7249266C5FAF6259D147B1C"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e9527-wk-Fact-1311F4C831EABF673484F6259D04668D"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e9542-wk-Fact-74191E6483010B2F6048F6259D1400C2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e9561-wk-Fact-99EA8C3DD7459D6DCA91F6259D14FD46"
      unitRef="usd">8400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e9657-wk-Fact-E91BC9D403E44A4F8696F6259D045585"
      unitRef="usd">8400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e9696-wk-Fact-E91BC9D403E44A4F8696F6259D045585"
      unitRef="usd">8400000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e9752-wk-Fact-AAD20B47A23762B26A96F6259D044CF6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e9767-wk-Fact-ED3FEF56915E66B8D663F6259D04ED22"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e9786-wk-Fact-B95326CA180F617BB6E7F6259D330DD1"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e9883-wk-Fact-1B5A25A8815C45D29B38F6259D04D375"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e9923-wk-Fact-1B5A25A8815C45D29B38F6259D04D375"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e10017-wk-Fact-36F280EAF4AF8E610633F6259D33A275"
      unitRef="usd">41400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e10113-wk-Fact-42A3012150808C3F39DEF6259D338233"
      unitRef="usd">41400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726862e10152-wk-Fact-42A3012150808C3F39DEF6259D338233"
      unitRef="usd">41400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e10173-wk-Fact-7E4AFAF29A6A13E19429F6259D23E69E"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e10192-wk-Fact-BDD8095E4C25819E96C8F6259D62EC21"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e10206-wk-Fact-77D4C7AA68C9FCD18E55F6259D621573"
      unitRef="shares">201400000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e10226-wk-Fact-7A39446017330B28FC40F6259D23881C"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e10245-wk-Fact-22BD166B27DE4C5889DFF6259D23EC21"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e10264-wk-Fact-1DA142A0CEE1EF433869F6259D239641"
      unitRef="usd">-261600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e10285-wk-Fact-6C7CE6CC1C5D4B37EC7FF6259D23D3D1"
      unitRef="usd">15499500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e10299-wk-Fact-75A37E368FA1706A9E02F6259D33F79D"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e10319-wk-Fact-44FC93C019D1025E17E7F6259D2332E1"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-5"
      id="d30726862e10340-wk-Fact-6356A98F4EFF910483A3F6259D711129"
      unitRef="usd">12260900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e10359-wk-Fact-D516332F4A10A5B32C86F6259D33F9C9"
      unitRef="usd">-7200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2"
      decimals="-5"
      id="d30726862e10379-wk-Fact-747D31A616D2468659E0F6259D334920"
      unitRef="usd">12253700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e10961-wk-Fact-A7A04EBA72156A666193F6259D23DA89"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e10980-wk-Fact-E9620FAFC318B07009E8F6259D432BA0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e10994-wk-Fact-5CF3D755765F9CAFD380F6259D2364FE"
      unitRef="shares">211500000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e11014-wk-Fact-5442AD5444B1616E79F0F6259D231562"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e11033-wk-Fact-1B0A29BE65ECA39CB03FF6259D3363C1"
      unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e11052-wk-Fact-9522A1ABDB21458FDCF0F6259D7148DD"
      unitRef="usd">-318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e11073-wk-Fact-DE382E793ECA727E3D63F6259D710E30"
      unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e11087-wk-Fact-0C1A3B125CBA5D77D179F6259D6204ED"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e11107-wk-Fact-A1426A742491D326361DF6259D33B325"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-5"
      id="d30726862e11128-wk-Fact-E27E94BBB0312023C81FF6259D234635"
      unitRef="usd">12612800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e11147-wk-Fact-4ADD76E2EEC9FAE436EBF6259D62412E"
      unitRef="usd">-14700000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4"
      decimals="-5"
      id="d30726862e11167-wk-Fact-FD437C5C3CF17E129331F6259D33A7C4"
      unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e11295-wk-Fact-6FC514C6BCCC38D75A12F6259D330D99"
      unitRef="usd">2039500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e11350-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8"
      unitRef="usd">2039500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e11369-wk-Fact-8A71D408127E2980EC5FF6259D2310CD"
      unitRef="usd">46700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e11388-wk-Fact-7EEB6BFCFE93B770E6D9F6259D04B1BB"
      unitRef="usd">2086200000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e11500-wk-Fact-35CE8F4B84A326B668F1F6259D71A480"
      unitRef="usd">55300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e11576-wk-Fact-53C30F8A2D37A0D5D15EF6259D14796F"
      unitRef="usd">55300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e11595-wk-Fact-1A4B4B1D5651FEEBE677F6259D43E994"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e11615-wk-Fact-992826AEE2E0FDF5FF64F6259D626D71"
      unitRef="usd">55000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30726862e11804-wk-Fact-BFCD0FA3E624B63D05BBF6259D621426"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e11823-wk-Fact-4AE50635D050D932282EF6259D620345"
      unitRef="usd">11100000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e11842-wk-Fact-4BE2BA7048BEBC870C64F6259D235341"
      unitRef="usd">11100000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30726862e12031-wk-Fact-AAADB3CCE69022E94741F6259D6265AB"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e12050-wk-Fact-E5D9A242A5B77C1AF2D7F6259D23F251"
      unitRef="usd">-50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e12070-wk-Fact-AD38E45116455405AD85F6259D6234F8"
      unitRef="usd">50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e12224-wk-Fact-CD765C5CA3AF84E508DCF6259D23CDEC"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e12239-wk-Fact-67B2AEBB6D23F1FC7C44F6259D33382A"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e12260-wk-Fact-8E5E9C50951166E93477F6259D6277D3"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e12300-wk-Fact-8E5E9C50951166E93477F6259D6277D3"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e12357-wk-Fact-6E3F446653CD7AE7FB00F6259D231BB2"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e12373-wk-Fact-70CF889F9489D3B48DE3F6259D23D344"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e12392-wk-Fact-62C0DAFD7C9C9E14F8D1F6259D337DD6"
      unitRef="usd">171200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e12433-wk-Fact-9875D57954B191E8CD39F6259D23CD57"
      unitRef="usd">2828800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e12453-wk-Fact-4EFEBF9D880145C225F0F6259D23685E"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e12467-wk-Fact-3233CBAA1466C0144100F6259D3381A9"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e12487-wk-Fact-AFC9E6982476E9F92D6DF6259D23566B"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30726862e12526-wk-Fact-AFC9E6982476E9F92D6DF6259D23566B"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e12582-wk-Fact-C8A2946CF0E49E9EDC48F6259D6274CD"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e12597-wk-Fact-8AE10BE6F4518152FDA8F6259D23BE68"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e12616-wk-Fact-14A3235CD76CC4AC35C8F6259D621BB0"
      unitRef="usd">24600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e12712-wk-Fact-F4CF71B29FD49F9ED47BF6259D23D5C5"
      unitRef="usd">24600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e12751-wk-Fact-F4CF71B29FD49F9ED47BF6259D23D5C5"
      unitRef="usd">24600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e12807-wk-Fact-222072075FA43AF83FA5F6259D33D0C3"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e12822-wk-Fact-90A4AD348B3A53348FBDF6259D626F42"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e12841-wk-Fact-7E5224FB116200B997A7F6259D23F997"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e12938-wk-Fact-82D5B3A8D98390E7AE2BF6259D71454A"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e12978-wk-Fact-82D5B3A8D98390E7AE2BF6259D71454A"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e13072-wk-Fact-398CD92BDDF1BE089C1FF6259D62A2A9"
      unitRef="usd">87600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e13168-wk-Fact-199309FCE7E06B5F33D8F6259D622E7F"
      unitRef="usd">87600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e13207-wk-Fact-199309FCE7E06B5F33D8F6259D622E7F"
      unitRef="usd">87600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e13319-wk-Fact-81C5C6B23E1F4963B8F5F6259D330DCA"
      unitRef="usd">1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q2YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e13339-wk-Fact-16AB48D237D4C4FF50BDF6259D23358C"
      unitRef="usd">478400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e13394-wk-Fact-FD3FFB85487DB5E0E5AEF6259D814863"
      unitRef="usd">479900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726862e13433-wk-Fact-FD3FFB85487DB5E0E5AEF6259D814863"
      unitRef="usd">479900000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e13454-wk-Fact-7E4AFAF29A6A13E19429F6259D23E69E"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d30726862e13473-wk-Fact-BDD8095E4C25819E96C8F6259D62EC21"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e13487-wk-Fact-77D4C7AA68C9FCD18E55F6259D621573"
      unitRef="shares">201400000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d30726862e13507-wk-Fact-7A39446017330B28FC40F6259D23881C"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d30726862e13526-wk-Fact-22BD166B27DE4C5889DFF6259D23EC21"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30726862e13545-wk-Fact-1DA142A0CEE1EF433869F6259D239641"
      unitRef="usd">-261600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d30726862e13566-wk-Fact-6C7CE6CC1C5D4B37EC7FF6259D23D3D1"
      unitRef="usd">15499500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e13580-wk-Fact-75A37E368FA1706A9E02F6259D33F79D"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d30726862e13600-wk-Fact-44FC93C019D1025E17E7F6259D2332E1"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-5"
      id="d30726862e13621-wk-Fact-6356A98F4EFF910483A3F6259D711129"
      unitRef="usd">12260900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d30726862e13640-wk-Fact-D516332F4A10A5B32C86F6259D33F9C9"
      unitRef="usd">-7200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2"
      decimals="-5"
      id="d30726862e13660-wk-Fact-747D31A616D2468659E0F6259D334920"
      unitRef="usd">12253700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-AC1C0D3B32FBEA5EA085F6259DC2B6AA-0-wk-Fact-5795A675490FD26B96AEF6259D810B9B">Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &#x201c;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x201d; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Assets and Liabilities Held For Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$463.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$526.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative and Hedging&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-083878DC3CF1AF1726CBF6259DC298D4-0-wk-Fact-6022472C73F4EA28C56DF6259D81CE5A">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0D1F7E4DFE911849DC7AF6259DC247CB-0-wk-Fact-A2825F6364A8C5C7DA49F6259D81792C">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &#x201c;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x201d; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d30702019e881-wk-Fact-5C318F41468C42C49296F6259D81CEB8"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-325A95F190583038761AF6259DC25987-0-wk-Fact-B9C2A4AD2A2A2CFB94CAF6259D91195A">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d30702019e905-wk-Fact-384EAE8AFCD3050BB9AFF6259D818C53"
      unitRef="number">1</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q2YTD"
      id="TextSelection-C8081AC41C2C157AFAAFF6259DC21F7D-0-wk-Fact-758CA885EC43D4A73A33F6259D81CA89">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-859C317D0F3023AB73DAF6259DC24581-0-wk-Fact-B88BCD9633B7E29ED463F6259D811D8D">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.&lt;/span&gt;&lt;/div&gt;</biib:AssetsandLiabilitiesHeldForSalePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-6CB55BDFD20724ED6839F6259DC295EE-0-wk-Fact-0503B7805CB00E0AE59CF6259D81DAD7">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$463.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a corresponding operating lease liability of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$526.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the adoption of the new leasing standards, please read Note 11, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative and Hedging&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d30702019e1023-wk-Fact-C559458B0AE3EA029A42F6259D81ADBC"
      unitRef="usd">463000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Leases_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d30702019e1027-wk-Fact-E4E44AA717202EBE7AFCF6259D81C14E"
      unitRef="usd">526000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-BFB6947E29C1388D4C07F6259DC26D2F-0-wk-Fact-93A728AA12924A07E0F3F6259D81BEF7">Acquisitions&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquisition of Nightstar Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no approved treatments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of this acquisition, we paid NST shareholders &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$25.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for each issued and outstanding NST share, which totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$847.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for equity compensation, which is  attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$26.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$18.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recognized as a charge to selling, general and administrative expense with the remaining &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of the in-process research and development (IPR&amp;amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$480.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have recorded an additional IPR&amp;amp;D asset related to BIIB112 of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$220.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management&#x2019;s analysis related to certain matters, such &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;as finalizing our assessment of the IPR&amp;amp;D programs acquired and preparing and submitting certain income tax and non-income tax filings and returns. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="2"
      id="d30700581e787-wk-Fact-15D8B185F4558A73008BF6259D81099E"
      unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e791-wk-Fact-F46BDA50B9BDDDB80675F6259D8156FF"
      unitRef="usd">847600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e795-wk-Fact-1A5F6B0102BDD4C2ABB60636F077DE69"
      unitRef="usd">4600000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember"
      decimals="-5"
      id="d30700581e799-wk-Fact-C0201D93BDBADF80404A063B637B73C9"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30700581e803-wk-Fact-346FB69BEC327DF67093063C1F48987D"
      unitRef="usd">18400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d30700581e808-wk-Fact-6EF9E2940AF1E8B32EA5063CCD0AA244"
      unitRef="usd">7800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E1273B518436295D0407F6259DC2432D-0-wk-Fact-E1E7D0A0025A349A6A2AF6259D813834">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;700.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;852.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e863-wk-Fact-CEF22BC1B1C39D57B6F2063DD613FDBD"
      unitRef="usd">107800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e878-wk-Fact-A98656F318698D0F5F8A063DD6209074"
      unitRef="usd">7500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e898-wk-Fact-882BC58AAE3F5F88E247063DD62A09C3"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e918-wk-Fact-81CF457602F010BC4D59063DD61C2F08"
      unitRef="usd">112600000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e938-wk-Fact-0FA964BD34D415FC3E22063DD6252E56"
      unitRef="usd">77000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e959-wk-Fact-4CEBE1935541B2FC5EB1063DD6178F59"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e984-wk-Fact-1A9DA871CE7E13DA12DFF6259D2371EF"
      unitRef="usd">852200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="3"
      id="d30700581e996-wk-Fact-8F1A586ED010B46BD75F065A9584D9D1"
      unitRef="number">0.125</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB111Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e1000-wk-Fact-1B9D5CFA253798631949065F0ADA7A20"
      unitRef="usd">480000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_biib_ResearchanddevelopmentassetAxis_biib_BIIB112Member_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e1004-wk-Fact-6FBB55B9968AE3D79F810660C3496502"
      unitRef="usd">220000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30700581e1011-wk-Fact-4E6FA7A7BE37DBEBB4A006623ADEA639"
      unitRef="usd">35000000.0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-ACE05C47ED409D91D735F6259DC2CF00-0-wk-Fact-046F4F53520CAC49EAB7F6259D818494">Divestitures&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#xf8;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$890.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, subject to certain working capital adjustments and other contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$120.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#xf8;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&#xf8;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2019 the assets and liabilities related to our Hiller&#xf8;d, Denmark manufacturing operations met the criteria to be classified as held for sale. The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;641.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;62.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance on disposal group on assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(113.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;683.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;33.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;53.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;88.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded a loss of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$174.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$113.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; decrease to our original estimate as of March 31, 2019, reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&#xf8;d, Denmark manufacturing operations of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and our estimate of the fair value of an adverse commitment of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$120.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the guarantee of future minimum batch production at the Hiller&#xf8;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#xf8;d facility to FUJIFILM at carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse commitment, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proposed transaction remains subject to certain closing conditions. We expect to complete the proposed transaction in the third quarter of 2019. &lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e783-wk-Fact-46EFC128053751FC2172F6259D43F6DF"
      unitRef="usd">890000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e790-wk-Fact-752E4E0ED4666ED74E00F6259D2395B2"
      unitRef="usd">120000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0FA3340258B557DC3A85F6259DC20842-0-wk-Fact-1612E5B7ED45276DC0FAF6259D81B2B1">The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;641.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;62.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance on disposal group on assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(113.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;683.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;33.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;53.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;88.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="FI2019Q2_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember"
      decimals="-5"
      id="d30711147e877-wk-Fact-772C51D00284A1513CB1F6259D23E93B"
      unitRef="usd">20600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e892-wk-Fact-9CC2BD390BD3FCDC0482F6259D33BD90"
      unitRef="usd">641900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <biib:DisposalGroupOperatingLeaseAssets
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e912-wk-Fact-68222E790FDC7DC9CFFAF6259D23A1D0"
      unitRef="usd">2200000</biib:DisposalGroupOperatingLeaseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e932-wk-Fact-5BC5E181CF6FC316A83AF6259D2318A3"
      unitRef="usd">69500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e952-wk-Fact-1D39CC68F771EC8D6C45F6259D238BAE"
      unitRef="usd">62400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e972-wk-Fact-EE29E49B328C5B31F85DF6259D522627"
      unitRef="usd">113200000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e998-wk-Fact-D755FA7DE530909918EEF6259D237867"
      unitRef="usd">683400000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1061-wk-Fact-DC6D9DEC35981EDE395EF6259D334000"
      unitRef="usd">33400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <biib:DisposalGroupOperatingleaseliabilities
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1076-wk-Fact-DDDB96CD794214BD65D9F6259D23A37D"
      unitRef="usd">1400000</biib:DisposalGroupOperatingleaseliabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1096-wk-Fact-8E042DF4EA4562866591F6259D23FE2B"
      unitRef="usd">53800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1121-wk-Fact-EFE6EC19270F9E01911FF6259D235ACC"
      unitRef="usd">88600000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1142-wk-Fact-90085B380DEE5DDFD8F2F6259D52C3AB"
      unitRef="usd">174500000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1146-wk-Fact-EE29E49B328C5B31F85DF6259D522627"
      unitRef="usd">113200000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1150-wk-Fact-538E11EDC3F7D473FD3A0669832E0024"
      unitRef="usd">2300000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1155-wk-Fact-7F019D09C65D9FDF9B20F6259D52CEF9"
      unitRef="usd">10000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1159-wk-Fact-752E4E0ED4666ED74E00F6259D2395B2"
      unitRef="usd">120000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30711147e1163-wk-Fact-136D8A2DB49CECD79C24F6259D52E80E"
      unitRef="usd">61300000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-94D50C3F47C83D67F8D2F6259DC25DDD-0-wk-Fact-7749EC42B44D80928B06F6259D81A5B1">Revenues&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;869.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;280.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,150.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;825.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,086.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;379.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;554.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;264.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;211.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;475.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;265.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;467.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,513.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;690.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,204.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,536.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;666.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,202.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;230.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;257.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;488.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;216.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;422.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,744.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,135.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,880.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,741.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,015.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,757.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,587.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;561.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,149.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,554.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;519.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,073.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;707.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;348.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,055.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;816.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,175.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;509.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;426.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;935.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;515.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;414.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,803.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,383.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,187.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,885.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,341.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,227.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;453.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;552.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,006.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;393.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;392.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;786.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;254.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;254.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,257.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,302.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,560.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,279.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,001.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,281.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;308.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,391.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,710.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(41.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(42.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(189.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(827.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,017.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(505.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(11.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(639.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;124.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;905.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;32.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,062.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;199.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;863.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,062.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;377.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;768.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;708.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;199.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;325.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;576.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;490.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,093.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;933.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;105.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;369.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;219.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;160.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;452.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;273.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$34.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$241.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$47.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$94.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-57E12AA4AD8789AEA4C9F6259DC218A8-0-wk-Fact-C7163F13C8B95BFE1B6AF6259DA2098E">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;869.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;280.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,150.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;825.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,086.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;379.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;554.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;264.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;211.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;475.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;265.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;201.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;467.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,513.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;690.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,204.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,536.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;666.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,202.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;230.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;257.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;488.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;216.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;422.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,744.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,135.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,880.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,741.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,015.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,757.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,587.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;561.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,149.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,554.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;519.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,073.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;707.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;348.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,055.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;816.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,175.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;509.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;426.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;935.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;515.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;414.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,803.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,383.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,187.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,885.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,341.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,227.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;453.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;552.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,006.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;393.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;392.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;786.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;254.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;254.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,257.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,302.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,560.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,279.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,001.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,281.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1341-wk-Fact-81FB72216292E686B55BF6259D7188DE"
      unitRef="usd">869800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1360-wk-Fact-E9AC7D38A07AEB01ECD5F6259D14322E"
      unitRef="usd">280400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d30743146e1379-wk-Fact-91AEF89F21871044B72DF6259D14ECEA"
      unitRef="usd">1150200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1399-wk-Fact-4EEB4BF2CE7931ECBCBEF6259D71ECEC"
      unitRef="usd">825800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1418-wk-Fact-47B2D795B2C5A1B633D2F6259D140FDF"
      unitRef="usd">261000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d30743146e1438-wk-Fact-9A8FC1978340B2686226F6259D14513B"
      unitRef="usd">1086800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1453-wk-Fact-8CCC75F6B0781326B29EF6259D14E6A2"
      unitRef="usd">379700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1472-wk-Fact-09EBD3182193F0373811F6259D14C775"
      unitRef="usd">174700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d30743146e1491-wk-Fact-B7E57EA2387C8E03A328F6259D717901"
      unitRef="usd">554400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1511-wk-Fact-A4F925BAF89757FEF4EFF6259D14F5F1"
      unitRef="usd">444700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1530-wk-Fact-56C778E4CE9B44FB5C71F6259D14D009"
      unitRef="usd">180800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d30743146e1549-wk-Fact-8E443015FBDD69A55EA1F6259D7113D9"
      unitRef="usd">625500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1570-wk-Fact-7872D4D74FBE82183CEEF6259D14D7D2"
      unitRef="usd">264300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1589-wk-Fact-79AE164ED87A54F2A62DF6259D1497AE"
      unitRef="usd">211000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d30743146e1608-wk-Fact-4D2E74D0B2798EC5338AF6259D711CF0"
      unitRef="usd">475300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1628-wk-Fact-52E2E8050F02935A4582F6259D14CEC3"
      unitRef="usd">265500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1647-wk-Fact-5E98303451FB860FCAE6F6259D71A66B"
      unitRef="usd">201700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d30743146e1666-wk-Fact-EEDA61B06196E7928A15F6259D14F2FC"
      unitRef="usd">467200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1687-wk-Fact-8B1A46E99A63E080B1E1F6259D14D762"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1706-wk-Fact-C064B5575B953EC03631F6259D71FF8A"
      unitRef="usd">24100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d30743146e1725-wk-Fact-90C6D03D78FB16AD4508F6259D146864"
      unitRef="usd">24100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1745-wk-Fact-146D5C873CF04D08CB09F6259D1497DC"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1764-wk-Fact-F88D5F9F05E7BFB253EEF6259D1429AD"
      unitRef="usd">23000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d30743146e1783-wk-Fact-1F68043F220B63D3B2F6F6259D145AED"
      unitRef="usd">23000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1804-wk-Fact-D2C93812953C70ADCC5CF6259D14B856"
      unitRef="usd">1513800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1823-wk-Fact-FF2FA97FDBE842FE16CCF6259D147644"
      unitRef="usd">690200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d30743146e1842-wk-Fact-45DC92DA922C409480ECF6259D148382"
      unitRef="usd">2204000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e1862-wk-Fact-B16B983B90DD0814312DF6259D148C01"
      unitRef="usd">1536000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e1881-wk-Fact-6F5EA0FF7D7ED3EEFD7DF6259D14541C"
      unitRef="usd">666500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d30743146e1900-wk-Fact-DAFFB41F902E483857D1F6259D711323"
      unitRef="usd">2202500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2166-wk-Fact-DFA8A651C72D9A6B942CF6259D1418DD"
      unitRef="usd">230600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2185-wk-Fact-E94F520DF0D826D86EC5F6259D14EBE8"
      unitRef="usd">257600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d30743146e2204-wk-Fact-AE73E333F705A05D8817F6259D147947"
      unitRef="usd">488200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2224-wk-Fact-8496B14BC426126A12CEF6259D14E6D8"
      unitRef="usd">205900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2243-wk-Fact-9C09BD7064A8577961E6F6259D1480F7"
      unitRef="usd">216800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d30743146e2262-wk-Fact-D65F0235CE05D09F2A7EF6259D147B33"
      unitRef="usd">422700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2527-wk-Fact-FA8A2BAE4A974F96BDDFF6259D146BEF"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2546-wk-Fact-5FC5B516950978F4178CF6259D141313"
      unitRef="usd">120300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d30743146e2565-wk-Fact-08847A66A01F50B11866F6259D14870E"
      unitRef="usd">120300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2585-wk-Fact-2048B48A179DAE44BB6CF6259D146ACD"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2604-wk-Fact-3B64D4289E65ABB45D76F6259D712FC7"
      unitRef="usd">115600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d30743146e2623-wk-Fact-155481EC85308175F3AAF6259D1415D3"
      unitRef="usd">115600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2644-wk-Fact-31B94762E4F7B79483EDF6259D71A7D2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2663-wk-Fact-C162F4A1E7044F1626D9F6259D149CB0"
      unitRef="usd">47300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d30743146e2682-wk-Fact-87EBD07876C82386EAD6066D37F9A91A"
      unitRef="usd">47300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2702-wk-Fact-A82A09F05AC42E0A3FEDF6259D14919E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2721-wk-Fact-8E17015DD7FC21CD30B7F6259D1412C1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d30743146e2740-wk-Fact-F459D01B7380E2C04184066DA807B079"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2761-wk-Fact-2FD644B3F3B51B3908D9F6259D143EAA"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2780-wk-Fact-30386F0630EAF2D73028F6259D71DCF3"
      unitRef="usd">16800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d30743146e2799-wk-Fact-53973CF3E5D2A278A7DBF6259D144F64"
      unitRef="usd">16800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2819-wk-Fact-9274106D7011C9854AA1F6259D148616"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2838-wk-Fact-2A718D30B914A6602288F6259D1435BC"
      unitRef="usd">11200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d30743146e2857-wk-Fact-20503103CFFAD67C6160F6259D714A88"
      unitRef="usd">11200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2878-wk-Fact-07E1A5970172AEAE6D58F6259D14CCF0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2897-wk-Fact-59BDF5967BFBA8373037F6259D71D542"
      unitRef="usd">184400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d30743146e2916-wk-Fact-2F03D5C2C308CC6A4245F6259D14514E"
      unitRef="usd">184400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e2936-wk-Fact-8ADF700AF36D092D5F4DF6259D141187"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e2955-wk-Fact-B811B5F8E7796A46E4D2F6259D144DE4"
      unitRef="usd">126800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d30743146e2974-wk-Fact-55261E1123EFF447F567F6259D140B33"
      unitRef="usd">126800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e3241-wk-Fact-9BF1FBEF7231A3A83767F6259D14DC9E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e3260-wk-Fact-DCB378AA7B9AE57BF4CAF6259D14F296"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d30743146e3279-wk-Fact-081CEAA76EE94875CB83F6259D14A29B"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e3299-wk-Fact-E39BAE16523827156DE2F6259D71944C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e3318-wk-Fact-EFDD0C40706B00508522F6259D14003A"
      unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d30743146e3337-wk-Fact-418C55BF288D562036B3F6259D1474AF"
      unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e3363-wk-Fact-6499A5A1F645D47C9A67F6259D71B5B1"
      unitRef="usd">1744400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e3382-wk-Fact-4C9FF429CDEFF01B635EF6259D140569"
      unitRef="usd">1135900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30743146e3401-wk-Fact-C3F1908781ECB2F108F9F6259D62D489"
      unitRef="usd">2880300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e3421-wk-Fact-AF41D42B035080F44111F6259D14CB18"
      unitRef="usd">1741900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e3440-wk-Fact-C319A772368453B5E72CF6259D146BBB"
      unitRef="usd">1015600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30743146e3460-wk-Fact-2B45585D36E41B2DB864F6259D23ADFD"
      unitRef="usd">2757500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4019-wk-Fact-47C77708B856C496FA90F6259DAFA4C6"
      unitRef="usd">1587500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4038-wk-Fact-2B53AFFC8D3C33F1CBA3F6259D047F6D"
      unitRef="usd">561500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d30743146e4057-wk-Fact-45F612077F5A8F11AB66F6259D04E4A9"
      unitRef="usd">2149000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4077-wk-Fact-8A68743F9EADC51C9565F6259D0459C0"
      unitRef="usd">1554700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4096-wk-Fact-AEC1505CF4AA2D7F20EFF6259DB223FB"
      unitRef="usd">519000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TecfideraMember"
      decimals="-5"
      id="d30743146e4116-wk-Fact-AFF4EBDCC82A5BC29008F6259D042831"
      unitRef="usd">2073700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4131-wk-Fact-8A2A78DB7A9EA91C741DF6259DB01152"
      unitRef="usd">707000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4150-wk-Fact-98E74DB402BAA220E6C8F6259D040101"
      unitRef="usd">348300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d30743146e4169-wk-Fact-AD0AA839E32A5FB88E35F6259D0487AD"
      unitRef="usd">1055300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4189-wk-Fact-30CAAAC724A6E1F86C78F6259DB20083"
      unitRef="usd">816000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4208-wk-Fact-7EF5C05B56145C2AC449F6259D04208D"
      unitRef="usd">359800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d30743146e4227-wk-Fact-BB304E20F0087B52AAEFF6259CF54804"
      unitRef="usd">1175800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4248-wk-Fact-D0FA133AA1CFD639A6FAF6259D042C19"
      unitRef="usd">509300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4267-wk-Fact-FC3A827BEE59E6253160F6259D047347"
      unitRef="usd">426400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d30743146e4286-wk-Fact-BBD5E1AF4D8EE02F98A2F6259D04C923"
      unitRef="usd">935700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4306-wk-Fact-3AB212B870B2ED659BD9F6259CF5D1F1"
      unitRef="usd">515200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4325-wk-Fact-4E55158B65F38CF178E0F6259D04F657"
      unitRef="usd">414100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d30743146e4344-wk-Fact-4B76965910CF9CA9B2BBF6259D0486F5"
      unitRef="usd">929300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4365-wk-Fact-D8018242BEABA2F8A3D4F6259DB23F91"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4384-wk-Fact-9E14C1F194C71A40E0FEF6259DB12078"
      unitRef="usd">47000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d30743146e4403-wk-Fact-15359F4F50A35787B53DF6259D04F6FC"
      unitRef="usd">47000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4423-wk-Fact-559AB257F0859FE98E1CF6259D04A06D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4442-wk-Fact-6F942811F6E0CF93EE71F6259D04BF07"
      unitRef="usd">47400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d30743146e4461-wk-Fact-989D4DE74F68BD370D23F6259D045DC8"
      unitRef="usd">47400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4482-wk-Fact-250A0DE76B823D622E60F6259DB2D26E"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4501-wk-Fact-31B61DA8DFB21D29C453F6259DB2ABC6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d30743146e4520-wk-Fact-8348FB26B4F7C30C57D2F6259DB2405C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4540-wk-Fact-018D5D2F82E77ECE6EBFF6259D04DA74"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4559-wk-Fact-F7F95C1D865685DDFA93F6259D047E35"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember"
      decimals="-5"
      id="d30743146e4578-wk-Fact-29524DB7113B14E2AA87F6259D045330"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4599-wk-Fact-142F6EAA2D143FEE0439F6259DB204EE"
      unitRef="usd">2803800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4618-wk-Fact-51CC373CE64B8E7A760AF6259D04FE41"
      unitRef="usd">1383200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d30743146e4637-wk-Fact-7B163BA5F835D720F26FF6259D049210"
      unitRef="usd">4187000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4657-wk-Fact-71D40CF366898DC6A671F6259CF56076"
      unitRef="usd">2885900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4676-wk-Fact-C9AA8FE4DD4D40E4C151F6259D0430C3"
      unitRef="usd">1341700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d30743146e4695-wk-Fact-820DFD41FB565DA6E5D1F6259DB24EDD"
      unitRef="usd">4227600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e4963-wk-Fact-4CB6B7669741D8791157F6259D04115A"
      unitRef="usd">453900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e4982-wk-Fact-7B66565BD011BAB22F85F6259D041064"
      unitRef="usd">552800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d30743146e5001-wk-Fact-50F237B84AC227EDFD62F6259DB25FE1"
      unitRef="usd">1006700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5021-wk-Fact-77D266FFC916C5E4DA59F6259D04D0BB"
      unitRef="usd">393900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5040-wk-Fact-E79C8FAA6D876455197CF6259D04F664"
      unitRef="usd">392700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d30743146e5059-wk-Fact-7C6FFE07A275B2989878F6259DB2718D"
      unitRef="usd">786600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5326-wk-Fact-A6FE922C63A54D025EEBF6259DB27124"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5345-wk-Fact-1392A4F3BA3963F875FAF6259D049826"
      unitRef="usd">244300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d30743146e5364-wk-Fact-6D805CBD6DDD780AA0EEF6259DB2687F"
      unitRef="usd">244300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5384-wk-Fact-BB638F6BEE9198B157A4F6259DB2CBDB"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5403-wk-Fact-4A41922045AF042F70E2F6259D049B76"
      unitRef="usd">236500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d30743146e5422-wk-Fact-5AB96724C2616287DAF9F6259D0460F5"
      unitRef="usd">236500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5443-wk-Fact-73253260B589F1CAD313F6259DB266FC"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5462-wk-Fact-7795ED022CF801DF9DC8F6259D0491C7"
      unitRef="usd">83000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d30743146e5481-wk-Fact-2EA28AD9B372CCB805DC066EB47E03E9"
      unitRef="usd">83000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5501-wk-Fact-9256AB9804C4101F7327F6259D042249"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5520-wk-Fact-99B62F8D355D759A4B9EF6259D04CD8D"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d30743146e5539-wk-Fact-FE388B9B0891F57A981B066EE4931C72"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5560-wk-Fact-4F07654D54AA3B1C827AF6259D045EBE"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5579-wk-Fact-A47948DC0912515B3240F6259DAF1323"
      unitRef="usd">31500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d30743146e5598-wk-Fact-AFE12B14B5F046D946BDF6259DB22D7A"
      unitRef="usd">31500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5618-wk-Fact-3E8DE411ECB19241DE0CF6259D041080"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5637-wk-Fact-6C5D2EBB823DD92B4AE5F6259CF59868"
      unitRef="usd">17800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d30743146e5656-wk-Fact-C72A81913DC78F182FEBF6259D045A4C"
      unitRef="usd">17800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5677-wk-Fact-8E57A52365F7A000D0B9F6259D04DBCF"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5696-wk-Fact-FE972358FD466C0F7766F6259D042210"
      unitRef="usd">358800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d30743146e5715-wk-Fact-44353DD72BC13C0DD89EF6259DB1C7FE"
      unitRef="usd">358800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e5735-wk-Fact-4C3C9D5567FAA88E0059F6259DB15C77"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e5754-wk-Fact-0A70BEC3DEEA936B1DBAF6259DB21B20"
      unitRef="usd">254300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d30743146e5773-wk-Fact-3C255406811C3CEDFCCBF6259D045AFA"
      unitRef="usd">254300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e6040-wk-Fact-2E84ED9D1FEF72BF78F3F6259D04C858"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e6059-wk-Fact-DF6E50827B3EF7639D70F6259D04453D"
      unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d30743146e6078-wk-Fact-FF94B2A6BF07CAD3DCFDF6259DB269F4"
      unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e6098-wk-Fact-0DD452C0CF6C3C9090F9F6259D044318"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e6117-wk-Fact-BA0665F3EEDB0C8098AEF6259D04B618"
      unitRef="usd">12500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d30743146e6136-wk-Fact-C471FE00E334D212C773F6259D040339"
      unitRef="usd">12500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e6163-wk-Fact-FFF155C081A1B02826F2F6259D043036"
      unitRef="usd">3257700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e6182-wk-Fact-7AA73261CFAC30E41E0FF6259D04F040"
      unitRef="usd">2302600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30743146e6201-wk-Fact-AF0A6B5FA115FD6CFF39F6259D1417AF"
      unitRef="usd">5560300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d30743146e6221-wk-Fact-DA93FA9B85AD9BB6744FF6259D041B2B"
      unitRef="usd">3279800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d30743146e6240-wk-Fact-24564DA590B243C1DC14F6259D048451"
      unitRef="usd">2001200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d30743146e6260-wk-Fact-C04EBFA41990DA29BFA8F6259D52D55F"
      unitRef="usd">5281000000.0</us-gaap:Revenues>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="INF"
      id="d30743146e6276-wk-Fact-4EF889880D25502BBBF8F6259D81E5FD"
      unitRef="number">0.305</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="INF"
      id="d30743146e6280-wk-Fact-9A7945088451B8278871F6259DA2A679"
      unitRef="number">0.182</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="INF"
      id="d30743146e6292-wk-Fact-267A1D8E541BF764EC87F6259D812BEF"
      unitRef="number">0.309</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="INF"
      id="d30743146e6297-wk-Fact-A47FD9637CC5C1BB2BF8F6259D81D36D"
      unitRef="number">0.163</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="3"
      id="d30743146e6312-wk-Fact-12DE8D784D22C901519AF6259D812A93"
      unitRef="number">0.325</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d30743146e6316-wk-Fact-57F7DEC4BB03B3C10E46F6259D810B14"
      unitRef="number">0.186</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="3"
      id="d30743146e6328-wk-Fact-D7CEADACFC634DCD0EC6F6259D81300E"
      unitRef="number">0.332</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d30743146e6333-wk-Fact-08634AF63AFF4AFFE764F6259D813307"
      unitRef="number">0.173</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-EE62B1AE759D04E07A56F6259DC21F80-0-wk-Fact-945BBD1D9D4A2FAF31F4F6259D819C6F">&lt;div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;127.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;888.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;308.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,391.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,710.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(41.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(42.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(189.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(827.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,017.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(505.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(11.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(639.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;124.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;905.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;32.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,062.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d30743146e6480-wk-Fact-32CA86FF20F8660C5FD4F6259D330CA6"
      unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d30743146e6499-wk-Fact-204088D903D7439A7EA9F6259D33D8F5"
      unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d30743146e6518-wk-Fact-8FD5D45BBD1278A8AF15F6259D33AC75"
      unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30743146e6538-wk-Fact-63399ADB4FB449F0D728F6259D43BE17"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d30743146e6553-wk-Fact-7E77D31860E9844B5408F6259D334031"
      unitRef="usd">308800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d30743146e6572-wk-Fact-E4F2EB0DCA86D270ACC1F6259D3347C2"
      unitRef="usd">1391000000.0</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d30743146e6591-wk-Fact-878B41A9906C25499AFEF6259D3360BD"
      unitRef="usd">10600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30743146e6611-wk-Fact-EDD2105C4E2122A6B1FCF6259D33ADDA"
      unitRef="usd">1710400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d30743146e6631-wk-Fact-E183E4D34D4F167F6984F6259D333ED6"
      unitRef="usd">400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d30743146e6651-wk-Fact-FBAC4DC61EFD61A86D6EF6259D33B265"
      unitRef="usd">41900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d30743146e6671-wk-Fact-33E73A4C47F786FDCD35F6259D33E34B"
      unitRef="usd">100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30743146e6692-wk-Fact-4FAC708444742DACAF48F6259D338976"
      unitRef="usd">42400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d30743146e6713-wk-Fact-620B143845EC65A2EA49F6259D332C40"
      unitRef="usd">189600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d30743146e6733-wk-Fact-688F0C291EF49904A209F6259D33ED89"
      unitRef="usd">827600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d30743146e6753-wk-Fact-6E43026B342D1BF26E49F6259D33EFE2"
      unitRef="usd">600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30743146e6774-wk-Fact-8B7427C8075A8D2D30B1F6259D33A6E6"
      unitRef="usd">1017800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d30743146e6795-wk-Fact-ABACAA696C27EBDFA71CF6259D33CD5D"
      unitRef="usd">121900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d30743146e6815-wk-Fact-B0B1172FA2A9BC6C06C5F6259D339351"
      unitRef="usd">505200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d30743146e6835-wk-Fact-FFAC713B85AEE9AEB8A7F6259D33F23A"
      unitRef="usd">11900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30743146e6856-wk-Fact-FA21E3F6769FA6AB47FBF6259D334D3A"
      unitRef="usd">639000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d30743146e6882-wk-Fact-822EB7DEE8DB6192BD4BF6259D33BDAD"
      unitRef="usd">124700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d30743146e6901-wk-Fact-442F8132847B9EAFD548F6259D331DAB"
      unitRef="usd">905100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d30743146e6920-wk-Fact-08C12B957E0CDC496163F6259D3388F3"
      unitRef="usd">32700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30743146e6940-wk-Fact-4A297960FBEB60C1CF10F6259D33A629"
      unitRef="usd">1062500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-F0DD8BCEB421203AF994F6259DC27D36-0-wk-Fact-47687C9AE448926A79ACF6259D813621">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;199.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;863.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,062.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,051.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d30743146e7040-wk-Fact-FDEE08D5EB349F05B66CF6259D4311E0"
      unitRef="usd">199000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d30743146e7059-wk-Fact-1F97C77CDB99BBFE3BA0F6259D434B75"
      unitRef="usd">176600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d30743146e7074-wk-Fact-664C6114E7A93753808DF6259D5202EB"
      unitRef="usd">863500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d30743146e7093-wk-Fact-2332C6EB86868144FE27F6259D430E8C"
      unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30743146e7118-wk-Fact-4A297960FBEB60C1CF10F6259D33A629"
      unitRef="usd">1062500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30743146e7137-wk-Fact-63399ADB4FB449F0D728F6259D43BE17"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-73C1775D69369635245DF6259DC2DACF-0-wk-Fact-A5C712DB98040A54B690F6259D816371">&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;377.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;359.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;768.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;708.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;199.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;325.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;576.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;490.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,093.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;933.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7359-wk-Fact-7DECC4F6C2FEA4925F63F6259D81BB73"
      unitRef="usd">377200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7378-wk-Fact-8CC966398D52F1AF1D65F6259D8134CA"
      unitRef="usd">359000000.0</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7397-wk-Fact-C142F4A8D970B81D58D8F6259D81A395"
      unitRef="usd">768000000.0</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7417-wk-Fact-4B96DEAB241EC04E4B06F6259D81C6A2"
      unitRef="usd">708600000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7432-wk-Fact-73761669D7215D054E4BF6259D811849"
      unitRef="usd">199200000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7451-wk-Fact-F1AF98AD1024576459F4F6259D8185B5"
      unitRef="usd">131400000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7470-wk-Fact-FFE26A4CA65381EA295BF6259D81965E"
      unitRef="usd">325800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d30743146e7490-wk-Fact-7446CB6773DD014EA3A0F6259D818CEE"
      unitRef="usd">225000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30743146e7515-wk-Fact-5B9EC13DF76E0C64D4C9F6259D71CF78"
      unitRef="usd">576400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30743146e7534-wk-Fact-09FB62AF2F4874DE36DDF6259D330ABD"
      unitRef="usd">490400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30743146e7553-wk-Fact-2EBAB557DC84FE08A211F6259D622116"
      unitRef="usd">1093800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d30743146e7573-wk-Fact-2091EADF344F99481D24F6259D621286"
      unitRef="usd">933600000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-D1CBDFFCCF56483F90B9F6259DC2B557-0-wk-Fact-E2F9EE5C5F6984AA550AF6259D81B9DF">&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;105.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;369.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;219.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;160.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;108.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;452.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;273.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e7884-wk-Fact-3CCE4C6E7F03BB18B3B3F6259D5242B4"
      unitRef="usd">-100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e7904-wk-Fact-FAA697E758908811AAD8F6259D529979"
      unitRef="usd">-2500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e7924-wk-Fact-EE25AFD9C764122DEC99F6259D52FB97"
      unitRef="usd">-500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e7945-wk-Fact-9284769667647B848009F6259D52B257"
      unitRef="usd">-7200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e7961-wk-Fact-EF4EA71EF902CA03BC44F6259D5251AE"
      unitRef="usd">52200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e7980-wk-Fact-70498F47F0A907BAC4B9F6259D523014"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e7999-wk-Fact-E2248DBE1FF929F9333EF6259D525BC7"
      unitRef="usd">77000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30743146e8019-wk-Fact-DF62E636750373112917F6259D52F8BA"
      unitRef="usd">32600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d30743146e8117-wk-Fact-72B2AF762786D499F545F6259D52C7D9"
      unitRef="usd">2700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d30743146e8136-wk-Fact-60394CA173CE6CD2DB78F6259D52FE1B"
      unitRef="usd">17300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d30743146e8155-wk-Fact-B66D7F1EC0D5017C0393F6259D527B4D"
      unitRef="usd">6600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d30743146e8175-wk-Fact-B18F299500A9FB259A7DF6259D52A275"
      unitRef="usd">27900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d30743146e8195-wk-Fact-E08F00601211B6F5AAADF6259D525024"
      unitRef="usd">105200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d30743146e8214-wk-Fact-E1478BCD82606A068B0BF6259D71BB8F"
      unitRef="usd">79100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d30743146e8233-wk-Fact-F627DF65E314112AF99CF6259D523A5D"
      unitRef="usd">369300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d30743146e8253-wk-Fact-E0476FADCA4DA83E9CD3F6259D52964E"
      unitRef="usd">219700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8278-wk-Fact-CC0CC7DC660BF5C38699F6259D334216"
      unitRef="usd">160000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8297-wk-Fact-7F5F6340692D7DDE0318F6259D814253"
      unitRef="usd">108600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8316-wk-Fact-67EF5E7D2920FD15A8F6F6259D6276B9"
      unitRef="usd">452400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8336-wk-Fact-18A0A15D9AE9D88D7F55F6259D235B1F"
      unitRef="usd">273000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8359-wk-Fact-33EE9637A600AB8233E5F6259D81A815"
      unitRef="usd">34500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8363-wk-Fact-CD868EEEBE689806D26AF6259DA21FDD"
      unitRef="usd">241300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8367-wk-Fact-85679E797E24A7A6E7F6F6259D8197A5"
      unitRef="usd">47600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_biib_BioverativMember_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d30743146e8372-wk-Fact-C5E01CC71F4883F56AF3F6259D818136"
      unitRef="usd">94600000</us-gaap:Revenues>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-7A81D1BFE407E6284C27F6259DC2E5EC-0-wk-Fact-848C4565D25B6730AD54F6259D911FBB">Inventory&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;205.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;427.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;144.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;776.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;776.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;776.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2019 we sold to Bioverativ most of the remaining hemophilia-related inventory on hand with a cost basis totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$173.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#xf8;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$890.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, subject to certain working capital adjustments and other contractual terms. As a result, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$20.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of work in process inventory was reclassified to assets held for sale in our condensed consolidated balance sheets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred. In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#xf8;d facility to FUJIFILM at carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the proposed divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-B2341BA6B4AF8947A98AF6259DC2B3A7-0-wk-Fact-ACCBA893D584DFDFA1C1F6259D71088F">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;205.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;427.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;606.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;144.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;776.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;776.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;929.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;776.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30715280e865-wk-Fact-86139E79C0CAFA15C552F6259D81D860"
      unitRef="usd">205000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30715280e884-wk-Fact-3C6BD89798D140C3B8B1F6259D43D57E"
      unitRef="usd">196300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30715280e899-wk-Fact-2381935E0EFB8C0412D7F6259D434427"
      unitRef="usd">427600000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30715280e918-wk-Fact-B803963A1A14069361C4F6259D43FDA3"
      unitRef="usd">606700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30715280e938-wk-Fact-859323E926FF4F6FB830F6259D4309E9"
      unitRef="usd">144100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30715280e957-wk-Fact-299E58E623BA9A6D08BCF6259D4317FA"
      unitRef="usd">133500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30715280e982-wk-Fact-3E2CEEE02EE1AA0C05D3F6259D9169FE"
      unitRef="usd">776700000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30715280e1001-wk-Fact-9181D14105DE5410A84AF6259D431780"
      unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30715280e1103-wk-Fact-55C665FC64E6E531FF29F6259D33D65D"
      unitRef="usd">776700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30715280e1122-wk-Fact-8C6C4783CB833F71AD59F6259D2325D5"
      unitRef="usd">929900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30715280e1137-wk-Fact-1C2B5E76F76A6337A79DF6259D7155B9"
      unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30715280e1156-wk-Fact-456048EAFFAFF27385A4F6259D4376B9"
      unitRef="usd">6600000</us-gaap:InventoryNoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30715280e1181-wk-Fact-3E2CEEE02EE1AA0C05D3F6259D9169FE"
      unitRef="usd">776700000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30715280e1200-wk-Fact-9181D14105DE5410A84AF6259D431780"
      unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
    <biib:InventorysoldtoBioverativcost
      contextRef="FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember"
      decimals="-5"
      id="d30715280e1220-wk-Fact-E1B3C73CB703A6BD4210F6259D91B21E"
      unitRef="usd">173500000</biib:InventorysoldtoBioverativcost>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30715280e1233-wk-Fact-46EFC128053751FC2172F6259D43F6DF"
      unitRef="usd">890000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="FI2019Q2_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember"
      decimals="-5"
      id="d30715280e1237-wk-Fact-772C51D00284A1513CB1F6259D23E93B"
      unitRef="usd">20600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-12BB1477257559D94BD8F6259DC24028-0-wk-Fact-D96926CAFD7855E9A54DF6259D71363E">Intangible Assets and Goodwill&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(542.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2,754.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;251.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,734.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,175.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,175.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&#160;and&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&#160;rights&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&#160;patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,449.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,189.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,330.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,308.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,426.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,745.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,681.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,727.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization and impairment of acquired intangible assets totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$138.3 million&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$107.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$211.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. The decrease in amortization and impairment of acquired intangible assets was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$246.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of NST on June 7, 2019, we acquired IPR&amp;amp;D programs with an estimated fair value of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$700.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,933.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and the net book value of the TECFIDERA asset as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$55.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our TECFIDERA license rights, please read Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the second quarter of 2019. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;130.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;255.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;210.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reclassification of goodwill to assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,749.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The reclassification of goodwill to assets held for sale relates to an allocation based upon the relative fair value of the proposed divestiture of our Hiller&#xf8;d, Denmark manufacturing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our Hiller&#xf8;d, Denmark manufacturing operations meeting the criteria to be classified as held for sale due to the proposed divestiture, goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the proposed divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;Other includes changes related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-2AF584EEF22EBB27741FF6259DC28B3B-0-wk-Fact-8BB5E502E15FE3C6A986F6259D7153BC">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(542.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;543.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(542.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2,754.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;251.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,005.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,734.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,175.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,175.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;476.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&#160;and&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&#160;rights&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&#160;patents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1,449.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,189.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,638.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,330.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,308.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8,426.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4,745.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,681.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,727.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(4,607.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,120.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1130-wk-Fact-994AE09CC631B6B907DEF6259D817BD1"
      unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1149-wk-Fact-C16CEF01B386A6026447F6259D917F00"
      unitRef="usd">542400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1170-wk-Fact-03DF73FC86DFB50D44A1F6259D91BF50"
      unitRef="usd">900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1189-wk-Fact-532E64959D73AD11A406F6259D144586"
      unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1208-wk-Fact-97D971AC6A8F78DDA9ADF6259D9176D0"
      unitRef="usd">542300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1229-wk-Fact-FD14907E23F8EFBDB645F6259D916C1C"
      unitRef="usd">1000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d30722939e1257-wk-Fact-6C0806524480AC621679F6259D710FCA"
      unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d30722939e1276-wk-Fact-BA2E2DA8D2356A1A4BA0F6259D7155F0"
      unitRef="usd">2754100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d30722939e1297-wk-Fact-286EF2EAD80FDE81B3DEF6259D91A5B7"
      unitRef="usd">251200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d30722939e1316-wk-Fact-EB6CE9B71175A11302B9F6259D91F072"
      unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d30722939e1335-wk-Fact-4063D7E18EFD3AEEA951F6259D91BD10"
      unitRef="usd">2734800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d30722939e1356-wk-Fact-EDAF46D75F2E8FACC5F7F6259D91B664"
      unitRef="usd">270500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d30722939e1386-wk-Fact-7226ABB795932687EAC7F6259D71008D"
      unitRef="usd">1175600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d30722939e1405-wk-Fact-E82B21AE7932A7892D1AF6259D811A3E"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d30722939e1425-wk-Fact-7226ABB795932687EAC7F6259D71008D"
      unitRef="usd">1175600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d30722939e1444-wk-Fact-2EE64B696FC270FDBA39F6259D71CEAB"
      unitRef="usd">476000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d30722939e1463-wk-Fact-1869D2AC0D4E2508517CF6259D710C12"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d30722939e1483-wk-Fact-2EE64B696FC270FDBA39F6259D71CEAB"
      unitRef="usd">476000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d30722939e1516-wk-Fact-3FB0BDE5AE83E9249197F6259D918875"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d30722939e1535-wk-Fact-548F9B1C1D749871C066F6259D71A5AE"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d30722939e1555-wk-Fact-3FB0BDE5AE83E9249197F6259D918875"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d30722939e1574-wk-Fact-86BB5650A09FCE953479F6259D81BA6D"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d30722939e1593-wk-Fact-80F471F5457EE70103BFF6259D91A068"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d30722939e1613-wk-Fact-86BB5650A09FCE953479F6259D81BA6D"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1646-wk-Fact-2D2A27A171B0A04C280EF6259D9189F7"
      unitRef="usd">3638700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1665-wk-Fact-210CEAE74230A1E120DDF6259D040494"
      unitRef="usd">1449100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1686-wk-Fact-8147DBAFFF35D7B477D2F6259D91297E"
      unitRef="usd">2189600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1705-wk-Fact-17D11B736CFEDA6E54C8F6259D9182E7"
      unitRef="usd">3638700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1724-wk-Fact-E0B7CC09E3505ECBB5A4F6259D91B30B"
      unitRef="usd">1330200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1745-wk-Fact-B2EF4B089202E2295B10F6259D71AB51"
      unitRef="usd">2308500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e1780-wk-Fact-ED3E9AC768467F96C658F6259D91D549"
      unitRef="usd">8426900000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e1799-wk-Fact-F807D5F02EAF0C37D617F6259DB25919"
      unitRef="usd">4745600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e1820-wk-Fact-C44244A5766C4B25316FF6259D233F2E"
      unitRef="usd">3681300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30722939e1839-wk-Fact-475618DC56CE76F74122F6259D91B2BB"
      unitRef="usd">7727300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30722939e1858-wk-Fact-61C718BBC07A6EABB63AF6259D918768"
      unitRef="usd">4607300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30722939e1879-wk-Fact-8B92C2F3788E45ADA189F6259D33FAEA"
      unitRef="usd">3120000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30722939e1907-wk-Fact-B3BD168EB3801729A63FF6259D621F86"
      unitRef="usd">70100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30722939e1915-wk-Fact-7779EF5CE57D18E76221F6259D624E02"
      unitRef="usd">107400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30722939e1920-wk-Fact-3A52F769615790191266F6259D23382B"
      unitRef="usd">211300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-5"
      id="d30722939e1946-wk-Fact-5865D5167C6731FB71C4F6259D71F434"
      unitRef="usd">246600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30722939e1956-wk-Fact-882BC58AAE3F5F88E247063DD62A09C3"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1974-wk-Fact-48F1CDCDD335C672AA30F6259D71D1A5"
      unitRef="usd">1933300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      decimals="-5"
      id="d30722939e1982-wk-Fact-E6D590D6A07A5D550192F6259D715122"
      unitRef="usd">55200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-71B85E910893DAE87276F6259DC2D305-0-wk-Fact-6B738CD867B94EC6ED0DF6259D710BF5">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;130.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;255.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;215.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;210.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e2069-wk-Fact-452E8867A439219D3171F6259D4343A3"
      unitRef="usd">130000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e2084-wk-Fact-2AFA437E0CFA9474DE07F6259D43B5A8"
      unitRef="usd">255000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e2104-wk-Fact-614BE69D44D6A09F12C2F6259D4334A4"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e2124-wk-Fact-4545196938FCCCACA0ACF6259D439D86"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e2144-wk-Fact-F636552FD8A2F319B246F6259D4334A0"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e2164-wk-Fact-2AC87C200C218923F95AF6259D4333DE"
      unitRef="usd">210000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-B8A95F4196AD4074EED7F6259DC27451-0-wk-Fact-4EEF552E83305E3B6487F6259D71DFFA">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,706.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;112.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reclassification of goodwill to assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,749.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30722939e2247-wk-Fact-A45E521E0B1F5359C200F6259D335514"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30722939e2262-wk-Fact-81CF457602F010BC4D59063DD61C2F08"
      unitRef="usd">112600000</us-gaap:Goodwill>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30722939e2282-wk-Fact-5BC5E181CF6FC316A83AF6259D2318A3"
      unitRef="usd">69500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30722939e2303-wk-Fact-CAFDCCC552573C3AAEBCF6259D91B8D1"
      unitRef="usd">-300000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30722939e2329-wk-Fact-D63D508540010D880C00F6259D336D62"
      unitRef="usd">5749200000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="FI2019Q2"
      decimals="-6"
      id="d30722939e2370-wk-Fact-2FA1F9D964B8AB9FC3A8F6259D713CF6"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-29F610442C231145A7D3F6259DC2EE8E-0-wk-Fact-CED09210624284EF1067F6259DB19B02">Fair Value Measurements&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,120.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,120.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,687.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,687.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;604.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;604.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;246.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;246.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;510.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;333.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;88.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;88.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,286.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;563.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,102.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,050.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairments of our assets measured and carried at fair value during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our agreement with Ionis, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing services and our option &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;pricing valuation model, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,507.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,491.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,032.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;996.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;995.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,867.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,738.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,745.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,737.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,953.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,722.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,802.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,360.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,948.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,037.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;421.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;498.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;523.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;499.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;499.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$255.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$265.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and expected timing of achieving certain development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to an increase in interest rates used to revalue our contingent consideration liabilities, the passage of time and a milestone payment.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9E6A6BCA7252AFE7AB65F6259DC2D5C8-0-wk-Fact-6E5EE5CE855E8B713387F6259DB168EC">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,120.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,120.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,687.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,687.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;604.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;604.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;246.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;246.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;510.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;333.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;88.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;88.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,286.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;176.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4,109.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,459.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;969.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;563.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,102.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,050.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1021-wk-Fact-40FC6302DAB5019D304DF6259D43FAC4"
      unitRef="usd">1120400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1040-wk-Fact-CC9BCB3132F32264AD04F6259D339EA3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1059-wk-Fact-CE34FC526B278B0DAA7AF6259D332F1E"
      unitRef="usd">1120400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1079-wk-Fact-A2668FE25BD6C6AEE336F6259D330545"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1176-wk-Fact-E5D2BEE0C78D4660DDACF6259D438BDD"
      unitRef="usd">1687700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1195-wk-Fact-2F4266E65D5B09BDA91CF6259D43D67F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1214-wk-Fact-416CE8D1E601DA138F86F6259D43227A"
      unitRef="usd">1687700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1234-wk-Fact-0825230FABBA91AA1733F6259D33F026"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1254-wk-Fact-34E41CBA0C06B38C0F60F6259D43442E"
      unitRef="usd">604400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1273-wk-Fact-4524B0F9E4C395C897C1F6259D43DE8B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1292-wk-Fact-919537CE190B196632CAF6259D33D1E6"
      unitRef="usd">604400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1312-wk-Fact-C55F0AFB8C2FA9B8E08AF6259D43BB3F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1332-wk-Fact-581F5D00974B7915ADE2F6259D4388DA"
      unitRef="usd">246000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1351-wk-Fact-D81CF2727CF5C9056081F6259D33834C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1370-wk-Fact-A6E5F27E1AD9EE617856F6259D43A3DD"
      unitRef="usd">246000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1390-wk-Fact-A3DA2CFB8BDA16F9E0B0F6259D431D2C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1410-wk-Fact-25C4ABEDDC1D7880A3FFF6259D43848E"
      unitRef="usd">510000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1429-wk-Fact-9693C37F6F7414D7864CF6259D33E756"
      unitRef="usd">176600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1448-wk-Fact-7B2F2892CC6E20620131F6259D43C6C1"
      unitRef="usd">333400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1468-wk-Fact-B33E5086C5A6E14DAEF1F6259D43CCEB"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1488-wk-Fact-03F5B0455AA183131E72F6259D43BE85"
      unitRef="usd">88200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1507-wk-Fact-FBC83B20A0F855C13DFBF6259D436335"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1526-wk-Fact-C2698E5726FF779DD5E7F6259D43CD91"
      unitRef="usd">88200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1546-wk-Fact-120D97D619F04009C015F6259D43A337"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1566-wk-Fact-33F9FA209E4438A2C705F6259D437F9D"
      unitRef="usd">29500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1585-wk-Fact-535DF14A1E3B2A5A4882F6259D3324D8"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1604-wk-Fact-2D3512B598DD529CCE31F6259D43906F"
      unitRef="usd">29500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1624-wk-Fact-82193BAD0D6A225F8465F6259D43892A"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1649-wk-Fact-1360F7F880C22EB0C9FDF6259D43DBFC"
      unitRef="usd">4286200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1668-wk-Fact-66EE3015EE4D6A08E3DEF6259D43B7D0"
      unitRef="usd">176600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1687-wk-Fact-64B3C2E1A044BD18CE37F6259D33C61E"
      unitRef="usd">4109600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1707-wk-Fact-19FDDFC8373972EEA7D1F6259D43ECA9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1810-wk-Fact-2DC400AFAA63C6B56354F6259D43DC6B"
      unitRef="usd">17500000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1829-wk-Fact-D06AAE3FC68A73DDE4ECF6259D43D189"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1848-wk-Fact-CFF9331EB4593C31F897F6259D437FE6"
      unitRef="usd">17500000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1868-wk-Fact-3A4B226C43561E28F992F6259D435662"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1883-wk-Fact-6F21BF6933C48630897EF6259D6267DF"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1902-wk-Fact-19D96FE7753EF0372F81F6259D43FBC3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1921-wk-Fact-0CC369BCB1078159803BF6259D33717B"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1941-wk-Fact-8E953F369AE23405D904F6259D33D116"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1966-wk-Fact-53FB5128E6E086860D7AF6259D436203"
      unitRef="usd">418800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e1985-wk-Fact-B98A597463543F8EA4F0F6259D432702"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2004-wk-Fact-E1D705F708CAB53A3733F6259D3336F7"
      unitRef="usd">17500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2024-wk-Fact-B20F10BC97DB233199C7F6259D432DEA"
      unitRef="usd">401300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2259-wk-Fact-D50FBD03024064FED0CCF6259DAD1827"
      unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2278-wk-Fact-DF8295B44D9F1AC1563EF6259DA9EE19"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2297-wk-Fact-0E48A92119B6BE5A8DCDF6259DA52FF8"
      unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2317-wk-Fact-13D1EF7FB1E29B895F9BF6259DABF825"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2414-wk-Fact-CC8335F0EDC96EB59D99F6259DA89576"
      unitRef="usd">2459200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2433-wk-Fact-53E7143F7EBFD279EC6CF6259DA9B91F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2452-wk-Fact-07AAF3B70ECB39450747F6259DADD029"
      unitRef="usd">2459200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2472-wk-Fact-15F365DA6104495626D1F6259DA46B56"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2492-wk-Fact-A0A95EB89646EF0EF423F6259DAAAD70"
      unitRef="usd">969600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2511-wk-Fact-44B8162048B15717D557F6259DACC52D"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2530-wk-Fact-EA9174FC2025E87595DFF6259DAD1070"
      unitRef="usd">969600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2550-wk-Fact-4447D2328DB7F335E023F6259DA459CA"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2570-wk-Fact-851F28B4C38DBF4E468EF6259DAAD5C1"
      unitRef="usd">260500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2589-wk-Fact-FD4852C1A660656A22B8F6259DB2B4E1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2608-wk-Fact-A2BAC8900A1887D43996F6259DAD38D5"
      unitRef="usd">260500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2628-wk-Fact-E9570EFF6182D86C1E80F6259DAC0A76"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2648-wk-Fact-1FE3030580E2EC290D6DF6259DAC352C"
      unitRef="usd">615400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2667-wk-Fact-0E6900FCD699047E6A23F6259DA570C3"
      unitRef="usd">51700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2686-wk-Fact-36AF9404359B419DD4FEF6259DABA207"
      unitRef="usd">563700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2706-wk-Fact-6BDBCB127A130A834489F6259DA6CE43"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2726-wk-Fact-0793612D5875F14AFFE1F6259DA97068"
      unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2745-wk-Fact-02AC6F0396FB23C6ADEBF6259DA8A048"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2764-wk-Fact-827B5508239835AD4BEFF6259DA7CDE7"
      unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2784-wk-Fact-6F1041C6272927D4C7CCF6259DAB47B3"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2804-wk-Fact-5AE9BB4560B65232094FF6259DAA4F7A"
      unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2823-wk-Fact-8A9AB1B1EAEEC8D68779F6259DAB7A35"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2842-wk-Fact-125A58F8F5948BA5EF3FF6259DADF3BA"
      unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2862-wk-Fact-89AE92DF17A85B9796ECF6259DA6E93B"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2887-wk-Fact-AB5EA34C12795E13F7C9F6259DABA835"
      unitRef="usd">5102500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2906-wk-Fact-ED0566593DECCBE62AEEF6259DAFD1AA"
      unitRef="usd">51700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2925-wk-Fact-E6AB31BCEEB643A085CEF6259DAA257E"
      unitRef="usd">5050800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e2945-wk-Fact-5292E62F6CF9FF640340F6259DA71636"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3048-wk-Fact-3FB7B352C73C49600C25F6259DAC7B6A"
      unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3067-wk-Fact-EED7B70E3BC79BDE1181F6259DACAE59"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3086-wk-Fact-3F85244626B6D3344164F6259DA535EE"
      unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3106-wk-Fact-426C00A6A73A12B46826F6259DA591C9"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3121-wk-Fact-D42F123F970F720ADC31F6259D62EEC1"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3140-wk-Fact-D33D938EA4AA77D0B800F6259DAC064D"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3159-wk-Fact-E4ABA679F5AA15A87E37F6259DA54D49"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3179-wk-Fact-A99860ED200D69AA8889F6259DA4429F"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3204-wk-Fact-671514CA5F76C68B29D7F6259DAABB18"
      unitRef="usd">434400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3223-wk-Fact-AF98BFE2187C849F86E7F6259DA4DDFA"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3242-wk-Fact-32529D5A372F335C8C1CF6259DA532E7"
      unitRef="usd">24600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e3262-wk-Fact-C2DF03F9580244D292DEF6259DAD6FCC"
      unitRef="usd">409800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d30733449e3282-wk-Fact-BC651C80D3E50690D757F6259DB1E809"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d30733449e3294-wk-Fact-75E090FD2E5109D73CE9F6259D04C8D9"
      unitRef="usd">0</us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-7E803F3F2BE7DF99CD51F6259DC272C8-0-wk-Fact-AFC9C15E92A2F500EC5EF6259DB14099">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,507.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,491.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,032.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;996.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;995.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,867.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,738.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,745.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,737.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,953.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,722.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,802.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,722.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6,360.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5,948.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,037.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,936.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d30733449e3557-wk-Fact-6995D65BDFE168D4199DF6259D62C531"
      unitRef="usd">1507500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d30733449e3576-wk-Fact-533BC3DA10002AA23F40F6259D62B816"
      unitRef="usd">1491100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d30733449e3595-wk-Fact-4BBF37D36635C1F03750F6259D62D2D0"
      unitRef="usd">1489500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d30733449e3615-wk-Fact-A47EDDBE23389EAB4630F6259D622BF0"
      unitRef="usd">1480800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d30733449e3630-wk-Fact-6D8818DEB40B59DC25E2F6259D62B819"
      unitRef="usd">1032300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d30733449e3649-wk-Fact-936A17991A934FD0D2E8F6259D6243AB"
      unitRef="usd">996000000.0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d30733449e3668-wk-Fact-E210481F074B2FFDC498F6259D62BD1F"
      unitRef="usd">1000400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d30733449e3688-wk-Fact-C41C0CA74AF223E91C81F6259D62E26A"
      unitRef="usd">995500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d30733449e3708-wk-Fact-CE7A88ABF1CAF68598C6F6259D62EA0D"
      unitRef="usd">1867400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d30733449e3727-wk-Fact-112B91E1E3C555E384BDF6259D622A23"
      unitRef="usd">1738700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d30733449e3746-wk-Fact-856843DF474B36B7478FF6259D62866B"
      unitRef="usd">1745100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d30733449e3766-wk-Fact-E18FDA6303655172D9E0F6259D62CA57"
      unitRef="usd">1737800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d30733449e3786-wk-Fact-12A420DD242B145FD257F6259D6200BE"
      unitRef="usd">1953200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d30733449e3805-wk-Fact-452DACC9F6884F3B4495F6259D6274BB"
      unitRef="usd">1722700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d30733449e3824-wk-Fact-D4387C793E1B38B75326F6259D62C353"
      unitRef="usd">1802600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d30733449e3844-wk-Fact-94AAFD48A42FB3DBCF03F6259D620DE7"
      unitRef="usd">1722400000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30733449e3869-wk-Fact-CB2F20886598B99758C2F6259D62F6E9"
      unitRef="usd">6360400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30733449e3888-wk-Fact-0727F0899F440E476D36F6259D623077"
      unitRef="usd">5948500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30733449e3907-wk-Fact-9792732673FD2702D132F6259D62EE06"
      unitRef="usd">6037600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30733449e3927-wk-Fact-09B9F415B98D31814295F6259D62E96A"
      unitRef="usd">5936500000</us-gaap:NotesPayable>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1A2EC7D2B719CCAEE003F6259DC21E1D-0-wk-Fact-E88B4E4950BC850DB2C1F6259DB2A619">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;421.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;498.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;523.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;499.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;499.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4172-wk-Fact-A1E437BDCEE9167EAA5FF6259D62030F"
      unitRef="usd">421300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4191-wk-Fact-81E5E276D86A7DDF2382F6259D62B8B6"
      unitRef="usd">498000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4210-wk-Fact-D42F123F970F720ADC31F6259D62EEC1"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4230-wk-Fact-D677736E015852AC6F47F6259D629C56"
      unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30733449e4245-wk-Fact-6ACFF58C36896C0429A5F6259D7118EC"
      unitRef="usd">20000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30733449e4265-wk-Fact-5D3F92B3D26D4145CC8DF6259D71B2D9"
      unitRef="usd">-1900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30733449e4284-wk-Fact-33C2C3244E3CB3B9F4C0F6259D6216FA"
      unitRef="usd">8500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30733449e4305-wk-Fact-7BA913E8E376F5770455F6259D81E7AA"
      unitRef="usd">3700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30733449e4326-wk-Fact-9C963564D325247874B0F6259D624EE3"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30733449e4345-wk-Fact-F5D3137F6CD013B5DD0EF6259D622B7B"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30733449e4364-wk-Fact-B0F11047D6F98621538DF6259D6272C7"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30733449e4384-wk-Fact-E487A22CF92D251C51FEF6259D62AE0A"
      unitRef="usd">20000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4410-wk-Fact-6F21BF6933C48630897EF6259D6267DF"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4429-wk-Fact-A224857E428533CE4514F6259D622CB7"
      unitRef="usd">499900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4448-wk-Fact-6F21BF6933C48630897EF6259D6267DF"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d30733449e4468-wk-Fact-A224857E428533CE4514F6259D622CB7"
      unitRef="usd">499900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30733449e4496-wk-Fact-A2620FE041BD1D7A71D1F6259DB0DB43"
      unitRef="usd">255100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30733449e4500-wk-Fact-864C9CD2E38C4A89A38BF6259DB1D37F"
      unitRef="usd">265000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1E47C018002B2B8EF10EF6259DC2278E-0-wk-Fact-398ACC0D67FD72A80707F6259D23515F">Financial Instruments&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;338.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;231.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;97.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;405.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;279.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;279.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,120.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;933.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;934.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;748.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;753.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;293.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;294.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;309.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;310.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;245.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,530.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,538.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;164.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;111.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;247.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;345.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;229.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;294.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;510.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,608.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,607.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;854.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;263.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;496.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,227.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,228.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,314.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,313.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,196.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,202.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,232.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,530.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,538.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,766.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,733.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,255.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,802.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$569.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$164.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was reflected as a component of other current assets in our condensed consolidated balance sheet, with the remaining balance included in investments and other assets. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is included in investments and other assets in our condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our Ionis stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The decrease in our strategic investment portfolio for the six months ended June 30, 2019, primarily reflects the sale of a portion of our investment in Ionis common stock for approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$213.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as well as the sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our June 2018 investment in Ionis common stock, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FDACD11091F6D9130302F6259DC28B9B-0-wk-Fact-4E9C3A1B65016ECCA67CF6259D62DA71">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;338.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;231.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;97.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;405.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;279.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;279.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,120.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d30735065e862-wk-Fact-83EF32994E216ADAA9AFF6259D81212B"
      unitRef="usd">338700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d30735065e881-wk-Fact-24381720F328FA9D28D7F6259D43B803"
      unitRef="usd">231200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d30735065e896-wk-Fact-38502867D524AB46E6B5F6259DA6F5C6"
      unitRef="usd">97000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d30735065e915-wk-Fact-0773FF878E42FBA74E80F6259D814223"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d30735065e935-wk-Fact-7D25EDF458AF49D16AC9F6259DA5A6BC"
      unitRef="usd">405700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d30735065e954-wk-Fact-073CA92425F991AC074EF6259DA7C18E"
      unitRef="usd">279500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d30735065e974-wk-Fact-9C056F4178A50877CEB6F6259D91B95B"
      unitRef="usd">279000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d30735065e993-wk-Fact-084DEEEB4B7A9236665CF6259D2306B3"
      unitRef="usd">194800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e1018-wk-Fact-51B97519F97A453073FAF6259CF5F3C8"
      unitRef="usd">1120400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e1037-wk-Fact-0FDD60946C90FDE18158F6259DA5B3C1"
      unitRef="usd">705500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4AF73C82A726295EB1DFF6259DC2CC82-0-wk-Fact-E8B99641E4C80C823C6AF6259D6226A6">The following tables summarize our marketable debt and equity securities:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;933.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;934.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;748.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;753.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;293.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;294.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;309.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;310.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;244.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;245.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,530.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,538.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;164.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;111.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;247.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;345.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;229.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;294.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;510.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,608.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,607.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;854.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;705.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;264.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;263.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;260.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;496.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;127.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;615.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1283-wk-Fact-1E618DE8D28AABB67E8AF6259D434BAC"
      unitRef="usd">933400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1302-wk-Fact-333BE0A532608DF4AE65F6259D43E4D4"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1321-wk-Fact-0D9970D0FB1217C54DF1F6259D438707"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1341-wk-Fact-FD6D703CBAAEE1974ACBF6259D435D5A"
      unitRef="usd">934500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1356-wk-Fact-46F86312FA2D96013D47F6259D43A9D9"
      unitRef="usd">748900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1375-wk-Fact-CF75BA0566D7FF4A42A8F6259D43AE40"
      unitRef="usd">4400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1394-wk-Fact-937E3B263A2BC1C4FA18F6259D437E50"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1415-wk-Fact-C59BFC500BD5A3776629F6259D435ECF"
      unitRef="usd">753200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1517-wk-Fact-5B54275B3AA7CC12D5B2F6259D43B22D"
      unitRef="usd">293600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1536-wk-Fact-AD523F87478B207DBDE3F6259D43B8EC"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1555-wk-Fact-A7B51A535158CFA44B7EF6259D437F21"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1575-wk-Fact-13114AECF35C02ED11E9F6259D439178"
      unitRef="usd">294000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1595-wk-Fact-19132C779D9DCE37519FF6259D43943C"
      unitRef="usd">309700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1614-wk-Fact-16B736FA83E3E2CCFEFFF6259D4379C8"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1633-wk-Fact-6892D2D90EDE5AF0F662F6259D4340F0"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1654-wk-Fact-BE1E31D9C0640C29E588F6259D439946"
      unitRef="usd">310400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1756-wk-Fact-218BD74E810F1DDD98C2F6259D43BF82"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1775-wk-Fact-C7642E78602450C6A151F6259D43AC99"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1794-wk-Fact-2D7D9E6A3853CD0E54A4F6259D43D797"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e1814-wk-Fact-5646483E484977998315F6259D43B861"
      unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1834-wk-Fact-453EA6405FE05386A7EFF6259D4360AE"
      unitRef="usd">244500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1853-wk-Fact-C1E0868547A29126B888F6259D438F3D"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1872-wk-Fact-1F1423BE035BEFDB9F42F6259D435C2D"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e1893-wk-Fact-70681206B8E1D76BD665F6259D435A75"
      unitRef="usd">245700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e1918-wk-Fact-11FC085268A7E6F3298BF6259D43F4FB"
      unitRef="usd">2530400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e1937-wk-Fact-3E17448BAD55E8CB3A41F6259D43343B"
      unitRef="usd">8300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e1956-wk-Fact-776FED99612EB753E31CF6259D43A33B"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e1977-wk-Fact-9C666B722CF40A00AADAF6259D43F8B5"
      unitRef="usd">2538100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2080-wk-Fact-38D8FADCF1CBA86496F51ACA06DF635A"
      unitRef="usd">117900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2099-wk-Fact-276FB041F2CD683B58141ACAF3B48B65"
      unitRef="usd">46300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2118-wk-Fact-38ED66DDDDF02CCB2CE91ACBD27F2784"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2138-wk-Fact-C68764E52A51CF8CD2931ACC8520E598"
      unitRef="usd">164200000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2153-wk-Fact-BDD175DDBF492C4EB9A61ACA08662910"
      unitRef="usd">111400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2172-wk-Fact-F6D7BCFF1A5C296BEDB41ACAF5F39A4F"
      unitRef="usd">247900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2191-wk-Fact-E851B9A58749AEAD00221ACBD4E80E90"
      unitRef="usd">13500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2212-wk-Fact-8E857985B7C9BFB6ADAC1ACC87145C8A"
      unitRef="usd">345800000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2237-wk-Fact-528FCC83ADAD2BD79606F6259D43197F"
      unitRef="usd">229300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2256-wk-Fact-37FBF1D6FDA889E88CC1F6259D4327FA"
      unitRef="usd">294200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2275-wk-Fact-5B46C0702CB86AECF4A2F6259D43191D"
      unitRef="usd">13500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e2296-wk-Fact-8E0E78E8FDDB9E3ED272F6259D43F33E"
      unitRef="usd">510000000.0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2522-wk-Fact-D8916DD078A30E330F01F6259D52C98C"
      unitRef="usd">1608400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2541-wk-Fact-D2FF231EF725489DF48EF6259D52CDC3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2560-wk-Fact-CC51B839DAE8E6CC4343F6259D52CC54"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2581-wk-Fact-D69A5A16CB1FE70F1720F6259D71D808"
      unitRef="usd">1607500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2596-wk-Fact-333FFE87232494F1144FF6259D7146AB"
      unitRef="usd">854900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2615-wk-Fact-F714705C3EF402F62700F6259D81E2B4"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2634-wk-Fact-B179B8D15942147162F4F6259D71789D"
      unitRef="usd">3900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2655-wk-Fact-2639EF62961F57F543CBF6259D33E797"
      unitRef="usd">851700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2757-wk-Fact-121D8F15CED75446CAD0F6259D526C03"
      unitRef="usd">706100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2776-wk-Fact-99A83F699A6EF73BE693F6259D81FE08"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2795-wk-Fact-3F9BE657BAD8E0DBF521F6259D432B54"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2816-wk-Fact-451F1C7F3A56124FB3E4F6259D52DE5F"
      unitRef="usd">705800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2836-wk-Fact-BC978F1687E197DE33BFF6259D52A6A8"
      unitRef="usd">264000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2855-wk-Fact-4F5BBDC86940FB26B1DEF6259D52BC5A"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2874-wk-Fact-161B3217E95841F65CA1F6259D529E63"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e2895-wk-Fact-4AF1F4E06671448DBFF4F6259D52EB38"
      unitRef="usd">263800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e2997-wk-Fact-B76831409D9B07443DB1F6259D626ABC"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e3016-wk-Fact-58E8144C47C83AB9ECC2F6259D52A755"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e3035-wk-Fact-4D3363D3D8C1A8BEC222F6259D622251"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d30735065e3055-wk-Fact-36A04079F34E1694AADEF6259D52F662"
      unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e3075-wk-Fact-70E72719B240030EC842F6259D52DE50"
      unitRef="usd">260500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e3094-wk-Fact-C1C2D85DD01DA86F4FE1F6259D52AF99"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e3113-wk-Fact-6A3BF689510B817F6D5AF6259D232EAC"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d30735065e3134-wk-Fact-33CDE00A5BFC0C5C1049F6259D52ADDA"
      unitRef="usd">260400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3159-wk-Fact-8AB89748537748F9EE62F6259DA63BC9"
      unitRef="usd">3694000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3178-wk-Fact-74E3037FA34A2F282FADF6259D52184E"
      unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3197-wk-Fact-B1D9EDC635EAF6662BACF6259D52C1DD"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3218-wk-Fact-ECE4B4B7B25669EFAD09F6259D528B7A"
      unitRef="usd">3689300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e3239-wk-Fact-13622D3512E39D8DE583F6259D52B892"
      unitRef="usd">496200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e3258-wk-Fact-C1134F383614E9A89962F6259D713012"
      unitRef="usd">127700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e3277-wk-Fact-ABC03C45AFA82AF4C05EF6259D524A5C"
      unitRef="usd">8500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d30735065e3298-wk-Fact-7E9D0B6B17462E7685E9F6259D5200BA"
      unitRef="usd">615400000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E16423A2140C911779ADF6259DC20B8A-0-wk-Fact-017E0D05ECA999086E44F6259D62F99C">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,227.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,228.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,314.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,313.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,196.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,202.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,232.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;107.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,530.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,538.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,694.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,689.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3540-wk-Fact-0F8D13A445EC76789C02F6259DA70C87"
      unitRef="usd">1227300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3559-wk-Fact-96134C8B66DBAE4E28D3F6259DA888B9"
      unitRef="usd">1228800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3578-wk-Fact-4158C8A7FE9AF38322F0F6259DA739A8"
      unitRef="usd">2314600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3598-wk-Fact-5857CF598ED04A72AEAFF6259DA81D2F"
      unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3613-wk-Fact-60BF20812CDFFFC225E5F6259DA6EEBD"
      unitRef="usd">1196100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3632-wk-Fact-BDD27EAB52586E91D35BF6259DAA9DEA"
      unitRef="usd">1202200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3651-wk-Fact-8050626D8CB91B7E4666F6259DAA43DB"
      unitRef="usd">1235900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3671-wk-Fact-5BDE8CE254024466F5D1F6259DA75139"
      unitRef="usd">1232700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3691-wk-Fact-E359CD17808F735C258DF6259DAA69D0"
      unitRef="usd">107000000.0</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3710-wk-Fact-EA68F0D8A8C68A38FBDFF6259DA6EF4E"
      unitRef="usd">107100000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3729-wk-Fact-DE45DE3D01F9271975A9F6259DA81654"
      unitRef="usd">143500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3749-wk-Fact-12D2385F2717D0D9E312F6259DA8BCF4"
      unitRef="usd">143200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3774-wk-Fact-11FC085268A7E6F3298BF6259D43F4FB"
      unitRef="usd">2530400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30735065e3793-wk-Fact-5016EC3E39ABB4216FE6F6259DA6F24E"
      unitRef="usd">2538100000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3812-wk-Fact-8AB89748537748F9EE62F6259DA63BC9"
      unitRef="usd">3694000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30735065e3832-wk-Fact-45D3E700AB947924DA81F6259DA98634"
      unitRef="usd">3689300000</us-gaap:AvailableForSaleSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2019Q2YTD"
      id="d30735065e3860-wk-Fact-0BF3EE7718C4269F5148F6259D52D88D">P14M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2018Q4YTD"
      id="d30735065e3864-wk-Fact-F557FB6CBB25E0D41606F6259D52B48B">P12M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C4DEFD4D7B358B959688F6259DC20055-0-wk-Fact-3518713C16072C8582EDF6259D623172">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,766.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,733.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3,255.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,802.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30735065e4084-wk-Fact-4F052B38E1A6FE29968CF6259D62A6BB"
      unitRef="usd">1766600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30735065e4103-wk-Fact-7908B14AD4F8157D583FF6259D629241"
      unitRef="usd">2733700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30735065e4122-wk-Fact-3BBFC6B449A1CFB27923F6259DAB5774"
      unitRef="usd">3255800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30735065e4142-wk-Fact-39E9D01E2A183C19B400F6259D913FA2"
      unitRef="usd">6802700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30735065e4162-wk-Fact-DF713B93EE8F46833199F6259D623B01"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30735065e4181-wk-Fact-F3CFF23636F703F287A8F6259D621573"
      unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30735065e4200-wk-Fact-783D633AFE3A9001EF15F6259D62DA65"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30735065e4220-wk-Fact-98B4D0F45588E7AFD833F6259D62EFF5"
      unitRef="usd">2600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30735065e4240-wk-Fact-1A8B6C0B73D259EB851EF6259D629D66"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30735065e4260-wk-Fact-4C81FE7258A8731ABE0BF6259D62EBB4"
      unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30735065e4280-wk-Fact-B206C7BE50F3A77877EEF6259D62EAA5"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30735065e4301-wk-Fact-85DE14D75ECACBD6583CF6259D622BC4"
      unitRef="usd">10200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d30735065e4329-wk-Fact-123D77F4DA6E1BFA2BFFF6259D719A61"
      unitRef="usd">569800000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d30735065e4333-wk-Fact-43F74E541074D49F708D06820C482862"
      unitRef="usd">164200000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d30735065e4341-wk-Fact-B6F030A3A98B5B7F3C73F6259D71C61A"
      unitRef="usd">676300000</biib:StrategicInvestmentPortfolio>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d30735065e4358-wk-Fact-FBAEDAA30A625EAED6230684E388662A"
      unitRef="usd">213300000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-124E16AAFC2F36CC860CF6259DD25F8E-0-wk-Fact-9221F44ADDD1374C227FF6259D628A83">Derivative Instruments&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,111.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,701.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;56.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,402.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,239.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$6.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$27.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect the net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$6.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$9.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of these gains are expected to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, we entered into interest rate swaps with an aggregate notional amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. The carrying value of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and December&#160;31, 2018, includes approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had remaining durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;four months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$19.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$9.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$934.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$735.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, related to these contracts were recognized as a component of other income (expense), net for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be materially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;81.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember"
      id="d30746986e800-wk-Fact-921074DE09AC0CA4662EF6259D8187D6">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember"
      id="d30746986e804-wk-Fact-90C2619FE7C6A7C1C625F6259D62B3F4">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="d30746986e808-wk-Fact-9EE78370E4A9E230F24BF6259D91C69E">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d30746986e813-wk-Fact-7710EEB842807DA6BDFCF6259D81C9D6">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-A456820D6C6129341666F6259DD27A20-0-wk-Fact-9C5ABCED398875757E91F6259D815CAA">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,111.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,701.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;117.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;56.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,402.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,239.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e939-wk-Fact-59851215DA6ADA2EBD54F6259D04F93D"
      unitRef="usd">2111300000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e958-wk-Fact-66C72C7169F15F4E627EF6259D6232BB"
      unitRef="usd">1701400000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e973-wk-Fact-526D74107BBD68654E93F6259D04269F"
      unitRef="usd">117200000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e992-wk-Fact-5D3E0862959FC7302D5EF6259D52D0D6"
      unitRef="usd">215300000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1012-wk-Fact-60E4966620A612E9B26FF6259D4313AB"
      unitRef="usd">69700000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1031-wk-Fact-7C583A0A566A0162D22BF6259D521FD5"
      unitRef="usd">131400000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1051-wk-Fact-9A1615E0E7306E86FA1AF6259D71A66D"
      unitRef="usd">56000000.0</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1070-wk-Fact-370B6E40E55C22AE31BBF6259D7155AE"
      unitRef="usd">98800000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1090-wk-Fact-E63FD1EA7B4FE887DDADF6259DB21572"
      unitRef="usd">48100000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1109-wk-Fact-D08FF9E3E629DA83E7B3F6259D528606"
      unitRef="usd">92200000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1134-wk-Fact-4BC54498CC48377ACAAAF6259D81F0DE"
      unitRef="usd">2402300000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e1153-wk-Fact-EE3E33C38F232D81A318F6259D6265E8"
      unitRef="usd">2239100000</invest:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30746986e1173-wk-Fact-254FFC36EED61AE148AEF6259D62C6D0"
      unitRef="usd">-6300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30746986e1177-wk-Fact-177E5B31FAFD347919D3F6259D81AF21"
      unitRef="usd">27300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30746986e1189-wk-Fact-254FFC36EED61AE148AEF6259D62C6D0"
      unitRef="usd">-6300000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember"
      id="d30746986e1194-wk-Fact-90C2619FE7C6A7C1C625F6259D62B3F4">P18M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      decimals="-5"
      id="d30746986e1198-wk-Fact-710891EF77B8B3C1E2970687CA5A7042"
      unitRef="usd">-9800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      id="d30746986e1202-wk-Fact-08A142B6AFB8B26F2A37068D90B4E75F">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-EF5DE23EA7CCDD43A169F6259DC296D6-0-wk-Fact-095B7D8F955A2D815762F6259D62E1FC">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e1569-wk-Fact-D8B19999FDA32A3B238CF6259D624E31"
      unitRef="usd">29800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e1588-wk-Fact-DE3F49734CB8DB08EF6AF6259D625B20"
      unitRef="usd">-10400000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e1619-wk-Fact-250CDE12804D6CD28FEEF6259D622A8C"
      unitRef="usd">3700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e1638-wk-Fact-38522A2195C8511FDF3CF6259D62914F"
      unitRef="usd">7900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e1663-wk-Fact-080ED99D5462DFCE9C6DF6259D628FEF"
      unitRef="usd">-700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e1683-wk-Fact-02339D1A21B79B0E602FF6259D621D50"
      unitRef="usd">-400000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e1714-wk-Fact-F0617BC51D0EDFD13A0CF6259D62908D"
      unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e1734-wk-Fact-A214194935854E83F864F6259D626DFA"
      unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e2086-wk-Fact-D6A8FEB1FB887AFB09700691BD2A7FF9"
      unitRef="usd">44600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e2105-wk-Fact-EA572E7AF6A01CE66845F6259D71343A"
      unitRef="usd">-43300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e2136-wk-Fact-A834CD1A743B41BF0275F6259D23138E"
      unitRef="usd">7400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d30746986e2155-wk-Fact-6A37EFDE82448747E008F6259D047DD0"
      unitRef="usd">7000000.0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e2180-wk-Fact-22F3253B7EB6DFE500310691BD1A836F"
      unitRef="usd">-1200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e2200-wk-Fact-E479455483780C8B710AF6259D717DFB"
      unitRef="usd">900000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e2230-wk-Fact-573598D7E20CA5564EE0F6259D71356F"
      unitRef="usd">-1200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d30746986e2250-wk-Fact-F580132D144611875BA4F6259D813B5A"
      unitRef="usd">-400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d30746986e2275-wk-Fact-ADB46811B1B17938C579F6259D81AC42"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e2279-wk-Fact-0A43F1185C062C87BDBEF6259D62574F"
      unitRef="usd">675000000.0</invest:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d30746986e2283-wk-Fact-ADB46811B1B17938C579F6259D81AC42"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d30746986e2287-wk-Fact-ADB46811B1B17938C579F6259D81AC42"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e2296-wk-Fact-6F6A179CB1E663FB4CA1F6259D71CBB7"
      unitRef="usd">5500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e2300-wk-Fact-19C6D2468E4FE65578B9F6259D62B8F9"
      unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d30746986e2304-wk-Fact-ADB46811B1B17938C579F6259D81AC42"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d30746986e2319-wk-Fact-0E8D44ADE3BB672596F8F6259D81B710"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d30746986e2323-wk-Fact-6EDF670AD27ED3D62C34F6259D81C455"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d30746986e2327-wk-Fact-17D1AF9D526AF59A8697F6259D62566B"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30746986e2331-wk-Fact-05ACF1EDB334962654D2F6259D62BBCF"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      id="d30746986e2342-wk-Fact-73733D18B05449FF3C85F6259D819E7A">P4M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2346-wk-Fact-909083BE32D596435A33F6259D9121FB"
      unitRef="usd">19600000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2350-wk-Fact-1D239D2206F85D264DABF6259D9194C5"
      unitRef="usd">3800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2019Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2363-wk-Fact-89B2D21CE7404F19AE00F6259D81787D"
      unitRef="usd">9600000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2367-wk-Fact-47857C7F3BA4771A9DC1F6259D815A77"
      unitRef="usd">7300000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-075AF5D8F266C965C926F6259DC2876D-0-wk-Fact-61BE2846E276FDBE5FA6F6259D810D28">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;23.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2901-wk-Fact-3DA3FFD54087E843325FF6259D627A11"
      unitRef="usd">11600000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2920-wk-Fact-304ECEEC2C90C36D78A1F6259D330E07"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2950-wk-Fact-C236E5B439BE3D5CECEEF6259D71DBB1"
      unitRef="usd">2300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e2969-wk-Fact-72D5DF082D48E6FCCB0BF6259D52C309"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d30746986e2999-wk-Fact-197CCB6228958F801136F6259D332EA3"
      unitRef="usd">2200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d30746986e3018-wk-Fact-3CEFE635FA79715F91BCF6259D23D1B1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e3540-wk-Fact-18DEC2D7E8D0E62FC87EF6259D71F3BC"
      unitRef="usd">23400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e3559-wk-Fact-56403951DCB833E01216F6259D71A1C4"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e3589-wk-Fact-627EE73898D62802268FF6259D71757B"
      unitRef="usd">6700000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d30746986e3608-wk-Fact-61264814CA0C0D6E8CFCF6259D7166BE"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d30746986e3638-wk-Fact-33F027FF62BF5D153D96F6259D71EE47"
      unitRef="usd">4400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d30746986e3657-wk-Fact-71AB2632680A50DB28F0F6259D71E93B"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d30746986e3683-wk-Fact-8716DF20665A9DA71B9DF6259D62D09A"
      unitRef="usd">934400000</invest:DerivativeNotionalAmount>
    <invest:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d30746986e3687-wk-Fact-4FEA25650C3D111DDFBCF6259D62760A"
      unitRef="usd">735100000</invest:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30746986e3699-wk-Fact-20221B93786627B4F9E7F6259D620116"
      unitRef="usd">900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30746986e3704-wk-Fact-E60DBCAA50DC236250A4F6259D62AD09"
      unitRef="usd">3900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30746986e3716-wk-Fact-D28CED96013096720CB3F6259D62301C"
      unitRef="usd">-5200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30746986e3720-wk-Fact-D52428CDAD87D45D7FC7F6259D62CB4E"
      unitRef="usd">-400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-77657BA7565CB86B44E3F6259DD272D3-0-wk-Fact-000E62AA9EE763F5F7DCF6259D62EA0E">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;81.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e3901-wk-Fact-4D0E6292891C1D996D0CF6259CF5F1A9"
      unitRef="usd">81800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e3920-wk-Fact-97EF2A63882816110592F6259CF5CC59"
      unitRef="usd">65800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e3955-wk-Fact-3372FFDCC4E225DEF5CBF6259D14B69C"
      unitRef="usd">5500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e3974-wk-Fact-5EDFA62D4E0CD3159033F6259D042A6C"
      unitRef="usd">6900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e4009-wk-Fact-4BC7638579EEE683A5BA0698DE86A7EA"
      unitRef="usd">2200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e4028-wk-Fact-B0125C3991FD1FA6B0EB0698E3667F34"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e4119-wk-Fact-6F6A179CB1E663FB4CA1F6259D71CBB7"
      unitRef="usd">5500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d30746986e4138-wk-Fact-19C6D2468E4FE65578B9F6259D62B8F9"
      unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d30746986e4229-wk-Fact-E107F55EECABB4192F01F6259D044B0E"
      unitRef="usd">6400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d30746986e4248-wk-Fact-080CAE81AC109A66F62DF6259D1420D2"
      unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d30746986e4283-wk-Fact-C016C61F4484467046F8F6259D04D2B3"
      unitRef="usd">4300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d30746986e4302-wk-Fact-4C411F622053B093E786F6259D04F2E0"
      unitRef="usd">3200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4D48BF0C5ABD06B58031F6259DD2089F-0-wk-Fact-96F4FD2233CD2456F39EF6259D913000">Property, Plant and Equipment&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,886.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,797.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, depreciation expense totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$47.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$99.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$64.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$129.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51,000 square feet of administrative space. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$57.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding related to the construction of this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#xf8;d, Denmark. As a result, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$641.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of property, plant and equipment, which is primarily comprised of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$318.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for buildings and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$290.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for machinery and equipment, was reclassified to assets held for sale in our condensed consolidated balance sheets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Additionally, we ceased recording depreciation on these assets as depreciation is not recorded during the period in which a long-lived asset or disposal group is classified as held for sale, even if the asset or disposal group continues to generate revenue during the period. For additional information on the proposed divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30726225e783-wk-Fact-AE1A9DBB29CFBEB92EDDF6259D33EB3D"
      unitRef="usd">1886200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30726225e787-wk-Fact-0B70B559E666F6DFBFC6F6259D62EA43"
      unitRef="usd">1797400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30726225e814-wk-Fact-9C54F97E22CD5D4C4129F6259D81D526"
      unitRef="usd">47000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30726225e818-wk-Fact-DC28A760BD29D72322A9F6259D81CEFC"
      unitRef="usd">99900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30726225e822-wk-Fact-8C4A8D2B43C234370C81F6259D91C13E"
      unitRef="usd">64200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30726225e826-wk-Fact-C6E91CE216F599163984F6259D915756"
      unitRef="usd">129200000</us-gaap:Depreciation>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2019Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d30726225e847-wk-Fact-26CC5617A8BA7C794BCEF6259D62F39C"
      unitRef="usd">1800000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d30726225e851-wk-Fact-C29D09488DFF0C8A94EDF6259D527FC3"
      unitRef="usd">1600000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:OtherCommitment
      contextRef="FI2019Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-5"
      id="d30726225e860-wk-Fact-A54DEFAC6CF2335F33DBF6259D43EA69"
      unitRef="usd">57000000.0</us-gaap:OtherCommitment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30726225e870-wk-Fact-9CC2BD390BD3FCDC0482F6259D33BD90"
      unitRef="usd">641900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-5"
      id="d30726225e874-wk-Fact-1EB8DB73B34AD8F49F68F6259D33398B"
      unitRef="usd">318400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      decimals="-5"
      id="d30726225e878-wk-Fact-45F64D2867591F233ABAF6259D91FB1C"
      unitRef="usd">290800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-5B3736B2C2A90FC38FDDF6259DD2C60E-0-wk-Fact-F0BB0091E7C9C0BAD678F6259CF511C2">Leases&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We lease real estate, including laboratory and office space, and certain equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our leases have remaining lease terms ranging from less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;nine years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;nine years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our subleases do not include an option to renew as they are coterminous with our operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All of our leases qualify as operating leases. The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;423.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;41.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;14.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;50.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;66.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;147.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;560.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;601.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(182.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;156.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proposed Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#xf8;d, Denmark. As a result, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating lease assets and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating lease liabilities were reclassified to assets and liabilities held for sale in our condensed consolidated balance sheets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on the proposed divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember"
      id="d30750655e783-wk-Fact-5A9425D0AA001FE21AE4F6259CF52E44">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember"
      id="d30750655e787-wk-Fact-34EA79FE0AB36C8CBDC7F6259CF5FEC6">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember"
      id="d30750655e791-wk-Fact-515B77CA63F47DCCBC6DF6259D0410E2">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember"
      id="d30750655e795-wk-Fact-5F03D5B2BA0E4FA0484FF6259CF51CF5">P6Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember"
      id="d30750655e802-wk-Fact-5A9425D0AA001FE21AE4F6259CF52E44">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember"
      id="d30750655e806-wk-Fact-34EA79FE0AB36C8CBDC7F6259CF5FEC6">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:LesseeLeaseTableTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-3653D8B04750A998B55FF6259DD20086-0-wk-Fact-5502341294A2692E07FEF6259CF5FBB9">The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance sheet location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;434.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;72.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;423.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:LesseeLeaseTableTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_OperatingleaseassetsMember"
      decimals="-5"
      id="d30750655e916-wk-Fact-982A881E359388C90474F6259D23AB24"
      unitRef="usd">434400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember"
      decimals="-5"
      id="d30750655e1008-wk-Fact-4210CC62A7B5C7E4F915F6259D14FCEC"
      unitRef="usd">72300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_biib_LongtermoperatingleaseliabilitiesMember"
      decimals="-5"
      id="d30750655e1033-wk-Fact-B6E9AE5FE872EF2AF1E3F6259D716AF3"
      unitRef="usd">423000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1068-wk-Fact-07F8B45417E3FDA5651BF6259D14C1A2"
      unitRef="usd">495300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0A677035A751416D56B6F6259DD2D868-0-wk-Fact-93A7BE1C2E333B61A0E3F6259D04E4AF">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of lease costs in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;17.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;41.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;14.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d30750655e1227-wk-Fact-9E232E66145FB5ADB331F6259D14B25D"
      unitRef="usd">3400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d30750655e1246-wk-Fact-DEE20885A3D98DD187CAF6259D233DD0"
      unitRef="usd">3700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30750655e1271-wk-Fact-96B807E854375A785A41F6259D2309C7"
      unitRef="usd">17900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30750655e1290-wk-Fact-952DD864E02E1362C476F6259D2302BA"
      unitRef="usd">41400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30750655e1320-wk-Fact-D7E291807C774BC359C1F6259D235E32"
      unitRef="usd">6000000.0</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30750655e1340-wk-Fact-19E6DA66E5CACE79DCF2F6259D14B4C0"
      unitRef="usd">13100000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d30750655e1371-wk-Fact-C3716E88A12DD4BAB25EF6259D23FBC1"
      unitRef="usd">900000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d30750655e1391-wk-Fact-F688F33D501E6BE1A9C9F6259D144EC7"
      unitRef="usd">1900000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30750655e1427-wk-Fact-5F5BF9B8E9F21213BA3FF6259D14539A"
      unitRef="usd">14400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30750655e1446-wk-Fact-52EF3BA127F788901F6DF6259D23634B"
      unitRef="usd">30100000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0FA8BE529936E6E0F9DCF6259DD232A1-0-wk-Fact-87D2786518C53A8246EAF6259CF5BD4A">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;50.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;74.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;70.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;69.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;66.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;147.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;560.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;64.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;495.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1510-wk-Fact-F72F476448A2B5FEBF3DF6259D23FC65"
      unitRef="usd">50200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1525-wk-Fact-3C6F3BC39E6645E9FF34F6259D23D18D"
      unitRef="usd">80500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1545-wk-Fact-1B67D0481758C721397DF6259D230675"
      unitRef="usd">74900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1565-wk-Fact-9135633810B7E55DADFEF6259D23776F"
      unitRef="usd">70900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1585-wk-Fact-ABCBF8200419AA35650FF6259D2361D7"
      unitRef="usd">69400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1605-wk-Fact-B732E32787DA67D0CB10F6259D23E10B"
      unitRef="usd">66700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1625-wk-Fact-9F15F84CEF38F6A3C045F6259D23CFA8"
      unitRef="usd">147600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1650-wk-Fact-80FE15569FC7CA5E93A7F6259D2396A3"
      unitRef="usd">560200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1665-wk-Fact-C9B079B508F89A2331C9F6259D238EA5"
      unitRef="usd">64900000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30750655e1690-wk-Fact-07F8B45417E3FDA5651BF6259D14C1A2"
      unitRef="usd">495300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-65279FDFE0FCECA80623F6259DD27600-0-wk-Fact-43F14451B7F202D36083F6259CF51251">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;75.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;215.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;601.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(58.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(182.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;156.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;418.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e1901-wk-Fact-77D1E72684827B19B951F6259D810AC6"
      unitRef="usd">87000000.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e1920-wk-Fact-3A1E898190DAD5DC1FF9F6259D819569"
      unitRef="usd">80700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e1939-wk-Fact-B3768A01D5772792E720F6259D817CBC"
      unitRef="usd">75900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e1959-wk-Fact-743E90644AC23CA3624CF6259D81C028"
      unitRef="usd">71700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e1978-wk-Fact-1EEFAD447BC64C8C4C6EF6259D8151CB"
      unitRef="usd">71000000.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e1998-wk-Fact-6FA8A0FADAE5BA1151FCF6259D811947"
      unitRef="usd">215300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2017-wk-Fact-F5F8B2577B9BB0A66845F6259D816A3E"
      unitRef="usd">601600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2034-wk-Fact-4C17B5B1AE8E509E84D6F6259D81EE96"
      unitRef="usd">26800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2054-wk-Fact-05711542E37DCA138910F6259D81A584"
      unitRef="usd">25600000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2074-wk-Fact-69914606D236DC951180F6259D814CCC"
      unitRef="usd">23700000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2095-wk-Fact-2B5A513BA2A6549524F4F6259D8188BA"
      unitRef="usd">24000000.0</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2115-wk-Fact-1593F794B286FBDAAF6CF6259D8123FD"
      unitRef="usd">24300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2135-wk-Fact-CE62D962E49D4A53D672F6259D81BCF9"
      unitRef="usd">58400000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
    <us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2156-wk-Fact-D08C277F7913D93983C9F6259D81C569"
      unitRef="usd">182800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
    <biib:NetMinimumLeasePaymentsWithInOneYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2182-wk-Fact-34A1BEEDE557E3ABDDC4F6259D81367B"
      unitRef="usd">60200000</biib:NetMinimumLeasePaymentsWithInOneYear>
    <biib:NetMinimumLeasePaymentsWithInTwoYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2201-wk-Fact-92037651648184F79D28F6259D81BFF9"
      unitRef="usd">55100000</biib:NetMinimumLeasePaymentsWithInTwoYear>
    <biib:NetMinimumLeasePaymentsWithInThreeYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2220-wk-Fact-E85C9C4E1D7F86053D27F6259D816504"
      unitRef="usd">52200000</biib:NetMinimumLeasePaymentsWithInThreeYear>
    <biib:NetMinimumLeasePaymentsWithInFourYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2240-wk-Fact-2DE186413A5AE7A3EDF3F6259D8179A2"
      unitRef="usd">47700000</biib:NetMinimumLeasePaymentsWithInFourYear>
    <biib:NetMinimumLeasePaymentsWithInFiveYear
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2259-wk-Fact-93366D1D94898F25416CF6259D819EA9"
      unitRef="usd">46700000</biib:NetMinimumLeasePaymentsWithInFiveYear>
    <biib:NetMinimumLeasePaymentsThereafter
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2279-wk-Fact-C66CB034FE659D94B67CF6259D81C79A"
      unitRef="usd">156900000</biib:NetMinimumLeasePaymentsThereafter>
    <biib:NetMinimumLeasePayments
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30750655e2298-wk-Fact-2B6175FFE3FECFE79CB3F6259D813CD7"
      unitRef="usd">418800000</biib:NetMinimumLeasePayments>
    <biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-57020AC20623390E8D5CF6259DD20E0D-0-wk-Fact-2B435090103F08C70EDCF6259CF573D8">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q2"
      id="d30750655e2362-wk-Fact-27F2C70AF03DD83C8EA9F6259D6200DD">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q2"
      decimals="INF"
      id="d30750655e2377-wk-Fact-BA0B44F116CE4BE43632F6259D621481"
      unitRef="number">0.033</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-2524C326173CCB1B4317F6259DD2F644-0-wk-Fact-7EC28A33B1F294432ADFF6259CF54FCC">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;27.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;46.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30750655e2505-wk-Fact-0820543F82216E37B40FF6259D434628"
      unitRef="usd">27400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30750655e2524-wk-Fact-9E48CBC7E90E3A9F5A65F6259D43B85A"
      unitRef="usd">46800000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30750655e2544-wk-Fact-2C4AA462F3A36B74EB32F6259D434C75"
      unitRef="usd">7300000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30750655e2563-wk-Fact-1FAF694030210BDAA572F6259D43E490"
      unitRef="usd">12700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <biib:DisposalGroupOperatingLeaseAssets
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30750655e2579-wk-Fact-68222E790FDC7DC9CFFAF6259D23A1D0"
      unitRef="usd">2200000</biib:DisposalGroupOperatingLeaseAssets>
    <biib:DisposalGroupOperatingleaseliabilities
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30750655e2583-wk-Fact-E3C36D505E12C7919E77F6259D710ECB"
      unitRef="usd">2200000</biib:DisposalGroupOperatingleaseliabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-8D93770C6B588FCA1026F6259DD2E1D5-0-wk-Fact-632A585B3210540DA298F6259D4310A8">Equity&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$909.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remained available under our 2019 Share Repurchase program as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.75 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;36.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;13.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(271.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(252.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(316.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;103.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(222.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d30752799e783-wk-Fact-450C6BB453BC2A393D67F6259D522B61"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30752799e787-wk-Fact-702D6C363B8C3451B42C06A0CA6A9A3B"
      unitRef="shares">3900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30752799e791-wk-Fact-104EDE293B9EB3F37E8C06A10D41F600"
      unitRef="usd">909900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d30752799e804-wk-Fact-C6D6204832EC1946EEF106A213DC12F9"
      unitRef="usd">4100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d30752799e815-wk-Fact-E27D322FD36422E59026F6259D91CD4E"
      unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30752799e819-wk-Fact-FB18DD1158E76EAF820FF6259D81978A"
      unitRef="shares">6500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30752799e823-wk-Fact-07C31B8D47FD34F4777EF6259D718213"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d30752799e827-wk-Fact-EEC7A3B95A27ED74A03CF6259D81B4D8"
      unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-8"
      id="d30752799e831-wk-Fact-B452EBBD67A787F99B19F6259D91DD1B"
      unitRef="usd">2100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-8"
      id="d30752799e847-wk-Fact-A1CAEC14013E4D37E760F6259D235A37"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30752799e851-wk-Fact-2574FB36243025E2558CF6259D915398"
      unitRef="shares">9600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-5"
      id="d30752799e855-wk-Fact-72B7F4F56DA6C53650B5F6259D915B9D"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-7"
      id="d30752799e859-wk-Fact-612932E491E4B5924E17F6259D62D954"
      unitRef="usd">2750000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember"
      decimals="-8"
      id="d30752799e863-wk-Fact-C37C7EFD0C2471B0EE4BF6259D71AC64"
      unitRef="usd">3000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1D9FC69F3BDF3D3A5FC8F6259DD2B2D2-0-wk-Fact-8174D75856F21282A834F6259D235A88">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;36.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;13.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(271.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(252.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(318.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(104.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(175.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(316.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;103.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(36.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(222.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e1080-wk-Fact-ADAD6EAF783AAA6DC31FF6259D5213AB"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e1100-wk-Fact-FC5B281E9AFF12527CA8F6259D81796B"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e1120-wk-Fact-90F66A6A0023934CC896F6259D62490E"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e1139-wk-Fact-0B976B1C523735E1B684F6259D9121DA"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e1159-wk-Fact-8A74AE3068D3E11E16A0F6259D2369F1"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30752799e1180-wk-Fact-25428E0E08BD0DBCBF49F6259D237069"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e1201-wk-Fact-BCDCAD15C56559C893F0F6259DA019F8"
      unitRef="usd">11000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e1220-wk-Fact-5A8F69C5B829D9959D41F6259D91BC3B"
      unitRef="usd">22300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e1239-wk-Fact-DAF55FA0993E0C67D86DF6259D91085A"
      unitRef="usd">30100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e1259-wk-Fact-D0C2BEA3ECC8970D56CEF6259D525441"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e1278-wk-Fact-5D00FFEBFF5E608D3B4AF6259D7166CD"
      unitRef="usd">-28100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30752799e1299-wk-Fact-C40C14A4E80539644F81F6259DB0C35B"
      unitRef="usd">36000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e1324-wk-Fact-8516F1A9EE6955349DA4F6259D235160"
      unitRef="usd">-800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e1344-wk-Fact-09416282FE8E7D7A78A1F6259D81002E"
      unitRef="usd">-43300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e1364-wk-Fact-45A3AD63EE8849B0E70BF6259DA2E036"
      unitRef="usd">-4400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e1385-wk-Fact-C1453C765A3B8FCB8AE8F6259D810456"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e1404-wk-Fact-732C500BF7DB64117BD0F6259D719E33"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30752799e1424-wk-Fact-12D7A870B0AA76EF89B2F6259D91BD6E"
      unitRef="usd">-48500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e1450-wk-Fact-EA456DFD5D71EAB1E825F6259D712B6F"
      unitRef="usd">10200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e1469-wk-Fact-D3E7357D4C0D542413DEF6259D23B45A"
      unitRef="usd">-21000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e1489-wk-Fact-073D69E9BDEDFFB6C4B9F6259D23DF14"
      unitRef="usd">25700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e1509-wk-Fact-BD5E0D2B27ECD97C91EFF6259D23B557"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e1528-wk-Fact-DDF70D4AA8EEED8BB109F6259D52859F"
      unitRef="usd">-28100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30752799e1549-wk-Fact-6440C377A189830524FFF6259D141ACB"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e1580-wk-Fact-F78C597B811F3ACBAB68F6259D62B795"
      unitRef="usd">6200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e1599-wk-Fact-B7EA0D5BADFB9000B640F6259D7198BF"
      unitRef="usd">13700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e1619-wk-Fact-6A82326B82C74DA096D4F6259D7104A4"
      unitRef="usd">29200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e1638-wk-Fact-D19E725CCD93D61241EEF6259D810AA9"
      unitRef="usd">-30600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e1658-wk-Fact-EFF9D6F37C700BBF7618F6259DA32B0B"
      unitRef="usd">-271400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30752799e1679-wk-Fact-87EBCA1CDEFC1D44DA24F6259D23F60D"
      unitRef="usd">-252900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e1869-wk-Fact-01B19C1DF7ADFE57E42BF6259DB2F08F"
      unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e1889-wk-Fact-1BB4DC2321646B7EFAD9F6259D52ABA6"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e1910-wk-Fact-45CAD75D0FF879CAED84F6259DB2CB00"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e1929-wk-Fact-92321B7093899203F92AF6259DB283EE"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e1949-wk-Fact-DDFE6D7EDECEFB585DBCF6259DB2884C"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4"
      decimals="-5"
      id="d30752799e1970-wk-Fact-99C1C50DD8DB7C11A500F6259D5211F8"
      unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e1991-wk-Fact-422E6C0280067FFA32EAF6259D52C65D"
      unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e2010-wk-Fact-204D1DB54A0BC27A56A7F6259D526F69"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e2029-wk-Fact-259606EB02EB31D92BFCF6259DB25584"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e2049-wk-Fact-60984DD5D42426B1E05FF6259DB227A5"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e2068-wk-Fact-43373B31E41DD6018769F6259D520D54"
      unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member"
      decimals="-5"
      id="d30752799e2088-wk-Fact-7E3A54DF26E4A28CF038F6259D5299E2"
      unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e2113-wk-Fact-1831EB7B43F8278C7B0BF6259DB27DB4"
      unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e2133-wk-Fact-F44BB06922597EC06AA5F6259D522963"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="0"
      id="d30752799e2153-wk-Fact-BF0D8D57B03E92A4BCE1F6259DB2CF87"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e2173-wk-Fact-581602670694F1D9E1C7F6259DB298A3"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e2193-wk-Fact-7EE365DC620985BBD001F6259DB2D710"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I2018Q1ASUadoptiondate"
      decimals="-5"
      id="d30752799e2214-wk-Fact-A7F837E84505ABD156C1F6259D5222C2"
      unitRef="usd">-316900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e2240-wk-Fact-6B81E61DC8BED74F4803F6259D52EEB3"
      unitRef="usd">-7600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e2260-wk-Fact-D8607F8BABCDF72405AAF6259DB24DC3"
      unitRef="usd">61700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e2279-wk-Fact-2201DDACCC9DB6E55930F6259D52EB58"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e2299-wk-Fact-D125AB16E26F804670B9F6259D520872"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e2318-wk-Fact-A1BCDF905A48808FD718F6259D52C542"
      unitRef="usd">-47300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30752799e2339-wk-Fact-B0B68B47669DB5C6447CF6259D524DAE"
      unitRef="usd">7200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e2364-wk-Fact-A14F4DAEEFB1E93D5901F6259D52FD18"
      unitRef="usd">6000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e2383-wk-Fact-34F8DD378CA4F3D4DC89F6259D522FB7"
      unitRef="usd">42100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e2402-wk-Fact-3DB3638E7962168E96F3F6259DB243EA"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e2422-wk-Fact-C629B55FF06C66AF067AF6259D52D1B8"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e2441-wk-Fact-412652A46E39A22FB0F8F6259DB24ECA"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30752799e2461-wk-Fact-BDE8E4AD7799A66C3352F6259DB29B99"
      unitRef="usd">48100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e2486-wk-Fact-841DD78D4FD8A0C046E5F6259DB272A1"
      unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e2506-wk-Fact-D5CD60B7A9EF86753EDAF6259D52D393"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e2525-wk-Fact-20145C544EF5FE89B5CCF6259D52CDF0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e2545-wk-Fact-E66C211CF5BD18C17BA2F6259DB22167"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e2564-wk-Fact-F91518CDB16D99DF9692F6259D52CFDE"
      unitRef="usd">-47300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30752799e2585-wk-Fact-53C30F8A2D37A0D5D15EF6259D14796F"
      unitRef="usd">55300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e2615-wk-Fact-D87D6FAE2DA719DE4CCEF6259D526687"
      unitRef="usd">-1700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e2635-wk-Fact-2D37A11FED790152DFEEF6259D522100"
      unitRef="usd">-700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e2656-wk-Fact-5C68895A5EA184375E5AF6259DB2A50E"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d30752799e2675-wk-Fact-6D95DA49B1445DCBEDA2F6259CF51FB3"
      unitRef="usd">-36400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d30752799e2695-wk-Fact-C868416D4A782CC006BFF6259DB2FC6B"
      unitRef="usd">-222800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q2"
      decimals="-5"
      id="d30752799e2716-wk-Fact-83E86FCB8C749BA72D4AF6259D52BBB8"
      unitRef="usd">-261600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-F68A1210F1D29B7CCA35F6259DD2F342-0-wk-Fact-9110668B775DAEFC3D34F6259D91A9C1">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3066-wk-Fact-929E6FB0C9BE16FA899EF6259D430DEB"
      unitRef="usd">700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3085-wk-Fact-A44A323FFD19AE400171F6259D4336DB"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3105-wk-Fact-745ED82F1020C79A7A4AF6259D43522C"
      unitRef="usd">1000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3124-wk-Fact-225DEB74D58B2320CF00F6259D43E864"
      unitRef="usd">-7600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3150-wk-Fact-D0E46A0091D5540E4B10F6259D43D48A"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3170-wk-Fact-25309EF474A47A95FA68F6259D437F08"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3190-wk-Fact-2905F5B8B3771C126304F6259D437F59"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d30752799e3210-wk-Fact-782F6ED1C983D39CDA58F6259D43CBD0"
      unitRef="usd">1600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3332-wk-Fact-F34E93E0FC7D210FB8A6F6259D43EA52"
      unitRef="usd">29800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3351-wk-Fact-1F9AB92FD2974CB1EBAFF6259D43377D"
      unitRef="usd">10400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3372-wk-Fact-EA7F6DB0F62074C2B86CF6259D436F7B"
      unitRef="usd">44600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3391-wk-Fact-7409598BF096162277F5F6259D431FAB"
      unitRef="usd">43300000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3422-wk-Fact-7FF3E3FE85174AF00881F6259D43EFB3"
      unitRef="usd">700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3442-wk-Fact-9892DD34CCFCB0ACB404F6259D43BF96"
      unitRef="usd">400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3463-wk-Fact-49886C073FEE81B3938DF6259D4359CB"
      unitRef="usd">1200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3483-wk-Fact-FE813EA5B094346E0479F6259D43EA2D"
      unitRef="usd">900000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3513-wk-Fact-DB41B5791EBF8152193BF6259D71AE67"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3532-wk-Fact-D8F2912412FF5F37873FF6259D43AA93"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3552-wk-Fact-2D7D8B5C5001EAC9DFC2F6259D43EBF3"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3571-wk-Fact-DA1FD042F985D48A87BCF6259D43F423"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3601-wk-Fact-C54F0AB6B0E0FEB1EA37F6259D52E0C0"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3621-wk-Fact-B0E30E485AEC49D72D59F6259D239A7F"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3641-wk-Fact-C3C11D290F5C44D79F9DF6259D43A9AB"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d30752799e3661-wk-Fact-1B478B3D548035826487F6259D43F61B"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3784-wk-Fact-27E58A78074D44046961F6259D43B269"
      unitRef="usd">2200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3803-wk-Fact-8EE98904607C99892B96F6259D43C1C6"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3823-wk-Fact-FC9226F136D6FF28217CF6259D4362D7"
      unitRef="usd">4400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3842-wk-Fact-ED80EC3356CF997826A8F6259D434FF5"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3872-wk-Fact-4AB868BB19612DFF4BBFF6259D4330FA"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3891-wk-Fact-0FA7DFF75D62A6E4DB37F6259D435BA0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3911-wk-Fact-E162D32271D89E0FCB5EF6259D433FA7"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d30752799e3930-wk-Fact-BD7D1B8A758FB192EAC7F6259D430189"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30752799e4057-wk-Fact-F369B9825F0087789A55F6259D4396C9"
      unitRef="usd">31800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30752799e4076-wk-Fact-C82173C565F5C57CCE10F6259D43EAB4"
      unitRef="usd">-10700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30752799e4097-wk-Fact-0B520EACEB247263A4ECF6259D434DC4"
      unitRef="usd">48500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d30752799e4116-wk-Fact-2EEEEAE3EC85135BE24AF6259D4330F2"
      unitRef="usd">-48100000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-3C7A393C829A07CED889F6259DD2F88F-0-wk-Fact-967381669694E08A0CA1F6259D5298B0">Earnings&#160;per Share&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,902.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,039.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;193.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;209.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;193.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;209.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-5095988AFE556107F3D4F6259DD22B30-0-wk-Fact-C6B9E0AE10E76ED031B8F6259DA488C7">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,902.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,039.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;193.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;209.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;190.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;207.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;193.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;209.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30753987e1077-wk-Fact-1312D56524962A9DE5E6F6259D623531"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30753987e1096-wk-Fact-E8C18A0B34056E42ED95F6259D71C5BF"
      unitRef="usd">866600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30753987e1115-wk-Fact-4C12FF47E79C07429E22F6259D717E32"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30753987e1135-wk-Fact-8C9FB65CA2C5D8213BFDF6259D5219D8"
      unitRef="usd">2039500000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30753987e1232-wk-Fact-3DD915C4195E7A211C58F6259D14C30A"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30753987e1251-wk-Fact-FBB66D5A57657FD9D1A8F6259D04C4C0"
      unitRef="shares">207100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30753987e1270-wk-Fact-D6A6A637EC02E81810FBF6259D2321A2"
      unitRef="shares">193400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30753987e1290-wk-Fact-D23833DF65E5DC2469C7F6259D046BE6"
      unitRef="shares">209200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30753987e1392-wk-Fact-5751B324E1913CDED278F6259D7191E7"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30753987e1411-wk-Fact-DD5FEEB703C2CF84CB26F6259D71BB37"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30753987e1430-wk-Fact-6F27A6F556636AF6971DF6259D714029"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30753987e1450-wk-Fact-C34E8235B209E8F68F20F6259D711F31"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30753987e1470-wk-Fact-276CE15A2F68BFE86E6DF6259D71EBBA"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30753987e1489-wk-Fact-D22682380E513186FE97F6259D714514"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30753987e1508-wk-Fact-DF604FE47373CC8539C5F6259D71F0FF"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30753987e1528-wk-Fact-610E82D6140287132ACEF6259D7161CE"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30753987e1548-wk-Fact-97A42FB55654AECFC72AF6259D71DF5B"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30753987e1567-wk-Fact-5D1AF68264A36DB2C56CF6259D712577"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30753987e1586-wk-Fact-1105087E5AA3A2AA5C86F6259D71C48E"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30753987e1606-wk-Fact-4DE99D56D14618FD4E65F6259D7103E1"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30753987e1626-wk-Fact-DEE4D28431B34CD3CD6FF6259D71F3C0"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30753987e1645-wk-Fact-9AAEFA125707B196A12EF6259D71AABE"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30753987e1664-wk-Fact-EFD4021373DBDE8E18F0F6259D71326D"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30753987e1684-wk-Fact-D9883D123D12914434E3F6259D710965"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30753987e1705-wk-Fact-EFA4D44B853EFAD7DA09F6259D7181DC"
      unitRef="shares">100000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30753987e1724-wk-Fact-D7E80FCE415B2EFB6107F6259D718566"
      unitRef="shares">200000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30753987e1743-wk-Fact-5713D77DEF68FCC5468AF6259D712709"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30753987e1763-wk-Fact-0055ED568A2706062425F6259D71D1A3"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30753987e1783-wk-Fact-735BC5DA3214A5F5DB05F6259D23547F"
      unitRef="shares">190400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30753987e1802-wk-Fact-8878D9126D3CB451B07EF6259D23E3E0"
      unitRef="shares">207300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30753987e1821-wk-Fact-561BED1750D028A1FC26F6259D23DF4C"
      unitRef="shares">193700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30753987e1841-wk-Fact-C1F390AE19DCE6838E36F6259D6231B8"
      unitRef="shares">209500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-39F693B8604FD1EC2A94F6259DD220A1-0-wk-Fact-5D43C1EFBF331FA09AD1F6259DA71F23">Share-based Payments&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;54.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;82.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;53.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;105.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock option expense reflects the accelerated vesting of stock options previously granted to NST employees as a result of our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-A5FF4B96F4FC3CEF8608F6259DD2D7EF-0-wk-Fact-4FA46E31CE608B634C47F6259DA786FA">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;54.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;82.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;53.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(13.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;105.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d30757294e998-wk-Fact-B511B8B9DB992AB4246BF6259D71DC3F"
      unitRef="usd">28100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d30757294e1017-wk-Fact-C68EEDE73D3B9F227A9FF6259DB214BC"
      unitRef="usd">17600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d30757294e1036-wk-Fact-173985EB2A1D14502DD4F6259D040D9D"
      unitRef="usd">49800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d30757294e1056-wk-Fact-9DEE8E331C091123F5EFF6259CF56F0E"
      unitRef="usd">39500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30757294e1071-wk-Fact-E2BB6BB3885C8EA92F17F6259CF5B85E"
      unitRef="usd">54800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30757294e1090-wk-Fact-8A5E0019CD8669E3CF46F6259CF59531"
      unitRef="usd">25200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30757294e1109-wk-Fact-E72295CA19D419E852A7F6259D719F5A"
      unitRef="usd">82600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d30757294e1129-wk-Fact-EDD003F48046F334FC44F6259D714360"
      unitRef="usd">53700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30757294e1149-wk-Fact-5A4E58142BF025B63C0DF6259CF56418"
      unitRef="usd">82900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30757294e1168-wk-Fact-741AC17027968767B1BFF6259DB2BDF1"
      unitRef="usd">42800000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30757294e1187-wk-Fact-69717924EA814EF78A97F6259CF55E82"
      unitRef="usd">132400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30757294e1207-wk-Fact-BABEC81DE8B988E1008EF6259CF54E25"
      unitRef="usd">93200000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30757294e1227-wk-Fact-334611AA556B9EF1852EF6259DB2004C"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30757294e1247-wk-Fact-6F1F12EB33D46D3F5C6AF6259CF51578"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30757294e1267-wk-Fact-44ABA89604925E034C5DF6259D04B937"
      unitRef="usd">6100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30757294e1288-wk-Fact-68730807DCA596141992F6259CF5F060"
      unitRef="usd">6200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30757294e1309-wk-Fact-3D20C17CD05B4C585BFCF6259DB2A441"
      unitRef="usd">80100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30757294e1328-wk-Fact-5F1156F1E986547E3849F6259CF5C5DB"
      unitRef="usd">40000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30757294e1347-wk-Fact-181CBD06A256337A3813F6259CF54DEB"
      unitRef="usd">126300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30757294e1367-wk-Fact-B7A1CB31B7389051850CF6259CF587BA"
      unitRef="usd">87000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30757294e1387-wk-Fact-5324F451FE0938CFC7CCF6259DB2FF0C"
      unitRef="usd">13600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30757294e1407-wk-Fact-B446EA1442B396E5186CF6259CF59DD9"
      unitRef="usd">6500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30757294e1427-wk-Fact-EF691CCA86EE7FA06775F6259D716DF3"
      unitRef="usd">21000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30757294e1448-wk-Fact-17FB14B47FA6E090A05AF6259CF5B8B1"
      unitRef="usd">14100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30757294e1474-wk-Fact-3325DA0BAD38DD2B6182F6259DB22542"
      unitRef="usd">66500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30757294e1493-wk-Fact-FFA01D15009BBD0CDA18F6259D714C33"
      unitRef="usd">33500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30757294e1512-wk-Fact-4E7CE436AD553471A032F6259CF57F11"
      unitRef="usd">105300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d30757294e1532-wk-Fact-5DB1A62BBF7E25466143F6259D71AE8C"
      unitRef="usd">72900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-7E5389B698B143C6797CF6259DD204B7-0-wk-Fact-BB7F8F76DA548D70A59CF6259DA764A6">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;15.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;42.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30757294e1761-wk-Fact-71B86506C4B2C3D4B16BF6259DB29D27"
      unitRef="usd">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30757294e1780-wk-Fact-A4E67E4FEEA23E1B9234F6259DB2EC63"
      unitRef="usd">7100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30757294e1799-wk-Fact-9D669B86B819253848DCF6259DB29172"
      unitRef="usd">15500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d30757294e1819-wk-Fact-EDD22506E9133AE680CEF6259DB2D0F9"
      unitRef="usd">13200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30757294e1834-wk-Fact-7A4C87C3FEDA0BC316E2F6259DB23EED"
      unitRef="usd">31800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30757294e1853-wk-Fact-9DB68F2272A9B9C82B0CF6259DB278BD"
      unitRef="usd">30600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30757294e1872-wk-Fact-C1B8DCB3E99D38829DEEF6259DB23580"
      unitRef="usd">66500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d30757294e1892-wk-Fact-E7476342D221A9C9239FF6259DB27F31"
      unitRef="usd">66700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d30757294e1912-wk-Fact-14051AAC2EDCAEEE369FF6259DB2AAD4"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d30757294e1931-wk-Fact-7F2B7959BCBE0DDC8027F6259DB20518"
      unitRef="usd">-700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d30757294e1951-wk-Fact-C34451D0F296F161A8A8F6259CF5FF55"
      unitRef="usd">-600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d30757294e1972-wk-Fact-46BB34011B7100B3C43AF6259DB24ACE"
      unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d30757294e1992-wk-Fact-B3F7F677881F1A14FFFFF6259DB2C1EA"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d30757294e2011-wk-Fact-9402CCB39DEE7D7327B8F6259DB27E6A"
      unitRef="usd">2000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d30757294e2030-wk-Fact-56861D01F6791F2A7D6DF6259DB2C65F"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d30757294e2050-wk-Fact-1E93843C56D5F71F7F07F6259DB24C6C"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30757294e2070-wk-Fact-8D95D9461642651A68D9F6259DB2B3E5"
      unitRef="usd">12100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30757294e2089-wk-Fact-9BE68D97FB17CD39817BF6259DB28975"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30757294e2108-wk-Fact-6595F186D034052637FEF6259DB2C931"
      unitRef="usd">14100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d30757294e2128-wk-Fact-61A18A823E386CD10BD2F6259DB2B1A3"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d30757294e2148-wk-Fact-E4D03D8B70BCB333F95AF6259DB20A7C"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d30757294e2167-wk-Fact-92ABF63EC7DBABC1BBE3F6259DB2B9FD"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d30757294e2186-wk-Fact-4124F5B5277754A53009F6259DB2C56B"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d30757294e2206-wk-Fact-6C9D33A95EE09BCF8FC9F6259DB29606"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30757294e2226-wk-Fact-DE80FADC9813280B4600F6259DB24043"
      unitRef="usd">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30757294e2245-wk-Fact-4A89E407E15788498D51F6259DB27670"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30757294e2264-wk-Fact-72EB6F30B48A080F9D1EF6259DB2268E"
      unitRef="usd">8000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d30757294e2284-wk-Fact-CE94966F68B92871737DF6259DB2C3BE"
      unitRef="usd">6000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30757294e2304-wk-Fact-73B6240E0F150233C17806A6B3B86785"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30757294e2323-wk-Fact-810677FF1DBA4AFC142306A744FA4814"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30757294e2342-wk-Fact-BF7E2C58CA3FD825FF0806A6F0D5139B"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d30757294e2362-wk-Fact-05DD6C6914B68219BECB06A71D653261"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30757294e2382-wk-Fact-5A4E58142BF025B63C0DF6259CF56418"
      unitRef="usd">82900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30757294e2401-wk-Fact-741AC17027968767B1BFF6259DB2BDF1"
      unitRef="usd">42800000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30757294e2420-wk-Fact-69717924EA814EF78A97F6259CF55E82"
      unitRef="usd">132400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30757294e2440-wk-Fact-BABEC81DE8B988E1008EF6259CF54E25"
      unitRef="usd">93200000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30757294e2461-wk-Fact-334611AA556B9EF1852EF6259DB2004C"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30757294e2481-wk-Fact-6F1F12EB33D46D3F5C6AF6259CF51578"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30757294e2501-wk-Fact-44ABA89604925E034C5DF6259D04B937"
      unitRef="usd">6100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30757294e2522-wk-Fact-68730807DCA596141992F6259CF5F060"
      unitRef="usd">6200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30757294e2548-wk-Fact-3D20C17CD05B4C585BFCF6259DB2A441"
      unitRef="usd">80100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30757294e2567-wk-Fact-5F1156F1E986547E3849F6259CF5C5DB"
      unitRef="usd">40000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30757294e2586-wk-Fact-181CBD06A256337A3813F6259CF54DEB"
      unitRef="usd">126300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30757294e2606-wk-Fact-B7A1CB31B7389051850CF6259CF587BA"
      unitRef="usd">87000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-64BC892B7BEBA480B6A1F6259DD2B36E-0-wk-Fact-B3C22834AF8782ADD1C8F6259D81070D">Income Taxes&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denmark assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Global Intangible Low-Taxed Income (GILTI)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to the combination of an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property (the effective tax rate decrease from this internal reorganization is not expected to recur post 2019) and a higher effective tax rate in 2018 resulting from the sale of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights, offset by a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax expense related to the proposed divestiture of our subsidiary that owns our Hiller&#xf8;d, Denmark manufacturing operations and a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Specifically in regard to the Hiller&#xf8;d, Denmark manufacturing operations, although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of the operations as held for sale and results in a taxable gain in certain jurisdictions.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the internal reorganization of certain intellectual property rights, we have recorded a deferred tax asset of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$856.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$685.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the second quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Federal and State Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;International Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have made payments totaling approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes on certain payments made by our subsidiary that owns our biologics manufacturing operations in Hiller&#xf8;d, Denmark. We continue to dispute the assessments for all of these periods and believe that the tax positions taken related to these payments are valid. Any amount refunded by SKAT associated with this withholding tax receivable will be paid to our subsidiary that owns our biologics manufacturing operations in Hiller&#xf8;d, Denmark.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Proposed Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#xf8;d, Denmark. This withholding tax receivable from SKAT will be included within the assets that will be transferred to FUJIFILM as part of the proposed transaction. Under the share purchase agreement, FUJIFILM is required to remit any future proceeds refunded by SKAT to us. We have assessed the collectability of the receivable from FUJIFILM and regard it as a contingent gain, which does not meet the probable threshold for recognition under ASC 450, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Contingencies&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and therefore we have recorded a pre-tax charge of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to write the asset down to zero as a component of the loss on assets and liabilities held for sale in the first quarter of 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also reclassified &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$53.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our deferred tax liability to liabilities held for sale in our condensed consolidated balance sheets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the proposed divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read Note 3, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4BFD5B727F0CAA25CA95F6259DD278A0-0-wk-Fact-0F6C0E6914CA0171626AF6259D814314">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denmark assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Global Intangible Low-Taxed Income (GILTI)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e949-wk-Fact-3129734233234053B136F6259D5227B6"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q2QTD"
      decimals="INF"
      id="d30757297e964-wk-Fact-2C0BC2F9B66A1FDEEE80F6259D52AE43"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e979-wk-Fact-6C5AF0BD23463090B391F6259D528E6A"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q2YTD"
      decimals="INF"
      id="d30757297e994-wk-Fact-696B5E69B182628278BDF6259D527E08"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1011-wk-Fact-4E8710AC21A61BA4AFDAF6259D528D96"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1025-wk-Fact-F6A051F2DC84440D4092F6259D52E014"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1039-wk-Fact-2D3320B987BB105D05E3F6259D5284CB"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1053-wk-Fact-B5968F98BB4D29AAAD82F6259D52F205"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1069-wk-Fact-1159262E6C993C878A07F6259D52544D"
      unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1084-wk-Fact-960BF2355277623A3F39F6259D43E663"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1099-wk-Fact-474A0309103CFF646A06F6259D523649"
      unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1114-wk-Fact-CA2C6198D1D69E1F071CF6259D5209FA"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1131-wk-Fact-EDD50968240707E44116F6259D523E7F"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1146-wk-Fact-B4EDA84EC6AE13807677F6259D52698D"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1161-wk-Fact-B529321409CEC8C5FADAF6259D528F09"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1176-wk-Fact-515A7582A8B40A48CC33F6259D5275A6"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1193-wk-Fact-D0EA032A9698AE2EB130F6259D5251A9"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1207-wk-Fact-E7094419BEDB8E6DF5C8F6259D52B736"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1221-wk-Fact-93ABC2F87F6826D88105F6259D527AD7"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1235-wk-Fact-86BB758115D20A5C65C0F6259D522F55"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1251-wk-Fact-0BCE2F82D21F82DF6491F6259D529843"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2018Q2QTD"
      decimals="INF"
      id="d30757297e1265-wk-Fact-29DBE4D92E44432007C8F6259D520443"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1279-wk-Fact-BD359459777F687D2EFEF6259D52B7C1"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2018Q2YTD"
      decimals="INF"
      id="d30757297e1293-wk-Fact-3ECC1875EEC0103E3010F6259D5202DA"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1309-wk-Fact-09085D269CB60D14FFBD0AFCDFD932FF"
      unitRef="number">-0.050</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1324-wk-Fact-179EC99B1E6A4C42B85D0AFCF8538E3E"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1338-wk-Fact-C554B8F2915A3F58F14C0AFD23842EA0"
      unitRef="number">-0.024</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1353-wk-Fact-35AA6450D6444697D03D0AFD4A068A2A"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1369-wk-Fact-29DF6566572B77E71458F6259D5249B2"
      unitRef="number">0.014</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1383-wk-Fact-FCD7756E26FF4B117EBCF6259D525948"
      unitRef="number">0.018</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1397-wk-Fact-910DD8DDDCA5C292D29FF6259D526D77"
      unitRef="number">0.017</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1411-wk-Fact-4B2E0CAD7F029A6BDA14F6259D52E1C2"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1427-wk-Fact-BA526238642074CAB62DF6259D5214B4"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1441-wk-Fact-43215CC2D71811F74D23F6259D5261F1"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1455-wk-Fact-AB18D69523007EDF7386F6259D52ACF4"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1469-wk-Fact-F9397001DD1BEC67E4A5F6259D52954A"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1486-wk-Fact-0DC1184F605DA119ABBEF6259D435DC8"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1500-wk-Fact-B2E9EB0DE005DAC90FDCF6259D526C10"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1514-wk-Fact-57590215743E3537C1A9F6259D523D23"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1528-wk-Fact-5EE9221660A7DA339FC7F6259D43251D"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d30757297e1544-wk-Fact-3122850EB26C228709AEF6259D52427F"
      unitRef="number">0.141</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q2QTD"
      decimals="3"
      id="d30757297e1559-wk-Fact-1373B3EEAA9CDD259B93F6259D5207A1"
      unitRef="number">0.224</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d30757297e1574-wk-Fact-A913B4916E069B6ED3EBF6259D5274AB"
      unitRef="number">0.185</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q2YTD"
      decimals="3"
      id="d30757297e1589-wk-Fact-B70CA1DAEBBC197DBBD3F6259D52B180"
      unitRef="number">0.219</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30757297e1644-wk-Fact-136D8A2DB49CECD79C24F6259D52E80E"
      unitRef="usd">61300000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q2_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember"
      decimals="-5"
      id="d30757297e1654-wk-Fact-034A54F7FF85212C41E30B05048EBCC6"
      unitRef="usd">856700000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2019Q2_biib_DeferredTaxAssetLiabilityTypeAxis_us-gaap_IntellectualPropertyMember"
      decimals="-5"
      id="d30757297e1658-wk-Fact-25C48B4196ADDBC807F50B09EDDF023D"
      unitRef="usd">685300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="d30757297e1684-wk-Fact-938A76F2A87DCA09A17BF6259D810706"
      unitRef="usd">60000000.0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="d30757297e1698-wk-Fact-938A76F2A87DCA09A17BF6259D810706"
      unitRef="usd">60000000.0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d30757297e1705-wk-Fact-8E042DF4EA4562866591F6259D23FE2B"
      unitRef="usd">53800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-08A0F941C8D9D117A569F6259DD2D98B-0-wk-Fact-194E8CFCA052AFE3BC44F6259D71EB9C">Other Consolidated Financial Statement Detail&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;60.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(95.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(102.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(173.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;203.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(197.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(34.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;159.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(75.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(42.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;42.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(131.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;159.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;863.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;212.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;224.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;199.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;146.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;130.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;38.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;727.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;609.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,318.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,861.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,355.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,389.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and included accrued income taxes totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$801.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$791.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-63E8B8B76EC01146AAD9F6259DD2D521-0-wk-Fact-D6F75DBF8E447F3A2599F6259D71D97D">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;60.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(95.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(102.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(173.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;203.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(197.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(34.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;159.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(75.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e998-wk-Fact-7B1F227E752840C88A53F6259D71547C"
      unitRef="usd">29100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1017-wk-Fact-D89A01DB704AD746B883F6259D711FC9"
      unitRef="usd">28700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1036-wk-Fact-39EC78C59DF6AD63B127F6259D71E76A"
      unitRef="usd">60300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1056-wk-Fact-EA4CEB60D496492F5DCAF6259D815F57"
      unitRef="usd">55400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1071-wk-Fact-64D9F3FABBF968274AB0F6259D712D23"
      unitRef="usd">47700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1091-wk-Fact-0EF6A5DB586DDB76CDF4F6259D811DE1"
      unitRef="usd">51700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1111-wk-Fact-6B3128268D1C8D4DB812F6259D049EB7"
      unitRef="usd">95600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1132-wk-Fact-B278C072A6A9C28EF030F6259CF564A4"
      unitRef="usd">102200000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1153-wk-Fact-8E99235A2CC1D5A93A01F6259D816689"
      unitRef="usd">-173400000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1173-wk-Fact-BBB18990A1AFF862C253F6259D712F9F"
      unitRef="usd">5300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1192-wk-Fact-E30C9356B86057918D76F6259D71AC5C"
      unitRef="usd">203000000.0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1212-wk-Fact-30B55D02939A4B0B6C6EF6259D717527"
      unitRef="usd">-9100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1233-wk-Fact-FC83FDC95D5EEDDB779BF6259D7160DB"
      unitRef="usd">1700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1252-wk-Fact-AC91782429339CA025E9F6259D8155BD"
      unitRef="usd">-13000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1272-wk-Fact-86806CFE64829CF1A527F6259CF5F362"
      unitRef="usd">-500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1293-wk-Fact-56D1732C64F58A67C1FAF6259D716CC4"
      unitRef="usd">-14000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1314-wk-Fact-0C5EACAFA0AF436D3711F6259D71B9D1"
      unitRef="usd">-7100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1334-wk-Fact-B1BF54109021D9418DD7F6259CF598A0"
      unitRef="usd">-3800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1354-wk-Fact-3D7E99AC2A832675CF6EF6259CF5CB1B"
      unitRef="usd">-7300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1375-wk-Fact-6E283E3ED149479B9713F6259D81F5B4"
      unitRef="usd">-5600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1401-wk-Fact-1D06C1D1506111B2621BF6259D239489"
      unitRef="usd">-197400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1421-wk-Fact-9D3C2F37AB35BFAE8012F6259D232D43"
      unitRef="usd">-34500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1441-wk-Fact-4F4E212D12754366EB0BF6259D4303AC"
      unitRef="usd">159900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1461-wk-Fact-FA4E213E25606EA300E5F6259D2321CF"
      unitRef="usd">-75500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-3D2122A9D883D927DC2AF6259DD2E979-0-wk-Fact-1F24EBAAB139C92E8424F6259D712D06">&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(42.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;42.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;(131.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;159.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1642-wk-Fact-71E0469F4F0FD027D67A0B12EF971E94"
      unitRef="usd">-174200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1657-wk-Fact-C6D86EAD6671B23741E50B12EF7C0BAF"
      unitRef="usd">5400000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1671-wk-Fact-D1197F618C868111F2500B12EF8396B5"
      unitRef="usd">201900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1685-wk-Fact-1981B1CBA79744C7D78B0B12EF801144"
      unitRef="usd">-1500000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1702-wk-Fact-0303B95ABFC854ED921D0B12EF9ABF60"
      unitRef="usd">42900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1717-wk-Fact-CE6A529AF66C2DF92FF80B12EF75657A"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1731-wk-Fact-052752627D18DA599FF70B12EF915131"
      unitRef="usd">-42400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1745-wk-Fact-07EEEDAD692AD242AB360B12EF875DD3"
      unitRef="usd">500000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d30759021e1762-wk-Fact-68B07F7CE298C8F992E70B12EF796C95"
      unitRef="usd">-131300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d30759021e1777-wk-Fact-96B711CDA63E5815DDB50B12EF8D0D4F"
      unitRef="usd">5400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d30759021e1791-wk-Fact-709B5E9F291C74336B780B12EF8A0249"
      unitRef="usd">159500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d30759021e1805-wk-Fact-CB3BEB0ED6EB66DF602E0B12EF93AC72"
      unitRef="usd">-1000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FA2997BC103FC4DCA272F6259DD2B28E-0-wk-Fact-BD8B4FBCD5E7DD20CA41F6259D71BAF6">&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;863.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;874.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;212.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;224.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;199.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;146.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;444.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;130.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;261.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;38.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;125.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;727.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;609.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;2,318.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,861.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d30759021e1904-wk-Fact-664C6114E7A93753808DF6259D5202EB"
      unitRef="usd">863500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d30759021e1923-wk-Fact-2332C6EB86868144FE27F6259D430E8C"
      unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e1938-wk-Fact-BDB45425303197E19B55F6259D23AD36"
      unitRef="usd">212800000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e1957-wk-Fact-385A15F813D79734575EF6259D14C483"
      unitRef="usd">224700000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e1977-wk-Fact-C448841029E726782A07F6259D23DB6D"
      unitRef="usd">199400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e1996-wk-Fact-4D37744F7DD45A710BFDF6259D145524"
      unitRef="usd">320900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e2016-wk-Fact-F072CB58416A848352BDF6259D149516"
      unitRef="usd">146200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e2035-wk-Fact-B2D68BC015F832171A36F6259D23BE1E"
      unitRef="usd">444800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e2055-wk-Fact-3B172870604FD6AC85B2F6259D239B5B"
      unitRef="usd">130400000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e2074-wk-Fact-083EC9609C074F899B35F6259D14E070"
      unitRef="usd">261600000</biib:Collaborationexpensesaccrual>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e2094-wk-Fact-3D8839FA287DF987E38FF6259D141D69"
      unitRef="usd">38200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e2113-wk-Fact-0270E61648E7F621DF42F6259D2310ED"
      unitRef="usd">125200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e2133-wk-Fact-B208E5442234260D9F45F6259D04BCCB"
      unitRef="usd">727500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e2152-wk-Fact-5BBFFDAEFB6203BCE239F6259D144157"
      unitRef="usd">609300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e2177-wk-Fact-D2C177CB69195CA03AC0F6259D33900E"
      unitRef="usd">2318000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e2196-wk-Fact-86E688319B1BFB671A79F6259D3356D0"
      unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e2222-wk-Fact-8904E7BA29021E7A3B2AF6259D33E1F9"
      unitRef="usd">1355800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e2226-wk-Fact-D6DAB453FA1C7269FD1AF6259D233862"
      unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759021e2238-wk-Fact-6800B1C121373EA4E3F7F6259D71ED08"
      unitRef="usd">801500000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759021e2243-wk-Fact-FD770021538CE8280A58F6259D71F2A2"
      unitRef="usd">791400000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9E1659A9DBCDC683D89EF6259DD2390A-0-wk-Fact-CB802719E78997CC585BF6259D912C31">Collaborative and Other Relationships&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;68.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;136.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;111.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;68.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;of aducanumab development expense incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. As a result of this decision, in the first quarter of 2019, we accrued approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the termination of various clinical trials and research and development contracts net of the expected &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sales and marketing expense incurred was shared in proportion to the same region-based profit split that would have been utilized to co-promote aducanumab had it been commercialized. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2018 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;165.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;140.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;91.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Skyhawk Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as potential royalties on net commercial sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$38.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our condensed consolidated statements of income and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership percentage remained at approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;basis differences are amortized over their economic life. The total basis difference was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$115 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to inventory, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$615 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to developed technology and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$170 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; attributed to IPR&amp;amp;D. A deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$225 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years, respectively, one quarter in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized losses on our investment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These losses reflect our share of income totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and losses totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$8.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and amortization of basis differences totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$21.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$36.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;712.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$615.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$680.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$63.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$121.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect Samsung Bioepis' &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$39.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$83.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$52.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$77.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$14.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$32.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-20982A016CA37C7CF820F6259DD2B489-0-wk-Fact-7942CE727AE0140E1B96F6259D912194">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;68.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;136.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;111.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;34.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;68.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1034-wk-Fact-EFBAE164A05731242AFEF6259D52AB11"
      unitRef="usd">68600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1053-wk-Fact-D5FC18004BCAD44EAD42F6259D52F44B"
      unitRef="usd">54600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1072-wk-Fact-312F99746438C5864125F6259D5263D0"
      unitRef="usd">136600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1092-wk-Fact-635F0E6560F3E961612FF6259D52193B"
      unitRef="usd">111100000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1112-wk-Fact-724D7FD84A0F56B423F4F6259D52DB47"
      unitRef="usd">34300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1131-wk-Fact-B26F8769EE06E40D8D85F6259D52C635"
      unitRef="usd">27300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1150-wk-Fact-1D34AF37A6B9BCAE9149F6259D529A2D"
      unitRef="usd">68300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1170-wk-Fact-D8C38730C8E4B9AC2F2BF6259D52D5ED"
      unitRef="usd">55500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d30760591e1186-wk-Fact-F421E1E50AA6DD8AA475F6259D916078"
      unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d30760591e1190-wk-Fact-A821BE56FC23499C31B0F6259D9170C2"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1198-wk-Fact-83205B9699764B97F7AAF6259D915357"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d30760591e1202-wk-Fact-A821BE56FC23499C31B0F6259D9170C2"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9018276EF046E8B18FF0F6259DD294C0-0-wk-Fact-93B6936ECA0BFDEA3BD1F6259D91A2FA">&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;165.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;140.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;65.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;91.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;21.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1419-wk-Fact-213C39BAD38692D371C6F6259D33495E"
      unitRef="usd">3200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1438-wk-Fact-A82C59C4E524F51874A4F6259D33BF15"
      unitRef="usd">76500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1457-wk-Fact-015E973F5550CFDA02E9F6259D81A496"
      unitRef="usd">165800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1477-wk-Fact-86DE013B087972C41DBCF6259D339577"
      unitRef="usd">140000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1497-wk-Fact-17177575544A41FA2140F6259D812E39"
      unitRef="usd">1700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1516-wk-Fact-D38D2488E59142089F85F6259D335085"
      unitRef="usd">65000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1535-wk-Fact-ABCA7EB95E9A185D9F60F6259D43ADA7"
      unitRef="usd">91200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1555-wk-Fact-7C38B092914F973E2FBBF6259D818184"
      unitRef="usd">128500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1657-wk-Fact-8E40E958D4FEB901CB27F6259D8118B2"
      unitRef="usd">200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1676-wk-Fact-2D866D0E22166719F666F6259D333785"
      unitRef="usd">14000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1695-wk-Fact-D1A97C0A13E0E78D8D59F6259D33D86C"
      unitRef="usd">21200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1715-wk-Fact-9259C2C83704AD3CCA83F6259D3379B9"
      unitRef="usd">21200000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1735-wk-Fact-5C7797C2E1BDC9A5F401F6259D81D12A"
      unitRef="usd">100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1754-wk-Fact-8A25906FD682CBF1A0B8F6259D330E7B"
      unitRef="usd">9200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1773-wk-Fact-1CEF2789422C2D278F3FF6259D33AD41"
      unitRef="usd">11700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d30760591e1793-wk-Fact-84AA08E595A60102F325F6259D819E7B"
      unitRef="usd">13900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-8"
      id="d30760591e1821-wk-Fact-9E44D095667D0875E991F6259D910110"
      unitRef="usd">2000000000.0</biib:AdditionalMilestonePayment>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d30760591e1828-wk-Fact-B0ACC52BA0217BEB96C2F6259D91F3F7"
      unitRef="usd">74000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d30760591e1832-wk-Fact-C4E2F8273F4FFAE7630AF6259D91971E"
      unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2019Q1_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d30760591e1836-wk-Fact-013E61936C5D6F2AD48EF6259D9168CB"
      unitRef="usd">35500000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2018Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d30760591e1850-wk-Fact-0E8D44ADE3BB672596F8F6259D81B710"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d30760591e1854-wk-Fact-6EDF670AD27ED3D62C34F6259D81C455"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d30760591e1858-wk-Fact-17D1AF9D526AF59A8697F6259D62566B"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1862-wk-Fact-05ACF1EDB334962654D2F6259D62BBCF"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d30760591e1871-wk-Fact-6EDF670AD27ED3D62C34F6259D81C455"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-6"
      id="d30760591e1884-wk-Fact-A1C9A0EF6B15869E8097F6259D917925"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      decimals="-6"
      id="d30760591e1888-wk-Fact-86BE074DB9124A6EC150F6259D91EA91"
      unitRef="usd">115000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d30760591e1892-wk-Fact-6214B49FB662B79E45AFF6259D9173B1"
      unitRef="usd">615000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d30760591e1896-wk-Fact-676B1E9E911356443709F6259D915A14"
      unitRef="usd">170000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_biib_DeferredtaxliabilityMember"
      decimals="-6"
      id="d30760591e1900-wk-Fact-35E266ED5B6DCD88D558F6259D9185D8"
      unitRef="usd">225000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      id="d30760591e1905-wk-Fact-53FC9B3E9926AD7E0E43F6259D915D7A">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d30760591e1909-wk-Fact-46BE2F2E0767988A3EC5F6259D91B219">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1927-wk-Fact-6FDCA9B3A57BCD5C3FB6F6259D91FB2E"
      unitRef="usd">16300000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1931-wk-Fact-0D7B85985912B02305FE0B0EE4736EC4"
      unitRef="usd">45000000.0</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1935-wk-Fact-C1B6B774626649B67411F6259D913CCA"
      unitRef="usd">5500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1940-wk-Fact-121A575DA28DEF6851440B0F9EE158B3"
      unitRef="usd">-8500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1944-wk-Fact-5C1F8D0A38C0D0D9B08FF6259D919526"
      unitRef="usd">-21800000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1948-wk-Fact-BD9485F2F7CA73557FA80B0FCB5F4116"
      unitRef="usd">-36500000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d30760591e1963-wk-Fact-022EF5AA31A512FA766FF6259DA0F1BF"
      unitRef="KRW">712800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1967-wk-Fact-BDECDBD4AEDE0731C1B2F6259D91A881"
      unitRef="usd">615500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d30760591e1971-wk-Fact-ED996A004E1BA124DD15F6259D91563C"
      unitRef="KRW">759500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e1976-wk-Fact-97B393475AC97FAB6F5AF6259D916AE2"
      unitRef="usd">680600000</us-gaap:EquityMethodInvestments>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d30760591e1989-wk-Fact-D1C95822DD79876FD44CF6259D91B75F"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e2001-wk-Fact-0D1D967ABD4E7CC22D15F6259D91D37D"
      unitRef="usd">63400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e2005-wk-Fact-9B4572A2385BED806239F6259D914536"
      unitRef="usd">121500000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d30760591e2010-wk-Fact-D1C95822DD79876FD44CF6259D91B75F"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e2014-wk-Fact-897D11EC5297DB0EA599F6259D918288"
      unitRef="usd">39700000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d30760591e2018-wk-Fact-A690747F2BD9651F331BF6259D91BD71"
      unitRef="usd">83500000</biib:Collaborationprofitlosssharing>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30760591e2037-wk-Fact-D822364BEF5FD2CC97F0F6259D91EC80"
      unitRef="usd">52200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30760591e2041-wk-Fact-A7172E6749013B78F8B9F6259D91C37F"
      unitRef="usd">77000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30760591e2045-wk-Fact-98E22AB6B2061E8F5867F6259D91B53B"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d30760591e2050-wk-Fact-4C8CB41E2610218203F0F6259DA08900"
      unitRef="usd">32600000</us-gaap:Revenues>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0E5AB135A3E395E4CD69F6259DD280B8-0-wk-Fact-3A49E0BC89EF164213B1F6259D717CB1">Investments in Variable Interest Entities&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, of aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$24.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$28.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2019Q2"
      decimals="-5"
      id="d30759200e837-wk-Fact-A46C2E6294E147EFEADDF6259D7170C0"
      unitRef="usd">24000000.0</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d30759200e841-wk-Fact-8F87BC379A3BBA28D7A2F6259D71E1B1"
      unitRef="usd">28700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C707E0A683EB6E2A111CF6259DD28B88-0-wk-Fact-DF3EABB533CDFA95F10EF6259D04CA76">Litigation&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#x2018;510 Patent), which was issued in June 2018 and expires in May 2035. A hearing has been scheduled for late 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#x2018;510 Patent, and against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. A hearing in the proceeding in Germany has been set for March 2020. No hearing has been set in the proceeding in Italy.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An estimate of the possible loss or range of loss in the above matters cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the &#x2018;510 Patent. Fresenius Kabi counterclaimed for infringement, damages and injunctive relief. In July 2019 the United Kingdom Patents Court entered a consent order in which it declared that the United Kingdom counterpart of the '510 Patent is invalid, ordered the patent revoked and dismissed Fresenius Kabi's counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#x2018;510 Patent. A trial is scheduled in the Dutch matter for October 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. declined to intervene. The case alleges agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seeking a declaration of the action as a class action and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;an award of damages, interest and attorneys' fees. In June 2019 the U.S. Court of Appeals for the First Circuit affirmed the judgment below dismissing the complaint with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial date has not been set in the Delaware action against Banner Life Sciences LLC. A trial date has been set for December 2019 in the other Delaware actions, and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO revoked Forward Pharma&#x2019;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for June 2020. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#x2018;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#x2018;127 Patent) (&#x201c;Administration of agents to treat inflammation&#x201d;).  The Polish &#x2018;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#x2018;263 Patent expires in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="FD2019Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR"
      decimals="-5"
      id="d30761196e925-wk-Fact-48DAF5B6C31320BDCEE0F6259D0464FE"
      unitRef="usd">70000000.0</us-gaap:LossContingencyDamagesSoughtValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6827095136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jul. 19, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,447,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:Security12bTitle@anonymousType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6824667056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="nump">$ 6,487.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">476.3<span></span>
</td>
<td class="nump">421.0<span></span>
</td>
<td class="nump">1,078.3<span></span>
</td>
<td class="nump">867.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">484.8<span></span>
</td>
<td class="nump">981.0<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
<td class="nump">1,477.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">587.6<span></span>
</td>
<td class="nump">516.2<span></span>
</td>
<td class="nump">1,155.3<span></span>
</td>
<td class="nump">1,017.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">70.1<span></span>
</td>
<td class="nump">107.4<span></span>
</td>
<td class="nump">138.3<span></span>
</td>
<td class="nump">211.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">121.6<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">113.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,660.8<span></span>
</td>
<td class="nump">2,143.3<span></span>
</td>
<td class="nump">3,647.9<span></span>
</td>
<td class="nump">3,739.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,955.9<span></span>
</td>
<td class="nump">1,213.2<span></span>
</td>
<td class="nump">3,458.6<span></span>
</td>
<td class="nump">2,747.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(197.4)<span></span>
</td>
<td class="num">(34.5)<span></span>
</td>
<td class="nump">159.9<span></span>
</td>
<td class="num">(75.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,758.5<span></span>
</td>
<td class="nump">1,178.7<span></span>
</td>
<td class="nump">3,618.5<span></span>
</td>
<td class="nump">2,672.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">248.1<span></span>
</td>
<td class="nump">263.7<span></span>
</td>
<td class="nump">670.6<span></span>
</td>
<td class="nump">586.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,494.1<span></span>
</td>
<td class="nump">915.0<span></span>
</td>
<td class="nump">2,902.9<span></span>
</td>
<td class="nump">2,086.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 2,902.9<span></span>
</td>
<td class="nump">$ 2,039.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="nump">$ 15.01<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="nump">$ 14.99<span></span>
</td>
<td class="nump">$ 9.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">193.4<span></span>
</td>
<td class="nump">209.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
<td class="nump">209.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 5,560.3<span></span>
</td>
<td class="nump">$ 5,281.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">576.4<span></span>
</td>
<td class="nump">490.4<span></span>
</td>
<td class="nump">1,093.8<span></span>
</td>
<td class="nump">933.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 452.4<span></span>
</td>
<td class="nump">$ 273.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838442240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 2,902.9<span></span>
</td>
<td class="nump">$ 2,039.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(37.9)<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
<td class="nump">103.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(92.0)<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
<td class="num">(47.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(33.1)<span></span>
</td>
<td class="nump">42.3<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">1,461.0<span></span>
</td>
<td class="nump">908.9<span></span>
</td>
<td class="nump">2,890.4<span></span>
</td>
<td class="nump">2,094.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 1,460.6<span></span>
</td>
<td class="nump">$ 957.3<span></span>
</td>
<td class="nump">$ 2,890.0<span></span>
</td>
<td class="nump">$ 2,141.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6824127248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,723.4<span></span>
</td>
<td class="nump">$ 1,224.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,228.8<span></span>
</td>
<td class="nump">2,313.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,959.6<span></span>
</td>
<td class="nump">1,958.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">557.5<span></span>
</td>
<td class="nump">526.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">776.7<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">683.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">980.4<span></span>
</td>
<td class="nump">687.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,909.8<span></span>
</td>
<td class="nump">7,640.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,309.3<span></span>
</td>
<td class="nump">1,375.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,077.5<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">434.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,681.3<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,749.2<span></span>
</td>
<td class="nump">5,706.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">2,820.1<span></span>
</td>
<td class="nump">2,153.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,306.0<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,287.6<span></span>
</td>
<td class="nump">25,288.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">427.2<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">377.1<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Liabilities held for sale</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,318.0<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,210.9<span></span>
</td>
<td class="nump">3,295.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">5,948.5<span></span>
</td>
<td class="nump">5,936.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">2,400.6<span></span>
</td>
<td class="nump">1,636.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">423.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,355.8<span></span>
</td>
<td class="nump">1,389.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,338.8<span></span>
</td>
<td class="nump">12,257.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(252.9)<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,182.8<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">12,952.9<span></span>
</td>
<td class="nump">13,039.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">12,948.8<span></span>
</td>
<td class="nump">13,031.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 26,287.6<span></span>
</td>
<td class="nump">$ 25,288.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77912953&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6826786784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6827042672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,902.9<span></span>
</td>
<td class="nump">$ 2,086.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">238.1<span></span>
</td>
<td class="nump">340.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">98.0<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">Loss on assets and liabilities held for sale</a></td>
<td class="nump">113.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">71.6<span></span>
</td>
<td class="num">(57.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Unrealized (gain) loss on strategic investments</a></td>
<td class="nump">199.2<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(187.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(108.7)<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">216.1<span></span>
</td>
<td class="num">(13.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">306.9<span></span>
</td>
<td class="nump">183.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(80.3)<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">3,423.5<span></span>
</td>
<td class="nump">2,556.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">3,255.8<span></span>
</td>
<td class="nump">6,802.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(2,075.1)<span></span>
</td>
<td class="num">(4,774.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="num">(300.0)<span></span>
</td>
<td class="num">(900.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Nightstar Therapeutics plc, net of cash acquired</a></td>
<td class="num">(744.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(314.0)<span></span>
</td>
<td class="num">(381.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(85.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchase of Ionis Pharmaceuticals, Inc. stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(462.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">309.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="nump">128.0<span></span>
</td>
<td class="nump">198.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(3,057.3)<span></span>
</td>
<td class="num">(3,000.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(23.6)<span></span>
</td>
<td class="num">(14.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="num">(38.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(3,055.0)<span></span>
</td>
<td class="num">(3,060.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">496.5<span></span>
</td>
<td class="num">(305.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,224.6<span></span>
</td>
<td class="nump">1,573.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 1,723.4<span></span>
</td>
<td class="nump">$ 1,250.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6939267152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>2019 Share Repurchase Program</div></th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-01 </div>
<div>Accumulated Other Comprehensive Income</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-16 </div>
<div>Retained earnings</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 12,598.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 97.8<span></span>
</td>
<td class="num">$ (318.4)<span></span>
</td>
<td class="nump">$ 15,810.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(211.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">12,612.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">2,039.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,039.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">46.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,086.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest, decrease from distributions to noncontrolling interest holders</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (171.2)<span></span>
</td>
<td class="num">$ (2,828.8)<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(38.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(38.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">87.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Adoption of new accounting guidance</a></td>
<td class="nump">479.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 478.4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">12,253.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(261.6)<span></span>
</td>
<td class="nump">15,499.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">12,260.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(201.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">14,037.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(303.9)<span></span>
</td>
<td class="nump">17,334.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(211.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">14,053.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">866.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">915.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">42.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest, decrease from distributions to noncontrolling interest holders</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (48.3)<span></span>
</td>
<td class="num">$ (2,701.7)<span></span>
</td>
<td class="num">$ (2,750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">41.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">12,253.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(261.6)<span></span>
</td>
<td class="nump">15,499.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">12,260.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(201.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">13,031.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(221.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">13,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">2,902.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,902.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,902.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(12.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(12.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (19.7)<span></span>
</td>
<td class="num">$ (890.2)<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (110.5)<span></span>
</td>
<td class="num">$ (2,036.9)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">104.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">12,948.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
<td class="nump">16,182.8<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">12,952.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(208.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">13,822.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(219.8)<span></span>
</td>
<td class="nump">17,026.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(219.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">13,829.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(33.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(909.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="num">$ (1,491.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,491.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (19.7)<span></span>
</td>
<td class="num">$ (890.2)<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (44.9)<span></span>
</td>
<td class="num">$ (1,446.7)<span></span>
</td>
<td class="num">$ (1,491.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">12,948.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (252.9)<span></span>
</td>
<td class="nump">$ 16,182.8<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">12,952.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(208.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6829190016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Assets and Liabilities Held For Sale</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$463.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$526.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6841713216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 7, 2019, we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid-to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (formerly known as NSR-REP1), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and has no approved treatments, and BIIB112 (formerly known as NSR-RPGR), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no approved treatments.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$847.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is  attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$26.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the in-process research and development (IPR&amp;D) programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with BIIB111. The fair value associated with BIIB111 was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$480.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded an additional IPR&amp;D asset related to BIIB112 of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$220.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recognized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for global intangible low-taxed income (GILTI). Goodwill that is tax deductible for GILTI purposes is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our condensed consolidated statements of income. Subsequent to the acquisition date, our results of operations include the results of operations of NST.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management&#8217;s analysis related to certain matters, such </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">as finalizing our assessment of the IPR&amp;D programs acquired and preparing and submitting certain income tax and non-income tax filings and returns. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830444160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text">Divestitures<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$890.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we have provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we expect to incur an adverse commitment obligation of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$120.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with such guarantees. We may adjust this estimate based upon changes in business conditions, which may result in the recognition of additional losses. We are also obligated to indemnify FUJIFILM for liabilities that may exist relating to certain business activities incurred prior to the closing of the proposed transaction.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we have not included these contingent payments in our estimate of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the proposed transaction, we also expect to enter into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM would use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that the operations to be disposed of in the proposed transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2019 the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>641.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>62.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance on disposal group on assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(113.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>683.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>53.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>88.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$174.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss includes a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$113.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease to our original estimate as of March 31, 2019, reflecting our current estimated fair value of the assets and liabilities held for sale, adjusting for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and our estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$120.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the proposed transaction. Our total estimated loss is based on current exchange rates and business conditions, and any changes to these factors through the closing date of the transaction will result in adjustments to the carrying values of the related assets and liabilities as well as a corresponding adjustment to the loss amount recognized on the sale.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of assets and liabilities expected to be sold to FUJIFILM is a Level 3 measurement and is based on the expected consideration from the sale, including the valuation of the adverse commitment, as discussed above.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proposed transaction remains subject to certain closing conditions. We expect to complete the proposed transaction in the third quarter of 2019. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6841669888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>869.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,150.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>825.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,086.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>379.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>554.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>180.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>625.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>264.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>211.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>475.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>265.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>467.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,513.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>690.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,204.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,536.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>666.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,202.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>257.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>488.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>216.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>422.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>115.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>115.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,744.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,135.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,880.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,741.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,015.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,757.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,587.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>561.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,149.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,554.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>519.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,073.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>707.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>348.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,055.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>816.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,175.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>509.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>426.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>935.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>515.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>414.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,803.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,187.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,885.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,341.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,227.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>453.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>552.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,006.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>393.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>392.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>786.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>236.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>236.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>254.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>254.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,257.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,302.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,560.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,279.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,001.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,281.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.2%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.6%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>308.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,391.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,710.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(41.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(42.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(189.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(827.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,017.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(121.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(505.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(639.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>124.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>905.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,062.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>199.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>863.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,062.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>377.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>768.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>708.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>199.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>325.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>576.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>490.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,093.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>933.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>77.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>79.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>369.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>219.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>160.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>452.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>273.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$34.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$241.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$47.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$94.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830438640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>205.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>427.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>144.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>776.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>776.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>776.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019 we sold to Bioverativ most of the remaining hemophilia-related inventory on hand with a cost basis totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$173.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> pursuant to the terms of the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. Upon closing of the proposed transaction, we expect to receive up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$890.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, subject to certain working capital adjustments and other contractual terms. As a result, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of work in process inventory was reclassified to assets held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred. In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hiller&#248;d facility to FUJIFILM at carrying value.</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843014848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(542.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2,754.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>251.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,734.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>270.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,175.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,175.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,449.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,189.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,330.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,308.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,426.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,745.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,681.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,727.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,120.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$138.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$107.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$211.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. The decrease in amortization and impairment of acquired intangible assets was primarily due to a net overall decrease in our expected rate of amortization for acquired intangible assets. This decrease was primarily due to lower amortization subsequent to the impairment in the fourth quarter of 2018 of the U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and higher expected lifetime revenues of TYSABRI. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no impairment charges.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$246.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of NST on June 7, 2019, we acquired IPR&amp;D programs with an estimated fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$700.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. Acquired and in-licensed rights and patents also includes our rest of world license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,933.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the net book value of the TECFIDERA asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$55.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our TECFIDERA license rights, please read Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the second quarter of 2019. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>130.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>255.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>210.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reclassification of goodwill to assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,749.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The reclassification of goodwill to assets held for sale relates to an allocation based upon the relative fair value of the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our Hiller&#248;d, Denmark manufacturing operations meeting the criteria to be classified as held for sale due to the proposed divestiture, goodwill was reviewed for impairment, and based upon this review, no impairments were recognized. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div>Other includes changes related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843121136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,120.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,120.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,687.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,687.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>604.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>604.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>246.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>246.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>510.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>333.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,286.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,109.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>563.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,102.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,050.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our agreement with Ionis, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For a description of our validation procedures related to prices provided by third-party pricing services and our option </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pricing valuation model, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,507.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,491.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,480.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,032.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>996.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>995.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,867.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,738.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,745.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,737.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,953.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,722.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,802.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,360.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,948.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,037.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd., Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>421.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>498.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>523.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>499.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>499.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$255.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$265.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and expected timing of achieving certain development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to an increase in interest rates used to revalue our contingent consideration liabilities, the passage of time and a milestone payment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830446928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>338.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>231.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>97.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>405.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>279.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>194.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,120.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>934.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>748.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>753.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>293.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>294.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>309.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>310.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>245.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,530.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,538.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>164.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>247.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>345.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable equity securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>229.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>294.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>510.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,608.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,607.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>854.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>851.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>706.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>263.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>496.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,227.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,228.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,314.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,313.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,196.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,202.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,232.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,530.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,538.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,766.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,733.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,255.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,802.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$569.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$164.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reflected as a component of other current assets in our condensed consolidated balance sheet, with the remaining balance included in investments and other assets. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is included in investments and other assets in our condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in equity securities include shares of Ionis common stock acquired in June 2018. This investment is classified as a Level 2 marketable security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effect of the holding period restrictions on our Ionis stock valuation are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends. The remainder of our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1. </span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in our strategic investment portfolio for the six months ended June 30, 2019, primarily reflects the sale of a portion of our investment in Ionis common stock for approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$213.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as the sale of our investment in a non-marketable equity security, partially offset by an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2018 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6738620496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text">Derivative Instruments<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,111.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,701.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>56.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>98.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,402.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,239.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$27.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$6.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these gains are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and December&#160;31, 2018, includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these interest rate swap contracts. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>four months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$19.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$934.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$735.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, related to these contracts were recognized as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be materially different if the derivative assets and liabilities were offset.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6833095680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,886.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,797.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$47.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$99.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$64.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$129.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$57.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$641.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment, which is primarily comprised of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$318.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$290.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment, was reclassified to assets held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Additionally, we ceased recording depreciation on these assets as depreciation is not recorded during the period in which a long-lived asset or disposal group is classified as held for sale, even if the asset or disposal group continues to generate revenue during the period. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843077936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our leases have remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>nine years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>six years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one year</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>nine years</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All of our leases qualify as operating leases. The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>423.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>495.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:35%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>41.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>66.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>147.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>560.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>495.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(58.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(182.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. As a result, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease assets and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating lease liabilities were reclassified to assets and liabilities held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830564608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2019 Share Repurchase Program). Our 2019 Share Repurchase Program does not have an expiration date. All share repurchases under our 2019 Share Repurchase Program will be retired. Under our 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$909.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.1 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our 2019 Share Repurchase program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.1 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.75 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>13.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(30.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(271.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(252.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(316.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(222.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(261.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(48.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843146112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings&#160;per Share<div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>866.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,902.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,039.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>193.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>209.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>209.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6829169456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text">Share-based Payments<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>105.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock option expense reflects the accelerated vesting of stock options previously granted to NST employees as a result of our acquisition of NST. For additional information on our acquisition of NST, please read Note 2, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737610592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark assets held for sale</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Global Intangible Low-Taxed Income (GILTI)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property (the effective tax rate decrease from this internal reorganization is not expected to recur post 2019) and a higher effective tax rate in 2018 resulting from the sale of </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights, offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense related to the proposed divestiture of our subsidiary that owns our Hiller&#248;d, Denmark manufacturing operations and a higher effective tax rate in 2018 resulting from the sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Specifically in regard to the Hiller&#248;d, Denmark manufacturing operations, although we are recognizing a loss on the proposed divestiture of such subsidiary, the proposed divestiture requires us to write off certain deferred tax assets upon the classification of the operations as held for sale and results in a taxable gain in certain jurisdictions.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, we have recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$856.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$685.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the second quarter of 2019.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">International Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes on certain payments made by our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. We continue to dispute the assessments for all of these periods and believe that the tax positions taken related to these payments are valid. Any amount refunded by SKAT associated with this withholding tax receivable will be paid to our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Proposed Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hiller&#248;d, Denmark. This withholding tax receivable from SKAT will be included within the assets that will be transferred to FUJIFILM as part of the proposed transaction. Under the share purchase agreement, FUJIFILM is required to remit any future proceeds refunded by SKAT to us. We have assessed the collectability of the receivable from FUJIFILM and regard it as a contingent gain, which does not meet the probable threshold for recognition under ASC 450, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Contingencies</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and therefore we have recorded a pre-tax charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to write the asset down to zero as a component of the loss on assets and liabilities held for sale in the first quarter of 2019. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also reclassified </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$53.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our deferred tax liability to liabilities held for sale in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the proposed divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read Note 3, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6939345840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text">Other Consolidated Financial Statement Detail<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>60.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(51.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(95.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(102.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(173.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>203.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(197.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(34.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>159.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(75.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(174.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(42.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>42.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(131.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>159.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>863.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>212.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>224.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>199.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>146.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>38.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>727.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>609.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,318.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,861.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,355.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,389.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$801.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$791.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6833095680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text">Collaborative and Other Relationships<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our BAN2401 and Elenbecestat Collaboration, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>68.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>111.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred and, beginning January 1, 2019, is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expense incurred. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to AD and mild AD dementia. As a result of this decision, in the first quarter of 2019, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense incurred was shared in proportion to the same region-based profit split that would have been utilized to co-promote aducanumab had it been commercialized. For additional information on the Aducanumab Collaboration Agreement, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2018 Form 10-K.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>76.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>165.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>140.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>91.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$38.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets and will be expensed as the services are provided. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$115 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to inventory, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$615 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to developed technology and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$170 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> attributed to IPR&amp;D. A deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$225 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was established for the acquired assets that had no tax basis. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized losses on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These losses reflect our share of income totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and losses totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and amortization of basis differences totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$21.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$36.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>712.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$615.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$680.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</span></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$63.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$121.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$39.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$83.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$52.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$77.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$14.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$32.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis and our other significant collaboration arrangements, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843076496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text">Investments in Variable Interest Entities<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound.  </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we and Eisai announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, of aducanumab.</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimbursed Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$24.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$28.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830444704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation<div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH&#160;(Fresenius Kabi)&#160;commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen commercializes in Europe, infringes the French counterpart of European Patent No. 3 148 510&#160;(the &#8216;510 Patent), which was issued in June 2018 and expires in May 2035. A hearing has been scheduled for late 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of the Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing in the proceeding in Germany has been set for March 2020. No hearing has been set in the proceeding in Italy.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the &#8216;510 Patent. Fresenius Kabi counterclaimed for infringement, damages and injunctive relief. In July 2019 the United Kingdom Patents Court entered a consent order in which it declared that the United Kingdom counterpart of the '510 Patent is invalid, ordered the patent revoked and dismissed Fresenius Kabi's counterclaims.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent. A trial is scheduled in the Dutch matter for October 2019. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case was filed under seal in January 2014 and unsealed in April 2018 after the U.S. declined to intervene. The case alleges agreements with pharmacy benefit managers in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">an award of damages, interest and attorneys' fees. In June 2019 the U.S. Court of Appeals for the First Circuit affirmed the judgment below dismissing the complaint with prejudice.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial date has not been set in the Delaware action against Banner Life Sciences LLC. A trial date has been set for December 2019 in the other Delaware actions, and a trial date has been set for February 2020 in the West Virginia action against Mylan Pharmaceuticals Inc.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European patent number 2 137 537 (the '537 Patent), which includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for March 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. A hearing has been set for June 2020. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish &#8216;263 Patent expires in February 2023.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which also concerns administration of natalizumab (TYSABRI) to treat MS and expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending.&#160;We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6725982464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), movement disorders, including Parkinson's disease and progressive supranuclear palsy, Alzheimer's disease (AD) and dementia and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology, neurocognitive disorders, acute neurology and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.   </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on our collaboration arrangements with Genentech, please read Note 19, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the &#8220;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock', window );">Assets and liabilities held for sale</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon determining that a long-lived asset or disposal group meets the criteria to be classified as held for sale, we cease depreciation and separately present such assets and liabilities of the disposal group in our condensed consolidated balance sheet. We initially measure a long-lived asset or disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of sale. We assess the fair value of a long-lived asset or disposal group less any costs to sell each reporting period it remains classified as held for sale and recognize any subsequent changes as an adjustment to the carrying value of the asset or disposal group, as long as the remeasured carrying value does not exceed the carrying value less costs to sell of the asset or disposal group at the time it was initially classified as held for sale.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ASU No. 2018-20, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvement for Lessors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and ASU No. 2019-01, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Codification Improvements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our condensed consolidated balance sheets and to recognize those lease payments on a straight-line basis in our condensed consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$463.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a corresponding operating lease liability of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$526.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are included in our condensed consolidated balance sheet. The adoption of the new leasing standards did not have an impact on our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets. In addition, our contracts contain lease and non-lease components. We separate lease payments for the identified assets from any non-lease payments included in the contract. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our condensed consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the adoption of the new leasing standards, please read Note 11, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on the composition of our investment portfolio and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards is not expected to have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard permits the use of the OIS rate based on the SOFR as a United States (U.S.) benchmark interest rate for hedge accounting purposes under Accounting Standards Codification (ASC) 815, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative and Hedging</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard became effective for us on January 1, 2019, and did not have an impact on our condensed consolidated results of operations or financial position.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will become effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. We are currently evaluating the potential impact that this standard may have on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities Held For Sale [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6734802896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of separately identifiable assets acquired and liabilities assumed (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AcquisitionsAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of June&#160;7, 2019:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>700.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(77.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>852.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AcquisitionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AcquisitionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6833271392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Assets and liabilities held for sale</a></td>
<td class="text">The following table presents information related to the carrying value of the major classes of assets and liabilities that were reclassified as held for sale in our condensed consolidated balance sheets:<div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>641.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>62.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance on disposal group on assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(113.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>683.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>53.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>88.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6829900672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>869.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,150.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>825.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,086.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>379.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>554.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>180.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>625.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>264.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>211.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>475.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>265.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>201.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>467.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,513.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>690.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,204.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,536.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>666.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,202.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>257.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>488.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>216.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>422.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>115.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>115.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>126.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,744.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,135.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,880.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,741.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,015.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,757.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,587.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>561.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,149.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,554.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>519.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,073.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>707.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>348.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,055.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>816.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,175.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>509.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>426.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>935.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>515.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>414.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,803.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,187.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,885.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,341.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,227.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>453.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>552.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,006.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>393.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>392.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>786.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>236.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>236.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>254.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>254.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,257.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,302.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,560.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,279.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,001.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,281.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="line-height:120%;padding-top:9px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>888.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>308.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,391.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,710.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(41.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(42.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(189.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(827.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,017.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(121.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(505.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(639.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>124.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>905.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,062.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>199.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>863.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,062.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,051.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>377.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>359.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>768.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>708.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>199.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>325.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>576.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>490.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,093.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>933.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>77.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>79.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>369.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>219.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>160.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>108.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>452.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>273.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6829190016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>205.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>196.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>427.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>606.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>144.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>776.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>776.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>929.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>776.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6835328752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(542.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>543.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(542.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2,754.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>251.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,005.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2,734.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>270.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,175.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,175.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>476.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1,449.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,189.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,638.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,330.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,308.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8,426.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4,745.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,681.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7,727.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4,607.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,120.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:<div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>130.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>255.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>210.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,706.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>112.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reclassification of goodwill to assets held for sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(69.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,749.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843136064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,120.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,120.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,687.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,687.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>604.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>604.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>246.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>246.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>510.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>333.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,286.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>176.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4,109.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,459.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>969.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>563.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,102.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,050.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,507.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,491.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,489.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,480.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,032.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>996.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,000.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>995.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,867.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,738.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,745.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,737.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,953.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,722.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,802.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,722.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6,360.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5,948.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,037.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,936.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>421.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>498.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>523.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>499.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>499.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6826552240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>338.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>231.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>97.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>405.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>279.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>194.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,120.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2019 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>934.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>748.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>753.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>293.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>294.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>309.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>310.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>244.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>245.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,530.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,538.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>164.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>247.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>345.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable equity securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>229.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>294.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>510.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,608.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,607.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>854.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>851.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>706.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>705.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>263.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>260.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>496.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>615.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated<br/>Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,227.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,228.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,314.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,313.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,196.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,202.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,232.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>107.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>143.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,530.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,538.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,694.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,689.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,766.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,733.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3,255.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6,802.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843156864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,111.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,701.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>117.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>131.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>56.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>98.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>92.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,402.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,239.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843218880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LesseeLeaseTableTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text">The following table summarizes the presentation in our condensed consolidated balance sheets of our operating leases:<div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:41%;"/><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>434.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>72.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>423.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>495.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating lease cost</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of lease costs in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:35%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>17.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>41.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease liability maturity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>70.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>69.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>66.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>147.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>560.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>64.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>495.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum lease payments</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the prior lease guidance minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter as of December&#160;31, 2018, were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>80.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>215.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>601.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(26.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(58.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(182.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>47.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>156.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>418.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</span></div>Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock', window );">Operating lease weighted average remaining term and discount rate</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:83%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average remaining lease term in years</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock', window );">Operating lease supplemental cash flow disclosure</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our condensed consolidated statements of cash flows is as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LesseeLeaseTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Lease Table [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LesseeLeaseTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease supplemental cash flow disclosure [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining term and discount rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6833155168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>13.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(30.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(271.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(252.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(318.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU No. 2016-01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(104.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(175.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(316.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(47.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(36.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(222.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(261.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:26%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(48.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843051328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>866.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,902.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,039.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>193.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>209.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>190.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>207.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>209.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6724711920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>25.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>105.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>66.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NST stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>87.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843102800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark assets held for sale</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Global Intangible Low-Taxed Income (GILTI)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843119456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>60.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(51.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(95.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(102.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(173.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>203.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(197.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(34.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>159.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(75.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(174.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(42.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>42.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>(131.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>159.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br/>June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>863.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>874.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>212.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>224.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>199.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>320.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>146.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>444.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>261.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>38.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>727.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>609.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>2,318.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2,861.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843076496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>68.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>111.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>76.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>165.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>140.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>91.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6848904064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 495.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838708784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,749.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,706.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred Tax Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 852.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6824168272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual) - Nightstar - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments for pre-combination equity compensation</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Fair value, in-process research and development, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Deferred tax liabilities, goodwill</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember', window );">Post-acquisition equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Indefinite Lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9972-128506<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=117412053&amp;loc=d3e9979-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6824153088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets and Liabilities Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (113.2)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets and Liabilities Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">641.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">69.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">62.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale</a></td>
<td class="nump">683.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingleaseliabilities', window );">Operating lease liabilities</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities held for sale</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember', window );">Long-term operating lease liabilities | Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets and Liabilities Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingleaseliabilities', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingleaseliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingleaseliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6939250688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 113.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="nump">890.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on assets and liabilities held for sale, net of tax</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on assets and liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark Manufacturing Operations</a></td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6932792112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="nump">$ 6,487.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,150.2<span></span>
</td>
<td class="nump">1,086.8<span></span>
</td>
<td class="nump">2,149.0<span></span>
</td>
<td class="nump">2,073.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">869.8<span></span>
</td>
<td class="nump">825.8<span></span>
</td>
<td class="nump">1,587.5<span></span>
</td>
<td class="nump">1,554.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">280.4<span></span>
</td>
<td class="nump">261.0<span></span>
</td>
<td class="nump">561.5<span></span>
</td>
<td class="nump">519.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">554.4<span></span>
</td>
<td class="nump">625.5<span></span>
</td>
<td class="nump">1,055.3<span></span>
</td>
<td class="nump">1,175.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">379.7<span></span>
</td>
<td class="nump">444.7<span></span>
</td>
<td class="nump">707.0<span></span>
</td>
<td class="nump">816.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">174.7<span></span>
</td>
<td class="nump">180.8<span></span>
</td>
<td class="nump">348.3<span></span>
</td>
<td class="nump">359.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">475.3<span></span>
</td>
<td class="nump">467.2<span></span>
</td>
<td class="nump">935.7<span></span>
</td>
<td class="nump">929.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">264.3<span></span>
</td>
<td class="nump">265.5<span></span>
</td>
<td class="nump">509.3<span></span>
</td>
<td class="nump">515.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">211.0<span></span>
</td>
<td class="nump">201.7<span></span>
</td>
<td class="nump">426.4<span></span>
</td>
<td class="nump">414.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,204.0<span></span>
</td>
<td class="nump">2,202.5<span></span>
</td>
<td class="nump">4,187.0<span></span>
</td>
<td class="nump">4,227.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,513.8<span></span>
</td>
<td class="nump">1,536.0<span></span>
</td>
<td class="nump">2,803.8<span></span>
</td>
<td class="nump">2,885.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">690.2<span></span>
</td>
<td class="nump">666.5<span></span>
</td>
<td class="nump">1,383.2<span></span>
</td>
<td class="nump">1,341.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">488.2<span></span>
</td>
<td class="nump">422.7<span></span>
</td>
<td class="nump">1,006.7<span></span>
</td>
<td class="nump">786.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">230.6<span></span>
</td>
<td class="nump">205.9<span></span>
</td>
<td class="nump">453.9<span></span>
</td>
<td class="nump">393.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">257.6<span></span>
</td>
<td class="nump">216.8<span></span>
</td>
<td class="nump">552.8<span></span>
</td>
<td class="nump">392.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">244.3<span></span>
</td>
<td class="nump">236.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">244.3<span></span>
</td>
<td class="nump">236.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">47.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">47.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">184.4<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
<td class="nump">358.8<span></span>
</td>
<td class="nump">254.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">184.4<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
<td class="nump">358.8<span></span>
</td>
<td class="nump">254.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,880.3<span></span>
</td>
<td class="nump">2,757.5<span></span>
</td>
<td class="nump">5,560.3<span></span>
</td>
<td class="nump">5,281.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,744.4<span></span>
</td>
<td class="nump">1,741.9<span></span>
</td>
<td class="nump">3,257.7<span></span>
</td>
<td class="nump">3,279.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,135.9<span></span>
</td>
<td class="nump">$ 1,015.6<span></span>
</td>
<td class="nump">$ 2,302.6<span></span>
</td>
<td class="nump">$ 2,001.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6931089760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,710.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(42.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,017.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(639.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,062.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">308.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(189.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(121.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">124.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">888.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,391.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(41.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(827.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(505.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">905.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 32.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6996075360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,062.5<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">199.0<span></span>
</td>
<td class="nump">176.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 863.5<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6848126080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="nump">$ 6,487.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">377.2<span></span>
</td>
<td class="nump">359.0<span></span>
</td>
<td class="nump">768.0<span></span>
</td>
<td class="nump">708.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">199.2<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">325.8<span></span>
</td>
<td class="nump">225.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 576.4<span></span>
</td>
<td class="nump">$ 490.4<span></span>
</td>
<td class="nump">$ 1,093.8<span></span>
</td>
<td class="nump">$ 933.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6850226720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="nump">$ 6,487.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">105.2<span></span>
</td>
<td class="nump">79.1<span></span>
</td>
<td class="nump">369.3<span></span>
</td>
<td class="nump">219.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">160.0<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">452.4<span></span>
</td>
<td class="nump">273.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="nump">$ 32.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6848488624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="nump">$ 6,487.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">30.50%<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="nump">30.90%<span></span>
</td>
<td class="nump">33.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">18.20%<span></span>
</td>
<td class="nump">18.60%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 452.4<span></span>
</td>
<td class="nump">$ 273.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="nump">$ 47.6<span></span>
</td>
<td class="nump">$ 241.3<span></span>
</td>
<td class="nump">$ 94.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842590752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 205.0<span></span>
</td>
<td class="nump">$ 196.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">427.6<span></span>
</td>
<td class="nump">606.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">144.1<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">776.7<span></span>
</td>
<td class="nump">936.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">776.7<span></span>
</td>
<td class="nump">929.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843142032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventorysoldtoBioverativcost', window );">Inventory sold to Bioverativ, cost</a></td>
<td class="nump">$ 173.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventorysoldtoBioverativcost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory sold to Bioverativ, cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventorysoldtoBioverativcost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6832339344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Proposed Divestiture of Denmark Manufacturing Operations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="nump">$ 890.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory expected to be sold to FUJIFILM</a></td>
<td class="nump">$ 20.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6938406352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 8,426.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,426.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,727.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,745.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,745.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,607.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,681.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,681.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">70.1<span></span>
</td>
<td class="nump">$ 107.4<span></span>
</td>
<td class="nump">138.3<span></span>
</td>
<td class="nump">$ 211.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining six months)</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(542.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (542.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">251.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,754.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,754.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,734.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">246.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,638.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,189.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,449.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,449.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,330.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1,933.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,933.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">55.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">1,175.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,175.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838755760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">5,706.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,749.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill held for sale</a></td>
<td class="num">$ (69.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6929114672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,538.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,689.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,120.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">510.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">88.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,286.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,102.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">401.3<span></span>
</td>
<td class="nump">$ 421.3<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">$ 499.9<span></span>
</td>
<td class="nump">$ 498.0<span></span>
</td>
<td class="nump">$ 523.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">418.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,687.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">604.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">246.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">176.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">176.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,120.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">333.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">88.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,109.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,687.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,459.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">604.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">246.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">401.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">401.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6609381904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 5,948.5<span></span>
</td>
<td class="nump">$ 5,936.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">6,360.4<span></span>
</td>
<td class="nump">6,037.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,507.5<span></span>
</td>
<td class="nump">1,489.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,491.1<span></span>
</td>
<td class="nump">1,480.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,032.3<span></span>
</td>
<td class="nump">1,000.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">996.0<span></span>
</td>
<td class="nump">995.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,867.4<span></span>
</td>
<td class="nump">1,745.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,738.7<span></span>
</td>
<td class="nump">1,737.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,953.2<span></span>
</td>
<td class="nump">1,802.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,722.7<span></span>
</td>
<td class="nump">$ 1,722.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6643499664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">$ (20.0)<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="num">$ (8.5)<span></span>
</td>
<td class="num">$ (3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">421.3<span></span>
</td>
<td class="nump">498.0<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 401.3<span></span>
</td>
<td class="nump">$ 499.9<span></span>
</td>
<td class="nump">$ 401.3<span></span>
</td>
<td class="nump">$ 499.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843114624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions', window );">Fair value measurements, changes in valuation inputs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 255,100,000<span></span>
</td>
<td class="nump">$ 265,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value from changes in the inputs, assumptions, or model used to calculate the fair value of the contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116651436&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6641324592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,120.4<span></span>
</td>
<td class="nump">$ 705.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">338.7<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">97.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">405.7<span></span>
</td>
<td class="nump">279.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 279.0<span></span>
</td>
<td class="nump">$ 194.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6928895808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,530.4<span></span>
</td>
<td class="nump">$ 3,694.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,538.1<span></span>
</td>
<td class="nump">3,689.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">2,538.1<span></span>
</td>
<td class="nump">3,689.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">933.4<span></span>
</td>
<td class="nump">1,608.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">934.5<span></span>
</td>
<td class="nump">1,607.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">748.9<span></span>
</td>
<td class="nump">854.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">753.2<span></span>
</td>
<td class="nump">851.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">293.6<span></span>
</td>
<td class="nump">706.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">294.0<span></span>
</td>
<td class="nump">705.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">309.7<span></span>
</td>
<td class="nump">264.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">310.4<span></span>
</td>
<td class="nump">263.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">244.5<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">245.7<span></span>
</td>
<td class="nump">260.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">229.3<span></span>
</td>
<td class="nump">496.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">294.2<span></span>
</td>
<td class="nump">127.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(13.5)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">510.0<span></span>
</td>
<td class="nump">$ 615.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">117.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">46.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">164.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">111.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">247.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(13.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 345.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6666599488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,227.3<span></span>
</td>
<td class="nump">$ 2,314.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,228.8<span></span>
</td>
<td class="nump">2,313.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">1,196.1<span></span>
</td>
<td class="nump">1,235.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">1,202.2<span></span>
</td>
<td class="nump">1,232.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">107.0<span></span>
</td>
<td class="nump">143.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">107.1<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,530.4<span></span>
</td>
<td class="nump">3,694.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,538.1<span></span>
</td>
<td class="nump">$ 3,689.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6640820240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,766.6<span></span>
</td>
<td class="nump">$ 2,733.7<span></span>
</td>
<td class="nump">$ 3,255.8<span></span>
</td>
<td class="nump">$ 6,802.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (10.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6614321072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">14 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6994845968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">$ 309.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">569.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">213.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 164.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6928958032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="num">$ (3.9)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">934.4<span></span>
</td>
<td class="nump">735.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 934.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">81.8<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">2,402.3<span></span>
</td>
<td class="nump">2,239.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,402.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.4)<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="num">(43.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">2,111.3<span></span>
</td>
<td class="nump">1,701.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,111.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,701.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">117.2<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">69.7<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">56.0<span></span>
</td>
<td class="nump">98.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020 | Interest rate swap | Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6642231584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,886.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,886.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,797.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">$ 64.2<span></span>
</td>
<td class="nump">99.9<span></span>
</td>
<td class="nump">$ 129.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">57.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment held for sale</a></td>
<td class="nump">318.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment held for sale</a></td>
<td class="nump">$ 290.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6850191456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 434.4<span></span>
</td>
<td class="nump">$ 434.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">423.0<span></span>
</td>
<td class="nump">423.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">495.3<span></span>
</td>
<td class="nump">495.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">ASC 842 - Minimum lease payments 2019 (remaining six months)</a></td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">50.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">ASC 842 - Minimum lease payments, 2020</a></td>
<td class="nump">80.5<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">ASC 842 - Minimum lease payments, 2021</a></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">74.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">ASC 842 - Minimum lease payments, 2022</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">70.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">ASC 842 - Minimum lease payments, 2023</a></td>
<td class="nump">69.4<span></span>
</td>
<td class="nump">69.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">ASC 842 - Minimum lease payments, 2024</a></td>
<td class="nump">66.7<span></span>
</td>
<td class="nump">66.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">ASC 842 - Minimum lease payments, thereafter</a></td>
<td class="nump">147.6<span></span>
</td>
<td class="nump">147.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">ASC 842 - Minimum lease payments</a></td>
<td class="nump">560.2<span></span>
</td>
<td class="nump">560.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">$ 64.9<span></span>
</td>
<td class="nump">$ 64.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">ASC 840 - Minimum lease payments, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">ASC 840 - Minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">ASC 840 - Minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">ASC 840 - Minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">ASC 940 - Minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">ASC 840 - Minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">ASC 840 - Minimum lease payments total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">ASC 840 - Sublease income, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">ASC 840 - Sublease income, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">ASC 840 - Sublease income, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">ASC 840 - Sublease income, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">ASC 840 - Sublease income, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">ASC 840 - Sublease income, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">ASC 840 - Sublease income total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">ASC 840 - Net minimum lease payments 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">ASC 840 - Net minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">ASC 840 - Net minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">ASC 840 - Net minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">ASC 840 - Net minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">ASC 840 - Net minimum lease payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">ASC 840 - Net minimum lease payments total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 27.4<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">17.9<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="num">(13.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Net lease cost</a></td>
<td class="nump">17.9<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease income</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">434.4<span></span>
</td>
<td class="nump">434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">72.3<span></span>
</td>
<td class="nump">72.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember', window );">Long-term operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 423.0<span></span>
</td>
<td class="nump">$ 423.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6643030528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisposalGroupOperatingleaseliabilities', window );">Operating lease liabilities</a></td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisposalGroupOperatingleaseliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisposalGroupOperatingleaseliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6828441616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,057.3<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 909.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 4,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember', window );">2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6850098160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (240,400,000)<span></span>
</td>
<td class="num">$ (318,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (252,900,000)<span></span>
</td>
<td class="num">$ (261,600,000)<span></span>
</td>
<td class="num">(252,900,000)<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="num">$ (316,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000,000.0<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,500,000)<span></span>
</td>
<td class="nump">48,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(33,500,000)<span></span>
</td>
<td class="nump">41,800,000<span></span>
</td>
<td class="num">(12,900,000)<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(252,900,000)<span></span>
</td>
<td class="num">(261,600,000)<span></span>
</td>
<td class="num">(252,900,000)<span></span>
</td>
<td class="num">(261,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(33,100,000)<span></span>
</td>
<td class="nump">42,300,000<span></span>
</td>
<td class="num">(12,500,000)<span></span>
</td>
<td class="nump">55,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="num">(1,700,000)<span></span>
</td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000.0<span></span>
</td>
<td class="num">(7,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="num">(1,700,000)<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="num">(1,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">13,700,000<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
<td class="nump">61,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,300,000)<span></span>
</td>
<td class="nump">42,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000,000.0)<span></span>
</td>
<td class="nump">103,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">13,700,000<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">29,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,400,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">29,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(30,600,000)<span></span>
</td>
<td class="num">(36,400,000)<span></span>
</td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(30,600,000)<span></span>
</td>
<td class="num">(36,400,000)<span></span>
</td>
<td class="num">(30,600,000)<span></span>
</td>
<td class="num">(36,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(271,400,000)<span></span>
</td>
<td class="num">(222,800,000)<span></span>
</td>
<td class="num">(243,300,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,100,000)<span></span>
</td>
<td class="num">(47,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,100,000)<span></span>
</td>
<td class="num">(47,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (271,400,000)<span></span>
</td>
<td class="num">$ (222,800,000)<span></span>
</td>
<td class="num">$ (271,400,000)<span></span>
</td>
<td class="num">$ (222,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6828354288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (197.4)<span></span>
</td>
<td class="num">$ (34.5)<span></span>
</td>
<td class="nump">$ 159.9<span></span>
</td>
<td class="num">$ (75.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">248.1<span></span>
</td>
<td class="nump">263.7<span></span>
</td>
<td class="nump">670.6<span></span>
</td>
<td class="nump">586.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(3,616.7)<span></span>
</td>
<td class="num">(3,356.5)<span></span>
</td>
<td class="num">(7,106.5)<span></span>
</td>
<td class="num">(6,487.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,494.1<span></span>
</td>
<td class="nump">866.6<span></span>
</td>
<td class="nump">2,902.9<span></span>
</td>
<td class="nump">2,039.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">31.8<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
<td class="num">(48.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(29.8)<span></span>
</td>
<td class="num">(10.4)<span></span>
</td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(43.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6672778928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 2,902.9<span></span>
</td>
<td class="nump">$ 2,039.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">193.4<span></span>
</td>
<td class="nump">209.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
<td class="nump">209.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6641744656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="nump">$ 41.4<span></span>
</td>
<td class="nump">$ 104.0<span></span>
</td>
<td class="nump">$ 87.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">82.9<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">126.3<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">82.6<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 66.5<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
<td class="nump">$ 72.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6828570224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="nump">$ 41.4<span></span>
</td>
<td class="nump">$ 104.0<span></span>
</td>
<td class="nump">$ 87.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">82.9<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">126.3<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">31.8<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">66.5<span></span>
</td>
<td class="nump">66.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | NST stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6641508048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Denmark assets held for sale</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization', window );">Internal reorganization of certain intellectual property rights</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">Effective Tax Rate Reconciliation, GILTI tax</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">14.10%<span></span>
</td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6614185328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax payment, including penalties and interest</a></td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="nump">61.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liability held for sale</a></td>
<td class="nump">53.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax asset recorded on transfer of intellectual property</a></td>
<td class="nump">856.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred tax liability recorded on transfer of intellectual property</a></td>
<td class="nump">$ 685.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6828309456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 60.3<span></span>
</td>
<td class="nump">$ 55.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(47.7)<span></span>
</td>
<td class="num">(51.7)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
<td class="num">(102.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">(173.4)<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">203.0<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(197.4)<span></span>
</td>
<td class="num">(34.5)<span></span>
</td>
<td class="nump">159.9<span></span>
</td>
<td class="num">(75.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(174.2)<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized during the period on equity securities sold during the period</a></td>
<td class="num">(42.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">42.4<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019</a></td>
<td class="num">(131.3)<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">159.5<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,062.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">212.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">199.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">146.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">130.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction in progress</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">727.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,318.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,318.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 863.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6672152896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 1,355.8<span></span>
</td>
<td class="nump">$ 1,389.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">$ 801.5<span></span>
</td>
<td class="nump">$ 791.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830840000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.6<span></span>
</td>
<td class="nump">$ 136.6<span></span>
</td>
<td class="nump">$ 111.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">55.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment to Skyhawk</a></td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">165.8<span></span>
</td>
<td class="nump">140.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">128.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843644288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">121.6<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,356.5<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="nump">6,487.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of basis differences</a></td>
<td class="nump">21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">615.5<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 712.8<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">63.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.7<span></span>
</td>
<td class="nump">$ 121.5<span></span>
</td>
<td class="nump">83.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="nump">$ 32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember', window );">Deferred tax liability | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6666092848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646688320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="nump">$ 70.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>123
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\+L)N,'9G_['Q65"V\.LNY!=02P,$%     @ X(WW3IE<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M?1#$*_BV(TS =X'C*R2OX#N/, 'K!4ZYX"$FWWR ";W# D==\"33S%<!F'E
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MM^?MT,X-%T:?QE8UF?KE]5]02P,$%     @ X(WW3F![AKF7!0  1QP  !@
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M*Q)409!^Q D*,*N1'\)LD#B0GPA+O)TLF;(6(10CCHL1$C0$ZOX>=;%K(\1
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M.AUMG2Z:\M@?VRW.9X>W_P%02P,$%     @ X(WW3O?#MFQ9 P  :PT  !@
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M9>:NF\M9^N6FJT_C[P31]<>*U?]02P,$%     @ X(WW3JKL*WC) 0  : 0
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M][X9S\G'BZX^3[\!Q-<?(C;_ 5!+ P04    " #@C?=.(9\#$H8+  !A2P
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M1@#5$QV $<3# /%@Q0'#,SXH#G1"79F4$,64!>4PJ+Y%#W2&)W)>'  @5AP
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M:&5E=#$P+GAM;&U386_;(!#]*X@?4!*2I5ED6VI:59NT2E&GM9^)?;91P7B
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M.O^RL?\UH@.?2G+E1ZCU'VPQ)-0N'+_XLYG&;#(<]O,/8LLW+OX!4$L#!!0
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M86_<( S]*X@?4"Y<;JM.2:1>IVF55NG4:=MG+G$25 @ID$O[[V=(FF5;M"^
MC=_SLS'9:.RS:P$\>=6J<SEMO>^/C+FR!2W<C>FAPYO:6"T\FK9AKK<@J@C2
MBO'=[@/30G:TR*+O;(O,#%[)#LZ6N$%K8=].H,R8TX2^.YYDT_K@8$76BP:^
M@?_>GRU:;&&II(;.2=,1"W5.[Y+C*0WQ,>"'A-&MSB14<C'F.1@/54YW01 H
M*'U@$+A=X1Z4"D0HXV7FI$O* %R?W]D_Q]JQEHMP<&_43UGY-J>WE%10BT'Y
M)S-^@;F> R5S\5_A"@K#@Q+,41KEXDK*P7FC9Q:4HL7KM,LN[N-T<TAFV#:
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MUK.C9"S^*UQ!^O"@Q.?(4=JXDKRS#M7(XJ4H\3[LC8Y[/]SL#R-L&<!' )\
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M_&"SH:#RX?@!SW8<L]'PIIM^$)N_<?X'4$L#!!0    ( ."-]T[](TO<M $
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M-"$>W^+936,V&<'V\P]BRS<N?P%02P,$%     @ X(WW3HP3BE&T 0  T@,
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M(9SM.&:CX;&;?A";OW'Q"U!+ P04    " #@C?=.6IS+N+4!  #2 P  &0
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MYBB,<G$E1>^\T1,+2M'B;=QE&_=AO-E>8>L /@'X#-A' !L31>6?A!=Y:LU
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MX_PK1 >^E.3&KU#C']CL2*A<,.^];<8U&QV'W?2"V/R,\P]02P,$%     @
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M%'X5Q ,4!\=)%MF6FE;5)FU2U&G=;V(?7U0P'N"X>_L!=CTO97\,Y_!=SL%
M.DKUJAL @]X$[W2&&V/Z(R&Z:$ P?2=[Z.Q*)95@QH:J)KI7P$I/$IS0*-H1
MP=H.YZG/G56>RL'PMH.S0GH0@JG?)^!RS/ &OR>>V[HQ+D'RM&<U? ?SHS\K
M&Y%%I6P%=+J5'5)09?A^<SSM'-X#7EH8]6J.7"<7*5]=\*7,<.0* @Z%<0K,
M#E=X ,Z=D"WCUZR)%TM'7,_?U9]\[[:7"]/P(/G/MC1-A@\8E5"Q@9MG.7Z&
MN9\$H[GYKW %;N&N$NM12*[]%Q6#-E+,*K84P=ZFL>W\.$XKR7ZFA0ET)M"%
M</ ^9#+RE3\RP_)4R1&I:>][YG[QYDCMWA0NZ;?"K]GBM<U>\YCN4W)U0C/F
M-&'H"K-9$,2J+Q8T9'&B'^@T3(^#%<:>'J_I2106V 8%MEY@^T^+AYL60YA/
M89,D:))\%(BC&Y,0YC\[N0N:[ ("],8DA(EO3,CJ= A0M;\7&A5RZ/R=7&67
MJW=/_>GZ"Y_N[3>FZK;3Z"*-/:/^)%52&K"E1'>VX<8^%4O H3)NNK=S-5V8
M*3"RG]\"LCQ(^1]02P,$%     @ X(WW3A!29#W; 0   04  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL;53KCIP@%'X5P@,L7L?M1$UVMFG:I$TF
MVW3[F]'C)0MB@1FW;U] QUK+'^$<OLLY".23D&^J ]#HG;-!%;C3>CP2HJH.
M.%4/8H3!K#1"<JI-*%NB1@FT=B3.2!0$!\)I/^ R=[FS+'-QU:P?X"R1NG).
MY>\3,#$5.,3WQ$O?=MHF2)F/M(7OH'^,9VDBLJK4/8=!]6) $IH"/X7'4V;Q
M#O#:PZ0V<V0[N0CQ9H,O=8$#6Q PJ+15H&:XP3,P9H5,&;\63;Q:6N)V?E?_
MY'HWO5RH@F?!?O:U[@K\B%$-#;TR_2*FS[#TDV*T-/\5;L ,W%9B/"K!E/NB
MZJJTX(N**873]WGL!S=.B_Z=YB=$"R':$<ALY"K_2#4M<RDF).>]'ZG]Q>$Q
M,GM3V:3;"K=FBE<F>ROC.,G)S0HMF-.,B3:8<$40H[Y:1#Z+4_0?/?+38V^%
ML:/'6WH:^P42KT#B!))_6DQW+?HP![])ZC5)/0+9SL2'>?2;'+PF!X_ AYV)
M!Y,$?I/,:Y)Y!,*=B0^S_ZED<P0YR-9=/H4J<1W<Q=]DU_O]%+DC_!<^/P[?
MJ&S[0:&+T.8BN./:"*'!E!(\F%WMS'NT!@P:;:>9F<OY5LZ!%N/RX)#UU2O_
M %!+ P04    " #@C?=.&V;;W]P!   !!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6QM5-N.FS 0_17+'[ FA,LV J3-5E4KM5*T5=MG!X:+UL;4
M-F'[][4-H93U2^P9SF7&\3B;A'Q5+8!&;YSU*L>MUL.)$%6VP*EZ$ /TYDLM
M)*?:A+(A:I! *T?BC(1!D!!.NQX7F<M=9)&)4;.NAXM$:N2<RC]G8&+*\0'?
M$R]=TVJ;($4VT :^@_XQ7*2)R*I2=1QZU8D>2:AS_'0XG5.+=X"?'4QJLT>V
MDZL0KS;X4N4XL 4!@U);!6J6&SP#8U;(E/%[T<2KI25N]W?U3ZYWT\N5*G@6
M[%=7Z3;'CQA54-.1Z1<Q?8:EGQBCI?FO< -FX+82XU$*IMPO*D>E!5]43"F<
MOLUKU[MU6O3O-#\A7 CACD!F(U?Y1ZIID4DQ(3F?_4#M7WPXA>9L2IMT1^&^
MF>*5R=Z*8W3,R,T*+9CSC DWF,.*($9]M0A]%N?P'3WTTX_>"H^.?MS2X\0O
M$'D%(B<0_==BM&O1AXG])K'7)/8()#L3'R;UFR1>D\0C\+@S\6$^^$U2KTGZ
M7B .=B8^S/Y.D,T5Y" ;-WP*E6+LW>!OLNM\/X7N"O^#SX_#-RJ;KE?H*K09
M!'==:R$TF%*"!W.JK7F/UH!!K>TV-7LY3^4<:#$L#PY97[WB+U!+ P04
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M_\$60T#CPG'OSV8:L\EPNI]_$%F^<?D74$L#!!0    ( ."-]TZVKTLWP@$
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M/ <<:NNW.[?7XUL> ZNZ:4S)_%]1_ %02P,$%     @ X(WW3KR&7Q P @
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MDXG6./)*VJ]WO$K%ZX%%IU+3U[XM&]MV_4H4#6'N #P$X#$ D7\&A$- ^-X
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MD<S06JQ0^8>C8MTAB*P$D2*(!@3)1"MV"TD4I%:0+] +M6JTH'0 "K1BF#0
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MG(G:"%@;,6H+DA@F"$&"\'9U(Y @^EC=%A(-"L6&M"8&18ZO"6N"PH%<K:K
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M LEA6("  N1V>S-0( ,BL#)=01AB>0MA+/\W$,:Z%5L(,W+@)F!"$U< 1;#
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MVEED9JDZ =)T2B(-=8X?=N=+ZO$!\*N#T2SVR%=R4^K9&U^K'&^](.!06L_
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M6^'>F>:56;T4,=EF^&)!DV8_:LA"LTG368,-?RY"O$6( VR6 !+Y 9$7$#E
M] FP]0,V7L#F:P=1>&-SU&R=IG.:NVWH+Q)[B\1?BL31/P")%Y#\O\W4"T@]
M':QO;(Z:9&&3A*ODI@I>G!][/7]1>6H[%1R%-D?1'9A:" T&&*Z,[\;\$>:
M0:WM-#5S.=Z+,="BGZX\GO\[Q0=02P,$%     @ X(WW3B_2S7'N!0  ="(
M !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULE5I=;ZM&$/TKEM]KLY]
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M17*K2&XI!JU4<DLQ<>$ANTYAU2DV.C%ZQV@8V+__X/]?7/C.%0HMU4;K.V1
MZ?)0T\);*_F+>]L!N^J.Q9V:WGK=+A?1N2L^('WO_\)-2_V&V;7MN7.B0G8/
M?<<OE J0;@)/?JZ-[.+S@L!%J&DFY\RT,K,0=)C:M#__*ZH_4$L#!!0    (
M ."-]TY#LX=7 08  '\G   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM
M;)5:[6ZC1A1]%<L/@)GO(7(B-7%W6ZF5HEVU_4T2$EMK&Q=(O'W[ B:6ASDS
MONR/M7'.7,[<F7LX7%@>R^I'O2Z*9O9SM]W7M_-UTQQN%HOZ>5WL\CHI#\6^
M_<MK6>WRICVLWA;UH2KREW[0;KO@::H7NWRSG]\M^]\>J[ME^=YL-_OBL9K5
M[[M=7OUW7VS+X^V<S3]_^+9Y6S?=#XN[Y2%_*[X7S5^'QZH]6IRCO&QVQ;[>
ME/M95;S>SG]A-U^MZ ;TB+\WQ;&^^#[KIO)4EC^Z@]]?;N=IQZC8%L]-%R)O
M/SZ*AV*[[2*U//X=@L[/Y^P&7G[_C/ZEGWP[F:>\+A[*[3^;EV9].[?SV4OQ
MFK]OFV_E\;=BF)":SX;9_U%\%-L6WC%IS_%<;NO^_]GS>]V4NR%*2V67_SQ]
M;O;]YW&(_SD,#^## 'X>P&1T@!@&".H .0R0U %J&*"H _0P0%,'F&& &0U8
MG++;+]<J;_*[954>9]5IQQWR;F.S&]-NB.?NQW[]^[^U*U:WOW[<*2.7BX\N
MT("Y/V'X!8:[B <?H8QR,2L?P]+4Q?P*XF0NY LZE78Q7Q'&G#&+-B'GK'"8
M%=X'$$X BP,(&$#T :038#23^Q-&]YC]*:U*V(2-\N;#A+99(C =">E(GXY-
M<0 % RAZ0C0,H &#T4SO3QAS,5/&>)J,MN/*AYE4)0JS,9"- 6Q&>_K^A%$7
MIU%LM%]7QJ.BF;H@[%"QD(H%5,2(BO5.8VTRXKOR05HG67KQCV%>&>25 5YC
M8<B\4_(L&=<]  53Q%(L4JE'AGGE-( N3R2YU5Z> *Y=6![:0"R@F\RO"!L*
M@46&<<+2#R"G*(R78X#B,M$!.EBR&- LJ\=TA)_DE"5B?#WP14MR#[:"T;+$
MCJ\*(%J6)=Z5X03+')@=7QK\6(J+8*JPG#)?3\%^E/[DF!U/;H5@0@8+!,LS
M4V#M E<\A@6::;K$,ZRJ#,BJGQ9?,YFV)C'CO/@X+E5V4<XN):RN#,EK:%98
M"%E&3PS'^L5]_?(3PWU=TJGTKGX ENDLM($Y5B_.0%JR0(B 19K@D3A6'$YQ
M20-(.?M CY/B"PG7:4C2.:YJ#EQ2%G!)'-<AG^"3.*Y#3G%* ^@R*6-K$H6X
M1' U<XI)XJ":C4Z\]?%ABB4A2XY+F5.<T@"*)B8&<8E@0> 4:S2 HD1B$/<>
M \N*H-@BX>L%6B$ "Z^0P*HB)G@B@55%4#S1 (KE-@IQB01NX"AN2/C:Y!&)
M05PB6)4$Q6L,H"B1&,0E@K5- (^1!6XI!-8V,<%C"*Q*@N(QA'_OYJ4C!G&)
M8#D20(ZR@#D16$C$!&<AL01(BK,80+%T1"$N$5S[$CB*+-2CP+4O)S@*B:M6
M4AR%O%ZU48A+)-!P05XBX.DEKC<YP4M(7&^2XB4DL>T"<)&^B\3E*RFF0OIN
M00CA$P*F0HO0-4OB,I845R%)#1B (G9@)-8'23$:DM2$0:A@%T9AK5$4NZ%
M%X:EF><W $ZE*DT"&UQAU5$3'(?"JJ,HCD.1NC  %>["**Q@BN([U'4%BT)<
M(EC!%,5W*+]Y@?+BHR)Y"32@D?L(K3160S7!?2@L7XKB/A2QPP%PL0Z'P@*F
MD \)Y1;KC)K@0S36!DWQ(9K6X0"P2(=#8V70R(\$+@T:*X.>X$<TKF9-\2.:
MTN'0DSH<&M>T1JXD-"-<AWK*DZ# HR#2LZ#K'8XHQ"6"JUE3S(B^?B\1A;A$
M< UKB@G1UUL;48A+!"N!IC@.?;VU$86XS^>PGAB*US#7[VNB$)<(UA$SP6$8
MK".&XC#,]9Y&%.(2P6ID*-["D)[PK" L"]DW@_7(4#R& 0]($"$$"Q/"ZF:0
MRPCTQ0U6-S/!99C TVF*RS#7=2D*<8E@73*^+NDT% (KBIG@+2S6 DOQ%O:Z
M%D0A+A&L!=;W%#IT2V>Q%M@)GL+B*K843V']9Z%>.F*0$Y'%Q5M$W:MI?^;5
MVV9?SY[*IBEW_6M#KV79%&VXUHK,9^LB?SD?;(O7IOO:U51U>B7L=-"4A^%U
MM\7YG;N[_P%02P,$%     @ X(WW3I,%7H3( @  !0L  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C N>&ULE5;;CILP$/T5Q > +V!@E43JIJI:J956K=H^
M>Q,G00N88B?9_GUMPR(N0\6^@&W.')_Q>(;9W&7SHBY":.^U+"JU]2]:UP]A
MJ X747(5R%I4YLM)-B779MJ<0U4W@A^=45F$!"$6ECRO_-W&K3TUNXV\ZB*O
MQ%/CJ6M9\N;OHRCD?>MC_VWA>WZ^:+L0[C8U/XL?0O^LGQHS"WN68UZ*2N6R
M\AIQVOH?\,.>(&O@$+]R<5>#L6==>9;RQ4Z^'+<^LHI$(0[:4G#SNHF]* K+
M9'3\Z4C]?D]K.!R_L7]RSAMGGKD2>UG\SH_ZLO53WSN*$[\6^KN\?Q:=0['O
M==Y_%3=1&+A58O8XR$*YIW>X*BW+CL5(*?EK^\XK][ZW7]B;&6Q .@/2&^#H
MOP:T,Z 3@[!5YES]R#7?;1IY]YHV6C6WEP(_4'.8![OHSLY],]XJLWK;,40V
MX<T2=9C'%D,&F EB/T=@A'I,:!3T,@@H@S@".I)!80(*$E!'$(T(HHD?+88Y
M3.4P<1:E03QQ!H)1-H"-Y$2@G B0,]GGL<4D@WT892B8J-X#,$23@,%R8E!.
M#,A9(& @ 5L?GP0D2  %R>1 DIFG.$;)+#X +$JSI?BDH)QTQ75)@7TR'.")
M' B6HB"%Y62@G R0LT" $9S':'V$\$(IP"MBU(%&[B)* CJM"! .#6_W6!)<
M%C!9$:<.% ^VRC(VU4-F>K(L7KHT&"XR&*HRV0(%7!AP](XXP<F,H6R>Q2F>
MGW_*DEEU@7!)% ]N^5@27!XP6Q,G!FQ%TR"92@)QR5)&8;C@8*#BX(5_$H:+
M!$[?$2LXL3&4V;-897.'LY@&L[\L@$L16?H5$+A2$+0B5AV(C6) R"Q62[AI
MFH>#?L0VB-]X<\XKY3U+;5H;UX"<I-3"<*+ 7,F+Z4G[22%.V@X3,V[:QJR=
M:%EW36?8=[Z[?U!+ P04    " #@C?=.4);3L(8"  "+"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,2YX;6R-5EV/HC 4_2N$]^&["$9-1G2SF^PF9B:[
M^URQ"AF@;%MU]M]O/Q"Q=-47:2_GG-YS6WN9G3'YH 5"S/JLJX;.[8*Q=NJZ
M-"]0#:F#6]3P-WM,:LCXE!Q<VA($=Y)45V[@>;%;P[*Q%S,9VY#%#!]9539H
M0RQZK&M(_BY1A<]SV[<O@;?R4# 1<!>S%A[0.V(_VPWA,[=7V94U:FB)&XN@
M_=Q^]:?K5. EX%>)SG0PMH23+<8?8O)M-[<]D1"J4,Z$ N2/$\I050DAGL:?
M3M/NEQ3$X?BB_D5ZYUZVD*(,5[_+'2OF=F);.[2'QXJ]X?-7U/D!MM69_XY.
MJ.)PD0E?(\<5E;]6?J0,UYT*3Z6&G^I9-O)Y5F_B"\U,"#I"T!/XVO<(84<(
MKX3H+B'J"-&S*X". +057.5=%G,%&5S,"#Y;1!V'%HI3YT\!WZY<!.7NR'>\
MGI1'3XO8]V?N20AUF*7"! ,,2&XAJS'D*N+R!/HL E,6RV!$#VX7R,8(D&HY
M/!19WQ6Y23,T%BN4_/"F6(%9(#(*1%(@&I8)>%JU%2:5F$9B7@(-DRE,/,#X
MCEZ.,>8E<8!6$0,H="9F2\!H"8PLQ7ZH65(8,%A%-_00L7J(6(\1P\+=6(F-
M5N*1%9#\1V!B%)@\?SX2HT!B*&:D%5-A)@.;4> [6LFS9%2,*-7_M 8E+W4T
MU'J, D'HQ&9;J=%6:K"EG<1E.CJ)D3>V94"EZ>CH/Z6U?J2EC+F#F[1&Y"#;
M&K5R?&R8V.M!M.^<KX&XB;7XTI]FOB&^XIU6-<:KO&K3/R YE VUMICQ^U_>
MTGN,&>+)>P[?VH)_&?23"NV9&$[XF*C^J"8,MUWK=_OOC\4_4$L#!!0    (
M ."-]TZW\D_$< (  ,\(   9    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM
M;)56T8Z;,!#\%<0''-@$0B*"E*2J6JF5HJMZ?7:($] 93&TG7/^^MB$<"4N;
M>PFVF9W966>U) T7KS*G5#EO):ODRLV5JI>>)[.<ED0^\9I6^LV1BY(HO14G
M3]:"DH,-*IF'?3_R2E)4;IK8LYU($WY6K*CH3CCR7)9$_-E0QIN5B]SKP7-Q
MRI4Y\-*D)B?Z@ZJ?]4[HG=>S'(J25K+@E2/H<>6NT7*+8A-@$2\%;>1@[1@K
M>\Y?S>;K8>7Z)B/*:*8,!=&/"]U2Q@R3SN-W1^KVFB9PN+ZR?[;FM9D]D73+
MV:_BH/*5&[O.@1[)F:EGWGRAG:'0=3KWW^B%,@TWF6B-C#-I?YWL+!4O.Q:=
M2DG>VF=1V6?3OHFN87  [@)P'Z"U_Q40= '!>T!DS;>96:N?B")I(GCCB/:V
M:F+^%&@9Z&)FYM#6SK[3;J4^O:01BA+O8H@ZS*;%X $&]0A/L_<2&)+8X%$X
MOA78CA'(]V&) '016(+@Q@6&"68@P<P2S&X(YG=E:#$+BZDL9B+'$)0( 8GX
M3J+%A/^7B$"):"01QO>7&8U<X##4Y?8'%6]O!4!&H7^+O$EJ#B8U'_OV(Y@@
M!@GBQR]W 1(L@,HO[LH"8/"$3>3#G>0#1N,)BHEF1(];16"SK1%^P"P$PA,]
MC>".0P'@=C%! ?<<FGW +=Q3"&JJD5L A*=TX,9"X\Z*T-3? VX#-/^ 6[@1
M4/R(6P"$@SL=;S >2BI.=I)*)^/GRH[QP6D_K=?8CI=W>#OJOQ-Q*BKI[+G2
M0\J.DB/GBNI<_"==^5Q_7?0;1H_*+.=Z+=H1VVX4K[O/!Z__ADG_ E!+ P04
M    " #@C?=.<B:-S5("   :"   &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6R55FVOFR 8_2O&'R""[XUMLMMEV9(M:>ZR[3-M:347Q0&M=_]^@-98
MQ<5]J8#G.9YS]('F+>-OHB!$.N\5K<76+:1L-@"(4T$J+#S6D%K=N3!>8:FF
M_ I$PPD^FZ** N3[,:AP6;N[W*P=^"YG-TG+FARX(VY5A?F?%T)9NW6A^UAX
M+:^%U M@ES?X2KX3^:,Y<#4# \NYK$@M2E8[G%RV[@>XV<-(%QC$SY*T8C1V
MM)4C8V]Z\N6\=7VMB%!RDIH"J\N=[ FEFDGI^-V3NL,S=>%X_&#_9,PK,T<L
MR)[17^59%ELW=9TSN> ;E:^L_4QZ0Y'K].Z_DCNA"JZ5J&><&!7FUSG=A&15
MSZ*D5/B]NY:UN;8]_Z/,7H#Z C04P/"?!4%?$$P*0*?,6/V()=[EG+4.[]Y6
M@_5' 3>!"O.D%TUVYIYR*]3J?1>C, =W3=1C7CH,&F'0,V(_1T#?'S! *1AD
M(*L,9 B")QF1G2"P$@2&(!P11"F<^.@PL<'4G4J(?&]B=S^')7[D+:@)K6K"
MF9H8Q7:"R$H0K<\CMA+$*_+H,,G(:!"D7C*)8XY" ?2074QB%9-8XDCL!*F5
M(%T?1V8ER%;$T6&BD=%LFL4<LO"50]_>;;XEB72!8J%AX?HLH+W9(%J11@\:
MO_=0M<$T$0L,)=E2MT![\\)Y]\8H6Z"P=QP,_R,6>\_!:$TL'2A[]CL-)9KO
M-%GH35\T&&W2^M3\AOFUK(5S9%+M]V97OC FB:+T/459J(-ZF%!RD7J8J#'O
M3JMN(EG3G\1@^#NP^PM02P,$%     @ X(WW3@BIM, ]!0  JAT  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C0N>&ULE9EK;Z-&%(;_BL7W!>8*1(ZE3:JJ
ME5HIVJKM9Q)/8FO!N$#B[;\OMW5ASGN\=C[$MY?AG9ES'LZ!]:FJOS8[Y]K5
MM[(X-/?!KFV/=U'4O.Q<F3=A=72'[I?7JB[SMOM8OT7-L7;Y=CBH+"(9QS8J
M\_TAV*R'[Y[JS;IZ;XO]P3W5J^:]+//ZWP=75*?[0 3?O_BR?]NU_1?19GW,
MW]P?KOWS^%1WGZ+S*-M]Z0[-OCJL:O=Z'WP6=X]V.&!0_+5WIV;V?M5/Y;FJ
MOO8??MW>!W'OR!7NI>V'R+N7#_?HBJ(?J?/QSS1H<#YG?^#\_??1?QXFWTWF
M.6_<8U7\O=^VN_L@#59;]YJ_%^V7ZO2+FR9D@M4T^]_<ARLZ>>^D.\=+533#
M_]7+>]-6Y31*9Z7,OXVO^\/P>AI_,>ET&#Y 3@?(\P%"7SQ 30<H[X!H=#9,
M]:>\S3?KNCJMZG&WCGD?%.).=8OYTG\YK-WP6S?;IOOV8V-5O(X^^H$FS<.H
MD3.-7"H>J4+$_X\2=0[.-B2T(8<!U,*&P ,H.( :!M"+ 3R7#Z/&#IK#. ^C
MXE![DQEEV4RF;*:Q&0W-:&!&>69&33([2QJJ>/XG/%_T"!$J;,M 6P;8\B;_
M8,A)/L6A]9R,(C,766S$0B,6&#&>$4N,=)N5AOZB4)FR:<:M2P+M),".-^6'
MY#H[5';)3@KMI,!.@@?(X #9]<DD8DR%^(ITFD3SR69*D70",F'C-&0R2C"<
M$E?DU"1:IHB_19-H'KT,J@1FE9!7Y-$DPF>9C$B4:QGC!6-/(.[YJ32)EANE
M0^/[H;)NHY*9;ND(LT\@^*7,$)A3PMP0P)@P B&&!#"%1Z+3V0Y,ZT)EJ='L
M1F'&" 09$K\4'YKF$Q7%(<,'@0DC$&)(!*<H/$DV 95BUP;S2F37!'%&-\NH
MD%0B5)8:P:V/Q/B3"'_,G"3FE137Q[!D:B+$&3^&)86(S!2Y8@-9$MN0,X1A
M(Q%L_!B6E"*TQ((BS@SFC$2<\6-X$EVBL*1EU:>8NSA)#"R)*BL_@"6MFF1&
M%H;67TEL0H:?$L-/ OAIKAS'N)+)#>&+(2,19$CX4GRH.)NEZ[0L*5T[R^T1
MAHQ$D"'!2^D1D^L!%''-"@:,0H#Q@U?1PJF+3!]X6,44G K#2J'BRH]?18LK
M)4#W1&72*BZ"%4:? NC3W!(S#:&ZH:7$B%$(,:2II/R8+_^T*$C$F<&,48@Q
M?OPJRAB?=Q<E2R.8+@J55B1V[8^-7)(LC6!&*512D:A%U1+9'B3BM@?33@':
M:<D,@0FE;NC;-.:*OJ9OTY084M-V ,ELS'4#&I-%7].V:=2V$3M4Q%ZF-::*
MOJ9QT[ K\R,&J[BUP832U_1NFE9*4AMR@40RRZ\/<]N*\LZD3 QK3"E]0^NF
M,5\TJEY(R(#;0S*CVT1E.K,A-R?,&0TXHTG8@!M$F297:R 3,N':$XU9HQ%K
M2." QDPHFE9 EK*!C,&E46GEWT";1'/<&^%?$R;1_!:M%88+8X,A:  $-7-_
MTF!LF1NZ-X-A8U )XX>QH1@1(N':9X,Y8@!'2'P:"@AMV=O'F \&U$,D[LRE
MEFMY%N8N-2IT_&@RM$\25G.);3!I#"(-DXH&L\'<T"<9G,T&93,)%)JF0@@V
M,7">&I"G-%!H=R,U&Y(6IZ!%*4CN\(/.94&HY9EPIEI48/C1,HGF6%&:=M71
M[*%9_Q3S][Q^VQ^:U7/5ME4Y/"5[K:K6=4-VU_I@M7/Y]ORA<*]M_S;IWM?C
MT\/Q0UL=IR>CT?GQ[.8_4$L#!!0    ( ."-]TY(9H X: (  +T'   9
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M^Y<%@UK;Z0<SEW,/S LM!M_>9/G'%'\!4$L#!!0    ( ."-]TY0[S$R>P(
M &T(   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;)56VXZ;,!#]%<0'
M .9B0D20<E'52JVTVJK;9R=Q EK U';"]N]K&X=U@K/-O@1[.'-FSICQ).\)
M?64EQMQY:^J6+=R2\V[N^VQ7X@8QCW2X%6\.A#:(BRT]^JRC&.V54U/[81!
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MF CJWCX0PK'(,O!$-4HQ^\=-C0]<+E.QIL, '#:<='JX^^,_C.(?4$L#!!0
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M,Y:;,=2,96$$?\I<I,+ ,^PC:"5B5B(5$BO1-5:XR&\EAE9B8(4._IA%,6%
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MN9>Z_1HUW\O^E+&_J(O3<(*ZNASC;OX#4$L#!!0    ( ."-]TXX@?$A$@(
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MQ1@7 H[&33,[5_VUV2^,;(<G@8SO4O$/4$L#!!0    ( ."-]TYX[.59&@,
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M79]:;UJFP>F\0E!'D81;S8*L3H)E$=:.*&!41Y UK R%"Z"2"Q0M,LHXS%\
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M4AV;Q 10G0BM83* =/F#Q48@L;'92P .EW#[!R!=_CCVLRC)4]82@.05K&2
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M5VC<67,?%.8#F\:!"0*0( "<<15G@E&>UFC+0!CE"XDAC.)O\A@S$!2"@D)
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M6^X9XU0H\9%8YZ.XT R=BNZY;":BW>I3O>YP=NIO+-YP;5K^ U!+ P04
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MF0OKP=D19;YGP57N+*+L4Z)!E&^\U5>B.?5;+*VSE]=:=888K?=MG!?6[0J
M]@U=;"G2OJ.+;-BD^4D_[!G]D3>GHFZ=-ZF4K/H=@Z.42NB1$T]/A[/(#_>3
M4AQ5=QCKXV;8JQE.E+R,^U#^?3-L_1]02P,$%     @ X(WW3O<A<M$! P
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M#XQ)JG)W']2)X:2N6%VCH >I7Q/USIM[1M.0K&[O4$YWD5O_!U!+ P04
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M+DP$C6@?LT0PL9;+34?KVR2/)@0\#T_71QOC-P1!KUX!3A"@!$%#X/<(*$Y
M40**1!!JM<(PD58*##/" PG10$*$0*OWHL7$#:9H,,% LA'J(S)]P$"_1BC!
MZ/YRQRA!C$2@O43S%A-VL@Q'#HV['VW>30L:.'H731#XH8Y:(R@ !_ <P</E
MQD.R-/2F!44=3W[@^%IF"(I$.FJ%H&3)--0:05'J#+0/!I04D-0&% Y0B7L
M<O\0 2X;@.@&!'J!6Q#MEL[KR),JW0U4/QQ<A"! PM$T>:% 74?1@-0!+E6
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M6*?,4[3)Q"BVZ5-$Q"D@X@Q+,*+/] NG7XJH*H545=],%"@<YXX@%441O:2
M7C+]1 F"L(@0(:2 $#+DH$(1#:'1%S*+R ,UY0'(;&QDEJ.917J5FKT*9!9H
MZ! Y9C*DH1EP?&/8_S6DH1FQSRQ#>H?9'( 4:%*S$:+P#/MW"1R &-+H#&DP
M%GPA8*1WF,59XTF!QM)%J;XZWNB:I1#UH;\=;)QM]5:VG9.CT>L-Y WMKFFT
M\369;P@PGI+Y_7"_^)-^N.[\(ZL/I[)Q7JNVK8K^!F=?5:V0OOLSZ?M19+OK
M2R[V;?<8R>=ZN&8<7MKJK*Y0O>L][NI_4$L#!!0    ( ."-]TXR!]3RLP$
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M-6ZZLG,5;EDHC!SB R+3*Z[^ 5!+ P04    " #@C?=.3Y<[7\D!   4!
M&0   'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6QU5-MNG# 0_17+'Q"S+"S)
M"I"RB:I6:J55JJ;/7A@NBB_4-DOZ]_6%4)J2%SPS/G/FC,<FGZ1ZT1V 0:^<
M"5W@SICA2(BN.N!4W\@!A-UII.+46%>U1 \*:.V3."-Q%!T(I[W 9>YC9U7F
M<C2L%W!62(^<4_7[!$Q.!=[AM\!3WW;&!4B9#[2%[V!^#&=E/;*PU#T'H7LI
MD(*FP/>[XREU> ]X[F'2*QNY3BY2OCCG2UW@R D"!I5Q#-0N5W@ QAR1E?%K
MYL1+29>XMM_8/_G>;2\7JN%!LI]];;H"WV)40T-'9I[D]!GF?E*,YN:_PA68
MA3LEMD8EF?9?5(W:2#ZS6"F<OH:U%WZ=PDYZF-.V$^(Y(5X2XM!+*.25/U)#
MRUS)":EP]@-U(]X=8WLVE0OZH_![5KRVT6MYET0YN3JB&7,*F'B%V2T(8MF7
M$O%6B5/\7WJ29=L$^TV->T^0_*/Q P7))D'B"?8K@MOLL$V0;A*D&PKB=Z<4
M,'<>(SPFB][5(*NI<%"MOX\:57(4_BVLHLN5OX_]5/_"PWOY1E7;"XTNTMB[
MX2?82&G *HENK)3./M'%8= 89V;65N&B!L?(87Z#9/D1E'\ 4$L#!!0    (
M ."-]TZ'<(6H8+D  $4/ P 4    >&PO<VAA<F5D4W1R:6YG<RYX;6SLO6ES
MV^B9*/KYW%^!ZE&FJ5,4F^#.[CFIHF79K42V%4F.D[EU/X D)*%- @P 2F;_
M^OML[X:-I.S.Z4DEE98E$GC79U__*\MR;QM'_]B&Y\DVSO_/=]-!_SOORWH5
M9__GN\<\W_SXPP_9XC%<!UDGV80Q?'.?I.L@AS_3AQ^R31H&R^PQ#//UZH=>
MMSOZ81U$\7=__*\L^N-_Y7\\3Y["U+L.'D+OS,L>@S3,_NN'_(__]0-^S8^,
MO'=)G#]FWD6\#)?%;_^TC3M>O]OV>EU_6OYRU?'\:?67//4&INX4OWJ=++;K
M,,Z]N]TF+'[I=\_^4OO"7[9!FH?I:N?=A)LDS8L/YNFV-*!^^3I,HV2)^_1>
M!WGI.;75_^=__:^J_9A%IT&<17F4Q#6+N ]666GTBSB/\IWW)EJ%WOOM>AZF
MQ2>Z9_ZT[_LU+]Z$#U&6P]2Y]SY8EX9_=?GA[<5[[_+]>>FT98!S6'L:K+Q+
MN.8OWI_#76E^^-]D/.P.AJ6KW*8I[OQ-E"U@A+^'05I[BF=G?N^L7]J%/CU[
MC#?P80D>&\]>WI:;K'S_+[WB)S-X=<FOKX*'FN.YC!=)"K<9X,6VO=L<]N8E
MJ4=HF<+Q)<LR9%W4#'87?/$NES!C=!\M:,2:.^_WS[J^WQL-!C4CS99+P-FL
MK7[QKJ(X]#[$I;7T>D/O513'X0[6G@(]V#?@.?X%&[Q+GN/2A0?K>1HM'^J@
M6 ^BC^DZ39ZB>%%ZX=ULWQ#729;#E?YWM*D\XV[/'Y1NE-8^ ])7^<K('Q<_
MNDH(;!Z3N [[1N/I&=#/;O'SNR@'C$WN/;_7FI]ZM^%BF\+L96JW7L,MW^;)
MXG/;.^EV8*@A4+_4>PI699H$-&09Q0_>[6X]3U9E9+Y\5?Q,3>Q=?%D\!C$0
M]"HR\'YV^WI6(I^* @@:,]6BZ>'ZRACT]S*3T$@"Q#=8Y-%3B,@?J"$;B!U@
M$(#(0Y*6CNPJ2&$7L\4BA*?@F24_7S/6[3I8K;Q7VPS@/ZM;W\4Z3!]P8V_3
MY#E_!.A8;X*X-+,:\C&$(9N?<>_UECBH]V&; \S&>(-E. #R&F>P&?@M2U;1
MDG9&>((D*$-00EJS#KW6QSC8+B/X_A2X\\?;UU[KY%2XM!?%WKMHM0+2 3AR
M8O]9HB$',_!)"0P31+TT? KC;?G2SP$S/=BF%W[9X)ZR'RN?@ UEP2J$989?
M%JLMP76P1@C[E4D?#A'!(4<I$6%X/EC\8QNE<"Y1#.?X$,T!Q8(L"_/2&F["
M##C%XI$&6<)"5\EF70%QMW"5,'';>PCC$-D</A\LUU%,7!,AMLP6OM$:SY/5
M*I@+Z_ V:7(?Y5YKE609WV8%F%S!EQY.2P/2[*LHF$<KD"O@\@$PEQ[(>72P
MQ7=;;T'"._56,L0]K)F)#%SD.@RR;1JJ/2P ,&!V_ M^S:)ER(NL.&60G!;Y
M%M?J 7T!S"QM<V8.Y PVN4!NE!YX/0QHBR) %1\3Q+A/D[4'TBXOMO34A_P1
MR$HD2"1CG;:]N,ST9,!Y"(<9JE=RX,[R%J\&]@6H#BC&9WH/OS[!B80AC8D?
MP"LU0UN#E4C(B\9]#]_P0NN_4= 5Y'D:S;=Y@,"9)UZ<Q'CE:4+(@) ;P@WE
MV6'SE89[%24 .TBN2D*E]1;<$Q.M$GEX%631P@, B6$UF7GPF(E>1ZLM4M"O
M&^53&#T\PC!G 2@EJ T)E=UF!,\>2 >+[2I 9"GM D2;)>!&)7S=".EDD 7A
M/#H[?]WK>@BAP2;<YK!_P)6'-%A7@_&+^ >RK#1\A.>0$3=RDT;.H4>M'?3_
MG<V1?"[R_Z\:"1?.2PP0I0/\&(.DMHI^A7T\ .G*&'I#@%\@7QG+-4CU@J<@
M6M%E*M+7!+>-HRZ"[-&[7R7/0$I!C&U$@+>EMV,";D15.AP>XJCYD1X@,Y@#
M-T)ND,Q7T8.H%O4K86EJL?-0S\M6PIF6OVQY(=5$-:F]"*$2C3-6O78$7E6^
M_PV)4]7X!Z+,JV 5@$*"4AZRV!>@Q^MP :*37RTZ*6&:.7A9,D( 1.9"D(@<
M!E@TXF])00K2SR&?D4&%,NM=H!J*_'81PDAS08W2BK?A2RC1)<!ZG%>(Z#,6
M3QK%$2$$SG'4L/_&9X#, FG/=VUOLT(KA^+,)$]4[O8#2P@ 2RL0>^JDL\NB
M^%8YUMLD63X#')1AX#Y,4>A!/D_O5QT>XR?+<8R/3>=0(T7*Z5AR8 FJ[H(O
M0"<WP0XAH!9(:KZ_.E3 A('2;6BD-+.MYGNU5EX2%Y*\?N'.&:M!RNIB$C^<
M <G0DJ&^]X9Y&3A7^M6&1WDO#0^@*AA9%ZV%ZT7Y8;3@_IAM@D7X?[[;H)"<
M/H7?_=$K"4A"69?A@L@KBR6/R0H$]>Q[$4S+B*+.*V.M5%L9V.[@&Q&IQDI1
M_1[:*^I>G"V79/&$$P(=:7E&(M,F@A.K )[M&D6I<%G)FI WE*6H'#BH)>25
MS26DU^S4RH.<=(GJ*[38E7.>__D?DYX__JGF5-_7<*?J.:K'*(&0I5Y\/==J
M70>(9H\AD/)@A5SLQ/NAQJCO2'9OHAC&C-  EHCANEZNJX>N X'I91(M<LDW
M(*^]B%&?*VDO<U1'M$.@K:J:ELZT7)6A= *<%2  K?.Q46U0:H&_%B\9_W4(
M4 ^GSD)?@T&D?'EXI6?S ,\,D0=.KU)K/S]0N]?TU>B_C>)LZ\$Q,)#])'P
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M#J3$LY:$!R=(D>.1VSKMU\G(U)8%',F(!85DTNKX1Y#*T(L&!_N0L&<!A7B
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M9&PM4L8#)< 5;YJAM6;YI$'B+O%?ID)RK\OB0%IY"[]@;'#57'06[CDT3Z]
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M)3CAE>EP(M?!(!XKTBG)BPR/R1I_HF-3IP/B'QD],A.6P- D!TV89\,T;?]
M@)98"PY78_<@J1:F2 K542Q:;U2T!<.VI8DXT(^:R%$@C8LP8/V5DL!/WF/R
MC*I3FR3-G6'_42:,"?;8\6;[)4.VFTF:#_E-([8SK5:6A14#JN+53DB5^M0Y
M8<XZS8TG1=D*E(>3,&VA Z0U&6%/:+W[&UL=,EH6W.#5'O>)KGU@[ $2=*R=
M 3HA6@?(TYI=@BU!6(?I7^TCE:^F>J*E^BPJ:?X\6<_1[T,CUU=+<6J3'EPQ
M%0.VR<0UUH$+H76IE%#FCA68>,+$=,%2M6.:)VN]O[VC?/'%"N #M*2SC')<
M,-4)1X2G=U5U30*0))(SRVWR%*48M*#2Y54J)8P0L9"11V+PX;(3& Z-,6"L
MZ"AIV=H9V^*7:(O)GQ-O'2W/,%D()I,EJA4;P[@=O17JKS>ZV!49U9WJ'&RK
MT7X0=M=@JS??][T6FD$I\_)SC*E+,.[[VYNSFXMK_U09[=A/?TV5J?I.BKAR
M"A@@=VH)+$"'33!%!.LAX 6D<%N8TF:2S-K>W\[$]U-_D(PS*^PX2G8D>&&I
M*SN@+3(6_P4&ZYKK87F1=]JKW>GUVYO*G?9^.&JO>ANT>+A=N*"((O63++#&
MYT.HWBP[5R6$IV)#&!FZ%(Z)AO"L%J:HYC& O5.(WCOI#3O#KBX*2Q28R3);
M;]%$92&7?E\M/\<ZI_#@R60P[HQT\$*YA@I-?S*PGG'FY!P$NZZN?4"%;#<
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MO^1Z*"B**;^'>;%<N$#%PEN1]*8J8SU.AOJ:]J*FWT;G8-]AHGG]L#H\;>_
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M.L2L;7B5*B' T)06S'\/-!<:M?LCEOV'[>E@0@<P@MV,)868 VU=>IIQO4:
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MK!=A_E%A_URX*)& :L<(<;_:HA3L*/O%A=7;_6K&44FM!4LF@4EQ<"EG4F3
MAXC*7VW*8Z.=,>0[YKM[BI=A4>QPTQP3'GTUS.L*%IT"D<PV2:&5_=$:6^=_
MN,[N3PM]</!K8]([Z5L:\E=J\.SRKI Z+)9,IR8'0O=!!(3[23!!MIMK>=P6
M8[72P77. !LD9MFW#Y4V!@#;M:KN[SB(*"[VM[U[<^_%:S_Y-J::HW1H//8J
MK-US)55.LZ_1BVW5B\[VW#E;I81=:,'KFN_T]&C%KF'TF5B,+I0=F$NN.J;^
M.PQ_B!^.GI=EG*^>YS#%L^*CMVX> WQ7>>L8.NZ4NCCXO9X3:?ZA$MGIL9[U
MV$OU_G^#R^\%7'I])Y+^X/>XA=-><''+H_R>6KN]N#[A0;YYGM!X]S,=D$1R
M(DN)S(7V"S,@D&=4%)8/P9'S,,:;Q#P5)]XN2;FE"<CD:^OPRAQDAT<",Y6L
M]HXV,J&).!0V*)JSVSR;C],V)C$[:[3<\$MV^Z4#Y#NJF#RE\CLN"^X[.<PO
M9L+O'0D/C7>- M[4L978HI@C=Q=*)-9&^U9+6??'IQO7MX)P15B[]'3%!KO6
M,;^P0X25&.*@Q6.T"C4$ZA(F.BK&-O4';N@'K)$ K]QUM^R<(3UMF1 $2Z24
M-4E-?<-C\D8%SHW/2CO^I<(B5SO&^>>A[I:$V<3200JH[+T8L_:MBZ"(=U%=
MC\'*NBT(S%09GFL]ZFX%AZ?0JR B"U6KK\I.)<T?077?[\@I)MZZC0DUBW/R
M<3&NX T>;H6EZ4>N E<'2Q^JHNI/O(G/60F8G* JC>WJQIC5MQ0_\;BHW$AW
MSZVN8% 2J$R(=^6>]JZI>3)>%-EV2QSJ90<VTJFA7W=< Q(_^YU>,4+N6K<=
MP")S)E>=2Q0T?GO<4/5!>M]P$O/M1G\;ZF]=8ZT=STOY;I5]N)8AX#-&FT5H
MZIK5?.-Q>:V&N:6WP83*5KJN@/9XZG0->C%3?4&]#&<3RDBM>R$-QI;+AQ9+
M54\.:H7D).'P1GM3ZZ.7\KED!3"]3>,VAL/DOX;I"@=_H]K>H1P(USS?1AS#
M'W@K['ASEBTH.;&FHZ3NFH?VX<H9W! /-!M;C?;FH1TIK&)  :PD@$F*RK!3
MC/M2LHDXTHT2U6AD*E*Y%_TI]B?K>AG6NH>'D%1;XL]Q>X,[GW9+PV&@"?SQ
MF&RSL,UE"$V*V7:#MB$OVP0+AJ>A7S5 L%QCA]Q<[HH>/RY80HI6%[QFR"SF
M#@2![CVO S[.LE%R'Z4DI-N%XL+4*8*[N5GBHW6/>^IIVS$A&' =Y=KB5O3U
MV4AC\_*"#=%987)?7,V_>[T>T>O5;:$Z&O@6E>+0S7K2;"7#V U^K6RZD[X_
ML0@TZ@F*OF0213;M6D9H?&"-M7_B,-V5)OLG=FV=:6. %"Y;A)0*PTR0Y4N7
MB;%&I03CS/T>3@@%;,U"K<*CQ:X? <M(*W*D<GI^0AEX -. 00]ILMV4T\*<
M VA3330EMM>-P45_,%8$"]E3SDZN^YB45_@O6^+^"J<II53PIPVRESSP"<O$
MRSI7Y/'-0UO)$'M/(N ,RA$FE!&AYQX&2L/4@,Y^R!4/3]8-XTGCJ3@, 75+
MXE)HM#.UB4QN/2B54:PRY#O>N4PD(RM.B<\CUF'Z0K+1<38@3&,G!>-1#KCB
M/AQN2/F@J?!@(G;TM.K+S/1I@0[O+WDHZ71FY>+UL9:)LI9:Y:5=$_B9U&I^
M5??T-><LG C]*ZQ,2^:L>L6D7-E=QTU8)9^$WL*W.&1[_DSI]>JH34*C.F )
MKN0:#XN$BUF"0&&L!<75 FEB;I$8(,&^S]']CDA9Z?$#U/"OU[L+L]:IS&R_
M6[DJ<[%Z!5=(_^ .J0AKS<>JX+55@UN7,"DLSE$\&S6_<:]0?J=II"NMV#8]
M->CUL5TM^>^:GL-J)D.I.;'G\HS'3? DR;YE\.G>\@OB3+A50Y:-_M/2K5&-
ME)NZYL"H;0\D'O0V7*THUD.22CDBRI6:J231P*<:+X+Y8J8\Y&VI.8/EA7S3
M#HD'.%6 P0JNU/)I^?0/&F*M[9#U@I;=E5A_G&:]7<M#.EJJK@V6)!X#?:/J
M)M^Z*]802TY0B>()5NFAGEAC+#]$-8;'7?ZMC^D1 VZ(-4)7RIU9D3_ NKT,
MO(4]P? C'/\**.2/)G9KA.-?2P<7$RQX .!_C%6$.ZNU_.3#%@ 8"8DZ6D3+
M@EK!XC:5!L)'J?2*IO1BIA#P(**NJ76;;D95'JZ](=J^=4]!=?D)5;FE]LX$
M.WJJ/1DU)L,+L$Z<S_I=-1R=>),QE2*9=#EP>DB5N<;<GV#,94HX_>7$&W51
M U374[%[@&J [-Z(2I6T>MQRNM7C>K"MWH"1I#>@*./6<$(1P2U_TJ,7$!=J
MP!WG)DLBU7#%BK3TUX"+- W87></N=TU-_O I=R$PI4RP\]EX06TT%&'"K&>
M@@51N7I#Q7FPGJ?1\@'P^MVL[;Q42(C\1'4M\3$S@.$1\A&W'*)*1MB8"(>C
M%J;,?)]#+$Z($I04#ZJ2-#C8I?@DREGDC%+]HZN8+<D.^XI"?3IH$7 T#.EH
M52N]XJX&X\W_ !1W W+ZFM'0E FAK'R=7&=K"L5.JL7-E IGX@AND7WS3F"2
MFH]A>-:X%(K[K2H03=GP3S&)E&NOG2YNCJ?=B4+S[8+QG:/W!XB/-3)/,D=Y
MF$?586[WFE;:=6(Q#8 2Y;"@T;_-(R\VC_0L*VP%([.\8OL>+7G-:@P;10_;
M-S=T_(LJ]5PTN/K3!J5>U1HFT+W1962+P(Y;?Y5((?G7 *,+4/#AA+?Y8R*9
MK:K!+JMZ&@NV&S+Q8T+(W((.*7JK*W6T:)KB,A!U<<Q3UC,;GP'=,V2C$YD0
M2!G?1!*^@@?)BB0C:6KMU(2+-X_/G4WQW3RBWK0?#WN1M'HSX5(*Q^7<-MPQ
M"-O1"RZVNQ5L<HI5X+*+!9/RM&N[75[6[V?F#CD ,4;='7-1XI%2Y6_O^2FX
MJ$9'@+/9]F$+>R'[_E<#6M\*C*\#M$D]H"D+KQN;7['T@Z"I?B)% ZM J?ZM
M(T!I5$@CFGP]:/G6T0K)-X#Q$D@K.B4INV-%V2BC?P[)&7T])$P.@H3ZB9H@
MH?ZM(R"A&!OM=RW0>"$H@%A5@(6^==K'PT+906V[SYM"1Z\H1OR 0&TK6>*H
M^'.M0V/\^WQG8L2*^FVIR+(.2*641UV_2Q?=);'FEMP7[WF*.YBB<1@WS@95
M>.O-\N-5Z6 P 587A.'1@K6EN[^&6V;@H>=>A7%X'^44-N%.H2,M[S"P<"56
M39W0GXD"+^;/=H4#%S-W5<WC 5<@I4B85M]7B<P]2>VE7R7U>6^6P)SK$94+
MFOAH%^BA99/L5%1[NC<ATU<?+6$J)C@MY4 ?67:&BYZJO.36@!9>ZB,SX"+-
M>*;*RBH.L?U34!'55L^G\^L-J0Z[V4W+[]'0^O!=8HL!0E0MFK/.*< "CUV7
M:.V-?5HR_CKLL>'OWP!^)("/.8U<5[T=2$ENJSYZ?Z2JX_KCH7S=8K?Q:24T
MVA1(,@*#9:);]\UN/X)FT2%^<=;UJ5I^71LCW4L8GC%P LH+JI&Z;G97X$E6
MKV%75J[7#:L>$9Q\!7JVQG18(]]J>4J5U0=CPB,L:?.M4!31?="K*/"N6XHB
M)KT(->7._6[?ZE1J[V.(9LE*U.3B$*;4P[@"8!1>]GH*=GHCGO$ ATGPE<=7
M9'3U#A!U417U) YCYX>:HZI*8)<3)JJ*DAM;0FVF1-=)J%#UKP509:$D# @5
M,>\*YFB$X:+7>%'EQ95JK^E*%E0P1)4+H7(7BJE45*T0@)&*%5+!HJMC74O;
MJ^IM@/\=LB_IK\ S] [-4*E92,]JR6PW*6]<R#ZZQM2Y1&4<&0XD#E]79&%D
MDTZ-+<+_TY*-)$ACBM_!1D,DD-<^<:V>:#*YE(8#NI!%"W8+1JLMXDAH/\2Z
M!7G,@]5"L.BWJ2/_?KL.*7KC1Z*#JM!;H5R&;I*XZ'C<]7- KHZ)+B\_[?;(
MO]%K=_N8J_XZC)-U%//()4-[O"4>BI9JT4!$+;&LG_X4*]WTN./!M$\^.Y1A
M+K0[F,Z.H@JMYCVWI,NH. \*L )=+MF%NN"QME-@Y^R] !:MPS,$\- 4>R9S
M.PZUC;$DE,(H1!'\C_L0.(\4D0__ ] A2R09,*UG59FN2.EE^Y;X6AW#)LFQ
M (.X"\VIFL7UZ;];_ICZI)$3@F&,8K[JP1'O8T#WT:?[&--]##4/")T<.]+
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M4;K88@UIN+!T+9+C+]OE XDC9(Y7T*FL]I1UAWTV!%G3$)Z'VU91D\JG\',
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M08(6997[['.T$P#5Q(AQ=O>@5.QVBIDC5"T&C "H".UVLH1U8X^)T?Q*DK_
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M\CS;V T+%2!:$A@E?=Y&?0(*PG@B/>_!<6LCE! )2%/"2?2)]-9SNQXHI=_
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MR'A'@DP-FV^W[*A1J!(P:+ 7NQH*[E378E.Q6/JE&S]'-D-HUY 05S .'\V
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MS)2]H- ;FW:06%"SL)4W**<"5/4S))OR9MS_Q(5$59I:J$IO#<QX,3F":D9
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M)WB4].-T!&R_\:YU- JQVL^,$4-)4F")89!%)P=H E8'_0+*C?327+]$8+4
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M\M=198PH.S,U^]F8K0 IA3;QD?^&-*^:(W9FQ/WH8^RM#]V@GK_Z\A+(;>0
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M2&A(0.5+I<D<R)+^EUS^JY!+VK,L&8W?HP#/O>1B.?/V>>^T)EVMSFRPX0.
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M9J)#4S'-%T;CVM]]X6(Z:39H>.]:]GD90\.[@ >*D@:S*/TN;TNU&RG@%:C
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M<>"_3 5[KE6@@%\:TPA5VI!=[P@PC,X#AU+!Y(!X<PB3WR2V!NG+"&<PRN%
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M   /    >&PO=V]R:V)O;VLN>&ULQ9M;;]LV&(;_"N&K#EAG6^<638&D;KL
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MK:#&C(.2XUB:&JSO2OS$#S$AU]3(KDE-.Z2>."2:&GM%0'+>(44)+B;&7A
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M;VYT96YT7U1Y<&5S72YX;6S-V]]NFS 4Q_%7B;B=@H,-ADU-;]K=;I6V%_#
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( ."-]TXGZ(<.@@   +$    0
M      "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ X(WW3J7#
MS2OO    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ X(WW3IE<G",0!@  G"<  !,              ( !MP(
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #@C?=.A/%E/3$#   [
M#P  &               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ X(WW3F![AKF7!0  1QP  !@              ( !7PP
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ."-]T[WP[9L
M60,  &L-   8              "  2P2  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #@C?=.=M%I_-L$  "X&   &
M@ &[%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ X(WW
M3JKL*WC) 0  : 0  !@              ( !S!H  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( ."-]T[DJ7%8_P0  )08   8
M      "  <L<  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #@C?=.(9\#$H8+  !A2P  &               @ $ (@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ X(WW3OX6P<:V 0  T@,  !@
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M970Q,BYX;6Q02P$"% ,4    " #@C?=.+KDZ8[4!  #2 P  &0
M    @ %9-P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M ."-]T[>+IFYM0$  -(#   9              "  44Y  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ X(WW3A*,GS"T 0  T@,  !D
M             ( !,3L  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #@C?=.>*[@!;4!  #2 P  &0              @ $</0  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ."-]T[#.[8:M@$
M -(#   9              "  0@_  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ X(WW3OTC2]RT 0  T@,  !D              ( !
M]4   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #@C?=.
MC!.*4;0!  #2 P  &0              @ '@0@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ."-]TY:G,NXM0$  -(#   9
M      "  <M$  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ X(WW3O@2X*:S 0  T@,  !D              ( !MT8  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #@C?=.'0.:AK4!  #2 P
M&0              @ &A2   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( ."-]T[KHX1FL0$  -(#   9              "  8U*  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ X(WW3HV353NP
M 0  T@,  !D              ( !=4P  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #@C?=.OQ[18K0!  #2 P  &0
M@ %<3@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ."-
M]T[*N7;=M0$  -(#   9              "  4=0  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ X(WW3B#5@JKW 0  RP4  !D
M         ( !,U(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " #@C?=.N ,!1K(!  #2 P  &0              @ %A5   >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ."-]TYY/VHAN0$  -(#
M   9              "  4I6  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ X(WW3AA4FR'N 0  904  !D              ( !.E@
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #@C?=.BQO3
MW+<!  #2 P  &0              @ %?6@  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( ."-]TZ;FNWPT0$  )P$   9
M  "  4U<  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MX(WW3M/VH973 0  G 0  !D              ( !55X  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #@C?=.$%)D/=L!   !!0  &0
M            @ %?8   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( ."-]TX;9MO?W $   $%   9              "  7%B  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ X(WW3N+6M5KY 0
MRP4  !D              ( !A&0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #@C?=./[LJ#<4!   W!   &0              @ &T
M9@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ."-]TY=
MIL'-MP$  -(#   9              "  ;!H  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ X(WW3K:O2S?" 0  -P0  !D
M     ( !GFH  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ."-]TX%G3_@3 (  ($'   9              "
M >UT  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ X(WW
M3@KWV*N_ @  R0H  !D              ( !<'<  'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #@C?=.:9<$C10#  "?#   &0
M        @ %F>@  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( ."-]TZW\).VF (  .0(   9              "  ;%]  !X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ X(WW3D:\5BV]"   J3H
M !D              ( !@(   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #@C?=.2EQL"U<#  #A#@  &0              @ %TB0
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ."-]T[Q**1@
MZ@$  # %   9              "  0*-  !X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ X(WW3D3LX(ZF @  *@D  !D
M ( !(X\  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #@
MC?=.Y0+- A\#  !U#   &0              @ $ D@  >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ."-]TY<:[P$V@(  !0+   9
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M970U-RYX;6Q02P$"% ,4    " #@C?=.ED&7>20"   W!@  &0
M    @ 'TI   >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M ."-]TY#LX=7 08  '\G   9              "  4^G  !X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ X(WW3I,%7H3( @  !0L  !D
M             ( !AZT  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " #@C?=.4);3L(8"  "+"   &0              @ &&L   >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ."-]TZW\D_$< (
M ,\(   9              "  4.S  !X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ X(WW3G(FC<U2 @  &@@  !D              ( !
MZK4  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #@C?=.
M"*FTP#T%  "J'0  &0              @ %SN   >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( ."-]TY(9H X: (  +T'   9
M      "  >>]  !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ X(WW3KO/WA-= @  /0<  !D              ( !AL   'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #@C?=.D,HLI]0!  !O!
M&0              @ $:PP  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( ."-]TY0[S$R>P(  &T(   9              "  27%  !X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ X(WW3K(H(%,:
M!P  2RP  !D              ( !U\<  'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " #@C?=.<-SA4=$"  "/"@  &0
M@ $HSP  >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ."-
M]TXQ)*&28 4  -(=   9              "  3#2  !X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ X(WW3CB!\2$2 @  HP8  !D
M         ( !Q]<  'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
M    " #@C?=.>.SE61H#  "B#   &0              @ $0V@  >&PO=V]R
M:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( ."-]TY#R06+608  &4H
M   9              "  6'=  !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL
M4$L! A0#%     @ X(WW3C9S9/_2 P  SA$  !D              ( !\>,
M 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #@C?=.7,!^
MU"P#  #]#0  &0              @ 'ZYP  >&PO=V]R:W-H965T<R]S:&5E
M=#<V+GAM;%!+ 0(4 Q0    ( ."-]TX(SF<T1P,  $(-   9
M  "  5WK  !X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @
MX(WW3N01TB7S P  &!,  !D              ( !V^X  'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6Q02P$"% ,4    " #@C?=.]R%RT0$#  #4#0  &0
M            @ $%\P  >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4
M Q0    ( ."-]TXTAZ,D-@(  +T&   9              "  3WV  !X;"]W
M;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ X(WW3D+  6='!
M-Q0  !D              ( !JO@  'AL+W=O<FMS:&5E=',O<VAE970X,2YX
M;6Q02P$"% ,4    " #@C?=.G;;$?<\!  !D!   &0              @ $H
M_0  >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( ."-]TZP
M:U5=C ,  ,4/   9              "  2[_  !X;"]W;W)K<VAE971S+W-H
M965T.#,N>&UL4$L! A0#%     @ X(WW3H+5;GIO!   TQ4  !D
M     ( !\0(! 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4
M" #@C?=.,@?4\K,!  #1 P  &0              @ &7!P$ >&PO=V]R:W-H
M965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( ."-]TY/ESM?R0$  !0$   9
M              "  8$) 0!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L!
M A0#%     @ X(WW3H=PA:A@N0  10\# !0              ( !@0L! 'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ X(WW3B_I"CMW @  O@T
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;72YX;6Q02P4&     %\ 7P +&@  .-,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>646</ContextCount>
  <ElementCount>483</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>142</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Divestitures Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestitures</Role>
      <ShortName>Divestitures Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Revenues Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenues</Role>
      <ShortName>Revenues Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2132100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2136100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables</Role>
      <ShortName>Summary of separately identifiable assets acquired and liabilities assumed (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresTables</Role>
      <ShortName>Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestitures</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenues</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2330301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2332301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetails</Role>
      <ShortName>Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDetails</Role>
      <ShortName>Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Divestitures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDetailsTextual</Role>
      <ShortName>Divestitures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesByProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherRevenuesDetails</Role>
      <ShortName>Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetailsTextual</Role>
      <ShortName>Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Proposed Divestiture of Denmark Manufacturing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails</Role>
      <ShortName>Proposed Divestiture of Denmark Manufacturing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetailsTextual</Role>
      <ShortName>Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/LeasesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2430402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2432402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2432403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2435401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-2019630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2436401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-2019630x10q.htm">biib-2019630x10q.htm</File>
    <File>biib-20190630.xsd</File>
    <File>biib-20190630_cal.xml</File>
    <File>biib-20190630_def.xml</File>
    <File>biib-20190630_lab.xml</File>
    <File>biib-20190630_pre.xml</File>
    <File>biib-2019630xex101.htm</File>
    <File>biib-2019630xex102.htm</File>
    <File>biib-2019630xex103.htm</File>
    <File>biib-2019630xex104.htm</File>
    <File>biib-2019630xex311.htm</File>
    <File>biib-2019630xex312.htm</File>
    <File>biib-2019630xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>acquiredinprocessrd.jpg</File>
    <File>amortofintangibles.jpg</File>
    <File>anticd20.jpg</File>
    <File>biogenlogostandardrgbr.jpg</File>
    <File>biosimilars.jpg</File>
    <File>collabprofitshare.jpg</File>
    <File>costofsales.jpg</File>
    <File>equityinlossofinvestee.jpg</File>
    <File>financialhighlights.jpg</File>
    <File>gainlossonfvremeasure.jpg</File>
    <File>incometaxprovision.jpg</File>
    <File>interferon.jpg</File>
    <File>lossonassetheldforsale.jpg</File>
    <File>oie.jpg</File>
    <File>otherrevenues.jpg</File>
    <File>rd.jpg</File>
    <File>rdpercentofrev.jpg</File>
    <File>reservesdiscountsandallow.jpg</File>
    <File>sga.jpg</File>
    <File>spinraza.jpg</File>
    <File>tecfidera.jpg</File>
    <File>tysabri.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>129
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-2019630x10q.htm": {
   "axisCustom": 4,
   "axisStandard": 34,
   "contextCount": 646,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20190630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20190630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-2019630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20190630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20190630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20190630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 741,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 13,
    "http://www.biogenidec.com/20190630": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 20
   },
   "keyCustom": 56,
   "keyStandard": 427,
   "memberCustom": 64,
   "memberStandard": 70,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20190630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Divestitures Divestitures",
     "role": "http://www.biogenidec.com/role/DivestituresDivestitures",
     "shortName": "Divestitures Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118100 - Disclosure - Revenues Revenues",
     "role": "http://www.biogenidec.com/role/RevenuesRevenues",
     "shortName": "Revenues Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121100 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122100 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123100 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128100 - Disclosure - Leases",
     "role": "http://www.biogenidec.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129100 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130100 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsPerShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131100 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/ShareBasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132100 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133100 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134100 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135100 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136100 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)",
     "role": "http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables",
     "shortName": "Summary of separately identifiable assets acquired and liabilities assumed (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314301 - Disclosure - Divestitures (Tables)",
     "role": "http://www.biogenidec.com/role/DivestituresTables",
     "shortName": "Divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320301 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323301 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328301 - Disclosure - Leases (Tables)",
     "role": "http://www.biogenidec.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330301 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331301 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334301 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Business Acquisition (Details)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
     "shortName": "Business Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Divestitures (Details)",
     "role": "http://www.biogenidec.com/role/DivestituresDetails",
     "shortName": "Divestitures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414403 - Disclosure - Divestitures (Details Textual)",
     "role": "http://www.biogenidec.com/role/DivestituresDetailsTextual",
     "shortName": "Divestitures (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418402 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesByProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TecfideraMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
     "shortName": "Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "lang": null,
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
     "shortName": "Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails",
     "shortName": "Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/OtherRevenuesDetails",
     "shortName": "Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember",
      "decimals": "INF",
      "lang": null,
      "name": "biib:EntityWidePercentageOfRevenueFromMajorDistributors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419402 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InventorysoldtoBioverativcost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419403 - Disclosure - Inventory (Details Textual)",
     "role": "http://www.biogenidec.com/role/InventoryDetailsTextual",
     "shortName": "Inventory (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q1YTD_srt_MajorCustomersAxis_biib_BioverativMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InventorysoldtoBioverativcost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419404 - Disclosure - Proposed Divestiture of Denmark Manufacturing Operations (Details)",
     "role": "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails",
     "shortName": "Proposed Divestiture of Denmark Manufacturing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421403 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421404 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421405 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422402 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422403 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422404 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422405 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422406 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423402 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424401 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428402 - Disclosure - Leases (Details)",
     "role": "http://www.biogenidec.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428403 - Disclosure - Leases (Details Textual)",
     "role": "http://www.biogenidec.com/role/LeasesDetailsTextual",
     "shortName": "Leases (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_srt_RangeAxis_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429402 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2019ShareRepurchaseProgramMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "I2018Q1ASUadoptiondate",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430402 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431402 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431403 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432402 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432403 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433402 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433403 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "biib:PercentageoffuturedevelopmentcostsrelatedtoEisai",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "biib:PercentageoffuturedevelopmentcostsrelatedtoEisai",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435401 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436401 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2019630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 142,
   "tag": {
    "biib_A2016ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2016 Share Repurchase Program [Member]",
        "label": "2016 Share Repurchase Program [Member]",
        "terseLabel": "2016 Share Repurchase Program"
       }
      }
     },
     "localname": "A2016ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Share Repurchase Program [Member]",
        "label": "2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "A2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AVONEXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AVONEX",
        "label": "AVONEX [Member]",
        "terseLabel": "AVONEX"
       }
      }
     },
     "localname": "AVONEXMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AbbVieMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AbbVie",
        "label": "AbbVie [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment to Skyhawk"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AssetsandLiabilitiesHeldForSalePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities Held For Sale [Policy Text Block]",
        "label": "Assets and Liabilities Held For Sale [Policy Text Block]",
        "terseLabel": "Assets and liabilities held for sale"
       }
      }
     },
     "localname": "AssetsandLiabilitiesHeldForSalePolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BioverativMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioverativ [Member]",
        "label": "Bioverativ [Member]",
        "terseLabel": "Bioverativ"
       }
      }
     },
     "localname": "BioverativMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Axis]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Domain]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredtaxliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liability [Member]",
        "label": "Deferred tax liability [Member]",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredtaxliabilityMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenmarkManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denmark Manufacturing Operations [Member]",
        "label": "Denmark Manufacturing Operations [Member]",
        "terseLabel": "Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DenmarkManufacturingOperationsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DisposalGroupOperatingLeaseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Operating Lease Assets",
        "label": "Disposal Group, Operating Lease Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DisposalGroupOperatingLeaseAssets",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DisposalGroupOperatingleaseliabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/DivestituresDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Operating lease liabilities",
        "label": "Disposal Group, Operating lease liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DisposalGroupOperatingleaseliabilities",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "xbrltype": "stringItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "label": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "terseLabel": "Internal reorganization of certain intellectual property rights"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "Effective Tax Rate Reconciliation, GILTI tax"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "label": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "terseLabel": "Fair value, in-process research and development, discount rate"
       }
      }
     },
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In-licensed patents.",
        "label": "In Licensed Patents [Member]",
        "terseLabel": "Acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "InLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory [Abstract]",
        "label": "Inventory [Abstract]"
       }
      }
     },
     "localname": "InventoryAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "xbrltype": "stringItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventorysoldtoBioverativcost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory sold to Bioverativ, cost",
        "label": "Inventory sold to Bioverativ, cost",
        "terseLabel": "Inventory sold to Bioverativ, cost"
       }
      }
     },
     "localname": "InventorysoldtoBioverativcost",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInVariableInterestEntitiesTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in Variable Interest Entities.",
        "label": "Investment in Variable Interest Entities (Textual) [Abstract]",
        "terseLabel": "Investment in Variable Interest Entities (Textual)"
       }
      }
     },
     "localname": "InvestmentInVariableInterestEntitiesTextualAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "xbrltype": "stringItemType"
    },
    "biib_IonisPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ionis Pharmaceuticals [Member]",
        "label": "Ionis Pharmaceuticals [Member]",
        "terseLabel": "Ionis Pharmaceuticals"
       }
      }
     },
     "localname": "IonisPharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LesseeLeaseTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee Lease Table [Table Text Block]",
        "label": "Lessee Lease Table [Table Text Block]",
        "terseLabel": "Schedule of operating leases"
       }
      }
     },
     "localname": "LesseeLeaseTableTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_LongtermoperatingleaseliabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term operating lease liabilities [Member]",
        "label": "Long-term operating lease liabilities [Member]",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "LongtermoperatingleaseliabilitiesMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NetMinimumLeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments total.",
        "label": "Net Minimum Lease Payments",
        "totalLabel": "ASC 840 - Net minimum lease payments total"
       }
      }
     },
     "localname": "NetMinimumLeasePayments",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments thereafter.",
        "label": "Net Minimum Lease Payments Thereafter",
        "totalLabel": "ASC 840 - Net minimum lease payments, thereafter"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsThereafter",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInFiveYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in five year.",
        "label": "Net Minimum Lease Payments With In Five Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2023"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInFiveYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInFourYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in four year.",
        "label": "Net Minimum Lease Payments With In Four Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2022"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInFourYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in one year.",
        "label": "Net Minimum Lease Payments With In One Year",
        "totalLabel": "ASC 840 - Net minimum lease payments 2019"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInOneYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInThreeYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in three year.",
        "label": "Net Minimum Lease Payments With In Three Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2021"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInThreeYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NetMinimumLeasePaymentsWithInTwoYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net minimum lease payments with in two year.",
        "label": "Net Minimum Lease Payments With In Two Year",
        "totalLabel": "ASC 840 - Net minimum lease payments, 2020"
       }
      }
     },
     "localname": "NetMinimumLeasePaymentsWithInTwoYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Noncontrolling interest, increase (decrease) other"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OperatingleaseassetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease assets [Member]",
        "label": "Operating lease assets [Member]",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingleaseassetsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "label": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "terseLabel": "Operating lease supplemental cash flow disclosure"
       }
      }
     },
     "localname": "OperatingleasesupplementalcashflowdisclosureTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "label": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "terseLabel": "Operating lease weighted average remaining term and discount rate"
       }
      }
     },
     "localname": "OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Out-licensed patents"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PostacquisitionequitycompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Post-acquisition equity compensation [Member]",
        "label": "Post-acquisition equity compensation [Member]",
        "terseLabel": "Post-acquisition equity compensation"
       }
      }
     },
     "localname": "PostacquisitionequitycompensationMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SkyhawkTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Skyhawk Therapeutics [Member]",
        "label": "Skyhawk Therapeutics [Member]",
        "terseLabel": "Skyhawk Therapeutics"
       }
      }
     },
     "localname": "SkyhawkTherapeuticsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StockOptionsAndEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock options and employee stock purchase plan.",
        "label": "Stock options and employee stock purchase plan [Member]",
        "verboseLabel": "Stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "StockOptionsAndEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TecfideraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TecfideraMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_WorkinprocessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Work-in-process",
        "label": "Work-in-process [Member]",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "WorkinprocessMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20190630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "Security12bTitle@anonymousType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "invest_DerivativeNotionalAmount": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r174",
      "r274",
      "r278",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r172",
      "r274",
      "r276",
      "r474",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r173",
      "r274",
      "r277",
      "r476",
      "r484",
      "r485"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingGuidanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Previous accounting guidance and the new accounting guidance.",
        "label": "Accounting Guidance [Domain]",
        "terseLabel": "Accounting Guidance [Domain]"
       }
      }
     },
     "localname": "AccountingGuidanceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201616Member": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.",
        "label": "Accounting Standards Update 2016-16 [Member]",
        "terseLabel": "Accounting Standards Update 2016-16"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201616Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r25",
      "r45",
      "r175",
      "r176",
      "r275"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r41",
      "r440",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r87",
      "r92",
      "r93",
      "r282",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r59",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r92",
      "r100",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r92",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r89",
      "r92",
      "r93",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r82",
      "r92",
      "r93",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r129",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r285",
      "r291",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r129",
      "r224",
      "r231"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r190",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r129",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r168",
      "r438",
      "r460"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r26",
      "r27",
      "r78"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r181",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable equity securities, fair value",
        "totalLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Marketable equity securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "totalLabel": "Marketable equity securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r185",
      "r188",
      "r455"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r185",
      "r187",
      "r454"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r178",
      "r182",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r180",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r180",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r286",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r364",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r331",
      "r332",
      "r335"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r331",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r331",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r298",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r325",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Fair value of post-combination equity compensation"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r23",
      "r57",
      "r131"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r33",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r340",
      "r341",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r70",
      "r253",
      "r448",
      "r468"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r96",
      "r98",
      "r99"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r98",
      "r347",
      "r348",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r98",
      "r346",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r349",
      "r358",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r447",
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r280",
      "r283",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "verboseLabel": "Cumulative effect of new accounting principle in period of adoption"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r37",
      "r39",
      "r40",
      "r439",
      "r441",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior Notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r68",
      "r135",
      "r263",
      "r266",
      "r267",
      "r268",
      "r406",
      "r407",
      "r409",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r133",
      "r312",
      "r317"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": {
     "auth_ref": [
      "r298",
      "r299",
      "r309"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r297",
      "r310",
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred tax asset recorded on transfer of intellectual property"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r297",
      "r310",
      "r311",
      "r337",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "terseLabel": "Deferred tax liabilities, goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r298",
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r297",
      "r310",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Deferred tax liability recorded on transfer of intellectual property"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r129",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r129",
      "r165"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairments"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r79",
      "r80",
      "r366",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r79",
      "r80",
      "r366",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r365",
      "r367",
      "r374",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r363",
      "r365",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r371",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Gain (loss) on reclassification of cash flow hedges, effective portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r372",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]",
        "terseLabel": "Assets and liabilities held for sale"
       }
      }
     },
     "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r2",
      "r4",
      "r6",
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax",
        "terseLabel": "Loss on assets and liabilities held for sale, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r13",
      "r18",
      "r301",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Tax expense on disposal group"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration expected to be received for sale of Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liability held for sale",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "negatedTerseLabel": "Goodwill held for sale",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory expected to be sold to FUJIFILM",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Expected costs to sell disposal group"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r245"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "terseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment held for sale",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r129",
      "r238",
      "r243"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "negatedTerseLabel": "Loss on assets and liabilities held for sale",
        "terseLabel": "Loss on assets and liabilities held for sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r22",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r105",
      "r142",
      "r145",
      "r147",
      "r148",
      "r149",
      "r152",
      "r451",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r105",
      "r142",
      "r145",
      "r147",
      "r148",
      "r149",
      "r152",
      "r451",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "negatedTerseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r137",
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r302",
      "r303",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r302",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Denmark assets held for sale"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r302",
      "r303",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r302",
      "r303",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r302",
      "r303",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "verboseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r302",
      "r303",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r302",
      "r303",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r302",
      "r303",
      "r316"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "NST stock option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r58",
      "r169",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "verboseLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Less: Net gains (losses) recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "totalLabel": "Unrealized gains (losses) recognized during the period on equity securities held as of June 30, 2019"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r34",
      "r38",
      "r196",
      "r446",
      "r459",
      "r483"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r386",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r387",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r386",
      "r387",
      "r389",
      "r390",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r387",
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r387",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r387",
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r391",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r394",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r364",
      "r369",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining six months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r225",
      "r227",
      "r230",
      "r234",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r230",
      "r437"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r225",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign tax authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r399",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r280",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePayments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions",
        "terseLabel": "ASC 840 - Sublease income total"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsThereafter",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter",
        "terseLabel": "ASC 840 - Sublease income, thereafter"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFiveYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years",
        "terseLabel": "ASC 840 - Sublease income, 2023"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFourYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years",
        "terseLabel": "ASC 840 - Sublease income, 2022"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInOneYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months",
        "terseLabel": "ASC 840 - Sublease income, 2019"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInThreeYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years",
        "terseLabel": "ASC 840 - Sublease income, 2021"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInTwoYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years",
        "terseLabel": "ASC 840 - Sublease income, 2020"
       }
      }
     },
     "localname": "FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r365",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r218",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r363",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r103",
      "r129",
      "r166",
      "r198",
      "r449",
      "r470"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss of investee, net of tax",
        "negatedTerseLabel": "Our share of Samsung Bioepis gains (losses)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
        "negatedTerseLabel": "Loss on assets and liabilities held for sale"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r16",
      "r19",
      "r20",
      "r21",
      "r246",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Income tax payment, including penalties and interest"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r167",
      "r318"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "negatedTerseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Unrealized (gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r146",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r223",
      "r228"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Including Goodwill) [Abstract]",
        "verboseLabel": "Intangible Assets and Goodwill (Textual) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r101",
      "r164",
      "r405",
      "r408",
      "r452"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r51",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r24",
      "r75",
      "r213"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, current",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory, Noncurrent"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r53",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r52",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r109",
      "r163"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating lease liability maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "ASC 842 - Minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "ASC 842 - Minimum lease payments, thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "ASC 842 - Minimum lease payments, 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "ASC 842 - Minimum lease payments, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "ASC 842 - Minimum lease payments, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "ASC 842 - Minimum lease payments, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "ASC 842 - Minimum lease payments, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "ASC 842 - Minimum lease payments 2019 (remaining six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r50",
      "r444",
      "r466"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r245"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/DivestituresDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsHeldForSaleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long Lived Assets Held-for-sale [Line Items]",
        "terseLabel": "Long Lived Assets and Liabilities Held-for-sale [Line Items]"
       }
      }
     },
     "localname": "LongLivedAssetsHeldForSaleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r40",
      "r258",
      "r441",
      "r462"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r253",
      "r254",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Brazil tax assessment, including interest and penalties"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r74",
      "r443",
      "r465"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest, decrease from distributions to noncontrolling interest holders"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r126",
      "r127",
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r94",
      "r97",
      "r104",
      "r130",
      "r151",
      "r450",
      "r471"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r94",
      "r97",
      "r351",
      "r356"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to noncontrolling interests, net of tax",
        "verboseLabel": "Net income (loss) attributable to noncontrolling interest, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r40",
      "r441",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r420",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "netLabel": "Net lease cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r418",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r424",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r423",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "ASC 840 - Minimum lease payments total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInOneYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "ASC 840 - Minimum lease payments, 2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFiveYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "ASC 940 - Minimum lease payments, 2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInFourYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInThreeYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsWithInTwoYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "ASC 840 - Minimum lease payments, 2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "biib_NetMinimumLeasePaymentsThereafter",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "ASC 840 - Minimum lease payments, thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of revenue recognized for the period under subleasing arrangements.",
        "label": "Operating Leases, Income Statement, Sublease Revenue",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesIncomeStatementSubleaseRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Contractual commitments for the construction of the facility"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r84",
      "r85",
      "r90"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r92",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r81",
      "r404"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r95",
      "r98",
      "r100",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r95",
      "r98",
      "r346",
      "r347",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r364",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r65"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expenses and other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments for pre-combination equity compensation"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r116",
      "r120",
      "r138"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r113",
      "r117",
      "r179"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r118",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Total transaction value"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Nightstar Therapeutics plc, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchase of Ionis Pharmaceuticals, Inc. stock"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Contingent consideration paid related to Fumapharm AG acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net distribution to noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r121",
      "r123",
      "r138"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r113",
      "r114",
      "r179"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r115",
      "r179"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r94",
      "r97",
      "r125",
      "r168",
      "r171",
      "r346",
      "r350",
      "r352",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r59",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r35",
      "r36",
      "r242",
      "r467"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r35",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to prospectively adopted accounting guidance.",
        "label": "Prospective Adoption of New Accounting Pronouncements [Axis]",
        "terseLabel": "Prospective Adoption of New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "ProspectiveAdoptionOfNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ProposedDivestitureOfDenmarkManufacturingOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r42",
      "r442",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Future minimum batch production for Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r92",
      "r93",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r296",
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r129",
      "r250",
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r47",
      "r269",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r102",
      "r161",
      "r162",
      "r170"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "negatedTerseLabel": "Product revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r422",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r186",
      "r189",
      "r191",
      "r192",
      "r193",
      "r195",
      "r453",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r365",
      "r374",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r285",
      "r290",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r285",
      "r290",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r225",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Minimum lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r32",
      "r54",
      "r55",
      "r56"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": {
     "auth_ref": [
      "r7",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Schedule of Long Lived Assets Held-for-sale [Table]",
        "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]"
       }
      }
     },
     "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r59",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r71",
      "r134",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r108",
      "r212"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in fair value from changes in the inputs, assumptions, or model used to calculate the fair value of the contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.",
        "label": "Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions",
        "terseLabel": "Fair value measurements, changes in valuation inputs"
       }
      }
     },
     "localname": "ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r284",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "negatedPeriodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r73",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/LeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r44",
      "r262",
      "r269",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r44",
      "r262",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r262",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "negatedTerseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r43",
      "r44",
      "r262",
      "r269",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r43",
      "r44",
      "r262",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r44",
      "r48",
      "r49",
      "r177"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r344",
      "r345",
      "r355"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Adoption of new accounting guidance"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r72",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r44",
      "r262",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r44",
      "r262",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r72",
      "r271",
      "r272"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r262",
      "r269",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r280",
      "r445",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r149"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r143",
      "r149"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3444-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=77912953&loc=d3e400-110220"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5558-128473"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9972-128506"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9979-128506"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b),(c),(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77891322&loc=d3e41620-112719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77914019&loc=d3e50824-112756"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r487": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r489": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r491": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r492": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r493": {
   "Article": "12",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "13",
   "Sentence": "Column B"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0000875045-19-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-19-000029-xbrl.zip
M4$L#!!0    ( .&-]TYGEO3TED8  $]1   7    86-Q=6ER961I;G!R;V-E
M<W-R9"YJ<&?LNVE8$]G:-EJ*BH@0 0$%(2HJVDP.#,J0B(J(B!$'(F.T'2!$
M2",@$4*B((1!2#M!"T(01%#$B$R*D !A4&ED!@4AD\HL5<I00(93[G?O]]O=
MNZ]K[_-^YSO7^7'"M7Y4JI):S[.>^[GO>X62OY<+@!4']SOM!Q8L ( %R!\@
M[P/V(D?_>Z\?7_*_^QT+Y-6 VM(%&Q?8*2Q8#RQ46Z"@MD!>!Z"1>2[^KPN
MO[\6+%18M'B)XE*E9<K(!:4K@(4+%!06+E)8O'C1(N1L)'(>6*2V6'W=-OLE
M&JZG%=<'K=Q^]<;]I09[BFHTC[:!&W;\?#%*:9F6]JK5.ALW&6[>\I.YA:75
MSEW6>_<Y['<\X'3PV/$3;OB3[AYGSIX[[^M'] \.";T41KD<'GTM)I81%Y]P
M\];M.RFIO]U-R\YYD/LP+__1X^?%):5EY2]>5M3RZNH;&E^_>=O>T=G5W?/^
M0Z]0)/[T^<O@T/ (].W[Y-3T##P[]R.N!8#"?X?^EW&I(7$M7+1(89'BC[@6
M+ S[<8':HL7KMBU1MW=5/!VDL7[[U:4K]]RX7U2C9+#C**CY\\6V95H;S(4;
MH1^A_2VR_RRPJ/]19/\=V/^*JQ=8KK  63P%-0 +R&2;LQ. _Y/#Z#M71!XO
M+(#W3E>D3Y_M."]-I>X@Y\ &@IGD4I-CXKQQPU"P0*28&#(17R$'ZHU,?/J$
M6%XB/=9G"[.A&+;9![OGCVAO_TC)V5]>V1EJXXT9GDRW(4[MG5M'V.7/+\9>
MK702\YF8'="^5(]QUO@"\%8U2]'67?A&%-7;W5(K6_X<YC[TRMAQO,SH\=Y0
MD<D.L?ZK<S31R>;'[KU5Z4O2Q&OU(TER8#$@39DP/]YS&N+&7]-.Z^$5:NSI
M",2H24X50V:)YV >293.O>:1%T4U#!,<L'41XY9+CN(64QZB&#(CL.Q6 26X
M/CR6D4],VY\7E.]9]>+1O).L5[9*FE%YY@PX/2J<J,-I4G*\I.ET/WZOV;[.
M"[9&(A*=\6R87_PN1CCNZPJV)'+6><+T8ZU4W4B1-J12>MUJKJ1@">/BG'=9
M <"%\#'&I;1C->AG(1[H>,EB,7D--0!JK&O1DEAT<E2) YI=4UQ5BM&^;YPU
M$J4.S!9W"KK6^@Z+8=ZD&[G7LS,4E:CSE2LFZ/X\\-V[ZX(Y9;)0F^=Q(H?X
M/)PYOG'>V$/6&I[**'6 OA0*TC.P0D+C1)3^VN2F/6U3?00UR39I-M5$.*[=
MX.&;FE]5,F=9]9!$6PHZQE-M1,JZCQ:7I%G>SQFQ]LE]2$I=^%Y!F4<O9X]-
ML"G6/77C(I1Z?8%+,#AQ$+?PI&0;7/08GO?LH1G"9J[08/0X=8' SU9)^[IL
MXQ!2 [&56-$X:0\4%F5K\X1"<&NSU1;K!:JXAO"51SN&I=PZ9O)<#JVYMZ=1
M#GP8X%73-;.>@S%R@!D2@5U%>57'196H^/+2%F?(\D0VQ-+('=4^%M"2>)&S
MD;?1D8Z./5VVZU2Z4N/&/[?9[JG0JR\<+I_M$&M+-$C"O :5PWUU'E^JB(](
M:2K,ZA#P#C.9IDO1$(5=>5)*N"I;!O>#(\I<=0D6BLGH9HKZ4%H41W%CHHF%
MC5*@>6(SZFA1FT7+\M'P\SEGVYVF4-?D@"]9B6(V'80N)C,>EK=3C3'ZE%O5
M>^;W@.QH6X.5>^O3:,7D0I(61AW<'R-D+?;[_M%?9SJG0,7*H;5D?%O@^;6U
M8]]QFQ5?$U3E@"#'<BYR\-ID2V]PC4P+=@H2HS^(A6'C!L0"R2X(5<>ZGKD*
ME -1,F-*BQN8>4,.*)4]4JQI6=8BJ#+B*9][Z 7W-0X8%K?;*F9])+E-?Q]E
MG8]G\X<2^7W,Z: 2EM?S,@B7,#7N; _?$K5<.^HWH :[0*0&CR_%$$HH[8DW
MX:RGA-7J&,94JA6,<"SIC.C:M*H>9BA:R8/DX1@]EIP:*E+94Q,ZKF*AJEC'
M?8:/EC@+N)J4[70].*6WKQY;5,Z;>#\0\3ZD?]W7 .HV4#93-U-&VQJS0=HQ
MVAL-9X94//M5#IS?5_;LM_T^![]P3.DU.SFKJ,>1J*X5EMHY[N="9E=IVVEM
M="W)ML?4W; G<D;4$R.B]Y(:,1NA/&:EW2.)#=3 NBSL=PH9#NW; .;%W8]
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MQ-%-HR?YF)9V8B^7\.,\K.)I6G![2SU?O7*; *4+HZJ[4[!ZH;CE<'EM[:C
M*G&*'M/KF&R16/CSC)<W;C]8R&>8FZFYP_P#Z0W6P<,YO/8AV3IN447KT]LM
MX]HZEK<N]09[$\NT31YX;1RXW?&A[_?><YV_. 7H=6>V[V]H$)H\3.DW+-WZ
M]IG3AI]$AF?-36P-A:]62UR# [*'VYK%I$^=5'<#3\<MT.)/X5IWA7&?N_;5
M.E0J":6ZSFWMJT]DN6#>ZIZ+V[]JJ^+WV?L29Q!3*&3%Z9M*61@[2BSY XH
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M\BX3"A;ZQH:D9^P]"FFE7I#IM:V%RNN8FL1@PD<8N[NCT-9.A%8;IF=9ZFN
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M#MB%TB6;J<@\FJR!ONPBK!#=(0<&G[*1VD'%86=]'24&<W3)5)<< .]#BG+
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M)6NPB,L(7'I%UI>INNBG**S0DTH9 5HD[0F ]!'[':(P\<D<:XJ9T"P6*W2
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M!8*\83=F? ?/#V7&ZP"BJ3+04IL2<\%D\S[4->$\A*7K/V>DTABZ[ [*9DY
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M+AVO7NSA:0O40SA%+4I'!YJ\O]<%%8?D*)'K(\ L<B91%Z_.C;KVO!)[7:0
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M\+/2LPRS#S\^A/C:F;ZTFMC&3;X@T[A]K<GO$GI<E=S<'D;<0I DNT9V:G1
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M>&M6</OR*J/=?0G%CKTNKY[V;;&Y=&>Q:,V7\"'^6WZ(R55SN@_%T(>P2UA
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M3('Z]A!\@;_L2JN7Z_5_;R>:PHQ&DEJMR[(S0;>NDZ9#< 47$HEK!$1(^X8
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MK%-Q7H\.?98&'TDR/46):$@(2M-#<HL81G (%,!#-G2DHG;#>QZ(^FNV^6E
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MON#R^QHQ )(#D;/279(O7A+=U_)+X,;\TJ3Z9 DZMYF+MOMH'%N)%ABPY(3
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M"\ 2H\/)HWG\C.P:IF^"DX1L/3RN'NAUA\***ZOG&-OBV9; S1"2[IM9!W%
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M>!8)I/$WE*30? T[=##J?L*=@WA5KE'W^E$HIR-O&_0R3QYTH=^UOLB-,_(
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MY^O24M<^*"C"5C0/ @/%OW><AMEBH(-2C(%3>&P&6A7O@E$2*KWNK:4JXJU
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M]DQT<7@WGR*+"^*A$NLB-N):VOAN@+A!G18S),C.J\YG&XR,LV8\+)JN-;[
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M94W^+I:*)*B?/N4S0 1"I!7WH4Y<7F7+57LL_E;R1@+[]RPQ2W22B-E#C$>
M&VBN$MA+CP:Q[AN,^#;18XG>W.LO+RU+OO3]?*RT^EJ+LB2PG;W_Y[?Z)3 ,
MY"@F28\"R$!(8)_SB)1K2.C^N"&QUP@C@2EY&TI@UO1RE-':&&%%>I74\_]H
MQ-^66@T7+EOD4D#]Z2G6[,B5P$X.%4@%I#-2;$^=BA<K]D&/POAHEH* ]#K^
M=%-_.KF5HN!OUC]^XL:;%"$^3%AW^G)ROIT^K_W? T??&QC^8FN_[4SZC52
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MH@Q>O0XZR,?RN9@'VBL,3"*\5-&=IY15)G2D0>=779/P&_)GLN?R=HA>R,B
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MR$H9C X[2!8:9(-M,QK7_S9+ZW.597)@3OQ['WGT3SZH93?B\%X);&D#-1-
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MN]0>?7A UGUT-/"QA</^J??EI?M/R*;"A I H>56X:7__!)??E^-_AZT&OZ
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M()$26UI_B*_0$X+:.6WL50C,G7W7-Z.;48S>Z7DU:U=W?FV9W6II?T='58I
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M<7%00I)'>,(/!UWW)U-MM<S*DKZBMH$G+Z=NMB>G&.O@6B)H&CKY^T<@I]2
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MV_FC2MNZ3 *3G(A9FJ*'YMY>?;\"TXPYNGI?P Z3;UZ._/Q<S#MAYT3_]Z>
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MB]A3U_2]L.\1D^AT)GDKMW2TT3",&GJGIE]$!O:22I\N/!1%+AR3#:^%#]U
MW'T'ZKAKZ<(U?=.F'19#P0.Z[7%%/EWG$>K5N'F>XZAWV$B*!]\2F)<<#M!@
MEP"A08@;3\.TCTJ)IYK1[:M^?=RQP;@K+NB/65%#T$0-I.:9 7(J6FQ[3]6)
M&PI\\'Z8\ 1.D%*4I@3VAL:>B:U(=8W&F6;<48Q&JB="BOCTD@"#0_C<2$ZQ
M">$>[@Z5^A[O\4RB6!C,T 7"X$/L6C2UN4&$(^XL'=?;<C2;&6TA]O7L>Z=.
M@U_5)!_37+X][#;@T8Y?>9HA7-JEA:S12LE _DSKBV(@$%*["'HCX$'[!YBY
MDUDP>9F^5[1,N&$8B*3 RNP2;SE'X%\)4/;!L\_53'O 5UJ#LO?#5)T+YP7I
MLX3U-3R<PH]JA3!K!>=*3H\G7BP\QT>CW[6?ZKH8[^P\%' >%EE\V8UDHO-%
MH!R=#=S,T'_5!]J4ZMOU7Y&<Y#HO+7FY;A?BGPY%,^W>#]O"?B/761MI7R;7
M P8\>4ZGKFDDDN$?<.$;^\OJNUVJ72,:$$>^^C%6L(UOP+EY/QT.?:G!KD8C
MU'QN''_U.,F2CC_>4%/?/_D?P6/VZ7[=SMU-ZAS_X[T7/#H=@'"L392],KT<
MB;PV1?Q._1O1OR0ZT4S1&#T09)LY^>O_6%0Q\)X\3%TP9^AF]<Z MO6Q[BAZ
M9[4AKEPXTH;@VC)NM&ER6-]TXV2*/TY\'^AW9,W^-2>.[ZC 8)9#]YR7^..'
MCZ$KENFOB7*Q&7CX &](1$.F<N/?NJN#V.]ZXT7V0,.IWC(HBXS=>*76 +4A
MA0O9'6:-8^VF@?1+9F7;3YS+$.5M*LEZ1:XD<?[R%?^[PBL[4OJ\E?*KKTWZ
MRXCKMR_EM*B*P^,JS[L]O(O$;W]8G5_H=>38NTLC[%VGNT4PK9=W_9MQSBZ>
MQ0/8WP+QLCS9<GY= %&\SNOVNV^OP[7C72\CV+==STT_;#Q<N>/$"7ST+P7E
M1_9]V-5PQS#^"2!-TT&9_;10>*$.OQJXK7\-6:$/(FN%B$7=%<8NO@2R/U#I
M6=<Q_?A@Y::OLK[*N1H7A-EUC5Q?,E^I?Z_?)[H]]<;KRZ;$'W7F"U5Z4]U)
M] 8\XM<-6JDF&32!?(9"RV"M'(BL;1#!U"P/1B3WAYX9#F?^Z5QZ::0))>JK
ML\$_O%YVY(_VA8!MX@J?O1C]$@&VY'6"Y-\I^[^?5:_KV/5H:#DE#7Z66/<Q
M.QQGQR[/S&44]-VRO_7US0>'/&_M^+5,[?3ZWM'?\__Y-72.=P]O=HF]"HV4
M HX>?WS2L7?QV[Z9",>;2D^97:9E5Z84?2?YE:[9?K2MM_PD0 \JSBBW__E0
M0>7!VF,_94_4J7BU^.:_4:6Z<V5+.5 VWBS<@YY#',1*6ST.4"@/UB%FX7:(
M\GKO\<?7PHY)$AI.V@YO@M^)U(:XP&L9WM&]O[1820,8TL:'48K/[#II;WP'
M>7C\'ZY"I*5F"E<9]%LXDE9'QD3AE%:D;W3NJ!\YD[4E-#JOR!;NYTD=7AP[
MY/W7;,C)!O7S&?-] Q\4KWV<* 5A/2XSR?N N,K"( JE^T$(]"U^,#(%Y<PN
MZ=<=.HM<+D>JOS5DBV(-6=JY3D=!:I5FDR*U)6)Q"_%7N39,O*U O<1%F!KD
M16ZIJL-9; C%9),AG8^@CYBD#7WK'MX]XQHK@^ [G9J<Z.V[A)L,NO#0;42P
MDO#UW77X=;Z7XE6\=-X3>2K1L5&9NK5/X([-$$4L4+2!K6D:O V0= #AI\>;
M)TCT7CUZ+R#5?T#G5((6B!7I6;=W)Y:S=1$QE5OJ.GB=]3SX"%;A."X>]D;B
M0J")>:]TD@WJY,>5"G=1F/:$Z[HS&IJU?G 1LUYTUM59ZYA3(=$Z5.BVS^\9
MS2=+S-UGTY#U;SN4'$\*M#(8R!.'1&9^<"VO1]EEL4H[2'6?AQ=LQ&4(UZ!,
MZ2+&B"G<&HRR9]-@7 IK&YK0/+P),;Y&\D)'#-0DBBQ,:!FV@2/3/?&<VXE4
M\8M]R1':MP92 ),0TR^'+&\"]Z"Q6F5ZWN60@8*'P0QY_OETH[DU\]^PVASQ
M"T5$OPA-X.:0KI%\?%H>#4OP@,Q1:WE+HTUT8ELK-8-L)_#3A.W^"TB5>M]Z
M&*T8X98]25I/.XFLJ(EUO!53B:;*BC;)+T[Q_]&P/%G-X;9H6S$Z;.XO.PD-
MA7R>/%',&G#$W90Z6C7*B<[%7\X<VFPPWU?YZLXU:)(?PDN-%ZU%65,MBLO/
M-S[OT=%5.9?;#@_$_3L]>6A00#82P7P'_2#/$20\ *8DE[VGQ&B=,U5QK!5?
M(Q?[D(^@R18O-)UKZ;Q5>DNZTEI'U])P#-)V=!$S_RVXOM>SB5L?YK?U1JR!
M$8Q&;\^=OW7E$7!Y2)I85'E.]19W]<L)9LNM%HI9SE%X"T&2X<XLP+6P/!T,
MI7\I2?^XC_CMH_="-WG=FQGE4.*K9-,@81VRE8NLZ/7G4- @35.'@S3_(L^Q
MX%$#=WJM)]F$9P7\^.Z=I&V'T32):^BB'8T]$ZM*"A;08L^H)MU5?*DR#;(F
MFJKXJT99J[I8FQAZ8I[FQ_=DRZJ<LGL/PH%C)]#D,\CGV?2:KLEPR(8V)L?;
M5,V(K #.$3GHS*P8>PXMAU1WBNQ1OROP^%&.3&^93%&W2<FI>N=:$<P3NZOW
MB&R 6!7_JI" .HGGC+/XGK2,8:\^M_C*02$ANFA3?WR,_>?OX7-%E?_Y,M-,
M=//,.1D,WI22X</D7!;V*7RH2C-*6C%J8*ZB%PC7%QW7!!+VOY#'4YZQ+%@#
MPET+^5-@< GH!.7,><D@#&HC\XZ\#JDW]>C\55/FK#ZO$'*V)X6_?-Q[1S"0
MZ,J4X6OW_AWYELWZTQ\J]ZGIW9R/T?'[(56^XEXWT4\M,M5!3?#L#>W";A\'
M#5E!6CO:^';V2=E[?!U?1E.T-W>AY\>8:X/]U/2XCD@M/H=HHAF=<A$< D/5
M21R'MV[D%8S9G;1N-1G=HKPJL'L GBCP'P"772">NP\"/:#=[DHXE((D9!&)
MY"B\XTOM?U>;'C^&?,XQ]$#(&,9?&QLSF)7#4?FTJ\)UE&KTX.@&I-K C#;T
M1O^L"]#QJ+O8FZR5K#_G&L3<5*45RY8!64^!IY26\4S;Z-U3]'*@2-*BM'A$
M#%2[;A9?0JEJ;IJ.@=AHH$R!C^J%S_0#W=$BQW[29@9"R!+X:D(+=\38[!<^
M[IKF;X7>X (Y8N&.'H/ERIQ+R\LB3"QBSII.K0#JB)O+7P];(:*)Z$:?$8F!
M%Z/M/5N?#@R[=L>_3?!+-SCEU8*FWN/T($79G=+QDR$Y,GZ&"[3O_5WLGPM4
MO<E T>;':'^"!LJVH0%?B@BV\!1YZCPIU7)4B*GOJ3VCP2HNCZCCO(JVPVWI
M>%DCY[W"^*K '>:*6;@NXGJ(/YZ?6\-@;JW4T!RB[=]VS,R,].93)\8\DBFS
M]_JFIS+"MW83(#HEQ_;O:+WMM2%?A""A%.)4"=?UIB%CK-4#9_..9L7\U$UT
MQ7+B"@].'<KR\0JZ[7#YJ2#]3^JEZ=+51O_28([>Y&:)SA.]H>[,RE-:Z7P2
M-#'.,B5&$%JE0/>HUY%6=0M.5(!+8?(D097L'C00>A1-T7)MHL/=D<+R23L2
M7TNV,T0AQPU]A'C^RA;76W6%Z=6WO3W_%:D*.,P22G$49%?ZN%XN7 ?&H.>T
M]#HL^TGTS;%&O(R@,)5"M4'I4^#N+F#H(%<2(K\&AFI")QWUVL,<V4E' HQ$
MO2Y4OZ!.S.7PQ\Q7&\%%S^=7AP#4UEG(6G1NRL$0)6J4.6[@%L2XF45X]@PF
MZ%Q=364D!\,M.J&<K25Q,;&M]LL'[FCYQL#85"B"2XGOKJ*A(6+::H!["'%*
M(1XK>4N?#:'QQD6/@[@S=X0>Z"Z:XNB'$8,%L6'"E8?0E^H%ACIOMK.-;#OJ
MB$$I*D*JT*5G2%L ^CV%)W^GX0S6TAD07'J O=;@N*&>M GQ*++KGX[9-T[I
MJ^7VO-JV]).8\*9=P\[4$\##2$.K,H=FIM^I(Z,%I> A%!"NZA<: 7G[D 2#
MQ*XN8BRG.9-K=>O12"V'H+#X)&99U>7C>OBD#< P]GH#:1=:FEPZM(@1^U8H
M1AL3KD^+3.:@YD7,(%NJM #I)>B\AB:;[^3HOX+]6\9I5R$S_M]P?/FUO[M(
M#N:1^^7QX\K5'+(E T$E&EJN)]8$W:AC:,:WZ;:HV]_H'(H);,%2=1XO^.:Q
M^259&'2/&'KBCD9J)KG28-96M](OZ_5T1Q?*24X&&,A1 9/Q,5M'9BOKTC]K
M5MRL1)\!U>_61YL[M^X:MY>G\2_H"'=/*Z)"\H&(XX$G0[?(/Q#=U4R==4$S
MWE2_ 71'?B4YPU-9=^'SA?,^PT"FX C\<@:+8X23%G[78U$;U2+FNH"JQEOQ
M,DS5RB7OY](+X?86UL87W6ZZY5JRU?NB#8^;&F$FE_B-I_%'<O"VN]B7_&P(
MIA3@.= *O2-H(40E-L#F%NAI==K\+DHYRE/GE&>[Q+6+S$>[%*? *#3HWFE@
M* "62Z"L_-_K9P<,V=0S#*<Q>XHR GL\:&8=:LHXI2KA<&0F6?6[8J0MV4O3
M=DU(!/WR\=<=G5#1?+!N+YQWE;CS+MT*S6T[ABZH>?:Z73U$2@6X+_#@@:G:
M0-,61R*ROZD46#4EM@HG9,>7D9P16H9@9_DIX"A^(,N@$/=F)4P-Y;,WB_4N
M,%5*8.O-T18UCU,#'J3A (HJ^6U>ZHS/KD6,>NL+./(X_*Y2]2+)D%0S!8$/
M:3PSM.#D0!S!<DQI,^-,,T/Y$P9']@=\D&8PQ$WPB-X$(4O";,1%JWOTNP(>
M LP#*&U^#8J7I@:CD W*EA9M7L@D.;T?)L+^G(F9''+K9?N+*71MF'W[<5B9
M\Z6,S,K91\L79@LT9(OQ?&)BV(>4*OW-(WOQSJP.<HTH:Q$3V;&IMR6(AG,C
M7H)[6QQM'\/&+89OO521L<!%@UA9ICTSA<<.][*S!<$Q29710C(27Y876P($
MQP^M%)BJQW.PDMF@O*)5SY&P#WP-1?DPZO[_^(OT?[=/4QF0*6B%'.V4S#%S
MIT_5+7A)6-MZ0=J9LK<'1JB\H)XJ3V>'^'Z7IS%U,;LI@>%ZTPZGPUG)I-EO
MZT^W;'J8\M[CL+%GI*ISY>BL,>4)+&(_FNY5MV.-"TS#;"@--22;'JV '0B_
MK$OOWD!R[%7W,35/N\TB?ZC-FOVX)^E4S]@EIS]IMHN8'['7:&LZKXNZ/;GL
MQRA9[&U(8QU[ M$+H/M=-)'&UF_K<XD/2Q*[JGU"Q<)-<-D=>G(%?59N4@4P
M?;M VG](W<PR])?7 Q_>F;#$]Z\2FP)0)[A@_Y?SW1Q"01)<);]&W%IDJQ=W
M>5;9MTLOU^>%K^JM[7 2*QX]!=)=C[Y;Q-"Z'\7%N#F3K:+=WXZ_FCU\>O=]
M^<HMU??Q2P&WMR=<#>,Z8\U%#^?24R"Y9/_]$?&G I[Y7YC;!Y?I\<^V)EO_
MA_AV*W-X=#+&J2,L<+61-!IOIE\?+4]<KG^@(B\?\Q*ND=<15J,_?C2\Q<;E
M_\C98."CX8X'T?J-71?=XD;/=\^\/7;X6='\D0$/>5T?D[_U]MB'=_2_KV"9
M_\_]!_]?FM'BX/\"4$L#!!0    ( .&-]TYYP-K6<Q<   (< 0 1    8FEI
M8BTR,#$Y,#8S,"YX<V3M/=ERVSBV[_T5O'[JJ;J*)3O)Q*EV3\E;1E7>RE9Z
M>YF"2$C"A +4 &A;_?4#@#L)@@2EC.BA7Q*9Q#DX"W V+/SI'R\KWWF"E"&"
M3P]&[X8'#L0N\1!>G!Y\?1R,'\\GDX-__/S#3_\W&/QV]G#M7! W6$',G7,*
M 8>>\XSXTOG5@^R;,Z=DY?Q*Z#?T! :#$,A1/UZ8]YFY2[@"#N"<HEG X16A
MJPLX!X'/3P\"_&< ?#1'T!,D^%!VD6N0><T!74!^"U:0K8$+3P^6G*\_'QX^
M/S^_FR&R@!AYT'WGDM7AT7!T,OQX+-@2C&+V>8;0S*:]C_"W7/N7&?7?$;H0
M+8?'A_+U## 8-\<$XV"E!_ X/>2;-3P4C0:B%:3(3>#J@?(  1O(QRR!F@,V
M4Q#Q&\7*8#@:'(]B((G5XPE(EI4/A^'+;%-D8!QAQ@%V$\9?2H)Z/E:M1R<G
M)X?J;=*4>;J& NWH\+>;ZT<U2@Y^_L%QU*A!JS6AW,$E;2<<,\HU+(>C[9JX
M@*NQG64Z"ZJ #J'/68IHD")Z)V@X< [MR-D%(=N0(,;  H"U/1E9P)"4Z,FV
MY%#BM]&/EAZ%:UN"6@X8+4&MQXQI7E604P:1?PUBN(%\-!@=;4=%:M;LJ(CA
M=D'%R2&@KE2U4)O+!_!E[0,,.*&;*_%W,\I\2G-8+E,DDL032>+HXQ8D*LP8
M+J0C;$Y2%FJG=%B()8;8NG^]6VM"1A;R-@3<(37M*&E/AMZ;-IP_,8#L^(-=
METQ$+@OR=.B2 '.ZD9;I[R:3QDR \1^#%$M+:@)*12"YJ;6P97*RD,E?;:QK
M#JT'D3TM,9#\L34%\,5=VI.00*E?6Q.!\!-D*M0X;N+W-&#1[T&*HATE&""7
MU8[6:JCPY]8#E2%7HAO9$!'#R!^#%+@E 7Q-);9/5L,B@5*_!BE\D0B ,>$*
MDWP4/URO$9Z3\(EX)OWVY]AY/\"YHP+VSY'K-(?UAVM*UI!R),*I3#JD$"PI
MG)\>R)QK$"=6_W*!_TXD G&34@?YL$*Y*0'B!KYBXCHE,L8@#??I 1/2]F'$
M^7^=*0_.;9D2( BC#O/D@YDM3P($^AUE9TVA+3L"A$',6PT\B6 J&CA(9+MC
MUPU6<@1#[XXO(3TG*X%["3%#3W""7;*"UX2Q"\@!\MF!(X&_/DQ,A0I%H"7>
MF,*8QG0(_GST_NCD_?#8&3@7B+D^80&%XH],!X[JP<EUX81].#_*7O[F_!AU
M]+>?#HOX"ST'3%",?U:_BU*.@*,F!L""66@,EY]Y6K#H8:S$[54[!3.1M.Y<
MLQ%:DV*/CTZ.AZ,M%1OVTR^]_AD@IK!9J2T#9=+*:/AQ-!R6M9*"]TC69P%#
M&#*68=_:%!IP&,W>\./[X5%1#S&RK$)Z:=VJI3J%+SP _BX4%*.JU5/)/1GU
MY$1X^Z2O<^*+&(Q00<83'./0=SS D"RV1&N+&=4 E]'"';_76+@<4@?@V/OD
M\+XI+".,3 OQQ-HNMNW .!F/WVN,9B/5YMN)A[TTJ_5*N13VC&]N(%\2;Z(*
M+G)!]'NHOZ:GVG%0,LI-QT'8L1/V[&2Z?AL26D79IA"-,1JSA^/WFNRAF8I[
MF#6<$^R)# IZX@<C/O)D@G4&?+DT][B$D+.O& 0>4LM%S179'*E!E\(;'P^5
M1WX4XE4;+)0J(^1.%KL3H7="_,Z/20]OVM0*_AY0P><2<N3:!,6M>ZC1\P<U
M9[?2L_-CKL?>ZST1YMT\]%S)@RW5;4!LUO*'QK,Y;4+FL=]-GKTI-A($NYN?
M [:\\LGSSLQT#7*S@M_;*YA)#<N.'-73F^&N4$6YG/I=-&[JQJS[H[:ZUY9Q
MWT:!3CW?3_%VNAZUU'7/M?L$Z3U80!NUQ2 &?0P3?20[G:4Z!*0C07LDX0M(
MT9-*\2:8<:ID89%_ZL&-)<.C8TW),,7C9!#U70_6E2 C%O/*\+&FVJ?72B]+
M-UK)VE9K3$C,R[O'F@)-E7;Z5Y&Y0+*NB+B02XLYHP$V3I61KC">Q=+/"5(6
MH_7RH0%'K49*)6JM1OJX7IB3:N9W2[UD,1@=_4BW-IC32O:/GBK$VH6488V>
M8Z0K[>>G1O_\Q26@&.$%NX?T<0FH1791@C2OC@\U,R!&X:Q%MJ&0]%CRUMZZ
M"H%Y"7.H\=AE/?32;Q<%:FN0*N#-ZXU#C5'2Z:.'IDD5[BW$'[8W9]PG.C.D
M 'LDV2N Z"_ #^ -!%(&EI4./;A9[B.-W"4>1R%RLICZK@AK1V#$8BYUC#3>
MH$(MO70))M&.=J.A4;V*2@E=G8J<T9N20DD<[49)1_5*>F^MI*,W);6LCC1!
M5JNP#]8*ZV'%1"MIV\#8A,1<[!UIHN-*-?4O1+Y"&& 7 ;_5BI46VAS&'>G"
MN!A-3]>K=&*TC^$,2,R6[$@7PNE4TL\ KEJN-O&;"4NM>LKAFU$]/0O>JD5K
M$[N9L-0JJ!RZF174K\"M6K3'.U'0<;V"RJ&:64'';PIJ&5C7XZI5UD=+9?4Q
MJM:(N5[T6]K#)AW4*O?OS93;3.5OAM0ZDZK&84ZDCG2)E%Y)_4NCPHVE4_!B
MHXHLD'GI4Y<T17M9%7@_)6V=(FE@S4N=NLPH*_=>)D1E*5H'"=4H:O512H6T
M^NAC2) 1JJU3*(.:EYQUOB"OASZZ  [P @FVQXQ!SL;8^T*(]XQ\JXE1C<1<
M5]/MCDFQ.2$Z=?(X1OBF&RF%%DZD%I<Y!M;MGS%KJJ=NID[.%N6W)LAJM:9Q
M/8VTUJ]RG$'4]FZI#I4Y9='MC*K361\=UY,@GE"+C5(IB-$IC71[I1+8/HJX
MA;<I0!JMU.A$ZULB%#UU(WD!MLA5] AJ%:%Q%T5%]#--B:1@[PWR@$;;/]+=
MX9E10#_-?'1?U 3_ BB2$A#>$ JN^"7F2%X,;*>->G3FLM:'"O<07VN%L!-C
M=F+43HS[375Y6;=R+8VQFNLR'][K)ULC1?;2+5U#P&RF6]3>7 /XI)E/(6#O
M)&L]&_)@YESPDR;*"N%[/);;QE=:Z%KYEX*K@OS[&%F%(K -JW)0YGSZDR:F
MBN7>OX#J6B!:*!HLA)W"F$,CW67G*7 OI6QOTDN@YBCFHR:*27'TTK1'GU)(
M+U1*5OR3BY5"J3372G.4YAFBN_DF_C!#Y@*H=(M">EM4B/]-C6696\\Q:\SF
M*:B[.,=*J6^SU*0$V]C %K%YU5AW[XZE<OL79316@7WD;8^Z=O*6PO*&^NUS
MV!Y=,_X$<= B;]5"FVO3GS0[;./KR$,\O;2B]^'GT3;W/L!\C#UYJ'^=F03-
M=5*+R9S>OM?$H3'*_W<44K5HF:!]4U=6R)4O=J# :MSFRISN]B:S2HUO>Z9F
M(F SURS=S2\@7@'Z[0;@0'ZE.J (+^Z$N!2M]C9TBSYJ5P%+)X/BSK(71\F[
M::/^G%R'3MIC+R?Y W1]P!B:H_#CKG<!OYM_KX]#[J(SLV77C8=BKPX)U*WS
M;U^2K!\<#%(QAZX(E1*5'^*66X3&OD^>Y3<:6AS3;(ZR-L0JA<(Q;F=.J)-@
M5X8]Q=_336--Y6YQ@*DYREI5:N:LE2I[=4@ISB'.-L+3>8%K'SY78JA55*EV
ME"0TLXT3(>NIJ<PEB-:E@@KX6H64#ON5,LP^9ORQ$*XH68TQ1^?>T7 J/#Q8
MPX C5PS4!06K-@&,%=Y:[94.32?:FXL>'-G%X/SB:.AD.G'B7GH]S^+_[767
M0!H3RI%NJT>BG?A'#P5O6^$NP!D+V"/=^G=JT/I7FU87BYX!)K^UMK&\.D@#
M:U[OT]W_J) ,9A*+$Z/IM?RM748U"G.M7W?M8ZB-LYPV>ND%*H5JD8D:<-1J
MII1Z&C73KTRS+%=;EU&)P;SZJ;N(3J^7GCJ2![@.J+MLM7NS"D%M.4YOQ)P,
MJGY:L&"U G1S-W^$:T !A_YFX@EVT%QMXHZ.X[E_!HA";XR]:_$8^6H[MW@7
MK*!G/:MVU:-Q%@X_ZF9AV+4LNK*D<R&&M'<'1$<%H_Y5I<=/*9#O)0F]G+N)
MXM "JRHVYF-75<007MP3'[E6!TL:XC,&BT-ML)BJ.8/:27$[,?(W[16D;6^/
MK= :K?10&VHVUF7/S;=)_,U:?:\9;-F[:8P<#>7]%UN,$9OA%/_Z'QU//QV^
M,.\S6*\1GA/Y*'J ,0FI5\_D(^B'>[? C'$*7'YZP&D #]0 G"$T^]=8*.5C
M(3*+JH,W<#6#],#!8 5/#YHT1+XO76O<"0MF:NU<4O2%DF!]>O RHS[ZC#A<
M'3A<\'-Z@ G&P>JS1U8 X8EX(=D\<,*&:T@1\::JH1?0:"/_H1U[GYJR5]>P
MF^R=-&6OKF$'V?OE[O;RMP(G^6<=)'HV^P7! M'Y9QTD6@;-3)DB-HX:)<3K
MW[5A(GPB4 ASW9:'E&;/4T0!_P:)>)X3#*/\/*'<U*(]_2N!APM75.1@!GRY
MJ'QZX(KT W$=8P@S#F3W1K[^'42'<J<D6A"-*MCQFO8#E-X&+Z;D$0C&)OA>
M=$%_AX"RE/<ML7Q'^7APIA=/N[$K6 -B;H!98=*5G^]MXJ7$BL&X88C=S<<K
M&;>(_[%WO@1X :7\=6I2Z:I<@3WSB?LMX6X'B+80!X_1;"\1E;:#7+7@G]#W
MK@B5PU*%<ILR^[90W>#U260YDHR(S$?H!C0ZPS_C-X!'?XWG'-(K] 359!0*
MIAS]!;USPE+;MA-4^YCDC6Q@*^Z2+Y!L)Z0LFNX*"%*P@!$+(D.[ ?2;Z&^6
M93(50[/&[9F-1__. Y.SR]O+^_'U)&_:2T^[%U&=329GH]&H0'?A85?)/M*1
M?=1EL@%#KG" %\@/./2*W^@LAK3-F^\]RCU3Q1LFR2)SEZPI61$))'[,$6>$
M^H2Q=*HW;]Y*B4*#@@-74+A[%2+"T$J8:\H*HT_SHH,C$)$G=0S@J41]\?G^
MH]"S@"$,&;L3I#TA^%P19-4WVV=45:F*<\"6CY!S'WIB1L\)74F'JV9V86@U
M:MF]L2;)GOODF9'PY(F(^5_68M;KV*MIUV'F:)B]5+!4?+O_275.) DD;!D+
M&K@N5;MX(_+-;3I;D\C1'?H2Z4BDGQ&C2LN=KM6KJ2F<$ZQ>"+5D"BF%H6AN
MT\&91>A:*@?*Y"<-_,\#2@5<D;E&;5\-D[<$V_"I:=X! Q-2=$_)$V*R&MNX
ML!=!RNPV87Q'R/9BLEJ-C LXAX)R;PI>5/4HKAQM),[Q"TIBZ"8-F['M\<\>
M6LG#@&%JO,L,H1V?%VHH-N(T:=J]21[3S<%+O,-GDY_7QA9=9,ATD+G(6J.V
M7622HB>9"265J/RLJWC;Z:E6I+DXORK?[]^=I,0QN>< 86&.47(A[!)Z"RB>
MD+F80O#%]0,/>BY9K875EMLMA'&66V)A^'^9X9W@[)QS286'V)HPX"LR[N+T
M2EVT&"Y-)!)IT+"K168][;ZD/;.QTLRIIG77LISJZ8VDW9@%G- [7$A$*]YU
MT.JFA$Z?2243V7==9"*YAZ.T/Z'BW=XKMQ<!E$<P@3SD>7$TY.GYRW5T_#+A
MH$G+CAF)2E5='GT<G@#LG8UOY<;0_("K>KE_;W@YGT.7)_>%B(CX062%#] E
MV!6F*US=PASZ/E0I?WSWSP-:++E(D@A= (S^BCJ*N-TMSCU5[,LBTC+R97(]
MG0B_7F*^KG77%B(N$0.H,&QSC[IG'B]7:Y]L('SDQ/UV'^_O$[.[P$9MLP[,
M0_G%@<VOR(/WH7[! M[-HYJ$/#1_ _ZM;@N)'5=B15M![GU._1FHS)0OB9=^
MC>'N&4/*EFB=<G(&YX3"=$=;K+XI!9B),9$U.[O%^1U%U"0(#;E9*6[25&(&
M&&(>$C:&0N'#0+BO)2P\JP[RPF@#OK_=$"GOX0J!R(QDS<V;;41HX&:+[ F7
M#1IVK?A>Y)+"N?2#T'M&?*E&1GCQ*"-SI/QG@=DF[;O&<Z4%OQK?W/_^,,[;
MZ^+#[CF>J^O);^.SPNZ<XL,.DOWU9GQQ^7!3H+OXM(.$ U>5,J])>!%=MH!6
M\:[#Y;,BQ?GB6>7;_0<IR0[!"8[.\,!K$>EZQ8]AQM>.R?@W9:L5['Z\<*7J
MOLA=+5BVJ5E(;-*P>_-,1W75$F+#MMUC<G+S,+Z^*!COXL,.DHVOD2L# .]>
M3(W2LGSUZ_W;C9HI_Y7!>>!?HSE,F6D.T(:]@ WD#Y:$K(^[J7T5";U4Q7Z!
M.?=MX-*&,WNP3FSKCS^7-\&/HG_D(2 _U)NPI'O7M:*'(E-D0P079U/I>1<M
M0O3-T&)I6/=B[W7AA"B18+BADP#8$Q**_B@17]VN8S7A,HN,B,B2I'M@W<P)
MEKI&7<O=<MR%980)%E1SZ"XQ\<EB(R]_!EBX_^D2\#&%%U!,GA7"T)N2,_A5
M)*7I)S:JO^Z:2N=[=M*QH6.<V[$<JMB)KB?5S7Y[T'W9AP82,'P#MIKW9D#=
MXYI@Q.Z7@*Z JY;"@%\,]$PM]A_K74,1PD"UT!]&+=J(I[95)W?87Q.\D%8G
MV5=>7.7/:ZIY\^[%%C>/^6V1!=:J7W>0%77J3RW^?!4I19&3JK<=9(10O@ +
M.,;A]QY4LG &W&_0JZE&M()\I0*HJE>T!=Z_2;V%_$8DPZM@I0QF>J%MR%CU
MZZ[M.*KC2-[5#8$\E%S#6Z[A:^/R5\27$QP?NZ[AM-3XE7)+ MJ<V[3QZ^3V
M#C=7;=KV=?(Z75+8G-MLZU?*[S-ISFW2MFN\5KK86[4'2W28=Y[EQQUPBT0F
M_9P2WQ>Q-8J2O.)V:B)]?<*&%4CGMF%7:BV_[3B\$3:O0&.+_>LR3QX+UNNP
M!?#=Z.2KE]R?J,\HM\+0B7)ZGH-G**<<]$!XB0F%4LXH3"@!]KQHF52>X6LB
MD&W0=3(75S&\&Q]CI-HLM:9-]Q(<17!,9[&V5?5R[Y7]'&$5@]'8I!O3+TMB
MPQWLEC"OR*$$W+C:;'B_?V<2!V$/D <4L[%P!0AZXP60 5'=:5_-F>$=XNOL
MXLY6/"87*.Y$8EELW957LIN8S.>!/(3C"7Y\HKZ!+%?R&(7J ZF<J%WTB63L
MX;JV9IZ],B8IFT;7R2 L;RK)VPJ+]MWSR&;BU2,;;O, '3"58C*$>T[DMTBC
MP^-RJ568=@6=;-M+[R]/.&T'^UI68._%9 3I'<!0;:AW,^P5]-ZX>?<&N>;K
MTJ3IUZ6+4>J.<'5N85;Z*2#/B8AD*;78*I'.[D:N;];AC<D&XO-[E)LT[.(P
M5Z&&,,_2Z23?1L[/X[I&^[?9#\WR#7TBUA:XDS6 (C.NIV6FJ& [H Z.8^(N
MH>K["Y0W2$"W$'&9&G2/G<?[R>W#^(_"(:#2TPX2+H9)@!?I19WC!84*IL!*
M?;L.,@>Q2,-N"8=,KC[>$X3Y])E$^<M% *?/XO^-"/W$/_*FESS+;:&[+0@2
M4,7*'Y 2Q5>!GX@KHSA:X.BT4-22GN+H$;T('5?S5+J'8VLLW1:,&.^2H5N$
M*UBIED9ST/W'(^E'1[/)7W1:503WZKJC"997[[,Q]J(72<3<'KRSQ2'%TMW\
M7%XM&-Y#?1_>0YWCN:+!ZRD2/RZ%^98+2%YZWU=^1!L:='#J?MLLP?.W:1H+
M%B)'4X,.LD-\PI<!Q8_/B/\%J1@#7H$?4XL.,B1K9W=K":<,0;/+/ZRA.F!0
MU3+L KGI;O9[,9'FQ$<D9<O8YK44V31L%">=J44'=!5_*E*_JI'U7^GYE+-0
MEH]+"'E%GOX=\'8RA4\_M6D* \:,$1=)%N7&JHOH A,>?<JO5(/<-=*]K[!'
M#,E"JG"BB&\>XD6B]&M?N5O(C8-J"S2=6*FO9J-PS]I6(K'"U<FY-87N'(G0
M"^0M:OEQ]WS]%*W@+\+<0T]8/#&'Y'TW52<X&K;M(),;!F8411:^P)3^W?X=
MWE=,(?#EM]2^"'37ZK,Z=_B*4(@6T=D)=Y.Y#_<6\O"^K6EZ1]Z6.+JVF3:5
MS7I.">8BS"Q^>)/=  ].2<:(/(E7E.-4XVV!NY8%5P[W7PG]AN3W,5S("E-8
M_ZI[,_:/R>W9P^_30JFZ]/2_1WCX!6SF+N$*_/S#?P!02P,$%     @ X8WW
M3O;^0EOQ+@  MP4" !4   !B:6EB+3(P,3DP-C,P7V-A;"YX;6SM?5N7&S>2
MYOO\"JWG.=JX7^9,SQQ9LKPZ1W9I)?7T[%,>7%5<LT@-+Y(UOWX#)*M45>(E
MR<P$6>[Q@UPJ)0*!P(= !!"(^-=__^-F_.QSFLU'T\E??Z!_(3\\2Y,PC:/)
MQ[_^\+?W\/S]B]>O?_CW?_NG?_U? /_YT[LWSUY.P_(F31;/7LR26Z3X[,MH
M<?WL[S'-?W^69].;9W^?SGX??78 ZT;/5C^,1Y/?_Z7\X=T\/?MC/OJ7>;A.
M-^[--+C%JN_KQ>+3O_SXXY<O7_[RAY^-_S*=??R1$<)_O&NU\XOR-[C]#,JO
M@#+@]"]_S.,/SW"$D_FJ[Q:=W'[^QW???^&KKZFU]L?5O]Y].A]M^Q#)TA__
M\]<W[U?CA-%DOG"3D'[XMW]Z]FPMCMETG-ZE_*S\_V_O7C\@XD?3CVDRBBG\
M)4QO?BR?_/@\H.27XR+TJ\5UFKV8WGR:I>LTF8\^I]<X:S?IS70^?YD6;C2>
M(WNK7JYG*?_U!S\:>90,M41Q4N3RSZ=16WS]E/[ZPWQT\VF,LOIQ\,%\<'Z<
M^AK+0V(]#N6_EJ/YJ,"X!:???]L;(S\MYZ-)FL_O==(2#(=;5F#R0_ICL73C
MTWE]1* WEE],QV/GIS/45)_3\\D:8^_2>*6YYM>C3P?EVYY"1:;O?8&_:8F4
MCF0K#N]GA,?BZZ]I<3V-KR>?TWQ1MJW^QMF.?L4!M].5Q]+I<0"3B!HY1?QA
M/AV/8E'7/[EQV17?7Z>TF/]MXI9QA+\]/(:C29UC&&_=#!%QG1:C<%BM=:4[
M[ #?+_#/@N^KO,;]W2].&M=A<I6&,[_*+]S\^M5X^J4C_-J1K#BL[VV@'@?8
M@GB]H?8]NN$'A![76_<Q'>;TT8>]L? RS=!'6ZQF;[Z8K3RZ@UO'WD;#LM9R
MUV[3=EA&VVW"+9KVQ^:HV":CQ7*66HMQ=Y,AV6KI !QN.0R3]WX^BL4M[09A
ML"7T=K;HC:F?W6PRFGR<OTVS]]=HJQQB:=?W@S'4<AD<:#88>^TF<G^K_IA;
MV6<'F7GP56^=OW*CV7^X\3+]FMP<$=MJF]K;:%C66@*K3=LJC-(NG-*JK+(N
MK+*JK+;<QXX@,2S;[?1-BZ;]L3F:H-\[<N,CK--];09EK.VB/]RT!IN'EWR+
MMC48/;S@6[2MP2COP"BOR6A;O=2:PJ!,'V;C)(0<07;0X;54N@=;]L;D^M3C
M@_OC,%=;/AV"C9:*=7>+ 9EJN98.-AR"Q7;0VMF@1Y86;O)QA+2?S^=I,7\^
MB;],I_'+:-Q";@>;UF"S-0+;4JC(],&-_@@2-=ANB]J6!'ID^3-JW>GLH _\
MW8?]L] :C]N_'XRAUMIP;[/^V6N+J:V?]\K.YG;X]>0_W&Q4ND$@IQG^^N?)
M8K08M6.R-9&ZK!^!RF-I]3:0-^BT'A;RPZ]Z[KREF+9^/ PK+9?MOC8],]9N
MP6[[MC]&$(<?5]$0!]GX[LL!F&B+FET->F-I$UGW[<KTSC>YNSM==WV(U:,)
MU1]"2Z&?2J_^@-JMJQ/)U1].6\UU,L%^A_0NH8&Q;+T#[&O3&V-O9]-/:;;X
M^G;L)@NTHLL-SJ=[ CG$9-OVPS.\\Q].'L)!BKT.:CI/\=ZM[%5^F28W;O;[
MKVZRS"[@[T:3CU?(T%&!FMTI]S;(=RF,W7P^RJ-UL/_5<G&5^XUF[[&+'H<]
M3S,4_JOI[.5H'J;+R<I=?3X>3[^4J+[6)_)'$ZH^A(,GL4<3ZG$(:SWZTU=<
M$7$9VNJW0^UZ9_"XG6U_J]Z9>S6;WCQ'%^U%9.0#+B7W*2T7HX"B^3AS-^U7
MZ2G4>A_,[?_;LOOX^]X9:F>=;?^Z-V96020_H6,5W[JOK6Y<=[<8D*F64#O8
M<'@6#^KUPRT'9+(=Y@ZUZY?!=^G3<A:NCS@L.="L/_:6-V@X?;W*[],GA^92
M&G]]'5$<:'"X;V?1Y472+$7<V-[@KT?CU8D6_MOR)L66\NZYGP$$,/HX69E9
M:!F'U4:.-N1;]*]"BT/,XZA49KXMY$XA5GDH[;[J=]9.ZW.G8((;A^7Z5=(;
M_/OF\R*#@1[*KCE!.RI-8@GZK\K+ME7;/RN[WI[VW5/;YZ3U^MUJ'_?=_;&O
M/.OWW^)M9GVFCGE(69^[&BOSY/>,=XP4-FX9&4_# X6^Z7R5\""[N5^E)UC.
MX:-SGWXLBO['-%[,;W^S4OU Z"9_PC]O?MW<MS0F\?UB&GZ_GHYCFLT?QGZC
M.-/XKS\@$TW;IDW4F;I(.*@4!6BB'%"9 R27M!4Q)<[=PX&/2]Z(Z6PS <..
M_'N&46^/EW&UJ\W*?#]?+&8COUP4J'R8_C9%M3Y9X,PB*Q]O+SCWR*>?#AJF
MB,R.&O ^&@@Z:N!%BLZ%)+@S 8?71HKW@/Q\%IY-9\C77W] G^1+&GV\7JQ^
M7%-QL_ =OA_FU=A\\>.\& >%(B"(;V[;EWPA0T)E>B%R1BF<":E'H:X1WEHB
M<%!&,0$D>@_."@O,YLQ"-L0X<^D(.L<D'\39"9*MA9FW2"O-9FF]V%8!_GM
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M$-XPHP.[^+O!_G TO/1J7QB\2R'A>L A_986[:\-MC5K4'+!)VM!Z\@@>D:
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M#G'LGPHZ?4KQ?"KH^[<N1RF@[YLWQ'KM!<6!2T<A"%PP4>%:,4+EG(5BAG3
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MFO(.#R_KQ&L-@XR^Y5;-75E7W5WGA A?[]FSA?_"_D\IXS<?MI8E.X%*8U5
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M40&PWX+PY3#9Q+LXJZM$8@4%) 9Z*SV5TDJH=X@X(S$9GZ/1T;*'0R@Q +L
MA2IY@SI5R:A_RZ8WV;; USD,:M)30DEPP#PT2@L/-75<25+C82T:T#&Y-($B
MX'4!_AR/Q5<EAO[W.KPGU]^#AZZ6&R7=M\E\/2WK7^UP#:W"!YM=NF)CVM6J
MF'U>KTI/[U/^+E^4$<1@MZ#+375@XQQV7E[.A!"I()24A$6)TD I:$1E2P^L
M:LU]_.JX_^JL<8$WRY:FSJ8Z6X0?5F4>\/(AO'(.]1MTE!C#+8<$*H(9\2P
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MQI@P3AJKPY"&ZRT/A1T;8_&G_HS>&H>AK'DH[ER*O"EH]BG]MG>=L5W?'J%
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M63;U 6 UF:SOUO,R!'!EWKQ9K/+=$?'KZVQ2]O$^+TKS!KT;33[]?F529E(
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MOQ(_ACX6,O4)\%!DVBBOT\F?V?2,<>E(J_#22(XLPQIRQSDBQ&E9Z<D &W/
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M";+2%@+0/O$\7K&R:!3I%:K!O/2\R&8W"Q-FY7)SS>2+#0@;E,YCRID])51
M [EF**!J,(>4\_I%(;##K!2O[%DTZL3%[C27#A7!FZ>+G=)Y8;/K+(@W+4M[
M98OE9H';C"&M^TI$T$A+0R!')9J60<4K/8U [4_.1KO8IW^.#(7>Q1=2;190
M"?,<,4&5TPA1Z3A%4%4Z!FC;3T#1KM6)Z*/TA-)03'BT8&RWKF[602*IT$(1
MC!3".LRT-HR>E?9,^!&6RAW%XCH*NA?V:Y:54M][<6Z.=I<XQ!3B4A.NK*=,
M>F! A8QB8SR?TK?)F[DY?:(X%+_T>CE;9,MEF(,_SQ;5!<ZK\/)EY8UXCZYR
MKI4[0J\6O25A*6&HTM8 Q)' RG$#*UP$['!.+MJH%IE=\4$<Q\38>D),B*>E
M3V@U=D C"@ 'KG8#%&N_Y(JV6H],F5[Q>F!'M&HSQZJD/"MG.V"9E#("]F81
M3+$NY7G;H.#)@1:)5Q0;)%5 &7L+, %2;  7SAF'&^6D#J'CJ2(D>YX.7CWD
MQB@O$&!>!5))4>NF/!FR9//1<B*=;?.\!F)G+-(QE_AXJMZ);.R7#R<V>#=$
M8L@0,8(*@*WT-108#.DDGI6&W<FL1RG2 I:A)N:G@C:Z#>I0DP1IS9DV7&D)
M ;'",L0J#:TF(R^CT<5D1ZW?&:$?D0NC3 $> P5Z"G1_#(Y67KS+5]GRT]?\
M?1Y >1<FOO=A. SRV'7VZ6OX]_OVOR=N\3J_JR0H::S!0"(1U#20NH=QDTH_
MPJN\NALL'Q2S7I@1'LPVPGV<?0MR^MF7 R*&/S8GR?F])HQ29J$,CABP 617
M7H-3ZP[@" .:\?@2';X^J./S=;$1\O_+BB,BEG]I3)RS^TQ46"6'9:PSW&$E
M#2-A:5OIC3QHGV06;?D?C3:QP>N%-*58I8SEF/A,/)\7Y]*E>6\)8P!AA0EE
M4$/AJ#<(5KH2ZMIOJD7;FH]'E&BP#>6G;M1XGW[?)"^=%4T\T3+1T#',K&-*
M4JXX"U/P3E_O+/:#'EQK0Y/NL8U^$;H$(QJ:/W'6.F0 H<I[@+V@8'=N(6A"
M=(<[809R.?JU]9EP7&9)6A.R\8JT;I%H*K$,'(6D+,5!'1?F03\FVI\C',A5
MZ#MLV1:9"^\)/-NA&'!/H-J,4Y/_6L^6LZ.;<:?W"UKTEEC%)?<>&A(,[K0Q
M1&PW;X3UT,E&FUUQL/DXN<VFZWEV=;U'KZ7^?EK+4_L//7U#0@)F0B#%8?!\
M$:3>5F2W'H=7:BQ[%E'YD8\!VU'O@<0OPX?#+ N(PQQ*7*($/-(56,AT2.&*
MO$LR.%E:%.$[#]M+5L;JMXR:H1Q 98E60"!-C0>JUMM)S<>] =.K95O44VN'
MWE^'/:/<LAD[:<9#EKZ+\(F@LY6,<$*]XTYHXVIOPP=/9'RQDE[MV:8(WWF0
M_742/XE&E$LAF350^W(U2WS]@E(UPJO AW3/XR-ZR6'I/V:KVQ=%1Y9/JXY\
M>%;<8:?E;\%2Y>7I;Q:3^7J:3=\LJKOKSAS;HLB0: LX4<AC23'EE,DZ4!]L
MH-$(BPT-R>JQVN&5O@L?L]5J?O*^XGA?F@37B@"M!'4>66(8\I!7*&LI1E@1
MZ16SO3WP%P[??LJ^K=;I_*E,?ZD@;O   =18.^T\U)9PY':)_<08;G"3]^0O
M'\2%2A@")>,,0,I=63F[.L7@,&R$X5B#N(WY$2N(>Q:VHP[B=DUDAQ! *ST@
MC"L#A8/\P128#EIF_C(AVJ94.)W\?AZ4KS'A66 BC$(62>2Y\B+X!;C2D%NF
MQAU[[6*RIIG/[1#Z$;DPRDCJ&"CP8R2_$TJ"5@1XIZP36CA-9#V%Z_%GD;4Q
M6-?D]_,P^[&2WRVRE#%O-#64>,&E,K7N N#V&R_#)[]WYDMT^'Z<Y'<C/,7A
M59'2"Z^1"6X:J?0&X%4EOW>E36SP7G?R._$6("NH5I0B&;3&VM?H2MW^G/;P
MR>^=B1(-MD&+C;VYNT]G18F-N4V+F^/%4?<V2 3%5 D K!=**<:,\;;2#A$Y
MPA-Z0T93>@%M*$I\S(HOLTE9-*N46CVD]@:Q SC+-P^U]#YDR[#""H_Z &_]
MY_)/&^"V(>BKHOY+Z'%]=[^)&QR+ZPTB0"*E-M83H"'P D$B@J]8H4^H;;]-
M/*H-M=8!P#$:X3*K]S>+559DR]6'=)5]7(7_3'=C?7K3_.C L4Z2@ !QU"/%
M"66DO$H<UW,# [C]X9%1[7:UI6(T($><$O,N7TPV5>".E7?LU&_ 2F*K)</0
M4A><'P PJK!2M(/#'\V/&Y)T0V)[J5W435Q^^526>O=T)U#7[PW8+2:S=/[P
M @__A;O=XHMM$^^_4^%M@RWA$RT3+HG7H%RW:.@()4B*W3V\3'N++E@/[&'7
M:+\.S3=WC[1/#)42:,8]$UYA"3$FJM(?.#?DM3!'MVY[L^/!;=K^4!KU)NS#
M'0*?@K G-F%?/IPP$S06$FL@+?$(EFFX%120=<@K&FP3MA=#'[R9H2500WE2
M3P4UP?N[R8O9?V_FX9-YZ*<;)X!I;K$@3@DN(#625O<&,,T4L^/>=NUBQJ.,
MZ!&KOPI31KDI.RZ"7(88P:&_"^-N\!#?IV$ ;G"?\)[G$P:!EQ(K+@T@NEQ=
MJEHW[M0(-V7[--B+&X&[0S24^3]D]^MB<ILN,W539-MUT$D.'&Z4**2<(T)I
M!K0F3!K!7:6EI1UN8(D618Q(A-YP&HH-O^>+[/OO:?%GMO+KQ?0T$_8W2,J@
MDY3",20)D)A!I-D#USL4G(L6P(O(@EXP&C+4>\8MSGOO/ \K-F:(8&5=WS!]
M.D1U/8=:AMHG$$>+I$6T?@\(#>8*/%U#J95)B^+[;'&SO5KF]/TZS3I(1+FI
M+"0(@U_0W%FM4:T]EWJ$]YS$BE=$ 6P<=&E-DX1 0!@&(/R?(R2,4PC4VA(S
MZ$GYYO3HTXQGL>1,O(8(KA^..5_NTHF'B-'AJUF;A*#/ZB=1!E O# 5<0\O#
M["&0@<HH8!FT0C=:%UT.C^9!Z1-]A '2,FH,1)A[H1@7RL@M#A1YJX8\['$T
M,!W)N@?#U/WB-NI0M4[G853(/MYFV>IM:>#2D,<#UH>:)&'L%-PCI1''Q %
M"2$E+$0'<U@\9)VQEF'KW@S_?)^V'\@&2P78(^[)DR&'&R7&E%>8HG("Q-"Y
M\#I*O-'2.HTL<.,.6'<W7@,V=$+J1^7%*,/38Z+#96APM;K-BNWUC]O+K4]'
M) XU*>^%]%0R99%23EBG '6EAH(JA;0SXUM6]&&N/ HZ@]K_(8_H' KL;Y4
M#\+22RD;H+*:,@ !*_4TQD+:Y1;Y>%FND5C0"T"#U7-YN:0\525T?XO$!&
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M0^&(T,8:JPF57E%3Y0=QHF%[*XI?M$P-CF1._IR.?IR@,,<HV9#0$4(ULT"
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M;^%]CM-YA/:T+E"_BLSVY,>VQ>)VLOSW[Y/%YGHR76^6<6T/ZZGO3-ED;E"
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M7D PT$)CE4L=6(U2@G*\1U^*#M&>@7,V<M>&LF3?69R.Q^A(-[:.'IPMGQB
ML,Q8AB6RV $)F135V:,P-2IO#2PW(:IS50[.E+^%]SE.6:J"OZC,]J1IUON@
MZU7/)G,#=1)!;YQP1"NF/+.85G2H+@7JAKSM.2S'RF$QS##2EV+6LZO=#_U$
M]YX\,E@G :688.(@ @(KX$7E(J6,C>EC.ZE[6=X.Y)'8D:' [@U0V(^T/CPO
M ,,TY<A$,(0F%@NS*\>1L$%LS*3U7U-46_-BA+#UQV(ZGZQ6L^O9?=+J^\WZ
M_?6CG, J!^1N67Q-^M&WXIXYJ6OAN0/&S]>NKOYKL]JFJC2EXOW"%LO9MVW1
MWD;1X:%>&;10&%CL@4>.46^5)!CRU";(Q-T,-]*$QT&Y*:'' KR=GAN@]Y(Y
M;!U*7C4G4-1+[O'24@"63=CV_ +S4P60\6#/.O*Z/UY20L[Z1R*Y7&S+A->[
M+6OG!1;YH27@PD>KAQBMI=FS14$RIB?\)&_C2&)QJ"EF#UB.I=0]6^I1W\B+
MXX-EP&E-I/,<8F(YT$)7M'DB,BWOUS/?RN&0>EW2D*4?+"<A. _S'^V/[XKU
M'XME,9G/_BJNDL)_?\C_%A>?5.7CK5I.?%3 R H/%%!>"X8-PLS+/;Y&9.B
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M.I>W.3N.H/0DG9T0_UM.ZU'+TM!^C>)Y66)YO+%6IP<'RA%6UFB&+%!.L]2
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MW-Q?+[S>+;")_7YL:E"*>*(T-10RC(2RQA+(@<;Q:Y68-HK@C$KU,=N^;EJ
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M64,6#8-/\V!L?DKI*\'Y0C,'D6HJA!%^SU[.ZZ#\_&D_/Q5U&=^%MR.?:-H
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ML;[#B@M;<BQB@7(V?(RGCA(96]2^3-&OHT.S5/(73^Q<H R$EW1.DX:_GW]
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M&V"V[L4@3+G9(6^>1+_#I&^J?1!AR[1V2)XY\5KG1-6X]6!$/85SG99I?HC
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M$;)-/U!.S!!"BHIY:X.*4@X7L:+NB A8$ NT:X+MT]L-"0GK0X40>J$;Q%$
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MQ0@%58P=8:71<EH'4<VF6,[XWLO1^1CRIT?6EV,1?\[:XQE#%/)=AP0$/D2
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MHL1U(S^@_;([##U':C^+EH#_N0G^NM_Z,*W5:H,L7A]K)P)5V/@_#C7%4U)
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M=]7.8AO.%Y0% 6)YA4&'KPR4!BUF3HF#/EZYKU)JGN6;.P'-6@6>GWBN@ZE
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MF]OLQXL(!@+@A"2. SN CAW$=A -4Q,_BK05(4CBT5Z1T..R]MF/X974=Y)
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M4.-&.D*_>ZTA[UO_CFK,I.FR.C$7?*7D4>'7 M97]>;NQ5!=FU7D YH+)0%
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M[>MO3:W(E^O;/_\7_-0<$?H=_N=__ ,*9%$SJ.9(/Y=A64S'&DS6S9V%*VN
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M29=6EN1R+A&V^%*NUT:>RKBDR3 @X9+'7JEX'"33K>.>.[$]@$CBIB1V4$B
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MEOEN1Q4:#_GV*.U75IDWM^?MLQ_B]Y9J<Q2WBAOA(V$A?U>N!^"-<QHG_L+
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MELU(6Y5;5>E]-B4.NY_<V5UAS_7M)*!"F@0@\7 4('>05]=VQ=819@ZF?:U
MHBAD+G]\^K4@<6*RU9YUGRH*N<!1]Y-$36B7(H;-D"Q5QKQWU%T51T("]=YH
M-.U+ ^)&#@R0[Y,81\EP@H-@)-R&0V(,S:E6>\P]ZUZN?%R^5DDJE0R1 A*E
MF4,9;3)$D\3%: :7!JG0'"O>DY_9K'#?:I)_VU\WF1E;7+AE:=F*K0!B#-/8
MM<,4 H) '*>A&Z1QDL#4%VKR*//YFO7FZ_HAWQS::[0_5N7]!_H9CQ8#:AV1
MUM9?#5C!\_Q2=/(ICVXFQ51'$8EZ+A1YR]2$"LWAU0P%FF7!ZZL^9K,AISP?
MBS*_WN>/]2J%@8== ),T]%)B>[X-AM%PXH7RZL,_AF8%>O6:6'\Q9%8#;9;>
M") HHSEZ^!/3'2GJ%E"9@1MNI1%GTT2UD;!B4G%D6>%O*;;/ZV[]*<V*':LB
MSMG]1=NJ/NSR%7*2T M)$D(01# *@R1VVE'3A'BI+[82-'<T[4M!#4#KJ45X
M9=U1C-9W!E),AF:SRB='2](I)DLMCY]['ADXJT%G'>$MW:UMDJL)F5+%LAER
MI<R:-_W;5+(D(U^KA)#$Q;8?P#2UO30.[,#NA_!1('@62.BCEQ:F=;;;/;,C
M!C/%Z3QGXDJDE*P9LG,Y?>$4$VZBS%,.?N@3,B%HO]Q$:M"B%0J !ZC8.#ZQ
M 0Z2*,;'T<(X$I,'V5&T*T4S(RB.:P[R68PTD3*3*3T,SII,&9&WG&")>UHE
MSJL9:C/;BLEIE2PKHC7\</VO0U$7DQ6H_02/P A$:>I@GT[L$H2Q'R<M$I(Z
M"7!%%GITC*]Y$6BH"A]A/ET5?L&%#@EN)]Y6G9XRXTW6:N&)RF]];&H\Q;/R
MD1M$( 8AP0Y*V?*.G_9(W "&J[;/T]=]MMN+Z8!*%"(Z\!HPMQJD0\["[H6Y
M+\J2S7:JNW.-_TPY ,+QQNOPB5EOO!8+YY_U$&23^^JM/J?X(\]8GLCRC'\O
M]@]_EM4WUH2!37FNRZ?#OOZ2,R(IE@;7%]8RBK5R0UE=U /*OF/4=;G>'C;L
M%K$DV[&WH%XA8D<^=%,/!%X0!2$(W7# CUS8]Q*]Y4\8S '/)2\ONY+>2M4S
MOWL8<.&;IY9B?4*.S/.\&2)F("^O[\PR#^$E!?-KOM]OFP^I5\"S?1O!.$A2
ME_@X=%,GZ@$C$/MBW98O"%1"#<6$\'/VW" 1O.WP@J[C6UTRW6=R=RD.ZU%7
MUL@NZV]JF#6VS&I-LU[:QKH[=]99C7DOSE:/3/RIH^#(CN7"GLSS\7]DG),B
M0F]@D_>-SLE^Z.,(N'$<!U&*0XQ<+QXF(5X [6ZRGY2<04H'!O&I?@]7:J*?
MLQ+W_UNG^+R^,$,UM%JH8(HOQN:Y][S>[4?]%<O-_SQDV^*.;<##==ML\[@]
MU-:($NPE(?2<,,$@#B/BA*%C(R?R$Q<F*.8Z(JQ^5-V5Y FV^D+H*\MQ/]C@
MRAHL:$ZP'&VP>B-&6VMB1>8:O#*=6U[6(6*IHGY?\.@P96RDP?2[U_HK3.D[
MJJO/+9?56HUV5;H?:)6]GF_I9\$?1;V*P\1#09H&3AH"/P@P\()N<!0"1VB'
M5-&0EU74(_;FA>[16PR^]1<S0+!^7I4C^.;H%_"!4A&=0_\%NF[WA$XDKHH]
M8D:NJMHHH<;;DIRI44Y2/69%N0+0@XAX) ABB /6LA+B?F@<8:$#C$H&-%,U
M_VK1*Y5,7@^H$$P-Y"\BEV=YOX!6MI"DE5+0%3^#3HJ:)*224GQQ=5_L1KBK
M=CBK'TA_.<8?^>.W?+>*(Q2%?A1'B<^ZN:4^3NU^0#?A:P^N8!C->CC $>@8
M.).W:3U;F#(Q%>MP-9>I,&36 ,WZJP7'&2%4\"C0>G$Y/N5Z+\[AE:\!XR0#
M[VBY0MH,:,&HR)!*^2,EU"NW;.Z4.F1;N/G?AWK?[-ITXQ'/9<=""*"?CK#C
MAM FW7B8Q#%7&CM_%,U:/<)F94=P0KU>YW#((=R+T2>FVV/F1KAD1'L>A4+M
M<A>B4K9=[KL/XV^S&^6>MOJ43"MAR@"55F-'I?H9$EMU^)IM\_I+OC_L2I;%
M'U/Z;E2'=4T/4QMY21PBD!#?]_I1/=L6ZEDR=RS->MTA$ULSF,T?WW+!DM0)
MKA0P9%8'K5D-&"T.B&:#:M8#SI UL12@BF8S5@&465/I>1C5[]A_'(X")< +
MT@1"+TVB-$+8MN& P;$)5X:I9V3S=^X_BO9LTN0B=5OX>KRS^#8^CV,6W\O_
M.'$T4J^/?IX]?0G;)/;U91E4>X\S]@(2$<?!01"GMAO:#H3]V'Z*7/&CCVK&
M%:^ E#CLB(8#CATLDW9"5-W5S,NT&5F08IND[FH68XQO?:UMGOMY5WTO:CI^
M?5O1KS>'];Z[4[S'T%QZ2)_(VZK)VZ[+[B__(\]V*YND=@ <Y$:!G2#Z)08#
M,#OV//Z%N$7@Z%ZQZZX:/%IA]7"MV\IJISK79=^%VF*81=:BEG$9S[J?<=X2
M7"!\ZRCJG\X$J[/AN"W]$SI19.71.&=*+E'V%WT>G;JOV'>-4W>=4W>]4W>]
M4^DOU8U3B]+J[EJQGJE)L]<V5?!Z<A%T4:>9L%JZK,'5Q5X0@1@^6N3EAO29
M9J8[!JA>V3:R09JZ=NS' 2;80V3(\E&0$+ZCL4L@X1*/.6=?Q[M$8[5O,#82
M+[+OIMLO'!':!(=(A>:Q)X1CLIGN$HC%!KE-+@B/W2<<?9\:]['8.WMC<1Z1
MIZ+N0NXQ(-PN96FU_,,O$&#[E@C]9L73T[;(-_ ^8UTUSR$<!W_L)FZ 8C=V
M$C>,0LQV-#ILQ'419Q>*93%I#[J])?^]W_U[J^F%]#QK.==Q1&.S?"85EWL3
MAJW:S@BKLX(O4AOO3(%8;:13Y:+V\";2N-QMQ'?>S3KO<@5RE;-G5>R>"N6+
M>\^ H+Z\S=4EWY>E OV0@ZQ".[$=-X$! !$D=I1&7I^"D,AQT5)AGA^1(4'^
M.'%;*BH(.$UW@%?LK0N&=Z/=N%1HU^/.BP;VX\3\HF%]8%9+4!?WV\\>TB4L
M5A;09=E66VSBQS@!'J!)A.VET$V1Z_1%T21-(B#:>DO-J.*E)L+-MN@?_!]>
M9<)+\L]49<)MDU25B1ACO"\B.R_&_G_RKT/QG>9[5##HV']DNW_F>]9(YBMK
MU=?<YWR;_]@C2LH_5S[T0>A!/X$>Q@0!B/SVBC!HQ]!-L-@%/3H0B+RB4I?W
MI$5)G5)DV_&MP6)G"[0P/YT,FT*Y8#D(17K5GD0= ;YJ:FJ/F*TC:.LO!MMJ
M<"]\.$&"V0DIU>DG,X15JX75<D^]F.@R!/MG^*UNSH.M '9M$J1);$<.<4@8
M(=QVG"&N'0?>N2FNY*?J>V%;(-9?/92%W\&7/$R\7I*$F?'FR(*OE#PT@L<0
M]_1=>JBVE)*Z'9!=+SAJ63>\;[%+2.([26ICZ-F$H!BG_?A)''*UXU0_JN;"
MU!:<X,E$=93RJ<MEV!03GC'&_V9U,L1@OFR7>:GD@)O""<U2[P8SY$R#7:_/
M-6IBCE<$85WG-./HE=:'H1T %*=)&/A!&'D >$[@>(B@ !)?\)93P0_7/C^"
M7[\FMU_%)$V4(#[=TLB,8.E< ^1B6=%+'B841I(P,V1$%GREY*&1$81NZW08
M*X2^[4"$[=!Q$8$P"2.['PL31TH71,?0+@]]H4G6P/L?,CHAS)N(7.@D3$8U
MKH;2G,O*QRM>SJJ(+(\FB8FT#>]JRCQ&1%9U8;EYO=JQQ]ENQTX7MU<J)Q%
MH0-#XJ>1E\(D)F[2C^W!"(FOX\X?4[_TL'5$MG2X9E_D1Z3++Q2>9>O,TJ Z
MMLUXWQ3;],[RGVK&N$/]]ZS8LC7&M-JQJIKC4B.[[OSX7:<.*P\G*/4#@-,D
M=3#5A\ # PH<$Y%E$-5C:UX,&:WHUP,VP01!-=N<J<,%B19+*AB>T7[)E35
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M?W%'X_II@KS 3@+H.<!W0]_%83\N]D-;9+5W_FBZUW2'Z%[U4*TMPRH_=5+
M,)^L+4NNF*X-V*P&W-6@;<\7/*YPCJ^IM1QE7)LA:PKM>;V^HY@IV672T8#$
M#>S(B3$DGIT@%& W'<ZDN]#UYJV4"@RD/2MK-SRV@ZC)B]@,-CG5:QD:!67K
M]8;1A0]7B29?"D@U1)\4&')FX5F:&XFUYQ4@'H&!9P? =0" /CL7,JQN8S^2
M7'0^^[F+K#:K6&4^SY#P\K)2<J37E2^VG,RWCLQ-DAFZ((7\],JQH/7<MT97
MCX]%>ZJ9793;[!S?Y^6:C>BPFV@ 6YD&=N!@0@#"Q^PG%KPQ9LY(VK.1$;CV
MHN@Q/#&EF,4HGW(L1:68DKSF$'-QJ.>F[=,$36B-"EK-T!XEEKR^2UL9.[S:
M]/:XUE#E\KG:L;H6N-_OBF^'IF'R;<72) J+$D4_]/[_8^_=GQO'L73!?X41
MN[%;'>'L($$2!&9_ D&@)V]D5>:M=/7L1,>&@I9HFUVRZ!&E?/1??P$^)/DA
M&0 !DIZ[,]&5F7X(W_D.\)T#X #XN!'SBJ(^GJK@%"<P3: ?HA#3-,84G9Q5
MYYJ/QHX,SKD"MC9H'LP:VT-J\CACU^@IZJDA_W=WBO6TF+"SQCLUQ]M5WE.#
MO-ZBR<Z.V77(!06?R//S$/VIC*]F,?J&AI9#@RF%*?$A##E!/((!\;/#9@8G
M0/%E7@L-.9?\M*Q$ /<^KHJE%)6_MD^6'O2F:. .#0CJO)J*NQ-"APOU"U7^
MDD]Z@-?HW@$+;,]5'/4->5/H#+E1O_._VXAM6OY[OMX7BR3 U ]200D)&*20
MQ5EZR+QQIGF UZ0%YS)U .75$M65]YAOO6\2F_=_^G_U_<![++KGEG6O^C?@
M4TVE7!.I)T]'!K^V##: 1"99U_MB-?:E_B^8N: _0WB<A_ ,LN#%S?U#V=!9
M%JPV)\U$8AZ?0 (Q(7Z<!(2%<7]@)$O$%%]_+5#KXT=9 !0SJ=<5QH]-)4:?
M1_450&<$ZB_[">:F5Y;GG+RQTF=$WSPTQ1S^*VMZ WA0OC1@M2KEQ"]??\G+
MU<<-S1_+7;Y>(!BE+.)^E'"4$0!HQ'#?&DM@K'EK@&$KSK7E"$P(2[GZ4&Z\
M98M-\P(!4QK5-&4,_O2DY80X"<D3Q-$WB'-SA\#KS%P0F*%<SD-G!EOQ_!H!
M*ZQH7%6R?]BO\UVQ:@HJA-@];HO[8E.7WXJ/FV7U4'RJ:GEM]N?;Z_S'(D.A
M'V41X1!$@<\B%N!^TI;%L6Y=O.W6W:O4$7!WM_7R%+*W%FBU+SRQZP!%'9N0
M>4U].Z&\K>=Z@M5KP7J_2+A_:9\RJFYE_?WH5ZCH$'I)%AVY9B9RZ<JZE[>Q
M.&1155Y_+W9YN2E6+-]NRLU=?8(J*V[+9;E;,$Y2$O@Q 7$*DCB0U\+T#6.0
MI'J*:J%!YR+:8_2*#J2>8MK@5$TD1R933Q</+/;HO%].I;(#./(3;F\S=D'X
M+-(]#ZVS:5#EK&MJ7I"Y+?)ZO_UY,A].$P1 E"*?@YBD\BU,"/J&"&5LL2GN
M)# U!3-H0&F0X7:0G6)1KXOM,/5+7_E.Y'VUYMM-)LRIZ90KRLRNR>RY.EWL
M&OF6S!=\7%"= >3-0V6&&/#\BLRA7)B7%BR22%X30_V88\11"C*&^F-$&6()
MTRFI-_AXG0%A7%G?%Q,\KR/XO_X/!(+D_WFKFF"D+6^MK6YE8N<Q6(88\.;6
MMB87JH/EUW)3;9L2H;;L9T$23F *89BE20HS E)RB.Q^XFLN"6M_O/,)PK/2
MO+(#-G)]]'->+@P+8PKG,2C,X5>6NM(4-<^+,!8A+4I\SOV$ T@B__",>X9$
M[CPLXCB!-$J4FD<4,N'/>=6KLH/F,;#'-MI)E:LFY[;>W5H$&8S2)",!2A",
M490D47^6+&,8(,,SGF:-C3+P3PY^-H>33(I;A].J-N<=E5&]&?#K+VO-ZSFM
M"TIIC=EY:* ]<S2?S=+D23GY6=X7J_VZ^'Q+A4[F-Y6\GN-;0;9;T0>+_NA9
M(Z6O?_M:_*W.EU)^ZVLIO L2D8CSE"84H#0-HP10Y*=!$M$XCGQ$=:X(F@">
MEC;JWRGTQ [O!&DSN$__W6Y/[N[SC??TE_[1&'*^EGTVCE;3WIG[6$^M1W"O
MFXS9NA,N9<_3>7P>461* IYGU5/[0GFK2/STY]N3ALF/LEX P$4\Q%E*<"J+
ML6D2^%U;, I@J!-LS%IX!_%"VJ$9+@S95MQA<D[T^*)]F6,W&U.OT7AI;VH0
M[?-0SH$V/-^ALL"(<FWD"T7-7Q?17XN'FV*[$ @ @SP+($O"$*%49/H]"AAE
M6C=MVF[['6A>5CWDY493]:S[2$T/IW3/^$KYEF?<%%3J47RIH-*1L^:AK\ZL
M>UY0Z91%]3-WK^>T7:. 9B +,(LHQF$4\3A+6-=H0E&J];3=P*9&5=P35^B>
MO1O&IYI<CDBE+77\1XMM9-&[3-0%C;/$\#PDS98Q+P[R6>3H+<&Z*<N;!2OK
MO.P^/HLX!1!3RGT44,@(0+S_>)]F2O->[0]U+$(-%#7!T>?CLK0XI4)/1!H4
M;PO&0#I6U7(O>VOS5N$TM#R!8)N>9WHJ#6E4TH>AWVCD<]->44-CZZ?5/7/8
MU4"O:VC9US]_WN??_[P6DX3\L=CORF6?Z3$:1#1)HRBCS,<I#F!,^L8BGB7*
MRF;>A&.=ZX!YI\@TQOD ZA1$<!S6]"3Q-<),%'( <QIZ.0Z#9NIIQJ2:F)ZU
M^YRT#B=J!D)KP8C*:N?122@!]'&^6:7D-Q#Y0==0R"&-"(@RG 0$A&$4H+!K
M"*5!&*NGED8?[UA\.S!M*<VZV-P4RZ(6HT@GT3*C324#=<Z89BXJ\314];29
MY*5F=.EDJ,YI,\Q5]>E3S%M?,_AL!CN(G1E([$ #*FL]14-:R6J_S#?[A_SF
ML!X0$4[\* 4^)B1D"4:X;R/ .%)65>U/=BRH1SP:FJ!/CX)Z.F5&3SB/4$P4
M4Y\=#;%TRI*93NJPI2:0SXT\IXW&9,Q %LVQ5S:Z@YV=%HWBHD_EIOBX*Q[J
M!15 0, 13V$4A@GA.$QZB+Y(DVWLRS@!]@[VS:4Q7F.-YM[YN!X>ME,TN7-M
M[2O9]>NHFU F/C#8LG+JZGEO<+DU77$[; 3^U=8Z?CP6F[HHVV?]5C<_Q4@Y
M 26R)@@ "G@ .84Q# -,.:&'1B$@ZNL>@YMRO='6 O1ZA-[-3Z$9A?<$I,X,
M?SBW*HLCH]*JN5 R/T9UUD]&9=9P+640PXK+*F_Q<':)Q1J!,YA76#2F<M+)
M]%5?.'U=+'?%ZGNYNR\W<KVW#4[5;=E<WK<@ (8(1''BAW&41D%$<-RUC5&F
M]JZ]W19'B@$'H%Z+U#M"E3=?MF#UE<L"X^HA85RRS2+#?'G6#Q3C\CTL7@SC
M72MNO$G+&^'#'JWSB2(6;7HEF-AF3"FF?"E$CQ/=\:ZH;F_WN[T(9L6W8ET]
MRI;E17[UMFBN3MQ531'- G(_8B&A*.4XBF,DSY?T&&"&4N788KUEQS'FB%<.
MM1:Q=P*YN?:P]CK0\L$NW1) ^[Y0B#J3ND$O^KQ'#VC$HTD]81:7;'M$+4+I
M$G4N4CDC? 81RYUMU1A=5O.^HJJN/V_DD]+R];SK8OM0;MH!ASDD#(> A#AF
M613+QT#[]C"1-V>J;ZZ8M^(X,DE@7K41PZPN!&7WS4+ZTU'88JZ]78>ZRR!U
M!-("V6K['./PK!=Z>HI[5-X)K)%O+SK'SH7MA.&,SF-OP((=SR\JLL2,8AE-
M_WS-K^6ZJ'?5IOB2_Y0C=(%C%$809S3"8<Q!%J01Z%LC0%ZHIEQ08]R&\]*:
MPV-,#STT[['%)C.#KEA4J[+$G$^%S'@D*O6$Z(3% RJO@S42=5KE.:-0:%JH
M<[Y#_G5PR<XYP\\7[PRF:@9IIPTK*KL=2$.@_W@4YFQV9+-ZWEK]:[XJKJLG
M^\)?\NUNTYSF)AGC"849]'$DEV;\?G\7!X! 9>UVT[QC6>] -SGGBV%4>P\"
MN%3W)UOF\GU4B5U#L!RY1B$,3.\5O0C1.T0 ?ADB:D]B]JZK9Q4U7^;B$(W@
M,KUCS.).>Z'L?L"X&1J=C)@[%[C<NF$&,<VQ@=5H75KW?;9V-4& R8YK"=U>
MQ0*$,$AX%,8!QC%!/@]Q?R, 3BE2"GIV6G(<WWX_MZA2M/AT'V@;1*K: LIX
M?.I%IB=4GB#SV!M4.GJ/[0)+%Q93[+ [CP452[:\>(#-'D.J:O5E6\BWL;M&
M1,M-\3"IZV)7+R !V$]YY#,NUW.R(*;]*0 20AKHB-6@AEQO4;;8SB\$=YJE
M^:KD,&[5-&LT6C6W'#M&^P(,26A;EMY"&U>R+I%T0;&L<#L/P;)C2N6@[YG>
M5*_X&&]S&?%U\6.7"CK^7%#$*<\X"#,(PSCF61RUU859D(FD3VF]>"PLCD6O
MAR]WH+4>Q#:]<MZ1Q]1T<D[.TI-28S]U=\A[T@BOL6*RZ^2-.+^@S&-Y<Q[B
M/9JU9V^%'X-E]?GU<IW7=7E;+IOUH\_[G1+ 9^! &$2,H)!'$" ,(AZ!K >'
M4U]S(CX*).<S]J=6>-5^IRXZNO/Y<9RH.O&?G?]T5PB&N&[R0&&'_XMK#Z,Z
M>!YA8VRC7ZQF3,"YTG;E*\@JU1!';NJFY&7!$Y! 2.($!  ':4!BQ((DACQ(
M,8GC3&6+;!0@(ZK.9RW5Z;/4WA*=RU'&<:'&IMKL7&FVQS::2]4VW&RP>F[_
M;52/S6 [;EQ[JZG&QHB3B47 .88LS!C@(BPQ! @)>TS(AUKKXVZ1S'KJ8/:6
MH6/7C3!SL.JU"28,[VF6X&IRH.S#_P9S G5;;4X%-!E6?HGKV/QOQ>Z/S;;(
MU^6_BM7'S;>BWLG,Z6]YN9$AJ+\?$F2(^\0G/$4PI""$'+<P*"(4:1V)L=ZX
MZV+% T+O3@"KO5_6 ELA4CTA'76QW&^[IZF_Y>6Z64NXK;9>G:\UEX7L.T5-
MQB?UAYYRD\_TX]43G9;0NLS[RLN*FYWW]> 1\9.]2SX(EWR0+KF258O3O4>C
MR_4%Y7;FMGF(M3OSGK_#Y99' TGNVQ-P:%[?\W7U_=^+U5W1]MP.!28DX8QG
M69ID,"21B!!!CR+A:H=_7+4]I2 O!6KO5L#V[B5NS:H5ZU[0EN#1':"IP.>T
M5^"]\B1B3T+V&LSS$5L55M6TUJI_9B>U=JT[K[0.6#00VDMK+UFQ+;\U%=/_
M<R_$YO9GN;DC=0.2_5BN]ZMB)7^SV@B\XK?$%\0/?*FV,L4GN]VVO-GOFL7\
MJKG[<;,3'A&H[CYNA.*)P-+92"')(I9@@&*(_0B3 $:]C2#VJ:&,OP/+' >)
MO[V(#)MBYY6'H-Z&!^/H\ X(UH\][\"H<2+;FZO\<J[1\^$="?'RNH]\/2G>
M@94K[\"+UQ'CG3(C3^X\Y<;KR9D^@$[?-=3"\_0XE;OP[(+_>^+N?&KQGJP8
M9;N&_"CK11*#.&4LPC@!4009IA'H(?GB?V/LUB@!F?EFC;1AI+T:-;^YW:JQ
M[K)Q=VHN>VM6&S42JH-]&BT'SB,BC6.JI5T: WY=ZWU6/8BYSR)"41S%A,=)
M'##&TY2GJ >%,=/:LG$,9>::WUHQDNJK>L^M[CMPW+C*_Y;/9J7]+5@'ZJ_I
MQO>M_[K&6HH 1AR[C@'=1"1.0$@RFD*0^82E$ 41/$Q$ %=Z27PD*+.. >-(
MOZK3W$J_ W^-*_V3+)4-8]N!]&NZ\7U+OZZQEJ3?B&-3Z2>K?^[;K0M5>)\W
MQ_6NDZ?%4D1"/PNYSP&#,<\(CL(>;DA"I5>^)@<Y=K@X&J8I1^)W3PP<\+KD
M=/W!+-[,LBL,C$2C]H)1XI0M+VE$L-$[QCQCV_@TO!'U)O*+:CS\K=I4CX6\
MQ$[NM\CF^\NAXC !''$?QBB #,&8A(>I5XJPUFEV\U8<1Z138(>]Z [;^5M)
MG&C(68XNB,!P7N<QBBW84=GN<7KCJ#]=\*-K)BTVQ6VY6\0$H31).81!"M,H
M830D?6L\"6*=463:AN,QU T;@>MP-]<O';21A] 9@BX,H*&4SF/X#+:BLMO1
M=*=DWXK-OJ@721@%#"5I1C),DB#  :3]QT=BS"XVQ9T,G-<Z,RG%SU8:([@=
M(R]@* ^5+]MJM5_NO&T':^PLM6WU8E:IR=<\!H ^[!=9FY'=JEW\<Q^*N@%5
M+_R(QI#$-,AX&,81QP$[#"6"$V+0U_4;&:?3'W#UX4'S]( !>6IS:T>$&4V*
M-4ARH@TON+@@$N:\S4,M!N"O;/4@TSLJV7_MR]W/7XO=?75REJJ])FV!&040
M92!.PP#Z/,J2+&POR!2Q&II>13FH2<>YY^E-ABU.KP7JG2 UNPS %N=J6C0!
MW7H"98=IQY="7N+N@J!9)G\>*F?;J+,W.5KD3%4/>5YN_YZO]T5[,_"O15[+
M!R\_;WZ7QY2W0I#3O"[K/S;535ULOTDD'S>/^YWXMB"O7)?-TESZL_EU*M?K
MNGH#C-(010F.$B@?;H@C"N,>;B1F/XMOQ?:F4M70R6#JR,"I1>K'.B0BKX$T
M4560*VXOR,3D[IR'L$Q/0S6S8::[5"CFFL*!9=&??4=9D/H(H(P @+-8_ 5G
M73LH)D#I(7?S3W>^/-@"^JF7?AFPI)9IN25(+ZDZP3)1A<T+-BXNEIHR-P_A
M&H#_Q0+I,"94I:)[LT4NNRSO-]6ZNOOY>WEWO^M;#2+"8I BD$2 \3B.8N[W
MK2*D)QQ#VW(L(P=XWNZ 3T]1!I.IIB]C\JBG-D<*C]"\%MM$ZO,&5Q>TR!;+
M\U F:]94;OJB;H+S95LMB[I^_?6IKNTH35,_(2GF04!(P"FCO6)B%G.MQ2H[
M+3I/A+P.I7?N^37=%,D*SZIIT]@4ZZ92;[([68JEP-S%M,LF\_,0/,LVO4C/
M[#.F= U\5MP66S'UW.7B5_,;,;64"V/M_699&- PX$$4^R3-""-!+[68A+[2
MH9&A;3A/T5IDGH#F';!I7,$^A+[+*C8F<[I)V6NDO2U5=MG3N)9^)!;-+ILW
M95/M[OCSIK\BW[;(FL$][S:LJ.QV(<O[IY\.9;9!@CA+XR#*>!SX<9HAUD<%
M(N;T6A>P6VQV'ONHGTR/6=AT@*4-53?<.]E45:%]FIW53PHG%1QX8AY)K O#
M='=93;E35<[7F_W\?2,TYKY\_%*(CBV"]%VQX#X,$D(8PRG)* @S<-CI3?TT
MIGI;I_;:=;X7>L0BAW&]R_\LO'+CB2_)\?R0_R@?]@_CCEME]BX,6_L>F,>H
M=6!7Y;KOVABS67DKLJY"<)06N^]%L:'Y=MM<U?90[3<[,47^8R.H7\LOM9^P
MX#'P,XA@@((P@ GT 0YZ>!'7NT9U-%".,R4!;+LK_]6=H;_U;N36LK<ZV*%9
MW#J>K]32IEFZ22^I.I=(77E',[S.#J\WQ&LM:98,C[9T2=D<Q%O?!=K:[M#+
M<Y9^EV8K10;GO"NM7;:?_-!@.U[HW,C;4=WR$_5[++9EM5J0($@X(Q0"!  B
M/LO((89A3)2"A%, C@-")S<M[M.KL)]'!N\4N]>"UUC><^8?A973.;C&* B\
M7Z]HK,C.P3MFR[5NO*2VF&O(VKF57M=.F,$RL',3JQ$[M<GQ;GG9-1><G%F+
M^:W8?;[-RF_EJMBLZL_;K*S;RZT%NGH1^3 F00PC7_SA!WX8)JP#1G$0:=T<
M.@(<QU%38O>VQ5+VV)6\R.5K_E#O1<:=EE7Q*,;^/ZM2Z( LL]MO-6^*&\-9
MJD43L_*3;D7%R=,,GM2"\VO4S4M%<CI\L$-HD??$DBFN AC"_,6*C-'<.H^)
MTY@&OWH7P8A<6PT)"S^*,@0SQD3#D*=AR!/<MPTI@ ;GO.TTK*0;P\]^[[=>
M?9]OFZ7QYQ+_])FY&>K#4 E0=L([&N7J-ID,9$W&E%\G.US"Q:OMZ0KN F<1
MICPF(4RS@(* H:BO-Z 4Q,Q@?)HW-LZ8M+R"/8!;M23*,9]FSUJ=P!CY]:AS
M;%P0J^$,SD.@+-CQ_(4C2\P,VYJK%PRS$&#$_,P'!,<I!0GI6^,X!<-WVMYN
MPWGY^V%UIWPQW;.Q::; XI ],+L$VMG2&GE2I9\F#:5R'KHSV JE;2!=5I1V
M=<3XNBLV30I>W2ZK1V%;U:R6;:O;<E=7VS;[7@0A9H D+,8<Q!C&*8NS0]Z5
MP$AY%\=6@X[5J(5YG)LLJP\'J%Z'52YAM&@U-@2L$:ZP+3,%UWK"-7^:-?99
MIJ#;;%_%$NUJ&RF*M)S;.+'-Z@PV2JR;5#GLA=KO?&_WQ>IP0VA1RS<[]UOY
MP/B"\I2F40!)G/A!A@E*8M V*1ID,-1\=MN\(=<U8"TVD<<V*^0[B4[[S>L!
M-"K.F\=B4'/JW)%WO#:XD-L'!VBC/\9\EJ1+,VH;W,XCN;5CRLN7@VWQHY3F
M-G?I][?JDIMZM\V7NP7G20P12C) TBR*01R M&F(!3!+PK?F@P,^V=WP:9_#
MZ %Y_^@AZ9P4-&1+(U5RSYI98J3/GEH.]*J]YS*>8>3,(+\9:$!EK:-H7C1>
M_<S7AY.&HH48D3!A88JS"+(L3J.N#103JK7DIO?)CK.3#HSF.TAZW*AE(.YH
MT=/,#L=4C]B=LG AIS!C:QY)A"'VY[>P#V! /4U85MO':IN+D=7)3M>>$!J8
M<<X0#J,TB0D*<-RW1PGCRDM@@UIQ+ YM #R >_LE MLDJJ9<8_!GDGF]I,[D
MKH9A'.HF8F-P.20?,^%4(R\[8_[%]&PH97/)T@;;\2)9L\.,DER3FYN_E_U[
MH#Q)Q,01<8 (2R.8A/R0$V(:<J7WR/0_U?5*4H-%0SCT*%$06V=L:*X*-3!,
MI%2/$0WI=,:,F52^T574]/#4IG/Z9V3W#/3.#'<UU..:-[J6]7)=R?NI/]]^
MJC9WG\IOQ:J]M_K?B_6*5]NO^;JX+G[L4F'8GPL,&* IQIBF$-( Q#2E+0KY
MN C3>E;8=MNNM;%!UIS([6\)DO<DWPNHWFVU]6H!5O,&6-ODJTV#I^1=3X6/
M2.6NH<3J-6"]SA<2[@?!_0?)???8AR>!>PWRL6^/U>/UPM3;E8?F,3EW9MWS
MVV:=LJBAL/G=W5:6Q\I'YV^[I]V:OGILFX P#H((P(#Y#"*>)KAK.\P0C)6N
M8[3;HNM5P7YF=?-35@#(9PBUQ=,&K\J2.3*EVD)Y@D^*98=P#J+X-G.7I= B
M\[,10)LVO90]ZXRI38\W^?IG7=:?;]N+(L2?FQ6]%_VT:&[ E6.\ R,OPMU^
M*^IGH'C,_8 @! DG\K@%#BCJ086<*9U)'0F*ZV2S,Z"IEFIP>Q\WWK;#JC,=
M=>\4E5G]K/RAN130N^+S;7\KC_R;F ;0@V/ZAW1[U>V-T)'?27RGL_XP*Q\:
M+EJ<#*N\]:7\F_!E-\C*39^-]&N_AT'WUZ%K'4/Y.[M ,IICYK"J,IZQU22=
M7R/@?MT_/.3;GY]O7P?P<;-<[U>RZHE6F[I:ERMY0B_-Q8A8%E_OBV+W'&.4
M91$#*<,9XA$-.*.<]1@I3K!R_!T=F>-P?%WM\O5!"62A98-?RL7RQ +OIC7!
MJQL;-*1^?%<J1.U9>U$OB'>FR,A]-E;W]LB ?FJ1UYGDM38-B^GC.UHCQ,_:
MX681OW>\"/.[9A"?"^^J@WIH&F";XW-9P62^G$&2,)WMU1Q&DT8*T2_#20+S
MS:ZD&?#EKGK^6.QWY5(,EKMM_O <2 QH2"BC?A0E <:I#Y+PL'B0Q4JUB@Z;
M'VOILKF#2,+^('%[)\"]'KE&9'#D"H4X/[T7](*YC@.&16M'/M$(R=/[QBSN
M6ADD:A'5B*)S8=,MWS.(C8X-K$;KNZ;'<9XUQ^(TS ),DB@.$A! ^7]]<R1+
ME"H:!C<R2I6M:6VM*7$*D6<LSO3BR_-3.4,BR" &34\X.632SCDGXTU)E?-.
M:D)O@[ 9R+D5,\Z>@!K$B_YK:%]WHI7T)UWG==OT@F20$)0AFM"8I"G G+9G
M,[,@H3[5>O)C2#N.!?KTX:T&G"R+:.!U8\7X?3,#2M5*(L9B4W.=SYQ(QR^6
MO6#I0M&##6[G4>I@Q9*SCY -94=5H9H&NN8^'5XX"SE(>$90&&8QI!F$/$N[
MMK"?$JT7P\U:<*Q*[;@YC"3SYQ8-^5,3(O?4Z4F0"6M.M.=58BZHSC BYZ$W
M VVH;'8MS2Q(-O)[\2AZU7U>%U_:R3'9[^ZK;?FO8M7N.P>+%!.A:91AEB99
MG(4\3+*^=4J)TKDCVVVZSHZ:@73$Z75 K[PCU*XT1S--LL6Y8LHT =V:Z9,%
MIMWD46K47<JI+),_#[VS;M7S7,L):ZJ:>+TM\GJ__=F@^"JO&*O)\K_VY;98
M+4#$$II1(!H,0T:3)$"L;Q$PIG1#I(UVG&\V'<9B<W'>PT.U\6J)\\K+=^(+
M]>ZJO5AOY,M7+W!V813:8'H>(\^*)97]?J@WPK[D/YN[7GFU/?:TS[>TZ6<-
MC$6 PB#+F/C_A"99PCGM;IX6#<<TB'4&FH7F'(^W'F%SI&][=O"-.];>INW"
MD+/(^3Q&GDV#*F?]TT;V_WOQD)<;^?+F(> >?Z8/O6%",8Z### *HX3 .$.D
M!Q0DT!\^(; "P_&X[2KSMSU4;R_?*/7D@/(:)7TEJ[4Q6;#CHB'SA]&]8VM*
M<0!^.KDX^<'YS#-4*-:>>ECUVSR4>0Q#E28H#KA5OI'X6UZNY5IT=[[X:['<
M;YNK K+B9O=KONO^=;A<,(M#GG*?<N#S '#N1QQR"&*.8(K3$"^^%=N;2OF>
M8MO-ZRC#*5*3"EU:;1I0^WSM':'^FW<PJCGL+\WRCG9IWG1LW3UJVCVI7_04
M^RG;]5.VKSR)]\0[!I>66KHJ69/1"P+MS#GSD&5WYCV_9MDMC[8E^#_*W7VY
M^;PI_K/(^]>6BA6M:@$,^6$6Q!PG*4Q\'Y* HAY8C!/?C2@/ .1<IK-]<SJR
MVA3>3X&N>:ZAJ(4>Y#W.9C'*C1H/\91=?1[)17J*W4CRJ4:_E/"K7K)_BN^N
M&T42'I,G7[^*-$E(?/]M+Q/?N?*^-W9ZPE!/6GKE'6SUZ"4W3RKUYYUC0?PM
M>/Y]A0,;!AL&"&M<.PT9/"^W?\_7^V(1, 821 &/XC"(4IY&C/>@*$[I".%"
M'<QTH:*H=^5#(SRW JWW3<(=(6!H^,EAL'#CH/D%"FFG]_>+KIU/D#@XQ7:
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M2V7^UYP@3,(@XAGU8Q!2'#*6^ICU*&"(,AWYM-VV8PT]POVP/C>(#8Y"6_>
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MTU@G&-"&8]T^(#O=-]"IXAC GDK!S3C$:5;/O,:9R3K!$/)TZEG&(=&P..5
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MTVX?IDD6HH@1E* @ICA.:-\P)'JUE!::&UEAGF(TW%ZRP;*)!#DGV%22IMH
M>IL>98$:Q.T<!6N801<%S )7JH)&JX>'8BNW<K[DC\6V7SH,?(YQ2!),_2C%
M$87DT%;"2*1WFLJL#>?+>$=8WJ/$I:=1AL2IR9)[QO24Z(2J!M!$-=^OTG)!
M@8;1. _1&6A#9;-CZ4G+[T5_APVYVQ;%Z=8$ 82Q")$4^FD:04Q1POH&LQC$
M.CG2@&8<YT:?A2QMY/OLWK;X)G]=_'FXUB<_@-73G2&LJHG/2(3J*= 1E'=$
M-9$,G2?H@A998'4>@F3#D,IZC].3IE^K3?'SUWS[9['C^\VJ;RQBXG,Q8A#@
MR,<A#$ *CSH8:,F281..):E!Y3TTL+Q;B4M/?4R)4U.>$3C34YV6KA:1UT":
M2')>9^:"W RD<AY2,]2(RFKWTI.8K+C9?2V6^VVY*P\W1[,HAC1"D"/@<X89
MB-/#HE0&0:@WKS)JPGUUQ'VUW7T0VO3@K01 KSX@U),:,P+5A,8Y<WHR(^%X
M1SP3:<QKI%Q0F$$<SD-?AIE06>Q3FHLVK^Z<?2HWQ<==\5 O$ASQU$>(\300
M""* 4=JWRC.@=59K:%N.$YH+^\D2H]> U%Q^'DROXB+/B,QJ+O<,(]7-VL]E
MMBZM EGB>1Z:9<V:YRM#5EG24;*3YLB.YMOMSW)S]_=\O2\.-Z*@4#2%L"^F
M@4)"69:FX""C"4Z)YGJTG4;=9U+'6P%O#Z>"VBM+VJO_JFUY)[ZQ%A.Z79\[
MB!]>%W7M[>[SC8=];Y7_K+URLUSO5]V-@=V+&<T ;_Y2'+G0%TH;WE/7RY'=
M9B";)PBOO'SG]2"]!N5D]SVID?>&BEID?SYB:M.H5S35.F=VI'41!7X$0\&9
M?' 9(,H(\ ^-1C2Q*:EO-N9^K\^ASKU-I0U]L\JA=5V;DY@9BY@RQ>]!O-2-
MT1(M38[T*]3)M[Q<RQI07FV_"@C'*75;&9K@#,:4!B!,."(P083B@%#B9S'@
M&4%F5>I#6W4\RSVMH#Y _7!;;3_4 NR3I:-AU>J#V5>3NFF(UU,]>YP[KEQ_
M@\(+<FC?#?-01@=VG:UBM\N<VK/DU?:QDH>(GBXYTO;6OG[ED08(1B1E <XR
M$,(89%G;+@Q2',4:IS&MM#=".5>'\OFV@]<!U7E)VPK#E[5P&FHU,[\#I\^W
M*#J$1L^46R%7YZ'RL4DV?*K\K0X\]!RG"@^O1 O[',[@7*==>RI7O6UX5/BM
MVCQMFH@F*?93EK 4^7$,DQ#W34-Y1_'@P*#=Y(2Q06#]L+05'_2Y-@\13DFV
M%24$2 >10I_FX<'"*=U#X\4%VAW%C.=T:(8-8S;G&SG,35(('@/Y4HH??ZMD
MN;+LAN>"5A9EB&0@2Z$O'_N!:1# OM$0,*81.88WYCQF'"$.FTM8X%4A2HQ+
MJ%Y\.&'2S@S" J4:$6%<:LUBP<7..C0&O$G .?6WQ]P,=-^B,963WC50ZU_$
MF#0+&$(LCA@/(@[#E--CC.'0'RCWVNU-I/AF,P0[#!L*OU-J;6C_":>V]%^?
MW($AP"G)@Z. F]F "@\ZP<"8PYG& W-[W@H) YE2B@J_5MO=77Y7D,VJ>0FH
M>?\GS9=_%JMSL0F2*)5[&BB&,4Q!$C"6]B@( HJ%>:Y:=QXQ>LQ-+5W5O(_5
MU.=Y-PWN81,'%^Y0""@3^T$OO!P<(-!VKRLV>+T6L*7YA@M/:$2?B3UB%HOT
MA\;0X*1/T[E0Y9#P&00NE]95XW1;VT'M172%-(A\D&409002E#$4'X!0$*:V
MXYHV@#F%-K,9DB/'V(IP3CWB+,@-W'!QY!/;L<ZI;P:&.RT?C1+R5"=H;JE_
M+X'/W$#MV#>02]7:6EG,N_OY\F@J1W'BDSC ,4LQXB%(DD-C7.^0J&$3CJMF
MVZ/^L@JO*?W?_30^BVY*X>5@-")[>@&G!33]B?37B;E0T#J0R7E4KPXUHK+:
MN^S7\7\ZG"DEU(\YHK&?I$&6H(@A0'L,&4JU+E^VV[)C97I6L''U6H&Y^?EU
MRTY0$['I^-?3-FO43U;5_TGAS+L;;\Q#'QW99E#A;\J@JIH^;_EI41!9BHG*
M?IWOBM7?ME5=_['9%OFZ_)?X9UYNTD)TY^(Z_['( @)BR%*IZI!Q0,*(]]AB
M$G$=E1T'D6/U;;!Y^P,X[TZ@T\P(1W*-FO;.SRO6-5E\[6B&UWKP:(@G+;GR
M;AI;/&',N*IMA?\+:CZN?^>A\B/;7$TYHL:)"I_$OX[8$IK ,,LB1 (_2WA&
M"3WD_RECR6)3W,D/<1L7]# I*1!N%>@4OGED6(M_ZRX6C.0?MZ'!@6,F"@W2
MDO<7&I[P[R TF/GW?8<&0YLMA88AC)N&AB.NIR@7@&,<! ) &B80 X0Y"@\;
MK5FJN+]IO5GGNYH\+[?>M_%O+%%E2&.D#R9YGH-YN%EOC%=+O T?DN2AVNZD
M,M"JWBU$HIA1D&$4LBA. A9G*.Y;3S#"BUVUR]=#QZ->FUKS\ ,\*_LS5U[>
M0_66 NNP%,R8=+,D:PR^]=*HBQ>8B 3JP+7$Z:5Y79Y/>D<6R"<4&NFCF1/F
M+H^&5BFKXQ#6+(BCXA2;$PHQCV(AV4D6IR%*(W X'),1,F1QTSZ:"3>\K[P[
M!\N>#APV6'(G\)5=,7X_"YTN%SG=>73VRF[;7G7-=\*TRVCP=%:=,9\DG,"$
MIR(L);Z84ON'!5?@PWY1\]IM4- #9;"J>>T\-MA8^'3@/W?!P8'/1@\.\UKJ
M=+G,Z<ZC[S<X&-IK(3@,87IX<%A 0D$4^8&/8@;BA">8L,/"34)#.W. -YN9
M-+F_G=W"IM%H5B9Y[L-4W1#E\:?)C?I#9=OR6[XKOQ4?-_5NVYQ]J,EF]>_%
MZJ[<W)&E^%:[7%K62Y$6[,4H+W[L4L'#GPO.LB *?2QP@0#' 8WBN+T-.LBR
M4/7\[RA0G.\M'-%[)_!U'SUSZ0RU[&DV7M!+G%ZGOSF^UB'WCM"](W;O'Q*]
MU\ ?_<4U<Z8OR.LH#IR' (]CZHN7WD;C5U7$/XEYX?K7?"?S"OF*4[79"23%
M9BE0'-L&F.,L9%$0 8  "&F<M.]\)XS%?@SUU-I.F\YE^9-PQ5USF$]/BBU1
MJJ:YXW.I)ZX-/J\#V#X-=PIQ0@U58NZ"6-IE?AZJ:-FFRF5?U3Q?5-YMRMMR
MF6]V8CI:[9NFOU3K\FGC+(D2)O+C%!-",4D2E+4B2T#"?.!K'2RRTZ3CV>')
M6W'U$;"7'Q![CQUDS;-$E@A7D\$)N-;3P1. WA&AUT.<4 ?5J+L@A):YGX<2
MVC;J^2$A%YPI:^$NWQ4R]_Q\^W&SK!Z*1HP?'K?%?;&IF^RT^6K_S!R)HHCX
M/$ZS#/ $XC (HB .0(I#[L/HK:LS7#7K<+#V2*4J/H'HM1@G>XU1D\-+H]:1
M-V8R?%U9]WP<.V51=4 W-T6\TJQ<7O^M$-BN\Q]?9%%.M2&[W;:\V3?+P=?5
MEUQ>(G% YQ,<@(CQ+ Q(QC%)$QRTZ")?RI#>-&\L5,XG@NVM+,LG.E VIOR;
M7DXTFI_4!'F.#M(3ZM8SKRKT+]**OUQYPA"IXL*4*Z\SQCNUQMM57FO/9*)N
MR0\7Q'YL3\\C"(QN=37M^+(7-"[LY:[^N:]W,N+U%BQBQ/S8#P!.""3,SS(_
M13V\*"'(7M2P"LMYV/CC6<&D]TM;&_,73TC0R2UX>6^5=UMMO?9@VJ95K=V%
M4HR)G3H\Q$SF3>LQYLUCA@=[KKS\=B<^;O0:&UN., PR3GP]_RCCQFR-,..0
M=QMQYK@A5O_/O=#*6_E<-*GE?EAQ")$+%$<(43_RPP 3"&', W"(?S2+=19E
MW:-QO%Y[,:HLY8/KM^OJNW??@'832"QY;7@$&=]AUD/'B0G>T08OK[U_[SQX
MG,#,)V(H$6\8*NPZ=?XQPK*]&L'!!=,VHL(7^04Q)^JN0/U2B7E0L2NWS4);
M6FR*VW+W10RTUV*8'T<LRL3_4L8I0?+:6]*CC=,XUKN=9"J4!I7]%J/(8VN9
M=],:X54WZZX0PDT\<>KOX5%F<D=;BSV_M$;]I:OWSP3RC>@!G0V>-**?H/Q>
M+-=Y73=[5.V:V;SG, .<9!BGQN@6\X]>H["@$=/&\XJ-2"=F945YUUWFO?QY
MO17 \N6N-:#YU[H9?:^ )0FF ,81]#/FIR1A?I@=PC)+$WNK;@Y!.E^#ZT%[
MNR-.+S\ M1?#7'IR> B;B0NMSYXZN[R#FT\L:XH-3VQ[$L'F.*DR=Y)A!!NA
M5\P_@(U!@D;\&LTG(]46+""""#-$0P91  F*B'^8/E*?,IWKB5QCT5JZT[^V
MZ%K^2O<DTFO5!.TD["]*DZPY;D2[VX#^7]6=76_;.!:&[_=7Z'(7*&8H4E_<
MBP%(D1H4:-H@2;$[,Q>&&RN),:Z5M9WNY-\OJ9C^2&R'AR)E[5Q,DZ+0>?F2
M?'3X(=*ZYH;/&Z^E];O@#'39EB '!&V7'$@LA4@H8IB4.*V*G90[QHA#Z- E
M3N">7Q[J[>-7NU#XM+FOYSK%.7Z[DW^#[9++OKR%98C6&W\.;_CI%ZXG+#P!
M3A_&#P.*7DK2^&^6WF"VC]3/RI5FOE(.J:?=?YRO:M605R.")9*(,H80ID*@
MDBA-:U6<EC%L?CJTFN#ST ?!^)(&O>'C?*\,ZA^_%*+#(F?PRNP,U_YJL5\
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MB:!O:;"&+/"Y@=EJU #8 #7&@J,!/8'ATPAQ82;4%P J _KC1DA[G^RPN%_
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MY1G)JCPK2H0JBDB12%9E^HQ6&N<B!O6!4!K"=YE6=J1K/?K^HKB]#7@^:>\
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M8!G'HBH94J%BGI49QIA#$.04(#!\UIKT79K1^&GUT.B511A\W'RSPTYPRV#
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MG]-%]M/71?[/B\E==I^^+2?I<OW==\OEPS__\LM??_WU3U\_SV?_5,YO?T$
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MYB$=Z%"]1%CC)<;0,J0=H-P2UP#H,(LYJ(TPRK(C]G0)Z7"G^&5:W.9A&=V
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M9%9J\[BX1L4_CS*0HW<2=0?V4*1Z"4)C]GI?92@.0EUN,J^OTQ.5U4(:AA5
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M!'(F.&*:(*(Y4A(SHQZMGCJ&.2/48+IE3I?(CBBBM<VU0KLV$HR\8Y9!YR6
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M((UA+QROBIR]2F)\=XJ=W"4F#D!J$ .68LBE,23\UZ! :-1#0*>G4^[] GQ
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M"*SL!+AV"_C9TOZW53H/Z,V^?<@>ROD^RNXIG6B@!$(*N*!].<2-0T[40S&
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MI9D&"AL,FG$C$G-IWOZR2FXX562WE;GB%;%J:/Q'$3O[(9O,TL4BO\FSJ0\
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MM<CL>TKUA%#J/7 ,*\> X1@9KIO1N!\HRWAKL9:]HSS4FO/LC>6GX%1Q>TU
MRJ/2OM#?PC\>RD4Z^W5>KAZ"EEWY-E3FQU"FK%P;5N'@N4&C+!9'-L-A.I!(
M[96EBF,!/0$N"%JK+?J.>Q^SM8[0I;#_K7648AOL*O>4<?R>WK=XBNV\%H/6
MC2R0*JQ6V$+M$,)59-@&'XU83&+M$2[=8R/=\POC0808X:%8W*?S/W]+B]5-
M.+&MYJ%OC_TYK$JTJ9N$W4U:9[@)!SXG/>)<X7H<@(@K>U>Y=VG__^R]ZY(;
M-[(N^B[G ?;&_1)Q_N Z6Q&RY9 T,V>=/PBZNR1QF<W2XD5VS]-O@&2QKR2+
MA2JPFG*$PY*Z"1#YY0<@$TADUL/B7VJQ/+P#O6^1 Z]%ZP"-T$(8;=/Q(? \
MFOFLD9M(E_.B9807#L/O[?UC?I&-^?B43-<F\\B#XVGONO07E"90.((HY<ZI
MN)<(;';8>.RR;,U1!D3TRI=C>^I &A@A.W];)'=R=?];M'"2;9.>S'Y/-D\_
M9#W8?7!(>D.<%YXY9^."$=>*!CEMW-4%,XR$NWTII+MQ^'BL'YJCC/?I*&.+
MS.%+H1,-HSD-<83.4 L=,R[:)+Z!+YK768'/(]R>AR#4($"/<-7[1UW?_CF=
MS7K:DO?=A8BTYX91HQ'P2B,".&F0<3 K)&64=_$C6=6Z*F"$U-P$TAQ<"?,Z
M#%@8$^UTZ63T!C&/3AQO[DZ]Q#PG5&2$:>I&0L[N"K@(/=/3JM?$2)%<*?SQ
MP_S?B^FJLO6?K<\9S^@R&*T-TPHIYPU$A$HAY!8A"IPR.7>)[1\O/7U-]_EZ
MF#J<)HKEC]@@].'+&1/P"$T[]!8H)@XC:.+<%2H:/- TIU\4<(YRZMV.\,G3
MD-0<'OT1;O OJ_WVL\^_[#= 35*Q5TZ$)AA&ATY#T& EH<S9[D>8Q&XDVWVV
M'GIVK9]'"9SG7S]O'323@# /==P+A$.&&+>7A2&3PZD1)JHK[&1GHCW"U<[N
M]/EY\E?O*][K?0<HJ83,"D$!51!0D8KN-#L$X3SG5/SLW'<_D1/>BSJ*718^
MC+ O6[)KEP&@J 0DF>:(*6&ED%8T"%F35^SW_/OL>C69O5FZ%M+!Y1YDI"<D
MZ\GLZ7 N^BZ#.\V\PX (IA05!BO4A!L2@'"K2_&W&G)XZE5'H1$$S*)=X)V@
MBG.NC !*-@$91 B=E0AN/$99#QPL'ES813]_A^3V'&9G22291\YK@0E&AE'W
M@#[*,@C',SM&R^D+!?2>I?2?+Z 7<1N1L!H(PH1!@CG0Q)Y2:>V55/<>*^EZ
M"N@]3XGC#>BU$$B"E>6:48"-@!S31@X1EYGK(N/@VCX[H/<\_*_'/GG?(C"X
MX"@")IQ'71B&H:$"X117V^A!(Y^S*(_P\=#?EDI7S8_PH-=$<::WIT_)NG89
MG(]^'4).*4$9-L0BW6B1&J^N)._!J+G7_6PX1Y4%R?YJO.R/Z3(E<:D7#T$2
MC>1-1OCC?._::W!"0 2P) 8#R;B"WC3'&DSYK'=./^5VT OE"VGS9XS]\I8I
M; 56A+#H@TC% &P0(@3DF#\C#.!^(WPOH<H1VC.;J$WWU_=J?K262\<>@U+:
M8IUR.$LM1*K0A'B#CY<HIVK "&MBO#FJ#Z;)4DQOZKJ:^NYNNDG:^+%*APA1
MI%_B_^_6=]N\OMO?KZK;(QP_NZ\@)33<Q]V.*B0D8YK*1@=,&).3+6"$<>9O
M@=U#Z_"B1GJTKK9EWC=W_F<%;73J+P"@D14 ((64D-IA09I7)@Q"FL/O$5;8
M> O\+J''2T1]//K[B&(^("%Q.8 0( T5PU%CV&W3EVJE&6MEO8S@@NV!L&WR
M]N9V'20VD&JAH?:48N,E<[!!C=-K29/7 VMR;L?R@;_ -.]<+F6H"6Z5E]CC
ME*L>.F*8UVRW#%."=;LH[^$,@*U^C^8E:3>?S^DI2.20T5)*$\EJ(*)&FP83
M+]V5I,#J@1.O;,W#X5QHMKK)(MG*R]^JQ:=O$< .<[4?_C\?2(NZ18>:!"LQ
M\DX)335QTB@#+=ZNBU8J2"Y8E.CYD-O,YX-M@G&:BNB>4R\X(U9!ZV4CI_&P
M:*Q+B0<!^0JOAX'V0I.U>S+[$<Y90E/1; $@4 P)K3G;%E92T:#BL%6H[S!2
M/N0+4]$JNYW.UJE*PJ?J9KW8!.0WE<!]Y&NJ%++>*O?#EQ?L:ITKOX\O"G&G
M48()+)G0#BKK&58-HL)"?1W[>G_$.IA7_P+:*/;J/$\T??]Z!R?BHP?\UL $
M%\XR3[GV0G.E_,X9BSBG-'[7Q?I+D?3Y@_?1*/2R$Z=59/.IIB&:'MI$(X8P
MI*576@#,&HF1RDK'.4(*CX([K?C<646= Y0_K:(M^N'[-A![?NONOL_J^ZK:
M_+BY^4@9[XZ'*I_72U!<0>-X>J'MF-1:Q46AD8WXLA'T);R*_I1=EP*],Z$^
M3^^J?U7+577[,?Y_,;V)?]L,Z9_SZ>I$Q'N;MD%39G3TOH#%0C-!M2!\/^,T
MS]E^1YG^<ACR# !U9\K\,EG\4:W:DN3U3P<B#,)88>HX!(AK(BAMQLI=V0BH
MMTN+7L#M3(1'56 ?AO"I6JUFU>UTOOG1<6ZT[B 0:ZS5V%K%B;%2. YP(Y'V
M.F<5&6$4T3!D&0KM-^*:OF_Q!*:OKPC <R<9QI;(.!.=$9;M[4PE8$X,_P@#
MFJ_#Z>RJO<[KIYXLIS?1%+1IS-7M&8>GYS2/EJ2.E@ A&GJM(=)&4])(8Z0L
M>NQWN:UV2!K4@VNEU!J[J7[=E+-N<7K_ZN>#<CY*1:URBFGA!6,/OHL&IFB6
MCB$9-XS"Z_XAO@A]VM(F>(P$1\03JHFTT:P!?C_/O-575BTQ4Y_'V'$FDJ58
M\>]J^O5;G!HJSL7)U^K7=3(R/WS93(_EA_5JN9K,4YQ3B_7FW*X"=8)[P@$0
M$%(B-.+"['%UNFB5PC>_% V,_MCXN(&S!S)N^@D4&8D5Y2PZ5<A!8SW9STT'
MZ)6E?AB.*ATYV44)Y6+]7UQ6G%X*#S<*&&L".348&X-)M%LMU8V4S-J<^-M1
M+7K%R=8;Y@4SBRPV;QDFL_3@I9YO,5&KU6+Z>W2!HKO]N=Y>FTV6U>UOD_OT
M8;583.9?-^U.) S)[#QH9P40TDB*B=14.VI!@QHM7."R!%/[(-#+Y!UEM7#1
M;7IGVKR<VK?_O5ZN3M1SZ]AC< (2Z[#$QG%GB)71JMZ;U9[D."CGG^8-GK9V
M (Z6 ?["]N,A><ZW( _U%!RA1*ITP><<(P8;:/;X*YYUF7I^WH#!B7AI&[(G
M-5PH%KCS4YL1A@)[8:,N.;#, XP%Y72[# @##+>M\IH.'0K\(@SIJ2^^T4:;
MX/Z./0;A/#;I7%HKPQDR%C'68,0A+IK[];*A_VW)<C"\=TC@2RT&_[.>KNXO
M-_DW7]]FRC_Y8) & 4N]$Q$Y"RWCVFS3,UH$!,6MKJH&FNCI>OQ;/8L38KD=
M]*_UJCKO76WK/H) UCH"G0>IZ).U.NYC#0Y.L"MY@9=+@N<3>"!X"TU9/YDN
M_C69K:M?JDD:[A/ON_@,WH_F4:Z#%O/Y6+, E1%&08^BR22$X8K@[>MD00 &
M_(*/Z5\;=IL9?;1=$  P2H@C'"O"B!8 FD9>X'W165QB2^Y'^?5P$%]R)E_Z
M:=X0$YKCZ&4Y1*BS@CK(HQVT2S> X@]4JR#.@:7=/K^.QMNC@CD[M=Q^F'],
M1QPI473\P*_U?-'\,UE\)VN>]/8=P5C%H;)">6@@0L 0RAL<M<$YI>9&N-WW
M0ZE#RT1A990Z<]K+I^_W?_T_TVH1O__;_?OJ1S4[\<2N70<!1.O+(DOB@LJP
M<A9A9/?2>RVOE(KE6'.(MWVJI3@I'V]T+\4X^0#NK'X"TE8P:(U43&E.C;$<
M-%@@ 7(R2HZ9HCT1Y!#_!H"^. W?S;^O5\L-*/#@RX,6K8(VB E%*19$12"%
M)[L#WB@G ?!Z+?=^67"(:]F(7Y)9J!.ST/Y9GT?11<'(8&>@9D(ROY^G6A;-
M='[=S.J&^"69A3LQ:]<J<,>%T%%.JRBC3"-F]Q:(XC;GD?@H7]1=CEG=$+^
MI_ (&;^H_F==S6_NV[L)AUH'(+1B%'!IH]4!%?82J(>U6J'K>MPT*A^A)YU<
MTD'8C[N36_"L=; V!<TCSF6T&#;!RXKNYR M^[BIJ#.0SX06GD >VA=U0_?S
ML?VF>J1YL 0*G!YH("2($X@:O[=/H9)%G<Y+[:Z=V=#&Y\P#_ *;ZV8[,+/)
M\E1RJX-M@B1""B&A8W$#D-HJ@?< \KRXPA&6@1G51IJEB>)LVR+V"D8;4/XY
MKW]?5HL?"9N-F1I_7<]O(K(;5CP6MOV>V_-7!@$(1]P8:"%0& KGZ-X =XI>
M60ZK'IAV_(+C4HHI17U3+[[7B\FJLM7OJX=(Y).;^=%V 2OC&31(H+BU:*,(
MWKWH3K=+V%]=D-SE25,/IYY25/SGI\^+#7#W<4?Z1QWU-D\6RTDJ'FT7/!;Q
MZR3T/L*5%@']<&"/25:2]7$?!(Z%BGVJIU@*G"2\GMS\4=V>L28>:16GG.3(
M,JPA=YPC0IR6C9P,L.L]-1P+#?M3SH6LTDYV_/L6R9AZ_9Z  (8Z[B;41"<U
M^JH>X/W>XJW.66]'F$%L1+[6!;3WEF;".3%X/7Q-D%8+IX 53#IGN='$[P.L
M2%ZIY;=@ I?BX0"SH:,*B]HF#Q=P#\%]+1A^LFUP@'('#"?<&Z4$1Q3OER$N
MT=4E,;L,85ZS37I42['#@\GR6P0D_9$>@OR8S)[<#3_(<>P@H6T? 2*NE9!<
M>X @$APPN7T )K&E&N=<AXZ2FCVRXOGIP$"8%UL"?TRFLV0U[4I]/1CT3X\[
MCJV$+;L(1%A!8;H)<5YYZQA&ID' 8GYE&4:'X]Q @)=+\)(*V-V=O[X=;QC-
M?@@A@YYJR@0G$.W+7>'HX(*<./ 17DT-1Z]>82[FU]2+:OIU;J(MD:Y[33W?
M@+!!Z3R6G=E3H")ZF5PS%%$UF$/*^7Z2$9BUEY[MI;_MO718Y$\S\5#.^-ED
MOA.Z7MB=.E(^WFJ^W&BL';\Z]Q5$*H8K#8$<)30M@XHW<AJ!<E*HT)^#8:6P
MO[CCVL5A#<QSQ 153B-$I>,40=7(&*'-V3C9S\&OOC$NQ:-'#GJW4Y!V'01)
MA1:*8*00UM%&L +N5VHF_-55U!G%4<@@NKFP/;=LA+KOQ:@[VEUPB"G$I29<
M64^9]," !AG%KN])5=^$:6?>]:F#4NS4Z^5T7BV7T7KX?3K?*#>)$Z=NA#G^
M;3F-6MXE8M@)=X2<'7H+T0$S5&EK .)(8.6X@0TN F:]*!WA6<K S!Q> >/8
MT#MOY(%XFBQAJ[$#&E$ .'![\T6Q'"=WA%D<!Z9;KUB/($',L\H=;SQ#C*"&
M(02]!TQS1A0S<%MI0+BH#]-JUQ]&VG2Z^VX>A[E.Z)_*]?+*IZ-? [DQR@L$
MF%>18E*(1C;E2=$J-Q?.VM):S<_SJ6?#6FHO>#K2$R\^7GXXV&AY$8DA0\0(
M*@"VTN^EPN#*,OIEZ?4H1SJ >1F*M*K\?:A)0#K.(VVXTA("8H5EB#426DVN
M+,=)CHJ/LJ4SHIW/MS_%O;Y>I,23R\]_UK_5TSB(: [_5BUNXGCLNOK\9_SS
M?OO_$U6ZS^\J1"&--1A()**8!E+W,,FH]$5+=9?F31=EUT7Q[H55\8/59G"?
MIG_%<?KICP-#C+]L3[#S>PV,4F:A]'&D-H+L4K'8O>P %CV'?,M<&QSZ/FCG
MZ_5B,\C_OUH<&6+Z36O2G=UG4-%)C%Z<,]QA)0TCT;-KY$8>Y$0!CC J83#*
M#0U\+X1+PTIC3&OQL^'Y>G$NU=KW%A@#""M,*(,:"D>]0;"1E5"7<X,WPI<"
MPY%L,,@O8]"_;_%DY4"+X!7%!DGEXHKM+< $R+V98!PN6T#H#7M_71$MQ9@-
M\7^;W&_B"<\Z,C[1,FCH&&;6,24I5YQ%0W,W0[RSV!=]/E^D4%JNWI_7R>T5
MWTOPJ25Y@K/6(0,(5=X#[ 4%NX>(41*BL^J,CC(\8$BFG GF93:F/9U;;TS[
M%D%3B65D."0I6Q1U7)@'^9C(28@PRN>_?9.E'UQ'<.WT["+LC5\[22609%)J
M(+!BDBBP*P0GHM?BV27K".VK3#7WY.KF?];3Y30I=*GO'_WKP*WYJ:NJGKXA
M$"*<$$AQ&/T^!*FW#86MQW&B7-=18C]T.EA2K*0J+I +;:!$HSCNN8 XS*'$
M26#@D6[D1B8KTG&$%"S.E@YI1L_3R"430/:;9M10#J"R1,>ICS0U'JB]W$[J
MHHFCQI%FM#43.J09/0_M2[*L[S2C(LIL)2.<4.^X$]HXUTCN%2]:?F4L:49;
MLZ%+FM'S "\=$GMZR6]S*MFAMV"C[-Q[:$ATA)PV)FXJ#2[0R2O+\7WIK7=X
M#?T\P=Q$(\JED,P:J'URXXG?;TQ4Y9RUG[V$?J\6T_KVTVJR6 W*WT'YTT-\
M]WDZN>2&_N_IZMN+Y&_+I]G?/CY+#K23\A]QLWI?+Y?OYC>S]6UU^V[>%)(^
MTRH89 Q!6\")0AY+BBFG3.[O\Z(.-"J3<%)NY\6\^CI)E;0'7]A+3HRQJO*-
M3J=/U6HU>UH%>?CY\^A+0_1K"-!*4.>1)88A#WF#LI:B3&K,IQ/F[[G2M]I^
M'KN($<,E$D)0[@TS&F&QWX,Q53GW@F>'M6SM(C>_'D(/KY$17!*ENMOKR>SI
MN-[X59$#QEJAE9>6&BH5(GR?2P#(=C>@/_U5$53"$"@99P!2[E)AF 9#AR&^
MTM/1+#H-=55TEBK>RNLI" &TT@/"N#)0.,C=[G$H,9B6K;[TADZCVG+A](NK
M\Q3P%E]<"4R$4<@BB7R<LB)N^[B1D%MVU0_TSE-QVQ=7YR'Z5E]<$4JB5 1X
MIZP36CA-9".ET64#,R\8+=Y:V;DOKL[#^[I>7%ED*6/>Z&A:$"^X5&8ONP X
MYQ9ZA)<RPW%M<.BOY\65$9[B.,VD],)K9*(M01JY ?AI7ESE4FYHX-_VBROB
M+4!64*TH13)*C;7?HRMU3B:-M_3B*IMD@T'^\\0]:&4!C& X[3S4EG#T8 4;
M;G*.,M!0A+JTOS@\SJ7XM\DP^>[N^V2Z2'/3?)LLOAY/U_]J@R HIDH 8+U0
M2C%FC+>-=(C(*TO#,*C^7TL*FPMX*3I]JA8_IC<I)6D:M7IX'Q*''<%9OGO(
MDORQ6JYG"3(?X=W_.OUJ ]SV+NS#8O^;V./Z[OMF@A\[X"TR@""E-M83H"'P
M D$BHF_6H$^HO;+GK27I/DH%7N9X[]T\JK9:KCY.5M6G5;H-W]DXDZ_M7[X=
MZR1$!(BC'BE.*"-:2X#W-A$#..>&=(2^3DD:#Z:$$5_?_UK/;S;9>8]=36;U
M&[&*EIF6#$-+7708(@E0@Y6B6<[Y**MEE*1L2<U<\FI_8_HOGX[GC5_I6^(I
M8 IB132,OHQ09OM@0!'FE6UU6SCTE?ZY2>T?*K*F( P=A_='JXO]'KXG<,6I
MLXXPS B,IC4"##=X<L>+1E07?9221:Z#%_SE55+,W]G+:":+Q7T<^T;.)*);
MKJ9W::O?2[_\\.6I6="%WCU\3Z""&"X,]81SSTA$%*$&2P5ESD/G42;,&)C>
MY552/,"YQ7P]44"^#<N'^+I  152&H$E$3K^J:1]6#@HRSG?'&7"CT'(/@+-
ME#(9H^D;!SN9/9JK%[,5']523,M'6EJB'Y"BOYLBG2TLQ_:=!.ZHU=I!0"'5
M%"CK_38IC(I,@?Z"H:&I0NZS*KE1D%\FBS^J52+:@S!M%IH.O06B2/1N%'$*
M&Q,]':4)W&,37:QKLPF'H,TKU8^'5<,%%XU=!/E/LW9 ;*S'6#C@*<8 Q(UE
M=P# -)?M4I<,;Z2_5FZ[?=#XD?;!4"F!9M%Z$UYA"3$FJI$?.)=S-#7"&[ A
MB''$P.X+]E*&\P,\G^/WG@C_?OGAP$P<O)!8 QE--@13WH=&*LBR7N*-D$P]
M:_I@0>J.\%Z&-"8ZD%_KQ?0_&P6>3+9RNG%(I6HL%G'K%%Q :B1M"AXSS12[
MLCOZ'+4?95 /V)9BE*GO[JI%,DQ^FWRO%B=)].KG X/ 2XD5EP80G6ZEU%XV
M[M359>+M4]W/+=X> "Y%GH_5]_7BYMMD6:FOBVI[=W*208<;!864<T0HS8#6
MA$6'G[M&2DNSZI"/,&9B0!+UAG$I)OU2SZO[K5OGU_/;TRQZO4%(U^12"L>0
M)$!B!I%F#_,DJ_[*",,5!F10+_B6#(IY<"M.<N>UCP='*#-$L)2-/V[Z#E&]
MW_DM0SF'P*.,&QB0.SW@6\S\>=6;>-\BD/I$R\ E\1JD>'4-H^P$2:$;>;U%
M5Q;_-ZQ_UB_6);GU^-QR]>06L,716KL.@DA7(D*"N*7'6>6LUD@^G)[HJZLB
MWQL;7F%9[W"/@VR=218(!(3AJ"0 .$+".(7 7EIBBB;Y+46N/DEP%L?.1/OR
M5Q>7*\Q=^NX"^6CY*F\-4H!Q)"6%$"JC@"608WS!HMT/6Z_Z$76R*>93+SY-
MGER.M;Z_.-%'7%PMH\9 A+D7BG&AC-SB0)&WZLJRC@Q!D(-W&/U"7RP*?#*+
MJT/UZ5M5K=XG=2>E'K_-.-0DQ'54<(^41AP3!P EA"0)B?;"6'QEY34&T/SS
M>.U^@+XDE4XFKSG<*!CCI98H;:$8.H<,E'@CI74:6>"NBT[YRF[!GD[(EN+/
MA]6W:F&VKPVV<<0GCX(.-0D.,4\E4Q8IY81U"E"7)!14*:3+QO)<ACOGJKH>
M!-FBW'EXK'(.?5YO%8 'T3-0RD:HK*8,0,"2G,982"&^LFH!0S&H%W"+!4._
M])1.57QZO44P$1A -<62$&"8A]$9W.[X#"(/<T*%1DB>X2VA?G NQ://B\E\
M&3648AWWKYT_?'G-$4^']\O7?W72=.KS:X*F7@LAB8HFAB%:26?T'DDBKBQT
M))M/]6A4T3E-DJD7W^O%9%4]O>_9[?G'DR*U:1N<@8(1I1V4UB+,*+*VD4-+
M4K3478FSQ\N0H!Y6+7W3*QH$.0Q[WCRH*(610#ONM "4,HYE(PVS62%OHWSI
M-EJ296JF,\_^44?8YTFJ,]>PDPV#)59$/\?J9)]BR#2$K)$ (Y=S #'*AV67
MYU;?.NF556V7KC9M@[;0">$H<1Z2Z%EI;QYFAV=%2U?\O-S*5$MG>OU2+U9?
M)U^K",;&3=XXQWIR\T=U>^8J=GY/@2FBD^LE**-,(QZ=^CUZ2F15S:)_4^\U
MZ@VNI&&)V';AZ]198 82$&U0)JQB2E@GZ%Y2@W#.60G[FXZ=Z9BIIU)G+<\O
M=$^>^;[>(#@O* >*0DF=EL)CQ/E>.I\5[\?'=_YQ40[VJHGR>6 .GW&^;Q%W
M>E8_01E O3 4< TM%\0)M#^/LD*7J==W1>?(0Z)?BHG/1_[4#5=W<7&?_J>Z
M-?5RM<G6<82,YW85D(W6@_)01&00IYISOT=$<U6VHDR]FLPNSL<.;'F>_G=8
M)8R$EC<WZ[OU+*5,^L>B7B[_.5]4DUF2*]6$U=67>E%]GOS5G:OM^@\6*D29
MTVDC8<XCA8EOL*.*%$V,-8X%=7 "#Z*9L;,Z53D>DM5/^@_<<(:M)4)!8+FW
M1IF]R:2=RXGR'F59WW'S.D<WE^+U@UQ/I3R#NH>Z",A+"6'$0&/.)!+2"[P_
MRK#ZZE+Z7H:=/<%_>0(^L7@Z\>])#R'N*M8@*P5VA'+HJ!6TD9]+(4L>=UZK
MS=H/]B/@7N]FZOF&D%>&24]HG*W<4HVC&M#^ALMF^5AGGX=>JXDZM%;&S.2N
MINGYIH]U0'&O&/<Z3G<.HMT#]B8] F7.5)^:I9]_8D+G*.?RA.[$U,"4080
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MDFXU(R$&^H*%V'Y;U#=5=;OTD=&)3IMB?QNRWA^[DSP"2\<>@^(,,\^C_0A
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M_<7,IOT(SC*2CK0*)+J_&@-!6?R_M:FPA-H +21DCK5:8XO)VF8>'VL6I,=
MTL@FA+TWR$* 62.M1#[GW'>4YE$OFG\1,](;P*7G[2[<_HJF+T#<1:<34\6]
M]!Y0YW8[L)6(M3LY'%C67ZO5.4(^^GAPE@A(,1,"&">YYHRH1CJBS4\U75MK
M^M!T[0YLN9C%W5 _3O[\91(M[NEDEA*%?/CR,>IP\:,Z'F]XJG$@& D@&(C&
M2KK;BDL><HW4UL*BX:]%Z=1)]8=XU!>^Q5GU[WKQQ[OY;XOZIEJ>3ZO#K8.!
M<9.3P@K"51282R_U7FYQ?6G>AN%5;P 7)U;RI)?1ETENS/G$.MPZ ,6TC8XT
M-T CKB2-1E4C-R0T)[AYE'[G,,3J#>#.,9O[H<RKU<UZD:"8S&_G]7SWC\.G
MO\?;!6D,L9PIJQ&&A#C,$6C&CWU6\9?S4^442&/: SV& +;XBG,\^_SCCP5&
M+(D#IH1#X[37+-60W>.3%<X[PD/4H2WH,^$L3XQC:\J13X?HG&.KE'9,21?G
MC3#<-G(9Y:XL0&!8FG1%]4+'(>GT9CV9/1U+JU.14]O=$;__]0\&K%)::(*I
M9LP)29BW#FC(B?7.V78T''B*F:UN3^4%>/7SP5AKJ4/(IYA:*J@0$.WDBY+J
M*WE_FZO<0S,K \J.*W'+XK;_72_,>KFJ[R*D1TJ:O_Q@\% SQ!GUB% (F6&0
MVD8*9DC1Z-*"ZVXW3=8]0CDD(=([H0]?G@SQX-O!HY\/W'&'A(/,Q2DBE8P.
ML&EDXI*CZZ!'KD+K_J'L[.OI:?UC$VKZX_A;O.>?"]$5I<(8ZT5T8C#R)EH@
MS?@(5%?R.+\G'=7](5G<1G_?X@G=RP\'"[#4UB%O19P75@*N_48JE^J%HYS0
MKC$[<ED[16]PYA_]+.O9[:I^X.I-O3QM%[_6*&"D@%#":6ZAL QP$K]T-W*K
M4-&*OP6)T$%UKQ[Y](!I:4?MPL&Z_5];<ZNQ] (S*[RE2&--S<8O5I [TZY0
M^M#!8Z^N0.=%DAWO(HC(+*9)W.D$$ 9MHIL:% 305_>"M1=&' PBZQ7L@C-\
MN4K/;9?OYO^:+#;57-[-XZH:?^SFJTT%EWX/9DY^79M#F]:=!.=1-.@ (Y "
MQ9V@Q*,M[(2E?,>7F^FO#OW,8+/6?02+#09.6&^)P011)]P>!Z+TU03F#TF1
MN@SX8YK[W2/6QK,$$*D8U4):I&A<VRTT<8W?'()']TSK5F<89TMW>%R[X^[V
M,K;N*BC"C46<)%91YAU'##:28J:+QJL5.-T=@ +/+?9A-9#EU35#BY[$JKKY
M-J]G]==[4]]]G\S3P+Y-5FI1Q?E;+>ZBYW+[N=;5/^<W]3SZ']/;],3ZU'Y_
MC)&]?VD@5B"83DH<QM93#@R7>^0D*'K26'"#&H!:ASA\:9T5VM?>IX?1EW-6
MMU_?PC]]^L$@/-66 Z&@=0P)+K5EVZ,EXB2%%S14WU?+957M$AC,OV['W<8Z
M/=XP*.T@4\KSZ A)JYW2W.\DC@985A7N$>U6N>JN!\2TZ(R\]..'KA,3619]
M D2(L)IZ#XU"VSR.-)WP^U8WI .=%34I+$_6"'CRP0"4<Q9! !B*I#!*$P4;
MB206K9::-SOQ6JOS^4%/#H:E[G@>YS)]G_36(N?_@2;!.JXA5G%MHDB9N%H1
MRQL)N?=7EH>SJWJ?9VCO!\U+\N5TEO^#C0+344@9/2R#B;=<0N;]3DH'R+45
MBLA7=@OV=$*VLV.Y-RQF:=6<;)Y<'X\C.-PB4.2$1MAB8Z*7#2"G4#5CEM%C
MN'XVG*N\>@A@2RTFZN9FL:X>UWX_R)Q330+1@#.@.&42H935P:!F_74F>KO7
M%6S0(W5Z1K;S0O*^GG]-)PKU$Q;/6G#CG.8!. JU@89Q+33Q6,I=LNHH#4?/
M*[6_];#QOI>885 N%]#T)(]_2WOW2*LHIQ= ,X8Q<C[NV\@8N9/3>VER'*,1
MKCH]F;S] 7IAXIPT?(^V"T(HJ#9Y8SPF@ GF$&YD919?=Q&-;EIOQZ1.^);B
M4GK*&;_KFYK?VNI'-:N_IZ'OTE6=M']:M Y,<4^<C.NZ$19)I:DA>[FAN[)C
MTIXX4 ^-<[%D8M5LEG+]5?.X1<\V]6GNTGOBU29VL-J)<-K2/JN?(*%QV&M$
M+='8 B4 V&-AM+RZ6-\A.#<DXJ78MTDZ_&L]WQN(6ZC:+F]MFD?)L?/6&  L
M5E 8+7!S(.N1\CE<&Z$)/PS7!@"ZV *WAZ+%LX27'PZ<<^,=@E):#QEWQ(N=
MV6J!!#0GYF6$].G)9L_&L=@"].2B\V,J??GARS^7VV20QU:>8^V"M(9*[XU5
M#%,,.',.-+)2JZ[LT6..LI^O,SW">AD*-0=B391V:PX];Q@(\YHPX#BG)N5K
MYU#81EKG>0Z)1F@C#4:B3%POS*)6^2Y.MHTR.PRDI]! +KR+\!'2R(R@@%>Z
MB0W&I<[07IA.YY,H*(T59UQ[Z5,HJR."FD8^@50.=4:8@FEXZIP)Z&4(8UY_
MO'GXPP$;Q+T12!OIL80:.BT;J8BS.68R_8E6F Y87H8ARV>.YJ?U[YO+G8_5
MCVJ^/A8L=E8_@5*D,&((2::(D988L[MWLM#[K.6'C;9TV&#TZA?MM[(V)<<5
M18&P!PYP:C%VN)%* I1SV<_/Y]"PE0V'79G.0[(4/UZ+6=[OM[]-[C>O>#Y6
MZ00L*NW#%S]=WDQF_U5-CITM=N\TQ V>,"9 ]$^5=G&35WB/$O,^YZF)N.J]
ML!CFHV*F75>_5G^M/O]9S7Y4O]3SU;=C1Y1=NPS*F#A)*>%8*.^$49RB!B&0
M%V\K_V9E/N)CXV2:5I__K'N@XJZGX)G5E$,DA/.<.^L5;_! 6+&<=,\0_$W!
MSDB/DGGQBX]Y$6?W%0PVV'IKF7 20\0TE WVB%J64^0*7O>I_-!8CY%_OEYG
M6X>/N@J(1E>>,X@H<YYB*3P6>T0PS&+?=1_G#PSU*,DW_='7VI>Z"M1HIP2+
MOCS1S$E!F=I/1Q)_F4.^ZS[_'QCJL9%/?8G:Z9&!3_H+Q%,F! =&280Q@\S"
M_<1D#.74.X7GWR5<(PUS\!X;%WN@7S#(<("I-@0KBI2 EC8GZ4BCK. =>/ZU
MQ%NZO1H(XE&0[)_SV^GRIE[/5]6M^RN58U)WZ5]=&7>HO\"I$LA$Z*W#Q&,3
MD??[S8!G'03"]K<75[?@]83WA2[.ML6G?YG.IW?KNT<SZ=R H5,=!:(B[(2D
M*!<B@!! NR8R 1-MLAY+M[_W>(OL&Q3HD='NW?SSGW4R&8X=.I_=5Z!*"Z:0
M@(((2@&"P+$&$^NS2HK#Z[X$&1KK\?$O'1GUQ\!];P$:Q[#P3DKL%").6@?W
M\Q+Q+'_CNJ\\AD=[="Q,1T>]D7#?67"IVI;SB"# L#1""JT:5!3-2IF)KOO.
M8W"PQT?!Z+3W1\&FLR 8PQ!(H@4U%A#O%-VC AG,JI!XW1<?@X,],@I^_E8M
MJDDZ0\IGX$-?P1!DI032&,D)31D(S>YAF"54F9PD&NBZ[SZ&QGID_,MG7: 8
M*,0\U-81I77*5-+<?!-)3-9^>]U7'<,@7(IA3X;[$-8:M3A;?IK,JHU0OT]N
M_OB\F,R7DYNDV^6_IZMOT_F'>74B%C"_\X A=MPS01A4P# "G&C.X@D ,L<?
M1M=]]U$<_#= V19'-CWT'H"5'$NLN$:(6>>T<WP_U66[U+2'2'O=KSK*H_\6
M6-OFH*>7_@-W%#$HH^V#'<&"0L\;O5'-",EA[G7?O%P"_S? W3;'0WUT'SAB
MR$:KBB@N2+2P.//-7D6A$SE!LNBZ;VTN /];(&Z+0Z4^N@^.P+1-&4\1M%+%
M?0O1!CDG>9:7?]TW/A> ?]3$;74,E=EST 1B@14R6&-%(<(>N08O0VC6.GO=
MET-ED1\U4_OF9Z "62$9B:I!1B%/M&R.CRDV+"<9([[NZZ(2>)_FXH%LU;]6
MJ]W(-L-HCM/2&O[NR/E3Z[8!(D.18(@H0R)XUBO$]W.*J9RK;GS^'<];"'0<
M"MMA.+([%.C$D5W;  #RBAMN) )&*,<DVZ^[4,&<:$1\_C7,=7"D&[8#<:1Q
MO[NQI&D=",':0H\D)@9XPZ,GU*198PB+G$33^/PKE"OA24=TAV%*X^YV(DK3
M. @"O?.2IDRR/!VO ]9<!#&"=,[I,+[.U%"#@3L037;.93>:[!H'QX@F3B+$
M%81*2BU)DV\O;I[2Y=#D.M]@# 9NWS0YZJBW:QBLPE P303S$G"9D&G>CS K
M65:%E?-/ZM\Z/3H#VS<USB1$4$)R; 37GC#%XM)G2)._A7FNLU:)\X^]WSH-
MSH3S,F% _ZY2?M_J5OV(/_U:;?/Z-+_\7"WNX"LDZMI5$))&[XUAHS'TD+L(
MA=NOE%QGI4"][N/I@:$>!?GL[D'9QXC:;]7BICKC(=;IKH*S!D4[CF(O,.+&
M.F>;M9A#A;-<[^L^;!X8ZLN0[\@F>;Q! (0P)@V7#F+"XB0CL@GOY(AD^5SD
MNL^'>P&T%%V>9;[_\/LJ+K+5[;NY^^OFVV3^M?+UXOP4SQF]!@D1\M( #RW@
M@B6\&G^4"YA5:Y5<]R."<J@_L//__=\O (^"_+'YU:N_V?7S L/?I_77:CZ]
MK6[^UTU]MT5_&Q]LJRC';/FY^FNUGLR>#B3^K)K?5K?_3XF'_I-'U=>/D/_I
M!P-S1%NM(?5$:$>]<98##3E):5HL:/4X>AB)/MU\JV[7L^K#EZ>LN-W09[DI
MS')$SC;-(Z\4]T):([!G."YZV()&>AW=AHS9/,+)W%7USXO:](]LJ?WD6=KG
MQW5>-X7#;J=)BY-9,JAF]7(=5:OOXS^^U\O)[!^+>OT]98Z>K6^CS!NC:QZE
M7U>W.R#J^?*\JJ@##2 @+#"P"DDC030 )8= []''Y,KJP_=+R./%,L>AL5+S
MY2PY?IW<52=KNW;L,4""!)8&0F,$0,H"PLT.'\IDUK'%"!D]-M+5EU!BYZ-8
M6\WO)HL_?IG,UU_B1K=>Q+$]C.=X0?0V;8,"7"'NJ,9 $NL-AWXO!T4DIW[U
M",DXN+;K8?'ON%@N%ZM'"V7\U_-%,OXH?$R.RX$]_\GO@Y'2(& ]<U%T3-/,
MP\V8N<TJ/37&M[]#;,DY@ Y.@H/+RK-/!.VB*POCQ-"$4>>4TYSMQLT DE=2
MO[RCKIYKNA-F0^IZ=\MT5-M//A. %QXP2K46P$A$):=N/W:0]01KC/H^5V-U
M/[@-JO/)7Z=U_O@SP7'K@'4DNM="<TPIA'OI)54Y]QPC6NQ[T7D&;I>YM-AM
M8?L#T=:7%\\;!HB@)09&BBM&=(0, M)(JQG."AP;#TN*>.F](EV*5Z\E]TPW
MQQ^^F&A8GSS'/=4XR.C<0:PY%<0RSIDA>B\UMR3GKF)$.T_?%&B1@34+YTNR
MZV,UK_Z<S-+XSZ36HY:!NPBC!4JFX%T9EVR#_$Y>;N*.?1V[VP5XU1WD[F<E
MCYW[IZ/92GKPH.14PV"\B(: 1$3%K=M(@9FVC02$DYP41"/<WGJFR2 8]\R2
MS=.RV>Z2=EJ=297GK8/D)CJ)7KMH_WGE4WG%QN#GC&:%/HXP,U YOF0"7?0V
M?6,%+I\.X W<HFM&@*%2:1[]%LT$QDAM$4VIP4BK>^264W&[;VS-D 36]G\1
M(QT[^./0%#S>*GB),$7.(^8Q]PI@(&0S?H;R:H*-;^IU55X]%*#E3,+)MH#M
M2=*<:!$4@DPP#AET-IHIF*: G*U\VEJ0LU:/T 3,)$R_8%[2?]A'9/TR25<S
MJ_LSB'1V;X$1[Z43D MK(]8<&K[')>Z&66\AKIAD0P-=BH /!T9/<AIL<QDT
M@:LO@@:7K2G92__!*(91G+<82T9@-,(-! UV%+"<FG(CM%I[(NDEH._L_#PU
MI/_<A=Y/MJ'WB^;=1\3^;C*_;2KRQ!8M3;.>N@]6:$H=)1$1AZG2$#'1H$&L
MSCGM&V&.RCYLN,L@WQ,/E^OOWV>;Z*#)[&:R_/9E5O]YNP\'ZD*]<WH,6GE"
M*<46,ZR!-C*%9N]D5I[GW&*/,*]D_VP;$.Q2#OMT-?VZ:7DY=[U>+LTF!BF.
M[N;^W?Q+'>?JADZ_U^O5PPBCW9-(TL:Q[]AEL 1X +40W@$N/>(:2,\0]=PY
MP4&K"3&4(?]U,FN&.[]]D&Y:+=N9[BW:!R2]M-@12! 2"&%#N6GDIX 6C8F+
M*_CO]=!+PN!$>6'8]Z^&XDO%[K7,WRM&VD40BS0@$CG@I),4F!3%*+B5S#-,
M6P4&#?E,XO/DKT=RG7IO<[!-B%NEPD(2;*U$DFJ&Q#9:TR!//+^2 *AR='CU
M@4(^\&7?X,3QJO7J6YU.(UJ]F7G>(!ACJ#!8&Z^IPP II+?>G\&00I$3/3-"
M6O6@Y4.\R8'U<J0Y^=+D4)- A+)&4L(%@]012R'!C81QJN74 1LS<3JJ^21K
M.J':CC?+ACC+:$U\K7_\[ZT'?I]XPYM_),KP1Y39_3CHCZ^0X^&707OML.6&
M4H:9%HRY7:RAP<@H?&5OY/+U5F<B6'RI>+12OF\1K'FT75 >*L6Q\L XKCD2
M0.YEE8IFU2T:,5OZWVUZ0+?8#=A34\Y.[B9?J^6G>OWUV^I?D]G1.FTGVP8%
M(3=*2^X@I%Q)YXEM9*8.Y=QNC7G]R=/_<Y^X9Y0+^<,?5M^J11SWLIY-;R>K
MZM9/YY/HR$]F^R>?6T?Y8G[RA\77R7SZGXUT#P--+)O?_O9(\@]?7@Z]C=/<
M2_]!.VOC(N2QD4(1!)RA>G/8H5*XA6B5)7X8_!Z>Z.['_\@3?'BVV^;\[>R^
M F>4"2&XD<1(&Z>0@;[!16%0U.,N<197F$UU6?V,;5&Z]!G>VUB;F-31@+8X
M&L@ "\.X 01RH#%/>Q!M58E@H+B*9K G4^@\^6!(5^Q$4B8](E)*9>(6VDB$
MG+NVYR1E6? \0"('^E+V\>.T%.^3NA,ZQ\_R#C4)*3\O91XB*:,1""!S> ^4
M-#+GQ>0(R=55O?4@:%Z2+R>/\0XW"DA1'[=J[*)ESR$P4CO=2*E:+K%OAS/Y
MRF[!GD[(%GN'N[%0UHO%)A_A_CW#P7?9K=H%R*-DTFFOK$0.(:.8:V1ED%U)
M/H8^E?[\[6V/\!:++7V1U[*-'?1P8,$]1LX0*ZWQ!#I"-3*-5(#H'-*,\#BP
MI^TJ&\=R1\@1TVJYVAY:N;^^5_-E]6NU:N$\G&H:L-060!O=3 BD(3K.,K:5
M6(&(8M''LV_'-^]J1_>LCG($_!$'G2#8#KP1XRCQ7F\2?$2+:RX@E19)*Z0S
M>PDY8%=WSMR7PE\PJ1=\2R]A.P1:K%B[3T9S$GN-L+%0.0*8( J)/4!*YL15
MM%^@Y)8O\^IK.HEZJXS) ;8443Y6D]GT/RD/=\/O?T1C<)EN5EY]T=VJ7:!6
M>R0$1X8+*;GUA.-&5@M,5I61GVC1Z1/D4H3R]:*:?IUO'8*;^T=E9M/8T]!U
M]:5.,>Y_':'7&;T$R1F,/J_547.<0B"HV$\L:VU6,8@QFE2#T6TXT(L>$?Q:
MS^OFL<43C$Z=$1QL&* 63  ?'16"F%-8$@QVTD*(54X]ZA$^KAJ,8+VB7(I3
M7>AT6$;B$93Q/\\4C7\'PK%FWD"E=,X[B1&6^1N,27T!7(I$[G_6T]7]I^HF
MO;^>5DO_X]=ILZBJ601I'D7Y4;4X83BSIR ,DI!HK"&+2S3BFC+5X"&XO[8T
M3!<];AA6-V/@:D=BAC@I32H!SC'R4A J:8K,VDH:A2YZ"E'"1AN,"6<P[DS0
M+TFOQM'I2+/GS0/$EFF%K>,>61FM4XOVDEL-<[(RC/(0XY)TRP3_DK3[YWR1
M1[R7'01/O:*6"J,E4$::B )II.<X*[_[^?OMX ;>)8F7#7XIZJF;F\4ZJNSA
M<G1W7=K"W#O9-C"EI.&>6>TQD4A(MC>AH0!(7MOQQV5-O+[U48J#*1Q^B])L
M5O^98@#2*_*/$:[%CVJY"PLXPL-6[8/$VG,- 6(\FAR*IFC^1G9OLYR-49IY
M/;*A'A[OPNO=Q_I^,GN$R>E5[GF+X+G2U&C#L'+&,& @TXU\ ($R=MQ5\*D?
MA(L9:W??9_5]57VL9AO;^04>Q^RT4VV#]4)J'I=^1CQ&6(&HJ+V!BEC.^X@1
M'HD,QZF^D2X6B+I>3N=5>CIV]_MTWA@2VU=DJV123&]W%<?VF1-/TZY[I\$@
M(AT5A#A,N*4&&;<_]Y88Y-PNC-*"&XZ1Q930.8N;J6>1//5V$-7VS'HY28 \
M5(]^GJ?M6)N@!#."1P- 0J$5<4Q$#ZLY[[8@)YW!"*^F^J=.WPB76L02FU>+
M]>9Z]K?)?8K,;*"8W_Y:SV].KE@M>PB:60FH]%@[;RGB0C_X[-;PG.5IA+G^
MAEN<AL&[Z-7Z07!.7:T?;!@,1@0X&N>1H])APZE&^]F%0,[+'_YS;7Z] EV4
M5N?SZ37YXB+MJ44<*JH)L<)PM[_ML";'5Q0_TS+5#[YC>[5\X<HB;^/1,H 6
M$\:DP5082P& !FX>IDLKF9&MCI('>K#S4#WP: Q1A^SOYW08O/$4<PZY4]AX
MJQPUN$&(.U/TM=C;.6QOS:N#>>('5%*IG:ZYI/HP?PCG;96 ]WC#0* SS!JI
M;71@%;?*$M5(2XS,B2@;X5NTRQ*R5U44>^RXGT4OC88.Z^6I3H*@6*CTU$$3
M#+B7*,[&!@5/0='@_Y]IC>Q9,6.SX#;S[-$IV=\VW*L\LAP!;CS67%"OO!-*
M[#*>,>8I:K4=E''U6AU2'6X4),$JA5DQ&WU:2RCAT.TDY8C8HOD?WLXZTYH?
M)]S"SHHH? N]SSS8DG#'F@7CM=$$,D5Y7*^E$IRB1M+H7N=0[FIMK:Z$ZU$1
M);>RC]6/:KZNEMW3I!VJ_Y-Z7^QZ/[*='/YP\)ZGS'/<(A5-5(HH1'J#FH/,
M<MSJK'68R6JGR\G7KXOJZXY0.Q1/I2@[UBQXH@ P4F&("9)"*TK53MKT8NU*
M<DKUH>YZ,%1++?:?X[=%"WBQF,R_;M:?$XG(7OU\P(+K3?U-AI4" @+!12.;
MQ%G).4;$F'[57/</;#$+X6&4R^T5W.3A)X]>OYY.,75F3PD/802,_AY5TENJ
MA24-'I;I*R-:)B>>VP6#8EWN^GX?<?"C>B322:H=;Q@$01@[[:32P'OAN-=[
M:8$U5[+I#<Z%%U?W/8+>D6++Q>H1O>*_GE,K_BC\MJAOUS>K#XM/U>+']*8Z
ML T>^FC@TGAJ#3#*8654M-<)V$DB&*97EMBLUQVP)TP+L"--E=T EP<3<![]
M?##6.D-AJF\*9?3"O*:TD8GGE3T>T3*3K]*7W,@&LUAFH$VH^/W)#>G)YT+T
M.*A0F#NLI27,Q36V60H%5=>R__2DS^?I?C*0[!R0NG$=;^K%][2[58T/>5#K
M)]N$Z&DRZ[T3$A/-J1)0[J6/\Z5, K$WQH"^42VU1NP0> !@(\/))>-8LR $
MTEI0Q Q+WRHIVI65BI(* W/NLT?T.F.8%:1'8(>T0WZ9_'>],.OEJKY+)3 /
MVZ@O/Q@ ,XG_R DF4%P>HPTO=U+(N"N7?5_]]BS4;$2'Y,6OD[OJPY<G0SQJ
MGQ[\?"!86"^Y(D)$6RW.'@I\(Q,V,*=>V\C,D!R%UOU#V=D.4;___J]I==SN
M>/R9X#DW7@N/A'*:,([]_G1;IGBOZU%Q#[JI^T&QLW8_3>Z6Z_E7/:V7T[OI
M;+)0<5$[?N#5JEU0Z2;#":@A023EF*=[3TP1A7.R'XS,VNR9!3TC6\KB/+ A
MOF^1Q_]4TV"5Q$Q$-PNG15-91%F#8WHB4321Z!LS+0;"N-A9Q\[9.G;,L?M(
MH!!;P8#4Z;T\!S9=7NPED.+J<ESTI](7V8T[(5HHF".Z4M^KQ>K^M]ED\T O
M92#Z_B@:\6)AB <'UB+$\&3;P%/*3*6Y8]@Q XAA>!M88RGF3K;*C3!T&/-!
M*4Y6M&O91;#$<0@ -51(Q1W"!.H&!4+DE1QO#\"*@\')O0)>\'CK]4'K^W2G
M?2+&I$7K8 SE44JFM0<<"@ U8HW<7M.BI5H+%!+JG0XOS[]ZAOSB5$OC/EDE
MKT7K$(TY@[$6&E ++8UVW&Z739@J?V54ZY4);5G6&>URF6\B:-/YUY,G]$\_
M&(BVFE&'%(%$*(^BD==(0Q0E.4E&WA)WNNCW18::#&!+T>27241H7BWN'PM_
MDC-'6@6F/3%<(FN\TDH)CZAIY)187=DCQ2$)U!_*G0_S_.1FDSKI_?&BOP<_
M&XA%4J8%%_!4&A**. >:<5H!<X($1LB&P:R>O@#NC0@'[90CGPZ1_TY+Q#CW
MD,0_1?J:9@GTO.AYRL!A^GFZ.J;U3EAV/\VO9_7JVWHQ__3G=/6?:A'I?'OB
M'/]@B^"8UPIC H3AVBG(-6A\2RJUN6;]GZNU>@A$+^[AM#F[/]TX*,T)1#1.
M&N!3*&XZB6RD-D9=6<VYR[G271$O^.YS?;?>9"2U553;S70[UZKOLVKW>%'=
MU8O5[F'C03F/L+&OKXAKOQ6""VFE2ZE2#1)[\Y\R]'_;^[(FMW$EW??[8^9B
M7UXF FN/(]RVQ\N<.?."D%6LLJ958HT6=]?\^@%4(FN51'$3Q7:?..WJ,D$B
M,S\ N2'S;^-GK &IUY=%SR&1WJ*>3V@Z%.%\\EC 5,2CA#.K*76&"<L0+R@!
M2#8Y5P>H9'>(K09<[>\VT6-IR7<)W3=1<*O?EH<[FAP8%4U)P;%/9X>3&!FA
MXZE1T,D!'4D69@_H:8_)?8%I5Y'E]G:V/G(.OG@R(&TL9M(*91"0$A#)"WH8
M!XUR,P>80-$A:)HQML=<G+M\-9E',&_NWBVF\TWR;,;?3K<UMS?9U<>[7;GM
M.EI6&Z\/4.E41U<JKQ@0EB..<<$Y8M7(RF-W>0KV+XUS9WH<!>W(<C\TT8I#
M!AU4'EDF'<=L6Q^,>V6HJ]2DL6>Z$_[F^6JSK%3$[I37!*\XH@ 38UC\AT-*
M%"ZX :7NM;S4$') *J.CJB.A.=-[W"#R5;0L9ZGFXVP=9_SQVF:+V\GRC]\G
MB\UU9,]F&7?#<@=LO_K/DV\?+?[SUK.!:H0Q00X;82R+;'9DYV3T4KAJ<.YF
M<3]4>"HK1^UZ6WWYD64)+NKJ:I98.ID_XF6E[Y\=1ZO#Y]'J6%Y83S,(T& I
M@% 62,8-9"E/LI"!@K")BW) 6TH+&,PO03Z].<XWW^>SZ;?UKO!>JCR[B+BX
M/Y9^=F!8 ,QI9%(9*!(W6>ZHU+Z@U#G9:S_F[@^WP>'GY1'9GJC.#<IJZ6I'
M!P=&A&-<2)WN(4750W"!"ZHU@6/+.&H% !5159O+M>/%_\B7?\P6=\M\FJV.
ME!9XX]$@G&0L+BGO"1)>(T#@SOOA50IM_CVP4$=L>:N<[6MOZ7Z[/G)T]C.!
M8*"%QBIG43PME!*4XY+[4C2*_@TP0C/T0WB00C^+*_<8'>DFZM$SON8; Q"6
M1>, 2V2Q Q(R*8K33F%JFG2;&^!F/S30'7+Z=B;$VGK%81_,846CRMA G430
M&R<<T8HISRRF!1VJ63F\ 8*Q<VGGW?)_//K)^PHI<3W.(DBM*9/0,)2J6T(J
MK2[.5"U)(\?5 +,!?FDJ=24_P,CSLZ[/[42;G[TR6"<!I9A@XB " BO@1<$A
MRM@O5UKWV*L?JFXBR@&"O706P':0_OB^  S3E",3F2$TL5@8(4O>(#:R.SLC
M@WEM.?848?V<3>>3U6IV/7NX&/%QL][V,RMR>HM\J/B-'UE<L3^S!P&E7GRM
MAUK?F$Q>=3+'0K-MO#MXCCA+K6\01!)JJ*A(97F8AUHJ2NWY0KEUY7@L0-OH
MO0%Z+YG#UJ'DYW0"1=NAX)< ;$QAUW[Q]:J@3W]2ZNOP+8^ E+:ROD^SSQ=9
M:C=PV(5\<%Q@P",M 1<^[CS$:"W-CE8C%"0CBVCTA(N7M6=:E$!?:'LQU:-.
MUC>?#Y8!IS61SG.(B>5 "UW0YHD82?'3EN6<M\_9,]QX^Y"MORV6V60^^]_4
M.J_H45ST+3[>R.C$5P6,K/!  >6U8-@@S+PL^6O$R*S?AJC8?VFM"V:? 7[%
M?",Y9K+ZX>?YG_^67=UDG[;</05]5=X4I%+<.V^MYI9A1>(9 0M^<(]&UJVF
M,_!UP.LS8.^PC;B<_=PV;_KW35QCU_?14%:K+9'NKV0X9U<E7TM+^E.Z+QI!
ML5XO9]\WZVTO[3SU((WF=11;I.7FW2(U:EB=A.SSSS,8IM*U<(D$9>DRD8*,
M%+)$%#1)KAJ@.[^S=7-QDNROG&X]A?^(3=7DM8%31+5S1$J."&%.&H(*3H'X
M_W&=%><QN7H4T-"A?-1T:_;B0 2AA"I/.87.>:VC2EAP2\IJ=[4N1^_N!U@M
MH;F6A(:.Y^-MX!J].%".L+)&,V2!<IJE)IWE08;\R'P6?4&K)437DM&Y$*VN
M_GOS8#U7)>_CXE%;JY1ZT]4G@Q8* XL]\,@QZJV2I/16886;)#\.4#$?AI)R
M)N'UM3RB^9 _A(&3\9"F[_ZZB]0<"K?M'1,HYL@+#Q@5D#G!J,+ESJ.%'$G3
MI>% )>]&,/UF2GZ=_+6;ILX6V?7L4)6"/2,"54)HKCUC4#--N#-8E>8ZAW3<
MYMO9@=>.6/I3":JW\^&80">XMLI*Q2&4D)F" H)ZZB<I'X"U2$UVLJNO?S]\
MU11';R6QBDUW!_]#R'KU; #$4*:H@=9C3(F7T)6+1$G>1*NK7A;K;P^QIG+I
M36'+UH]NY$-*VM/G@K 6,(\40-8HCTFDI#S_F<!-TC,'6.=J<.!J(HS><BQ7
MV3(2Z_/E-D=TL]AVGE;S>?YG2FXM$BE?)%K5KVY5J>7O?TSFF\FN0NN32,ET
M-[_]Z935!P>B%:10 T6,EQ(91O&NOQQ2A%>[/]X7Q4^*(NW)B3SY'<$:[%@T
MCIDS4C!N8=36"OI=1/PXC+8N )'WP_*^CI9'&LI%'ZDI-H8*+<VJO2 (YK"F
MWE/HF224&KF[MN>09K)1?X^+ EQM5.0]L'T8H#L:)ZLR/#734=IB2ZE0ADK-
ML3(%Y8:;D61X=P6'D]!6B^.U;WCOOGJ=+U-F4JFW'+[:?7!0B,8E9X0+[DCZ
MFH]G "AF'I6^D?7!:U>8>4=<KHT/DS)CTO7QR?S1!C@"CT-C@L7($4VMC+/4
M!B*F@-W-VU@AFNPD _0S=H>.%IG<VU6/R3Q;?<[6F^7BN6%T-/9]9&2 Q@&8
M;G=C)YB6SA*""WHQ ",KIM\)J+IA=4UHM6KG'0HXUWI/</&@]TXI[!WW7!L
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M4)P/*W^#RJ>7H=695H7H\$JI<:C2(G1E"VV[R:J@R(MGY<;7CH*/*+[["$>
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MM#"YU4A1=L0S#^1_]DY["F 4&K&^"Q>V@R>+TVK?*;)HUM;B <5T3<\"]U,
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MBGD&DV>-8$%G^RA\SZ:98P'B.#:6:M_Q'1'AC"[:/N6^/F,N?Q[3VC(6>WA
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MG7-,.#$<F&/":6'_E!=K6HN:AG'=8+T2([O5XB+&=@=+>;@6T-7\!%<#^JS
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M(('9D.<G\QMQF%8&(37I)HG18B^P?/8!S4J@9[EOZ.$O#GPT?"SA@1=4=@S
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MN!@;)PTS"R+R:GFQ")D^&_W7F3W&4"63^Z%H)DDTL/I@]3DPKH92BY\@Q.(
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M4QF5XE1!D@U*YC2#%$F-4G2=$E1:%Q0&'<:-]Y([V<3!)L::3J@HBS,%NXS
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M+8) \J(DJIJH:;JF\;JAT&)^;J7$;,;BZ" M=.YSMO=YHS.MU >>KWFV]5C
M'"=\[-G[[=D[J?+[*KFP/(2+(RE*I02%$V1:4ZG_G[TO;6X;2=+^*PSO3$1W
MA*RI^^B.G8@Z9[31+7M:ZMV83QNP!%M\AR*U)-6VY]>_!9 @($.R* JD0#&G
M=V7Q$(E"5CY/9E8>G"&V2JDH1@)MH.2=>=CD"#/:;1^"QY0<='G/=1EX_7Z5
MU_4DA&"]"YYZ*SESENNH"*L"XUZP5G'T>KS>T9'7D6"RT^((X/6#Q8)7H_)K
M*GDB]I62.R0QX@'+( )+MG*0 J\::09#-^/UKI1<4MUI:O1^\OHF_OW>N?<G
MXXO)=3[X.)U<#R95Y3ZD0V]*Y(36.BXI$5I&S!71/DI&J615R,[&T*JA7#9.
M&']:R*2HA]BNCZXY[Y;+(8#>8SK>)]U;5]MX/<HHD2@C7DNCM-'1*JVE6"5F
M"M\ZU5I/V[I+B#XB'3<, J7J@5*!/WN_8LIZ3 .3UC&KI J$&RZX8UI6.2.*
MM7L+K4V#75F[C*O=-*ONIYD+ZOR\M?92:]?54]T8I\("CI)$+K"T%J$HC%ZE
MA3BYH9YV-P3I2&XG]-0S=3P(K_/=/-V5P7#A>_ZP/%/^\6@PSB'Y>EM]0 C%
MM;)CCX3#'G,D,,:6"()M1<J:J99O>CH93^[J^W=GV'?=CT=W._SSV9MD'VK\
MH<7'RX>K7YK^'X4$VN!_3QV)5!I+N8TF*(3)*K?;LU9(^BF0T'V++LJZ;>JS
MIO#W0?%!U<%(V-1QI[SAN$<6""8>)V^>42&"1:NFP(B:5JGS$VV$CNJ=N>['
M>33X[WN@V/NDOVMS>"/6%DVALC00+I (AB(4^(K#<7N4^!,Y_ DJNPZ'2PX<
MONT&7?L7&UB>2'_(T\[)JQC!//M2I9XOTM#_[W8X_YI>7?80_YA^_2.?S?.\
M#"(43Z0_Z5-P?[_, %T?K!D>#1:$&4<=5@$YX5>MAJAI^P5U.#!.)]=N4HX%
M2#=C-1=@9DO1+MYWGGW)9[\.QY-$"E]/$N1,DQ3-^/+NIX12W+_F\ZM)>J40
M=%'-LN7C<<EWU#@43(<>F [[I--K:C%K!/P"9D(A&@VRB"B+M96A2D;QU+1Z
M\[VL%G=X[(ZE>AUS,4%9X=C],86G]:AVIH/PUKH8D;6,(^^<JX[S='+?^Z7P
M76:HXQW1=C_/#P$F#O<XGW'6:-424!2Q&!0?N#061XU6E6-8]DS_.TP3$))L
MX["P9VI^2*& AO/?)[MAOTP#V3 -DC>OB#1&$R2*Y+P0:.71>\E:C157*K\,
M#MI\G'\<SK<ZHHNI8PR^-_!T[[1O77W3=5]\ZG5 2&'"B%',%FT/<66*!XD?
MH.)U]*V[6F[1[3 ,4*L>J-7ALAW'=:O\B#43R%./<2)!27P(J-(^)L,#\>LU
MV:X;HU5(M)L,=%#+'JCE/FG?NOI&&Z,CB3-!(^M],!([BB5FJ_,B)YYA77;F
M)'(E7D<IUD%X@6$G9[V0$O:0;O/:DL7"6^$=<B0X%Z3P,9)Z[(QXY!1I6Z>X
M:Z60B]UV*@(&[C$#O\8TL<>T6-8,;7707!H4 Z;>!&FX734 UE2UFHKM_A3W
M)=L @X;N@88>,!WKQC1G$9E2Q"A"O>+."&Y1-;652-Z9(C_-T5V'CMEN>P0#
M'>^SLN^33J^IQ0(W1LJ%0)2C(5)IC:),""-6#C,7JD,ZWL.N_.!;;W.SGB;_
M>9%B#;'F#0E9T%J5L;$$48UD42N5?J=(QRK+$F'$OU7E]]/)Q^%\^YV^F&9P
MG'HP?+I/*K>NDO'&$"J*H_(L:$LM-T%[0US%EXPQ^20EZ^P$5>-N35K0I!YH
M$N09WZ^-0C?:!C%!2) 2"^4IX0R;5<FA9.UVU8]17E=I@!J1W32W[&=^(&CQ
MX:8!"]68$A."%3:Z&#2U4J(@O*X:35ML6V-6'R/+KM03=7P$VT\M/!0?<J&F
M53^OXICVQT$VGT^''V[GV8=1/IA/!DG.Q8::3D;IPS\EKW.1-#XK#W$7'S#Y
MN/@7CG.WQ]WIW[HH4# >)!<^<;8F*C)O5RW_#!;M#A_YO X^F89\SR>G=Z1;
M503 5&8@> @@;X/C):F'1 GK%"$>2X5-X-3+0.*JPR[FK:R,+M2X,[^9J9VV
M]@-]W0-]/6!V9O7\"*&%$9I;K0ERB&G%<*C860K4&O#8$3OOX1D1L/,^:_L^
M*?6Z:BQJ-28L<&Z(]-Y@YJP.QHHJ2<-JLA4U[LQ19V*G@Z# 4=_-86_+.;?#
MR:=\/$@;[_C98J5)K)>3V^*3GS7J;=N@_DP^_],V;M2CED\/,7$S0T?7^:B8
M8N*YX(1I08SV@0=1G9I33EL5(W<0<L\.SC?> &#*;,^4V3VXO1@'; 6U>@Q.
M:\*1:N3C!>6P,LA2AK@(C 2O>=4YQ7';;J+Z"!QU%BI10G1;)OJ87 %S7A/F
MO.P)]FNSMGIY0+R1*:9HG5O%'"8Q,AFD=D@RH@,A%?;)0%L5!6N88KU-Z-AX
M=_3SK!DP<QN8V4-H?#DCKI>8MR[*-3)(E=/1"NX,<=PK@JF-?H%RG&#M6Q47
M:UAXG>7%4+W%IOCWH5POP>SQ>-P.4>TJ+]^(57KGKH+J=)>9J3V^(2#\U[_N
M0UHK*#@(_[ 4_-".UF[RZ6!VE4WSG_89 5Z[UA^2IH,L#X"R0<B@L%NB8[Q_
M?&RS67I;GDW'Z8)F-2=#XLLK/(K9I],6BAHS>I2+VCNJHU::*J08CVQ5G&=D
MJ_XF+/?S^WQZ5NSF<I>OF0!3_4TS+DE684GT_4&=QVJW,4E(@ND9PT,2S.M/
M@DG_7W=ZC44%42!"Q1 MIBJHR*N</*9Y:V;!NM!T7S+,<Z")'6,%*3& 0&!J
M@:G5PK-&SULA:-0D2!^\2\"&"96R2FPQDK-GF%JMH]_GX%G110@2C@'IP-9Z
MY;96H_XA>7O:LH"5"8AC+FS4M+*U@G8;NX'WI:4\!YOTL=RI&]CC[)/7$"/S
MP]'M/+^$*!F8;KTSW7!C@!?Q#J. L R&IS<HW>SW:-M#1[Z%Q^4^AS@9V&Y@
MNX'M]GS;#3<Z/OL0:)#&("PX)@F<K/25[9:>:4T77!^<(%(&&-0?#%JG&&:+
MF^"U&6,;WK5>FFJ-P@IK7: )"XG4W"J-M5:J.M#D'K=*9Y]DJG4;9V/'NG?5
M9("BKQU%^PB6O:@GZQ$*KHM[LL8]EYQ2:QECUD>&O55,R\I%Q<DR?)85V'4,
M;WMS,+]?7M8G=(/ZLC[GLD+YR>O/<049@X*#\$'!G[WN@Z@O^Y_R9N:7;[.T
MMNQ3OCBGFPUN9_GE('U.6NS%[2B;I\N%LK,>@\$A 0#(\@"8'(0,"@ME9]V7
MG6W877V38XI]Z+N^T<D$9?6H(^J]QMPQK'F0AF#L^/)D C-'4:N>H3*XS,+>
M.KV]_I!/WWTLXVZS=[?SV3P;%S=G[1*LA<&V61MBC8YW&[2#O)(7I()G:_P^
M*?:ZJBSJ<4?16B$\-UP*+J-/&FQ6AXR.N=;$T>>J<BL1XQFJ3)#<;3]QT-A]
MT-@#YFA53TKQPJ3_J P.D:"PPBC:ZA2-8--J/ML!1_^S.XZF6YQC!AS]VC1^
MGQ1[355FJ*'*A"I*?10\<.\($]K)BJ.%#6(+'-V9*A.DMS&:N(<<?1A.>9=U
M+D#YSZ=\UAA=*BFWCGN3^)T9'KFWB%>4SYEL)0P^@!-+$;?@8@>..9 ^D/XA
MDWYC8*E24GF-B?#46<:Q13)4RAQH6-<Q?X(R=^V:[S3*!CJ[#SI[P#PMQ$JU
MN< V>"PY\H@H@Z,CHE)M'UFK1+T3GN[4.=_>&%/@Z=>F\_NDVNLJLZJ5V>%(
M-3(!:^^"4%0%6L_;Q+8U_J03GN[4/3^@-A1_*9W3U?/ES\;EI(V2OZU2[0CZ
M\\^-Z[O(BPG16[K";5W#T[<_7!M<VPZO[2S/!]G%Q>0Z?>#7!'>#\62>SXKH
MT?PJG^4)X[+;RV$1<$HPF&AOMOBM'*R4%4]_'(ZS\<4P&Z7+24]<IRN>';<6
M6]V#;Q??7NN;[]^<+=X*_@UHE3^OIM5GWR2R>/MAFF?_>IM]3%?Z4S;ZG'V=
MI2OXR]5TN<BL)*J9TX0+'2)VC/.@J+4>6T."B1KAB'SQ-]F=N[/>DM5BQ=GS
MEEM\2OGH\^)+/DQ&R90;7$T+*ON/&0O1<XVQ-"QP*:FQ)&@6<4P_ E&TDUM^
M_S7\];P,74X^#ES!N6DGK422M3CCH2WU-'TBG6TB4GLF^()G\O*^!=J3=W\+
MIX.34W<\,*=^</:[/3OQ)^:WDW#6$4+L>$7NW:D/IV?!#])O9^]^.?'F/#TX
M.T___!I.S\\&[V)ZZ=?WOX6_I_>=_'<H5O_NU["?R_UA!8A'1:9Z^HY1,MAF
M/ZZ_FOH;]5/M%_V@U_ TR&R\^XYS@)+E7][L80'UB\?-CQL7=NSHCO^ T<);
M6!PZ7.2CT?+5LG2S>)PN\Z)Z?,\JSX?7B6].\\^#WR;76<NM^CR\G%_]I/6Q
M0DPHR?]<6;A)4J/L9I;_5/WR\[>V[)O5:=#*E\+BS<.'18NO8NDKJC=]^QK^
MSDO?>ZWSEP[]RUZTX/5AGTEUA45J_?" ?%)XH#T4L]/H0 N>.[TC]\!QG$P+
M0W5PGJR7?/!K>L/5;% :!B%!V.7@OV['^8"BHP./(<$F*3;)V?#+T[8(P$P_
MRW9VMIGNGC3<L[6*T/Z!8\NC.V,+V-*;#7+_EE"P)5X2+#8; @Y(TO=M<R!(
M<1 M !HC9K?9GKL;NEFGV]T3D&;?ND6VE]91L\@GW+-^I90P1&BN5=TX%U-,
M/!><,"V(T3[P4!]"<XJ_/81.V_^DW/V_3&:S-7MY;Y8L<L0TVV*1UA/VQDZ4
M!5))^H"7/83%[0#AON+=>@B'TR6N("XHAY5!EC+$16 D>,VKF5..VU9R^V,0
M=U]'\(T@3@EQ+'8)<(!CAX)C8/>!W7</*N*Z$P=SF,3(9)#:(<F(#H14J"@#
M;57YKF'XM3KD;I98>*01.=Y>4W P_  PP?#;.\!;%^*H;LQUU]$*[@QQW"N"
MJ8W+H3"<8.U;"=9K&'Y=05RZS"UF3^^+Z7<0 <-W\W17!D6BZC2_RL>SX1_Y
M,H (+4*AX^"K[S@(L@2%?0WK.QB%[0\IW_F.LN/)%FGZ]_$T3]_][_QR\"D;
MCF>#'T;)"LQG/PZ2D3G++V[371SFLT'V1S8<E2=^R< ;S)*U=S08Y_,B]W^>
M?7EN2>0!5CDO['9,Z\)(BB/"R'L3F59<1T$YK\ZD,/6MT$1I8;FF@56;\:82
M5YQ,SY*PSE:2-)?_[W8V+\I^DMW_[N-Y]F6;QUFTVZ8&4-C\@@SPF!;OD[*N
MJYZ<UX.@<;"&8D=4=!0GWYK$6+G5Z:E6?Y$MJF=G1S&HTX,8T,(>:.$!<ZED
M]>&GPUA%XXGAIN!1JBFM&FX+'EN'G]OETF["9QAUVQ@0R+3':KQ/VEKIYP^/
M*:BN%=2%(+"0E!M#E/9>2"0J!:6^W6UWNVSZ! 6=I1N:GON^IG9*J^TM_)R]
ML.VX[X_@6Z_E6U]DLZM!@3R#J_SR4SX#=WH=$^ QB"&X-MBUH5YQ:K4FB!0=
M +G&E3_-3;LAX/<@QJ=+_".;I^=F_[A-Z_]8]-XPL[^7HNO,D5X'6ZCL-DG@
ML;VR#ZCS[5ZY#X/ N-AOX^(QQ:<-3ST2R15C 1N'D4%!<[LZ +>"[D+Q.W/1
M,27'"ISTUZ6 A\S0O'8"/(V$2H(TLI@BY36M9ND(HJ-K]>G?$D-W;/T3?(R
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M>32_D3FH&N.O<20F8F\3=JH@M DFK-#3WM.N>"?F8)?).-OK4_24_=7/M !
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MO/WA/%.F5 ZN\M%E(=7!+(D8Z&]#^L.D5DZ"O/7)3#522>=D)%2N0CN:B];
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M6D.U(8PM(U/,6ZF>HWG=TR/CG6H>\.-V,]FNLO&G?%;TX6TT%KCWU/FH:$<
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M7=EO'1,V:F'PC&8KKPHJ>=UD3JI(O-&(2!T#-R%*:2NHI,RU^DV7@+8\%U]
MX,GX8G1;W*[WDVGQ;6:^&/-;5 B>3^X>3YXL3P)W ;)K]U( A 6$!;-K4RP1
M=5\G(GBTS*/HJ0XF.(X,6[6_Y8QMW>Q:%+8\W^9J#<+4W<ZS E!X%:  9A>8
M74^!2E5#I?=46!6#U5(SIJCF;M4>5%MD>FQV?0]D-^U?U?$D,,!7P%? UT/#
M5X;J]GTA&:(Q$&.%0998(PE9MN\S""G2C@#V!U_-9566^SX;7IZ,W:+6%/Q;
M@%J 6H#:W4#M@U-O*JPEK#&R3DOE+=4F*J0<\8+;"FNC0*C/6%M7<;\K"J9=
MLS8Y7=7D.G\:[JXS9*<()W3::K_3\=?[H;R;3,<&< =P!W!?PXYFM1W-//?<
M,"\0H\92'KS059P".]\.Z?8'VZLR_K"LF.\L6('E$2+B6((9#4@+QT3K&HQ<
MKT#%::0=10HQ)@PU2E)?.>?$!Q>V?DY4]4_H_J2HXR%*8-D!WH!E!Y9=9R@L
M&R@L+'5:>.%41-I2Q#"OW':5'/@>FW;?Q^_G.^A'6LK=G$@!D .0 Y #D#_1
M1><(K7#<.$JP4$Q@Z;@3T7D9*Q>=$+]&^/5^3.["4Z9'BNAC#9XR !X '@#>
M,RQ7CFO+51M5S$5G&BMG S,L,%4AGHNZ%93\=3B>3$M[M4,;]'[SMGMC5.X&
M/L$0!5P&7 9<?JHA2FM8CI$&I WRR"O"4<21HM7(>Q7(+@,*71FOY) 3_P^E
M8/O-7T_S^6!8IGL\L\/(P?+&:U[XVJU&7O--.-B%@^Z#]$'W#W/A('V0/DC_
M,!?^,KR_9_Z_$+)N)1)9\O*Y(UX9I:(S%)$JH8 8UJII34[7(L7^E\EL]HT;
M[TLWGOSCW/<FZ_.(:;:;I  XK3H8=>_933C8A0/5@_2!ZK]+]9+47<,PQ<1S
MP0G3@ACM P]B0?6"4$[Q9E0/+ TL#9K:@:8R7&LJUX)C):0F7.!(.%&K5JA(
M\/A=3=W@_&UCP[V+?(H7[WH F "8T%-,$'7&*#:6(*J1#!;9]#M%.E;LC3#B
MWV+"^^GDXW .U TGZNN?J)?M% 9W9KTO3]@'/Q3SU7\\&HSS^6#R<3#/OO1)
MKWL&;@>[</#(0?J@^X>Y<-!]D#Y(_S 7#M[<.N4P2M;!6($"49('(5'@RE(F
MJG(8@Z+#[EMW[J%.9X6#=YK/WWT\S[[<FX#]/IOFX\X"/B_2>XW2'M=U]Z8B
M BIF@)% ^N"+@/1!]T'Z8(T^9HUJIAO=@ VFTHK@4)".2&/PLALP8M+8G5FC
M8#6"U0C8L0?8(1K8$9(32TQ *.J8_J5.DE6R@D:MQ@[K8$>?\A/6P1ITS !J
M &H :K8 -:J&&FZ95H(JQ(4QU#*APZJQ-?6\6ZCIV!;A !"; ,3A)%\L1P:5
MV[&TF ME^/!U,+[#88/ADL3ZA"D] ]:#73B$/4#ZH/N'N7#0?9 ^2/\P%P[2
M!^F#] ]SX6#U@?1!]P]SX1!!OGFTB([@QO@<:KTBP4<DN??,8$1P0#P:BJE1
MB*V&F'T8#C_\=/?PJ(J[#<<7Q2";_#)?_#LI8LQ=G5<MCL>A?A;J9T'UOZ?Z
MY:N?\U(4'R:CR[6Q0*L5%A GHV$)!K##"FF*N1(%%J3?H^5*OC06=%U;_\V1
M%#LF  X #J\0'-;$@F08U'8!\MH2$4F,"0^$E,RP @L<8D[K@#O' E!@*+M?
M?=1O^<WM].(J;9JBM/YB<GT]*3YY<O&O07IA=IN-YX/Y9) VU*#80(-RM.Z@
M\5?OIY-/T^SZ:)#-TY_#V3#XBA I .F#[H/T0?=!^B!]D#Y(_S 7#M(_9.D?
M;NSGD:H"0F7=69%2167 Q%(J#-<B,FZJJ@+A8OBVJN"\B._<3K^6HQ!+7WQF
M+O[O=CC-+]>(_1;OKUWWI>=>!GZ+X-+_FN)/[G_3(O3[Q"CRG8MM!8]GY=5O
M%'ZB/1YQV^N*AD,&) A,KP5.BM=]@B0VCCJ%$;,,,^R,Q:OYK ;K[X+3?V>C
MV[S")C<I3H_F5Y.]0ZE-(^0::0 I "D J6V %$.B/DKGRD;DG*$BX*"E(W35
MKSY@:7L*4@ Q #'@EA^ =]JSA0/!K$4P# @&" 9:!ZR50#)/>[OPLB"!!%@+
M;!:0_AXO?-_L%([HRD[QBBL6HJ9$4A,]I\*XJJNWLK05K2OMDQJ'+\WX<H'E
ME_YVFN[+^W2=D\NS992^;U$[5Q(-G"STQ> Y9'P"GVJ-E'>.&VT;O94:(:8]
MDMA9ZH/WE4OE?6A-@[WC4BU!JG:FS'6ZH^M,&>@11$%5'13. (IL8O'0NHK.
M81DI,H%&QP/Q6NM@5S#BHGD=,&*2S(H[D8W>9\/+D_&R5U]G41ZLCR78/&#S
M@$?>8\>T9PL'KEJ+JQK='X35F-! A!;$B8@-,A'QZ)*]*XGSKX2KTH5FPW%^
M&;+I. EOUAE)*8UV4W(*+/6:<.IPL>DQ:-(U-&G&I4UFL[$F:,0\U7QE1JNH
MU>L*'.Y[4C+XYF#O]!-3!*X/(QBGB&&4K!R.%*&.">XJ3(GIA==A[NQYZC!
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M\+K _' /_1ZU:GD]WX!X$VEPA'!K--<!:;%*%T6!QZV?^MT9A];IN1_M";"
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MP9;;#=W?7#/X&]GIV; ]*PW?=8#K#^OVL?W%SN,4:]NB2>XCD(@DPI"%( "
MRVIP*\$H%*_7W6+M"->G@3D.WO84WOK"\;R=[T*C!,<!I8%/$QZ)),:LF37H
MD^2I4^N?SK>;&KL*X2::_CO6W5/6=9K)J^,4!+"#4X0@$:M_20A]Z,N )PU.
M*9L*]5@SV9J9J [<'+@Y<'LM<,.X';(7 H%X*'TJ(X%Y% *<U$T%?1R]WI2
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MQEFE6T^?X\O=H<_QY>[0Y\YR=^AS9[D[]+FSW!WZG.ZS._0YOMP=^O;9JX<
MANT(7R'B$$>1]#E 2'(2$-CDP%.QU$]L<3Q<7+GRDB*_ZGIORKMZ _[53E5R
MD33GEG<,? <#/U3%AD"G.ZZD,1>(($'#((B@2% <U'[Y!-&E*I:^<?!K5;I1
ML-;JF65^>,G%<J5N#B76CQ)!BQ(BQDP2"J%/*"6 BIC16LYCDBSUT-XX2JRC
M'LYQ]'Z&";]EU[-B<*FNH^Y/.LBOKG+]X'SPAZ?^4,[2R51'#Z>7F:?NF^^=
M7BHMT>M\ZJ3(OQ?IU8&73M7'74!QCR2!,]ZWGC['E[M#G^/+W:'/G>7NT.?.
M<G?H<V?IZ-M>+P9";5U/% <^C6@DL$@8D12P.*I]G5$LHT4OQIGV6<R*VU-M
M&QHKL!2#?\]&139\A/M2O[\U&BN;T?@N=8[S_PAM6ZY^D_5>/M$1.K?8)?]G
M:5;_O"QHL-899=OO)]D#G-AOSR?"[;0S/PB1D&'HZW@(3*(@(J0>M8L9$O=B
MQM_3\2RK(2/*=5QB>IEO'7@\U\.*#P!P3E8''OL%'GYG]*BDDD<4<!TY\27'
MI&X1ZJ,@B'%/P<.QOF-]9RONNZVXWS".@8-Q!^/['2:?JBNK30<7)G<BPXG_
M/3O+/13Y-&C=/A(GA/@^Q5$<"!DD(0#-D/LP1(LBWXCZ%ON&8C*T^#F,9X7:
MB!.ULGQX6GEA^^;^B0RX.\^QLP"=U?"2TA@<M#VJ A EC/&$$\9C'!(6*TBI
M$"3&9&D\S)S14&%':RZ(JWSVJ/&5/4(.5T7C>'U[>?UA=8&WW:U\%(%8)'$0
M\8A+2!(6PSI*%,2QOQO,+M0AZ:U(QR?I:'@TJ2:4K*^O70 /D5,8]A1$G,VX
M]?3MMT @N-7^. MH3 -.20@YE"R*,6]3C6BP&P)!+30=3;*A3(N).JUR;9(
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MR"ZRHLB&+^\5N\G>DP_>HN?="*=B;5;MZ!'S;[J&_C\VN3T["X5!J]:$<<P
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MNUF$?K)Y89BI%:LGF&>I=61IJ1Z5EMY--A[K_Q:92<ROOL<0X:7#?REZ)AI
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ME<YW"YM+M,N;L8ZK]FY782G15LW?C573\2QL3RVIF'U79VARF^_#(Z;]#J\
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MNRJ$_AI7K9P-?V]>"?,F_.1ZEJ3C3+JO\;?/%$X6F'@H<]+81^2R>E6+U%Q
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M4SKY=3JXO<[6)G_)17:Q<?KM?WX^:T*_E<EFA;P[)]3=YV@B4ERDN!K%L:J
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M>YT..>14;@3^R\#G5><H()VV& H$)?8 <RP@+(!O.*<[!GX[@4+6SBDR0&2
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M4N,,;KS6:^=N^8%$X!&CAXU1PBN,.BDPP(1"KP4#WBC'BGU3,=9\/69GO&<
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MP%X5RK@&98.-M#0$$UXI(1P 16-(#:GAZURT6NU>].$$#A'7$=?=PC6M%(.
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M(2+=REVU0V/93E[>W(R"1:W?K5(<(P:-5P8#1Z #OJ!@'YS3'5-P2[>UCS!
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M8G";<54RN/S[W6,B+SJXW86_R/?:XT2%WV?]-.Y&\Q;Z *QJM;7VWAP9"BT
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M36=IW@XK$WF]7-A)IO*ZSIIM849:!_W)^#*]RJ$5P# ?C@((;V[2:=9)(5X
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MO_[VW[/KFQ_-;L+S9)5U@9*% CH=%&]Z')V>G2?^KP"1A"_P4:R2E9Y:]4(
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M>,^BWZCZ0(2#VFAC,*;>0$!*X>IXOX%JI;#+!JR#\[MI=C$9++_P#BMAXXE
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MO,W*1^AM/XLW>\O-XFFG1PV A<>Q.H6S2.BXQ1-0.WW0Z3&#:CS+G@A-;_U
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MU4!8;&P5PLH-V "1]\D[N>GC?F^>T%L1\<C_W>1_1/P^Z-6BCC5F),4:6:@
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MA<'8R4==2AN*TA:E[0EIZ^2\_<=H7 E9)Q^P^S*/'Y/Y \W NTA+_=[DNWL
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M(\Y6L2S*2;F;1OM&@EO:/$$2T1#1T,4X-PPAKMC %$X=$Y)"D K('3-4+=B
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M2[(MB^,]XP/$+LAQ.!;'WQ-])Y/Z^90.G,FQJ<E!*D@)!*20**"T T,5I[&
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M4KZ:U60'=7(.O-<!;^ H%M^)Q^*8/!R3AV/R6-1B'%0L[RC&B."0J9#*6!$
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MGJT":@/4T>H$7Q!?JEA$-(H1QB3&6!;]GGRL!%W@%\GK J9CVB&\K4U@M)=
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M75H !&4,8"(8@3ZDDM"0EKGPDFN)K;&.8<%"!2.D,,8AA0*4]B'PE2_B^=J
M!FL^MLQAMT850WIS8UH##&\*N\%T_\M6E#-4)!WF>SW+D#:7C.BJ#&:K#"
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MS_^);59UXI[EGK6'9[6ZC*G5S>0;JRXZZ"*B)7.W8;OO=T"5Y43B69%XKK3
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M8OT=YWOA>8LON[177=&#KYCPUR0A?+""6;2&3*:2^?KVD&_I+HEFU_B%2N9
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M WI9K42W[\&XH99-.ID;3^[=8CSR?_8*?KI"2!=?\@367W#2G_[S-EPWJ *
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M8SB2S(V=CV^':[O(29UEWY++\H#\L6]%K%\"N<W=\VYY$<_:,]H<US' $J8
MD-!02OP+#6M[9HA8:2U;G1CZMC!CB[H,,<C>=@6W5EM?/B?K^U#5_;ZL1X!K
M?ZQOS<2? R[> !>B&$CK"">*<"6I4TQ4P,4=6#F;NSYPQ3CU&\>I8QBC _!Q
MS/Q(+L&,!-11+33F'*80,0Q( S-TI;GVB_A1]/8WYT<H\J/(CR(_N@-<"#;
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M$#H ",?+,"@0#6XX!HBSA&..TU3X;Z1UP1$'W$K!D8,(B.P2-]K,S8H,H\N
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MHMB1(6V)(7% EQB2(H80+2CV?QIN%) 59@EHTK7J#Q8KF?=7BA"J_O_.I[.
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M/1A_R4?)Z:AWO_5X*VWN-XJ6;GN#^2V*;#\W4:^IPMTMDO<<6G.R=%H%4:.
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M DL&6&?\ZY;M\4%$O(_"O;8WM\/Q][SRK6_GD]ZU%[OD=IB-H@W?T(8CU$"
ML0(X95(I($8":,( J#-7 &DOQ/:\3UVM=:'_ORY6.O1%;?$\1SS"'4UW][1X
M7;TEM.'>2DA+ +>0<B&(%(;".LN;\?:J)SWO2F]?;P\D(![5,UI?K\5LJ1HI
MLIHY[,VN4, ;8FE@O4>-F&CO0.7S'O3VM5BT>F C6M\NJ_<^:?&Z>BL:O4VM
M))(QQX262'#(,6^.:&"]RX/0V]=;=A@'K8["7SX[OUBXRN/;L%"O/@6]RT:?
M>V7&,5@RXU@S[RU;X" %".,T-(UBBFFL!>-B)754SZ>#43Z=>@RX'(P*"#C/
M;[.)1XCA]\]Y;_QEY!^N?^&',2WO/EU Q%2-^C^/I_Z/YFN;GJ:^@QR?"G$I
M,:/^1O6<JO=_\\%T$+[1 ,]96)3I+)NT1_/9-IH9O%QV(X/H (/81B_8CC,,
MC)I*YP("QKEST&A%E$LA\8C#%"?$*2+@2G7%K4/*6J>]WQY2_I-/QOUL>AVD
M4""(?MHAH$3<V /<.&+&0I;JNCAN44I%JK S E'G0,%8'# 48KFR=;\+QO+\
MP=:WAY?(6"+R1,;20 IK( 508UC*)"2:><LKM4UU8"S0,(H16SEOLPO&L@^0
M<I2,98-@#-R_:,SY_'(VGF7#N%>R*641#;Y012SUG@_2#B"J&4Z!J>K2,K)I
MS>JS?/;IZB+[]F@0I8V-#Q13!H^&!>R33JZIA00L58XG4*60 \0E$YQQ#75=
M$%(;M^&IVB>T4+2EA02U6F\J*EL'E*U5R]C)OL<;F4V"FLHT3'+()2)6>=MI
M'1=*\LIL4BLV;.C^M-G\5RL*"S':3;Y>-[L>1SU_W5@[J<[K*C!I%%@K[TD+
M:*S04@@+ 1"V4F!BT89U:9ZVN.THL(S-R0\DK2#-;@?>CPV!EF0:Q.K]99 K
M+SN-8/D7T]=773_>Z/TS/5H080T+Q]B_@DI1RK2T#@J*ZKQ! ,C*2?@ZRI5/
M?A\LJD*N(,,"./Q?GZZ:P-JO?@1C_SV_MDM2H&[\&LRVZ32WR]9?+5>Q6\OA
ML8I##-@_BR*B01'FH(/(:HP-808[FC)5,8MPK.#M4*0UIW^W*+)/8!'A(7*1
MC;D(78H($J*T$I(!(A&U ).4+G*A =$2\S?E(NTX,JS=DGJ1BT2PB5S$HPAJ
M=O>8X!@(P$VJJ&20A"Y4===)P%;.,^Z4B[2%(KO,%=HGL'@8'HXD1^"Q<$I>
M!NJ2P:@WG/?+4H)%-D$1:$FR4;_ZRB-!EQ>(#_;BTQ_/+X?YJP!GZSO3KS1"
M?]S&1#UKKCN(T!OM*M&E4HS8(V,:ZJ0#JCWA$U2[M I *4+J;>"0)/7QR4#T
MZ4*\3T<%(JM1O\KRVFI*!M@BI7N)D,3MI>V1K]T#X)M9D:T@6X<!;%W(6BH^
M21V$E#EHI6"4<(L%D17#]"ZKWA)DM9>_ MH]/__<ZD=D.B1D>MODAT/C;9W,
M+=B,U"W5\X0"IMH ICQN8LP5%A#7F0;&;@LAVTL80JS=-LX;BU W4Q4BL&X#
M6#N(GV_'!SL)C&M"(5NJC*JY\EB(H>982$"AH""MH%!PK;9'%MN!0L%W2Q:[
M"7A%!/'/L\P_:?5^*]<NY_5L?N-_TKLS."^4^?OKO !#B, /=W2FB$X6PQ^,
M/!;./N+PQA;%_G_R))_.O$3,\F1VG2=7V6"2_)X-YWDRODK&\TDROO0+48CK
M-,FFTW%O$#('DZ^#V77Q^>U2>Y.BL<F[HIU)W=YDY?,B+GF[7E.4))L5CY7[
MG_CGR;/>=3+);\=> D=?PD4&X[[_@C>P7ZZ+6&<O/%MYD1L_?Q]*2Y#.;^9#
M/X;?\R3K_^]\.@N?39/9.%Q\FM\=XR3WMZAV LI;_M\\F\SR2?C!)+\:^KLD
MO>ML]"6?%B'7Z[KXK%_LO(R[+B;5/_9\UAO?%-,9OK@T\/>3?%A\Q2MYOS@U
M./UP5XPZ*S;G2P6$ZC#T8FJFQ3BS7B\?YI-B?+^'V?#KY:?@3N4A/U_Y[X/Q
M?#K\GGSQCQ"^ZZ<X5"C*%YLW0>:2S%]Z.A_.*I',FG.6X2W__0^)&_OW^^4T
M9D._+"7T%5\9/?*K=\GM,,^*)\_ZR=G8ZP!ZEU1+T-)DE2_#93X6&TD]/WU+
M!T6G+=_NY*_O&KD.@A66IA"Q G&+];@:C+S\#?PT36?^C4(9/JP"6+ ]@]$\
M*RU#\7966,0I@Q0+YJ2S+&SE V4U,=(9DD)IL41>U/Z<O5B(Q5V91:W)+&I<
M'\H%E*S\\&OY()?C80BR0KH B]5__^L.FC_NGMS=?_1FW>O]1?;-#*:]X7@Z
MG^07_F=ZZ#7@I)C'\/(\#SKC9_@](SH5$FFNK59$ ,W4HEZK01HS^WXIX1NG
M" E,E!-<(&4,3$7Y50$!!Z;D#7[M\KZ:O?@^\,3#5R^[#99X,L]/_EJ.)/%#
M"1M)]TS;';&Y)S6;C!*^[N'1R2M@$[)MPF;C?>/+[ %<>$ H_90GG[V*KLSR
MR\7QO'>=]^?#_-.5O;H*L_E[7DMHN$78_?:@,!P4*W<1&-&3XDJT,U1SQ!U(
ME4(T59)6*\&% DOB"AQ+@0WG_E,%((<,+;((O;@2'"H5W96WM1>0[=CLJ8(9
M-+.47.:SKWE>4H!_?CA?(,A5[IGN EWGL_'D>S+SZQAL8<$-@C'*JS5H/AIX
M]C._N<DF!>_P9N]J//1N\?3C^IQ@B3@'EC.X^O[ ;"Q=X(XW"^Y-9GB]?(=1
M,*C#NPH$2F^^X,^)-_C#Q:=_.0$GQ6O_Y+WJ]0,K<#&X\2;^+/^:?!Y[3G3_
M:;\.^K-K_Z<?VL)]\#HTS&ZG^<?JCY_N.PLG=49 G5D#"X/T2,) >0]"?_CI
M9,756=P?/?'99A\=SA6?3\$XG-!1+5"T2ZE:/:^L^61I)*(MU!,5?;UKE +5
M#H!W<3W)\^07_X7K:5(XP784LE#^/A_E"0;OCC.^&(7DCI"<#[Z]3$3>%% >
MCSRU.E_[F'[^@JG;KK#=W<1Z0/0"!3YR['F+7.+.",C#(B&B2#PM$ML%B\W"
M_Q%)NBXV1X(41W&&_[R.5TQ68DZOJY^R3V=37IXDPW-)9)/X#/T[F"",$2:
M8@TQ*Z-=%"&N5UIFKA..4S-7QI3J);KSY77RH$?SLOQDLU6,ZYWB]^CI([)P
M-WUY]NE RGTI*<'TA^.T%JV/K\MY(%[;E_ISH13H%#FI6=B),-:&;ID+;5=V
MM3OF=K1])85X5=M/S]P;Z?L^J754Y!U9]TZF@6UD^KE<ZI9-E0/:>,//,)!
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MH0%"MDB'6_WWO^X<]WV\L,1=&MP045?9B=/&##?D-!P%T<-Q[[>3!TZ& *&
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M#:K8Z8XJ*)-6ZZG'Y,<CL4RMCZ^3B+!F6@FC3:_EE!G!K#*,<:@1Y@1:6D(
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M$^1,3[*4G:##XV%ZDM25&@\/#QK&\88WOQ?$]W[T8RJD$R_QG[(4;@@TN\/
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MG(=C(9C./'P/2)^*+W?5WT=N>H!9RWD*FYZFQ $Y\1Y\(M?2E/DO-[F:UOB
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M5QNJ4(OGH37.9_IK\&\76OU4'MI=E*G<E4\+.:BE!<,V)$-V=4.U1$GI&>;
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M6P/13;'\,][>O17@V/-51=L#2ZJD"BJM(A[X*V(/EAO%"T*F8L-^VJ RB].
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M L8C?,K&7>&,??+E'[0SUA/2^RY ON51TPDB?;J%7R+R[3]@R>-XR@@X97>
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MC[9VP=NWWC?&18Z3B9PS_(/=!\?"?W*,Z2"(OA"Y-X2CW +&3G-:L?YC''@
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M=)C$2-6U#2:KO_KUR\4Y*HQ$G_MT_B^[1W^)"<P!!N1L_.6U>W'>!_VOLX^
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M &*Z8BL/CE\>J ;&*>Y2'DBB6>+F5AZ\3!Y@* RMCIMA^[!*$VP:$4UO\7+
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M)T$$XP2T^G)&"H&#%(D3 ,#83#XEI?=)JVNR"!06Y?K(ZN$P,!_U,0:Y,/Z
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M?0H[ V%CNC$5E+2ST$U7&,0Q52!)OW)[L17]V<"QWQ.SAS<:^3-R84C/ZX?
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M3QFN=.&*3%\/F68".8GYW*HWU@CDK$>O:X1QFN*M>8M]:Z38V&?L1(%%ADH
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M#'^?B)F""X[CK[8U+>V%6X.KP2?[GA>P\P[Z3V]KC\,E'#'X./ 7S(T6Z?.
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MH3!P.Q:A'C5EL(@?1R=P38)K2E, A52@9-IR7P_-H!632F=^C.MF[ -@P%&
M\TU72:[R&)B5KO]"NKZN79..SF:)9HQBNQQ#76NT=U W M3):./^&MUS@! #
MKI&:#48 P&$*9+&:O-3#-1K@#AH//.A/)B&PAO&"]@'@!+Z NBP:0WD'D7P)
M_I#?SQTY$1E=$3R(F.,IYXED):^>ABO*?3+EEI5PUZ=;!B:;&_J*F-XVVV:]
ME5CC61]$SAK,.@%)8*)\B.=S(.1$=@JC#XR]6_).WAJ7GE4WWJ4?O#?(!B'C
M!G8 KP1^X7%!]_0P7<K<\4Z .RBBGO*9/Y\ZKL.,<1P" 8=Y#\>@G?HS],VO
MX\NH&]]RT-0.D'JH;R44'ER+8"S!*U6>B>1N,^!2"#?M,(X'BT=^L$#%: H
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M$+;/+\XZ ]/L#=OGG5ZO-3QMG@_:%^8%_''>[+>VAD3+>_CU&Z([]GX:P7>
M$&GL@RT1P0J<^LEVPKG+D&T3),>N;WW_8-PY=C2%JP9X_I3Y.<@$%@D2ES]J
M]W._6;X2G=50H(D0V?% L, ONO#!'@R(UIC)+W'1GYT(",DJ@NH((TH U&OF
M\K!FG-];;HS;-Y9&4U]F1E,G:;V7Z6CJ8<%HZH<@!0=W9C=&&%B_O,'(EC_!
MWMIA_<_YS1N#N5'!IW(IN4IS ,S_@[B9EMD3<OWOL.;:_'"?U])I]9NM3L&U
MO/GU:^#;L149F=M8'Y ZRG5S&-=J[O)H;WZ]\ ,CFG)#[79K"T? =#AA7NC<
M;WUU8P:?3$.# Y3L[6_^G[''A0K8:M2,9L,<;/T5-</R@221!B.?KB!D,V[,
MX=>^'1JPTM9?">?H[^ <N'?'LT!\AIPV/I?D8$ER( 9@W/$ CA<X,Q; BPP[
MYGCP*9 !#Z@A8,#@F1GSX@E3+0'"J4.5!<#:U!MLN1RLZ\>!,7;\T(&=LT"]
M5O3^A].I)W!+CG<+R_C!PF S/X8%C3O0^T$.@>YYAT,##(9E#;%+&^;W6.=0
M,_PQJ)$\!/W%XC4C]F#KWWDDA@HL#* <@!%L'M_B>V'=^#;EH0X+<60&C)BY
M<&1_,@$.:XP7!A@K/%@!)Q:&ON6P"$YZYT13.N6GZ^1TRQK89J*LM(RE8B=/
M9B=EY28/,!.D6#?T%1L1!W;I[Z<..@1 \[G%W\_D<_B+@,^8@Y:,,>4S?SX%
M.F8G 7>)V%(6 1K3%'D(D1\3;QZST EA=13Y\/Q;L]>J=PPXI(L*%NP3UY\X
M ?ST?S%0/) WO!2ONF;,XR",&2A><J/PY2Q4>\HR/)*7\7P.W(+=@  E?8WV
MH9V*S"G:,2P(KP;FZ7&+-#WZ*0%C[G@GP' 4GTP/;(SC$#A%"/QJ2ZSDI=6O
M*W\!ZN:B4K\J]>N5JE\VU]2O0)+#.NH72QY-G\1Q27.V$/:ZEZI;W_YS/3R]
MNI1Z$G*K2>#/Z/W\?N[(N<G8W9D'$2.6Z 0VZ3^+=.E:H4*4:G>%>Y!:8K*5
MZZ^7GZ^&_QT*R_;3U?#CV66]R,>C>0.D!^#'#X;F%_@I\?3F?RY^)%QM2]Z#
MQ!UT-FPW3CNG%YU!H],QFX-AVVR==\Q6L]<][_5[S;P[Z( 9[%/<#E=Z!?#9
MJ@K@=9T'@3T7_D9_$O!;S7]0]$76A=#J=A]V(:SG63HH;V4WGRF^@;>R<CJ6
MRNF8I88,!11A?;?9W-QQ]I+JSA^<M%L_B$@IM8/XQ@#X6JC:+O+M! P^F< O
M0>N>!GY\(_1:D-HS)U)NS! (UIDX%BK7()9@33#<4:XEB]96=BM R^(F8#/A
M+U!*<>87/FTU]FB$X-;4Y59CMT >9L B_!W*#%@)#%060C&,06@-L%DGX);Z
M!@1T' BC([U"6!-M$M==O2Y8-LZM&,&(7WF^=Q+.N86[2RZ G#O2;ZW]/IHR
MT VXQR=.9,Q0Y9B[7'LHC/%](5I0P!'34]3PPSL.NV)XG7,XA4.Z";X',&HF
M%)6(6U,/1-^-0#RPP<BM<S(F-415:"BGCH "Z(O)P KXD7+_/ A3:1M2N,]@
M8X"8<% %(K8&T/,M,D!)'<L#![U,(0;BGNWWT0*>^R3YJU70D1!>B5F K<+?
M!E\EKCV!*#Q4]Y'SE2EG@>M,N+6P7*XCQQ[UP\VO9H<WH9%60F] $A.#S>>@
MYR%^UE; 5=@8&F.<&!Z_(QYA$36%-%N5WP/S0"I.G)7&1UA$(+#&;P/M'W"
MKU.T/UK9-P1DD/ ;6%%:%H(,C',6@.FPUI(F+B/^VM17KQM9K$PD4(#<(M1I
M5^(FT&9&<&E/: O!3KW0I=TRUP@M!QW'2HS5R3\AM@JJD0N\52!]'KCB:((-
MQ7-?_$"Q _@RBH&]3;F7[(YX%"SI![RFF;+R"<N/79!ON9?:SF0"S\#KEEZ=
ML"Q:9@''JQOHIP@Y,7M%G"DC%JZU-02 ](:K%<#P<($ADE-+,$7%4 4,T?L/
M8/M"/T70R1/0P^$4EY-.M"@IKTOOK*P,LW()52ZAK;N$'A/"Q=ZAS!JP&1Y&
MOB=0*)Y/ C]=(-&3TD=6!K\RL<)E[3+OS49BYP4\G]Z8<5\]O$.*&:1'5&Y_
M>=66ZX<HN21#P8LQ+GW/"8VA\L.37HF</PZ1-8\!B'=E93)#V(L04RZ82).=
MLIR*U1QWM"[C07Z4T2 -%?F>UV,$[K(ZN;6 ^([-\C_PF!'WZ,K% ,18^3-(
M:5[IS(AP+@+RJI70S3@J4#D$UAO1GPYF-N@KQ]X,V+#'N4VKB-\RX8J!']B.
MC2 &G5FHG3ZZS8"#XSY AT1'/,H'I3V2C;"M&WCI..*GC/SX7<J/\\)>#1M[
MV':,997V>(@LO=S:XV-Z5:'N*(Q6!] 1+4A@799_XSDJ1,B,M^U^M]Y,,B@\
M8$IB  P^_*@82>SBM?2V.SCY5.2,D-_";)S0ICBFRX9D?&:3+<0*I '3NPT/
MK'T7=A,Y(;W?![7-]V++Y7[DV#S'/H4WA!GCP&? M9EWPX7+) [0X8@E$:A(
M$H W9)[[YBN?'L:!G6F0%;,I)E)*?DH].L(%DR>Q5E_+47HJ=5$8%$F+THQR
M_AJ95)ZLE'$B\>#60=4E1U37WQ=3=O>],$Y?K@"M605H7UF ]J#U5O*Q7Y-1
M]%4:1>40*KM55BNY\7K\#B$(+A$_+LB>+W :Y)R!0F?].4LU(F)K<=>5-/++
MF\8;^C?\RE+_3GA^2D9]137R?-^<&4C#SZ!X7ODSYGTPEDDJVP!1L269V"&*
M:I_2+_%ILC%;DMP6;]W:96&#X6;W2;74V/'QD2/L,6Y*N(8!/W+9)%F.^/&-
MZX]!EU<!S"AP0"\CY<N.P1J(9VQ<(],&/CIW0N: QN3,QG$0DEY4!)1,<7"%
M@A4*XDJB7HB87#YPD0O+VT[@W\-EN\8$L"] SO?N]/+RM#'HOT=&B95$6CD"
ML4=0UE'K1X4^I^)G%?BA^YT'B$> [\&,&9>X%7CHHS-S8$<U]#3&X]"Q'895
M%)/T@;EK?:#U*X2O$'Z[",]=[HTYF)L1BXQWY\UN8T"(/CQ;0O0<<@?DF$G1
MFQAT/LMO&44/-L#P;>J$J5)$"DY!]#57&)DH3@]"N=*,*BHM.,#I\'.SW3"-
M=\.__3!H=S\8L^&8B$_$ZS<DP8R_UKYEGJ62(Y<5^0<K[RKUJL+C]?"8%*26
M\>[&=<;<LUQ8Q^;&Y;\)F5WRFT[YS GGV"[*PC1B%HC(]+N/_[A\OPG&BN*H
M+,;V*R6I0MLGHFVW9[R+_ D'D](3BL_'ZZUQT+ROOCS*T"68.A29P&,8=\*Z
M$28X\SP_%B 17B0GI'H 7[/R^6KSOF:<?_YM^-NY6/'3^=5OY[6LR5\WAME^
M$I'4S.A%M4>JQ7&OEA7$F* QGY,U!Y<&XO1MNU-O).&<G+Z&->6.ES@G;EG@
M^'%H6  S"C=*UT0F:+-<KR":<(3*92%+.T6(:>M>O';GQ^V[: N\+&06%Y1E
MR$PCT(E%89&NF:AXIJ0>M8QVQR7).LK2@8".@T%"0AY6B.+)Z7.FEE+W- 6O
M;OP.YP@>UNUJ\KT8&*0&)SIQ^7,>J(QY@9TW,6 V]F%P.;-I+^K%5#?CNJK,
M)ZT:4BA=T[=<4PU5X"E128(_52'K&J6C4Q:Y;7"@0C23QCRZX]PSXC#E%V6Y
M:0RFL"2M,U/JA/__T 6%&>U[[I)Q&"#T/_L@+\Q>;=O47Q3&&BV5 WRA<H K
MO1Q@^[&$/9QL!P$N94XA;F$V,E:E8<M+(NL)2 +/0DI&KXB\8EDZ)4M.'*RF
MP*3!?9;-ES.\*@J.JOAJE0SX2I,!,P4;10[#524:#Z0&YOR+1N5@K"S<58Z9
MIO'NQ@]C>)B#YDU&[M?KKZOC6+G&68$31KY[\FD!-K)Q_;_8&8^-$9*GM_A0
M^5HJ3%P?$SMMXQUZNCL?3L(%9?]B=K3T>7\%$\,!)<S[*53)O>3.JS"LPK!U
M,<QL (8-/WT=OA<%4)3."\:0DS9OSB<XA=;4^<N?@T+F.<QX-[H<7K\OK]MN
M[0ZJ1<5C.=!42D5%:"OSN7*>+>3N/:"]6^?>C\!ZA>T1">+?.3I67:K>8.X-
M$MFWWSZ_KX*+%;JMC6XY-[**-\(J'_]QN5FDL$*_"OTV1#\5+I31PBJWHL*_
MW>$?M4M2,59X[HL5^6/ (ZK4S,5<<U)9$\9)2"H"G2]I_P=*L3>)7<.-9V,_
M9!9V)PJ8[5@QK,*BZ:+*IZA0=7-4/>/ ,]?$51+I_5Y-Y%?>\C!R;E18<SC\
MM^PJ>,,]T9B!S1?%*/U_)[#C[]3K =[CHW47.ABL!#P6[^@__QT?K[[6TA+J
M7.I 0:0PEP:.[>+@1;_!B^ RC6^JD2+VGACYP5P^]Z@56L;2SV95^EF5?AYP
M9^YKD%K4UQ&I,Y Y%4,;"%PV4KSEZ\<N];;$X0W3^A(G_Y*/;FVB5]5TKXJ4
M'DND5)'BC4:*+$.*C_3?8SBE+Q0='52X5;1Q>+Q35L MT7XS70)X[>?K;]H0
MFU:KWE8)A7HZU5NSGWY!?;8C8*Q2O\#[@CT+U4#MOZAA++- A<;D+OB0E!71
MIH76,ORY:!L[#_@M9BK"H<'F]&1 &;?)9W/77W#97&3NA]$)O'JL-)6DRP2@
M"F8Z4?U9MK;%Y3<2ZF ,(# FG!=.!\,F7#S A!DU,5%FF!6V"U3#)V2?Z:27
M%WT) ,$74,\,T2(7M !/:6DB#>WY+<M>B$M>/P&CJYZ">^>D>D^8,!<AT=,L
M'RR6!X(\64$/^90/K.]1F1X3L!C\.UST>>725*.:)*P^O^?^:Z:42N-8BT[R
MLD 8L("MSBU=X>/AQR7BPHS;_UY^/KWZS[<AU43S_\4\'0!WZ[NQ%V&1])T?
MN/8=%ALA =H!NQ,-MI.'$3FN/J45'4*7'(['_W:X<>E9=:V<02>=_E(AZRX3
M.Y-Y2-W35K/3/CV[Z)T..HVS_NE9ZZ)QUC'-YN#L[+3=>_/K4<Y#VO.T98:O
M\R=.LIH^='G5ET=BJ6$W>*:#.YDC$<J>^=*MQ4$"^3-8$E.CX]D\N1LG<S<I
MG% <HG)&#>=I;*3>-W7I=[*1?T8BRA%I-6/X[R^?S_^OEAU4]NU\='%Y=GXU
MS(ZJ%4WOTU$&"EG4V)MD-(VF_FYA&LU+=9[VO%ATG;;%R$M*W?-A>Z)/XMP%
MAH:?T_P.*H>2&CYR:@8L=H&3.%%I  7#<N8$?QSX$3DSO)!;#KIX,A_XJ3>"
M7<6Q9ZYZCR/GC,9SD5J/@Q=P#H*![X$+!/8,%IDGIR983F#%LS#":!O8!C1Y
M04,BG.HYF> $ [*/'ML_\Q92<PJYML&4MR@<!)F5)/;KW9R$S(#/%O3#LD]&
M2.A2VK8KL88*']%.=;DV8R-$CI /I ]$&WE1J_=DK!%HHO*4D+%0J1PH"!I2
M$#,"\W<F.(4S4X->Q>_IG<0"@'T+6Q&4PT_7*/IGL2Q]T:WS+Z.K\W__?BTV
M[L<1')0G588Z?!(D%J<3D&"BN$_.;<IH,9C%K:K]2 -"'-19+74U5>QIB2'J
M5:>%AK.<XIB\HQ#I)>C+R]_RJD!6W*P&WXXMYLH'^0I\D(J<[:))K[NB>RDR
MLYUG\J\7#7TRJR[;11JIJ-P3V%PTS2<_*7_"[W7@@BKM']:X\(,[%MBJ/]7P
M[]<_&>^R'[XGCYR+IA^H(2A5X9JCA<Y?LP_\%!8_H3.V1""(.*WD<^7O<]NJ
M@IU5L'-OZ1=KZ@55J.Z%Q&0FE^K0)>$=SC#!>:.Z4)&QL[+:/W]P1"(G\A/K
M$V]$D(V<PACP&Q!=V@A&93RC10JFHYK;F/8&D#,<U;Q5,DQ#Y2\)C1C;.[@+
M9:@7FA?42 &$><0\Z2A-IPO"HBC)?>PJ'SDNG,96.@<9H]AU7MI&8$#@Q\FR
M=VIPH;*]12.'A6JL0L:,[J(1-I=2'1XUKT7/?)??,C$,.+'_@5%;8G.6T(4\
MS*#%E%D!=SE2,7ODQ(=,[TZ&[A:ZJG)>HP=L FG'*MU414L3W=0/LJ#4<$&9
M8P]!S.,W+"DP0E-4W,PDCN(@:Q0K#_?6QBV]=%7_Y=>KO['9_,.9?ANGRM4V
MTEQMSZSU7\4L=MWX13N?'&HJ^JY,@!L:M\R-"<E@;^+HJP=X"DPD[D"]B22R
MROZ28M1$D8]2Z,+$A"-CP9%O,&N*;TL2!K$ST02HQAG3[&5#,B!;&2%I\D+=
M^(.HUP'V):@+WL7F=)U_B=TD.TN/CH:+7CN7^!X98;7*16Z9-34,:VWGGN*;
M"+M88YX6"P)BEP+$DL]((,X05P@>8^&W0W,,R'UWWHX=8]D784^*[)?DQ!FF
MEMZ&! +9BA@EPRNA+-09>CJQ917"(N/K2F0#+INP)<G#:>3NE ;L4B0/?D+)
M*9$CIGW3-B1FX0!?;L4DJ2; _1PQ =ZQQ(030.'DT5LN\S265K!\;P*H9(0,
MQ(D8&\YQ,68MTM@#("\S)H$_6]%\*VEO-.'<'C/KNP">BR27=VLOMZU29P9Y
M-58[H\^$6Q'S:V(+\#.<Q"B51.4'.1Q%'-."MVLCRU6I!^T7I_MD]VS,*50O
MS7,/$(OH4(Y!I_B^2SX^CG?/(J4FI-<&/[-XX,G$@% ?\UMXX:*0?\*-I?'=
M%#?GF&1<6\VL:.)4.FY>_RIP0@"U1L_J[)0@!%)ZXKN.GX2-U'4)V9"Z:G'*
M,I":%+EP\?Q>ZAT!'9B00H6>(OB)+3]+(02T&<-IQ,7)3@0";5+U3=XQZB0X
M/ID" <G=9(=.Y\H9X2F\_[HQ2H^:O1,ZL 347WJ"!OJ#(CX+U]&RI.XB3Y6F
MCN?)?6?*]AYZY_![AC$$:4U04ZK\^1[I3JV7L,#+O_WV62B8\)<$_W#6(BIN
M 8T+!W$9SWB 2IX-2R_H_O15,U&>$*X&M51=,$>Y]162:()?10O$$> O*)*R
M@2IL\G:/B$28EQ%J8$=X2:LQT; 0&8+00>'12";[Y0[//$'W,\<^$85F6693
M$[B6V@XT+PWK>."^L-1GGQD-!^DAD3H'01U5FS0G!$.4*S"T;IPE$DEH*<39
MD<2U8&3"LA($T6]/H="2+,==H-B _XSA$&D4.YDZ+]0O9*&3K&$9RD'T7-2?
M2*8'**KAJ> U=:.LP:"'>_))2_&A<-'#YF%!K[[N7EKU+>6QT-9_\WW[S@%M
M</NNIYWUN].3ERY.NZ>G9R;6<34ZIMGN7S3,\]9YLSMHC :#H7FDR4NC3+'7
MU\"?.)'Q[J,?AN^-ZRG#)(W-TI1$%=F<%J1&FUJ6THKOMIVDM"<ZSX)P+D'H
M$@A# 4(M)"8Q,Q3YMJ"5>SSX*=R^:[73V$&#7;HL9=;*D_J8P1,NY0>/'3\$
MLP0,CE!+L5\:"PGB(@;XG#H^GSNE&>==A2%>+%I_E\PZ1<\/AK4%'IXH4E-^
M5L#2K;_^;5<KFBE)C.6MV3332; [N!&P%='Q[("5LJ@);R)E5^>)^Z<2,3EM
MJC0-IRY@\6$V<V3[]]8:U'MEP[5^:X^HIHSA=-"XN! 1U9 VLC"Y,[5Y*QA&
M<1F>>C(_'DTB@?24X#ID9*4_3P6@:$6^-=GVHF;+&G-\<F1_X#W%#]M>.8(\
MHO;S\XB4B38\/V^<M3O=3F/0.>^>]8>-\_.+4;O1..VVAYUNWD2K$I".(@'I
M4$UG-)*1)6I.D(^.",M@".(?W+4I7^D:N/]F-C3:5<"$<?TIK :,&"6)9D@_
M](,=6=,O';K_&OAS'YGJF4-UY105!-3^!R@=//C;#\UV_X-=,\ZXAW$\XQ/S
MX@FS(E%N\B7)9-C0J;C4Q'_'PO@R/\F(V#F7->9,&N3S&'["EKM?7_S^S\N+
MRX^?1"*/]!@G'Z*W3OD7:;**5'C].,(X-T6B:/VD,D(;\$K.9/_."Y6Q3Q%]
M#![I\$XS1U"P%5]1W?@=P\ 6X+*F=<_5-4< LI!92;1!9+D(,\/B*-CC^6[T
M[_Z@D8Y<VKZ6@$D%+)S6$*I_RB-9/(@PUG'G8SOI&Y7D /K8GW$8S9*T+Q%+
M42.;,#,9_>A;J O;5YU$FC[RX&535 .^O750-](P%Y!;P0K#![-X9HQ9)&+:
M%#;U16,'1_2]NHD9]9?@PAP(J&"0450X3=Y88Z%0$(W,X9AA?.64E'W*9%C*
M:<OB*U5@Z?EDV@;]L2O;>5$60&;TURX\ CO%[*4NU3' 4[\"S&7$"!1AM=!W
M%<QD*H6 9QK#UE*,/&&:K$AQ$WE]LGFVA&9JS*"\E!M@@8R<2= +*Q[Q?^8Y
MDT6*;!CE<C6Y3OB"+^7W3BA#P!2_2LDWV2T3 7Q';]DBS%49,5Z#ZY7%;LR'
MA0E$+/ 2J(BDD1M*4V +04Y)XHQ,[\F*#PU\DD8S(L2 7U(23)H7CEJJGW:\
M27/31#K/'*PP:X'$+^2'<"/J.T-3#9B-M&TQ)TP.B-,_)ON,^F-0^M8?>OQ[
MS%V'W_*E/!V<5LWT7)@$!K3:#.UB&6D%B\$/>,+_D-LD]J%XM@B4N4P/A5+Y
MP#_?03KGH8@+HN>4X9*N)#2E1%AD\"MI(Y3H36%.<=+'C.35)PIRQS+IMQ@Q
M1=HN"A*N!T$.,I5AA_>75+PC+XW#FI (+$Q+;:F9$JJCH=1MJ._U"=[Z0DO/
M+@F^_L&3S 8B6<F\-&T8\&*LN!4RP$GJS%S&;?B=R*.=<2[S3 ,'EG>87,=R
M,9EWXHA46*U1J:V_4Q@!E'> 33PM<@K<Q(Y-Y0$E 2U(F0L^#F*T0<@FTA)L
MD7WJDCH7D5QA(:ZT6&;K !O-;D)K-+Q%'C$79?GIS]!2*]YA]FE5&E'L-QPS
M%R\*3#*^C<RZLO=6K.*C#\9'J2<$$Y'Y?5@4O?8. S^/4(;F1R=&BCT19%UR
MVGJ!()$D7S!J=1:Q^P1".X")V:HW=Q@,$_J(UO+M;;/>2AHW)A79DOOYE,T'
MRD>B((HR".%>PB((,8%:KJ?2L?,VK5V@4*[#W&K2VJ- F2Q<2FH^178[9>FC
M&VH#7KT/%-^MS8Q>G4?5]Q7.@Z/S&%"_0.4PT*H_5KIH'C$/O^D%*B+Y>1F,
MV+I 4]OB4%9.I$:<# #@S&CMFAXR71?+Z=(:=T;^L]MT%3/E"-N_M5SV>Z'S
M@OII4=/9)5ZL6?]I">-2.46AYT>T<4T;[8@=8#M%>*T?A$G[+-W'8FMDI6O7
MY-+3"AXT7ZORTF0RX/7Z45&:6LS_-)L&"XP"3%[P9>_-Y!WJ%00263FJY3?)
M1&&*ZI1&X].;@:[EUA>#9E X)9$,K,[BXFK&7,)+-%="'BC@1(/;D]H+63D
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M[ /J0YI;'4;P@3+OB_-6C<?AFIN$$,!^;^2JY";0%;H<'R^X +.WEQL896L
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M_HSMF[0<"BS2>#87QC^)&(Q7,$K6E@8\HBZW$[T578W4XZZF6Q4U U^*TBO
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M@_T^SW)RZ/YUZI=H7S\; 459R72.I<!'X!#S*C*E[ZPMICROKGTR@;GYND.
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MO&SF7F0@*Y#Q5\Z+>Q\27@D:D(=CH4Y.<W'T$-"ES@''!J4[:VWLTN(AX3T
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M5"[A4QV$\4*&6&K2:^7JH:=9$_R:+#[952I.,,"U6/5^#_RM_^MKEF+MH$O
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M;;) 5@=M'G!XP:RC,'/!H9LCG-FA;S 9K/U',/+3(! G':KY0H&_PR:-Y>4
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ME[VXC,P]('\2R^X18PU&70Z:&#?2+24AZ?<E('9P7AGCD__A1=.5'V!J=Y@
M_0#4)\:M1\&_-/W@GEF8E_05_&_TJJLC9.9V7.>0Y_EFG>E;!4LYZ:*:J<QC
M?Z-,HS!^]AB+1],??WGS^'9\JY1>A@F]P<@C;1Z&[9KCU9$]]7#:]EY53PG@
M.<4YJ0]WQ/<Z>)2LH&X,N )&"7V&FCJ"#)"MATZWOSWJ4",T(*8>MW2IG/W@
ME(7]6^85O97CAMY4GN\ _J&>0[%_^H'H Z"!;TT/,H9WTQ?[_Z4 2G@)AD3P
M!WVQ(^+*6O@WNNH]Z_A5A,9@+WP5V#_4AE&+*HF8-^3<5,^J;O>%*8!EZ6U.
MP0XEU&JP0:!W"D59!!SU:'&!&[A3]PTP"P,R!>Y=7(%GT$"$#@IA--^C^;ZQ
M1_J1"+1?MOF'Z!T5)M"BWVZ60V<,",>7R)@^7!7UN+-  P8IO+G8,C4N0ATN
MK*]/=7[S(MX3>'I?EG$ZY%=6>RGAJ"EIP_Q(["T7+8QK9PRHG.O:KQ:OF?3%
M9 A1"IZ%&,O9L-:HNP,6V0:!T+@$AB&(A8%3/:N3&L3K >)W:2KUG>EJ8JJ=
MI&FL4:=G<Q45,DKP)K"_&8V!XFAI;C90A/W_AH_2SV5]&U;F_;S;,EQ;!,EJ
M4&*&<"V'8DN- FRBNL!WB5UWSCQ1! [\- .1/X(EP/_L'4Z&-")!. V\Y#+M
M7(7FP'\5)(&L12DK_QG *%=56>U&I_:?(OO;@&1 >F8,$K /5 #*H6M%O>AN
M%VI*!>94&]559O)4R4NGAD9E58A+QM'#GFKLJ2VR:55.$&-\D56$0>701J\5
M!=F(P+";ED3TNL#0]:TQQJ9((C_-R_KJ;AI!1PJ2V4[A45%"PQ4:,!"7@7/#
M_:^%23,1\W$W#T":;P9%#ZF!X(N5 D;-;D:J\ITZ?0>,8CJ!>C>ONJIF&6KJ
MUG/>]R2N&^,[*3"P5QXM+[7#DPWJ0<N"T@%@LTIR5.KCM*I]F+^F!1,*?A V
ML*3"E;^WRRIKS$X)<QI4L +$%.]Y[M-*/QP4EG O>L4ZR+K@<1Q\ 2M9,Q&1
MC FZA#\)I4%,2&EGPCD521IP^L9\(.02?RY\;6'!YQU"%O4K']"$ZF ;J&.E
M@7\Y<1=33XJ.+$K9U'/42P,%ER9SF>]ROJH!' _Y:EL5@HPGZGI8KF1IV@:I
MZE-(?FRF*2]CEGDNSVI-$K2M$,$ 10&3"F5[/G=P"H< 8*@:+,$R3RCGY\Y@
M"%>=]4RGLM&X?"1=34;.7: &)(Q,(+FO %P ]CFBZ-9I(W%TC'?ED&X,I0AC
MV>O%F!X@W"S B!9![0'!L%ZV04XLQ?_ODD7=V@^\S$JSS#!XT8-.6(7K$^5F
MQ9R P&P#E1&(>U 7?2\N/E$WA"Y_X#[:PA-,W\@/>9]?0DV-ZC*(5"I8S!'6
MQ!1FEOG.E\+_  HJO,TM;:'?SF8)4+57=]&W!?/S?,3\?&W,SU@,& $7ZU+_
M=3B+6^KW0++IX !<GW.Q<]^%J9'OH.T R2I,:"U<?,82!Z33ZDAY^BYO ,,0
M>CB5<P0183:3@B>-D@,UJLU3&]5(^<G&7*;ZMS\=/'WQ0QI'KTP!<?CZM,V!
MJQH&9$C0%BS1V3_^_OKL]<^_N)JK]MG!O>M;[ZUE["_DI]B#197L1S 26IOB
MYOW^#V,1<[1;7V"W7*_1-[5OP6:][!\N/SFE&I[SMDISH],ZA8DQ@)R1B2J7
M!70%8541A"7=UEDF##CY(D'_>23M&8_49Q^IUUI \XT(:,+.U(=M#F+F ,"Z
MZ\.&)>,:H5A)@W.%N4EPT@0EJAOR,C/$>Z#+@8KS.7<!LN(/-[ <ZGA-W0.%
M%9(EEM.:;GDR3^QUYE2;D9*GG/DH:SSX$X>>_= PBE$/HP^HB@8/L0Z&L 'T
M8#SYX\G_[).O*%)^!)_R"U6/8;.]H<)Q=.R43F_AW//O23EE.*95%<U>$][&
MYE+ACG5YFP<WELFJA#H,S7Z1:.O@3R2U/6LSXS$"]F! ^]UWPX0D*)$*OY_Q
M)G%!=W0Y&*94Q6%TJ;QNS_A(%3J>U\\]K\<>+,>S#]$QE_D9*70KAU1GL3HL
M]3-",LUI"J1^ LWBHMO_*EW+VKK>K(BT.I++,B=Z&A2[<3!\A!DK\""IG)/
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M55[/@H UW'*5Y'9!N=VGX>^QC@I!'\[Z$F:ELC[/8"@-!EVM\@_A #$.RVA
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MF4[L=0_BO1=/XKVC9S>Y(#?U?M?Z3V[G?-U7>,_BAAN/BV[]]7[AUOWS;6R
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M<C\^T$#8"@]48 Z%AXWM.%%DU6P0\QQ\>O12^4C-Q<X#X+33M)>V91+$>>@
MJLF9$QXZ[\>J Q,4D:F-9,/8/KQB)$DB@JIV:@#0'#P;5H4Q4C'ELK(\.Y9E
MFT],6(@>(CU/8(JLW>+.;0:I2BD= %Y/+ 7\3LX>QY377,6@'GBZ9(-RU!.S
M6[R6E7 1M[T^A=RB(CCCDD!MTW+Q'^OS>7-3998*=9?@,%7HZ$QJ/I+H0!VQ
M[TSF_T"A+[#:2'\I_%79?Q;]QXF^B[1%.7S@%"#SM=?ZH<J)4Y#LN^+U^<-9
M';@6F:7@Q(*S0'Z0>[%SPV,=PU6IP."0S7/X\?+%1&%4 =H8#M&EMXU\?RTR
MF5J#)#-2@ 4#AL%K<4YN CS4%;0U%GN,_)15H;85,?>[[[N.Y*HDIP*E6%!L
MA&QYQD.,MV)4Y"O.+(_!\:3JL:*W@_[;D\Y]7:('B?"?0_J^I^C*V<.C*X-;
MLS.EMJ\DWRQCFPAR5=VOL@KN&6UI2V"UIJB(8:31?"0<EBLIY.?S1I&6\K-2
MD8ICM="'WQ42/QR(5Z[R1,1%VK&2%5TE?$]L&-)VUI'4.::8O4S%7%+6M;,R
M*<*+;%8E?+>2*IOJ;03!V^/Q7NJBZ0S[6@$]P5($_)C1ZO71Z# C).MU1O_W
M9U-\LZQ<&A)W9$IBCQ5NH_^LF1R86]/$O!"6P;=J(A5Y0XL,@1-8JV:);%N6
M@Y&AGS'AIJ&:."L0SBHQW.8GWLIN3KI-ZRN2449APH!*\E[V?]JY)<\7X(2,
MU4"BU2A ,"M2,_(J21Y8YW+(O2<8$I6-@'>6QJZ@7&%5 &^ON!B)I:+BAP1I
MVJ%.-*K(LO8/]X_V?.J0#K]O-=Y68\^:K.^](*C+?EX34/8,92SE:Y3#%((0
M"SXWD6-1 ?3HMO4R%FF*R6Y:$[#/7KZTN.C6$)Q);3.Y9CT)M"W'-JP(F$YU
M#% %N1'(TJB=>07'9/][F(L+<DH&L7.1O8?((S+1.?0>2)PB<"!\-\6%ZYC
M24N=$Q+V*&/S%OA]*J@=/-R(O*@Y;S#CC+;4EH!9]L=H1,K3Y1I3SB%SU:7#
MO6AEO1DN=X:BD>&9K4A@W<M*% ^$UO<Q4DMFL%EB9SXRF\,&&807 ^'X?80'
MN[!RS$;F5AD9379X3IH\*&GR7"Y\OX5MJ;Q]L8GEPF>@^$A9@W 1<#P7#K?+
MT>>[A,HH8@SJN0@?5U#S'O&N$QL6:)@GU<";L2&AY8L^0.32N>#.AC"HZ>JT
MN&_]%"$]8R]U*LK?@+34.A<M=GLE'>-Y3TC*!+C*^E:M,WM=G$ ILID=.N1C
M$J#P$#4!9D6I^*MF^6R7)XOP'3JH51Q4V:8LC2MYTL*4+IL _LSH*B]TWRB&
M\D,RY%7:L$P;/>MS!Z[TP!S> %+(_9ZE"G0LVO=\2<ME@I+4'>48PFIJ(31G
M="@/@+I61SPHG%DL:K2&+NSE]Q2 >T1Q[YTD])[!;%O7T?00GRH0[4I2VJV^
MFKG7+/+NL&]&<'VA_!,+8R53L,YU;"XH\4*9)?93Q#MUH+?/3$I:D\V,<8GU
M66Q&:]FF&=956*D@ #_O>P*9Q]101EBE3,<1BZK],L3C3K*ZVOUM$J?(\8(O
M^#L=ZLB>03 '*:VS8^L,_#VE_2JJIK7\RD . #&LYX\]:3'CM(-T=M<Y]MN6
M;[ 3=XX0^JU0TL(9D:G%;@D>FU+T62H"08"A\0B_X6Z8"1E P']+%Q(  3,'
M)DQI=HJ ":N4&2K1'86OL%7C<&<10M-U@M='6V14#FH*&6%YISP4-?1]84-Y
MJOX5?.<E*8NU=KT6LN,%V0VZP!1M#;O="PIU>+MAJ\!=1V[O[T<<Q4=*&7\^
M]OG4?MS!)OIQIR@%L:WR1SUR#?H4# &KI,BUTYMXJ<&P4NR,)[$#FFH'C2I@
MZ+!3V"]T84"1>XTEM,&OW+%N+SA6N&5.%'V;3S9/#EK7CDIR .)EJ<[1WO(4
M+B5\=>6H_:ISZ!@";8XDDC$?@]"AY0 $G0D@'1OSF,K*YHC SQ+_Q!+_<A,E
M_D*Q7Q5:=QW0SEAED)  7)(JNC8W*:"F,!8YRH=(-Q4 FB>V41S-J6VL:_!F
MJ\O9MF2^EL9?T0V'Q1P*)L\I]+P! Q>@Y67,)J;X;R(*#Q+?L$.YV+3IO@O"
MBF8_K)<[L.F? 4;B<32\_ @LJ<RXC2/ *;4H3Q+ZDT;*A;FUA5J1R0^C+A+P
M,2=R5CMOV#@/70U$5:U_OUUHPH&ZQ7M<L7)@C.4I\MP4+*;.*N0D;RPV\YRK
MS&Q;90-&KCRE<FF+-5?+!3230.L3\UCDS>-E<*$T92J(R#@-*Q!H?0<Q3^UA
M:N?MJ:1DA08GF*O&EL[MKRD,_*IB"-9YK.2"9YQ^:IQ^M8DX_2F)<KI3Z2;C
M6;ZQ-I@:P1C<NT5H;4(:TY4&18MC*2:(%61XE)XNSL!F^,SWB;Q3L>05F7NH
M$ T$(!W',D4ML@8%C6QUXXZAXJP!#%P]S9936CRE$A,UE;IQ#96-T/EI6']2
M8%SF!MC&TE[O4\^X(H6DEF< K2;V97[3I?H"Z$2$[%3P';!+3IFY^L/I+Q-L
M",Q*=!@R%]G"X&)B[MPYI5Z0R][A\45B,0BXX5IA?08IC]LOTGA.L#XG6+\1
M^'^]B?#_N0RN;R+TF\!!$:KRHG0RH<PDIC<J"00 F51028I))Q29$:,/8@5;
M9.Y/.P>;&75BIM)EI0\$8/Y5T.UU/;2Y52#-!2QY2JZW]+IUMR"@ZPX-[?5#
MU80FD5^$"4BIA"[QW6+I^C=(K/ 7W)4P;,[C,ME23F<J$SG-IZX\S4\/C6S&
M1<0A^ E,2]@!GGJ%;)2EJ 2&ZR"=P!-005%+^8TCQ0M*X!;Q/)LHV&'I=&-C
MAE7*BO'=[1'%9<N4THD5_:YY;,XDF @L_Y-E@]8?&^RR&[.RVXDHBOCLLA?+
M[ ZB.Y\"7O,E@<3 W$58#+)3[(WE81&V,'%Y3+UYJR6YF.Z>KM;CQNZ^QZ''
M=5.^[+A+QLK[Q3JV=,P?FYAIRK_ TL2@C[%4"SWU-,74DC'S<-[>G,FRH=JN
M=7+_@!S4'XV7YPGH]#3#ZF/D=-B[ O H>&F!P*9#$GL19Q5945Y=#HAR"GY>
MQBZ:O> ,.C'IN1:\ YM51LW2[*)(&GR2W$9%2WA"J#! 5)C>K>6"?-G&.)XD
M(,(_.\!/; &]V40+Z*H6$S?8LHG&T'#BW7152UC6(_\NS&\S[*D@@\EFV8LK
M'2GJA<6VIO Y*4Z*E9?T)$MJF6BI,=%*2@P^1C&F-/P[Q.Z1>UA-L'5M Y/[
M1_LD4+-EY0U.V0E[[M&JP-K-C7A9HW'@^9R#=8."+_ &NU0E]MK#IL9ZAHNG
MAHNWFP@7%\ID+Y!#RDL5-A4NQNYR^;8< $6/S$4"O(B/U4_S&6D'4V!E8L!<
M4UL/1+O",9GDKD("(*&'AF_U+([+FJX]#%()"N$-L2ZR9W*L\/:R&@_#9 Q!
MA/,9;)*F7M)9[WN':"_.!_C'JEJ<'3]O6\G^VFL8LXF["+U(T+A2C.(82Z<X
MS44I8VZLVH)D2A.#+:1PWJ' G]6A4K$+;@)P4H,Z4^.2 -8J75PX[F[U]@IS
M[AA\>T;$1X/+7G\3(?$7/'-'I5L?^&)3D;!I;Q@XM)?E^L9*$5X?T\1-E-H8
M1V7&=(7?"GY',0!F7 @VSD2,CM9]',@GW]>V2/%C]^HI'-8+]OE\>#&XN6&?
M_S&X'ES^7'4EZ2)N3G_*@'9)$L!/[?6"(ZKG"W)[=06%!G+,[9AP$_XM!(6'
M_$3ZB*6O0,'^FR?AR18I\_Z.R;=%ZWTYYX^AZ?WR\&]_W7O5/VK^_\#JVG5_
M].LC>%$B9K^J/,$$EGYP >]M-#_)\OX>&'HZD2(J;V-FET:NOCU$^T82A#\<
M]_"O^+W[\9C^O."[_P%02P,$%     @ X8WW3J73-Z-+%0  AH,  !8   !B
M:6EB+3(P,3DV,S!X97@Q,#(N:'1M[5UK4QLYUOX\\RNT3,T45!G,)5=@4T7
MDZ7>A+"$3&H_RMTRUJ;=\DC=-MY?_YYS)'6K+S8W,T"&#S/!=DLZDL[E.1>I
M]_]Q]/GP_#^G/3;,1@D[_?K^X_$A6UGO=K_M'':[1^='[%_GGSZR%QN;6^Q<
M\]3(3*J4)]UN[V2%K0RS;+S;[4ZGTXWISH;2%]WSLRYV]:*;*&7$1IS%*^]^
MWL>OWOW\T_Y0\!C^_6G_'^OK[$A%^4BD&8NTX)F(66YD>L&^Q<)\9UML?;UX
M\E"-9UI>##.VO;GUEGU3^KN<</]$)K-$O.M=#F5?9OM=^Q$&Z[K1]OLJGC&3
MS1+QSY6!2K/U 1_)9+9[+D?"L!,Q96=JQ-,]^LW(_XG=K<UQMH>$QW+R;I^S
ME(^@K8FBP?;FJ\V=G1>#^,6;^/4;OOWJ[>#EVV@0O]K9BF&J^UT._U$K_S\_
M<B)3L3X4.(W=K>W-7YO#[>,W;83*="BTS%I:]#4,AU_[48.QZ;<KJ<C$9;;.
M$WF1[M(2AX-LW9@L;$$?IW:(ODIB.T0L(J4Y<L]NGL9"(R'0N=LVMK6YL5V=
MR36)3L1@"32W+>6C)F#,XQBD9;VOLDR-=K=>C2]#HB*0*Z'O82]7WIWVSG[_
M?/;IX.2PQ[Z<?S[\/_;UY/C\"SOX=G!VQ X^G/5ZGWHGYT]A*A_.#D[.>T<P
M@:/>&7L*%+\__ORA=\*.3PXW4!>^9I\_G1R___J%]?[]]?C\/^STX\%)=1X9
M[R>"12))'-7_7-E<H<]FS"/_V1'5-K%%&I,U-5(&7)S%OL.IC+/A[HLWT \J
MQRS&']T?77JT\OA$Z$Q&/'$+F:GQRK5U**Z8IQ]E<G?3#GKW1=_:J.E8.XWY
M1.]=0?72M4<;;X.USI@:L%.A!TK#;D6"?<E4])U]365F6J9$&](EAKD9_?19
M@E9/,[O72U"'I[DV.4XA4RP;"O9>J@N1LN,T\IP_2F4_-ZSW9RZS&3M->,I6
MN6%@3$9\QOJ"@=$&FF(VT&K$,F!=Z@O^[5"/O_WR9GM[<P\;TI];>VN=RC"K
MP5.':C3FZ<P_R(!JT9^Q"UQE@_W.5-YA0((8C1,U$P*7'MN[ADQIIE+Z%A:?
M'0P&,I& >DQEE%..K"2A05:2I*!3'@U]AS0DBZFM&8M(#B3,$1X""C3[7<8B
MP?4PM-5C7!4>12I/,[_C=^>MWW[9V=Z[97<K[\()6RX]@LF4\\6?TWS4%QJG
M/ [8U\XI1_9EC5Y@$4Z_?#6N'USOX(F#*==QL7DW6K8.,WG_OR(J.!%T^\C
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MV&$UH@4H%<Q2Q/PO:$UMZ-QBI#*-W?IB0_)UB@$P;T6:XT@DZ-T]QE##WXJ
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MY41!.)G9[%Z@EA<0L6;E"BQL+AOAW248C0LWJN/[R3#\H( /9:SC9IXIF0R
M)HD4\+>)?V(MPD0EX%9@JUY%UH'9'C['<=CJ4D9@4 :1G>?;-N^:1^1-OL6K
MP8XJO^89,Y:$&9/Y6O&VF!$KD&PT/0UX5-@10D<9T7U&CPH] OE=H(VOZ6X/
MU^59,I8A&9.YNA18'/FKA'G#EC;N0P&@B67+CF'$3&#XUR:#_>3B=*@P(0%M
M#$_IRL8<!($;-)8H@XCE9)71Y\$X-]D,Z@K:BC):"GSEAVWFQ7L.-QS)H=AG
M D7>)B0F2H)PQJA,8 #^#6=6)+EF5'9<]O:B^^:@5;KN)^)+E91EE=,\32E9
M5FCM>&YHK7=MWKFR#X) JN5"8\,\2,BT+37?FGPGQ)=&IU'NWF;J*4OB,UV9
M</?S[2:"KG?_EQCMS:L'8K0%,;JYVS<429E:#RI)YL'%DFW4.I0B&[E:CTQ,
M)!6I=(*<&X+:S+WD\1!;W5IKZA*8> BPR-E5).&F$0FLFZ&<42/RU@A&!ZMQ
M_?Q+1V1>)WL&Y+<?=G)EJM:;X#6$M=!NDG$MD+0@QEFCDAZ-QXF,J$1L?IS$
MQFJOSU6+3$"_GMD::F(?4<LH4\2UN)MV;G:[YE5\W%T9KW4H!X-^*&U$;9E-
M^"K,2+I=:>&[%E6Q3+OX]^VG L1+"IM^'^ -LI8_&H[ZDVL C6_V8P3IL<#C
M0J*_)SK>!Q6QL])H#&F]$QYVR@(?A-FF SB0 T"HL<@B.IOQLOOK6K,X)J0C
M@GXS4R5H:Z9J%:,X!V/4^B4^("O5.%O+& ?'@/W*9L;YH@Q$:!-=7Q?;%S-%
M):HI$K5FRA:1GZIS'QA'I0C,R!D7^+RD)B3:!YX-QM[9V!*YJL0SJ"-4T0>>
M]>0*CUPT2HQ+Z$D$GY25+Y[!-[AN<H9-,MQ^F@ HN9<O+7NY"4<JU;:XT=9L
MHGQAL6)UH"8H4@['Z+!^82"PXNZQ=VB-H@2>,.""'%%\PGH]_I>XH3+5!?0>
M29RB5]/:,3'>EI)Q)*SI/C>RJS?474LZ&;WR=KLM>?J_DMQM.%Z/T2AYL#!$
M;VX8XK06JP/6S4DV[;$("SH8J<YX-EL0#'!&31C!HU1L&X:,46YR*G7%^QX&
M HOXYAI D=#Z-F&.2JIM&:8+0#";@L5*;@%2[("KCY="X+&*:_R>IQ@6>SYW
M=KLU;"FLW'F*Y\Z.12+)&D$#EV1T&0?0:NSKS:%&=.L4%T_"C4$ZS_',P<:=
MBUJ_W"2[0!DYL%7*]%R /'=($30*Q,-<A;%YH>5.%V!FUNZXNU@$F*R^/5?F
M08RMUPEL(0-U8SYK<1N#/+OG1" I0V 7POXY.>O?RZ/3Y3DH,S"> F<3GA0$
ME7B.'DC(Z /B*S0UQT5JAJ$[AG)DWJ'+$,HSU]*59O.HC"FBM]!BW%IS%JP[
M/)BL;T8EKVCTQZ^(PK?_Q+=+DJSCS,1?Z&_9M87-<^>.UF$7P: 6&=JS=JZ'
M)R>'+$H4735D#\UD:,$*HV>=AU?M1,!AJU1UD#KZ#>6I21R/S;IX*6/\/+?R
MVJ3=K#?7MBT+D]9K]U!X?[MQ]=T@ZO"!(>I'3( 20?54<6E^UNS.YDG,[PQ]
M%4S<!K&"&/*B8V+-86FYJBHBOX1HK:Y0['>F9$F3?>O.!Y%VJ8=RO!3D5!5@
MQM,Q&4M_/31TN(%]M2P+I:*;&JP>Y!3?P/27:'MK!&,QYIEUMO$^&.?HK]HI
M86MW_P.,Z3,0)< W_8-#C7GA%.J\!S.PE0C-*7B,XE[?*>NU@MTHS[&TJ.P;
MU)INU"\#>(3753Q*I#VZ.]*>#/ LJZFQ=0=VJF.'[H(@=W!TE2!AX"0U8+SE
MU8 @0<Z\H-MDK%U@JPT;DEN>T=7R&P--#M!IT1Y[LL(D[B!*AI]]=AZ8D[\M
M^2-[\GF<B4@0>FJ\9\V F#V(BC [<^$V@&64&;]2_!LL=V[(Q B!.U=;O^&&
MEM6TK5%\32A3#JI1#:3! H]X+&J[L./@K/X(U\+3D^5RNVY+F?=2O.:V&CHQ
M2$LW!]OLP5_7D=O^6U)GSL>7VNRQF6G/,8=[N^\OGF+,X0@%,;'W(:#)<@YF
ME=3:&D84AM"/_9*[RR!YAM=?132M#F(Y,&_<*8U'ND"NM)X2"6WPD;M+RXN/
MEE$%)_B^Q2Z;%ZO8R 35[8)NDI65B*:N9\=2U9@.KCB;=_D7IC.:(XGT"CQ7
M308I$'0L@'1L#,XN5K-/$/*?X>5'@Y>73Q%>3A7[4Z&KBF>XL58R)0G\1)KW
MW-R?AWK1!'500$7VT+=N/10"-6_20CPPMVEA=:8W6UW-MK42@D)>NA'S*NTQ
MNJD/JXOM93:B[N.:ZYUB$U 6<8N7W>8&X]#M2>EV,HT!Q<VS6N+Z@%QEV LL
M9:E0U;_[!$@ 2QC,4GN!2A^&5M.J%,.G%H<3YHI2:D5N,D#Y- 6[?2C'+OBV
MX#*L=T6&]([ 1NS,0V\*HB6&G(G*S<X%>V!T IK2F/"FZ Q>5!Y+4TB+< ]-
M8LOLZ)-$"<_L?42@2@@(55IM<V.7^ZZ2-[BJU'H!_A+? V*?X?354X33S^F@
MH+MX+W*>%_K.KC7=$1-<%+,,T^YOCVK\7<BN^C &]VZE75@T@YEXXQ>65SB9
ML&B48SZ"[DG$9OB=[UEZ%]62;VGN6T;Y%P!RG XFB[Q!0:.BIGEC;7FB$T;&
M&Q'A'PNQ!=7N9%1YJ$92-^Y;MD%?O\3 GQ58S85!RRMI[XJM5Q.4>F(,2&T"
MVN8O7:E%P&.$W4Z [8";<L3,58].+YKP3V26HL-0&LC(!T\="WR<;X^74"@8
MQ=3.8LNO$NOB0']JA15?I#BNOT'QD5G1CZ$J:><'J$IZ]D;NK8E^?XKJ\XN7
M07KL,0T3>2FCC5ZH5:94K8"AZB E!@"7"2KU,@FR,LIME%&B8#_L3> G Z %
M+(A<9;.@$T1__DUHEZK1*I(\H9K*C (:TNO7EF910 0:VDMOPT0?T5\&7TBE
MQ:[,I<4IP9QY625+A0 FB0]:8.(<&XKOEM2/9"I'Q<@U\T/[?9LS% DY)$Q+
M6'*\9"0<(8CGUS5""M^ OANTU+$Y6KS0#NX)+_*A@BV5I2:NC1=25@Y?^G+N
M!X\HG^HJ$G@BM*U(6% 4T:Q2\&\BMN1X;N)J*DK'S:Z%I<J=:7?!+WC)YQ-B
M$G/I?#E657BQR.\LJ_^:-Y,:S\]1W'HS?WFW_Z6W22,^Z[@+GZN[GCNV9-$?
MG.X]'O&OL$0)*"<L$43O/,LPZV=L,)RX-VFR.JBF<)%8/$)#X;N"UTD*VC3+
M\?X0K(8!3BG1A\*S5DIM0".U/_$0PAS*DDNK48[&3W79'7)77$,O)D_; CY@
MO<I!\^R..2=!UY_%A0W\5N"!<FRDMK3"6XMB^:R-3SWY0[Q]9,SQ'"BXE='P
M^BE:.F>U'(/!S67:/,V*@A\2R2Z'WKW<M7QW/9'CLC:VK"039*K9TI+RAPLH
MO(?E\^9,2EK>'E#=VIG.J&6JI<8\/3FF\'&08(:J+_(I'FYKHV!!*FD^P=:A
MIQB%2LA2BM1X%KS"*=MD#XI9*Z/V2P5TXHX"%WS"P<Y"D!$)O)^IU-[RW[0&
M[E57\]T9[B$D]\W="V;FG1E9WGW%I\HD;7 GJSNTGO ./A1D7+E?D6O+?%#<
MS%P=Q<O08/TR!B/Q8/O,38>8'V2IYV5<%:9,"U=C ["PB0&X\%RC2X0O/*L7
MA,/PIU!<4-.DS>'M61@)Q/06H83S8&S:JUY27N][C6@O3_V0CV?I:O&\_%1\
MD-"/3/T>N:5T;Y4[$E36\I2G#$U-@"IR4P5@;TDH2:;,/]A^"N<="_PW'"H3
MZUQKX*0&=:9,*@6\5;K\X2[WXUA><=>"7-43%JF' ,6M[F-&Q?=XSIC*]#[P
MZ1/>N8<"PZ;981#1&"B!S5+F%JYH34V(WMA(5:IX3F0 7*UR ,R/$7(<BP2=
MRR?MH?\(!)R<LB\GEZ>]BPOVY8_>>>_3N]!5I]^ZXJ:N 5E"DD(9V:O(^U2"
M&A7VMX4HT%-@&LW$VO G#!6>^1;94]YG7_ZV7R]% %O0ROMIUN>U"EL<SG:7
MK"T6_9SY1_ 21<+^5$6*:<G[9/,7TWS#U;6KN;.SI*MVCH92#*I?OF*?C(3>
MPK9Y*"[[[DG4%RU)RI_V-_LJGKW]>7]SF(^2M_\%4$L#!!0    ( .&-]TYV
MBFFP,Q\  -KO   6    8FEI8BTR,#$Y-C,P>&5X,3 T+FAT;>T]:7/;.):?
M9WX%QKTS9=?0MB3;B>.D4^4X[IUL]21>)[VIKJW] )&0A&V*U!"D9>VOWW<
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MEA:W2AHH3-%RW?QEBTL3347-( =5.N\6)84K;*_N%15341N<UL(,\0K@8E2
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M:6EB+3(P,3DV,S!X97@S,3$N:'1M[5MO4]M&$W^=?(JK,^V0&1OY#Q!B'&;
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MLIY#VYVW]_O9H[][CV[ND$>?4PU^+&,23<E-+">"^2-6S1P[=V=?PJV,)?!
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MBIQ[E5B,%!9&%B$9R!>&ENIMRT1N<X.25"6 4&UK!,^3RK<*V,I[Q&*@_@*
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MI"VR&#)'Z;J)0D\NT+0UJX92&VC')ZNPEH:MRQ^VD(,[IO@ 2<@OMT9GBKL
M%'M0C6?843+7ZWVJ54#UG--B9K(09IY-V78_LG0Z(X)?,Y&=6M\:7_[A+7HV
ML'T91T;-UW!D9!];>CG$RXN4@1FL"+-%]D"@;$%K5\J]N7842CXCE9XS2=L
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M^/BUE]T^0V5\6R-_"Z*UX)6VR>TNG\S*:W_W>KFYIC@K&@:[U]!F)E3+"H/
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MU4[BMA#;,+($\=!J=Z*M>BULL(BHU7152XSE%G!5LW'.R(U44AO3>K63Q@,
MK#=J*3@B3)Y>9JI#5O&VDR4IK?*"LFZR3+$<=M?FM"4M#7H-L6R*NXV\6VQ%
MK[\,L7PZ[23X$LGK!M\S<[B01[W$K"+%PA!Z.%"%Z$A<)0P.&?6!T.B2$"3+
MZT1JPWPZE).1! <C%>E9YBX@#-!CK3>-$;70<&N&(&EJN+VLB7(+B^DA*CHI
M[#C!9V@-='LKJE%5Y$G1;\O5))V. 6&!L8(/]E4&<]%P%S!8E7YS+8KYE8?7
M%&,&]6=&;35:F/VT7N>,A+$1L^Y-5TF_0=3Q(E,%.L!'W34(=GA\'14S4(0:
M?!=6A-'6<VB$* * =@<@H^I<\*N Z=2&X"("4 <GP7P,#J+&*L6Z8%* A@."
M(%#=1)B^@;0#HB5OW6T'- A.W/K8I"N6_J["D*[2)%V_18KC-I6YI<OF=FDB
M[E!9W-DXS#21;?Y$FJ@*#('W:9*7FZ0H,^O,:*V7)KO&G:U=+C.[?QFS<>5Z
M- &-RQ'&K8DB-:78N;W^E_B[*^"=_D"\C!W$TO7>A 49(Q$$)Q$B+Y5+8XAM
MQ,P2FX6)=XZZQ.;6Q\ZX5AF\L!3AE\LK&VR<\;LW%@FJ7&VY)29'B7&WK*'*
M >A-C%&6E3M28I1J; OH\A)9QDB<Q*W%(=-B$,8SQXS"SUH3<JVN14\@E82=
M\&O-PRDI=U,F$ M)]N>=?(P*5$\1([_6+WH3:ZL/-5:FH17'M6.^34U<;=(N
MMVX^@(9);]@A%WD5%!BX+T/::'- H,)K:Q0T5 V9E,*>+ T52\>H!%N15;6W
M-F56=U@8<- ^,QGKK,>%':^:EXP.4#XV& 8S>QQJ<R-J(W:$=::SCAK.:MYL
M/E\M%WHMC3?[6RZ?HTE18;9L(XX9JN0*8[-G$X8FJ8V+P305J3?A7&WM:DP>
M&VS6Y%FI.NA1S6';,U.F:-,2[4[T@9*KWKA4)"0J;,]M>G:;<=>6XF?N[I+;
M4ZW9\BS?:BHH/N\76>[.($ H)NV!G_"R@@E28)6QZLP8-6%[!$ME:&[%NCI;
M&-NP EX9R&U[<)_+IX-V:6(Q3PMG*S/2:HX_[_LS78_FG7 ^K^7)8@ZDH'X\
MO,WH#5LP&SZC<:(AC>"&H?:6C<),LZE<S^TR3O6Q#B]S4(N?4=PR[0D\&[$C
M8UYE@J0#1\::;WG>M+\+B,6ZNW*0-( *;9P(!.U8,#)2!FT$&4^P&<C3A>R,
MNI*,RBJ<P@,*63 3=B7:LC,P(U86B?EB+!=% (_Q74 ?7 S-I%0"^ER/^B,8
M\/LMI\'@(=>;E6YA&!7T3)DGVF@YC_O++I,R4CV&AT5S$@:LKR*M@8B53@36
MPW%D%Q!8Q5T;$U5DUNF$/(.WB?YLD.+$F@&GX3K38QD1>L72'GF->F>9AS#2
M6:V']_ZQ-0'W57O'QY*%:[@S[(UL1(23A31MS:?QJ%7PS@PI^FNI.D;ATL)H
M6XVMS&OD%$A4<:)XH=;J#Y/6H,<3^!I)YTA]Z8*V--0<.U*T@%'95FI->Q,G
MT(B!/K="-@F;<Y,H1%[&!7N[9#,<(CYA$E.3-=G2QA/K-HE-5EY+K,EDKRFP
M76H]4'MNWN]Y5*^&26N_E6$\EVI))YW8"--;0]9D();F; O8MV@WQTVRG?NC
M(/\E-N ^/])MX-.C4[L;#HLATM:F]<CI18%70]FVA&>HEP?3*M9MML*^*E-&
M,E^9Q7C5;F. 2Z'*?-:8C,9=W+66<2TI('E[*N(0W84,R&$4+Y5&WB&F#=N<
M(B@A%JI0G3@UM@M5EWR:C(>JJR@MW316*E&DN;=N!IU(&Y$L- 6*'HR8SE:6
M)6P)-8KQO-X<_=H?N+'*@4C?QBF6:A@M:NBS>1G[@@,>Y9TATX29=#!@$I@"
M224(8Q)NYSFO,C.^!SOJ(--;$-HU>KVJ4TL;9M 9F1FC)-!VR9*! "L_,?K-
M&8;6.'>15*.,79FSJ%_ZIE/1$&D.8N<MK]9!?'6<M,L(,J,DW0#5/DS6";K/
MU@>P5F#VEK'G!$(O>55PFVU4GZWX-3=9T7VGJY#3)86QC>J: T2DL&M44TQ3
M36B!Q13/[5+L<:*_3-*QOK#5H%3Y*K.E<G/=;04#6L&5,>WTDWH_RP)ON29[
MC2*V(1ZJ8CK)(76$!JLPCCF-45UQ '_E@&'*U_'$ \,U()I=O/#!:.NT YH%
M3D=% ,).(H&U 08".N[D2!<P6(PLPS\9L+I8P#<XL"<7\,S/5ZOY8&2.R^ 7
MU1J62M294O9;0KR-Z-G.,G3+H+R36DNDVK "S[: 1KV!M7 ,$<)4&J9QL]&I
M3H49&LQE99TK"[@^1X<RV%J9X#SA364N=.-Z7=XJ6%<;(VS@8! P!OE^9)M,
MTA#@07U9I76)'R]L6VWW):T6>5-BB!1Z(ZR.!VM$I%.TOZA+A3SU8V9JI%H
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MN0N&*J(; \,?+ -!=<=F>UP#,R)G&V.DH(J:;7,PUS<F,,.[J[:\Z+2PVTP
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M8-:NV;.:VV3C<,(KG?I$EALS3T\:+=U)V"'=YB@!FB" "VUOMJ[7JQ'<Q.J
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M6]R>?>4C!^O8HK;HQ6.C/X!#+DX@'UKT:7FQMD(1+.-S;#9NS#37:*?5?C5
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MS2&4K&-)CUV0(6MQ_00._3[7P >-'M@6BIFIKV?F:CK")WYJ]88RR:VW=KE
M,( 9XG++F@-D2T\30::85>EL.'9=6-:5EFDS^+I1%)M IPOF8Z#<!D%*2QLM
M+E5#7M:!TFXZ:7?1WX9F0KTVRH!JK]:>H:%00*L0&-49KRLW6A/.]\T(\OGI
MLACTY'DQK,X%(TG=O)BX*PW+Y>E$$!2R=";2L([[R?:( .I*F*4DW88E39.
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M+#*&RWKV: K5AL6@$5:YHAUU4ZM IB%/<%+=IP%%\*-\B$WP=*2$,]%1&]+
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MQ3M55N\G39-Q/ S5@%)!EQL[%0K P]-41Q0_@6OV*G.!B='I2[YKS;>_MXE
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MU^U_^_X/[?_<_F_L_\&! P?..7#I@?H!]L#XP/3 XPX\^\ K#[SEP/L/?.K
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M1Q=5:S?+U_W3Q39VR0>9&Y]FW?JERLD;N#/VGE&YNO*^]Q_9<_C('O#F#S_
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M82Q3?<5<V/@&=6^*KW8;F!U,V>,D]\HOS;J+;/\#LTQRY%Z1FE>FM^DPO5D
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M0*:HJ:Z!+-4,$Z-\UQ"G7=@V5(?X29&5F:'B4*;[NU(9"<?^WU\^W;/:7E,
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M'0+2 1):682\MZ=N?%"P?S?NS5Y3R-1;+3U#=$T4*SR_)]#MU"G'=<@.5=,
M ?QG)>,RZ[_O$2T8ML",FG5*0=AVP?I.]+CSKRYZ0Z_^A]+(^'?*==)\4,U
MZ7OO/X!ZL$*PU=O[H=ZFGDKR:7CE5N$M+MV(>>$H_8#4Z8(K>=ZBPKL?PY@*
M]Z^MWAZ9[7NWQ'FPF;+<K76H*]%;J$')GU%'K[RS^4BI7B$:U#266-R[?F8@
M\H[S)[6XP,!T0X[?!^KD__"<WNU'+ZJ'?5ZSXY HWZ!7R_\G2%KP!V"0VGIG
M37&S]?7.]QTG\ \@S2KL\93K^.37H^XYV8YRPAK5??_=T.;UA.!Q+\_U]!_
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MA;--U_(4R(QOK;[+G##G7Q34FV=Z:)Y'EX<J]T1)% $_ALQ>/6LD3DL5R?;
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M8R#>QZ],"#">"F,"FX6O_:RPK/&[2*7 R7$"TTE^^8]_ %I]R4ZD4L_RDOX
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M(%KZ!+V7INW>M=4UE5$-5:&"60AW_=$Q,[H/KP8A+BX>3#YN]+!!M?!K8JK
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M&$AAG\D=<(MO7)NV J8)#1V9:5KD#%DSP;;IF(O3ST_X,C400#>^B&<(,E*
M":#3G,O0BX*2"?.EZ\U-(&E/5. (8^Z(R,(UWC9%*3TBG)UEQR^4X5'W_F5O
M4^F$GA<Q9F;D;Z?&QDC+:5:0&4&L=3IPBDU"^+>Q80KS7I6SW<OUZJU5YKYI
M:?AH;5(L4Q%D(X'GJ%HU,PH_.BZ-U8O:(@)R8>[U RNMYJ::%V\"F%U(W1">
MPSFB:F1DQT:0I(3^:W(:DB"[%:5HQ8NW0Z$6H:%%Z%IS 0AJN<RQV?DY^D\=
M!)2H:DMIPK%RHT%,WD6$!Z-TG+L"F4?4@YT.O@\$*1U4>U\P3UJK,'0S1?Z4
MQ#"^R(]0.]6+M$_TEC7&461-,F>JU.5;H6)R!FWR+NF.N7_N$TJR+WV7(6OD
MGONBEJDA((K3FW6#<(&PL">>O>O_[^\!_#]KJ4ZD$&*L.;H\,V\A&&\%42-9
M*JP?;H%_U'C57Q:8.[M.5#V#JW/*7#<8%1"N:6:T8#S?2&:P#':2[2>=%JQ^
M+(GPPDEE*68^/"PUXIM\7>]'4='PV\;IWF9A!H=+E^G ?\JW HMCP=[5UR;&
MRSZ!/<\N[X#=*<C5.:_<U@ZQ\/-JCQ<KSP7\)3GDN^=E5T$#+8]A>(U2XD+,
MEFD6XQ';?N4!B..-FI$G11,=$!-1'V5"0_5\[LGL/"%!_PV[1<=KK847RJ.:
MGI$-E"<<@EZL7#<ZD9?8)Y-&YX2.?!->.,2SB>,+C)3E/0?)\,TON4Q#[XAU
M!L\0[^R;6XD@>95=WS_"(LA)2/:LW%2MOW3O]EH?6E4WYTI9@,BE]A,/$5Z>
M@HG&\P=%\\:,F1VV2ER^WQN#]L:K.8#_&W=?'137EW7;"0D2@@>W$-R#.P2'
MQH([A#3N[I+@+HV[6Z#1QBW!W6FDD>#N[B^_F6^FON^]?V9>U52]>K?J]JWJ
M.G7JRCEGKWWVWFN5=7IFK$3V^41\<^&>L!$UT?P+M?]'ZM_4K>[%O)H&FERC
M#F'-9E>9:-1)RX-Y]=#&J?KDR>*O[HY4V/(/88GJ,WC[.\+OK.<II/099+.V
M;[2F_ 5(DLH2.P*3I!9Z/<6U7M5,E?.-AFI6L//XUR%UC^:P&ZQ?M"H^D#@T
M;XF.ZYV!PMLD(=;!F4I(I1H;-C4SSG^>Z [QSO?JD+@>??(2K]H12WR0I"]_
MBQ@-:)<G=_OT98B'#X<]<3+ ?6?1I[E>PP(8S838](&=;:C"?*]AG]G!+P5]
MK18[)6</4T*.DK(L.EA,N.E(GW&S(L4T;L)5RW^9N LSR;:6,X?O]^6)FA0&
MK+JL5L*W%OK7:-:2&IR=@\W--M77#.<F/.@*]QR=,NXL,:>'0]HJ?=O%JQ/V
M;0O#JL'/@+2N-IHB S&-K'=@-H=N$]:/'KK>O4*+//6U[!KD-:" ;YS+:'2K
MDRA(1AH/%>Q3')&-W2L\X:-;^+VG5ZP6%L7*N"5"KQ#&._@RBRMM+UF&YHA:
MJ)04GEJ&S_08EB06TFQV;V:Z!\.PM<02:GEK9G%&+"0*J14@#)3L[!S[Z/B,
M=AE="ULV(KNVA^N);9S8G+P("XSBTZ)ZS<,@EH]-5AF2LX\*Y6<21^$IBSHR
M!YPE!XPO\;EL/TERD@7=5S\Z+*NX0$NEEA"O.H_9W$"0=4L&QPQ%JHQ9PBK[
M]M,!NA!UDQ<)V205_?UMZQ^$?$ZIBW63QLDSYQA=(AN-OTT6MR2$&MN!*Z*V
M:[@$W3W&6G K.K@$GP%#QE^\G2M&SSZ:1"WK<!V05FKRDSSH+N90'B*#V,U<
MIXH<>S^?1X):JCG/'FKV;!*,YZ24*$JQD6,+*6K\2.2,:U4^RSF#O4LMB(56
M+4_C]AZ"(D+1DTF[!;R:\E]A<"86W;VYP(4LTS"3TR14M=G(?>VWSQH]HT=3
MRDRHU"Z642<A'H66_E7,%9"5/2]DJS^/8:E1IUA_H)5&K@M"AS2HG &'4'J_
M&"4S$TU*2*QS7V#D6ESERG)FT^A%ZSJ)C5J1@4Q_9V!>&Q]1$=/OC% 6&IW7
M_0Z8Y*Y(/H,=,2X;KA8%^O>NY\143H:SX;0C?0R8:7(Y^0FS_9L4($!XO$@3
MG=SF3ASQCTVXQ3O2T"1$E-[Z04;X?9,+)R%@_P/-^)4'2>)1=GC\FD'7 @8J
M'KMLF2,?A<$>DYNS=\T(<<ATT(JZE5E8&8Q##G2ZE;G1A'[B\2%8*KN,0UT6
M\0S"]%?^7!ZKJ7O7C9WY4O4Z-MPA=88(1[6OQJ2'*&'DQXFG]*$.I:H-7;IE
MS[8*F!,<1B7A2\6G.HS:N\$%^WK&_E;%^$A.2==K.S@K&_Q:4_&".K^<4X-F
MXG<8850#.JGB48J>\$YBG!M/P]RX?KNM4/\N>T/=44?_V9LB*GMKA7ZM;_L$
M(U:M:7)#M?V&$23/@'5?\B\%$S?XECZJ1M]LW&TK\D&ARP3ZVB3",]]'SQD@
MNNFVZ5,\\[.JX;#Y8W.!B)\%-B+69Q/;AIDDM^?,M JUU> +."JAH]EH*H7I
M09@3=6L3=D'[6I-JC/!]N$Z"+TT^!ZE!.-UJ5%4WPE>0N [B;T .0A5:1'*-
M+-4DOX6L<X4#5>9&O(J2!>,>1MW)M_!3WZB%KV0%!YJZ.A5$H U=?Y-E6'\V
M)^6(3TO3C[+NR>1FV1E)15P%@[W/^9RYVTN<CZ>IYS'9"_[RQ^QV[]$AA0':
M-@1[OTE4#I8,;H]Q=U_4+3:C]K>B?FQMA:;4)VN.^G2-&1*NQMC>N2D8%8O2
MI$\7AVK+T_U=#!+[T;V.1!!>FW:8%AKU8Q]XH.<ZPRT,U/.)!/'YM'[8:\P4
M?M?MA7I/9)9D,D!O#Z=D-4KJ=C<?'8B>'>M*)D_?L*&R0W,EI" ])U4$P[@_
M"Y"H(:RQHI")B_,P$0D[&#GW.:B:1X.6A-J^CSE+7$$9K*,>=5B^13#]/&=L
M<\HP@B,1@4L\\- 2UF]]WA;0RZAY1=K"J'NLNJ'W V=;XJ(W;YBRA%>8HQI[
MEM$9Y5(,<?ITJ2Q (3^!Y7V&BU_/,(T/,=!F6H<30TJ'[9V4.E\^OJ]BZBW^
M^F7.X&>N8:ITQIK[$0BXK:*YI;8Q?7)4E@P#4U7^()DFI_X- C<)H)QJ,T;J
MCPZE6VR$/0-LB"-(+T7U%7I7Q./[?H'KX78.J-1V"_WC5X]B>%ITZI:YE65(
M,-S%AE%OT,XQ.NG'C9CF89'2/_:G:6S4T*/)3I^\.DS:/5'MZ[>(PY_?V2>=
M&09WQA2JJI.)7A$XC-OV)[/K]L?@<: 5)_*>'S<F4%.O6;)3G#)5=Q$7)01W
M]R;S9O[\&]VDYJ+# &=4\'M]Q@P @@?5^(L%X".* /WACPCH,KRN-[,L@K#E
MQT+HM>[+@0"Q&9_JBK7>^&1=WCL% R_Z+' 8Y@B0^[=D]"R-0ERT]CF&YN)^
ME*Y;=FHWO%VLG\A7XBV5Q((S&;GLDIU3#' WZ?MDTAT'<.'W*D"Q%TE^]6S;
M'5%:LT!SPDZ5:&*\N=R(D>UOD.EVSVVB_,ONZ(E7^*R+LDZ G#3T3-L9DX"J
M,.W!C3)!6TK(8%"Y4V6:2+>(2-;[U??I)UU3D[$=044--WP]61,"K^AK68*C
MY?6K,2-AE^%VHS7*7U:112R8Q':D&T'?;*W(O'HY/8A^"PXE(%I73;]2M=DA
MYI90O*K1(-"F+A-ZD2F6(A58LAB];%1A#0Y,"QVII7<Y9 3_OE$BZV*K6*:E
M!-VZH6:VI<K(G%VK-ER3J#VN=DIS& ["CGRYOWAG;J _PH(<17.L//]E?;K_
M6Y&P3Y(-G$77<)\6,]Q[? 4S'G=N58,"[$+U=F" %18C=44911$X><^1R"U!
MKX(*9F@$_*"II**25VU)RN$_XSZ[YO(:ZL:MN&._,'4Y[)Z?<CJ^A>G)*";6
M]H4+STK>F#CAEYZLG?MR4F8TN<Y56MVA$+,]95%B7I-=T3.@- M_>>3-26L1
ME2!EHZ!!)C<A&5/G"">?C[/;&\[RLE>.XL=R:AH:]8G<;>M\F&IGGIH460;,
M+[9F:<](6IH>5HVW]78M"E:CQ4_7'!8HT[Z]R6S%((O8L20ZEK0S9.2K-:H\
M;#=RA\'WS$%KWJ UX$35 )HL)S'OG&M-"VKZ+KTRYH^4SUC2?F5(,_N+#2.1
MAKLXZ-B55#Z[JX_.69WJ!$[I2TFZ,]*':VI<I!_U=OZ=U,89]$>MVNLK<K^V
MSE&U$+*@2&/.F]>@-Y148B"D7HOJ?>0#<),R]^$#'QBCNW_11TH/*PY?KHDB
MPI8QB:#DYTO9/.\C(5,+LJOX#2.0]S<6Y_-TJH-L=D=';'G[P3D=_D#ENFB$
M&Z.^06!T'&-)VPO\SU=*$&WXTJ+K;B6-%%^=V[T=FOZ%F/4B'^\,5RW^K8 @
MMH8L+=M=$Y4E.V=.VR96'$&71UBR*ZK89DUU%F%>=?*W2YFK)"G?PY&S(VW7
M[ST\/! '][YH.I.VB$B7WEFD?N'5BC,[P]S^S:^[G?\@Z?SD.;G?:R_\="5_
M$S>%A]?7>Z(00IIT)]C!;RM$3M08"P8FU*@=!. E4XQ6O%URD9*<M" E/+E.
M=%5*PHL3/)6UX!S'F2,S-C]GEX*ZOIA2'UOV7B>.WE)8C'P7O4=GB@"MDEK?
M]K:EA68%O?.W_KSPDOERH=?]JO)(5]0:+YMWI]L-L;4IK68]A"%O4]TO^FO3
M0/$)AZ7:.>/O21]T<D3I7TD<$+:HX=VW1<R=15XH<\)SO4<(F^BYI+G&GB(?
M#J3*>C=^Y?C?X9/78?.$>J!:8A@9Y@,V7^X1K55^7EZANN99P%N?N3A1]/WB
M3#=D3W>8S)X]\K&)V5CM,O9615<^(^JC_H\]P^8$1>4;>R ]1J)G89J _IRI
M+6F7T?*U*MGW=SF]UV3]>U3SDS^K6$QWD_>6L'Q"O[=J+JUX(.^R=[LO3"S<
M$5Q="%:.79KKRNG:4B@T+B2$$.LHH(J-FR926"AC@PM*&ME%L-FFWXOB$HOJ
MS;X/$*\*>GCY\$G25$3LZ*;$(F?P8,IDL5KC MYTBQY56QT;3#&2ZE@G-\ U
MJ.<T9"EXJV'<PM!-F%8DD\@,%N'8.&PJ(:-J<G!RH/3X'AK9!HDJ;[62E'D[
M3_((02MP) ?#JN&-_7 ,#,%?]?X<N>R3B'R3^ M\O=^2;;Q) YMKI(25G> =
M@<0"47RZUG^E=?/H6P1G^%P3FR3IZE8*[DW"%3@7%&QYUR/8Q8C%D(>'AT-#
MF]CN8,F8,'\]!0 IXTGLN-X:PJ<%=?(V?8'NHJ.N)KNX+QI1\#T%+EU&E$[K
M]=0,IN@UM:)-TWEO:G(A>XCU6BTZ8RB'K3P1C%P6/\V8GZ,?\MHACS/$(]XH
MAB_6/<TT\[3JC3C6H96LU_>%V?ZM[/"FV]$1!\3:&9]EK@=W742"//O%:QQM
M8])H>S0+8I+^A=73!'44B'@)<K,2E/FUU>*V(U&Z'*PG]D&PEM'?0RWTT>)!
M/6"ZY+!6P*0]\7T*K_L&/>)$VL26##=<]A)"Y1[=,GUB?DCM4V)JCRWZXNC7
MK:K 1!ATMSRH;LY\(;X*-]$\BH<;,J.A1?"=;>3C,?(M&\]DXLQ./D(I5'T:
MP0+U0LPH&,0^;#Y<1R;HFFX43&"#QM[%_#[=(DG'&AR\8(-"54C_@2K.7CQ1
MT2EK[1ILH" K($OK00MQ/H18$1'\1/B4@_ %X/P:S:!% &58I+J/S?V8GN50
MH=)_=5+;IKO0JKQ$LK<K=C^4JU N?/&!@0'W%V-0<[1<P$;Q,P#-/==OV,%S
M=6=>:X1.Q/@(&7!V,KR^\5K4X .[:5]R[TBQS>8!&]85\UI*-O57\[/84E]^
M9.A?-1DZ3DIW^U<#92XT%3#F7<CBO>>VOA'O![)H&-*96UPHB"OE3A\T/*1M
M"%ZSNE52P?:AT8OS0DPV:^7:?PMSO/[H2/#;]F@K+:2]Y-C8:<?OE>N=KFMB
M(X$(%I$21E!M=\3;[WCUU>+*B^/7#G7I(LC<GD)R7Y\!O$KU?O>XR]EG6DB;
MH="G(?Z.71*[![^]Q*FKU$F_V[<Q#^3[JK>=/K7/@+F*BV< ^*<(D_B5]LPS
M0&;=;_T9H)8-'8U_!O0;^_U^!NADC^(<9C_UN!4_)+VX_4I>,UIY)TW\#""_
M*W@L<LY^$J=\!B#=33_99UL_ ZX8VT0VJC"&,!^37/PF>5=NG@$SM(<<!<^
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M]AGP@[?O\87Z$_*'L5$^C-VM^P;?NW@_GCD_48Q%GNOXJ_A@OQD2T-.W'\^
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M6$=;6EJYR=J.RAH?:&H$'!@<,M>AEA8@3N,"Z?R8-+U$1NI)"5GNO2@PYS,
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M^&ND<A3@Q30@9[F5!,[5P]5+&;>=.G+HRQ:RIHYCYRAP+ZV0PN6B?E!ZJV+
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MX\K\,R!#\HGHT)HG./M^[_BAR/ 4[\<J@CC>R?O_W[==(AY4P EI"<8)!5%
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M&$)!AO^U7-C3Y1/[JM-0EN_%6?921Z=N23_.F[!8+'G:W.+3R[YGP$1T_S,
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MR9.+V8;A[R]T3>1SQ<Y^"_#0SNC 6:L6A[>^T@]EQN&=CPJM-5,T23T#5=4
M/1F(=]%TI3YN,%::[ T8N*^#78J?Z,FN[U1^Z$ =-+>S2-,D]!*YG^759;\%
MCMN=$I(]U1>2D9E3\S8*EP0,M'ZA(D:'25-WB@+THC?]AW "J3-<1ONC.X'!
MGV%%I]';#8$RPPX;FF-S3<R/<J\26J.3+,Y0KA)MJ 8N"<':'U3"&(054-AW
MU)\!S%!$Q:)SM&BGT6MNY+GU%J\46./1_CXIM;E"S,=+&+__%&NL%>)6ZH:7
MU..(AY.G9W/,)WW-$,_)._^U,N-R[GJAC)XO\-V0E'UO0G,53"A$H8V'L*#7
M9H56EB:1WE%M^XWP.RE9]L[*!Z&S^@NRO5Y=LZR4"IH[?^G^B2T; 3P3T%B6
MR7S<\K*D_:\))LQ'56)*A_/FMK(R>SLHSF*98N?WY)T1T319E[E30BFZ<CA.
M397'&'/PN$R\6QK[QJT=>77*KBA$0L8ZPI] 2JYS*]9)GSD8^+3T#=MK>4L#
M:K=C+!V(WH C"BT?(E_350_A%CAPB>H: +CY'-@Z+$W>2LKN$5^_MAJVM:E+
M$A('^:DLO3ZXTVEJ4%-0>#">88:6,(F8J"S%#.0^?;1M!D7\67UUSF5)]5&V
M"Z#@(UZ*YB1&S52;=,H ,FD4+U&*BM72U;5WG*6%%BH-###9PKIHW23D(U)B
MN7D#%GQ,U/0>T9Y.2T91'8WO?VFM_QL9&,5R!_?/ )*VU&> J_S8KJH\FLVI
M]-'3V,,:Z\FLE5$KYS-@1=-OD_T9$%JGB4Q$T/#]OU**G6 "^^1''(_*/J^L
M7DPJBGH5=C\#/)\!A/9-FV,BGAY*1RNKS-/&*$%_)0SCC$_=W*T_ W;ZC/TB
M<D/QNT-:Z/WJ11_RBC$P?$_7G@9$SL2:J[;S5HS_M1S@?U,,JT>(U^OD$$'-
M52G7Y:AG90Z/,@VD1OA*]\!Q06_KP'(#.,H>07 H*_Y9WX;!]5UO!LL[W[U^
M<VGN)HM*#N_N@4T'WI;2TW-@YP 1$NJW8&XP=U0WUI9NW^#HUYU([N^]Z^RI
MC.:L:U&K!PZ""C3:)(Q5QZ_(^0]7-CD.&,]S82(K,)&-"5+?XMOT"Z[MQ8;C
MA.]W<YM]DU?9?T7[$L:J*D=#M)X!?G_.>/%+D>&5W$KAS0[O;$BTG@^KQ5_1
MO%OY^S</.RXQUY<QMYPBJ@\C=T3G1[K7 _]>-QJDB7=03^\UMJ2+]K62"E*@
MBHU8#UOD,7T\A97<#W$9QV3\9)1$0G;O]#'.0,*"A#PNVK1[%FDGX.UJ]9I)
M5!N-+$4D1DLL3D<.MB=B9XD=W\20 ,VI"#WQT@R)DXS2HM2GI<E/I *=$09;
MON-H7HE)O-N61*,C+;), H20Y+IY_RX76V86SM($+5SY?4ZM]GFZC,C+R*T%
M\; /GC@EFTB<YL\ U,FP5#?(,8$18M'R7'S/W&T&<2<_"4&GS$T-YZ$R8ODI
M/5;053/WQ-I7^I5% *^7-JI<8XR<W/)K7TYC:_66.6)4GH7YQ*=?<_-"[29I
M)CCJ1CYQRT"U%F(4F@5".XA9)V$,'H>,23 1D#"ZR]RB@ )*35T_UZHA@!(3
M@1L6+.#MS;QJ;/W.2NH9P$<%EBUU^/-#;=FN1!L[O"(;/RA_>[SEAK-\KLE[
M= Z@ [Q# _PY_J&Y8\I:NP^'!BG!'R>6Q1P:(1)V2E\P!!<&L+-B+UWELK5J
MDK$3",4E=$(CVU>TZ9:39NDYZ1)+R.BY="5<B=CG?[:V;*M^'P<XVT-OK1A#
M.1>[ZG-M0H*C/AZ=W6LN<@8C/BQ@>\HR@\TPJ"G-*2'K)F]J?TXEU@_^AYCL
MZ[868+P5.S#MY>*1-9)A3:.O5S>0*86+A. \N(0CFZ+_VF1-C(G.6=P'Q@*]
M6HH"IE85L?V 88/=@YYZ)Y(C8KAV.B5_F 4$0U>/818]"<RO7LL55COVU=9^
M'O%4>[%S9V56^HV:"U_QI,6./5*NK[LN7&%SJ=WF,:#(J60P!KQ_ /9YV] :
M0EEMA5:(<W'[VLO.<75Z(V&L+QL+>*IF@<QQRC:CP)5=-<-+K"\:Q57;'%3Y
MLHZ9%C2WYUVR3-+G$P_<XL[[9;";L3F*]('>S8;>B#/'?GFVOH/ZD.+P'O]U
MJ>2I]F<LETJ3QZ7MQQ3;9I^RX/BD.@QNM:8G[(,ZB8J14Q2,^H/!XJ6S@@^D
M"9JZ\J$X*'4_F JPTC0F,RV&R5/X<?"'285H<"BD%#%(<%YHBM.]0W^9!Q'!
M/2Q!_X,@B%;3S(5LP.,>5Z;60KS(JVD,$S6]"G*R<&FT Q<,U! 9%L0+H?IK
MR2*!RMFJ>I:TH:\&LXUPYN7/_;ILCL/\$]U$&05#YM[;U&ISG 5TL?G[4?0H
MYZ#F<P:Y\*VMBHFT  D3_;!I3'YZ44$,7#;@2F7817Z:IU0?YQVKE1XRZ=O)
MY@Z$\M.HP2]%UG&8O'/F5&$KVI2,&HW.=E;!L&3N(.?W/1KRWR*0YUIH7TZ[
MNXS^G$^U(<,*!IV.*M2+QRI:OD4N$7$I^ER8G<I@7<QK$SI<.(!-JJ)K@:H3
M1NO0O<;N ;\Y=7>G:NH'FL,^JO<U5*$=.>3K<(,!/QHVV1L7J2-3F: 3\#D)
MANW6<?3123?$\*:^+Z\.U"HOA2_Q:H]!PB$11J]!LO"KUNJ$+5+UCXEXOF:>
M%IXX]P@409WJA+.YS/(P<:=2^Z^\:XF3%\GC64&.=HF89\<$^XLQK]**#@/:
M[!?F4JM""3P_"1C;SUV_ -9%T8K=-HV@U%W)UKL_T5W,E,4X3U4-/N8,GTXH
MUW!GEEMPY6?]_E"E "3])'FPGG*XI1^KO)8R8MQ2'D/=4)&;6_QM)9,;MK4,
M^LAHE<<UX $VE8\-'M=+9E!^X]728D6LS6I'-G=($37FM53%%?5ZU$'HTTO@
M=5U=8UM3].A$-'A/LR[2?$%O&Y-H8D$6P#HN5V.PP. %/*S4LR@Q#]_<U#?2
M-X-5R]*DCP1X)VV;<+\ZQ6*0T#I_FRNNTK;V'2N0?#E:[QQ'<ZS"Q64Y)SY4
M5^@!$_H02EC#/943M]MRL+@^V:R=PYG!SPK4^9TJ;M_K,+QZMN4[C^;Y23C
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MP[E%TR1\EN4]G(Q;PSF;%!-P$;T2!&78L6O'U-:P_@>EJ!=N#Q<>&$O@QY=
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MGNUM&P_,$.7?=!1K_Z#X+NPWZ/B5DDQFI:N8$ 1_(@RFR&CE4/8^P(<]Z'T
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M'NT0&&]X@I3?OEZ\VI>=VH8)"3X[@D7/IZK;\RH-?Z5=P8 .1[N$G[W R4S
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M:JMMEWV\NP<XK?\4PS>6AH/_;  Q._K;%#]ZGWJ+IYP*MS>4O3'M4ZA5XWI
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M\:0)6W_"_U',Y<%MFULG+=FM)*<VR=.G7^3^SCH3F_W;LN_W@+:A"ZF[-_>
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MU1BEGM#6;+4*MP%-%Y1Y'BI8?5:I;!'?,'O1&.>WL4MHMYEG8OIDR$SC=0O
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M&5<XI?#%L-OK?MWT/)H*%&'3K_O7 -X8VY?X)OE]R7O_: ]M,:S3.L%4QT%
MD9L2AH.K10RX6A1=RWYO) IN;&:ZW;PF571<& ^Y"_K32BW KT69-8/_CJU&
MJQO;'X"6N]FFMQ)M\JO0(CO0_%N%?57RD\\S>KL_W;+.BQ?M/+&!9&,(L@F(
MG>,X7W!3#&/%YN*5( >%M@R1(LZ3> YH@C9X/W/P^[&F_.WT2DP(?,C<&^AG
MX1% P6I_AC"ZAAV,)00WIP8-KTPZ)\-EL+1@;5(G"3IDNO 3/,Z#$T7[(;(?
M'5!L>XJS!PSOKGIL=^.1,@/FO\ 1T) K%%J!1LJW/,7!0V/!]J^BP_/MI@QY
MH4DSJ";HN?DQB]>[:+RJ$.N:O1S(XKSX7O1<Z- &U9;A/$'##&%BV1R]J;"-
MYS9K:\/K2W89-$>,;W2)8;N$.^TG*^8.*8TVX**Y_7?U+(;,L0'KW2EP3VWG
M-V7!#LDU+SWZG"2E^@&TD&^)$%@]!O_L2P!GM?G0<//ARCC.C0O/*+4>-.?
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M<OR/2T,+ESBTC^/E,.%NJ$4,D];<K,5KS\D!W]E#O,LU?/@V;,U:Q4 +(3N
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MUX]S3=D8UBBJ4:;KL2DOZ8X0Q:>PGZ'&W;A%N<V4.P%I(2ID?FN!!+JJ12K
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M\*QFLG0?(.ABMS&7U+%C+$L]>8B0^"RRN.]GFO!8:T#&;;7KQ=4U/(IB\'Q
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M;V,W/!<N_!_>;@UM-EQ.'$MG%$WQK*(^<H,)G1?!/!I)D3RT1?C7DSD@M%U
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MOJN)T >]G%GZF7GS]5+_>$R9I5^NZ2?W"N?I5LSR#K^8(/\]X9CN[_8K>,.
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M-I',#/KNBM,>IC^L^3]+7R?Z$U!+ P04    " #AC?=.=;'.7]-0  ![6P
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M\7<&E\"O*(-M%^MS%W_K/R_*)NTF%,)Z[*6,&A,W7C'?*!PLX\JEALTEUTN
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M22:71G*&LIDLM4;5@^#YCA;T>LR^(,'9 +(\R8&+37,"XSB5SS@L=2*-^[4
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M;Y\QE--,+M9*?F%U:\?"MF9G>Y>LN%LJF6D/1^I=<2>&*DSY:F1.,"Q#_C-
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M>N8Y8HS;Z(7%#9(]J1[_?0EX+,AGQ*9,B/\II='_5!'7K%8;4_]:7M'_G.+
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MJVFKB+M8SCT8 \'Q*2V;K/+ D>!N2C5M/9SM ]X??MK&,4&U+A,22*K<.=6
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MJX)PIG_N'-QE&=O$VYER*]3 A?-[#;2:BEV,,*I>W$$UPNK_B*SHZC3&W_Z
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M"-+,;L(*CKQL[31S0PO6FA0#Q8/<;J0QM*\Z"F4YTQ)DBA.S/R>A=+_,:;<
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MW?_<0"$&2U[3J_?6/23OGUBJXM?M4WEF8]R)WHI*ECS<6?&@= N4]F ":Y7
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M.QQ<'OW_?KO _W5@EU_^#U!+ P04    " #AC?=.@[ST;A-_   =AP  #P
M &-O<W1O9G-A;&5S+FIP9\R[>503:?CG&T5$00B(+((0%1"5):V"*$O2BH!
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MX,9LOKM9L-EI#N?XB/TNU9'"+.'G0?OCK0;=M;,M/SD"';%F%*^\1_741%?
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M]U+ .%Y89GQ1L:,7J%UX66HPN!-LZ:)H1<1A/T+H7SFU]@Y\A,8LZ>%A0TV
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MK.B-BDKF(S7F"FVHF2U\U:LK4ST][V:"QY957<X\9SRK;[P-UM;4AI)_GF-
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M@PQ:&D+!<@F;F70EG*DRZ,?&7AA<HL%K%VSO _]0??+>UM&J\0'!(>/<@!=
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MPPC1./5-DC%:%1/,&GFUVH"3 M$F97YLN"(8S:K,-74=/9_(U@\:' F3)Z?
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M1?<<J&;0UI/BX]CJR([L@":?FF73#,1.4<]%<[LGH5V'6ZPU<J%MDJ@T5Q)
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M6_1EZ]2!(&(=PXN!?[OHZ9TS1LB(Y('CTD-!JQCOMPA_FC'VVDJ5$M&Z>:2
MA2DX.= !^1.+6O6SVZUW"*5]T=%HTI/3'&(JC,WG9H7@CK#KX2$[SQHB&[#K
M\8XN5WUU.&N,? J&3N,;N4=!KO';J^X<?/X>'._\M@[CJ[>A,T?M]=39_*L_
M/MTI=HGZ[:5+ZG9*OT7@%EVM8N3N0JH=?8<,:#Z$!>VY\WC<DG^+'!>-' 4+
MJ2DB:N525F(]%]Y/0ST9\215QRWN6<RM+(^K46Q@: <05LPPE/P9JK5UBD2P
M;BZQTECC<,^0#'"'7*-S\.EY0OCA1; 9OX?_K?S[-(EY%\[482N?1?;W6N\*
M%"LYU>E%#+HS#&6 +YM%6(>W^DIX3JI7]I&,\%A+J.FD3NE6:J*X.MG:;W@R
M6MN!M^!%JF>O(OB1M&%Y41XSOH*K DN&Y^*_(>1'R"]L,>)MUEV[RX1; ALV
MG:"2/*-XIY]!MU/#\7^QH$5&@QKBFQ60N09B3##!XA;O=0+C33TSZ#WNBTBM
MRL$'^3NV\#)\'I.U"QH]2PG'GZ?[JP]Z#;:ONJG\Y]5=4U_29<#2XV@ZKH:P
MHZ6ZL/QYZ-4L+5KD<+N<4IFDV! ()DH,^RL6+REI=1/CUWRF:YD\-8P+5=[M
M5&KH"FT2=!2/IU'X67D! @%?*S7EWDUZ-[T5JUE['BJ?]8/=(!U>N4^8^*.?
M(]]T,="S^]M]YVX:B1!#<Q-C%6TE$SK'XC]%$[OH^OUP^"#/TB:IED4AY\,)
M T/O%S/WQD3:DN*U"<AZ-;2.3H.S]_.^:F,FV*#@4.>TLV7;X:X*BH&(W4JQ
M.-(=4FH^8&1L=;3'=!P7H^K^GCR[YJHMV=>7O,J<7]79HJ#FL-H_VD&Z<0,:
M,S,9T 5144Q;CDF2 <BXO_QLVM^?3K\FPG'1TN4"M =:ADEH#Z"2<JJTS(6'
M!:_Z(6J#[F#FR_PSTD'ITGL_?G3:*3# F[1K/]D=,>!U9,>EA<>\SZ[6(:V'
M?TR].);OE-Y3L**WR,7HK?ZQC+UO@O\8N5V\ME$UX9??/F_)6=NRS['B'B7I
M2IW;E\B0C\1>&6!Y!,DG@&=)\&8Y-,5-9"KF'N/+?GCRKQZ_+\7&_]54,B"G
M&\1*5;%Z!+2C?O!F52)DP,&C?WTW__=)Z0E4/%<7#'$[.N:?$UP+R]_8HEEN
M15TG+LGB4HA T2^GY:D8R;/4<WD)CX)N/WJUU/67PG511B]UU.)(,-T048^6
MLISJ&6B#H!QSQ-'A7]^^C,N^1"_]7^80@D(H4\QHV$KX.EVK* -N*_)8TI '
MZ$Q>P1VN8X"'V:L"TBK?E2]<AM67EX5\/7>;!=!"?N8YY1A@AFA;[YS3[UB:
M'.&3-D]?]7J*1EA]<09:Y^I[,,G:SO%4*4DN(>_("E%@[LC)O*V-VU[:;?E4
M-N!UW)B=-OF%/2,# &GLU_(6]K_*7LZ_3G_@_'&'"2._P',WKUXE[K_6@*^?
MF2UO8L0S*L,FEH+!LY6P\#'U?HN>,42\:<IB$E29#4'RL!(1]I7@^J=:I#M
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M[I$WT9I'%@4IPT%V8$O,>,D\G1709?=Y,5VS=N<!W8H3MZ.VWELN47AP)N>
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M>%34N*7VEK_%34H+*?G/"?5_ _YT\Q]02P,$%     @ X8WW3DYAEHSKA
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MRKC;AX_Q#>YM=<,U)K0:>C\CE"##%)B0;-:?&  SJ9^'.O0A(\Y,*FD7Q^9
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ML>2LF9X=!\"9="$6SZ$EBW1&OQE7_S08OS2RU%2PCF/%7/-N]U.S'_K9U_8
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M[>1)1H^YS?XG7-H"/4H9WD!;@5Q:&,X98LNT !KK#3QI#QC9@J'?MN%LF*H
M)&PCCYY%G%:PMH-BVL)<&*DF(S1"6+#I:[Q1&VWG?7RB1X1_E<5\;82KX>3-
M%4@@ZB9+F>N.)F,5D;J@D43[],O!V@: E1AEH>5C$>@!C-\F&%RH9#ME/K(B
MA?#PZ/9"$V" 6;R#$JN53 ]I//7>''?YUAT.A12\,((3VKTAZ1/.]!*<@-QC
MHH84IA[>7WQ1?10S8[BGG^ CA-_&UN':*5NDAL#A9'\!=#T>W9:7C8]IO=%
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MQ/<#'9 UL64^TQM'F&5/XDLCBL:>N")3[KTUO"/>^94V+],!6"E2[<?!AIH
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M;I2*@A_JC!=*79]UBRQ)@,?EN0F#]F.>Y+NX\-W_X0;_7]E[\@]02P,$%
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MSXO\3Z=@LV'3\,\,G7;9P:1W6W<O?&2C=R'C(G-P*R"6OSN"'E&LD7&8^:7
M+<3XP(^J*_MS5 88 =J?$R3*\ZNJ6!G=MN4[KY2=*_?OU7#Z71A[A<#3 T*
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MFO+4"57TE^L%#X;=WNP]N#/^K:;HN8-^*_3U0N!1Z0XA\#J5L1(;JS;@12U
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M2/0B8OO(/Q"$B<3*EY'4"$%0<15;[T:70RQ6SL@\7>:$\AS+#C<R2Z9*\_3
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M.5FK&K.":+V;<YVD7_8>CQ$SN!<10#^%P/B%?HR>"J*]>D@7AQ"MWE1,=#=
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M82Q4W>6>=K0B'?PWC5WXCWZW(ZO\BPG^Z^@,,KE\\/#?;5?_S[3_B:WMST(
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M%\$C=T>&3K2#),,>,A=(RJSN@ID-F T"&28DR:[( I6(DCS=$KB778A5))R
M [GM:O@TNPZC<%,/6*<HW6X)#TGED$'2GY''XS!*6+RE2RUDT+3%9 6[MKX
M-FSP;MR'I\X9+-HH$#03/=(^*NU=V',A*=ML?Y9C\PF&;NZ]ZS>2CA\(E7_T
M;%=2D]G)=+:+NU_Y[)O!,/]^SPJBS>P<L4,(2& YY^$3QN%!^ <P?97=:-:-
M-VR*!SFSG.2G[%\$UWS"KC=P-O\103P$LF8R79;5FMHCGO>Q'&4'AB; LI69
M]&'*6I(\R8=UCRH>W L*@83%VFN?)P>/=M4X<<(MK4%L?(TCNSU:(-M?_HXF
MY8,VA$LX..GQE>0$L+M!;9AQ/M\W]$HMI_"=CMN@;5_Y;BMZY(LILR8RVY[!
M4UQ= G"*9WB8I*4*^*@0$ MR&+1QY+_9#B<%/!=TQG.?:HRUA,XV%SI$)O$.
M5O#3LY3-?C":#.3H3V]SLSBES^W!Y$W/R<B=]^)/ANMO-(BA@LXR7_I;W+V;
M7_BO'B-(=.$85TE?Q^J0=='_RB(QCTTFLTK[XPCF;%P,2\;B<#'>;P[U-70
MFR!0IM8QY(JO!7EB'"+KS')Y6JD;3WE9^;-9\I-JB;'W#SAMFG)RT/U\*#Y;
M^@JX>.'';I=<E.]G,.$D3F8Q;E;&[&;^B>Q-YW^8.LD=W_AF\==$.$9RL8N_
M4,7?Z4/?WF6\2I%SGTBQ]F>(XW-/@;B8Z1_1'OY%6HWN]G1JV,V+-]=^+#X5
M8.K:%1QN,G=H*32'4N"[\N1^M_N09C^+]3<;?'/O0*9 4A1A]1:0VBA#46M;
MGO%][KLB%D>P!5.9]?'AX!AWYH>@_ 7!%-XVTK[N++YAQ0Y[K_+P-8O#^<S
MG/QJDX&$1K1RW-S<YR']@%1L)VH]@JQU#/#8%LV& >6TL%5O_!7S=X?,-NDK
M")2\9T3FCC_]EA728(QSJ"D(/^TZB ]XS)V;GD7IGA#;0LZRR'D4==9%GJXA
M7W@*;];],OO4L^UC)TZ\W.QT@_\MS=U<Z\TBCF2YK!S'PPJ!F"C&" 6U$(I6
M%0),-^CWKGGZ3A0D6\F3XPHH-DP,[(_&"('YE[2!H\0.1RRB9O_!2805&BTQ
MH(WGZ+Y5/_SIC[+'+J VHM%/74PN%.H@<E@BY=.9I[T/+^_1]+:QNC!>!Q [
M_UE768+MRH@@M"!UCL,(STAYMR!0$?189/6P%1'1R8U'6* -9>40:B/BTE_!
MO\?[^1$%CO$0;$ &;Y/%IO*,J2B$:[I.BLVL4X(90D!.DE2O@1E?(!@B,JJ4
M^_L6L^,8SC8<K-G"UZ!$D\ ^ DD(C-G^@2I3=.5,D>J92"A'M6FK?K"SFO5N
M>093AA+3]=;EQD,=PBXIG9C.[[LW79%KV7%OK<VYV?\['RT$>$?UD$3""X&L
M3K!=H-:.R"3>A/8_62;@_V)!&+S-R#/7!B6XVY("L!)-:AMK2@E[X5^*QVI-
M;76IXLE&9Q^8FFM_$#VX_0[&)X_6A$C._Q')PT78;?4/49@"GW[F^$_" /C/
M,QF(D?D'T6"]B>^IX,G9+V-+( FE-4V%"O^$:U@;Q:(IB='I;&P,6DU0I[%7
M@(CP>]<_$6ZR49*2[3,8V,8XG?HU>G5:")PG5813VRKG[Z"[_MF[D"_//SEG
M]N /GI6^#<TK8^&2MZIJ<R!+X^W"<YFG#&\$ O5!E?M"P&_F8N,*P<0%I<CP
M]6#%#$LFZZSJ]/74[#2M:[\C$$\4^!3M2K4W<^(8B.(???J"?:62:7Y@=N/V
MOKD^-^+3S"1-U?<MQ7C>N(C/OSFLB#]4=XA,XA4!U]8!5R9FD[O@J]<!F&%"
ME8!EW/E/!<H\T^[RPWEN1O/X2B9&F;X?3SOS.D#/V^S^WL'Q#(..:Z<$'L%O
MJL)R*R*\WY:_3<3DW5B__X]V!U*VJFC^5-TR^C'@:+,P]<?6^Q$;%C?_=U^7
MI=F?JS4QM8+ZF%:[WWKQ_6=K]L/$JK'[(4BLZ6ACPB'(]3Y=6_!^>!?(O^\:
MBFF@4- Z4'O"SQWTTO)P0V9H[C1S]0C/Z$U-]/"H3VY/=E*3  /2,ZXN++RM
MCE.?P'V/O?JJ>(P\/O#'8=6U<I/2-J/:[Q<W7[\]._&'I)6JJJBFUO.?@?VH
MX[]G?O^AT(7EYVOH7OPRNBK,Y**FRZ%*=LH=(S@8NPENKUNNUB*7324<:3T>
M/>N8,=?@PTXZV9-;45+FM%E>P?@3='0#\%I79(50+1KQ4>;%.9D?S[JBG9[)
M!M;7BXEU<+,!8Q'GK8NL;3PUZ_,K<@Y9/$35ON^Z=/'@IL7VS0NC=Y3_T]O=
M?]]DWJ,&M+@.S5^-9V%M5(*%,41SAC$!J^($<Y 2AU:%-=JM0>?92/K.25>2
M: X\F(>G<GCHK>!2%8<AAS=L4?LVSU/J#&)(3*$ETXZE-&CH])1)OFM7:[](
M>KD2#\=S>UAE#*:Z@P0!"U'CR]OE\0W=3215X@;[$8KX!&L]&A"T53/N&*<5
M82RAG!+<\V$\PP$>-(A/^D-C8\\UXM86#BXFM+<E!M?/[GL"4H[T]C,QUCP2
M_Q%:3M Q0(NT\. D[&+9P G@JA<X6L7&Q*HYD&N4"O$9'PVD_$)"BZADXP,6
M 6R2,CZL<5C!?^B($#A)9@[O[#3VV*+0:.B!;V6*(H].>HF/:*IVF'9;U1O'
M* ?+)+IKU>/$?(2 4CE.W0\C;XQ3\[T^Z4[,+8#G74L\#4]!M_*5BK.5T_*F
MEJNO7O==-GLR<V]9_JN'NX?AI@"]1UNEF2T:\G#W;<Z,96.&")S] @ZS?0M?
MM]B9#5LV:6Q,:A1L[K8(">/:[^<+=GHUY?BCU?J-GP8QQ/6S,[_";A8V+WTK
MEV]XV(>%X613'7^UL1GQF#*'>-)E[!?O1C4A0"$:>4UX8;H7'_,S!;H$63B<
M35/@W6;T+ R)NE/J55:\[QK11/')+ >0%LMS]7E#.-R+UN"9]N(()D[,CO#_
MHY9S[VKJS,(X+,6H :*"!$D!E:M%3*M<%&*B J(+(;5,80 A=JCE$F-J(>5(
M0J)R"<K-I06F*$1 H-QKN39B@@F!&1D))%RC$$Y2JP%"3BJ$,W("D_D.,^]:
M^P.\>^_WV<]O__$^$ NVCK.^4CEZK-*'!.90B8DW4(L"<_W<'9H*OQTN>W75
M]_F>Y;!>6KMVCPI=EW?^ZC7:$37Z.FUKT^@E\7Y@"E.8_6&0NX[:&-KX!&;B
M197.!A9,2X(T2#A-;<\Z8"QP&RQJ *KD80^#"N+&:,O+;<ZG!0%N$X82'[XK
M__LWFMCBAH9XU\G,2@2[WX8M-B6;E:9O,'P#9^A1*J*&0,FZH4>+/^8BDWRW
MTC^>7YDGW27Z0=MNJ9Y'R,58;()=SP1" 95H#=%C\@#4H@.!U?C85=9QES'B
M"X>LQ)A,)VX-G!@B(_B#SUTNC!)./DXI<SB26YW<;5<155+S_F-\2U3LMP_J
M4LIVO9Y)45RK3++T*_/S^RZ(FD*S_>*T[?6S3;Z>9NU<3C)I#W)*3]:ZK9,V
M7K$=X7)5R>V-/7 !-*S62>@VP&(_!(2PTE0GHT'K#BA://<)G +2X@8S\7=7
M7CGB$^&.%OC#P*\*.$$7(Y#U[:8V*%+M'((W#L;Q>IL'V8$L<SAZ_1R BH09
M^B21(>' &/VR(,#DELHMG0Y"5:W,.F4*6D7?1IV[4+YAKS]965Q[PZ*^HYZ0
M]F^LOY\_-:-^=NZO;VZR8V81BK&V[\;Z28 \Q$=I'55,93&6JR:+G&<^@$,O
ME%P.QDJHQ>JY\YMF0\YW.9;IE*)-,YN#>NM;*GN;>4X!\CE8PMUP@;.->4++
M#4?DQ.BJ=!]<YHP-9[0CGV>+E2US1Z!W U9L3NY: *K8!:(C+@DGY'TA>AOR
M4UGK:AC9"8C%[(#;P\99&-N/MW&5[B]U PHAMR_(NG7;J[/'$=^]#QW+ISR5
MA 4*1-XTFTF33%9MY:DX(MU.Y(*>>Y-H#W#F#:5J(T7,QV0C(7BQSE(9GUI!
MRLWC0<T1$"HGG6,UDUK>XU#*R^WS!5NQ8COLB(=\A1E5C,<O_:,5O+U=6U/H
MNCOX7JB]:Y/$8?N8N>NC3STOWH] N58E;_DS=("WCY.*,6?M--FFG+ V5NPH
M$J)O!Z5#&#, ,S]2]X05V#WFXTB*A9]"'$.B$.***%SB)_P>_=7[J16Z$L$A
M)1#6+_"$?[JN#HNCX^ :L82TBR"UB)D%.!$&W72<BF-Z3;:ISDX"'.ORIEEN
M0S4@!#F%B(O[3R8$40\H+7TWS0JK]D&A1:Q]M,;DBJ$[A"SH1!L1 TC%<_BI
M%1YV%B"2T:D5RQW@8KQ7Y"CAZZ:@YEA)=;* -\^;#C*<@6]DJ*G*'2PS.*,^
M3.\1)#!59?M;V3*#2G)XS_^Q(KBGC.@I[QJ>)9.G]D0^3KY^AX&+63Z0?4Y.
M>USAQ?0":@V\7.$VXEZ6S1B=18)J^XGVD%-I4VIXRP($I(7EO8Q/BJ8F'^9T
M,9J7SO],#;@_'1NC&:.D]F24?Y8R^4,FZ^A0$I6^];)3Y7]W=>\XVA0U64$"
M>R3*'$62B+,KE &2%#^3EH:_MJNE58<Y]Y,+36Q8*/ PB:KS2B\]!\MVD;O#
M)OBZFTG)[W-+(S;2F6HA"MD;9N4^'#I)R&J<&N0Y+K-/()].">=K,Z5Y)"I>
M<>8/YUN<#KP8[X1XCZZ^HH/==35PFH3D<)7MGZ+XH\D[&DS'QN;,.7!0[TWD
MJUWUTIZ1AH[3+'O\%(]LPJEX[<@ST-D2J/H@4G#STQWQ,0(H-)];T.>2\?.,
MA$'B$B)\O#/$6^+'?K]G]W0"Q>T+5UG9QXNB*$O:I(M=TG+&?@*W@+@#<=//
ME@^T!@XZ8UB'5%[XPH3=\CX+_5GE5S+OY<@AMK7,>_5U/%Y<Y79XRT)L5"5=
M1=\5FDCULNAR>/[OG-J(P9O$R_"A5E80?&/]HLF_&E(G!!ZP6AUZ.UUW4V .
MB^N !ZIS4)>NA+6EG:K<3>#,!_*L%HD'H))<@AN]%6 .3CIAR7O@$%_CD?",
M" $T5928'3?I$UA)'!(_ZM&>3UN/8.V'CU:Y0\JA,//#SIW"G-7*M+]PN'R3
ML-R]QK9#SAN;V$[)57MA?U#SKM?D+3E!<A^*F8FT7PC<]+EKW%53%R]D1O!P
M[_'5BU,Z5=:Q164.Q5Q@C6R3,4[B0)18B(:W#5\2%$1./3PE+\,9.1=[NN.\
MXK2<Z%YF9>(E?L?3<TN'DR;:=4Z#HN-++?^R>_K$!:<N7Y)"'H8?Y9W>SNH&
M,<D*N2#K.Y9%K*O6S+D7&U0O11O@TA5FK[:53CM8ELZ[(&]K_;TWIJCN;5'K
MV_8'C*UIGJAWH5J>_IVA #ZA%A8E^(YUD0LF'3)$1BQH_=LZ"0CL%UA ;4((
MKRH,:*M+I.K]@V"C.CY,_+&M >3L7>#/OA'8C7:BI5@D<,(=TDIS?$NRH^;\
M](,-*C2./EWG>IN\]HB]\W?,:)J.<E*Q\4]E!Z/^&?1!L@.B@"MSKO#%VO<.
M&-/,VD4!V*\C)_M\ZX"(F&6"&RVE*?7LL@'L\V!D,)E@7.M9ZFNI%<5TDC,"
MLMYJQ_\T6IVR8"6N7T>"X7+( ]QN?++A^";58:1RG;"0AIR'&Z$J^;JU&SP$
M92I#QSM+G($OQ1<GJT9.X@83G.2KGNR#+.(X-EIVM9T0,[^(MUQ<"P--S+%
MQLQ,C !"D9.]"4IR3;6S *9.RY"+(-Y6X\_'YB.!K3,2SA-J++$.'4?1\$M_
M!&OXOSZ[I?#*=[5P+;K[RXO'F)=*6QAKR.\PUFZ:_:T=#>L,C?!4[0+/KE-:
M.+<?'IO7Y54(;Z7S\NX#7'#YP6/DM,RDP7'QD>!(HPI-WJ[QGW-[!@67HV*S
MH_7^.2M91W61O3V31_!'**7&OPL\6=_)TDNFN2K*'2+!!*.J5JF6H8]4<6\+
M#B*?Z5><MO;)?+*.8BP0!LRMA\5@(L!\L;%/C\]M)>+>L Z/^E@%1?#'D2!P
MT03)<#WHFQ\]$%9-;?[XH1$^)JJ0WF%]KG:,%BLBJE4\B_IGSCFKZ\\\ZR=8
MA"J/CFXY<HH?KM[B?7_1+^J';GY^?DGG"[KM]U>^V*F7YI)^C5Z:@4@#BH;"
M#5L6%D+=ZONJN;[+:D18DWP]M.E%BBH\AJ'<I?D8_W;XS7"U)G.Y\]X"?Z2T
MNC(P?'P5S8QK?AWS1U=W\DUOT[U$/-Q;/MS> J-4@T7@-!(^3^;&8L1&_P'V
M]A)) $6,W_7>X5WQLL 56$:CX\E!O^FCGJJDEC!7[!?K7M"\,/8^(*)GOO*H
MX:-BT^R"<&)E>-/L%1[+2C<V$,*A+1L[I-1Y*[)J;4":K[3?-$LZ1SR,)$,-
M_:_;;SNAX#4U,QX]OR9^N-B>S\\H9/MK%*']2K2ICU2\(N1$ Z 6;W!R5G6[
M4P4DB ^[!Y98 QR)P&&<=(GHQCH&^0]B+!:=,417X(=A"=MJ2G)OTL<Q9%G=
M(71@&-L:OW5GXAX&MOY"B7E]R;,8W.)S^AO,OG3Z#IGP:\X,-AAFUK,.R8EF
MK.-=<)9)-YS<1PE'?%+<Y4A@RZPF\QKW!@.<ZN57K(DU-VJ2/UXKRKA2&S^M
M68L-?Q) DSSIOBSJ=_18*M+[?PE+UGV1?7!!&WQ7+DEPU6-O==;K$WI2P'7E
MSH(2^Q0:D:M:C)-B*#,I'9J [E(5#1\UMOHL6+;2'#+9:3R]HL6'RZMD+S&U
M5*RX"F>:O=DK5CB1P&9TI<023A3SKY05/ :8I^17.[-L@L=6IO=,D64KE5X1
M>0IQA+R%5EL\)WLY,H>C HGGJHMVGREJ^K]^^_F_C,V9_P!02P,$%     @
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M"AFJ>#1+JC4<[-;YVZ1[+JKZ9D_EG\'A)VH*8UW3MQ,HG?+(>\ET-/")$=_
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MMKEL'Z QJVRDJWCZX>APWBU22/@[@IX<4DAX+?[JEO$,G<!<:L*-<)X*/E9
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MVL'I-.J#@=S/UA,_2&V.=$L\F4E:;8E0PO'6F$*O!(B$ EB60)0=P9<<=6^
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M4'\1J8B3F@!AJ /0ZZH ^H;Z?KL= K,>9)I<Z2'62-]0&HY)C21/&^9AXG6
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ML">WB6DY8>C4.,2;6I;!L+>[WH42_R*M>E<[&G0;M1]$QMS8"F;WDE'J>*H
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M5B6^TH\RP:%VUPV&]6KA37V&:1$E\D8?E,'X6.C6\2&4(6Z47CLRA5 /SU#
M_^CDJ=/T03=ASMP^>7['Y2GFI7OPZKW&@HJ[B$90/AB"&;1\1#0B;)<\0AG@
M?;K/UK$).&#I#!DKGY_Z%3IXQ?H>P8S_,XRW#OH;SS6W#&T#>B?5"L=#E*;I
M2(##,L*TH_0'"1'CW:K^IX",U/EZ\[WS'2@]MOC(,*9Z9-)F5C00Y'F>7K(<
M7OS^882&-OXS[G;<)VY>@5D;J8[7BDC@;I;!XAC\WE9&+!I.NR@*=O@+7]S*
M4[%3EE^P1G5![0Z*>YW++6;NZKS*TK+*/8$-9G[-ZMBW/>:C+B8ZZ'B[[M7
MP@X[,[?BV M!20X9=2Q49/7;WUW/7[$XF7ZF<FU@X@.S]]DG/P0,57N,8;J[
MSY<MXZ(^BDE]Z$!X2H%U U0YKJHE('? =0BN''1P;VRN%^3A2DI&OZB)?PHA
M.A ORA-0I@0,9 APA-@.I )T?7X<&6MG6Q4H->,0MEIDEW/%1\%\2MSL[-4!
MWY<01P9;:T1,)/[].R":DY!RESW%-0%I!HZ=1G(?8"S6%J&-H(Q#4.E3R,P#
MBA*:S1VT=+)S]:V9VD/L+S"&COI60XY.PW2SJ:7F4SXVAV\6[*2T2W]]Q:AO
M6,[R 1#W".?+H P'T#'&SE 0C.BTOIU+3EG(T,1['.(L,+2G#:+3$G+*IU%;
MV0W1-J)>[\$PR;Z3 PMS*!GL?,RW[YW,4^QG<Z8)W/:! [=X?/_VGY:2?4ZD
M!(I:>G81Y,7R4>H/JQW'KMN65XPWZ52Y5F !7,\H+_NC,=(CCN:>>_,QW108
MBMN_;)I(;[LVVI/VP].K_CIR7_O5W\#B]9K,-^<*/4:/GWW\H/)*RP/.KBM'
M4BN'<E/ST5?T:SQZ?,(^;C_KX4WB-ZXLN'MK\'FU]!:!/8YOG10LO@*:7("J
M!>CUTCYTO0P6ZP^6)\Z'&6:H!XTZQDK1XD, C^PC8C/=APVV9?OABJ8:'QI8
M9)4$-AJ@LDH\+TY%7C/'7;^/GIYO968H<\-EL,R8E5KT]XFRY760"G^B#1N+
M79/G3HKCK:'KB,VC[]Q@>X<DR&!P.\2XPW 6)BIIEY8':D-_?59E=6I.SN\7
M4^;MO)S"?P=FHY(>26>A/<6!GN1XBXF6YPW-C\+'_F)E':L16-6S1\YHO>^[
MF&B49+7(-3Y?CDV=\'QP*7"H33CM8*%>WOU^\DW'D>RI#@>7SITZ&3M='-#K
M#!ERJH#_^#A/WTJ!"NU<.-+#7;4R6$'?BL<7Q-QQH,D;Z@6L!7!FB)J</-<O
M5CNS1BT* ^@(J(6?1]7":[%VAO4<-U_(^U'.]0PJT!ERJ+3(>XK'=>5Z3NL6
MP,'5\N3[RUVWE+-&X@B1GTP.%ZP#M3L:'_FO @._%#\\X.HM%VK9E_?"7\YE
M]G$Z)V*(9:\)9ZOMT!I?SD_5/W7M#C@?&VA9OOZVA6LPVK*QSJLLU\5(M^K'
M9#,B9VYEOY3C8PR9 ,)Q.#E\/@YE 5U8#DG9"G7PT>J$J]#4>(M/M,FE_?NE
M"$D^'2$^^1) =%(,QPAK!L)"YH+-.@T6OY:6B9U![X3"T/%>E6FB$A2]G8TK
M!)5GSS^;QFJ&4W0#(M%M&7!D!FH+80/TZHYPD=*UCW!)DK_(2VA6;I^'0\Q6
MN7^\5]>_B[#?SE 8;<:/KDDI^_@I"*$Z.VLYKXE_R.N4K@-%J:,8<C#)L8+:
MRV@,379[;)]]<#"\U/U,;$9#=M @J)E]H?+WTR=+=_HL%'V<8J<9T ?2QKME
M,.SP\%1P1EP84HZ\PNOY8+>7Y F7([K=)]UBRL0DT;4'&ZBK?<17ZVLE16*G
MFJGFO02+D!2NWO#XX"[Z!CRRU;.77/_)<YG)%U6!6BR.[L![R^";O%/I449>
M/!Z?DVQ%26.HT7="N2O,"6< T3JOBW?@,'-]@[)2$"D433NG\2B* 41U>B@=
MWIK%!"%D6\^X9-VW[R<(AW:%1[N;O=Y>-#AOT$)/_EJ50?5T?="2^V"[LZJN
MWL7...&!D[G!3=W=9TNNTEE;9RN_]Z?9_(:48GJ7FWX6Q )4J>,\G,3QFI=8
M\3Q&1XSE72*#K8-2^*4-+;QT2\.H"M^"M5M;-(_O)*>U3S75%#X ?GO[;-]'
M1>QE&:Q]#W]^6?$#:=R&%$_\PG<4)X9^DL$:9F2P:1VLY(;)9\P_*:G7U*3;
M?9YXGD]38\*!7Y.]]FQTW7ZB;W_^]<\[TU=??)1N>Q\73^T\\-^KK3?$$]N+
MDD'6AG\L.Y64;LQ<W*!ZL\7C:_1K8%#86J O/]^O_ ^4G\'63^1RZU%OW*YE
MN2 B=M<BOD]41":/0%%/)CG$=<!<Q_M'_G;?I_@E#T^XYH^]SWEX=2_FU=R]
M/@\SL-AQ0(XQZT8QOE=PN'VXAYF/-B6YO@L.)%Y<BV@_66DRN$[ZH ?]^9.S
M](V<LHOX72+&W/S@S[^7Q;Z^./*WKFIACCN*4W/_;2&)S'DAWO#\Q2#A:-7Q
M:)SJ8&"QOH;IH6FJ:.8\]PE@&&AB\EC3EO-/RTTS=G(7..CXH^CIR(?10%!O
M5W510]SK$[[QOVRZ#=LW'OHR_@R&L*X!.]BZP?4X[!\;N5!H9VP?S3#P?,,I
M=,[7\FC*O"BD. ]>"7/&C76%/7R/'W%GN[RL'[1XE)WH%658A7OS1L/SX]'?
MP+=W$<D\[;"H2=(-C#Z^#!FW'$4XD2?DM*F:M<OQJ%IND!EID5]DL$Y2PO.C
MP%?.6:C[*7%@%)%8C4) =VA:OI50S?=WG]I"^$CR?@8\(\XNY,E,,S6I^N8V
M"=W(QC=+W(L:F4D?Z2#^"KFU1Q@TL2B*.)N:+$%2B"Y+!E-[>!$K73LGEU<Z
M0/BC#.;O4(3CP+570PV]HTUGY59EM/O4P*Y-62SB]K[P?.2I_7//H(+N"\GF
M3A8R6 AYT3[Q6S2)<G0P]! B$?T?KA$548S0GZ_TR6"S,,JR=S@V_S]>2OKG
M:0H"?_']/RDK*G),F3YV"-RYO8B1=_<?O_J?0=ZC?#?U(7UHBY;+=<]@0A[V
M(D&NNC-M?D@[5>8EF]FX!>1ZTN?*<AGLJCA$RE>LAG+^?G:9Q)C=2%H(LP)5
MPM%NXIFY^222W 7D2=NZY"[@*%:]R6T1_;X%KH/^'"6?_Z&,(BWS5>Z/9+S=
M['I<^V= S-\+68<AC[\7:LF,F>HE:>Y\U5PD5,S'BC.X\J:M:>(MX^C4AIDE
M>1&C/Q]-E\%J6TB2(]VM_]+36C!=/IXIO2-7LZERO>N&2YO_GO%O:[[_>*7F
MY/EI5/'/O@/?_NZ[%H M/8:1Q_WA &ERJBH3FI+'&)\C(<\R%C)<:U[_YV_$
M##PJ%^=5DD:L[\EK_=(!*4_2LDPQE<<I'C[A>GP#S.,EX>^W"7+^_6V"D\#R
M$ORN#/9][PQ"I(A>Q@9BS[<AOI__S!!I(R5[+L"?RI,C+8,5)6__Q_:T:?AV
M<WSVI_B%/1]'N*,?/;W'WJU-B,+]Z:.2Z >+\7VH;VP-2ZTR/N[Y9.'@%/<N
M6A?-5X)N/2,.H2SK&P!'IJTEY U&\<EQ!%MK^7FO4E-Y&TL:GLLE<"S*X%.@
MCG2/Y$F]JCM:$;+MBCQ"<Q]-R-M&P<';&7 FWU82:7_B]'+ITIR>M+S15D[C
M48M&N'&J-F/VD9SF,YH;Z-4KA_",=H:N5:\^WMJ50]P8@*@/Z3""'\_KR+EM
MH,1(N-% 2C V L_Y:#Q_!>IDJ=T3]>Q<<J@G:4UY[+>V>:<K\KC-1G.+Q22*
MW,S<^Y^:&;;4P0@N;5TK@Y5RSO_D_&OS_MF::!8E?[:+>(8K, ;HI35XXMMN
M5]I )M*TCN[UT"EL\LW*+:;HXI6LWL;$E.RS'3[;R[Q?)V>*5[*_#/T@="MD
M7_$[HO>L6Y_<RB]-JEZ_'S&C]_1YX7%WUKF@?(/?JPYTG@\ZP(XAL!]<?9QC
M8:OOC&R["BX*W<_MQD=^>/HV_J![]6R 6[9G3?YVG_#KA?I6I]>^O_TESF];
MULPD-;V:%, PX'E[C5R$_)E9GS[UJE8_VR%YUF/5P4K9H%&A.X*ZEE[U^++B
M2T UVB^4$):O(SPW'+$O,-*EL[1*=1O3=?"C'.,^O+E349-=^N$HJ6KZ[-6U
M.1CV,W-J@XL#9MO V]%ID4!ORXKQ : WF69WYP8^-UT1[F&%SZ@\T_[UP(WP
MR,SV%6W/DBG^EX-GRTI]'ICL?/RTY&,QYA&[LOO'8V3GB*Z>)/1S^)YP_CV1
MF<99NAK=X+%_HB@]^\#I^JM/SP4]^+*]_9N&4V].P<;1\,6<UMZ?6E3T[&6Z
MO.K-]S-V$XV) W0=4.X -XJQ'+&Y$!._K'N7N%E\' JO@B*Z]NLX"RES2 5\
MS5B[SAY&0CVNYW UP5&8YG6F?Y9F-8YIO 3=-P^Y-$ SJUQC=WQK3UK3"*76
MM$L%F4)YT1@/#O]H]_D5L*]ID1N4@E=/H9U3.9WT;< [J<;08LCZF>:-%"#A
M(I;4[EPUBH7<SIRH%N_S)6TKWL<,+&%6N&Q9+:QB7MJV+4/KU5 )?]V!&SXZ
M)8^?#.+>:E14ENNC(MZ</OL[V?+JXX,E+24'Z<T\CE!"8E(P8N>_W_5@\41J
MZ&4; RB^F5(I#<\4(L9>'QM&7^=IB<_F\:W3:7MU!;T=&;'?(71G,R5!O$?@
M?)"HZ23X=-1MT,K:.K(@NPPGW=$GU@XWC:$IW,(3')_B*1?[:!I/&^-K>IX:
M(?Z$;@E7D$G-QH6"%JU3]$:@I& ;9R%$>::)JI?1%:E+_I9U,J?+P+ZHJ,>/
MWX+UCKU8!_!;(EX-A^5;C+& 9Y&G6TJ5Y\"K\=@Y D/CS0IE]L-944ZR3__5
MVK.?ZR)^_W+_OI-WQ\F3TUJA-@3>E(30SU,[H:]H6CD.OS5KRTD(HB!H.XJG
MK4?="XOP12IS-M^BS%ZZU#Q:>37W.>#C+^''/Z;=VW)SM;&IX\;=_U=Q;Q;5
M5/:]B\:R0>E"([T02P1$A-C0*(1$R@8!(2H* D)41 @AI%"0*"%1D5Y(B264
M($2DDS8JA"A=A! H"Q%I(T%(5THO>ZO %D(X\9PSSLOY_>_XWW$?[L-ZV&.L
ML?=::\[YS>];W69>8=['A"'7GG.KF$1;]5D'7;<KGXTV=M_HNVOI>;LCZE_U
M6%P[NNW+C6["&M2;=RVJERC:[;) $V-I.#E%_ UE=N;!Q8G+VJ^/9H8D837G
M*4>.++,]#!(3R6W>E"X=+/PH8DX+XPQ:[)-0[B<71+5]>S)]?L_FL0O)E7<R
MK0=?\_\,6_8_05TJ3V+N/)655EMXBN4VZ68QA]X RA]*E^-_^W:LGQ7GX>D8
M1BQ^.2!AI1WX$G+(\O;(S&*LV9A^O=N!\VFWPW+,&&NS0,PL' AH+7"J@_ 2
M$F)2@+O[)5)F6G8.W^D&.B\\?#Q%TZA1,'6YR21Z+QB9\UCXDQQSVHTDV=3U
M?4TD"1(>;F+],G?0UHG0&W^>'SAWFV)-$@E5\4&(9();Z)HL>0P"G*\X=\^^
M,*I@JO_^9M?]NL#KHC4$Z5RF+LU0%@=>[A+_R:AEI\;@AN\2%&H)%2@EZ4,(
MB=+K9J0/U"/)5_%_'S.BANPT)*7_Y"4=04:0']#I#<PE(V6>P<43Z&W@(H\)
M'9U%63^90F\!G*L$N'0Y!E7"W9^YX]T%[OOJ1''N_MR!KV6IG=QIN]_)>.]"
MK,[.EW^S_>L/_$:N(!_1=X=K*I^J='^@S"J:O[[N:LC]3\*10<N!=Q:)9=Z[
MHRU_>["3G,MI*C#12/CW$]>R"N-(:WY@X>L5AWRFP*-5F,!*Q,AL<0Q34"29
M&:AT?*C)3U7ND-GWSAK9/N3OFU("6 BB,<9<$4UW*E<G.0']*U84&![VG6'H
M(D)JDK-P*E.J0TO_^.O7J&)B98>@08 C]F(#7"Y- W6AC'PU".J6/D4;RO;U
M1?XZ8#,G\Y,Z99AZ\[W=7K#[=\U=8J4Y[W-K*I@^.Y"8F1QB=78X:.K:HJ#^
M 3$.F@-T5F%A"!WY@*,KG6HA[RK8"0S=!S)[I#',F5&Q-5R2/+/HP*W>&1C
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M>I]=U^\__,-FR?R^IVWN#=O!_L#<.,;3:%^>E8)[_/W3F5Y4TK@S-1L^*2&
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MEIBD"P4'U-<-1CN'OSXG"-QH<X% ='7G],V/FLR=>L\B(KV;OB_!=CQYA4!
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MVB>RWC#M/TA$F8I6UL0T=KMZ 8S$:*0R7F!V!Q=T\@A,YUO.+ &PGU[X8Z6
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M[P$F:TX/2N<9)L9/_Z\]Z918D+F@ *%$QK*7_ W&^&(_Y8 M8@U);L-)^3Q
M(LW..\TZ= 2M]X!O$@3@LX?Z)@NVTW\#9[/O22JM:!K'GI,)OOVS"M[X%ZN+
M7,+4@'J6K2F7ANK@(XZKL-=#U/5\U"$P>2%U)8MJ3]GSWHZI,V5B\'S@.V=X
MJFLA**?=42DM9D)FR82KXJ9]&>LIV-"B<X))]/:Z8Z2ZN$;>'6P,";\4JFCG
M T!%S.&EM.R4X5<>M^R;#%(%0M/1UN2K8B7NBI&8>:O)\RDTYP7DW&I1AZ?D
MUCR(8Y+'3P+\!#T<2$N1G0$)'3G^=PQQ2=:V1/C!Y\"[AP1:E="\[.F;5JJ
MNG'E,>4"'DAPAY2 =#$_\U> T8%)I.E1%"_E2J8I5EECB#L<S>_8+4?$1/NA
M?G%.YLCI'!Z>2$U]ZAE5*IC4Z]K"UPB,+_E$G]NY8RW([60\5^J8,Y&_GP-[
MOR/7AC$T8WK2$&O1IA,X_:H6>]G!6KJ"G*(-)PLT6(-R;0*BMB!'1&[1I+[/
M9276"77K$"J4$^ HCYUJ0VRB!5<'3(W!F@"]V]6VG ^BC?H6SK1=@#.P>]^
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MG0:'E*8#(AQ\>D%NMO)GBPEE/>B;:L>5] PO2]FWJB@7BLGTMANC\TP!U8#
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MR0'N=16X."<&'ZXX6^!#;5K7<ALDV9?R<&M.'Y4>9YJ__?86'VAG]LQZUE1
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M_Z/IM\GFS'SQ'L/$H^K'$C= /7SX6,7*'5#O0R9XH9X!&Q<=&918D#9"WJ&
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MCWX^B9O4' AIX2*_U5,49J):N/ZAMZ(-+O!KK$.OS]?_;=A#*YN_6ON-Q&O
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M5H+Y^1F;1:U:HW]UP7+Q;9(-SRD?EZ]A?QQ^)V+-(GO 9=;W;I%CT!&93&I
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M#O1_KEGJ>^_^K8WRGPK5/N:T)3YT^(;A0]9!*\1HDY!+11.*0J=8615]=G+
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M#F>P"[@W6TP2-N5T:C9$U'R$O->M9*VLU'*9M6.9D4;79/X"<3& .D619"9
M9J!VR]*D\.%4^IAUT&XF\.5OT@$^<@N[)@A?P+SS@$?,[YJTIG925.Q<D=1Z
MCQJH$31M?+MA*9?T9CUD(^4R^O;NC2Y \^_*+E)86E?^*+.0<0,]51675?)(
M"FM#2V$XL?-I9@LG1A%#?=:#3Z@8?Q]Z/<)89"C1QQQ2+(S-"L/B#WW+'&JL
M,__C%-JEK;Z(C.3['ZAL'G>Y,^ 9/FM>'IJ<&&'F[S91]O+'>*"'!]_=Z DG
MN^RO4(U=7G7AQ=C4')=6-9R?-5G].0KSSP0&H&/+C+HE<Q2>L<@$X$N,1:?'
M>> ?),(J3?0^;K%*"JM8(XA,9:O%+IUI(<A\?= K*>S-LN2NN4K'"*7QS BE
MI[DXB,RBWI,090)X$#VMS)!LI^;G,_A?R)_F*=^:Q-\I[9DT\; 4QL1 OORF
M_S':$J6]%\J5PAP5NZ0PR'N.):)CQ!ZRS>P+@8NTO'IZN< /^'(S5;QA2%:E
MO[Y_7Q;9]8X7_4?,&9I(3>,<R14JRC5 ;>Y_]I<31?"0?&\7][NB%*:(%OB*
MU9&Z4AC?MU8*^YY 7I4%84G,06PJ$T4B-X'R:2W':P/&1/I QS" U_E06L7>
MU"O,S_R<8C)V+_N /_K.(T>?2^W99S=@[T--[!@@:!?H?I!8<#ASE[ZFN\HM
M3NX/T^U7"B/,+DV.G1/+M3,-RVZ#\BF_/&.?O54=;*'B%97A@4=VOEW8%PNP
MV.\DC^S\I+"]K%0I;%[NB10VTSC+>J^*7O:@</>SEORY:X%0G<21HB(#5'G9
M1$[$$*7 D#+[4 JK]:!,-S!NK!G+LLIBS7U5ILP<'5EAG48* 8PX7H 6F^Q!
M.*K[KFP0/53W<(21$REM!Z6PSWL0SU?%69.[I;"A"&&!9"GG&W*]6I1,V<P"
M3K-^GG*>;Y79Y:94]'( \0NKU7 ]0R([TWNP[>C3A)]FWY'K^_Z0PM::WO<N
MT$MM1'=&>.*[$%U\]I.P\F&Z) 1=VO[OXNMYS/)$R9SBRK57'W(K:<_+TF<)
M484'ND<X[M=KLL7EO7<;W2(W3N1I+EB><-@[YVDS02A969C[%9%,5H=@$G6H
M=$H=#2,AF]Q!-+OH+#'#2:9?_B#"V3X^:%P^NUGH1A TBLMJ&2*KZWSAM2O+
M9A=Y)X:, &9=.=8E(J0:E7=G@CP+GXT/?BF%'5T<9NE4<$@:^/4+I-_IG?J:
MT(80@9ZS</4&LCY#UH!2V//8+C0-H6:5$0)@V29*R " T3T7(%9K8VZM6W>G
M&Q7RT=O\SLW9$MKMG4_E^P\NQW=RW>\\(K^EL:NF+<8ES(J77VZ@=U"F9$?W
M>S8&VH,1%Q$6CDMA3Z+ +:RKG"V6FR[M'%1)/+[YU^Z-+!7T?SJOGC+U$(4$
MKR6!#+://SQ=Y%$R\@;H/?DBWDVKPW\X![^/#25UJM0O1E1@ W[]T>R\*^*P
MTZ5+69;FWNKPZJE)K:HN[<%#X>?^^3W$SMI ;6'6(Y=8=MSQ1?R1P?)%\PB$
M==X(_7!GBXNRQMM]A6?;,;H[!?LOB&\=?'SH:EWVEZ]W#R)C<V=Z:E:=IS6Z
MY['KZ$!2=(OXP;<6DZIQXH"D/WDX6<8T;DCVT9;C>UK\2+(CKCCFA=I"2#TT
MQIL8965DI<;\:I1_QD4M("_"Y[2.S3QZW6YZ-(A51KD "?W="&P==*+I,D:=
MA(5:!10U(K(M2 _<DB_@*4,8?D5&#$LW"*+S:S-*B*4G^F0ZP'FJ*,"Q-3#X
M5V!A^?WR(%._'UTGA6E?-2-;C)+0ST QK[/UXJB9.Q'K!@QU=RRJ.@@RG5U>
MI!7P?)\^S?$ZA]STW=G$\5' ^)L:^UN>X1F7(NXD#H$*4"M?"<OV1V>@S.9&
MMQ<;]FL%K@>+',&LNN"2L2*'<P./ZKC[@,\?GAG&E=66/ P<Q?KA[H2G='T6
M-KW,/OKPE2N!LV?J?KA+.UWK]_"SWA;JN4="AK[ZQ/QRY_:S7RK<CU1X5C^B
MM\X++<=N7QQ_E"/Z$O3+6Q6OJO87_SB,\&>;<][M[[I_0'"I](3W0==M)6[>
ML9]7LC.>?\$YNC#&7E$^<E:B*/+$TC:R(103"FJ.=7'C&LN$\!TB'^80ZH!,
M;A0P&_ANQUYS"[HJA#S$!%%&,:,>1 ?G 3N;LM[0QW[=)=/-[O?*P_Z:6;FF
MV5>^2F6%,&Y*=@Y8HA5GR$KRKXMW0=Y\0I*_,]O,]>RP%3W9FJD(7&,8-958
M0 '5@9/$C12-XQ2C.<:N7OZ,W87*-KW6LI4Z^X9Z%6>(8$X'DUNP?-H6''UG
M3.ME*:Q3QZF(X4S!"WM3?72"DDO#<?L&_6EIO/,9IUG]-24#GO;7IMY4O)U[
M%(3C=&2/AVLV/H_,(58(W&CI,7!%/$++SO?AFS*\;6-:Y>PJTQ*<7W,K^T"+
MB0V).IQI[2KV<<697QD]HJ-WR(56J/9^^X$O];ZNKW\.#^1K7 A%5C_QK<OR
M3EN9;'M[QEL#\63=I\PVQF#3@\\VNDZ'FEL&P5S/NFKVD53G,7' J%TO?+[U
M>>;1M_K<6<D',/G46[?>O(,>?^+.2Z@2)9$<A%Y'SQ2;]C/A1,7C@.8](45?
MMD[?M"=+BCOG^8,M6*&>DQLF8+#(P%&E@ZOZ=[T899:GXYCH4#YS;:6 M&/,
M>=Y;U 7U^$/WIEZ)S;L(M_4-N0%G^Y9Z=W0;90JQJ189 6:!E^AN5(\&KE,&
M)?3Z]=^?AM\)<,'EE&-QJ[^]->^77ZR8?Y807T66Z1[YQ663L?=.:W.OUTYR
M?;FKOEI-35Z'WC#QA:^JC%Z\R 5L7"VS%D2_X3\=Z647W#?(_3V*L!#GE[OK
MFMD%7/M.VQ=^3DOAPRNTT:'[3UIS:":W KYXNO=@'_/UT52-R\1QQOK!<FS
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M/35\B(^[E+G4N[T&G?I.#LDC-1O3[G"5KE])XL.N0LDS(HK7XW5_N,?S868
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MR^,E8;JOR]Y\;*C+5G[N')>US8?=@&)X,:,C//D 'G93[-M3TKMSZFBFN/(
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MG+K"2 $>'KC@,-ST0X?5JNRSD -;!Z(QMYMIQ_#)+/3JY5Q?I^W'Q,,^"HH
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MN!:[F06G#]>U5WC\H#TEX3!P*(2INU(-2EE"H443/J3JD,<KA)#I+_"V)CU
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M=0YTO[ V_:=.VB#@7_26XP!D)?^/ZL[UJXEK#>-!M!2I1$"@@"2U6-$B1%%
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M:>W\K7]9\K;GF)[?E3X9\[CPYI<<YF7A'KN%7T!:(D?O-+EC@0P'2 X-ABD
M;8H+9"FV3,+@1KEIYG9];,M"6DO$PWW@I99JV/8PV#) S,+NA!93IN882F..
M)GV-[*6/ P_"%Y?6+RZ(9;]$6/*W5K*]18VQQUY3-\#50H-LQVM4?8H?=/=9
MA=0%ID6)/$C)>69@4HJ0I!*VQ$IG"D?!8E:4>-BMY61V_\U1B471,#GAZ*.
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M*JNN4&Z*<?"6UA$4O$(2*/7(&>TKZFA##3P7T1ELC5%:PB?*P5@\?)IJTNV
MTG<'%T4J@398]5_(;FX0+0FC!6D$0AOK%]22AYH=T=J82T4;!<G<QP6<YTM,
M']DSVEF!%I* 71@/<<ZPR6*+B6WJ/$XO3 ^VZN 'ZC[NPRB#OXO%Q@R*;K!X
M"*_Q<C0W6N26P#'U#<-NXW/6C&7+%$!Z18VG[8EGF?OUB'Z%1H$.XDYX4R>/
M8!YFOK:/1(D3-V(76VDJ"B ,GQ!S_:16L4WF3S@BRD#JSI]CF@J(._9W!<+E
MHYP<B"7&)\K-W#?\%BQ+A[S;>#[QL6DYOM;^B/V69^GB0])+PAS!=>KN&MA?
ME!LD1K?NT1>^K+HZNE@+,ML)&01UR@4PH5WN5 MM'8R=7,I+K</I82Z)/?6;
MLOBZQ'YS9VCG_=+384M)"2'"6>W0[\R./$-(TVI8*:1<NKZ+8A<.N708<XTX
MCF3+T<K:JJL@353HEY44#*> DC:F'L84T@_LFL>I#DS\!M:W<M#@G?D.NC0Z
M(L0V:?X%V:'1Q;//9BL;+1JW#\.I(CE:B*M6 *VS"4NH5JY>6 SCJD..@!ZH
M#E\M)^]FVR*.N14)\:]/84V(?GC>GK-HY5/[H+IWTB-]-22Z*L?8CYP1#%4]
MNT^.F>CG>_?7#(6G$XSEO,&#]6().M5)K;62QL/N?NT@&*ANQ1JQ::C0[ ]I
MQ01JI[D97#MZ)^%8U\R[6J=:>@9;'RIO;S!GK9QP"OB0'KTIJS+4IRMP7+CI
M0Y9\Q7NA!@D@ZS?Y1;>:>?\*QTGL.B7VX]5D>A-.FW*I,#S0/$MDRV,FWR+
MY<TCNU[7*@!U.&GH&%/85D)W0*K*V_$TU86KE6$OBR><M!N-[E2.-Z']>9!
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M=!2[7:FUA]R:6?&(^K$6-N*;!Z-3I2N"BX9X<>5D%^'B%8KM9>%+/T&+,;H
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M;ZW50!F.+6)W@X*D$K@:=.G@V+XV(0L\>]CZ4%"K E@^6Q.A?+2G-C:XOS;
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M[,^>Y74:6#;3Z#WD3.%!1GXH#B7=%R>41.#]P/X[PMTA3\$[M<5E9:;/AY+
MW+[AZ=G$\[6K622,0QQRW'\[OIA5[_UBS@$PA!C3'9"^B-#$O&:QD E'7R@-
M=XJ>^ES6"5F*2EIB\5.[LL3HYLDX]+%N3)S00\O-+W;7'&DU.1;?>__K/U>/
M!A#<G["AD(0*MAUKV)8N=2O#X$)\=B-0HTX.ZI ;\[^^JJ'F ;E=8WL7CHP%
M6H S]2&&\IN5H4NWK2-HQ1,GO9-2)WZ?40NM6GO#X-;.;WC+K^"L*-ZCA,'U
MG0L,62K;5LP=+!$',AY2_'JP=N0$L5L"QR1,KMI--7$7H>D-1Q(@M<,@/S$B
M"D]W*DFVQE@4"LAW9YOU3IN%:1%:1_2[YEXT'A$)3CUE/Z/Z+'P/WX=X[MVX
M[]$IU WP9R3@4^MQM?PV?*KY2C@-Y'6\)NM]/M0U]RO&&.*+S'/$J,1TX:P:
M'-+*,:J!21? ZKVO';2<)KTA%)TEM1+E7.M?1]"U2:QB3;XJ&>U<&8[="'9<
MCR*@B$[T5(I1]A15GS\S]2#G!/B)G/=J" \M&W>\KEGG43'@.S@XL7X]MD>5
M[?7;G;U6'5@#^6^$ZI F!+;#\NQ@+Y#09+X<.EF5W>OH)$^YWV9>KEJ2XA#,
MI[B4C$=GV5ZRH1=--G2[/)QT.ID4.>WHW6L]?9X5$9+=/_  J$?L6DDAW9T4
M<:I'T6DFCO0@R/$JU@R)E#F!+KP>9S!.TV2[Y(?G.3? -\5/MUI'[='^V.;7
MD8:Q$Z$U!T*S;5CE;OGC3H+XR!=#D^&R'0K I\=6 =BS Z">A5\@QR84;+F'
M=<4!ER;0QUI0@F2Y:^%JJ*"%J7R>HTY&BP7ITY&V"0)M4A5G_?C(=EA00D0K
M4ZR%'JA4JB/X(5?,0'V1Z_/9K@]A!/@G1W^>P>Q&JJX1''Y4]B-\!^QL$JS"
M&%=0,/!-X9"M(>Q(,'(Y]3K*^'G&*RF1O]!0]/.]J?/G9NJ:XT(B?GS@?$VS
M2_4&)KB+;7E8AFB^'P+TA3/WP))O8250Q!<NT%FGR3E[P:==A3EX<*8ZNFB\
MP>P]GQXHF@@7H(H^I!2,-S@,WTV/#BH9)NZ\,5YO=&L@00.(9#YQ;!WV$!M/
M\<$0D<USD17>D)S9&KB\.Z<M9KB$/DOYQ@9SIJAF"9U62<+LH047=Q9.#/JD
MU#3ZN_U?N_96V/O26O&HRU_9+V_9:^Y7[:UAU[LFGJ\B__ __@LF^5P__)TO
MV1@_[.=[.2U*K_'A6V;?31>_^ J[7T[PCK7WOE2RUDHZF]?:;^.V/NMJ;VWK
MBMRU#WN5VDQ<N<Q68%T$,0@Q\_^; %!+ P04    " #AC?=.+Y0@R1I-  "$
M5P  !P   &]I92YJ<&?LNWL\E.V[-WR5),1DG^U4DLHN10K-%"&Y)2E"S%TJ
MNYA;R,0T4\38Q%2*.V**-"2FLBLQ$S.H)'MJQ.PJ^UQ7=E=FS#QSKW<]ZUWK
MMWZ_YUGOL][U?)[W\WG'Y_SCVIW7>1SG<1S?[_>\3I)/$BZP[K"SJS.P8@4
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MF&X7[H:Q)R"#-#Y&;V1LD+ZN&^]3!F<?S6T*1-6#F5EE7&2*#W)]0P(WP\*
MC0O$KIIDJ-KK@^QV3RBE$1P].#@CBCA7%!I?\2%O7?;A_@TO()H!L6DW00>>
M/0JM+D\0S.B/+](-86/A,;QNWYEG$98Q^<^%AW!4_A'&(WA$Z'I;,WVQ!2,[
MQ\DDZN MP G7+6X64]CT0G.=!K4OI]COPCA_F6]GA=8QSL+O2H#(;;LIBGC/
MI_@S,*D(O[>FR]Y@@*X&MT/M/*TLU#H<I\V;;I3O<85XO-N[G>^2A0\MPBDO
M\/?9>4"<M'DEAU%O1M<%D1VO8ZU,V2":6XP&3.>)U_TL4B((6W'\1?Y@Z\PJ
MD49M31<*(3J><0S\P%!!(7%5?)<DPJ9P-HK*?;W/%Z4)YS+%JO27T@J>-?WT
M&SCR"KNZKC2TOJ0E-TD4L"73A<L0J9,6B' !2#P Y_+=/3S!+54)X&03<ITU
M5LXF6;PQO.=(H2U40&*ZF[C"P4^9W/ UJ-U?*&GLVDR06]<\Z:'R@6X]:&6!
M"/!C3\0/Y$=$E?,EP*>$0X/VQ"#(C2F-ZWD)L!8>92[-3 WQD8J!:-*<>[13
M+Y813%86^8-'DSR[9S;7V+:0LO!J$+65O:5J;7S6O<M% :C<BI#<KI%QGM'W
M7+'\-YXBEC0B+< %D)R7$,V<^5Q(_$QUSV<%KH2C!06&ON 40X6@)SIXQ;&%
MH 1]3*;!'BS-^OL20-G,?B\MQ,;/SQ\#$_WZ*6Y]U6:7]IGX]UY%U9$$#*8,
MF'$"'GTRN4A0@R,>A*(V#>!=RG&SS,!MH'(9+Q\C/\P)%6\BL0K5H*R,(OBU
M8U],^_3N'SWNQIY=W+Y*ZDD?CYH&K1SW:(&/!*@C3@D>^X^;E(93UDWC#U1,
M%IJ!'23F+[HL/@J3S@!OPH9-.BXLAA0M*0IH7B R->_*,HW9&'<8ZG]D,Z*3
M)/1OSDVK##5+.'O[[9]Y<5-[N8J4SQ9MC!<N60UN?(06;,(_'FAC^V4\M&1<
M)RZE,S-V%#*-MV 295V5ZWB4U;!<4SSC,YJW!HZ+PM)@C&OO!4'WO-N58/=7
M]+I7WPEKB4WH!D60A %=,F*&?9H7;!>310<@'U;>7083FR@!% F*L >&+HV)
MV6:B4I1%,EU_W!:O(@%^#R&HU#94,_HM1(X5 1/QC\O5PFH+D3K.28^ &*(*
M&DM.#%S_$B:6P$BO7'Y6%233BGPQD';.(B6&IO4%9^,&CDY[0A9-!$40G6K-
M2-.)NSZ/E0GQJY 24GL?&Q9"$;9AZ7R_Q4>L#\F+97SB554/F%H;CTVC(V<^
M9TF @Q Z]4+#Y2=?0@/UGO?$NNG>A6,A:S3O]'C@!JB0 HXRZVE-?V*:VJ,@
MAANDQ=+'.(/>UTI%FTFMWGF=:=8<1.A23)T<RT^]/C<=#A;+ORO&V7G 5WA8
M95$(U$&6QJH2XK.:+T1-XC#%*O49?"TR.LB?F.+GP:1I?)GTT;P=)M:NA2Q(
M='6<XR&(0XIQS>OTC$ <HG='SFG[L%1P^>GP92GPW8</@#1F7A:)JT]T!0DE
MO&]P/&-U0SC/(A$I(]HEX,B\DRHR91*TZ\WBB"V4E<T=LY8 F?')M:]X%7).
MT HHY2%UO' [6'D_K7S\&&X@%']I/ZIW.9\1XHY>N-&%V@23#X/3BZ08"2"#
M#X,?@BGL?9[6&?L\O)!*L2^K7><S/1RAU4F\CKCFI>3I]M]R"[7[Y_H9W95F
M7VM?%@:W(XHFF]#!G=?*06,FP:+G/)3U7- 1W$91$\5"X2T&A@/5T\:NA9,M
MR'7SBE=\3J6TNW=O(GD\ZY[&;@J)2=CL>[ZJUZFFHO_[P^A5=8N!B_MEU3W_
M0PVI*AY"JEA)<Q)'Y-(2K1AZ?F-H%?QEX0G"VYP1??!Q =^I1Q3,GU$89]3(
M-2=(@+3GH3K6=Z=TOM?PA C 'Y<N:.6<JWO9,]U@GO=P,#W4/4:7NUI*R,FB
M8$@NA:XX1I ?1"%.X?TA+:8'X %%N]9WQ9IY#_+:6C!JXA'TBYFIIO(Q Z/N
M&)IJ4RF.,.,"MK5XI-*BN,..GC6#_,'JBIT_$C+\P\_[,[Z420\$1ZOZ@WNG
MSO?-P9$54];:$69?&2\2%]\+SVKFDG5/#3G&?75<*'V0L^>'?2FKW3@G/_SQ
MM8>/!K7DB\==]_4/#D4^#K#]X!Y]>?3DERN5EP\:G!U$$>Y1W1?2M!_/7C!]
MQ*'W#!<!(@/XE50@JRZ7TK4#R:0H)MA[#)*[)G(5'A_+H[7L\Q[B!4O#4P%_
M&#)^0U;![ZH!M1(CK2@W,-68Y@+#9CD66X[E6H-.]8*1+ FP3A05$5SL'QXH
M#QZ\%)>77$$:JYN.H.'LO&!K;@A]*X[D",<^Q=&.]_X0H;DSNO@8J.X-)QEE
M#K%ANQ/]&%X=:R:3J%QM-^S<R_2NO1ANVW@W-=T.K0F3F#H.F4B_]-T]^5-#
MF8I.KU44*PQ_>[DN+&KRC[0I,R.5\'6SFA5:]Q0OQ]]W6?9^D(\U%,L/;GG<
M-]=HX_O\9:_U%53[\=[(+I=8ZL3N9QC? &?M4T8=)7W1_A^O]9\R[:XGG?C=
M9NL&F5^5W80M*!KHR!IDK*?;B=R[[$^ P@7'@1K*I\E3)('QC0U2O;(H&$TA
M6(G[".L@XU2"\N0 87,58[ET2^\\18'06:@,'X@28.#?[-T@"RXMM4&1%D[7
MS2-F!IK7]*$O5W-2_6S2")IP3V<+1[7!DHO0A1%O!G+0^K$>:^&ZYN9)KDW&
M/#&9[9)EG5%Q9O%4@(<S6,$A65FH^,*<0_FMMM'CQ<R>,?%&QO/ZKLH[G=-:
M.KNS+[&C T)KM<P>G3(:N=/[>>@#^US?'ZX1^@.%/<ZMK3RSQSG#QC4[WC]S
MW;R=;WS6RLS>F/=:6^09'5$TWMTA"/_:A_<U]'?9!LE^C=>\QTO]UG^PV:E!
MGK>LZ];=HWWB@3OJO>ZY5.?U.^1F?ST4N8&H"AXEU<!\F8+:ATO!?D9@()^I
M)"XG-3ZY<WI7I4BJ,LM$-GV$'1.6HK#E\GG==@IRLA -ZW*EBD:C'V_)50IN
M/381*#L@<N*M$6&A>&F9!0L*23RTZH0.1H>^>8RNLIS-"+O78",\@4MZ@Y$A
M( D]>1KDJ3;^'KK5^,)%_)$N*=?&KX3D,NDZN#A^748DK2&4STDQ .!W97BO
MWC/5(#9K56Y]I'0HNQD#D2A]W/E%9CQIQH DY25OZ.LC#HCV<CD*(8AR![,:
MEV[[O47CB#+_E+LLK1GJR2'KKW:/[S649YM>SO&JVXD:G0B4 8]444/CG6D\
MA.)$GC>I3JCEWH??5\P)77+^I/0DT_S]C_?A ?9FSW=/F/))%U8U6VJ;[)?2
MXUI22T<481M>"G;-G+3X8!8VU6 K2&Q2PBYLHL,)0G>_D%J"_$"ER"GV 28D
MB7OD&C^D$K6G"4IH]=8AW^(CE7%N_)PD@=FZ, :"8#@BL@8[KZ)K:83/TOJ3
M).X;L5DNB*&L'&<H-SCQAA&M*--NN@E<?J06\D[C9I? B<CDI=U)I96)TK-D
M*)H7G!*37^!X#-+,O2#6[]X U;'(&J'1F"\P>G]OA?T^/E)EG/A@MX$:2,^I
MWQE*U^^JG@.G&SL*K];:H@K.UQN5<!7CPA^9U50[NM75GSCQ*O&-?\L?#^1O
MO6D)Q83F7:(N>)9^\L5DZ+ZM4=R8$"[;5<VH\SEI$7$0>K>0\%;3=Y7-T:G"
MC9L3]ZK;):Z VWF((>K"+4C_8R9TNIH&?!'MZ1-;XE?")X)!'S>0_FQD[\ Y
M>%*X1F2P7$*98JS[T7! ?7?\]S3(I"T:%\[,<>>VOXR]HL![6A-+/A:N*U1N
M7U"'OPDHF1*@VB)5Y,&GW1"O@BLB*L4MZ"J7+%K,3/(EG9QD+HU$MX;J6M!L
M.2_(YIKYG!U%!_ZH#L4E1^2Z@-]+XDI1F0*?7JN.[4BM\=V#X><Q\_>L"LRM
M#Y*//'/*XK.G-4PK[AZ;^,C6-?&_H[A.<5]-28-F[>Q6U2;LVJ,'WZF'I.?X
M.><^;O@9NA2;F3'L'A5U<2'GTD!G5%3L'XMQ7A^[#F::#MH<<XV.,DU^5,AW
MR?.^''#_*F&5Z"1\[V$ /",HD !3'D(GF-+&T!;KP(H+;QCP0[X)A3R LA\0
M;\.[5X,^&0)P\0WF.F6%#VMV7.?'<^%>7,YWA-J!<MB&5YA6)+)]"4>4X+=5
M]>.#^)3U^%,U/?MLG*51N+Q+K)//Y,@2PQJCF9@7J<OY]'6XW.-POUP;C]_$
ME5("L3%DW&(2$23E(W =Y.,#W0_4DGJK,V4@4/DU-/PX]\E)'*4YOE%*H? 1
MO$FB(CS;)D\[16"=Q-N!FKF52+50N@*81>'O'#2/%2+7CEV*'Q#VW;:K%0_4
M/LLX.AR3?3A7::&@]^D+TQ+F,YM(D2[/S%$*F=@&2][DL/+"_+Q)A\',P9X?
M,>45#FZ,NG?$:*I'J-&=Q1<8XF/7.%/$'XO$<;.-^:,/$*/1?(O6(0F0CEE%
M_)W'160BY>T]PX.$FAB8U%J'U"6&D_5$JV C/CK]$GTE;!UZNLRXS>+Z$IW*
M)VH0>I!*]@Z1V!HD #])R#1V <F9L13MR?C%Z_;>8IW^6.0P^7-^BQ<\NA +
MJPETR\FZ@0$XBM1%S(B+$XM\[]S@(KP#H[ZO0;]X^!0'YKCV!M?W2HF&!J9S
M<V[]M]K<V-B2Q\51>WLK(TWSY"E=TWA9;H:^M56"A1SLU^M*/A%P<9_Y(+/>
MFGX_K\?6=F+\M%*ZGWDI32^R/KW90N/6R2,*B;9=EFV_) !J#O!T4O_?W5;,
MRK52V+V\W#?D&Q+@!>,-3?L3CC[3BJE99"'T\#9P0"QOV>0W>I?5= +O+[>$
M\W/JH@1VD\/8WQIZ8E[A]ST,\!OO'?>[U!@;5=X1$6%]MZ+8@RC7^R9E!<EA
M!=)A%R85#1XC_G(U%JVCBC_6+3R0  -[X21,W2T)4$Y>;I$ 74X *GWK@Y5_
MK^7]N%5NG_6\Z$;5ZU4G]'=^8 &[ON3%_D%1NXI:">W8H+(@R_V)%GQ7$'RP
M])"YVA9T7,,GJ8D?=3@_=U,I.!=\XD!GSJDG^/L-7UY\:_P5\)3M$QIWR0Y1
M]TD"=$Y3Q:ND[*>E>T&(_+5<+06-/XEPO>CX<KD$"(TP7#@%)U#AUM'F3,&^
M:%;A!JPBSI%9A2MOYB#FW!W]22Y]>*=HS49!IW:@+TQDWI0 9T*6;O5$O.V+
M9:B&.W0Z=%DE3-[[<>Y%-R0WK8CE,5*1*^AZ$XPUXNVA\6VMRWX2P*6>,6#5
MJ-#+I"C.ZV)6X@]!'84D/D?]Y*1.'0GOQF_T0Z383I?DDNCZ885;_:_L=K/0
MFM2IS.9-.SI>B?Z9BJ/\^3'3%N*]C[R+>6I[43R0?O'DH>U_IFVUUZ&8[1G[
MRB_>QCCG_K[D@>:\L&*HL_/G#'5J<&B*.+K0*P%6GI8 _#'A%;)(S"9R?T.+
M @@*+<+@$$N\#US!#0AR@*.*8!_N<F?+=PCU&CTMSQ5R,GQLC9LP"J?@_%:#
MS=V,\Y,6:UP%BLLVRZO%NKHGH#_ZS_5<^ K]5NLY[J'G/LY0H*,PN)E638,5
M$*.YT8N'S!"Y@R17>)EKINL%M26*8L0FL&OY9#TV9<BGGM)L?@L.9RUI5E7"
MEWI9@;KWPY8.!K$T=^&PK85;TWM/1NQ^@LN_UY-4<$2W9/V3HQ656/=WO7GU
M=WY_EA7]+?U[^7JGCS<P^T)Z,S(4S:5!ECLY.1EAT[L0-[V GA6&2H!K.R0
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MWC8+>05993S.NL]N5O7GJ>>N!$58'7,+OT(==JX*9=/SGX0LYBY%<(;O^'R
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M,!K\C?,YDZ"""674CC8W)OCU?H732D3./0T:($(PPR2FH)!UD%2%HTDC^N1
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MI#944Z3GA.2_TT[]TV!SUA),W;F)GD>J8!]HG^&)T>UMALMXS0YQ.1.]A+3
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M+I*.H^EP\XLW77?P&&1+S4JV6MH2/UKI*A;DE+*#-8J(%THK4Q^I^&7HZ69
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M=X/"8DM"JIF-KT$2W'9+-XS"W5]$7MCH>)$I:K5Y[X4'?63Y"N!L*J5?;_H
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M02C_!*K*]S QU&:!7UL<75O>$<TQ>2>W0K BEZ4JP:7HP2Q1,-/6R[1A(4/
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M1PUN\#O.K@O;T)#Y)?D1@<%A+M&.)B5UGE]HN@NER#U)*\:QFM:%-:F-PE!
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M2-M\W-$?Y)OE%Y0.7294 #9S\O2<.7<41]+Z7"7%OWIYTU!Y]NU1HO36I:D
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MI0]^W@\[R*@X^;VZ0&]0 :S?-B%OW,.4Y_28#$:SWR%I?^-7]TK^Q(#'=U2
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MU<A*(W .W,I>!LOX"2-(K(C2O\L#B9<0F;P=<&3# %$?V25BU..8V4NY$%_
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M!NH[S&*T3\A5NO] =+]0*Q7 H=[9UJA9!: _2/:S?QA\)9A2BNOB0UQ:D +
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MR$W_H[8WC6HJZ]I%8XN $)4F DI*41%I8D,C$!.; @2$" @(")%"I(D0$9
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MS_ [J.Y-5-[$'-L=0#B#M"AM! <I)Y(@_>3#HX5P7E>(%61>0G+D%=<#'=?
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M4I!V2+.;QH!01L#: G5?B#P/=D>A/8N]P]3C-V$\U<&:?_2L'$UR71W9E&/
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M0*()CK)K3#)O KHB1.P'8W+)>OR/ C:U&MXQ=F8EZQ74Q,<E8+<S/ !V*\+
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MRJW [A:Z"LEL\A]@L8V^I9/(V[!K7X,G,^QY$-DIWR?SU(GPDKF\=2V#.5X
M:&GO9\D3Y6["Y&N[90EVPK,0$AC!1V*WHE6">6.RKHH"!R"$;4AV%1#G-F$(
MTF"QRZ]K,M2M_OA$RG?59)L?>^R'B=<6E:\<_5]GN),32LR=G\AX$#\WQ<_N
MW,"\)PZO"O*%OJ\25L_7<XL'_3-Y$FT3T6I7^A>FWM139<=#J?*C]J[WQE#'
MKM<\#6HAU-L9W,]5 M^NZ+&@5X1USV1COCA%T3=AOK2'-&G1WNE[>)*IW^W.
MYK!4]G[F<17L7OSH*)1YN0&T3ZD,!F5W-O9J5PD- _R(!9WR1FS+TL(5_'V;
M\\CCP@.0C&!#FD]/$)TCWX4>\K!(\C40_H!A#+PUK86")\_A>4/LQ>V0W$50
M]@U_=-1*W0Q$I(C42.G707@B&5>I4\)W#;\.GJQUT8:SC?2C\WQ.38\4B5CX
M%0ZD :8*5MG)9WA3K;0X[&ZFZFBGF,A!Y9RU5 X^5E4'2CPJ(*-!L8+$J$&W
M.R_5 :PV9$QBL70.H?4P^T8#*]LQM.;MBK*OS]!=I6]K(PDPX4=H:'W;++[&
M*T$7OX=\'31KB7=T!:@/&:? F-G6B1UHLR+H+2< LG3-=!D04WT)4M9/@<Q"
MNM?SV:W?5MCL6'YJ)%.+5,X[[<L\/,A4)F6;@#L;];112RVFO4E3:;C!> _H
M%F"\>W>6\W$8?<=&*5/BNNC7U&96._6!T9,"]T(GLAL4R$^%X5[,9.U@)6CI
MMH&J.=H),PB,:F/CZWJNVNO'?5^NOPOQ/48:D(Z[KI6X>.VJQ".28/(QF-J!
M>H#?+P#W^3PF[ZV%ZN^0S^K2?O5R_R[.V5X7@!GY :YH+.AQWB;LCXURXB=4
M&]2P1Z/Z!_D=YCHDLRXGQ %;(!D>*X&J1)83X&/PKW_=4.DA($;E(@"#U@A\
M\]I*+;][C[?("*B/75Y,P&B <$ZWJDE%ZD[(D8]/OOFR%WWH.82U&D2;E_F(
M#@_DY/54Z-[>.)S_X"PNWIG*.8AK<>;2@.KK@,-#0>+?\^Z]R[@X-^4A(9ZG
MXMTUWS P9 ^LQJ#QDU;^F[#N/LHHT6L%)>]#N\U*&YD)#"9NKPL4$:<G '':
M35#.;&$-"WC=;2@DI8OU:S2L%WR+*UDL*Z.9AT5=F",@JQFN1#J-DQ2>!7*?
M\L5@(B-!5(?*\)" &%LAE*L<^>YV[B7HTUN!/B..LRJ0[43K51.^=(X#=K#Q
M^+9VK!<M2GU2O848B]\%3UR>.$AMW<'[I'N(3]S#H/DQKR_H^*>-]W$)8]9^
MJ/-]^Z:#<%+>MC-9-;E(H"H[WQM7[IM<<O#BU/#W_[V*\__&0A<(,A-KZ5N$
M1\&)1"%ZY=5LV,Y(3%[QN_ [*&W;;X;/3<Z,*AV6.S:L<OS6E6<'V0K_7J7Z
MXU.?_ZD'WW7W\B;LL0WV7T]\,;YVO_H*!7H!.T*3NC$),\=.Z^? WF&C*;MT
M;6^)%BZ\VX0]L5W;A+W!UY,\TCR5<G&IE7][-J#]G$.?E5TL5H=;5PBLW.]6
M7TTJ41RX5J3AY'-_?$YT"ZR/)\4>Y6O1X7]Y*3UQO5B%LZZUN(YV]96?<IQM
M: @W-WW&?_;9?=<;O?L%"KW(EQ.O)3KH<52E6J2J"XD_99JKO;63G3Y=8-&'
MN'(KW?8-]X_&,Z_';H0V5_ZE>KTU]);AO_7@JC;%A=IBK)!Y':I\XTKE.TU^
M5C2]L0DKAM*+)\^D0/2!+$@'T\*[>\#N;][=ZV%G;^B=O>EJ)*_1GG/<</+D
MX#'!KB*%+D.+>Z^YMGXSPVOUT88Q6-W)&[2#3_\ ]\]Y^CY-*XMOL\_Q75;#
MG6FW+2ZQ]7MO(<_;;SH_<LK&^<@CYL&-/!:A>Y\XY)67"'6 V!8:Y!2B.+%3
M: ?VMSMWK;:Q8&2M5V(6\PBMR3<FRHY?*JY/B7(P6GB#?GUCK,(QBQZSI*E"
M"$YW!&5I\GQO)I_^ .N+@M3K6XDCHQV-BXDB+1>2EVL]8R-;Z 6@6J_.8K;V
M,,SI9#W0+('AXLE_BTH4;0=EZX^^ZR';\SHKC9H_F;B[^VEW=247UCNG.[=S
M46#']Y)"[TU8O=E<[8OKW@A'FJ+0D)>]0>6YY8!1I, V6UP!*=$$R"T >BFG
M-M(Y8>%L76=LXAP%D9AZ<,9M9^XTP]6/IZFYN*\J63^2<*S0&'6 ,LBJ[F G
MF]>D[A=>!XH?E[8^J4<\&8]8R ]J.CUKT1_</;]QV^IPQ]58$Z I-[G2N[&J
MDE_I;(F2^9Y%J2YT(RA71BGG)'XF5Z/F;/BS,O<7.6X:4*PG*-?, AJ6:"._
MYD7N)I\!F.S+8$<J\QR).CF>#:PZ]@@-!5@YLA51]KOX 0:APOL5*6NH>6WA
MKY&FY*ZEW*V-4 $1X#KISN*S;XH-[R*\"#U=UX6,>40./BES'$GC(*5$)TEJ
M?&*DT"O/#5K0E,0<GE[#1XL42,EBFXAU&S*JEI4X43W5BMPE-(*,/:M(R90C
M9"SW#@-5ZKM&B4/I19C9#YW'= QA)PN0U=V/*"<GA @H.8(/WP;%:(?S5W**
M"?4CJD7E)*-%$TAC$AZ#W8OVX4<X<IP5<C9H,;H-2_CXNMN=Z\1WIW4B*\;&
M+'W\COVYECD\@DQ&:_#]+&_TH;%TG\:/>;R"_.3[$]8-"/QP,E_[L SU=\NG
M^3+^1P9JC,NMG$=T,\9J9D<UZ^P?_1C^"NDOKNAPT8<$!&+BB'IBI= SI("4
MR7>KY1-C5L=W1-I&\M79-#'+PDB03X)T=H3*/'4O^FCQ)]*$/?5!X[$\'DH!
M2K7/;KV?1HJTZ1&:/<?=MG.M7I[X%#B9F8C91NE6E0,R.2I=%S=A?-D";6X3
M_]UR8I?F56[%X5/.I/!FS!YNK<Q6_NSY03UQ(MDE- 06>9X+U?F?QWQ&OG8\
MNL6M7%C<F4]4AZVM_->;M1B!_/KDVHE=YGG%R4=?2"\-. OF]?._I-_A7M1^
M^N3<WW+OWE;-I?P]]6GVVR8L]?E3(>H!;J$VY0%-T!^A^>7LK%)",]#N$=_"
M/\$+D!^'#W/S#.W*9<D4Q6?_>BD6OLDS-'4(:[<ZZ9;YXRP(TCJV/UQ)1M'6
M8N B<WH)XVB9*T%5J6?94J#B.C'-'3*0V1=J\]3S_$=;=%U;M\GG@!G"9'/J
MXQ_U-D+UH6G\/3)&T()!=&]LJ=B$+5VGQP#]AEW56OTGB_Z^??:#YXE0:DW4
M*;T9^Z03$;>30O-+COWUYM8@M\Y/IOQH42TUS5C9]) IKG3;YS08,OZWL, N
M;;7C[I$SNU9.7-)8;8$)6!8;S\VF?#=A+;\S$)Z*3\%M'-9N8<AS2I?H-"C!
M$?OC&6A)1VA8]0D:XF!E:HAQRO/KM%@CA8U%CK8<FW+V)>0J\()L^))+Y9LP
MR.I8?TVY2],9=@A&"_C+>4Q,B[" +6VX7("+JY%1LP1E.J+$C.8@27-2/8FB
M,D-!QPOU @5RZQ?@*A=X6'BRXH^]5-[\;6U"RSW(37UHO-L"1"7H^6E> B@%
M51-NPV:AZ3SXIS/7Q"%.J$F-'<EL@VKAP_V3U&1&""@].<7.035KYI-^FG*%
M+L5DLUZA7C[4P?<@L:_U">UXV*@G5#FAB0%[U$J3MQ@=/)JX@6T)89X>8EP*
MY!'>,"P[_W.7,0F*;1W?R26C^,BD,,4WE6[>M)>I47/H"X7DDXR>YSA92BM2
M(;LC5\:H./-7>[X!8J0^17>_5I!?*(^K75.)<$MW '<FET0DK)V3&M@VZS(Q
M,KOBV^^/.>PR@U=&2Y; H_575W,QC &]0,\B$J7;=&B.K,$W?J=7_O?AWF5I
MK"2IQ*Y?>$9@67EXW:9>K$'H?C4XA7<%,X%'RZ;13NN_"_<#*';.-CXKD1%1
M\%UU.WBCT9,5O9Q\\:"MH= LN,)YS%<Y."4RKSA'/:XVXJ+ \N5 <*2[>T%W
MN&QBL6]8%V?/=)C?\E?6E&SL)FQ[)O M$L[Q4^SN&-G=*!'GASGDDRO1-(A6
M Z4YF%, -P/$"@QBF#H0W6JHBF$#LMR@<"KA'AI#/G4O=QOD"0R0LL9=#H:T
MJSEQ=3D&V'!R&(3DX^.S.EK$>TW&@LS426(\?CN#P$<A2&9VH%=4,!Q),A(A
M]Y//@40V;N\T1@UHSQ0@MQ ,8-_=M+,V8::#ND2$]^K:[>JB8<F139@)@ZN;
M/2EC*5;P*\&#Y%!>=TP6KIT8.\)*1N,+?,(68W0CU#D.6<^'[M1VRW0*SDEI
MG[%[::"L-UY&)YV0%!+RO&UFS%RYC(.[F9I]2YTL>/M:W&3E)HR(_[2PT'E^
M8'X3YDV-2?.A:*1;B%H&8^H/3QLE/ZDNO53PB1 PD^K=2'932G=NJ.^9 NV[
M/F"47P]YQ9JP!BN#S??U0*+(=4E2JCEX/VLMMCU;F\BK%A(ASW5KJ)R="M#-
M>QD$.CD0<@?Z6W*WOF3T"SWR2$\ZV!@$%% EQAY<J"UPM6QQ-F/3Y_TPWT9M
M ?]X_BQRJV]Y_O2XE1CW+5B,.MY'6;VY2X+O]I!'BU1?V0&YKRN13<$;+-F:
M9((S2(M=.HAK<\8EXQX%98"4C$! T.8HVLO<9L+5"P8G(FNF&38! :&\G! '
M8#XI:<NJ:<GZ#5&7LD$".6*RR5& 9V]@.2QIAB$_50%:M6H<.AS-,,B#5*[4
M<\F!(>'W_]$ZFMV\9O+U28G RJA]8?$:\(06X1'*USRH/_YCQ-QG1/2)56VU
M\HK7)=7)GXHAZJ$4AH^*HA5>$^1<QMDA^D6RR7*^DD4'C3ZNMVD73F ?U31=
M7.BW S_8F!A$WEG^[C^7*_B*4J6V&.G15+TI9Z'@4J'ORU3>P6_EZR[0*"\U
M)K7U^S&0&$4Y)/KD)@>]Y5%5QJ"A]CZHEP?%3G9+45N7(%HIR86M+]H/I%26
M5KW)]Q'I@)@WB*B*J8%&;#+VI74]F"U8B :]'*$.%?&3> 4QG<<FYBH",?4\
MU#Y"5OV#9>0#51W ,<$3H+(W+.#Q:V8/=.$2PM\;@*+YU;B%18H" 6-</\0P
M*;MA(E"IW-K/'E?M@9V3XX4(Y7$K%M K8)97S]E0X4>P8M%8T#G"&2DY#"U>
MYC+4Z'_7:/M.L!OK2BJFC3(>9)X'YE-J(XI],C$Z@U]J +)S3&71=)=8$'N[
MM?E2QK>KFIVC7GJ$>0Z8>;11='RIP.5_:I_TS-=V)S 50=.,0C)VB+GU\W42
MK9DJC^FN(,-H'1A-L?R-@#OV,Q#KOT,(LR'*;],A$WO0A.<DFA/H1A/G98I^
MGP[9.#@ H%VF76SZ-6+!BQ?_6\+9/ZZ^XL0?\#T3G:*W*\% \<B)$U7F1P1'
MOO1L_^N_G<>IG7AYHOET[JZ;N]1Z(EM*F=W$31CZT":,9;X)XPP,V+UUT6?^
M$8!S2-^$Q>)^7MIW5M"=J7PL(">N_%G0QYXS2<^\N#03^8=',I[$_VIT:/V?
M[K[\\T6=P8DZHUO;4HM]O)_O# T0"S7=31C34:@Q"3L)@P5M>X"5.EYTJ\Z<
M_.!X?L+-__'<\/_2HFX._S]02P,$%     @ X8WW3D:MU?$']0  (08!  8
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M>@AM73%1^ L4<$V$Q@J4GT[<LRXEWK:);R:OE0,9JD.T(W>\:ZL@ \=7Q,3
M;@<_K\^^=-BJAUC!"6)E-6TE752D33=V8MLX\0:IDI X<(F?FTKR5]3%XHB
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M*BC+2F.H+!@[O@JJ:\.#^SL0;1E"NN:8Y!344=;"-8A&KFI:]XVN'1.+6.'
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MG0OH>2H]?MI0\(1F$7-VQ,3NQ>%#LU\.;%N1KM$0%K7^WBD#/< %2;W%;'(
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M>9GD6DY4 &E0&IW/H,HL(3+]I& T&C<H"=#W73JV+6=;WYSPS91HBKN3P:Z
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MY% G7<P_"2M=O]QSOV]YS_W'CPTYXPOT*<P/Y/SO4L7E[M';ZZ]B=DOS)4=
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M7UB0G,WF80&/XCIS6PE?J\I#:;\$_]\55OSG_[3 6 T_&8$39)S>H[3 ]_@
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M)&S]';H[3DCEU$UP(3.2XIO=/(=&[">F<2&VO]M5_F<=^C>I$P&Z$ Y39O
MDB,(Y4)B\SD2M-;E;>CO&B^1IEP(0YD+B1N>(&XKO*\N9I,_DTE<R#EA],=E
MQ,!/Z.X?C*9M!+MZNWJ%LJ!$M4'0]5GC"AR$TC(7<IT7@CPH^PGNQ%@.?(#@
M!8V6]JA@"HOXZ 6-U9>8!KD'XU==7$V:CM%.WD@_^^KLFZJ.XWLG]%06T1_+
M'O*C(DL4MFAK_$^;U-Q1FK^<HL-?N+],LC/2_#;G+J[L@110[5>S:;[I_ZZ<
M_RD))?>9*KM?TUMEM24X&::&'W-Z:?-UYGNM:I!*>XZ#65EVO=_EPPV3+](J
MM.H;>V<]!N*52?W"5_Z]K!W;@.=ETZ^D$IJO$B:BSOQS  WZ<"'#_BRI'TL)
M&X8 N\1(0>V0GLK$!//0P13AQ;UXR6[<>UZ7RRS!V(WC7$@@H7?T]X+Q?QT[
M1O-:K_IGFQ3SE6Z90A,AM[B0%MAKGC#.)TRX<2%<R$G> .UOXFD>>"(7\B28
M"V%GH'/2"77)K=J\YWHR1WRW&5^3'(T0,N#GCUP.$C[DB#/NQ]VA8^*(8HQ>
MAI\5@0=% D&=1"$S%K4C5'CH#J7V TAX/9^*33#N8>LP"&)@9*NT56G^3U#S
M?2*&<U &.$BC(NH\6_UDZ!U1)+@<3A+TW8'C[$'9D%(4-M)J@'R+U<443H"?
M!/4=P$*FH>&^]KR ?"-OUK0-F#<!@V#/746(D ,FS+0,):_6-0#CS];"Y3[Q
MK:MQ1,,E.>$\A?('SQ2V-)-!XS7TUAJ&+<#S)K\:V+6L:?81_=9,7I1;! +:
MFR1BZ-,\!1.O)YD$/\X^#9X)RY_)-02])Y9CFY1_YP<BX\94 /Y$O#1V@[/)
MH+40!' :=7[N!N$8ADSI_?5=V)6>( 3?G(,&(--\?A-MBK/<+<593B '[:'#
M#9TMF9H5#"70D-7)L.0\"0@N&?0*O8+7K64%<N3[QP9H.Q:M#0/$B1S>$Q7'
MW6%A8@[; %V)C!^VS;DB\5Q(V_94ZK%/4!3A_SY@*O@V=$UEWLXU\!Q#[F-0
M"6C:NM'$!^:4LO7? 5T1[ M,1,RV0\+X-=9X=%"%#6.:CF[M'.%-,81@K26_
M(PU#/A/T&FR8^C7_=E:BZ1QK<;0K&F=<V+";=1&:2619:YSJL +#6.N+)\Z<
M ^=F'5\NN>]SH>IEB<9-O3CT-^VO/4PI2#;'S&%^DWTDDF,V3J7L0#4)ZT?[
MRU?^_%][O&@>O.5FPHDE[%, KOZ!E!M>?LRD !D@LK])BL7<4R?UVK:SZO.^
M#\V*$/[W^(%0B9?N.WILA_?U]5Z3/'%@KZ-S?X]TTPL3&Y<XT9AJ%?%?Z/^\
M63**\!TC>' A";I<2)X[86VYD-8*IA' &-Z8;<N#A=[3SYEI36''_N9"-H]A
M=B-N$]:^=OT:V:"Q\D$B_7CFN!'07D&@-]X.][3XR$)&DL\ ZC/!-&FWJ:B-
M<3'<60#QD@LYD!X9[%Z.FIT;%OP()E"=:X8?U=\**1@IW,B7S !S%MGG&.@A
MI5;.:5"#Z0N-A>^C!64EBY%:*!%0,3:2CMF#0S2R8!W00T-#LWH.3Q8-,'08
M9!R,=!Q@GR0PDO=B"0Y]015R?N8=QGVU?KY4O%3/LORNT,W@JCTQ7Z\J'$]"
M'G\F:CF,W4+*ZLZND8!Q#::Z%=_)YKNVG[X40?E=#%))1E(. G$51@:=<^Z#
MSQ2+%^:;;_6=T9XW3W@ZTU>QH"1]PWU]U@.:WMNN:Q,E*=.N64WVH)\JM]VX
MKU.3H5$PFNG=Y')R>0<9E[+9,@Q=O,,T1)J!#H SA]F.V%?)%F>@195:,'$/
M0=^VL0O)'6J5LYQCJ0RKCP6PB#<UPN"5?+U'S\.48FM(,7J':/7G+8(+1T=]
MDC70T:_GF[D0T:;CN*MU8 !P%OV',T[V=R;HJ!!T:&F$'A-O(+F;# @Y!:(C
M.(=8GM&]5JF,Q<K(0C!IQZ&/'5@7&H\-[35V,51J"RW**!]SOK0I]SLAX?BU
M0-=']+#0P!*<RX5;/K=./JYPUGU6KOGEC&W;G<G84A?!)Q7F_AM!<M+:I]_=
M*.W)C\:&] :JF,ZM3SYK_G!KWWKA%P;C5Z%5CDK C2GR3<8:KK3#6%S./A,U
M_S!R$G[L+0L1=PLHCF%K<O;3&,#2DYT[8"?3HQH(X(A>Q*F5LD_VKV.DQVHG
M2:W1EWQ+1L$L^O=Z^G($D?7X4OBIQN+.HOOD;@VR1IZ3#VF'Y[/WSKZMHX!/
M #&9]U_+FO;W".VM-EV%BMY,^?%9YMBB+++IP@7VZLCW1ZOS200#AYDN]F$L
M%'0<%WV/6%'TYN,)>UL9Z5V+3^QET1SL*+W6O._$)3HP] *M6&9F5:F@^JU*
M?!3^B$.*WDB#]K-N5!@)\BOW6MF6JH1>, QVT?ET/F4R>R/X8]J%#RXU09LW
M&P>+W3]BUN_8L;X_:_!XW=+]1$)RD NQH!CZG9(5[);=5=NZ 3X/9_@A/L%/
M?F2A\NFC:FU,9&TD-9BCWM2K-?J'QNV=&[UO-%Z3FP8BO=)I#J_G+!%&J<YF
M@7<8:HURAJBQZ6MAY2&$-_]VV*@*-3O\B%3\<S:T*:=X;AN5Y[.1&9U1[CCL
M$^J1[WTV*K/K>B^)_OY=4TT.WFSQ_JO, W^EI9P_YK!$L71>8VW51VG/VT2%
MZH9F6Z,JY=XHV*?Y!%8=4]%[46:3G7_P;?G^AH!B%9-SS[+=%7-HM6V))D4N
MIUZ\0)VHZ?$N5#_G79QOZ=7;O=#UO4*!D=&NSX4,\3/X8W&& '_[MF?K>%2#
M7UT5TV(Y'L7'0I4#,B8]ZX)JEL"?447>SL2(2C1]ZJ-DO$8EHZ$:6,HO0J-G
M0_>-Y1<@Z2#9[%:ASZ-Q"WRW$<,D-0Q+%#8(9S3".NJ'_0:>LWSI_$_)&J]\
MQ+ 4AFQN88CV4A6@.#^L^:$$C=/L6=M)%!,6_ZJ)$WV-5:*R?)TGQ^-@9(<W
M6/N!D?O,#8]=8B4'.HLX6-DDBM5DTK_'A< +B[$&@Z[.,_.E;A<'ZIT3UYS]
M)I\-MZWW5X?G3DT[95T/H2?M__6SKNZUM'/R0OF.[EROMX-><G/7 ;=1+[Q<
M/2LW-421<])B'G;(>6X[FN+W2C.//U:^Z4//*YJVGX5]_, &8];A>F/F+]F=
M\P25V^^+G\Y/=9XNS!C(NRPU$/2WNC3]_C&2A6A41^^7L</\<0$=/5,M/6WN
MZW/(@_FJ@SB)6W&?Z-5*L3FX+O'5AZWT'&-MRX*R?B*L_^V*S;-^N*/Y*FKN
MA>*6S=3U[#SI[&]]&=$S1'&X.J*]W+?1'BFGTY(8O!$/.+18"G?4 5A-]! 7
M<J-'W4\[G/\*&%8 WO2* XK-P **:$V.:8LEH-2J8S$AZX)F+;U5H&D&^KD8
M_7 8XRC-H<6TNF()U2,@IE5B +X7T&DKA_Z))5U\R^KNJR6*-Y6REAF5Y#I:
MKL+[3,;XU1^!0P;G\GTDAA]%%1M5^H2^L8'G5[2]'A%4Y4+JZD DJZ6KG<"J
M\L-#07-AV:T5-U*"?'<%S<EBJP+5'FY_X8$?8V#IWMV4+_.M(B.F)+>ASQH5
M X7:Y'<F/TT^[, X77**5:RDEY5L.=;]_&(LGUG"999QI.F;H2'0]FJ$RQ:]
MZD=%S>CM+VI[X]T<;,_\-"E:%^,L[6N06"6;=K4"_ (,?_#0C;.?;WK=>N<\
M9"^?>"A!O<U4U*9)YO2KJGYEQCGSP+(IW1"'%NV_>[=?E^MV'H[\='?]08W*
MP'>[MRO9BJ4K)EHY%TRTO#^?9^JNUJK&F1=@H(2?'UU_)"H=+=[<7,C:&XRH
M0;:4*-ET-WW$*UIV27W!8MQP]TU,;:1,'GQB76(>YT(N2>,SW(OBX!T'$KZ+
M;KW,9+B-.?I1YJ<R[NO4CXYDKV8?(B#0[XY84W>,<0K11T2I0E5AA\Y4FG<<
M@HO3Y..UU2U$CWF5")P[(Y#N<=N,$^7PKQ-J8]#+I"T=5ZM4/T(E^!&-W/J+
MQ:G[:/91;:[K'1VQ><P44]')A5SKEN!)ZH6 N<O_>^KV[\795N'_>O>TIB/]
M<;:'MNR#!S>$[X#Q["O_=4+9SN&-G![\631V\VH6?;-MU/93J"IH:I7$-'W7
MT'\B/ORJCS/5LN2L$]^!%)='M?7JXV2U>Z_8>5Y\701O3.3X.W1S<BP-6AN\
MJ 3HMYM-N+3WUOAB(E'J "S.P(_5Z0@^*9D;+JCRS52B*L:@:$$C)16UHQX<
MYJ=AX\;QQS6QOV@& 8@H/XP"I=_VKZK=%,K$WW I,"K/&:==#[KQY*3.HB\/
MKZ+Y)_H0?VH::- K4*L6NW_7"F*8Q$AV..LQUL7X_<XA.;D^OWLXZXIYO;_Z
MR.(D,SILOU=F8=1,E%:X+1T]@IEP6/0$U.BY+V'19$_&> )*F37P$1-2T$%'
M).CQU$H<YZBEU:I9[[JLPZ?0C:I;0?1P#_T*G<5'*'56??QD@EE#]S.]G^<;
M:I<B);)T^)E(GCIMOJ1%.(;_BCK5=P_G!Q 9PM3YK&\!C/HV+F0/=F3",^9N
M@UY&"Q?R#"T<2!0<\8&?!6)XEV+8USLMP5"1GFF;]U6LHIB)\KH!LAT#P3^[
MX2!=LRT-P?\U2X$0;B(2Q_3!0E8D0S.*B1@F,*&Q/)B6PGJV4Z3P9]A\ #*.
M\@YG1D^.V4#QTP)A FS/:O PG3#$;-%+?LJ&^=TI3%1HULG$$!D6)Z5SFJH8
M\V;VFM4=Z$.4.XC(T& J= CC GY@"D?CI5@4:O(3.2'0ES5.S3"R9!&H@K[-
M4(E%;6($0J96$$T=%UY:$XX>/TRV!FR-W_T@(QB46.>EQ(G?Y#J5%D"W0![R
MW4R9?Z2#SAHV;8:-H"^!@]I$?K"3@8BXIP%79E\"IA.:3A"H%O.AOT]@Q*'V
M R99C%UG])\S"/YBFHX77!D@)@7E2-HW1MJ!0?01X1CIQMQRDO>X&-G.-UBP
MJ+"5?1G<LQ,$\H0_K>!SZ9RH\(@%G=!B*=,Q'%T,(%M6.UE\Z&ZR*(\8=!(-
M$,S/&M,Z:)$UWN6LCB #PS<W?J"";>%- I=W/%I\,<+>PXFD^+L03AS\$(Z/
M16O^N"P')D$/@UT,X>0F99_M4R0F#];'19;79$CBV!2D !8_TC(F695):X'+
ML#R?!B;"J WB)>]Z:\:%08>KCSO]PTO0":,VG*45-);4D0R:(KS?MIKNF&&?
MM1^-97?N8K]\?K]P-NUZM+VKE#G]4%0\_2JI=SGRQ_P %W(()\H?M_Z9;,;8
M3S:\G=GT\<$J>;MB1GAJS'P3<JU+I?T:\4*'80D?8QE4V<-''Z>2_T(PR!_F
M+G(A+^_8K\M3CNO -GLY.VB -..R$=U3T^APD<5V+GI9[.-O7/%9W7KN_/GZ
M[C:5WLJ_/DN[&:L61$G]U?"X[6CE@ZLDGE.@"[%B=@_BC_XN2?>[+(8>A/WR
M)V4<N;-(:$_LW.5U8A.-[;N>Q1%9WD_X44Q/9BNM)7.,\O_M^I7PYYS_>;?7
M_WP_Q8GRGYI'_.</G"=,9+="G^+/-/-S-(V7+PNSOW"DUTXU/=DM)_P:PZMP
M(8/O*=N!O673"SN%LYD.4=I8K48=9.^)U-9SYJS9#?L!:X-BR][K7X#A-C&M
M*/'K_WQQ+2M+C8+8_EL#Y8/T7[F$Y\5E(>W.F4NYY^-6R3Q84R0>)@PAL@ES
M%!'\P?\]3S1M-_RS\&0RYP_*/UR(0>4.A;*]T#3Q.E[Y5\Q*!V^BHW^I-2UO
M\QP4^H'#C [[< ?'G+\5MG,XD+2+D&9OD7Y@0*5D]@OA6/3&J5GT-EY[!1?
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M0_7:JP<ROZR(70G>MLH7,"Z9&7X<5UCKNZ@YUS/GHI90+N6>TC/'D-+5"-Y
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M84BGF[*VRW#>E6Q9WE(MY4(&_SRW4H2_Q(QA_X5-WI&:I&P_])Q\]!(8N32
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M06,^ 2EXV';)IY7R1]X0RX4+@W,AW_05<CR2O<!LQ8]B.-C.<=5M QUKI*U
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M)GJNX5;)4LVS,P\LPB+Q)S)S^R>4;3Y\.5!3^RI[5C/6@X5.)->O40R^XMT
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MW'&?(&Z3Y@>&S_WPW,17N07-?X!G@45RWK<NW'KL_R?*=_HUZIJ.Q9D-6/U
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MTZZFW^.30FR=N:=?_6:FD7>BIX1NH4Q"$D]"M&*AL^F0;RZ837<)]@38ZV@
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M:\/+.9F+HI&_!$//D[0!\[4]?T\'_6_7IO)29KA3]< M4<1C ^8!Y)_O"#Y
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MKT;V !2A0MDEZ!\V_95(C@PWRV$A[WENPDM=['T.)4U.VID7"_)_;L#0TR,
M;?K]XNH??E$=5H'HU"]0@\H8V7$YY83C76,CL9@D'I(5V1PYU9N&0G"Q@E[R
MEG*>'$<H^.%52KUW"@>)(F#&12%>;R$Z0/^RF8F-=S_K-IV5(,.](A>VC;>
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MK(,.'(?G(M7)P<]()QG4//PF,GS)%Q*BU$9)J)__$+V1&KZ$KC^! GC&F+7
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M7IRL%1"Z!480#F#+WP&7FKX8+9E 3A+<C!7PG;)K##(7PSFB7&%#-A>>T;1
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M02F2Y.!9824.LA'/COAP0S6!?852W1UO%0:7;Z_ C%DH\E$(*4590":>]2]
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MJI#,Q)WN34CH3Y@^G)!B'M#6/[^_^DNU9<9BF:$:5_'#2X@R0_4'5,)A;^2
M7#<9-[70*/=)?CH5Z&1&SW&L\N*6;QU.",&?:1M,J(H+!9$Y#2F!>-"XK2K2
M.:NN)BJI_'YEY(+@SL(=DPW77K9W8W,MOWWUHW(:[ UA&>H"[)\6M>^4H=F_
M\1WNG0L;*/*V 6V*Y]%]_W5O\A_^!$M3'E#80"%_G8D8QX#5=R1E./_GRL$7
M=:Q\_^N[=F(&[!E"_Y&1LUT&,^M]C$V'%K:X7!.7KU.^0]9=2.N6\K-3_4_3
MZZ;)JS6*5V";R]L-\#!JAU<NTIBIF^:E"/ZM=P4VR*\43)!5S/>>/K\W$?OM
M;25DPT-5X#<!3LA8+^U+?YIH7WA^ ('9?]:13#%W*M_US"JC4WJ@\@W\KN3S
MWV>''M?X%3J^^;LYYBZ]ZS+:JZ!#%KLQ,OZ7_DS3)UT!A8'6S6'V9R-Y^, 7
M(1CJ8&/IDY'(Q82LJL?OK<;+GHX$31F;',O6?S\RWF'QMJI3\\0OQ6X[KVZ/
M/Z7=OJ?RHDY#)WG7"NPF ?BFY!+7KL"F7!F!B?BQ Y>M2>^;4%TG"L("3-(Z
M+T1Z:CWQ3/@<4+F_P_OO(SL"(G<<+WX1&#V5DGG@P ##Z>+$VM<5+Z[FQ8P'
M93KLME'_!3/UAG[_G)I":_Y^CW[1X<[BWP;/(;S8C#:J+1460XW CB2+FSKY
M>8@U$!;@2Q:*YE7YC)_)3)!<5ZHDWS=H0#;374#93E8#)GBB/'K]1<S67H=H
M:[X4]:5-K'L-6Y U5$\W.1N5+Q.9AJ+R[<DV$ISQ),)J9J>RZDE-.]Z((J36
M-V8"7IWC+FR(!TSX]6X&1=U1O@8\#&)8J4]ZTXW?B'854W44SD,LQ+L(%FH(
MK2[FC\2ID@<N=YZ/($5Q\7HLLVFD#AD'QO#]@ [(0^8+#^EE68Y,+B>P9WA+
MQUXO'5*<K!NL3[;7[,3H,2%V'+SCS,YZW7!IO\((P'_YG@+:M5.-F < YU&.
MD-J50I2:%)!#UOR^N1Z$<Z,-)+MJHRK/DK?6O>Q5;B=0A0NIR.;?PY%O[F/?
M?)^KZ6"GX1MH,^?!X&YGS<XH>%ZY*;,7[0:RQ59E35TBO=.JEZPB+AD02<._
M3"_Y*[S %5C67%EB)UZ7:03<0+M)J&;D];WU9<[1+A[@!\3:P02?-G4>Q1[*
M3"1:50X.LIS(X= 8(.OL/@Z-1B-YR6QALAS;#(HZ*G$9@4DI_"_WI<WLZ!"3
MSCOE:X:8;H\M[!N.$<1CF(@8M#FX;^DXB"] .0R X3[,=(EQ*S+[ FQY]@';
M,9XO-)<R,JAA*-JX*UC>\(R4W<W64%J2DZ& \[(VI.1K>FQ55%(XAU\0U,2I
MT2+_+"!;6$QDH?7#'! (YQBVK"I:KU!L@1#X"<C1^_(O22KM"M4PKA!AR5_Y
MCFJ4,((Q?T<^VQL?[>(&.LU$A1/ Q$ZE&6##2P?AG:)UK-64OZG&%(/I$J_\
M.Q(JAY:5I-@+,63$/+3KTRBE/A1=H3*5+-.^ZO@VTT_@ZOI0YU3UA1=Y2FKV
MC"V8+!/1L)>#V>;0E*AC<4PPLV5I/2G?=[F,["I^>L6O!F!W_5AS/YNR':++
MPDAIDU^980F2?'H>RQ'$I08>*SV.@0$*RMHF*+F:($#JSWX:"AY:@8D?JH9D
MM:L*M)%LHJZO@*+N"16[ELL57D!3QRF$4=-0 E^XEUN^ U(*$WDY\>P-:S\(
M[ 42>!;:7I+=UH<VVE?Z! H5=1U7'(0R=S'$N?%OUA[$1K+YWU4>4OZ K:NT
MHPSBC3$Z'$G46W.>$@$X9>!X*[!1EV-L )7)M)"$0[= 5## GFF6B?0F&S'&
M )];Z;J7P]XH.@.<-;O550ET2Y!<&HQ,!9$%#6_W\I3(TI"^KZ+#I6&GEFM8
M3L))ZL:$8K#8JY])J" ?!5'IE,V*3:7BNJAB2O</:R)LY2 UYU9@18O5K0P.
M,;'2/1RP"VB#&ERSN:_G[6VDQZ=V*W 0-;R"; /%R=K,%.KRSCS%24 P$[)T
MU(+8&;KQ!7B6JJ^P .NDX5SZ"%N> @FB ='AI@'F)2E6'1)T4G;VLQR/+.J5
M$27YR\@ R/0I.=&G,+*SBR^AY<^+1FXBC:!MOG7]2NL@ OP#4HL=C1RE2A,S
MR0&QL960>L?X[N%Y9&I28DZ\^>] #<UQ=H0CA?.0PEE)>&<(7C)\7XS2)?EP
MA-4W&)/(=>0PF7D*SAT:D9;AI3ZDILY]REU]"9I 3&T"(D-M6:,/KTY&0G20
M<VR9P=I,Z2G?.?PUH<I)?->)O=YQ!;8IE+379P#9C=>E[)Q,LF)_668T*&\]
MGL1LHG&-0ZW[6*X$UD]$78+<(!ORO1<:<N;,.]+?^RN6/J7^[SM>_&<'!K/\
M@'JQ$BO4Y"79Y.U")UZ7!/:1G=&8QE/CR,:A?HDG(_%I2A6#'E ;4>KDB;3T
MG,Z L^WKR8LBP%?7_K=!1=@0)CZ>K]CB3#4?K*9^.#=AVK/'.<$B:EXO3Y&<
M@UX%%.?%W>7D[/VJGX5U>ANUTQ-K_*U\"X?I<=*OS,C)7:O4GS.P/+;=<_#)
M *TU.6X??Q?+Y_:%R)ZV*SO*@F@E<?(&V3]?;LV8U>;UV=_T1&8Y> "B+ 56
M,M0<Q>N-][7Q"&[*/1=5T5^_E*SV2V_EJUH'Z?LC%P(3"IH/?EDC:_8P6ORH
M;?A\<+ODB?M(+Z>?<:@ 97OU>,5JO[L''G^TO=II&WK\ZK76Z+'RNQ<>&FVL
MW%YAV&KY[,[KU5O\D^23KS62T_3<%J9G7U<\:-@X=F\A1N6!.;,)GZFHKRLP
M/=MK-.K29&M!? ]V43%_H.)!ZGJ8*W4#[IMUZKU-W[X7B]"K?L'JO;. &=;[
MJQ7]Q/_DINAV2 T3@);SB_056&!DT':U?:EQ_$^QDP/[EYV_#1<^/#"!CK<,
M1]S;A.0F'^\[N/8$,C3CEW^<?TW6YV]"W+NHI[5Z7U'2-_YX3'./%SINDN;W
M^Y3J'$7.0-S@PD3Y=;GFC1M%:87WDN:ZQXG'21-%;:WGXF&K'Z3NQVF3'8'P
MM 21!:F4(SS12\J6^K&)4ISI=%!6;764L+SFR0BA<1%3&G.G?//@O'=]FZ;7
M0/2PX!!07;"8F#EG5?Y]+@71%>+C?W.Z];_1@_LT7V,"_<\>7+VQB0%'GO/@
MELUE4F(]Y=Q/'EME27O$OUYU#EM3R^>NP'YTX:S*-6T6 NF*PE 4*%!ZAI@K
MV\-78#Y?58+ZU6FI2E$(HV1UH /]W>/4<S>_S#L@^765QF]'\BUCU&$'XR^=
M6ZNI^2O\_VBF;8<]SM+XC8_XBX,]=%!7=:&W%TD%TV$'A_E9F96D#(+S;[VG
MH.<OG'M?T)>VAQI]"+)P_]+YN>A74RV9HZ(_<EBY=9 =3E_'^%(KY><C-BX_
MO[R<Q2:,LD=K\,#OY9M;H9H*Q:E:2"TYQ4P16@=&%_TUC*]?MP)KN,0JK2 C
MG;/^1!;:8Y#OH>_*]6_"Q&MWSE8=Q#)PWY0I5&T[%<(@>;A\RB:(+J7FXN'*
M TU=Q,Q0Y^47*[!+_,RF/:K<M#:R))PWJTO^>3F;'3Z&Q4-WR2<E57N/U/4V
M1.&-A>_P$5& '*X#&?@-SB@"STMI\.F R$I4-@F;AFQ$S7# @/9_ST:RK %D
M)C-86I4H]^TCAT03-#.8*=44/E6?LD?95[X!T.32L^X@U/O0JR4,X&UV%@L1
MA=G>T @PNJB&I'SI<*9T5MM-ZAIX?)")K-X]D(J]EV<GH=/&'2!00LRCUV6G
M4DQ)-V?]GP\J3,#N+@PV#;^.=&&62S5 4=9#89*O3R4X+>'4@ME!8"%M%GU=
M:G]9=G1XWD77>J.T/\$U" 473CH7.'M6/J#\0K9?KEN!1<V:*'3 V0+%21 I
ML<F,J9JCCS0%@OA<%-I;_/TK2X\T((7GSP=3"^A:(O]^EG8D915DA<F_%^3V
MB.3!)HSM[0Y:Z!09O7L/+UQ8<$;F,5VK"?>0O?9&"J7O4KQ28";*5:XEL#:\
M[*U_BSH+F'!:V6OQBH [$C[GMZ7#BD.#V AXCDA'N6VR;S((F:7<R9?1=#ZS
M](# S ;^CS7./5OOATQ=0^JCL6!+!%42&.6,SWQF+F6/5LKO8_9"HFA@EF<<
MF!3/AF,)HRK'_5EI!TQD-L -R/H0#8B2U73B5Y%,#H+='*P.2?O-*> *PA:@
M%2H\*IVR5-1S'A05H5/N$5K":?'VVR2-9?9==U7C1_U'<5)B,N,*TF0HQ19Z
M$ZH3;DA.;&D$$]-8:\G7 %2:<MU[\M87I5RL,049K.Q*5+HV+C_"Y3'ACPEF
M[,R++*CRR910EYWG4%F)S$C:&6J(7&O3&PZU5ITA95(/KL#"D4A%4+K49,86
M8$OOY$Y M&C@P83$KTV",^2(VUPX);RA;"XQRT=:F-AY;3$\2]PXT)""Y;"V
MJ0PN4>O5.3I7-&)VJZA0&A+.3>+E"N9A\,8G*S ,^V]V^6PVO7%B)D0V=LP!
MJ:=P&R#6TW.<Z+4]30](70L<S!H0FX,Q>PVFRY^\@#S = DMCXF4H-1(<9WC
MJ\#L+ QRZIH@Z0X'K@]]DYG0,,8D!@&D<\U?TI=V7*D1!LH+E^\EL%-78/6:
MG31S!;X%N%("[\"-WFEG:8'V;(Z%,=Y .8S<@#$GAT!_ MD'@4-N%03_H,^A
M.P98QI.8#6#YTP=DZ^= -5MJ$=9%!#4Y;Q]!ZNWEEL HC/KS()6.F\"O5@I$
M)LQP8#H$,I LH7)Z%>LA@BR?EI/>Q39E +=OR30:0:<L,I(QA5_',N ZCKJZ
M'^S_BK&/O-,RF?75QT3 ]$2;VG!68*O&":'[P,<WG@93SE/^$=4S9M)U9[]4
M F;F8YKM29>:.K#OFCH0R%[FF91[9T@UW:QU8/<7@=@W6"KJ:J6N@HK;$;;0
M4REU ]D9;*R5ENWU+/4$0PN!B<Y%-D='I*NX7'N;J.];.0*C>CH$?EN0H53A
MV<P$J!S?Z(L_*G?7%>[5"AUH1#83KYI+8YEX5@@7FW"6'D/W+U60:J3\='24
MV"<:+B5V%0:MP#HQAK3 /D8^-PC>J8OWA*A/)BFV8,^M9S9$ BB0H;(3\MD;
M2+/=28'M$4H4:4+NV\^.0!:4)&9_&":; QC=<+G=()/X=(QTAK+C<XU$]5Y,
M8G9!;0\AJF2(EH^QAH)2[#CAW-HS4+8'SC"R!'U;C&RN#Q0K\(U-,[;Q=#BU
M@9G"@.*D5\;7+-\D>TN0:>$20[.SJ@?.J@ #Y31H .#P)HGPG*H81:"X B1V
M8-5)X3+=IDR'D",<+GM-US/R>9E/ZPHLN\6Z^5&H%*>R!\)?%2B!(@7.>Y.<
M_PY[$4?#-IS,+&"O06^5/Y421V9E/[.,@!48YX1/BO/XOU1-Q0D 4W.!Y;SA
MU;BS+]XS/T@U(/R:$=%XQ)3:TH('10V:EH\LU\_-FE#>]1&NDLPYPCN=[+7*
M42<, HIZ&DJ*"@9-;B@. &&=B!VMRW=9=D$*YP&F!F4SWX8;'> %9.<Z5N&D
M2%H,RY0TRPEU=L9S@EV=\+VRNL$49#=V/07S637CFD[:6H7[\A-RL 0'(V]:
M;L!LFD3L (O*)*J$!0=F:<QM(%^^7Q4@*4B)*AO70T<6#F$,LV44^@/R?D"7
MNV%R42!D;8:N\D\,SXMR%Y'IBJBUFC-51M]E($.6781V6CH-!4K*!+QI?#H&
M_F-W5'%Y [#@5BK!*W9JL0E$$]*LS"1/9>SP[8T+^<1]35K0)7$5LM/IWV#2
MJH6?AQ5F*[#U#Z!:V=);'PD]L\$502VX@KU"%%*/ Z*">7L7Z9V,S>"M[@Y1
M;J@]Q!.OP P5J)<#<]AWB2K\9J'):, ID[(IBK5%E3P5[I4=J#P,$J))+?<M
M\GDA.MW7WE8JL/7+]TKZX:EW@EBY&S6_?C2"[,5LH;G,)E]IHS"&2NCUQ,+X
M$#-4*KMI@</7^4QQ NB<LF2QH!M?2-5C>@'Y7+IVPCXFA)3,G,0X'1W7'21[
M5$6,;X'4G#(21 @"7DL1RR"9MV/TVTJEN,QY8A-;3,<C%>?!NDZV_C,R0:;#
MSW6FIZG,<W LN*8+GB44I,XGJJR.PPS^1)]*$^TD&+H$KPUUH>#3SR/3_?L2
MJ-FAJZ!L8%'7QPL0%,V-A1W;-[YM"(8]]/D_(:IOR$UDQ^RNEEOE#ZUK]]V-
MWLGB;BWJ<;GUZ_5_<9],KDMWQ%F/W=//[+G.B_426]1J4#N/);S:IG3[)7'C
M"HS>LJB7!WOZ'TUNN_6?CETB1$=8[3!\97__L/LMC<Q=!K'^AS7$!@5#+=OO
MK2JM3Y[;-NL$FV_OT904Z&G"M!,,87\L*L.;9'R9H$WMX"2=]\><Y8*-!76G
M7JIVD(JR,F%AG[J176-%7BXO7,'!7Z[N9_QHN>Y?>A^[4%K+1W_C5Y-D]WF[
M^F;Y2U[-_$T@=$UVCV=O""OUC.O!+7E9_#2P?W)F=OAVWG:U53<&7%OJ$/3C
M$3O@:/ S-_E;VMZ9N[*["0[U_JO6P\^"GP\ONVU*CO^<=,.S[^ZW<FQN;?>F
M O'2A[BN)-5@U%J]7D[WY: +$C0V)>FEJUNL,7R"CNO"YMZ0O=^TG)+\Z78>
M;"(:;25Y S>(HOQ4UQ]=I<!)?>TX+8CF9]V?\M_BO(&[RLW-P$SA@.FZZ#7%
MV#RRF_V3TT--D4VA48>U-3['SL]-4;OGIWT\8-:J ?10<VOYH7MO# RDWSQ@
M79 X49U$9QR5;9J;+$^ZH?K-%MBOUU_-6<*YJ]04;K/3WO5Q@G+,M]@>T@2-
MLTF%Z0%/[FD(79=68 :)TZ)_E;-7_&$6>Z&;2>L2;59@U=?1_?_YYYD('YG*
M-].UE,93MX-0-";A,11U8M!A!3;CX^+R)L6/8/-\Z>@PE7#JQ?.6 AOAN=OV
MU=/6'VPNOS?HH(_JR*_XGU8$]OZH1=:2TE/OW:1^@+];%27&0=L'PJ3\&]^[
M%<$U9ZG_]#T+G'C$7_J31?P>A@*I _L6[L&GL+Z#5QH*G3FG!F(V3.,&OU0E
MF.L\X?QU]D?)<.C9YQ<[#F^(L"KRT,L1[U[WU\BJF5_H.LW0_UHQ/+C:6GP0
M+;Z;,E#^\D/8MO)F=0N<4:#_];#G;3>-;?<$G64>A5UX\6Q7W_/C:RUW:ZQ:
M:WDN'?_F4_I#A<< 9A79:/F6]0!FLY!D($\!%[YL6SH+X4/WC6\_/(];K4B$
M%@"]:0F.\YU\4IY])[A8,MME$2<O*SX#S(R-\8;3);@,ML[$<)5G<?7(@U3J
ML7L3 E CJ4@V^AV1<5SPK4^*+:2:*TU>RZCF9,<^AQJ]LY%724[MRAT@S Q^
M VT#L"7CS?_1HVR:HYN1CSN%[@"Z\]'JDAD_T9%^Q=ZH9!G*A!08"E07/H$Z
MD1:0P(<-+)<)G0C/E$)D?7<F\\ 2FM3:1=4G[VH,8I5*=8]0URIV]Z-14C:2
M?+5I (,=A]PY@>5F+\ FSJPZ%" K4&5J7\+Y?0UB_$@K3R6=Z,1HZ9LWM)QQ
MK4:0RK%([#1S@RW+'K#5R3:@0"KHG$$&0W$RXBB2IS1[@1-F*[5U3;BH0KP^
M60WXUE6^ SKVC(23QCR5PD>BQ"Z?>TGF?KWQ;W5D.$[;M6EI=GKT?-NJ"2["
M$>C.?J8T)1L-D1U78%HFZ>*^97@'M7YVYFE*RB.R%WC7^]%[5#=QI$:RIFK)
M <59MG&OS2(64&N=.K%Y2O1  G+CE+P)LV_ 4:2GB '+YFF9LX\$]O5\W79'
MHBY).L#E15L#8LV9%*/O[BLP#>'R0W;$"HQF+_6A%RS2T^9;'52AT\1SGGF<
M7?/9K+P->*,2G8\">C=5F^A TR([ "%-Z?5$7;>H\*AH,3+769"K=(*<CO7/
MJ\D*\:>>"^)]7K&\P9H9P=*)FER6HPV';L1Q+>Q6$9APQQ(GR2N/;">)=N=A
MU5E;%9;+]Y3K%!@@)EV&SV0AH 3&%$:+QD/H@**\A!R%'6@G"^1B-T&S'.&U
M6[*WV_P@XOF=\A-JR]K'E"G8,HHU^1BT#"YTCMM Q4!8-W73+J:%&*Y%]H"^
MB9>0- %=BVF;4 --GVU8+J6&X_+QFAA-_,BDT)"B73_(//^,' T]/%\Q!D5Q
MDG"J1T[ KW7@KX)\CM="^4^GDK[>_THQ4^DI/@U9.Z$PR.<NWGZ"MI-X/Z->
M$FDI>\NW@ICRJDL2JMKT"JSN:PTC%$^J.3%\H02O%8S,"Y,H;SV!;LJ3O09V
MS<K23[ ;ZEM9):E8?UNUGB0@]M6V?U^9(F1;V70=VNB O&"([)101?BQ<QU-
M]@2#?*U*-NG8M35*;>&NATN>4,^T?'CY$4L?"A,O<P,7C6IRGN%Y>&T*$K+#
MF7EEC'(HV/Y'>\D!S8/%')8%6/6X8A@RYLN+()MGB@ !RYC4S:5O8(;+B.M7
M8!W'*!BH98"[ EM'08A^?+'HE$N]#,\O7PLE+SF2S:@&)'R[<E-+/L>YO*SJ
M?<2QC567077HU"><GL*Y#7AD++3XE*6VU.U!L2;9R;.7'RBW0M,2.@>;Q:Y/
M)_\,A<M$^5AMIFLE9< ,WX%?/=E25<C/4QGM&N%#:2)/E-&RYL\$R3"@RVH&
M9#RZ-DL_JB1$7BLI"P^&$IRX*.@4UNA.%\6JGRAC3F'/S^9C33!;E/UP:4W!
M"LQ<X;>+9:7DT=<DX'04^JQ^E;KPLX6S16@UD";_%7#B\3=!<&^JKI>T-"41
M]Z)7:4'*[Y*;$?.(6U1>-[/B47#4[O=0HA\42Y#TPM^UV('&$_*&Y2=?J01Z
MH5+EB?+1VP!J!V(#Z#6C)FDMM 85+E*:$=D5VB*F9@A9#8!(_GLOR^B,PGY0
MN8V4'SRL.+GFAC0J&L>CN+9 *)FO^9E22=&->\%DCP$IS?]C FHT7)Y:VH'0
M09I0=G"6MBO\!LF.2Z?'%0% /7OM',V0!PQ(NSN6[<0_UA=5C3'ITFQ.?55,
M=V@_93,!X=H$EN7GUBB\P!W(7'TR%L#4/23]C=5;@9V'4?X]AD\54F=JEWZ9
MPF\@AX5+9TQ49]!.> OO&-_.5F'6TVF*63'7V2LSGO9ND'R6)HVAB;V5IM-T
M@WG[8*5)P8O/C9BMPZRM'D#$9V'(0J=OF$\3]/3*8IF 4$7I8S=0TYE&3]Y!
ME3)ZYA7K%E6 Z)%/"S!6)$:'<@-T@65.DWVZ!0[S51*&WB8S%V6'ND#>8O,H
M>ZJ*BQM0JTD,F2!#X?;P,X=G)DA7G)%..J90VTL>_Z&VE.]!T8[ -JH$-%HJ
MRJ.KS57ML4!Q* @0E;$"NVS.UHM@&UP"O#BN<?+,.]W4]6AW"9$6]"^T:[0#
M;TCVJ(2O^URBS9=H832A;]Z (./CH ,NCX)I&5(-[(T[S6^1+M^W_%!IJ_!0
MA3@8++G#Q2-'%3\GZV[K8EEE0'LYH:9-@ F'(V'G?2,%'@'*:_3[R 8@3<7%
M!0VX=9&+Z%J%/31]CS1Z%CPZC@ 3"]'ZH,LQH.N.?<8]Y)/?_S^-R]AR2RA.
M962ZG'Z)1-@#N R%;TI4M-PEZBV5LWBJ)H%(^,14S3,K>>G,QSQ1STUOYN^7
M:/\DIK3^4<Q'WJ"N/KQ980E=<=-83S:2=*[=IJ&_7/9J6YI+WOR1[:MT@H.C
MS*.2[>Q(T3N_B']LCRZT3!L7"L<=LW1(6PI/[;^?97E8FFMT?/_0L8/^L/*\
M[;!'[2LP2_D*#+T(WA7_*'L>=(V#-L#/ FX:% LOB_V/A/L_OER!$=KB^.BY
MV?+]GP__H,H=\)KCI,N:]%_<U$<?7^_RV*7I)PI0QL[TJ\#NX+UX?LPS'.YH
M,8U30TDK?&CYC;]T-'FBH!R[+O9&[P\\U$X78-/U%3DRU9^GW6 %FY0:Z=_3
MX-/\I*#MZEM=U=VS@UO!G4&>928YQ+DJ%W>6(*SNAF/RF(D7<\A1U\Z[=?#D
MZK&>TL>BZ9*W,YF_][<U5 Q7/<5I$*SFWWC7T*875;3-:3#\T39_3#6VG.L^
M[MW==/3;<$%<>5+8T\6YGKVS@J8CJH%4N/%#X[H^=:/C>US"&9J65[V?-<_I
M;I@^/<!TCWLT.3"]Z)%553$9--CX"Z;R,:%D3NC;U<0X';DNZVM_=R#=K7=B
M<.;<[?VHQWUSKV/"?OL276(?J:)?S[A7BWO5!BS4NG$QS/E/OZ>F),=;QB\B
M^0(6(>+>FAE3/OI<RJ<)B[U\;,#-)(3MH=2K>Z$Z!,-5:QM;O'\3S#;B__[%
MR<K(_P!02P,$%     @ X8WW3FV[VA]@GP  ,ZH  !(   !R9'!E<F-E;G1O
M9G)E=BYJ<&?<NVE4$UG;-EJ(BHB @(" $!41$8%60!1#HB(@(D94!D&(BLH0
M,2I$(H0$168AK3;0@A"5262(,BJ&1$B 5EJ908.0266&*H500H:3?KZSGG/>
MYWQK?>\ZPY^3K+U6DMJU:]_['J[KVE61?Y+S@;5'7-U= 24E %!2O 'Y$."L
M^/;_[/7/(/]/QU"2OP6T5BE=47)25MH,+--24M92DG, A&*>*_Y'!^!_?RDM
M4UZ^8J7**M75:HH.=6N!94K*RLN6*Z]8L7RYXFB<XCBP7&N%]J:=!U;J>)U3
MV7QMW:Y;]YZL,CWXLEGW1#>XQ?;\]=NJJ_7TUQL8FFTUWV:QW<Y^M\.>O8[.
MAUQ<W0Z['SEYRMO'U^^T?_"%BY="0L/"(Z,(-Z*)-V,2[B0F):>DIMU_\$=6
M=LZ?#W.?%A85EY0^*WM>75-;5]_PZG5C"YO3VM;^U[OW/;U]_0.#GSYS!4+1
MUV_?1\?&)Z ?/^?FQ0OPK\5_[%("E/]M^O_4+BV%7<N6+U=>KO*/74K+HO_I
MH+5\Q::=*[4/>*F<NZ:S>=>M5>L.WGORLEG5U/8$J'O^>O=JO2UV C/H']/^
M9=E_S[#;_[<L^[=A_X==7&"-LI+"><I: !J0R;8]30/^OVR6/]\(\=/T"J*S
MN#%'?+&W"GVQ4XT[)EL%.XDJW4["DTON@21+.$$XO4]XA04=Z?"KAS&@D"<H
M315!13*-;I1>N&/BWPTFYCU6,_/&QP9:QN?R]H7-.R^:8O=.\&HPMQCN(A[5
M9!=T*,=_.F=:"<QY2U%!!@A>"V]S>WI;9&NJ85;)F7S;DW46SYT)0BM;D5[3
M1;+0[T/%C1OT2^]_GKF@W&E%X3]&5P]_3S=YK9E!.OXB"(?5J/54._H*=H-N
M]W)&K!Z(U.EI53*M<*8JF,6[M1%RN"NQA=R1NL(\"D L;UGTJ13PUDT8FCPI
M"?-_M)CX9BB-5DN;?BF@?>:U[49K7F&:D Y!OFGVG9]KQ!G2IW.>KNP6IED#
M?',E;0DY%F0R0$"L@5E"=>:MLK$@#2:D!B=QVRRE/MX)SJ_CK(=.)4S++,#*
M@LKWL*E8(]D90L=+(D24C )'.$_(2VK,:?Z ;FEL>R.873[69I.,7A;5F>83
MI (F%8<)/FQOX1T?(!C)@73#&98(8W1OA;BIW&]LO"14MJ&GXN-#\V>R'G1U
M*WU:I8P8ZVV"'$#J1)9*=L!+H!M'ZU-HS.[7."$Z"5V+260X/84[C^Z<<%7+
M, KJ);"6PZ:<$6-(/;%7FAUH* <.]T5]P!P=M/;YI*S"IC0T3,W2B8Y#G$HZ
MG&L5A*,EQQPE*[^$@R'L*4C\NDJ" 8.*19TJ7%CY+0AKVQB0/+I)!P0L32+K
M=!<#RZ=KALOT^Z,P*XCM_LFG/!U:%J<6*=<@<Q'SN1RHN5$'R0'QC9>@?FOH
M9<:F.-&P26<;R@JR84N5_<"96V&4,N+]@;B HR B ^G\!+[_?O!(7]37KCK,
M*G9TL- CK!:[MBKU&BY63,DG[Z0T[V8:2,[V54J<JR;K&[/?//XD4<&JGB:.
M"AKBR>:P1H<WC.#3,U@:E3,2=W"I[89^KDWZ9>1I 8)J8E73;_?K>P_=SM.U
MX] @TK8R+"8K-4OV!*1-30L0*V0?3<41H.1%6) N0I/DSM\4]P3V;29K99I!
M@4DU^(I)/90.Z'I+0%T^]O-+N.%,8;FZPZ&NJ&&K*R4;W_[]TW.;2KL<T) #
M_,+?Q@?)VKV4,)X*'""P:K]+":$F\FHSJEZ"/"R<!5'9)B8@MI5J,"%;UX,6
M[.[CP_L$81+](OC<CMH.FA%QB2..P=RRL\P(5[M9]Q*GQF-U.[ :S*=$8=>J
M3@<0::V-LM(G)'<(WV+>S3 %<X2==PG#>"&"/4G7YDH.@0L)<Q@UHKEO/_*R
M8D;MB?:Q-).)(.W:@2B*RN?\[2)LWPY*P]R>>0TU#NL%-H'ASF>M@W=1C(FY
MW*%6]$L66PY\$@K%QOO<<'E8-0FZ"7*:SKF[T5WECT7I$EP0U?CR@<SL6F7%
M5JV<^Z_IZ33PF$TB3Y>$%NP+Q'CUV$C<^=B[M%K?ULXUX04H. #\J8C]<P_$
MN=!@*C),-*LY@=5@$$K"38SZ'F!R JLQJXEIIL%"*\,E=HSG7$Y.;MQH2JW5
M967>#M9EVN?>4U!T(LFHB'1 QF5 673V4H8IMIMD([(*>+OVC.1TCU6='$C,
MM69!EAAPOCT>:27$IAI:B6EEL"G;Q PRR:+#F8/>74.8WB+*VC&MB7QT*XV+
M$=@T&WL<[95M"6>:=I]EU57WV9"<P\ EH0:+W[EZW#_S18')RP%2K(BF20P^
M!2;'UZ;GA_M-F?8AL95CX(6.&]_L)CV&AO#WD'OEP'(6K,Z7 W>9:V"Z8,AF
M)1N1E,>?*2.43%"4R, $<R-J*ZS#9ZG#^F]S<VY+KO(TK>H0=QIW<#$)#*N;
M=-A7,/#PR?A.7*-Z53G?#:8X?:]OI)]<PE*:423C)2PQVS.D+6AOG]WP]@5!
M4P.[HTECX2U/4W*C !%ASFDL38^B&TBL^TCXPO <[&I&)*5L(C58A-<A!NTL
M@UGL194[=@+"$Q[LZS:P$9A?Q;K"^GRS#FT<UH#6-NLIA"-5VE*17E6X C5(
MG"S8-J,(5VT>C!'YW'L*LT^!3?0DI+<0D1SSD;9K4K8!K*^LF'S:XA'HTWZ,
MT5MU0EB+4B7WY?JV3>/%MU]V271$QMO9?'PJ8Y. DX %>>E("Q%-JU-(34"M
M@AO!(,D>B)?$0 @IJI.[RT7;HBP]$3X-E_K^WIU;Y'M\:,*K5?,!/"13_04N
MM,N,&L#Z!A%E_8$29R%K2*VU+<Y:W;#S5/I):14C6HA-\<_XD/BAM7BZJ8G'
MIFA/BAM&U%\5L(_7]YEW[]#G^!AF5"P,1)N\ ['BFWTHPW<0+1 *:47KD%R@
M]O8,_'Y()9-T6OJ@D*B-\\3LAR\*Z(G9P2TQT7<&[, IK= @O5Y\94HCLZ^2
MD-/(-/QCY((%H-(A!U:B^4]^DL[ ."$^M5S NS5@N/N!@)Y,WA0J02^YFF?:
M8Y+].ZDD;!'Q-%-'UHW2["&O]R>YP6@H\J!C%<'81',Y\0U[)RZ77"=8D@,Z
M89Z%S.)8<2<;366I,6UP)EN[D$KT,[@8UNTJ@IKF^L^[D^EAU41?WU[D.2%=
M>1BF<%2\>R_G>$!;_$=O2_:S]S=://<H'/I,S#0*0^ZK'(NI*OYAWRG1F4'K
MPLD^$+Z5FDFV@K.$/-C'/[J9K@'7_WR+7D.R$2;"L7C(39#<&K&?N!0(5MTJ
M#92X0C?*JDA;P0]%_O-+H3'6B6$$H1%5'7;SZ">Y56*#8DO?SGZ.Z>1'<_!I
M+*U::HJ)Q2">O'?$13B;[N]:HY[:@_2 _ >/OZFK@;-*#Z@."YH.:B8[M\@!
MU0O==CV++IVW9$:2O:=_GXS1>%*.BT>8PIVRU=?0";)ELD&6=@EL'W(-<A-?
M@9^(9I6)1H+E-*VB6L1ZB6U1N(GY \$L9[WD#$EK#YA)%<ZJP?I"DS?"@'./
MB1D,G4A0U.YX*IJ\6=:6MC@Y$8<5?Y?FD1R>PU07R"%CMA;7N2J4:=G'\'CF
MSJ<A N&#'=Z@"MN2=C?("72B4B.0-@ZW";Q4$PT8%UQ&9 ?!D4]Q@S+[ZNZH
M)A^AI^:''H)'+,(8XDET<()2JKWFVO"&$20TG+B0(EM-[J.MK%M?@3@:N'6:
M$J:Y3N(^.,<RPH;M.M@U I?SV_*@<I%;HFQ#QY9WE^RP:04VA@Q]?7V?:O^:
M-BQX[(-:6ZJ(IAXD.0_UE[8H&(H<6,_<-,;2L(JR4;&GW9'M(EV'G464!)D#
M-$Q+->_%<@P+,G>036%16XS-+9NJ!YZ]DFAAG+/7JWZ;.4NT!AQY$!B?[X2W
M=;XU<@H6Z*4+TC%IJ#U,N YB-2-66$W;(1+D@.ZF/H:M.0>3/+(#OL?GI32*
MJ<^)UIT^V,01,U .W)FMLM,T#CC]3O#ARHAZY/'>.O<IAK'PEUTX8H4"YHJP
M &JK!-%%-H-S3O0Q5"J#)'L55$0]H/F#@)+BO_2QP!$JH(&=1WK(!KC?8 0F
M013Q#LXO'^-IN,/8,*%!3EON]T3!4GE H)M_[]E7@Q!ERJEPDHFJA@L?DSP@
MS20DX3&.58-/(=G$<%<F5XYQ(Q:F(,%L.GFU'T'=9+Y2#M3O0$;R:1FHW5WS
MSTYZ]>+M LKLFG#.S-L+&#6;W2P0@U89(J%!FUMVLRF.SQK@N"7;SB6[\1IB
M\EN*!O):,0ZU(4=HPZ:G7 \WV0'B,Z.,*2U!&^OZS>%(!2.+W?^F)WOP."BK
M*Z_/>Q8:(PSS'WFD-%^!-D&MI[0\[2?OG6B<'[W#-!HSQ*34T;0F1IS P322
M\G/XTF!+=#27DG(.,K\C"7XZQK3NMC?>M>3YIC;.\GB7H*]JU$__6%U3P)#>
M:ZA\=H@MOM9K-9?59T]/J6=N'*CKU(,OM0OF6,O(>ZAI; YJ%>AZ#[+A^#N-
MMMP#08ES[VPETQC7Z)L9L8D)?E7V!2N%.'^/D<]%=!/K_"4-$NJ5]+[DYM(6
MXBBG8"-$N4TV<Q'AIU_?[SS2/2<'U&F&DYW"4]U,(]BBLHZF1K1]BUK3+WM/
MT@)G<)ZQ+=QC>2$F&<_])_TC/LPW#=J"P3)5*1]SQW#A-O)T23C3X.4@PTJH
MF<;<TE<IVT!:#_N"V)88J1S@S"87Z,#AI%DUTI[NV@[BQX0GL.O CQXY<)()
M:31$ETWD5N"?<\>4#W=%_:Z1+C2?AD ,6T>"[I&HEWV W/S@6R+-S[A#-7EL
M?TSZ*'@I1]#)+11B;S,,^!F4 /A>*8SQ 7<GEF-A;.L#TGZ0E6 OQ1\>E 0^
M'1?+@0M)[WM/]\[KCTVCK\B!SYERX!#DD'*9$5U^)BS(^*4B?=6RX$C('L/Q
MM.2@;'ME&XB1WO!.9>*>,Y(K/1(72,6OFZ3[.!RA>@[*J*H1.L6R!PRC<I0Y
M_FNX.>EPB$RUXRF,QL"Q KR&) 3J3XY'[D)?" QI(VM$J+3H'Y<X0[PI'![L
M. (3A&^:+GU_[XEE^\BV@ LMM%6A,D=0G(S^5&?Z9%R?:S^0N!T'$?/2X)L*
M]O (1H-T=FYV,M^*X@&2BQ_;L+M!?%N!-FP*.K!-G, =O-7,C:$T;8DZ141=
M/VZRN@%2:7NS%!C)CM'+$"J+/ _V>D*^B5'?/(,]'K0]^" J 98\Q!'2)SO0
MH1^4A38I<RP-'C$: SJTT=,0JRJ#^W7\:OKF=X*# >F'\OSZYM!KQU ;!DD[
MGP5]8;R[*<@/\ R0&@I'/'"I):07B]8,'3$)-J0M(SD(I9NQZR=1^P9(-Z%]
M[5@]AI?0"8_IL2M/IZ^3'.RSF@^\;NGD<"A)'<5VJV<D/NV>*G3?6M.;V%39
M/RS]6YOW96D86.?E\M]J)(^ERR277M+>QR1=</=#47J@FM"!B@ZG?];6U"!B
MCD&;QPOL%.0PBL5-$*">0/9V<7KOQ>J1IT%Q/M\(KW4&_L(=^A+FP]3W/#KY
MS:[DM?HO"0_TFLTPV03RFC/4FOT76E1E5G"RH#3>#&XJ#H0I7OV5*".)#^0V
M_6W)FORW8=LM882^!V36) >2Z5$4-<DI.&W!1*W/WM*3;!5]M-?FBGE=7?WF
MR87=@;;'"A9[3^6VO(\XTF+YYXXZU8BS]Q<_JG5:3E_E#C,N"4>,Z%L1M:UK
M4G),3I&O,ULY:D]"R^P65(O&RYWZ_V*\?GC9:GF#_OF O;)^Y&WC'U]^<0EW
MF*2[/;^R=^-9<95O7)5@>RA2MMITR4NRBX'0$&*2<C-9?(JVK-]1KQ0ZZ=.@
MR,.E%I8VPQ,TYV#73).4^.F5YD(Y,*T&-KB!]R"'9-EFSS+)@9RW3#-H(?-\
M37?E/$T9WJ[F4>DZP)[#BAL&&<9EI/6@'78=X\ 3TKX!I/?SL$%_E3O(2(C=
MCEB.TH9KVG'\:5]O2I(<6$>V(^WKFIF=)ME&A&RM*__DY[[.)\@:TD^RBS+<
M7?O2>)N4=NUIZ,+!39'%XX/+C(\X7=*RSZAX:A5D<K[?].<FO,V)%#GPG.79
M<.UG]<5W9?/&#L?ZIZKLAGW:.D_V5O5V-+[HLWK<5/V:>OU%IG!@8F_$Z/[W
M%=I^P\[;ZQV _2H_?9]*W"-\^<FI>-0N4B2<]Q@N?8NHWEI306Y;_(I=+[FH
M"LVVSZXAA4F?,<R$:"W2^L$(I%O(,UEOCIYC9R(KA+5*8DQK*VR5F<,/0 ].
MT/)!^UD-C$T;;7U .)K!Q7.<]#DT-1+NHF(14\GK094,B3(_UD,S<[$TB10@
M(+R&-852K.#*/5'^I5E?YJ#.R6Z&)4'P087C0W;HGD&>*V7F,DURW* 5\UD#
MR5%,2AVF:#S:#8/+1[T7U)8-3!X-FS[[Y_B@^YKL=Y%G+V1DY+<$?+!JQ%P^
MGW4V^[ WY]C[4'_B27:V+5SP?="U5T1KRWGW#*YRCMA0BF50G7N1MANXC_\\
MW'#>2=FUU^Y.VO$NL\0_=D^NW=\<CZ9EJ A#;ME3UT@.0-%3\]!H4)[8>9#D
MO;01WB>T^BH':@=>0RI"GV)049Y%&H]IABR<\8D)4?OB+%6F AL)\8GVV#5$
ME0#HSB+U5MVL%M$1O4$2V!^%5>6.%:R#C+_GM+%2_37O4"YT<I]2-,C]_G(@
MGKP"5A'_T35%N818ZP*5M+3+]&XDEQ"Q?/T49 0XR*;HDDX3;HK0^B1K4+/-
MR4U80EN1DX"\JCZ35S1!4Y^=Q]&330P88+\<F#V6RD<OAR-FOX(+=Y V3U#E
MJQKZ>*Z@.*,8]00(V^!,6HS+J@ED-X8%O'^]J[WQM,:7OY:*^DA:_&$LIM>N
MTK>EP+"O]H,^7HS*?Q;JZ#*?F56M?)GUN3[:)S+ +Z)^ZPJ]>\[UVN?7W\UZ
MK-G2.>0L'*F1 VH>[;+M\&G(Q@V^!ZFT!FG II4RCF,R>Y9[:<BU 3Q6%RVT
MK%RVY)K QR9+W#?P-D0PK8GOV[U")6X"NAH)TT4Z]U0.X$@H^&$LR&L9 0(O
M+4S3X6UNTQXBRN<A=]#D(3C)(9MTD8*%PZ9"5EK4$$4WE+E*]AY:0UEC%Z'F
M165W"#M3$;HR R+.H[&OSF;M^(T/@DJ-WC:>-O)TL<>S,S#:N6<:Z21$:(?1
M'M] Z8$#?S8>#!M!=._0V=_PJK9KH,.]=UK?M>[-:NO*VJR&^M2HH=@L[X"4
M'7>TCCU6O?=6MS"V-&R1^IE2NR/")C'KBZ_X_ Q7[1XN#B#<_O$)LZ' Y<MF
M]^4..R\7;)PQO>?\8B/B;H&F]+4<"+/1^A+*T@LX"NIVLBLQ(L1;1*(/984=
M2RV\O6WQ;YHQY9QF J^V/!V?$DW>F+JC[H..$$LU!WE)4T/-@U?#&W79GR97
M-S[PFS",#EY2E5R#VMOD %>?4V .8=JHRB3?AD'*>?KGTG8'+J5E>)]7EZ+R
M+[2-V,.E2_LG@LQ!XY'D:R*,@3,BG6%QI1&=;&^9[SY',<IP\.QY#&7FK.#7
MA$A#/6T\,[Q.8JI=W*=G[OGT?#YXAAO0&A9Q]<EYI9"&NMM&H5N/;TE:59BT
M]7#AH1.=1WKM%O*G[)8L'5[GQJ8GU]4V-(2--N;/5(4\?))A>+K*^L)]X<T+
M5EMZWWRP1%9\W(]60NT@>8+S"U2%Z)%Q>+785&0T5"B@Q\N!RT:SJ;)-KV Y
M$"SJU")YP_DX/GV]RV/22M@=-$!Z[<ZIFJ#54%.O;(3LZU\*-)-RMZ:"$Y."
MJGM@J6>_0MWA]4F!]3U.^]P@;$O33DIXG#*_8=J[DH@5'T/41+<@M,)YAI4R
M-*7E&%,+%@GQ6A*ONGZ)DP"=3M$E4 Q<!)0-I  XXB)_B(;P#W,LR1?25T_J
MR]9#]&0!R*(RKC9*VZ<(U'BD>LFD&R<F.H%A>4ZX;-":,&2C$5J?^W&2<\\Z
M;\GGGSW-00N[LGUQA5$=6](MKDZI=[!6$7WDP)'77;,DA\=!H0TYU&?#X_K^
MNQ]&E@1BWT6+?]E4V?V:OE!3\,-C=NZ==?&MT5CZ7-+O'WYVJ?RLA/1%A-E6
M[&WTBU X#BH5J*1.7T:?GY12VG*P&] X[ :2*FPLM$G+9BY3Z+]@,LU(IC-I
MF),J.;GD+K&%5%\Q^Y JPM<S41_T6TSL!A@7*W!!VM 9IG$_70[<D .7\+IG
MB"(Q =81J;V6X D$(5ZA;]3G.\H[4V,N%F1 &N+)$R"9&AE)$658>N:.'GT!
M!4I^N-^L&AJ/=G \/V'[,6HR+WWW[9 Y'$:9N*O]F.?FCI8@@]J>PKY!?ZIG
M?9==>IR3?6+4/<*%ETD?][GT]8O< N;O!)9O?O&G[G+"_F#J3UG<&/ T;=O_
MR^TK(ZZ,-U:P$LJN*9Y$K0=GBHO@DYR8K"26Z/3%A.9%L^FDC+CHL'*X*O2*
MU=9TMO]%SDXLKJ>5$+$CQK-)U'Y-+?'>?L<OU*#\T,D>EB;Z(N8NMI9ZE[R>
MW(_08!R W@A-,I;VCXE'K*'OZ4)\:J-*,RN]0+L+B="_*]L(XTY#]+=6L0)W
ML"JC@D@>/0$.?[_'QZJ3?+LO!X/YLORG<)KF"IC>[*#OKU>X: -&BBP4@!*L
MF8C8P+0(;VRKBXU8^HV($ Y2[=6<MGL&MQI^':"LFL,;PHK,]P2_)YS-B?G^
M)H:';TQP[8IZX"1^<LTXFW8V8\=NOO+$T_>/[[\'WF[Y'3!_O!<98FHP7_33
M]"WJ_-FORDU7#T\H?=38-\@??8OF?D=SS3%RX';\&<E1:1'3%(X\!)]^(C&5
M/AGME:D/VR3:\VYA-;'\+V1[",.FKX2I)\$SYH&UO55VJCN07L_"SR]X09CT
M4LAJ/EELDURG;GGLA=C&!-87J=Q!GY^]HPW3Q<G2PCD>5Z>-;-;%0 N, A!I
MW"L/GR'2$+6#Z;41-LUD98B5<A;<T LW-+. "/M[.Q9XGQ>OE#\?0ZV&7$LC
MM^3D,KRX\>3F[.,.>L<9)$[\WO%WHH*16DO+->4K39X?0/Q)SV;:C2VZW4%?
M0F@-P4,B;)NQF@?L '[DM3+WP'5\FM88UZ9UVM<%Q@I>$SY$<APS"U<F;LV1
M5@HG,9J\(-Q5_]!<0G8Q@4# G3/.>+/=Y<G2)MA-B$Y@A<@!@$L*@&@9#!RD
M=N;E*R@GU1H95\DE/@@$6SOOSA1#9@WL9KI_F"%"_"&9G:?NVMM\(Z9IA*8K
M>RE-MZ;'IL[F[GF+ROZOX9E&O$^\E-A\(=MB,T$#NE]M:JJTY?+]3=LY*JZ^
M)Z(M+14\C38L"8)/GA.^DJC%0;:"^9R,XEQ+(F-3M B[9HA8XOY]];E$I!.J
MS*3ZYQ&#H]>L[MU;4']^W7;L\2A-D5/EB@@]0HII@.F5)!M0?ZJ=7VYSIT #
M9O$_C?9>E.97()T%-FD434E(%4D)+$@O<1<-?7_58Y:MT'C8V@;./\S-H6<N
MZC5\AFQ"5&87;/L9,NBN$&IZ626?0[F7:$5A]9-AI6$W;G#)M/!*4[.ZK$<6
M^+ K&9;(O$VW]XCV3[5Z'QQ- W[EB6C3!%#$UV_#? [@AZ3;X0TFF+NE=-DF
M>$A ;QEG["L=&S1<^;"*J"Q@UD%N@0RHJK!LDNL]\J"(E5R[KSP"%8'PA%9,
M?WQI7UE;KR>.<)(@#JG[^IQ=3[PQNGP96GBQ.,H4_7,>>Q<!GJ#\<C>7K"V5
M?6P0/Y8# WOA!&S#/3E03I6VRH$N%^"<' @/EP-SUE_D +_CB!SX^AQ=9T]9
MU+]" 2\64WYXX[OWKT=P<UE2M08TO*N']6L[==H3*TL<HDD,PK"2K("YXRM5
MQ"6*\GEPNE.VII8N.U*X=-)7#CRY,2H'5OHK/IGY2-<IW9*6E2NN^"92#B18
M6<J!^\]D?0IV-A:HH /-V5ERX)TWRP4X2_G_^6R>61-PW6J5O.3ALUG^^OJ&
M)7=?'JZVM'0=N?C)1R/OEG-^QZNUKK@2NCX\I@3&9>]'0^CJ"5LY8!U#K;QY
M<^3\C[OEQ@]=TSA(8U6?4X%N[J>^A5UO3-/=@(_[939F5]4S,T6<+YUZLK0]
M3+8<:F>KH\4A,*94@H*SA*50 Y5A6CI>H-$[A]6#G]2YVQ?U$]YX6%0.S%?6
M&11EMWQTEM)*#DV'E/K[?]:Y<H6H*;XDS4?I!9(<:8+2M[,K8 V>P&DAHPZ3
MS,4F?@<'LHKAX),*V3MMVT*V9/9$G%6LWH&<$^# @["G=C[W#X3FQJ2@_FZQ
M#,9_#=!94BPXB0H6GJ<0*+/W9+J_;"0N7]RDJ\(H@O=!V'FEKS(YL+&W<T;A
MD4FI$ZJJ3V( 3OHWP,FX"@7)SRR+@/!'&[K)YLT4.;"J^ MVK5V>ISK#/J*4
M^-H\?S"H)IG]D;OC:OAFH7WO^L^WOI*R6$(UK 9<Y;D,JT.T/#18##:D7/[G
M1K$]KE,=BTH4QEFK#07NP_;D"K\[!Y=_&@KWOZ/7()8%_JT5=*;H^O:_!<Q=
MGVC#V*6OE$2C?\]>MGG&5';'C@5^L[%9C/]!H?P>-KI :9Z7%=!.A-,TF7J3
MT5BMV3KJ'?*JOEG4;\0 %Q#=ZE$^1MH4B>:@58C7!SEZCBI)R. MU37$!.?N
M*8FO,"#0P;,OH[7RD:&X?)W69NP9E?E5=9.?/U486AY]>\52[V7AX>;K*P][
MM.Q_IVQ^]W=+?E.J5!&L3#?8]Y5DI;>)V<!OS]%"UYN LAS8I!;$#VF*^:R?
MZEWSB*><[6%>FNSWONI!Q<N>Y^/<1Z5_ES',[*W.]K\604&+IPO')RUFK#?M
M.O.YZ>ZMSX=V899/G5*J]Q1W;CF[^[#:FZOM&R]X-VZC#_S[]KZ%IO/'/4BH
MG86\-I#]^QSR"A^:;#]&'"T&* X\@Z"147&_0N\XN$-]'L;4C#DYH!(^X$M6
MAFE%LNY(N+R%9D()EOH>@(W!V*#^J #->+06/NDE7UU;,]F10&^=7=,JP"XC
M]Z&V0E0JTH82'"RRJ)L=,Q)0.-@UDC/P37YG*E.C0"ABF^P%9W*$@0;T30&X
ML8IYCPNO IP.]E]X&&%OI&KHH>[:Y;&MGEG_*MY]X]U]Y%6ROACOI#=+Y\./
M*Z)U-U40J.(%?^,/(]B^];F#TWLU.50#TK$7@W+@XI(1U5!BV4M2@]Z\Q:K8
MT5,-<Q(DYYZ2/'L( ?@5DPZ-I<E,I8G%Y$RS02&(27G 1K,0&I(5 GSBR HP
MATU;/MY^!,RYC40K4H,]H!E)B$,:^E##C+-*N?-&XU4V\_O&@],[6?WV:GGY
MSB>;LH6R16'LF]3BJYKM-K %6E+T0+;JI!P("5@Z3IG<(#E '_I+#O2WRX2*
MXK29M?:?[7(Y\.,^!MZ$D>;CIP_(@8I(:"4+;RH'?!%+Z7+@<1H0M\YK_XK_
M3B.VMV-^K=O!FD)?E -%,1FQ3O_Y"ZG3@/+.*E\.?%+'2+>;9D[VDT/>]7FY
M4+:G_.MICR\H1<S]U5%!^;1&#HS'%1/C8I/?4GX9$*A+2C2I32W].9_Z:_L/
M[-+J'-F?%2K]ZQ2GG@2\7-;]JYUP&':*,7E$*_4:_)0PYN;O[]S%7W;UJJ;S
M5!PU!I"< V?C498XA*%LE\3I@9 ^K0YY"+ZG+YT()6^"R'F0CJBA>39Q)P?/
M5PAM[4%VP0:P(!$,6A!ZSK9$; D8IWWRX=IDDHW]X2DN3#M4VW.^BV!\TAMR
MF +Y9'/>ZU%H,G/8$DP6SN1 L3(3U>=#?K).IO;@UT&2"]^(I@H_'Q5'PZ95
ML(9'G*G0?(KW+#1H.X1I?S.[:H3DUDTB.+1\4L#G@_+Q@HW0I0>5H8-!*B"2
MMAJYJ>),QCXO*'KFQYQ$#F@5:%XY_!4:B$>OI?ROO2=Q5M#/!W+@O3N:GX@6
M$UAU*K*7G1Q#*8,J/4.9L9'=WJ8T]U\V.(/4E@[+NE#ZTERRW@1-6^)9C#/9
M3*1?MD.H$S'LT:,)?E!T.J$0&:.9-%5G%2,'#H,#&5M+G1C/N*Q4^WQSM^I,
MAYM5(]\J+\^\=9I(@X\MB+_64@^!=Q=]IWY!@QR37?UDW7":$2,:Y+9T"+[3
MA*Q$VIJHB/.C^W.PT'(%;TDH).(Y#?ZRLM()T5M'=#QA=AV6.'JLN\X)>V3M
MI];E.6L#%+!Z *4[B=I=T\4P$&"-8-Y;A6#' G,1(<+Z5//;$4BGX@EL[<P]
M@6<LGR6F),S+ ?TQ.:#+P!83J8>AAF0;@GILBXGR0%23 1[/#Z-?D5B(\BAJ
M0-RH"VD:C!5G@[YMG2EH0S("/GD0^DA#-SMA6_Q=R^G$&K9^D%XW(U .J%[)
M>!9>SVV_]7C 9 C;+['%72N:R#T(9RZY],Q5WOC1$N?<\F!RQ"@/,TB',8:R
MST$:H"\G M_B@%H!WWI.1#2CUS(W2$QA&E1Z-+DE'9P4-'!FT]7X@Z!;(F',
MWF;=)V+OR307.!V<(Q9RR.O!DCH!;P4ZD^%(.O#LP'*4.8V]$7'>Z["&*^4O
MT]MHY58K@/0+FA47P&Y+N[GP"7PJMS1E<R-44A=6"%,.@<FW&><@%4[.U8XJ
M&,]NI*5< $=OS7G&GJX':4EU"'WB=;0V?#]V2V]4F7WE9DX'BEX19A@A';+A
M!O-OE$(A+13E6EI*[M8:R+F-I4G IN4B$FM/1I>?T50*LQ#<Q'(<6V=H$==*
MX.OJ1S37C_D&;:B!5GS/*R,^?8^;E .:I\-]'%'T:Q=_L"3K;,5$N!#B'8$/
MH%LZE\'1K?X+">1-1)\I8AI/Y,O1_#PII,9?GD%M)>T<J(N+;I8#V@SU(N+O
M9XA^XZAUKQD0ZXZ]Y\KYJIDYK"JQW+EZL$[AD/$1!.N;/6*Y;!!E(GW"NHA?
MVP&FLVGZ=KP[%#4"2YET%AY2X<PNESCUD;? 0T)*(DH%IBBXJ[85V:@A>61B
MQ&G93T')RUC4 _LY??T;#HX^>8_OX59SN?%QQ1!-_#M\&C28P^%->,3<0(\S
MO4@7H5&@9C-J&=3)H:T=@MV:V1YX YAWH@N%@"F<F+8</GU5!MX%LQ8N6/QH
M;-TVZ]<3U9\;=_)4[]25DQQ*;6>SS1IB.M\\D2Z)/'>S7-;K_P<WNOEB5X0]
M0MN/V+:'H?N<*"4\FX_04,A7CQZ&3:2@:;M[!=*K8OA3J$)FQ1:.U3LL&#)K
M2CY_(;4*Z6MD/8,\_<MR((RB1-H(7AQ,VP12VA&?JT6"TDRR1><3+NM.!7FW
M2P7)$!;@A-N8)A-6*W.$'VS9GE62 W!4H_]DMJ-Y6I1?5*!"$],21 V#S'/=
M+'X>MI;"INK)WAGFW*:$\E; "JA2ED0OV0; "1Y0<O-"SIEN\CK)<BD-&0<R
MEUJ8:Z&C".V*#R.I0DT]8F^K;.O+[EFD0T1YZ&(#)V_X4ERT7P,81'WZ)9Y,
M)3E)*YDJDN-0!5D%I*38#W5\</W9NHA/1+I1^)@-8Q1-YJ9PK"9]-HIG'"8'
MU%&F.+)QKT0'6CW;TI![XVEC$6K=P#QZU]#1?H+5SCIC2_>^V8JO#.DSAHI*
M6Q[]5@PED;P+IK8Z!E4*FM0XY,T@JQF;:K(1OBBPPK:B$+603TZPD)YF>..6
MS>VHO;WLQLP'Y1,'?_IZ]U3:9VR;4,>;2;0:1M'--I]&Q>FP&83SA,N?PC8'
M^TC!_'0$=Q\'Y<!B20M)7G%@@S@=,F_%V:PE/CC8)5M/6CL@4:V 3<7(UY ^
MIUE@'-U68 M'/ D].<8-3&()AL,[1&<A>X4:/"?&IK)JT*TVQJ0K-=!",E.3
MA (U[\YWIK"4F%L]E]S#L,:2.(J0I32.4DH6<! ZI.4T]2JDD]Z#YR-P.QNE
M,R#3=V(EX6LQR92U$K/R,*X<X%2BC+'.CJX52HLI>PWFYR?AP;ND*#EP[V"'
MC"W&+KH]&ZQ9<ZMSO"OR[737M4=K1/8BM#'ZZ_%J.?!"FB.[-V'_$ZE [BWU
MT7+@K#UZ[EGF/KKW+YJYEXNNY/G&?Z0V_2JL*0=,K5\J.BAT1;$X2S _@U!2
MB)N+ ^BIE90Y9@^S_#;Z:_D[RM1V[.+Y%XA3BI.E1Y5<UAW_5SO,(S06:!Y-
MZ'VY873\@]6FL9OM*C0,F2BJ!,A(8L[;[$;>M Z4T&QBV@0W"327PX7BI_!.
M*/E4?2_E O6N(G._0=0TDE:1Q(8!%KSF8[AT-EE/#MS9]]9$V[#T=FV@#F?Q
M4DTI,8&#5H^PF]7U'T.AP?8DY('BCL<R=B8MM=/KX[$8<2?FRITT&0FU:YR[
MJ$"7@T@O^F?2T:2A9GV3?? U/GH]Z2I&4]:UJ[29IX65')7>4P 5FI]4+LQ'
M")(J00VU5YIL*;8E2+^^":8)/$W:,-Q8GW3AC7O7*H?/A*&U%& \/X9&L OR
M58;'NTSV ETJ0DW).IKLA+L<6&XA!VHJI<_0\YGDC8/37R[<O#:_E*Y@ U&Q
MOD(5R;KJ]:4*&/]=,:_5A0_U#G=.8Y>.O70S.-$M:V>B[ZFJ)-1U^RDW;[R@
MU4KN=A-D*'=@X"Q_::M,;PXQ?5SEP+W97PBPT)3W RWPPX+I,$5VRX>UT$&!
M3E%:; 1R8'&%OQS@6<F!UN,K9]Q87RDM=ZD4!5%,//>?Q[T48HF5K""/NCB%
M@&E0 .I^H]<FBH"2 ZMW.2D"0::;^'_IXB;9+$,H[/>F2W_P)-[ E:^Q,C>)
MY2B:RQ:HI)&1DA5P,DAO,>Q,L&L*:&4B^NU>7H3,W]93ULI,B/>-*G?)AF1:
MG0;P]>_"%GAL8=!!K\&B?"PF*[/A<7BVXY6:,&FA>M9 ^O,8S-VY89N#(+.N
M_%.8/V5HQXZ_Q7(@]%9)\M\_3;$C+M^WSK--'#2N1K:2!LB;)_CWI%F" O3$
M&IXD#VM!NY;IQ?[SN=_1ECWM/G4K4I/[QPY6.#UZ?JJ(;N%3TO>Z#.-AC\.5
MUS1@LR<7)TBY+/"H@E*,4U3(^A(G\)^'[-8%X!8UDV5;85].(T.F!W<4AQ9H
M@)VML4TZ)_I(RF#A(3"Z30&"]96@<TN._]$'IR4 W'Y31$\.LAR\5 <9_^JR
MJIVDK'$:ILA4;X:3-Q,Q/F!! ]@SY X29M]N@6.A9 Y%DV"%$5?#*_BT^" ]
M$'U'D<V)E&7,[>,CFWJC\&M@R];<D"32R6MEGY@)(4^LGT#!0IQ"*2&T*D@>
MA/.\$W*@I:V?-:8KH$ET'.3 UFXYH&;DH_".;Q(%/*I8BB"$Q,7$0':T5P&G
M%I2?OO2Y.:OQ!?HD??3S(YMXLCKY,UD7'EURD_@T0NBIEGJ$ <.^Y#/1OVV0
MC=:WN<+8*40DR=9!#LG,=</P;562<S$73CCTIG%@:I9!*0V+;EPQESV0LQNU
MH:_RV^O;L@%ZFAP(QJ3(; 88!,&TFQ 1+X1MH4EA2 LV@V?"V*ER2^)*.FG.
ML4DVC&[!X77&$&OFRQCGK/.*2"BXC #BFF<K#@@S]IV!5!*MS""2H\M,.4&8
MC_K9$I3ZG[:Y279$!,AN!1DH,LF6\B," :TCAORRQ4BV%,N!#T&LWJZ&TA%6
M%8MV*:[BE5=FS/VK%2O]LH,SK]UW;SOF%';]?T3X#]HMR6F"$+%NW!'UI#@4
M$=P4FY4WQ0TXL'M3]>M7GO>EE6+RCW7#/S94?1/M1;@I5OR_)I'OP 7D@7CA
M#JLSEX+*GY]ZJ<WV/&_1]H>TR,*KW-+5?KNYB7]7S7?/-V.5SY$UK93U6\'!
M%'MC]:A5=+UF_H'KW/3]%W]6GGW]+N7T$9VPO+-24<B5&=M;G906Z2LY\$3A
M/R.6'+ L_UMF%G @3!07,\(U2UKUO5:K+6'UD]I)A\O+,#Z7G&(>G+$B&S^"
MVM<)(N\.J3O;1XV=J]E!6/W;8@'6^LBI:]YAO<EVX/U'K\^MJ@H[<N+&,<\F
MU[FE'&%5G+IB5<4B62*1 EZ1 Y*J0IG^=+MTM2('^,-RX%<@%MD=%"(YI&&M
MF R#!:8K3/Z.-EM8M6CT'QWWPTM7#R,4_*Q3ZL*3 UG]/S]L^TI]5BC;K*)/
MZ1K!PB[9<N GXOY24EU8= @/M7X@C^.X,J?2Z55MA.NG,T87[Y7Z79_)6UZR
MIT/Z]\S.4NR;(!ST]VB+7ASE*_KB)^JOR#XGE\LDIRX['&L%\<;W44Q#[LTH
ML.?(Q% ^8_SF^?47!BTAFFO/W.QJ+N;B1?7:RBK_0YWK-]V-""/_7;K#5=7;
MR?$6MC:$,"$D*FNETE$QG^XFJ 75_@HVB:F[.K?]5,Z.=>=,PMZ]<=V9UG3_
MR#LU=QMS!78$:OX9^C1-=FGM/YK4]Q5IE:(\/O!3(*HBZGJ6CH"+8LSMW+B"
M0J&QO^40<2;8<_U?J1NW6$H;^Z/7:'U413ACO9L1/[R_LL2Z-M*=?IJ5MC0Y
MX(7XF%86$AQ6VG*V^I:5P+IGO6BYM1BPO8[9LJVSIW)P_K=_R_!-;1HQ9T?'
M/0X/:ZP\IJ%B6O ET\VIW;0.((=+O&',TC9BQRGXH>A#I(+-)BO8)/XN6:L:
M3A!T I*8OEJ;%9](X=WV""4X@.UXZ0D_?YEE^A;H_.0"2U/[IWO!^_%YSQB,
M.G:R?B'GZFE/E;'2Y+FL+CLKHX.>;C[]@ZX]4W;%_82E7X3 R!.&<;4^-/P
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M_K>Y[=\-!LZ7_7 M>G'SDI[]SEULKS_&*X+.^:RK_M*HNPF[J^TL^*6_<+K
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MW3FV>XV*DAMGPB\*]_23U")O\T;()TB>T-?ZPK@** ,1TVS<ZPL>+^/E$!Q
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M,6'9=M)OB)(L[_W 8FV2T+0(_^HMWRXP:%\%6=V+*.OT(U=I+9YRA;(%:NA
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MG;O-3:G#Q8)/30FE[H"B'8/LHR2L!Q6'QKY\K:[)PGR:<VH5*0PM<G="U(O
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M!&+;R;(@,KG1CI>SJ<V]INAVY#A.#E)J'\6P!D"I(C'WR4^YNC@1.1T&;H'
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M,'.Q+VAL9 ES<J#!UJPCX$7NSB^-9?G5P5-L6NZ;]V'SE R\@=:*&3@P[^\
M)G;P5J"'^E'7NK.,O(XOB3E$IP>,PM??RN8G_N*\/M-?UYCM^*)!XSTV%C5[
M8FKHPIV1<^?.ODP^^R%=8Y*%Z83&.;HYT^@?A@3ISAX.':$X2,NC54R$XM_&
MJ_T=O/H:6K86VGBX^PULOW#SC:2KW_),79W3^2R#C0&Y6X<LEC7^7U6(_ZFQ
M>9\FD?]]<2)F72_Q)]:GL-Q[$9BDZSN34_W^_V[7_7]I[*5W_P502P,$%
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MR6U-96T"1!?HUN&,YD:%=32E%(PGBY#&,!EDMM)3%';@4\C&=R@:8PX?A88
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M"YO/#!%7-5[>\=TGN._Y6YFE=-."B^1SB*7@-X\OJZ3,#U&)4G,0ET[]I>"
M],FP8B=T778"2"E1D5RN+ 2HX.81.\:,?>MQ:;]A;\7A[CIK?,@LG^:HW\$<
M"$D4UI2X,Z'"4>]^>[P!]'2YQZV>U2)KE_'V<D/C=P4<;7KM3KAJ]4ML2UO0
MYNM'=X:UJ=W\R<7L(D  ?Z*,H6J]K#';^G3_^1NU.MSTI,=AS-O>)4E9Y&,[
MBRP*->J/2[M=6"Q.0!F=4??E"\=Z\->?NJ_YQR3BPRCAWV+X%QJR.B__6OV
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M ]>NWGVL1!P0O&K()*.K*$/!ZX#.?^\7G06-;[MX$*(DYKKMRZ8%N/81"RO
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M V%WRX7)>-_<O'BN'(N_))HSF9>H:MA/L68?H-5*74,. :K/7^PC+C#2"UT
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M#LF=D!.)"@"]! A<,A%2%N?7X'%' %8<7?/TY#+\+M*4< "0>$@R'XQ,D"W
M)YX$W M*)O(W %]&U7L)VVPU7MPBFI PTHO(N-<2/%C,+\F!9/VJA>F6:+)(
MCY'H#C%YB)23VG9 \4.^OS>W-7$6RT-(32)M^G[2Y ,FHKQ3:CP232*!:T?>
M](:[N3*KINLO5>S<F^.>&7&9X(T+P>Q\1A1ICY;\7F!QQ#!J*XRH16IR+<A
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M&9RU,+D[@%ZR.0O[PSD%J48X52]\2CA'U(*B6_(W A)M*''7A@0OWDCHRML
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MS$R<H'V:L<NN9E3=?1TR6\9>>C-2>X9@Y1C3(89MK!F;7U:WE60Y\2=:=+!
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M\]FW_5KT9MJ>8>?2X,I"F?/YVRHNY'@?M;<I#+WB9.N^M>N*P";;=4_K,5K
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MK+V^=/3]_CZ+=Q^[E!O#"HZ<3]WTSO[<G63WS:LF.$JDKPZ@E1!O)KK?A/9
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MI62)D&GBDI2"K76[<$MH.&="I--?1=])[&.;-;_!MF=)<5ED0MA3PA8H\HG
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MW0*^5^XNU#K %I*%-C/-/%;7BOF_:G@4-DEIR12\IU5R.S6;@$[%6OA:/Z6
M/,)?%9[Y1L>++/=[%CBVF:8:[?[Z[8EJH,KO1S4U&0=[')5__F,1E?_[T#_P
M5G=UU,;%Y:C>KX'JZFUA'.U7/VGM\VPSOG=;V^ ?[A99 IRV3^?'9E OR4R:
M#+Z$FWAKIIJT9A1OPW,3<MX^).Y%XZMX0L8=@<T+?$$+?0/(NF/Z@BZ#T4#'
M+Y+7>12^'\,I3VFK]0>"GUI4EU$EI&97<&IZZ3YT%LM%W$5:@40&#Z$ZA*_B
M>S<9$I2YQF:Q'!CJTIMK;W-FYQYRN]2G]^9KOP;M$MO>"SSSM3.;V ]8+6M!
M''GQH<"^U.QF>%<<6[\P'P$3FK_K-.\Z'=E.U7<R3R>?!G^SXO'C31R-^<:S
MI5#N6X2*!4D>8RXP1RKTV6[AH=<PDAOW%^/GYMMR0HL,6H9+JS^AF?5S%1%%
MD*.EG7Q[\S1/SNS(FX8L]OC1U\G*>>4+-"9'&17$42%VH"K6,6@0GY_PI! :
M_XL%GU4''<8H-PF&- &I?]$$Y33@]39[F11K,;]V6H6-B[=UY>'7MK=H>7$9
MS!%W24Q6MG)S=5]V-TH]P]>A>V&H<Z6T3$DP()+SK:&>%7,!"KH%ZN605#G!
M* 4!*J:T"_MX"(V/9;XE*1/"QN#R4-7Q:N 12UNQ=I!PEDN3G1#M&'P,W.W%
MNYN@3](]-N[O=GHD/;@9=O2PE.Y-.X_5R="UI5C0C"PXMN)"6"W,M;4#C5M1
MZP@(4(D;V3Z?/*H',FX] >X3K4!D%9#H#VWCSLL)=@-M%;Q9U=:3448!]F"@
M'W2+YQ(NT12GI^L3LL?\W*Q[ESL.YK:NO@)_]6/=G@-='J0B=:FRZ;>_D ^@
MS B0M'07G)]9Y.*T)E#5)2D1B+3L;,06.ES4*3$ ='F!+12VA&);\>:;NM)0
M*D35"90VTH#Y'+K6TDUJ3@,3$VPM@?E6Q*:NQ&$NC8E+S-&6V,5-0U#EW$(+
M8V-(H]UR#T]2&X(]N)$C&UH-UR)+\+UY-Y]JU4)1V&DAW,[QK)9 :OQC(#O%
M(L_Y;;EI86I$P>< ?.XIX->=IP,A'X+##!+.5ET:B@E_OFIR2'.ACU9'),D'
MK5&X9Z]=D(Y.1QI 32M>!!2D+%%MJW)]H==%^!2^QTVBK< :B@&\3O6*-'R#
MB%J5+/I.@HXPVTR@!T1S2Q)-0QHE_*KDL0DO0>%/77&-:WGDI%]$Z^3V=J19
MGZTWN-X?;]K)9V8A62L;!!Y0"2_&BS_/]+B+ VT.@KCF>36\W4]R(EKS!5(3
M3^9+QS?"^>CUID^>3N=OAY* <^9 0;NV)EARIQJG'H"W1LL':PQ6<3M"=(X#
MOY(7]RUN<0U1=8()9?],-7DWGMZ.QE&MHC2Y_7Q= ?.F=697J.C![_$5;WS[
M4AH4 B9R3?. DI:>+WCGI;(]HD\J6<M%]%M&A#50 [80W\5+2)&TXJ$Z>H(L
M11'3*S"2V"Q_@Q;Z)OKK@<?]@FBNQRT0PPZ@/ TF;5HT@!C\1HHF4GF: QP+
M03=S:DBS9E<H4HQ+I 2D#73Q*39 'XI\-C&* -%MN;@TW]":,O80.7[72( '
M=P"@).)LU4.>C4[5UIM22ZC]@\N/K)2&/JQ:J5^OLS76SOZ=H%5=Z^KN1X%V
M"W=CKK4/TF4A/:K  8I>.0;]6L(,$'= '+ZS).]N!JR&F,738I@B@ZO6C]Q*
M0(+K&D#5=OI:"G.YZX[ D(M;WRH)M?8H4@*#JPO<16[O10?TX03&_*#9&JJ?
M_>N^GY+86D#72)B7LYXH5W)'8 Z.JAMXL+'-[,ZJ4G*B]:4B7D=7 D*)$4Q*
M7+:Z+:E+% ^3RV3+ISZ&I%M9(ED0D3)/L'L!U9WL^0E= (1MMVBC[WENME(_
ML3I;+USXJ=5IS9]T).XGLA%:8IC$4L7E[X4&^*FJGE#KQ6+!GEZD,A95U75;
M(#M&68<EK1+IZA>%%3N !@>$CPGGGTWD9-5QNU2FV8LSHPH]C:@;/+,UP3I,
M;Z2,I%W\)")J715MLI93$>02X'XX4'W)^Z+Z9">L<U]G6"O,^BXYX(W=!.TN
M*A1]!ZU$7$?8*A$_&="UR-+@05159Q&JA9:,EC'Q<XA%W65(4ZM3'5R@6UQC
M$]?3>[LGZ'NZ+3XYH>Y0Y!>5!\++7;O4(!MWH/;-]7Q-<"]5=ROBTOR!*_[V
MDZG,_9-W ^TP#H:=Z_>-C<7%383U,G0(/F,>;/F.I0QA2N-N/H5-X5]_\$S@
MTRLRG^:H->H ?6C /15H1F^"I!R[&V\40Y'-;&(9T'<<7$N['1[-41C!6ZM3
M_.H&;9VY(8B_Z@=+-%I;9S\^(L]\ E'\M-0BHL0]*-HZ@GP>HE66QI[G9;>0
MU@J<(#0H@Y!"8S1"'X2,P=-0FY[;8H'R%>FF?#70[#85J3TB,.T.;YA%^GNW
M:*LS@)*4%T\&SY$4S!)J7AU !9&Z?@M2]0^HZZZ:3B=W-LJV$^$0-ZR4<'S0
M=A5XS0V8(1H#*"9:'B_KPB)(J=Z5(&4"<FNWY;SV:<)A\'M>L5]PO5Q[LL">
M#Y?#9S-5K/53J%/EW!&#TX!I9C0ID%0<;-V62_J=S8>GH:O_#*Q836JRWHE$
M!'-4)>;G,,18V>L,1O(]XD2R_@)U0+J=INT#D;BJS"TKC"1K4AIR3U ]J<E#
M#N_]%T3AD^&8@/W )YI@>X[DMR(H=T0*2#D=)E(+#$R(. H?-C+^/C\DS0NE
M@BE+09 YJ-J"-*@"$Y,$#F-Y^Z"&@"I@=OQV:]?=ZH>AX0@U7W_HZE*'6^[A
M@7"RTJ1O;0IUJ+T8DX6A8MAQD^R(A$=+65=B=/[[_:UV"6*$&<A-Q.YZ1BP!
MS:-J<%P@,C".[HX0PZ0)+KT6\+53Q!U]'HGSM!I9.Z6C<6UT54E%!1[<6Q%E
M4ZI+$KQPCW]^*HBX-6>XC:CJ)MO&=B?SC-?THLZ)84/7#D"T4D)8MV@#A'"&
M:.50^S\6^N2X5C3T+:;ZM6M0*X>F G8.$#MBE+,*:!R?=KFBP9(;@78?![.6
M:CN_R_I=2)E<WB%U#QR_V;@-M&G6D)0WGOA V<U(W6I7+=S!?KFW5?TA.J]B
M9[<^8G>%7%$(-7E\7ZTD-:Z%L7</O$M#=0:QHHW'<@4460OT4!_7/YLY",HQ
M4K8"]X!^\XEE7)))]>_P.S54%=G7H0C[?OGTL,C"3\@4T_S0\'*AL]MK)9]@
MJ^[3,2&.L(L3.=HIW+PM+L!XHD6J&5.DW1T^K+7%H;O:#=EWI*<Z1.>OVN0.
MM][J/-/F+=%:-FY],V,)O6UMG>M#0DR>)LOB"Y(M[,L<-\.\[Q(BA1319E$O
M&EY#2N"H" S/\^QD/6L9?K)\S>LB'2"_+*:($S3-(ZW%QV\/<6W.-ZJLZ,>=
MJ6"%)YUI2)/-S=V?VD:)O!$8-O/SJ'3K,DV@)(8MG01O:Z]O@'*!S":28N/9
M,8\$-KS9W[B=W1Y/V,]%*S!N$BQO1)9.T)7]4 D:Z%NV)H5XG,3;AYI=)NSF
M<N0G1K>\K \S2<N\_%Z[J_)I7<)ZG=IDR\/;D[:F[<XKVQQV)WV=R[Y3_3O>
M&TAE>%A:;E[UPR.6<1;^60SCSL[?G1?HK=@1S/L,H)2G ?C(]@[]VQ&N:(T@
M=AQFW5Q[ZUZ-@<ZBLR_:C? DA[B/_=10T^TUO1;#IRZEL3^,[A"6<'%-Y'C4
MFI^N7?("?2B&ZY&X[%14NI?VS!=".U7W;3DUD,.6-9MU"Y[3M6)W%M:JU$:%
M1[*+/HWT6T<\R*)LK!@:&FY"%/?\(ZHUO[_APF6AIPO-;/*=:CEC7SK@?*<]
MI7%;9)F/0V08EZ&4*NT/O&558RZ>Q,H=QT>WB+;U.,ZLO23Z-!AA[#9ZXLN3
MUW 5@0+DS&\P2XJ*O$O4A!Q:LM!J IUB2):71Z<]]?4O(3=N*1B>KJWW2&CT
M]+<*9COEXGBD38YG Z^TFJB>ZM^X1>/;^T6C'5+OD0H$:6@_H'JX/QP5QY&3
M:)$%CT'<^?Z:&F P<^V#T892^]#:ZRSV7/'H]3+J"/M4X745;PWJ[-<L7\+1
MSVR+O>G.,GQ"F/"A2$K46Q^:6$"X#J&YZ&0-CX3Y2_WA;E:M69F<4Y._%MZ?
M-0]P"-$::'2[FJT1D!>!V]EAS![YS!YA_QUZ)NW8W/VCTETG2961,ZSS+P1(
M\!!J#7'+G\W$)JWU$\?@FT8@/P\&R]:R"#KG$VIKAKU8CFZ/(%D)MK.\5;WI
MJOFBZ Z*/#H@@!.4^3D@8,3#K/N-]9]I7IUX1K.VZA]%MRCQ3M#P@=Y&+RY"
M&6-5KWI'L/_%D$/I!'LTM>S@X*_E2R5GK]#6?GOP5;[[B]\'JF9%E<[J#2_2
MDF'?+5%K(5<?T"Q></$9%.G<3S@Q5L@J ++OX':>H7@#//S33I8'J#CQJ[,8
MNW;P^66JB>4V*3/V6%W"_DBC50'V0/F2FS 7N1Z??0(D-^-BT?($:1[UHF40
MSM9!HIE]V%.3&%KPL6F-.4H)YYW^JYZ?;W G$X:]!BW>:,U8S'J*.C],+0_>
M>$[51CPI?2RORO-FHE8+T,"E"N 7SR-!(CI4\>;H%?A2>^*B1[4P00Q;L3I:
M,W#YMAAVX57-HY28@Q\&OZUVO_E>)G%C?'JCSA%A/.."B1)W+A<H_TN83U=E
M"^QZ+(<(KH^AH_BKAN$,.-9;XU+VTR\!^/#3KI9=B:UM*068'+O6%ZG7SI\/
M*_)I+?' ZOV]JV[0XN@ZJT2"#5<,6S_AZQPO,'P2)%(#NA*KI^T0!X#YQ.H.
M$]6#/1:IR#6U?3^I.H?[SDC*$>LV]K[9F9G+L]S:VEB+9+5TY>.7>_[=:_X?
MQXGHE :_ ]2(:[C++XX\>96SS^&ENE&QT]$6^</J6Z_UEI,N8U _-_<Q@+W#
M8EC:H"?-23$L+_AH1@W?Z-[=!S,#?9BIG+IG<^M2E3>;.X2I98T&E215JAR^
MX'+^7&$Y;,+'76W3%?S6N'=EV$/]&?=]PS 6?6X6 WUN07V^Q=5!JY,-GW37
M=G\X%7&4>45@GG/&.GG5F@N;G$N__K_MU?C_=6BO @&I8@BW53/8JN6"5-S2
M[FGTGEGTG($08'#1%PEN0$ 9W\9-G^.:WR;]LOYU_OD87;!<MWO]?>>O?IVN
MZ]1M8F]:*^)I$C$6K\QC+*^?0$$*)#'LPY0 GH:7\-6K7*V4IHNG'IW4>+XK
M."_X2LKM/%LMF6LNKPWF.O>D](4O;\_M-0RED>ABV),9E/1;[56]NV#:Q/*W
M,/AOF8#K:LJ3->V0$O-7OBK0FI9",FEDG:P,:'@?W&N[YO1HUY5<WU-/KAX\
M\J1*;=4M6'ILM(PP,['T9/-7'^06!??CY=T?@,U8S_R,DI-9BG>-#KI889S"
MPK#UNA<*[WS=.G;[*OR)S&%4'M'@"\3G92=8DE+1B)TB6\))2JNUF6!S2A.Z
MJBX>J8@EFO75H&^/FD Q/'0*8AU=@T/8W8/4"HYR;2^>EFX2[04#DRUH"M#)
MI?96:^\[X>L;79X':Y#CG]O:/PT@#MU;O_6FO=K6'^OM[+6:: I]I$N4(;X3
M5% J".TEKA/H]1%W3?UB:127@ >[N+_BSX"+2V61Q:1S(U.1VL9N.[%N9?X3
M8AAHU-#OR!O],EGTW"#?U0GO]UEJH>$MH_97BP?<!=C#\@;FTD, 4DN6:'4=
MZ-V*T\3'\51;9'\WVH-H?EVJ2!F#U/ZSB!9Y(Y8$4&DSICMM]<QNU>!21M5[
M!,H@[AAX(6 #\.NN8+?![<4\C#4*3AQ!JTL2$+&Q\9Q(#H)CGQ'[ZDN:UHND
M,)L(QUBX4+H6AJ$Y3_"M/RI\4MWT9#A8)=MZ'85K^+,!.R_]/J1(8FV4OS#6
M5&<63%E?Q3.]5@;10QU+I-P_4\DN,-80%=_SR(EAK:HW&QT-F(P-R+JQ=X\'
MS"P;\(UFS^CW<.'[9FOR#HIAWC5D]YP1$TO7X3=._0[1819S*2O[1%WO"R$Q
MS)X\1FK>5^V1S+YM7=<RLMTL41N>X@;%/6LB+#^WIMR=.=\S.-R2<]NZNBH8
M&)WJ&3GM4-X5]HRI&W5WP7^?]+@=2["YH"W'F3G/5FJ1Z,Z;1$W,\OA;5"QR
M+WCA.V++5!_>JXVD2-]"[$.IBV&7.)O8^&NG&OJJIQ\*9&G!C(WA;FCF K61
MOOUE/\&7KCB@\VI@)W6<P24B11Q4C6JB2%EP?;!Q"Y<41Y?MWR+1^8"GEM(8
M.3G4$J$$,8YW$]Q6-D!,GGY&OAE(2YBK%MK8TVM 6KPMG!1SEKMB//R$VZ7J
M4*1U1J+ <VH+BH-(SS18,\,KMGBR.Y!&I@DV0#94# K^LT$(?YMSJ0SH:LH>
MU);IL3S\--&SI]$@,.SI&T9B==Y!F^BS-THPN]D^7W+]?/3CO]7>XD_I0:Y
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M>+B8=H>IG#0A#XX"YP,Z1C@V&L1Z@+ <(*$'R&CF,<O2"/-A6YP#R12V<CF
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ME G,BK;D"TSM6L\*TY@ 1K1L-D[43M831<(]H/N HV]WY1YO87K"9&9C36)
M5;#3V?,B&4R)1PINX7DFYWV"[IN=F8*"4W;3=K4"T'I/A$F<OF@HMNGQ6G(D
MR@7M%>IU5__B'R/VMA5SZP.1>) R8O+.S=.3@K/JE,'"^JM>X::W))HPN0?6
MN-G#_D<;90.UWDD&^V;$ /8Q%FSYO&@9[/B02)4RX"@MP\SJR&![M2":W*08
MRV!W[U#K5U+'1JF!\,6SC'BKA6N(^1<RV!?<HN(1A>'_:)TR&LI^+%T"[K-]
M%#\?Y&1X6_O@U^2A6%\;P\MOC:YLW&ITZ<D=PQVVSY\IU99IBHB2>,H6&8RY
M3 ;K_-/T;9L<T/99U$^%VV6P;EN.-_/8'(.>K;*8@E:6[$X5*4J7TD76T:%(
M@Y=5=%]@J(D9GT;9# 4_M#18'H=;0=;C$BL7W2>%?K%EYZ$P(3ZIU;JAQ'^V
M8Z3*=D__AP&##K+U(_\,C!KU/%N1O%D.:PYF!4FSF:UG+C$$JIO-19/P80,3
MZ*V8K=MP"J= *JG?Q5+)&/+IR3Y!,>A#:+6)4@5]7[M#KI%Q^</2#<<W])B9
M,T_/GZAA%$M#[DER4)1=N1G%B4RWH]^&9NYM1E.\+MT]^?++RP<![X[<9-1I
M;;U2\;7/@CN]>-7QG9?2& '(W)LJ,KL#E<S0P'V28W5=H0S=>C&5YRSB)VQB
M@9XTG1CS6AMQZ0X'[ABQUDX\J<(C*35HHW5!RHV(PN\U]G$T_'F5NHKJVU^F
MBA?,)28TYY3.3FJB+C$>VZS#PKR \O+)_E!.@<2_!R6'_"5.?49:=1G9LP*T
M]-W&59V-KL@R;K@2H)O5U$(SD^QY-+)+%YV4GX5TS>8.)YJ0)/@P4JVCZURD
M^\"8H8MIL->76S&ZGQLTD@YO=S)\K3-S!K)1NZ$4,Q9"7#,LU7H&T&(E^GFD
MX'U0.JAWH+/6!A%=&U9,EINZT\**+K(;\5JNQ)/68ELZ%&^%2?*L9@-/R4XV
MB7V-O)EG9Y+QQCTRV+/)!H82>2L;_%8=>Q9<UB^#)5VH!#$W:X^)D=I04DOV
M;I 1?Z:B"V5'*(%*F@VV=5N9^WF^Z)+LR?6?7W[[XH7JS@H7G3_*NRP)M@V=
M6Y*A^5GJ=?Z/]5SJF 91!LLOQ;G6[W[B<GC;6R'*/J"AP.+)T+IC#^Y^!2HS
M[W:E#J9>CB;T5Z^H#EO3Y8W9'#K[*'*_O;W=CKT[BSE&[CL>*,0=/:,&5U)4
M@VO-@3KCA$(7<!,U^C;9&U!D:!/(-@31*".N^#')K388'E<VE#' /TY=I8RI
M9+4:]KW?U51I[?9ISNM1U4C^%V_?UH4V]:##"C2#=6<O0_,RF%?<ID>^*Y.W
MO7OP6UE4B>U 9YW!0;ZFRU8+_X'OA]&3O]V3P0KGR?RWC)R[V(9YY+CJ$^B.
M"P6I1A)SPB6L->"60@%_S9;X$-5CM3:B16T]TV2_AHRA3P?$SN 6NEI^H5.)
M?WJ!OO,?"X3G.&_OMR:'AN0,BM]C.RE:-M2 QR4QX&64K2/SQ)FF60[)"K?2
M69SI@AQK]\T<I:\R2BYI67V\GQ>HN;'26IM'Z,\N#%YE&_JMM)N_J];MC=Z=
MX^O'7^SMSCB.,KT<53ED]&Q@3&=';59:B<\1[WFNI(XR](W:GF'ZD^VUR RA
MJI&(S=G;N10DI. ,,#A4=5^2JT@G?@)9:[>%+I";HZX SWEZ',KC6F"UQC!K
M4U>95:LNWZT#22YU=7W18U8Z23B5$7J(R&'R9# 'B"T<=VUBKV0A23HBX]@I
M'_>% [VHO4*]9$UL9TBIWQ]/RWM"S4W=7\7!TKQBX]*+1N:3OY6^2?&.T!MU
M?JEUZD7"9[;FC\U*;H*=/8=WN-T=4%%]N\XR(XG!?7DTXZY74EA P;T_O5LI
M:%]?ZOWYS?9DA05;RF<<G.W?IE5P'R@14SF,)$]=[\].(GM .R]OU*F %S@3
M?I=G.1OF1=ZV,=HCTE8X9IR(31DQS_?/RIO+G/P^_R$)W3 $A4,W+1!Z<<?)
M^SE'"U/R5FK=LW=(CGA\N<2S_3)3Q69WU>0$K[6P4 B5Q*YQ\Q7\NUFV>,3_
M5,A1$#)8O?,!^5 OVR"WKUHKC%*V4H4E[(!.IIG+#ACF;!LB?;E5VG*[6SNV
MKBYK/@6=>J4WDV9'5)\+D,$T(TTGD)+799%*BXY%"N&)C0O6\=1A9#Y5D#@D
M@Z5W1V8V8J9T.MF ?; ,]OX[K"_W&;I5A)A7&<%!FU[*B\PTX@((7UPVQ91H
MG)3!?LQ?WS7\Q+6<1)-&S6.E*\JH<Y&.GVOWRTM.I*D,IHC%2%@/56M,-<<&
M-LH5#DN.^"A3AA3G-D-4E\>"DZN&>BUYA4 6*5SZ_Z,MHS%0I@RV"9' 'JVG
M3A6L'/[;%X)P&J=Z4^L--N%+G0]G+SF#>I/3:5QUKX6W0;B%X/OMK$V+N6+T
M.KTK>PT.4^77,1N5-MG0I3F]NOWAS ^0\*^B<+>P>#[CD-1>_9>\Q[Z2+)?!
M;@V^DL%.)5$7S0.!Q)FVJ.U\IR>C9YH'>;U[\[W3(S)MD%JIX[25Q?KCMQV4
MC)Z%*:Y75+S$+!$0YTQWN"XHE\A@17_>*,T?F<_[[OPLTSGGYN# Z9MBF^2X
MG7WH2DFK%_DWJ%#N#/HF&RE; &H#0_\$V0;<Y$-J$_G(V72*'\.RAK EG_%A
MC-5FTS)8/&XY:T-?_PA?5VI OL!EBS(JGD*X *UYKWZ\@5F7E<8C:.FO27EE
M::H%H?9W\Z&/I?D:7]_?LK2[=?!'WP;$>%?T\.7+$0;W@-T+#Z^.1K_YN/U!
MR,?=QNM3;+'# R;BPJCBNT4>A6YGGKYD&006VKG='/"<$Z]]M_7CKMG-1E\V
M!SBT!AKC93 <)8.1P2C')8VQEI-P,SEWVF;<%_/0ZZ#5?>(+.:"=L"UZ,X3P
M$[R8GE0DR5EC"6OM2+AQC)F%Y(1^%O<FKI%WZ65)(,N@&TF8+LG:U'84M/HV
MD5/L:Q0VF21T;2RAKB;AA:&S',RZ/9/793 B/9%:>?49./B.NR_UM70KA!69
MX^5EUXO+D1K2&A6:Y$IH3>TUP:1! **\N5AP<,I9U<.U8^I5J_N0>S402J,A
MRV0PIUY+CWL'/+YK.>Z_W7YU@\;P[X:WG6\\$/BM_;@\:"3[Q0SSS0#>(KS2
M<!^ZLQJ)^N;YY.NWPS'^'EE?4N_FZ?@&'ULO] I-1^D6KGE?UG8NNZYTKN]2
M%HJ-DL'..;<Z"ZM2%]S\6<J+Z=)=Y"V=N5 6J"G6J6>L@%J$&Z#30H:FOZ$0
MV="JQ#& =Q2XA,_L)F-%KFM)UMAR5@?1R]Q=)#?0ZM]Y-\OYK<&8"@D&F$Q
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M$YR*%EW*+ PT,*KCAO _$TQ=*CJF6C%.3U,./@EY;T= O[.Y=(EXWMEYM_O
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MT 5FVV6PBEF.#!;/7DM&/)'L!%QIZ9QYRFUD/3O)8 V83&O4-VSX#8_>"7F
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M?U,\Y@MC^#]L/U#'L,A%9PX\=YIZUQ4%R77@!G,5*0<I@SW2L?I1T9M6O3.
M:ZT-N 8]\G4M"MC9NMII5WK1R9'J#*M6::9I<81>7S+"K=OR_L2XEVE"Q?N%
M?K23;N<$Z=Q\H9@KN5Z!7%C%EMXZR7W?(R;=XHF^A&;BQJ#-!1FHS4;</)?"
M?KL5?O<TTDY(_B3/C0LK7KSX<6;!OBGKY86J\A<,OZP]6>4[]?!.6>.E[[?'
MF;S?;C-CNX66_Z8K(%P[-O\#4%G>FN\?[I"^LV_[YG%? OH=#UMYQ2G"[^J-
M3VG^;XUZL[2 A,J03"?>2&A5XN)8Q=XP/B%1!CM;KM[7IV*WD1"@$?6Q^P0O
M";][E>N2ZO*J'^0DYV#%.[^?JDHQ\5(^?STGSLDP,.W7+=^;S?O&Y@1X?+'H
M2THVW=]I^2HIAC]X\07C\/.J#"'JM='GG377KCM5D_J]0CQ><;%E\Y.C7^"/
M68K4-\\>RX<YG+AH/=+S6?)OIL6"&$LQ7X_W4,?V6$LSI[Z/2>79_X8F(LX#
MN,6M4>R\']0Y:Z3TK41NB-S _2FC/12_1L)?TV7Y_Y+/5.OXOY[G^%O>DNS_
M/HWV3TM3(R5,:$9NXLHTJ<-5S(\]P^CH.>SP/:XDXB25J\R>\L8.!4XA]DI*
M)L@^4HN]TO5<&>Q:E':B";/Y5T+")J3KJ&_FA.SY!?E%.N7FX2IK$R07 (9#
M<3+8Z(1<MQVT&!WG+<XV$.<T!A$SUJ7R>Y\@+?LW/N*_/U+WZ\<:R\PU$=!6
M)8EZT>^@(U)B%39N5SF84'!SR8(!2<(ZZ_3PPI8][V(.Y9PL47^7KS>E)]XV
M4)@0(HS<\^2''-,\K0CG$P1#C<6RA94=K=?"/PBK[XB.N>?_GGSH#I_!_L=E
MV!R&G@SV-:"+.N9;+H^A=1\;!6*D3H&,&82<9#L'E9+=[+4D7W\1U]*4O.^8
MK,@LP=K*9L OKK52FKI&R?EZR_IYEZ\_<B6?L!E[ ON-3MD^KU<WSET)-?WG
M4B[G&ULOKT?S0(?J8D]L@[Y/(]ZO\,N)Y^Q/E]!^URI-!:/5ES\5KU.,&_A]
M&X7 +*+LH;Y1V2<?9CDB1I:UDNM\K1,0/SS/LD>;E>08V;I"/B[0[[]F(]$9
MT%:#QU*][M;8 091O?>;6GIX:.O79.-/9CO>&]EF)3XF\):NS:I>3MRIN&V:
MKW&FEUMOL,D:RSM:)6J\=KMOQ/KR'^)Q]<NI3D^^//)#3?AO7KNV[Z,#_#5]
M3ML*MP"7X[A@T?85)H']8R.4*:W5D<$.G6*.K&)(7>1M>T[=(8-UDX_T_@59
MO^*VXK\CM@^](G]AU/;3TQ<5U;<"CNC@7]DP-?Y:4U6=3C)4N'.R]OI-D]\I
M@:#MWQ\.^4>?K?,;E#0VNZZ[PAV5<&5Y EG9P/NR,O>-XKQ 7 8_!*W_Y;5S
ML3AP/$@&.RG/L@X"+JND/5+I!_,E& :]5(*"<8N#*[Q,<MEZL-Q$$X4JZ(HQ
M48]$\G9:XY%9+'EI'#NQR6/&]$EZG,UX]N_8RTO\;L9M3-B@A0D\4? HVV\F
MMC6Y^>H<[NRS[+8+UL2?J,5]"Q_Z?Q#ZOA$X?A1AM1@>A_N!)A&EK G,5-0$
MJY_))\M;<=M ;D+/AO/G8]/E":$U_^=_]O&!?\"M#/:?+S4BJN1.#V8,(Q<:
M^1_@NKF)IG-O?E769;Y_8;P%&)4>(*ZB?MK"G[,B[_ZGDK+H(4]J_0N8&=-T
M:;Z0UA'.?F><30Z7P6YIQ\H%2_HO0LB8"V?E_+V@3),&C.2:(D4N<]8B%@\\
MVB"_N?"OA]+F2P2.DB1=YB)-WM8N2I8/HY$_I_Z+,'WE52[_-^PZP%!JGXR5
M<KJH(^S#96U_TTOS^^6F/?6*##;&^,">1JS9/5&''20[]+MVRV"VASR_4PKG
M.K$_25&_%$0=7V MH5GQ%Q2]Y8F$Q\;\NV7_>99\_TZYD3S>#/9\0KPNSY?Q
M&)WQ#PL*E(1_4$2LH2:^Z"M"V$J=_7.C?VZBY.*O_E6;%*9+Z-GRL6.^HB]N
M>,6LQHN0_]7(,*8*RN7V6D?:BJE"2#3HXMEF&6Q-X0VT.MERL8CM+P]9'QH8
M/<B=3K;C7/7BCY6($6H!83J]++W.RJQC:3^]>BZ:;?0FH,-VM-7U;$B\EOL>
MRI&3]3<9+.H@*=WW>5TGE8!<WDI4HQ,"#*TY5'JT9DOP-4/F6R!E;\,[6A%J
MBAD-ZJDD-E_N.;0;M<M0RWOTA4V$F97NO>\_FJ\,II?GKW-.LS[YL=?G."+7
M$OL-*<' I<J.,ICC?0%;8HU R,5.NYL,!I<[ABCY>\<@20XFU986&4P:H@7!
M9Y9'RF#[_OCU^_8_^5*WH;F94Y12-]S=LU*59!E,,>=,/?6B_'V[PR<A6I\<
M>58OUG/K!ER,4;/PA/?9V,B;]&I\L84,1A/*%9B)##;\$R4GLSBQ_'IRX*S$
M/-TY.;_:#P%=E'?;#SJFK5QAFO!/Y"X1PB$+8\GJF^I483E*IQ[Q\S :(X/]
M?,@L)LO'1$E.T/7Z4_25PUZ$R?%RP?#$V-3PJ1=TJ59U"^/.T8_?AH2[+^U>
M>%?X"3M"67O^?IJ*=4MW\S=H3-_F6YE&<6+#F=^ NP/&<(N#[RIW.[A_<_E1
MT)]ZM>/SE"]S2EYSI[%_4UL MXD!(=LDJS6;=#U3\8\H/)9J-I[@,K'% ^@3
M#V@;^EF>?LY0/H=Z=>.-0GMJ$PG[3]V.316IN66>@1CK</]/+5<:U42BK.-#
M102,@A 625!6!<VH;$),5!14A R#R@!"G$&'38P.(!%"6ED,RI(9%;FB$!%9
M1#&C@# 1$R L7E$#A!TE="(B>T=96NB$U]YWY[Z[_GLOY_2?/GVZJKZJ[ZNJ
MT]W1O/&34^GV@B3O,G;=CQ'MUS*-KI_(.GBX<+G<O"-K,B>V-U7I?U>X$0!A
M #I(F2>)45J"U?!7%-\DHMS HO@E?CNY$4T3=Y#SC744 ;'A<03']QR\K 5
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M+-F<<:ZED:7=W?A+EYW)ODEYN= H1OGH_D^6\<:W7,I^H_GU'[/.!-7L=I_
M&D;3-=J%/P"]N+UP?!%SHX2,83I5P@FH;N M6TE;[,(L)8C+PW<C<:?9YV/
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M-&@S7,$^ELWDTD7RD2Z9UB:O!A5R6#JD>$%C5A2#&2[@I1H@H'>59*_>TW4
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MS)M_M^EH9TPEKY-X1M[: VW59E;[Z"*Z>YNU3;I.8RKZ%!^G&]Y9!3FTCAB
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MZ_&J9*L5#3XJ"U^;EOK?GM74 ZBS 3'"N77#)-RH5C*:"'IP\@>P:C_ XM?
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MQLK3ZFE.] E+)$XQC^C5$Q J5?%]T .N@C/GG4,E1\!BL4=F:93]6'4T1:"
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M%H+N$*B(K9WKO&O%TSJ&0<>:GCC86*3;G#VV71"P+<K%F*@7V Y"C2MB\YA
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M)IPY ?WE'!D9:3T4%&C4*S5&-5Z@N[N/&?^;./"/'C.Q_M.0U.^]C5HE!:K
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MK3BE[+2W<[DMXRY3:EX5 L9C2S9%H.CZ^YPZ2BKV.'"+"<$+](!,3D.[Z7M
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M;P9"!1/)!*ORKG$4_^:=93=;U@'!4UZ^S)F_,;)3Y\3:W3=2*A?76C3;L68
MGG7.IQUZ@F/5PB]BV8>Y<F3<-;+QS'S(A;Z0N'?#5>M;N'I8*SR5 L&JS.'
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M1W8[&K;_[7FA]<Y5<+8&_P-4RU]D+V"^(DQ!0[@>(\8K>P4#]07:-($2T(L
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MO$!\2'O/N=QZ2A'^/)/@X%=O"5-2A&^2: '.N6/.#2#.&*:^'J<>#&NJ,O_
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M9SBK3U*IQWN>--:PTUW[0EA]\S^*_<;;0Z[DW @(M-DS$E'\_EA-8/CL('#
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M=!)LSXRBI"FV9W?,UTOMP-"[3)/"&999OPU2'XKA4A@$B4M55YP "R>I0<.
M^ U%FW1-9=<ET8=LM'?\^V$^-FFDB9\H!)#-<Q+4)ED4$TA*%%)3:)ML,R_X
M9;GVVXY9<GRV(8MNY);D4=#%$2'/_(//3BZ6E5X9E-;[+.I-Q=[-/AC[SPW[
MC'TGO_N-NY9>.8B8BHBJ]I3ZUL7@-]<WW/$_;.4NHG*"C#B^!?L'%-N()N[
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M.- A<&FC#.,$OAFSCK@8,6ID6:1Q#VTDLVX % ]+<&&&-YH 57NH8X#N@:_
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M=$-H91382*LSO:C;9;)E"_+-O:.+]+LR[#(\G+4;4L*BP;[?H#$P.*RB4K)
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MK7X_RCE+B*\-U+;P&KA[?60:$7XSLJ1Y76[ZI+UU,KH\VLP0PXVW//&@]:C
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MQKAE!.78%#S GF"U3Q;H@08'-HLLM,X_/]W2IG_][[_?_Y;H;9,=E)G3\"7
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M[.OQ[5+947PQ@6$"K0/7[:7+H>T<F6@F3'1Q^8YT!YISXEQP4%!]FGC=*+[
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M.Z$2JY:U.DVZF?Q+(,CSY,?K9Y+F]C7%G7KYO4Q"V,B/_^L'59N.XXRH-,U
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MKC07,HZ<D7U3_,TKO0Z[/];%._MLOY:^JU <X? &5! -:\<)L=3>H\<ZLZ7
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M/)N(/]9YG9B(FZ;"MK3@\03FHZ8N3BDJ1HNYR1)#<:SF=VQPX[H\TFA-..P
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M'^B!/8%K->5"9D\3@*N$'5WJ1 07<G.>+HBUQ;5B<3]_<Z"\A-SXUP ;ZO/
M;>+_323,,WM [",_7IJ?G_[5Q8GA?6&'.O"18WD?RFD?)W)2KK%T%@6YD#/+
MPER(VP->6Y:?6?JY<2IL07CXWX6@? I4Y&;Z5AQG!S?]AO#[-OD#COT2SX];
M^!C'V9OROTPI4/#?I)F(92[DM%M;UG,N)"U(-IS\VN 5%_+;!-ADO^(%O%W#
MS#9BH9<+D7<-XT+NK7,A&^[IA$PH\&B,]0(ZSH5P>J/S>'X<Z]!B98YMO.1"
M^ [] ?B8N$[<SP9O?3Q;!"FZX_ ;A42N!_%$C7,*%_+M":]OI5+S/6@V3_C
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M(2P+1QN#SG(A5K+7NW;VG!KB")]/Y!6&R.\2Z>P+OTW^\(K3D28.#TGKCW"
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M"2^?Y&:[K,%BE.LN,,3Z':OU[^FXI^A4^CD5!Z9=/I6Q/)?N]$.N8!_MU5$
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M"?7:4_*H*T1YK)163#.L0<GO^0(D&)M>3EFV*77+#9F'*!T,9%_ILSYG[$\
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M7.1P=DAH&4<,?(DZP[0F7(.<Z1)<KXJ!;? T?7UI88R#D/-'$E=<PNP',+0
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M].6A?0.;OM9:5(YF?W_H:Y/3;]=4/K5EP^R*YS,?7#2L\8#[RU9E%'<#=H^
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M%8F->F!:JZ5.&4MQDZ3  =#G)I#4/MI#Q"E7X+3!OZ'/#>5=K'D">(Z"$.R
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M,&?JXON<ZZ(P@N]*YXF>WZ]51%TK/^2!:GQ+6SKD_NL(8MJ4QD%)1&&?E['
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M_GP+SXH!N^A,T8YF"2_]'HT A\C:R!E,E43M>]() @HEIY@R3UYH;! ]O$.
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M J.\1NAA<<U0 *N?,+6_:3_ ]H0:03PK*(MM(P6AV^3U:M]@G+IZVE#B"NT
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M;>248W0#3W4@Y")IN/-@=!KC+X0")(!9@#@2DWC07]YC]1E7N7B!)+5>/"F
ML2(AS25:IEA, 4O8'+Y *-J <0>N=%N?/P!@\4--OFL8.QO1)9($UQ;-1!TT
M(6,H-)0D5B'B<<0;/]R9:E([2;+IB'%W3)/I\X7,SH*6^C]S:6[ CXJ77Q8;
M[MRP*IA:1)UUQW7C:T@)@7C_8R*L[FYDI)RG/*\ ZRS46;%NT60:\1GJ(-8@
MI!#*:LV4:[,1^8*Q[*B$2.SN^'O88 #=K2@.Z1GI@B&M1#BAUD9A7E$7M'Z*
M9I5+7&]P5%S:5N;WB'#06:SD MY;8-M* (O.JX >N6<P*:U3,73L$4ALNH<J
MX9OBRS"LCVPY8LZ:DJ\@_1ONJ[P6B,"*K0V_S"JN(8F5-1C7;)VMWRH2^9+Z
M+R4E@61.,X!OQ<,GN4BP.YIKT9!<"92@X-P3'^@(&H8JWX0B0PW];6[];:A=
M;CKOO@FIEEXSVN0(?+*Z9$J5' O(-"/FC=Y#[\EF2ASIS\,NL9'CVRPJK3R<
MDTGG^FPK3WV9)_V[:J]'(CY'@Z$SE>RY9^0.0X<JYS=I\!X**)QW^QV8*6B?
MPI3: HKDPL6J17W9T199]P3WA?R1MS_S;"KY.EQ1.NX\IIIS'[3:^)'MH[^\
M"8X@]/Q E*_LUO!6P3?\7IP&]ZS\W>Q'NKV-T,.?\$.F%;KO3S6EFN2UO.)<
M]T<&U "K20)89<5;\&X_Y[,\NL-=2WP17NO<2HV![UTO1C>=0E1[3VM8,E-1
MAZQ(L1O[ ]!2"])02;=C T0(VC14*I^*^:&QLOXXE^#B%[9WKA*V+M0SI!I$
M.9MT#$.>WNQ8C3&L;YM*1,@ ! +_!#7Z1Y,ML_\8)KQC<B=XIIJ""6)TY(B#
M&3&9>\-TA["6S%Y+&E]EL#9)FC;&B8PX0PS3S [)A0A71RCO5^/P=;H9[:0]
M8YA2(?[VM&CQR';09AC@1#.K!.9>'7WR!UQ^'17Y'.O!P%H^'/64 Z9HO=<@
M@BGX,";,RA9KSDJ"WZBC-YUX"R6X/=:X-=\BCMT+/7W+=01]NBG)"&. D,Q7
MPR2TXHY"'KEC7 - LQKXV8K8!R@^96F$=S(>/O%,82&/8:^"BI4LN"PFSY,_
M!)YI+(7B-*1ZK@)]Q+>^AE=<_!E;/.0X?)K<A2)2Q4.I!-*^EN/<"]!CM'X"
M5H%%/+2(ET0<Q=2SSM;C 0H6/]T?IWBD>D"C20O49S8LX/T81HKIAC-=>9H5
M=X<HK_T&OWBT*O^]\V^H>?N>+VD?UPM4;,?'\-5 $1KJK_[I:_]N2Y0@^Z0_
M:KT7S@SGFM31PZP.CT%HUQ$-(TLVID9"/,!0>&>T9F3@P2$C9.E7,L&Y"W$Z
MP0Z8)7&@$S%FQ?#XE^0-D1Q>P,]+;-2R1#E_$*<VP#4#G3OA>\:W\6V>OP'U
M7:^X6D! QQ@ZWNBZ$9S22YGZBM%"-4)M(;E?? VK;T[X3<JCXW/V0_6LJ:B!
M19S2<(L"AFPVRKVB54.ARRB8:N>8(YV4B,R4UN5S%WQW!+3Q+W*?#.!VU-,\
MO+JV'%>HM"D%[!]#+4>%0O!<0TT],-4^<;7321_ P#U!^K?E</@^B-3U;GY*
M7 "KSTM9'E..:W)GO@H+BS1M:!FN6<50=O&*$7M<<'1D-:6+^%4 LQ\^JY,%
M%[9E<:S-])$-#_O+D9VR\BZ@.$GI]9.D?L*/H+);(T-=3LGS+LTS1:]8OVN>
M^+-*1:1'BO^-=$@7'TNJ%G:4)HEMC27YS2@!S,_=YM"2T#5B?2A<=X#T[,=X
M6XMX^I3]"-:6 FG? #AYY0N2BYZ[AM>UCD(!U_3EY"L*;I6[^SUY+2];NOO;
MC77X3F100'_\$T)[ O$(]B"(I$G\QA_(40*IT2V[N;^3NCPEP60B*PG=-HK3
M9@36P.46QK1=EI 239>%36NOL!7AX[ : 8_]RN<9 4S>U<LMPE!8YC4>6BY;
M"MWP77BF%L0&1-B'/$\0+0G3T>3.4AO(E'%MVXQ[6AV\1).7()Q<JU6BUEN=
M"#V?&T'VX41 5-?.AJSS$J^4/PE@,.IM4CQ>HKL5?X#K!/5.XQ6P%W@97%>V
MC0+V%-#_%">]A!!AU%)E, F6H'!HN 84[ VA'FE1@M8T4/R#_7NY5F!T04X"
M4VQ_NY,\-4YKF6M6?#,BZUKE@._.Q54%+!K]FS_RT*WAEB-<Z]$:"@&W%PIA
M92O; 8^BT5AG9$<2FJ78R*9(=$[;[%QPNWWD1Y,9<VEJW_P:E+EJ_YZ.O<1<
MT>YJ4&QD&?M<!38J*LM<L:ML^#B=QC\&66UK8$WH+8K^C^1)*Q[3X?!CD/95
M$)V,W0',T7!R]'Y:DA8+1\G',%B$^%K?)FD?EKO53KOP"+G+@S]T2U=E//PR
M?[S--S728DY)8HC7MG>R@DB@A . :"1C54>;Y)BK1R?:T.C<10'L(%:[ J*U
M.\5NWM?,#[.1P 1TXO:-HC\WV#;%="_G*-&CZ]YPZIWA_G7/W T$L(NA MB7
MG:SD4L">@X%\0.=N?+5/YS;E*ZV5017%&C/1<?!J5!PV<!N)Z6Y[B;%A,J)U
MB(<Q-*&+0.A-] E@"D:Z?M/-0?3+X @Y 67Z#N@F<M%,=QM1-TUJ2)GICBU]
M((^E^0H,89*?(I3G&SP;<Q<0"* BCM5[R0+4(_$R*'Z<)S.)S@-NBP\3-#H;
MOK6_C-;^,C'EEU'YZ]&8!X^3'1+P&/F&D83KQ^\=GT:VX0GXO>Z=6ZO)5.9O
MP+*\%)31H:7:U'RM0K/";JQO+*#7(E"+MG7%0S..:27J8>^40>/+T$,]Q*U0
MCA$7%^40/?_77U+\_W\XNG_UW'^I..^XN4QM1ZQ+T YV](3YD2,[4N_XO.C4
MJ1CR<$-ALJH"EU/PP?[Q?+5_I[6S^5.69XN,K@*$?3K_?(!LQ1_F)Y>2H&)K
MZX$+X:\9\TBN]'Z^Z*-M)_X(O#8H#2"R9BG UL^V>KR$43C+X VP^E<NP"\4
MYKPP-I3A8:Z;->IR<.KF+^#QKNNBV(5JTK>0_KS58]^/Z'GG>)5^EVKSQJA!
MW.OW(:ZCQ8]DQ:Q26[NHM:W@U&_VMG:O3XZ-FOM3Y3XV/9HNV]3OJ;HI<X!S
M\7/_D:N["6' 1?]0QWLFU^P+%_LN;KU,TE7='KJ18G[)I%EBX4J\"H5F,W8E
M?@T.YWK0L3O G=-HVG;O&3Y_DTU,PKI.EY_ACX;[KH1:"LM+%61T!F1-6*A2
M(X+1862,_*K%LTO7/V74C]+-^<2C(VQY],K@]B63TYGX9&X$4P"+:3F),()>
M3??8B$/5CO'J2PEP @IN]&C[$O'(-RN_ W5/S*+"!+!CD/C6$,-]U*>2'EJ\
M(:9M-4HIUZ)H.'W?N>RFSA;3Y\Q#9Q#Z[OS^%N41//,HR.,\!5>[1C.*3RTA
M=E8!^LL\=BV 3 A#'^+^7E,325,\.#)Z^5')%(1W;X[CZ@86^#L]X>?Y%66?
MG'+^<9Q7B;R;1=PSCME :&$<L;J/V1ZGF#,%'2O%8_[ZN/.,=7;%?,,Q"J%B
M_8N1>7!8">1Z!LS)!'U7_"*F \))1]UO?F0J/-YX_Q<B([=%I9%7C]WMO2T'
MA7#H'P!^4<X^T#D&NY.R8*BPU'*H\J4>](JU(M*&D#7L3M1M=C<#K".9PZ-&
ME@6>$*&KH:O2CTD5Q_BBH'C^3%F9AU+?(#Z(NNN+$+"H=@$L 2<"9M DXO U
M<K%"]Q_"G$BJ'.*?AB0Z)+F&0$L"BV?3F8GL6(5]\_>$?P!,2PL"1I_[CDV6
M!S*WYS?<C6_WH 9U5&H^4([N_!&OSIPZ*H"UF5#O"&"_8<RLP=KNCDM$*=\G
M&9W(:/B^6_@]$*I3\7BS1P#;M#[D+232D5#8EM>)+\(B1N_2-\(;X8J^HUOD
MF-JL0#F'2)I;S(>2\<)76M7Z*R;;B&Z6%ASCQF8QGI75XJ.W].-T5Q4U^&7I
M\H\(.M3=M$!DLG(C@W(JDO;SX_0?S95"/_Z#;C."1F.E-CF2F)+Q:^E;@V=@
MFY_4^Q!R7'?H$9A%JX;(S/JXY2:;?%?_S1;X\-BDV!7:C<$PGJ&Z>\*$!&I0
M-TM#_^: ;JR&UOKV[-!&N5[[KYH5,^MANSV5PV=_**\_@:GD4A'X((DQ;1:Z
M-7PJ!L :-PR4LT%=2OS,B&EU;D69QWK<^M[EI$;=B?KGOPE[C2_M5U37@\9S
M$16*_P0W668Q']QL<#B5T%GR([52.\U0]1:P$:QK,"<:=IKZR!1;%]E4EIT2
M^/C(CT>1S&\4Z2PVV\WEIOJ;DC*C4W;56UTGT^6//G^]T,E?JS&@Z/I.E-;Z
M;(F9X'81(16?E3/71.P TPO: MBA>S@J1X;RM?^IXKG1EN/8HQ":C9+\&*#9
MR,+O79#O*E5*>U==$S[^C]''L<EA<Y7ZV/J)V&M,$06BVY:X&O 3,<T]HZ"0
M9;/#\&*9V4AQV9F3Y:XE.9\<(^:':8,61N]>-@1.?AJ;P!AI=[_2DKT-'C:J
MRC&4N?\%7S:,:3A4?)G.>5[@^[]ZN]*GIO(LFE8498N*)"-;I%UP0\811 42
M:5MII5D4$04DVJ@! J8<08(^\A2%L&=L1!0:HJ LLF2031 2( D9A]&P"2T@
MV5B$2/.>2OA!0C+QR\P_,#4?[A]PJ^XYYYZZM^J\#'P^TO3<P?KDBROSW7//
MMSVU)SPD/%J^.-C!CG2P6&A'>%HC8YI<;$X/8-A!._2B'8R(Y($9O'#"2HT+
MR"^# A';1EKL5?4!+W2'LG-(+, :1W?7LY@,ZUP^S\@MN#H8)'KIYZWY&.OG
M7LV)LO"XYK</KW 3LU7_7'HD0W9H/+/E$F9@AUCN+ULUJ=[7$IL*_=AL#%Y.
MW:/[A8N$GX^[X:T+#W[Q]Z#2P*&>EK_:ZZ?HF$\=AEA0Q*4 7W6P!@?>H[!^
MPVGW9=X8?58%&J75.<AP*.I3C,N$(*OGX;"%QCY,X;M2:8M%,ZYV/:87>_.Z
MZW=:L>LC&JM_-7XX6:..SE(*Q[G;M!\DM?B. H*"\:1"X]5;/T.6&B9"$0J6
M+2!U;(^58RV,L1B'IZ&[^F)<C5VO-PS6L\TB\TI2B^C/15ZMS32#R+P_LO%9
M5OQ[H9O;EG^RW#DA-F'T$5>2DPBFC"U04'_+ 20-3N%AG7685+_PYL%4GV)*
M*;C646B1+PK=WDS<R/ZQV^YE.K_0.*G%L\J]\U&)%^7""G4^A>73E',1A6?B
MU,X >X0I(.X"KZ4%A*--37T.5;/C_9>:DN$9WQ53O'7?-R=%.52/YWK7@IN5
M$84'!N;HBFA[?N$:;@-JGT*+J;(]U;*1X-E#=@ 5JE;@4D2O\$9(3,BK!'P1
M]FI^!%Y2[)IP!JX_>M8>N0?^$>/*6D4=&N_V_#O+IS^&MBZ\<&.?7=I,=?T'
MW$*LJ=V5Z LO\RS)JW68*-8=MC5C#Y6PFKM>V4 \D'X$D"^A^R8[]3".GG5S
M<<^99VD\$*VQE>%G1?[)Q DU/W=^D9;R=>(5,M!XR9I5-!TX9?#B%K8R_#]I
M$_^M'5FE.LQ&Y>SBEU<Z3&]\Y-SZOEK?6M\_XLP#O>.\$Z9%"X^\HZ]-CL#%
M(3J,2"C2-(_ X@C25 ZC%6XWL\LC#4]Z4))CR,!?A['04A(O^D$\D_.XF(#7
MG_9F#_'JR)_>D+10E Z#X"0Z3.:IFK-!A[07]S6@Q%42ZS6=O[L?'3L29:O8
M[ZY<S$XC_LI3VIM10H@OG:4Z3/WGD=!S<Z4"X[5S<&5/CB/U$UP3KB93WKQY
M/1/Q)5IL(YXHM%QTY=K*K=E$'2;X@:/:?D]'V"A>O;I;I<.<KC#B=@W#4:=5
M(9H'DZJ  S2&)]75Z<01V('0._D6)G"-]9XF0>_VL980$:W.E-)22<NU=I&A
M).1ZL9R]Z@.8;!^JH-^1B;*(.,#B:W<@ X_D' ,J'F?)3(;BRT.F%I/3Y56;
M3O0ZSY".M8:51Y27?1QBO0[*U9AG)9 ["%9.[H<5!GCB1B!3N]+GI9,I+3\1
M;=HC+)@9Q&V:&Z!+[4%7BFZ$LK!IX^%.QA*<)JQ_5QUK&;?*;?%Z3E%$18+\
MS2_H6#.AS,G/<").0 +VM\!M?'I=NB05$<K@-")^Z27#$OKY[WKT'OU*Q9-,
MX2B)[13/?&LC<KDF6F'E!6/I7;+9M!;WQ^VXQLHIVVW=+0$RU4"=FFWZL3'N
MP<&D9$\^!]ASTK0;(D/U7<K8:01L)<,%^,M]-5MZZ'F^3 (.\I86W.R8)YDX
MB^\.:G'H[MNHE>H!*A%8#;]*,!<<3&Z4>0?[@*JG$5KLNU]--_DB2X/)NV.5
MIM?FOD_#+!BWZ3"U]JE$*^UKVV5+>6XVJ(]Q-*W-%HOP[LYH$CB0:[>;[Q-0
M,LA?3&I]6UY*%\NJBV';_'(0*++\)13<%#;C<C@?@U)ZG8/[9)RUX.;)-+Y?
MW4)7&P_Q:0V33=04@;YVTEJN#>2,WB5;MEQ 7?R[B6LA<]MEP%7V9KF<U(XU
MTYBAW$PD6]:HV64:X6:J\#XJY@?!@F2TLZ("<(Z]T]IW55")FY&MI:73\/F&
MI>-%MT@;H4TZC($0927Y"[C;"#9NCN6:P'XG\OL;[H["01W&I"6^?"I/G,&[
M1,@JM /O9%AKR*\.]13QU@-^9QZ'11F<Z"':>3P%RH[K9>O)(, I,7D@6F(*
MMSLZ8<T 1_Z@##HG,Z7R1_<T+#WE0'8EH+&M\  Z/I^L.:;VFR[<--#"&-W<
MTQ*!-@8!DAPV\HS3<_*ZJ77A# (X+'6@"@O7\FIZ6@+E^55>WDV#<^P!RV]A
MD>\I4L\,[C*ZK_ &/D.[G0QY?OO+(\DV]WX%PZ(9F2,F(D+&P=)CW79*<P '
M=5$X"L*=@O,+C"8%@P]N3 H*PKQK!^8^')7P@\C,KQ>3VY9(W[)7QEPT%JMM
MYDAWK$X,XXCN;_OC1(N!=]&"Y[^+H^;:.8-YF?*TG^/OB;;NS?S(R5#L'S';
M>_NWV#9.B53[O0X3L)^YO+"%,*A]6N,US95,C_8I]Q\$7FI:6,K8F$K;!TY.
MC(_/T_[%C=,OT7/Y=IUCO*#%W,$M2?!9%>&,"C[=Z2>$#8?])B=4UFPAR]'%
MI?5*H.9AI?E%QG1HL?9,EU([#A\GO7BX2745[%ZUD<4<M358XV$0I/C;H4WH
MLE;EIP;)EUG#I0667BC*<P(.!7QWRF2%'P83@S'#J"Q4U@GR2 7TRO"65AA/
M>;>'':SB#9%"5.R7Y4?ZQA:S\+E!OXV,?.X)S@WFW)?"9A+#,)0^F5\I4IXA
M/5<[EB7X9\_W5]ST@:OE\;QD15>7S4)376W0#W_9\P=VS$-[ORYPW'ZJ="R$
MA_RD!VR%S(;Z0^\<V010!+"YVPKU+Y ]6%#,KM;\N?LK%J<Y#^+5@73Q.9!#
MHU53<4'W@RH+MX%SBAYI:Z ':E93KJR9;@[-E&>N5/K6OD#O5SV+.@NWN]07
MD-J:DYYQLK3X4L&2OSPY'5WVI=.SC5UGT% >+9-@E&1L3+ >MG%PO7!RQE Z
M:SXU1$F)+:U!/>\0B>&G&Q:W5I4#(U^S#_23VJFM2R%%MXAN2VS293).8X0.
MO)*[BM/C".9.O W0%N @(UF. A$_EX340(=15ZGX;A6TPE! 9>.'Z87>V[]*
M_D2/)-33[_ #0_'-[_H$'V/I&DI<=&SL>0BOUXS$N.G%=\P4:$,Y=+F>9/*U
MP%75D2WEIE.0F2K-.>GL.NW[?5J7]$Y+E@!KZ:V@UH',8CI!BR-E/$&NWWL&
MX+:XH4SNDY(/='$(NK+I\5#D/*FTSL^PBUPW_TE4RNCEKD(,[SAJ N-E1Q"R
M$(L!O6J_VMZ9.4_4\4Y,>74,-DUB$FM\,S\?WGD(B)%<,BKJ$*\]][3W3<E4
MJ /[5.+HY^F.4<.%?+V%0'PYEM">;LV&:TBC8JZ@5, VZE(?IU^FX:'#X 1%
MT6JDP\@<14O4MJOA1#-FQ^E0)R2C(6B^G<3DK6080NX(/I65LCMFR?\(2+B)
M3X/VE@6!$OFPUQ)13S;N+79J# AK&S5DRD9O*X)K916.&;Q:B8!ZP-EF[=;!
M"8331KI%7LG][@S]\.F!2F?O@UXSY-#N;]?J2%ZZP^.^OJ--@YG5["?Q!T,<
MB;.?Q&H[P)/2,B%WN1BG.=O3 AO>AB]+,-JN4,.^K[3D&6G$!9" B 1YR36R
M!%CHPE*0+3RKZ'J"\6UE^J#N _<H,K;QR,CO0O@Q/8R/CGPX>VS^TO\@F?C_
M5]_IWO\;4$L! A0#%     @ X8WW3F>6]/261@  3U$  !<
M ( !     &%C<75I<F5D:6YP<F]C97-S<F0N:G!G4$L! A0#%     @ X8WW
M3L8QY/KE4@   UT  !8              ( !RT8  &%M;W)T;V9I;G1A;F=I
M8FQE<RYJ<&=02P$"% ,4    " #AC?=.-3C,TJ:M  #_M@  #
M    @ 'DF0  86YT:6-D,C N:G!G4$L! A0#%     @ X8WW3GG VM9S%P
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M,#$Y,#8S,%]L86(N>&UL4$L! A0#%     @ X8WW3F<D(OH$R   "?$) !4
M             ( !%$D# &)I:6(M,C Q.3 V,S!?<')E+GAM;%!+ 0(4 Q0
M   ( .&-]TZE2EZ[6\T# #QI.@ 4              "  4L1! !B:6EB+3(P
M,3DV,S!X,3!Q+FAT;5!+ 0(4 Q0    ( .&-]T[4#ETPVA,  +EP   6
M          "  =C>!P!B:6EB+3(P,3DV,S!X97@Q,#$N:'1M4$L! A0#%
M  @ X8WW3J73-Z-+%0  AH,  !8              ( !YO(' &)I:6(M,C Q
M.38S,'AE>#$P,BYH=&U02P$"% ,4    " #AC?=.RCF0K?45  "$@0  %@
M            @ %E" @ 8FEI8BTR,#$Y-C,P>&5X,3 S+FAT;5!+ 0(4 Q0
M   ( .&-]TYVBFFP,Q\  -KO   6              "  8X>" !B:6EB+3(P
M,3DV,S!X97@Q,#0N:'1M4$L! A0#%     @ X8WW3O;LU*IZ"   \#8  !8
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M;FQO9V]S=&%N9&%R9')G8G(N:G!G4$L! A0#%     @ X8WW3C5NY[^_B0
M%)(   \              ( !$I ) &)I;W-I;6EL87)S+FIP9U!+ 0(4 Q0
M   ( .&-]TYUL<Y?TU   'M;   5              "  ?X9"@!C;VQL86)P
M<F]F:71S:&%R92YJ<&=02P$"% ,4    " #AC?=.@[ST;A-_   =AP  #P
M            @ $$:PH 8V]S=&]F<V%L97,N:G!G4$L! A0#%     @ X8WW
M3OJ_\&!O10  6$T  !H              ( !1.H* &5Q=6ET>6EN;&]S<V]F
M:6YV97-T964N:G!G4$L! A0#%     @ X8WW3DYAEHSKA   !9(  !<
M         ( !ZR\+ &9I;F%N8VEA;&AI9VAL:6=H=',N:G!G4$L! A0#%
M  @ X8WW3EM'$U7$3   %E<  !D              ( !"[4+ &=A:6YL;W-S
M;VYF=G)E;65A<W5R92YJ<&=02P$"% ,4    " #AC?=.Q/DH%C-_  # B@
M%@              @ $& @P :6YC;VUE=&%X<')O=FES:6]N+FIP9U!+ 0(4
M Q0    ( .&-]TYCI/ 66(L  />3   .              "  6V!# !I;G1E
M<F9E<F]N+FIP9U!+ 0(4 Q0    ( .&-]TXG10E5D4$  +%+   :
M      "  ?$,#0!L;W-S;VYA<W-E=&AE;&1F;W)S86QE+FIP9U!+ 0(4 Q0
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M2P$"% ,4    " #AC?=.WC!8/!21  "3F@  '0              @ '4JP\
M<F5S97)V97-D:7-C;W5N='-A;F1A;&QO=RYJ<&=02P$"% ,4    " #AC?=.
M LQISN94  !$7P  !P              @ $C/1  <V=A+FIP9U!+ 0(4 Q0
M   ( .&-]TZ2RW+\'H<  *R.   ,              "  2Z2$ !S<&EN<F%Z
M82YJ<&=02P$"% ,4    " #AC?=.KM5(U@>9  "@H   #0
M@ %V&1$ =&5C9FED97)A+FIP9U!+ 0(4 Q0    ( .&-]T[2CZ(D/HP  )&3
M   +              "  :BR$0!T>7-A8G)I+FIP9U!+!08     (P C .,(
(   //Q(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
